<SEC-DOCUMENT>0000899923-22-000079.txt : 20220506
<SEC-HEADER>0000899923-22-000079.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220506161616
ACCESSION NUMBER:		0000899923-22-000079
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220506
DATE AS OF CHANGE:		20220506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		22901266

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
		BUSINESS PHONE:		801-584-3600

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mygn-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:6c4a3a2c-b656-4a66-b2d1-1ba9bc2e559c,g:c641d519-fa56-4157-9313-b107a5eea025,d:b6fee90945e74b97b833695fd82463c2--><html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:mygn="http://www.myriad.com/20220331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mygn-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80L2ZyYWc6MGVhYTU0MDVkNzRlNDdmZDk2YzM1MTdhN2U4OTM1YzcvdGFibGU6MmI1MTAzNjRhOTZmNDI2YmFlMjJjZWM2YzUzNTViOTEvdGFibGVyYW5nZToyYjUxMDM2NGE5NmY0MjZiYWUyMmNlYzZjNTM1NWI5MV8xLTEtMS0xLTgyMDky_c528dd38-e7da-4dfe-8415-731268e71924">false</ix:nonNumeric><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80L2ZyYWc6MGVhYTU0MDVkNzRlNDdmZDk2YzM1MTdhN2U4OTM1YzcvdGFibGU6MmI1MTAzNjRhOTZmNDI2YmFlMjJjZWM2YzUzNTViOTEvdGFibGVyYW5nZToyYjUxMDM2NGE5NmY0MjZiYWUyMmNlYzZjNTM1NWI5MV8yLTEtMS0xLTgyMDky_b022a6f1-a418-4dc6-85f7-fe5af47db679">0000899923</ix:nonNumeric><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80L2ZyYWc6MGVhYTU0MDVkNzRlNDdmZDk2YzM1MTdhN2U4OTM1YzcvdGFibGU6MmI1MTAzNjRhOTZmNDI2YmFlMjJjZWM2YzUzNTViOTEvdGFibGVyYW5nZToyYjUxMDM2NGE5NmY0MjZiYWUyMmNlYzZjNTM1NWI5MV8zLTEtMS0xLTgyMDky_5666b331-c172-4cb7-89e9-1b85bffc1b62">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80L2ZyYWc6MGVhYTU0MDVkNzRlNDdmZDk2YzM1MTdhN2U4OTM1YzcvdGFibGU6MmI1MTAzNjRhOTZmNDI2YmFlMjJjZWM2YzUzNTViOTEvdGFibGVyYW5nZToyYjUxMDM2NGE5NmY0MjZiYWUyMmNlYzZjNTM1NWI5MV80LTEtMS0xLTgyMDky_7be0842b-c680-4cb2-bbd4-aef014f913af">2022</ix:nonNumeric><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80L2ZyYWc6MGVhYTU0MDVkNzRlNDdmZDk2YzM1MTdhN2U4OTM1YzcvdGFibGU6MmI1MTAzNjRhOTZmNDI2YmFlMjJjZWM2YzUzNTViOTEvdGFibGVyYW5nZToyYjUxMDM2NGE5NmY0MjZiYWUyMmNlYzZjNTM1NWI5MV81LTEtMS0xLTgyMDky_4f14f016-fa3f-4603-9bee-a9150e68f42a">Q1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mygn-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie26f4d836b8c43f3a81066cbd86c0c0a_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i9ac025088f904137a68dd99ae7162c5e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i56db6c3d57e14c2b8658a385a44e3603_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf33e5d604a449409285140d03ecf9c4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0028e3d51994bd79cb5c6bff0d75e18_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a6fd51a77104485bed5515365b14f90_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51af4328f7a04a4b8cac37c1e5d162d6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib08aef4ce0a84366ae13a13964bae0a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i778ef826320848759f1d194633ed0c53_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i492d83c9f93f475893f5e08b0f651c9e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ea1b38b6fd442f28bbfc072c2cbbf70_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38f47e17df9c466eb0964b81d156f640_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5272217093641ce807e8a88daa1cdd8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i665db2c7846646668f3cef8865847df8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3215774ecd84e0d9af76636f9dec725_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibca09dd596a045b28ee64d75c60c6fa3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51360db4a9f443ecb44b43e6f565af3c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07d7d32725ac4f4c924775a73475ec21_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708aff24e984491496d2d81e7aeae298_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c1c491ce07b46bf981a8c437b57ebe5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65bcf7eb7d084073a1d31f6c3266039e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib058dc224c7c47e98c2cf75604eea5f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fdbf8c5ce07414fae885bf9107824e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca9e1f471d94034b7814953ffe2f26a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8a8f0a93ffd45eb9e88163c16f0d327_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812ea76259f24a58ae8fc86475a6e3e3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a8239ce03e247a09242f5f72f3b8f29_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib37c60806afc4e62a8fcc62ed49d169e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i652588d3da5a43d2b2cf4ef648e7a8e6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bb1c337d99746fcab9d1d8cfad76b30_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i048b28f83191461ca446a385004cd1f5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1519c8391b842399d132e8fd6ef21f2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eb5af63f8b8413cbb2c5ccef8a23335_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a00625e25ad4bb19d387987d29c1b37_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a0861127f384074bea6194dcadccff8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i168a53dec81546e9841245e8c2ecad66_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71aaffb802404ab2bd2254ac4935374c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic48d92006ed6462eaddb141061226da3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb41f2d374db4b62bf6fca7d3c8b87a7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic124314e94e44fcfbb72df064864b2f6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef67c76df944005bcce30f068506e34_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f84ba2616749a88b3f961574d23e09_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie57f1eaf9e8d430c860af6b4ed687e97_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30c094758e7a4db5b59bcf76bcabd03f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f731ae454a94bd9a075b65ce61d8ee5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie79831c4c3804d78a024b6129000343b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdf8e565250c4b04bab9ef9d5c4ff45f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b03a6430a624a6b8f8e6bcd7cf82f56_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97fe976f531f43a09cf8064128efdc2f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057ec40f04944ea984f6ecb96adffb38_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia76e2445fd4247ce8565ace69a07cb58_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b860be39e224a04a1a68674e503b529_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ddeaedfccb40d88221e0e2d74fa96d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87691cf56a19478eb1f6544cf57295c9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e4cecae202247c880970efaf5f9ee3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b19f57c78b44ad683bb1b4bd44e5f62_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82485441ef944386996ccf0d6e192050_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f3f03808324e1b8cda4b6e447e0038_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a108bb0e4d641a9ba014a3fb5413714_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ea03d11e0304ccfb26dc185eac9a3d0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f29514d91043cb8814629006fe138c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d668be165244dd1be2739e4bddd8d6b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1e28fc7eb7c417ca6677b3b6e228c4e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54fe3cc0d3b14d139aadd0a94943b49c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03a8be3329254025993297729bd21abe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7b88a6e741b4f37bbb83847c7547ff3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45649325d565477e9e05700b9cf7f061_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40fb715741a94f7e965b632953843495_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99e56a4a61a6448ca8284c81c5072352_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48867d19db404992b557cd1387f4e47f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87a32a4bbc484c8ab0294925b08b160c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7abf3b2881464b55837ca122fffaf119_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3255bff47e5459f88724051e2d8e564_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3a1622be8904dc6a17e7260d663d789_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba63cbfb3f734a24bab843e8ad4d779e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8dbe812816b48cb830e84114c6d8f60_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibda7b5c57b0c429db2fdc77635ae5e5c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ca0e6bc0455492dbe206a7d48a02709_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29edbbeae1f74f208e45c112f01268c7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied55de41f92a4292af6d62bd5c0088d0_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bc19c6cc66c4ff9a3b4c1f8519220c4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if788ce35f1a7443780443d8285c4dabf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icb95dc894d0d4604b1d478d160dbf2ce_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i136db30e02474345827ada253c52a3dc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a42c624b75245bcac04b9a7d1f99fdd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i079b9de7e87d46e9bcccd402328b76f2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3979e6cb59c140e695831c1612356572_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33295928e5bd414aada50cf100d5946c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29a7ee8981794d99b60509cd1fbedcf6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bd84c1ecd394413b497049a3d8c0482_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11689e851c8f4f9a9804225d7cafc5bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i353c741ab7484eb590076cce6cf8785f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia61c6cbe23264dc3937f411e7be9e941_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14b1f730f55149ffb4bc95c14af1afd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i357d6b9001eb4f34ab4e5759c25bafad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6ed914040924d00942b5531f455cea3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e3194cd9264422920009833989a9f4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e4529dc74b46368324bb8e8304fae6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic383f28c706e43be88cc15989d93d8bf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1149c109c7944153bce0f07495ff3516_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4683011548b54f0d9ebf8e148ae0cb58_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib523b385ec3e473889798b06a5b0e42c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i093a64b69b8c4abeaf4706d4a48aced8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0db6ed20d3b7496abd3bc2149d9f0911_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib288a6a85cb34b21a1848dd46ede7ea7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a9e29a9d23b4534a84fb267bb955273_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73ec880d0b0e4b1ca8cf3ae965faa17a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57812bb46fe444018878a29051cb790e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d28eeea16924dc8b5cbe6c78890f671_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4b68d2f71a40e0873b52510f156925_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e850fa3529c440d8963459b76c7b82e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcb86fc367024853965b38c7d1144948_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfe95fe4dd354dbd98eabe24039da4d9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29cf1314b6ca487490b61e18b013ff26_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2604abe8133848178f910dd24f6b3462_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8170fc4406e43bdbb3216785308da75_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e05e765ecae4061bff51a2cb034aa20_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9035568ac69b433da12c2f4a2affbff1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab78bf60a5c942cc87ccc71b20df6a27_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf0f4b68da2b4515afa573f19f88ff4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4ae2273e9614043945b8f236bd47dfd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id72e536fe9d14ae6ab7cb34094bb9d39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bb9b95d87db4378a84eed47d440eb40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de004c7a5244c518e0a748f1c208172_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i528dc644c9ff4943b02b055e4f0985a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e871c32c4824df6aba031d957b820f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf97501434e045bdbec15630658c5c1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07615525c7da4600a164f6377287dda5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e2f08fba40d4ba3af31fe0475b3de3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bc70dfe49e04a118a51198b256f8dae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5de6b4aac9841a5b074aec661dd7e40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78479d9de84a4fa987db5df225bb0dc9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9714eb29e60483d97d657c738112562_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia84c478ac57b495fa98f396e489b0dfd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i859a42bcc97943128dc28bd68082557d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e3c14443da2478fbd20257901c8b17d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10f83fadc928439aae7775e2a66e9369_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia71dcd4c9af541eead967fd44feac0ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5990b598e2d1460597cd94495019968d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51f0f49e3b5045d5b1be9e63528af3ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9a60ca8f13e4a989f4559d73febd0b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b8d4e9c04da414c897ed06bbbf510d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5028f46356f458f8cd14be716668ff9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93acac9c7ae94d1aa34a4be6c6c75cfe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8fe2de508784dd7a2055d130fa36acb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i174cf853880a4694890b201c320822fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49163efc76014827a31448fd386b5085_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48dce0415e7b4acd9af7a58cea440e09_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1016b9209b0844a8a1fe882aaf69c3fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f00404949054a39b7ce601ba38532bd_D20180731-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-31</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0837431576cf4579a0f3ff1238105f8f_I20161223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c833d35617e45489ec45fd17d8b7885_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab8dc65629934bb09610a94e1585f5e2_I20210221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41e34ef04eda424fb7d05a478f98d582_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71d2eeb4225b4d9581fbf31f410c3194_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2304a6ab41d9426daa1dd160660afb17_D20200401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b494a8f5d504446b284a79c8608ed05_D20200401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65072d8099784761bad742b663d1ac97_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29e8864078c14a39bc3142c044233017_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9856b6ac715043c4aba22142b3f40f4f_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c4a4127b1ac49719e15e702d9dbb3e4_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e2100574367494095bfa2718fab642f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d18f4068d394dcfba0bad4c86c8ef8a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10eb9ab7fc8b46e6a64d2ef084755cf1_I20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e4a2bcdad04bc89e6ef5fbff976fec_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bad2fadc9ee42ca9a12a98237615f28_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mygn:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mygn:NonEmployeeDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife4ee7239ab34cb7986b1613a6ea4129_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdb73b76a7ef4b6192ddf53020f1bfc4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d16553d025b4028aa1658a83e5f4561_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17685ad6b9cf47d5a2539fde84607b3c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i425eb7ec3ba04e4d97719f260b166abb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d5670611ac54c00895e101571e289ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e88ace7ed394a94800fdca61421e851_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83a6571b146e482389af3212034e29e0_I20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaac367b814414abc8b2dc1fcfc86625f_D20210923-20210923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-23</xbrli:startDate><xbrli:endDate>2021-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5030a2b3d82c4d60868c0b2191a2d4a0_D20211205-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-05</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86d71b985caa4964a6e254ec96cb87cd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafba3568c8f8479caf7ae3e55c4f2129_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2566e34ad9de42d492126a12c9a969e8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72551335efb84f1dacbfab6e1f4b32f2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e442b7e778a40d0b0ea4e18405b7a44_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ccf0e5050c9430eba39a50029c3c70e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1114d9d3200747a2a214afd2bfab8814_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie78cb4d47d2f4c79b9717d147044b377_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c40a24632bf4346946172c6e98b52fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b99c5119ccf4bec978689998d8156c9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf2e4709d4e4f3c8f8de9d3848531a3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i165aceb443f54911b03d14bf7fa31bef_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f49e0371ac14b658fae67bfe038cf32_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b97c328c10c4fa3b4b35d35fc41de1f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd3dfbf88a4f49d29528546627f27aa0_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mygn:CBICIFPASettlementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mygn:UnitedStatesAndStateOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i725231d93b934c6d91bff94381a504dd_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mygn:CBICIFPASettlementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mygn:RelatorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e805b5f43a48c59b3233b51bbc2f4c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:WestSaltLakeCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i9b97b4edf342400a89726e31b3e19c6c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:WestSaltLakeCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib6fee90945e74b97b833695fd82463c2_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzc5_08aae016-c111-45a7-9dfd-b98b637c76f1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6MjdlZTczZDgzMTBlNDYzZmEwYTgyOWUyYTIyYWMzNjAvdGFibGVyYW5nZToyN2VlNzNkODMxMGU0NjNmYTBhODI5ZTJhMjJhYzM2MF8wLTAtMS0xLTgyMDky_312fd540-7365-4797-a17e-3816a28ee3ee">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV83MTQ2ODI1NTgyOTUw_7237849f-b83c-4b3e-9922-9292e80a97da">March 31, 2022</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6NjMyYzRhOGRiOGNiNGIxOTg0M2E1ZjFhOTRhMzYxZDMvdGFibGVyYW5nZTo2MzJjNGE4ZGI4Y2I0YjE5ODQzYTVmMWE5NGEzNjFkM18wLTAtMS0xLTgyMDky_afda960b-34a9-41f9-bf32-f52ef8e60e62">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:&#160;&#160;<ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzgw_90070082-c125-4e77-8bfd-7c160fb350f2">0-26642</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzgx_19af4560-3e67-43a1-9f55-e0b71d18c005">MYRIAD GENETICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzcx_c048f429-f4bd-486d-9c0d-20d451eca5c0">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of incorporation or organization)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzgy_faa73ebc-bb6f-4a3c-aa70-fd5ed8c94b91">320 Wakara Way</ix:nonNumeric>, <ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzcy_b9391e86-21b3-4040-bdea-540535b3451b">Salt Lake City</ix:nonNumeric>, <ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzcz_377422ee-1301-4a60-abe3-2cf55d9e9268">UT</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzc1_33f91159-ec65-4f9c-8b04-5b85a0a82af0">87-0494517</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(I.R.S. Employer Identification No.)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzc2_abd421fc-3214-440c-8616-32627ca4f6f0">84108</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Zip Code)</span></div></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant's telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzc0_0703c19b-f90b-4ba3-8226-7389b6c68cdd">801</ix:nonNumeric>) <ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzgz_77429f4f-01d2-4f7b-bb63-741f77c1f7e8">584-3600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6ODhjMWZjZTU4N2U1NGEzZWFiMTkxYzJmZWY1YWQxZjEvdGFibGVyYW5nZTo4OGMxZmNlNTg3ZTU0YTNlYWIxOTFjMmZlZjVhZDFmMV8xLTAtMS0xLTgyMDky_0c7e8a10-fe39-4dae-8f1a-f259be7c32ea">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6ODhjMWZjZTU4N2U1NGEzZWFiMTkxYzJmZWY1YWQxZjEvdGFibGVyYW5nZTo4OGMxZmNlNTg3ZTU0YTNlYWIxOTFjMmZlZjVhZDFmMV8xLTItMS0xLTgyMDky_a7f81fe6-b5dc-40b0-8d4a-34dbe83a6c24">MYGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6ODhjMWZjZTU4N2U1NGEzZWFiMTkxYzJmZWY1YWQxZjEvdGFibGVyYW5nZTo4OGMxZmNlNTg3ZTU0YTNlYWIxOTFjMmZlZjVhZDFmMV8xLTQtMS0xLTgyMDky_f2322ca4-a058-4686-8622-09dc52bc7222">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzg0_9fb65da9-4dad-4532-a6e3-84e44eef5478">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzc4_115b0fe2-02d5-4b49-8a61-7ebd706f804a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6NzRlNzU4NThiMzk4NDkyYmJjNjQ3NjZkZjQwZjE3ODQvdGFibGVyYW5nZTo3NGU3NTg1OGIzOTg0OTJiYmM2NDc2NmRmNDBmMTc4NF8wLTAtMS0xLTgyMDky_851a9c77-6758-4b0c-8e4b-2b771efdc69d">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6NzRlNzU4NThiMzk4NDkyYmJjNjQ3NjZkZjQwZjE3ODQvdGFibGVyYW5nZTo3NGU3NTg1OGIzOTg0OTJiYmM2NDc2NmRmNDBmMTc4NF8xLTQtMS0xLTgyMDky_7561e536-fb32-40ba-b6d9-8b2e48cb9020">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6NzRlNzU4NThiMzk4NDkyYmJjNjQ3NjZkZjQwZjE3ODQvdGFibGVyYW5nZTo3NGU3NTg1OGIzOTg0OTJiYmM2NDc2NmRmNDBmMTc4NF8yLTQtMS0xLTgyMDky_676c92a1-d679-4365-8d35-b3d975b57e76">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzc3_31e2a2df-11e6-4f1f-b2d6-ef291b6f3c03">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;29, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="ie26f4d836b8c43f3a81066cbd86c0c0a_I20220429" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzE4_38a403d0-31b0-47a4-9d62-e5b50f496f33">80,343,165</ix:nonFraction> shares of $0.01 par value common stock outstanding.</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDEX TO FORM 10-Q</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:8.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_10">PART I - Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_16">Condensed Consolidated Balance Sheets as of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_16"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_16">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_16">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_16">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_16"> (unaudited) and December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_16">21</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_16">4</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_19">Condensed Consolidated Statements of Operations for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_19">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_16">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_19">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_19">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_19"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_19">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_19"> (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_19">5</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_22">Condensed Consolidated Statements of Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_22">Loss</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_22"> for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_22">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_16">March 31, 2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_22"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_22"> (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_22">6</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_25">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_25"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_25">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_16">March 31, 2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_25"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_25">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_25"> (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_25">7</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_28">Condensed Consolidated Statements of Cash Flows for the</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_28"> three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_28"> months ended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_16">March 31, 2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_28"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_28">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_28"> (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_28">8</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_31">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_31">9</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_85">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_85">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_85">23</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_106">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_106">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_106">30</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_109">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_109">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_109">30</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_112">PART II - Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_115">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_115">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_115">32</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_118">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_118">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_118">32</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_121">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_121">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_121">32</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_124">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_124">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_124">32</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_127">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_127">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_127">32</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_130">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_130">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_130">32</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_133">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_133">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_133">33</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_136">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib6fee90945e74b97b833695fd82463c2_136">34</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="ib6fee90945e74b97b833695fd82463c2_13"></div><div><span><br/></span></div><div id="ib6fee90945e74b97b833695fd82463c2_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNC0xLTEtMS04MjA5Mg_efd9ff0d-16e6-4f02-901a-51b106b98ed7">165.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNC0zLTEtMS04MjA5Mg_4425a626-34ee-4919-854f-79bf59c0dfdb">258.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNS0xLTEtMS04MjA5Mg_d2035172-1151-4bfd-9bef-07f36c332cab">103.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNS0zLTEtMS04MjA5Mg_7303663c-4556-4dfc-ac45-3cb884904153">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNi0xLTEtMS04MjA5Mg_aa798d60-ce82-49c3-8cf5-d729a99e192e">101.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNi0zLTEtMS04MjA5Mg_dde02d49-474b-4976-8f45-b514d7983c6c">91.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNy0xLTEtMS04MjA5Mg_365d07e6-a05a-44ca-be60-d14a19f06b46">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNy0zLTEtMS04MjA5Mg_5f93c88e-aa1c-429e-9a24-4110b7534db9">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:PrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfOC0xLTEtMS04MjA5Mg_acdeeed4-53f7-422a-b768-882607b9235c">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:PrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfOC0zLTEtMS04MjA5Mg_11dc6499-7d46-4a89-bd00-4b02e9386140">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfOS0xLTEtMS04MjA5Mg_0bfab051-1159-4f4d-b833-11729f333e6a">22.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfOS0zLTEtMS04MjA5Mg_858d6e06-4cbf-4030-9dcd-df6eeb08f83d">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTAtMS0xLTEtODIwOTI_7d15b95b-6f69-49d7-9f9c-0eed72709999">427.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTAtMy0xLTEtODIwOTI_cb4ff5b6-d7cb-4902-ac07-0b575c5fd786">484.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTEtMS0xLTEtODIwOTI_06e15c0e-cd19-4730-b619-8060329d428b">70.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTEtMy0xLTEtODIwOTI_44ccb1d3-c75b-4f64-b77f-aec6147e0452">81.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term marketable investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTItMS0xLTEtODIwOTI_97de2313-44b7-4efb-b7d0-d2c7d1c0ca61">70.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTItMy0xLTEtODIwOTI_82007a54-a257-4986-bac1-807028c96af9">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTMtMS0xLTEtODIwOTI_3219d0ff-9aff-4405-acbc-27ab987b5191">45.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTMtMy0xLTEtODIwOTI_1aae7e30-091d-4e3c-be8a-e2e524726051">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTQtMS0xLTEtODIwOTI_e25ca4c3-a0b4-400d-bc14-7a8551c723f6">393.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTQtMy0xLTEtODIwOTI_2bbde91e-0fc6-419a-8c38-a5ecfdc10402">404.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTUtMS0xLTEtODIwOTI_13aee6e7-c086-4917-b34a-0005b9df2142">238.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTUtMy0xLTEtODIwOTI_1f5a9561-a8f3-488c-8ab8-3a85ec5200df">239.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTYtMS0xLTEtODIwOTI_306ad407-6473-4c3e-81ce-e2519bc54ebb">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTYtMy0xLTEtODIwOTI_ed85fc16-4186-4ab5-a652-ca1253a8f67a">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTctMS0xLTEtODIwOTI_10d91772-7a6c-4d63-a3a5-f49450ceacf3">1,255.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTctMy0xLTEtODIwOTI_ed92aecc-d072-4d56-abf9-de1b904013dd">1,320.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjAtMS0xLTEtODIwOTI_8499419a-842c-47c0-acbd-3accdc1b8e73">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjAtMy0xLTEtODIwOTI_f44ab0a0-ee47-471e-9cb8-e7b4ba21fcd1">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjEtMS0xLTEtODIwOTI_d727c76c-3398-4ac6-a464-d4d277c24629">124.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjEtMy0xLTEtODIwOTI_5f378c96-f0ef-4836-b7c6-ea74181e293b">156.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current maturities of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjItMS0xLTEtODIwOTI_2e1a2c02-fcf4-4302-8344-47b84ea1cb75">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjItMy0xLTEtODIwOTI_d1775fa9-37be-4751-97d7-a86fea68fbc9">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjMtMS0xLTEtODIwOTI_b413ada5-aec4-4788-aee3-446dd7075630">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjMtMy0xLTEtODIwOTI_2c01b1e4-906f-4bd8-a721-a9491c1b0e2d">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjQtMS0xLTEtODIwOTI_a6a61645-ea31-4ab6-8542-bde79e9e0688">166.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjQtMy0xLTEtODIwOTI_50747cf8-0842-49e8-8ac3-2594e41f256e">204.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjUtMS0xLTEtODIwOTI_d8f973fd-8117-45a8-bd2a-1d5a9cd952ee">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjUtMy0xLTEtODIwOTI_b31e2e60-65c0-4ca2-aae5-5b375afb4998">27.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term deferred taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjYtMS0xLTEtODIwOTI_5358c939-0a41-480f-8fb6-b94bc8779865">29.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjYtMy0xLTEtODIwOTI_0195304c-b5d5-4cf9-b7b0-2703cd2a5ceb">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjctMS0xLTEtODIwOTI_08c16d6e-1d63-474c-86e7-ee89a30e09b7">76.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjctMy0xLTEtODIwOTI_40f1c782-984e-4a90-9b76-d9a7ba8d1b29">79.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjktMS0xLTEtODIwOTI_f1e97d09-aed8-4f0f-a025-0778b10a311b">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjktMy0xLTEtODIwOTI_cef5496a-a952-463e-a08f-407b4b88c2e0">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzAtMS0xLTEtODIwOTI_63432da5-9ffa-42ce-81d1-fddf230830a9">305.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzAtMy0xLTEtODIwOTI_f437db7c-d9a9-41ca-984c-d5f1ac040b87">352.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzEtMS0xLTEtODIwOTI_be44953c-3a04-4377-b6bd-95440bc26ea9"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzEtMy0xLTEtODIwOTI_83b2f149-33f7-45b8-bb43-48ac5aa81d6f"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, <ix:nonFraction unitRef="shares" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzMtMC0xLTEtODIwOTIvdGV4dHJlZ2lvbjo5NDNhZjk4MGRiMmU0MWViOTZkOTg2NzJhYTc5ZTM1Nl8xOA_c6c5afa9-55d2-458f-9a9f-a6bf5b2780b4">80.3</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzMtMC0xLTEtODIwOTIvdGV4dHJlZ2lvbjo5NDNhZjk4MGRiMmU0MWViOTZkOTg2NzJhYTc5ZTM1Nl8yNQ_e560e107-5087-4832-b970-3e8b7194ba57">80.0</ix:nonFraction> million shares outstanding at March&#160;31, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzMtMS0xLTEtODIwOTI_f3c7cba5-0f13-4af8-b356-4d6921612045">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzMtMy0xLTEtODIwOTI_ee756ea2-0c34-4911-912b-05ac5f18c960">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzQtMS0xLTEtODIwOTI_6203842a-e1ac-4f4e-9e81-3a1f618c5061">1,231.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzQtMy0xLTEtODIwOTI_2f5e8258-e391-4cd1-8962-721f5b8ce276">1,226.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzUtMS0xLTEtODIwOTI_4cbfa476-c16d-4482-a6d8-838750a5aab8">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzUtMy0xLTEtODIwOTI_9f9edcb2-8714-402f-837e-e71d5d4c08cb">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzYtMS0xLTEtODIwOTI_584490f6-d5bd-45e1-91a1-d529ec744694">274.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzYtMy0xLTEtODIwOTI_53ec25fa-968e-421e-ad59-82a2d6b56dcc">254.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Myriad Genetics, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzctMS0xLTEtODIwOTI_6966b4b3-45c5-4ed2-848a-2424fd612edf">950.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzctMy0xLTEtODIwOTI_46708cab-fa17-4cb2-b323-7cb4aa5f512e">967.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzgtMS0xLTEtODIwOTI_211178e5-83d1-413d-ba45-219c7e3b473a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzgtMy0xLTEtODIwOTI_5618484f-78f8-4756-8d7a-04edb8beff4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzktMS0xLTEtODIwOTI_ccbd7f67-62f7-44eb-bdc9-2ff5f0583f85">950.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzktMy0xLTEtODIwOTI_f4b5cf3a-0e0c-431d-b8c4-5b979273095d">967.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNDAtMS0xLTEtODIwOTI_99cc4121-a4ff-44ba-a557-2289e6446310">1,255.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNDAtMy0xLTEtODIwOTI_d4b21085-6ee6-4ede-9a34-359a8be940b7">1,320.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Operations (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions, except per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:76.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.589%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic testing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icf33e5d604a449409285140d03ecf9c4_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMy0xLTEtMS04MjA5Mg_72d245ac-4f00-4a58-9a35-0ab7c8749752">164.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if0028e3d51994bd79cb5c6bff0d75e18_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMy0zLTEtMS04MjA5Mg_f687c43d-0364-4704-b528-c24ce1d1a0df">159.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7a6fd51a77104485bed5515365b14f90_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfNC0xLTEtMS04MjA5Mg_c5c3c2da-1fab-402e-afec-3501fdf60387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i51af4328f7a04a4b8cac37c1e5d162d6_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfNC0zLTEtMS04MjA5Mg_35ea64cf-6e72-4266-8e79-015ac600238a">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfNS0xLTEtMS04MjA5Mg_a92ffcba-e909-4542-b2e1-b6898b31c3f4">164.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfNS0zLTEtMS04MjA5Mg_3db83525-7b5e-47b5-a102-e0a4d06666cb">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of molecular diagnostic testing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icf33e5d604a449409285140d03ecf9c4_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfNy0xLTEtMS04MjA5Mg_6481e913-5fd1-4037-8542-5cad98659866">48.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if0028e3d51994bd79cb5c6bff0d75e18_D20210101-20210331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfNy0zLTEtMS04MjA5Mg_ee06d912-ee1f-423c-ba61-2807cb2e7816">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7a6fd51a77104485bed5515365b14f90_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfOC0xLTEtMS04MjA5Mg_0ce44e0b-825b-4abe-b05b-b59930ea9631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i51af4328f7a04a4b8cac37c1e5d162d6_D20210101-20210331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfOC0zLTEtMS04MjA5Mg_f630e04e-87f0-4f43-a972-1aea7f53a50b">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfOS0xLTEtMS04MjA5Mg_b0722e66-1764-4d17-bd45-1cfca1d29839">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfOS0zLTEtMS04MjA5Mg_ef49d763-7e7c-41b6-8ce8-9f3e9b8d6d23">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTAtMS0xLTEtODIwOTI_e9e01cde-f4de-4094-a3b5-c0a202c18223">110.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTAtMy0xLTEtODIwOTI_265f57db-1572-4122-be81-f85f0a3e0690">146.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and long-lived asset impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTItMS0xLTEtODIwOTI_f9bd8f9a-a2d5-42ce-a8e1-6638acc7c05d">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTItMy0xLTEtODIwOTI_24301a75-1f4b-4455-a83b-68fcd52f0aed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTMtMS0xLTEtODIwOTI_e893476f-7680-4dde-994c-af3daed10ece">190.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTMtMy0xLTEtODIwOTI_d3171718-b73e-4b6a-ac35-3d0a6cb1628d">219.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTQtMS0xLTEtODIwOTI_eabae140-31a1-422b-b140-c2a41e9a411f">25.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTQtMy0xLTEtODIwOTI_e51a44bf-a5e7-44b4-b010-bda83c65bf4b">46.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTYtMS0xLTEtODIwOTI_53c97875-704d-4a79-954a-4e7ada3697da">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTYtMy0xLTEtODIwOTI_ac4ab547-133b-41bf-894c-15281b796d30">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTctMS0xLTEtODIwOTI_89327339-88de-43af-a306-fe04b3f54400">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTctMy0xLTEtODIwOTI_ed0a80c4-6742-48ad-8d44-aec4b2a345ff">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTgtMS0xLTEtODIwOTI_1a0e98cd-b2f5-4635-98d1-3ca5b4a46f90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTgtMy0xLTEtODIwOTI_998dad7f-1161-4e9a-8763-33bc598e6397">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTktMS0xLTEtODIwOTI_de03e54b-bb13-405b-9dde-e4b2edb49a06">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTktMy0xLTEtODIwOTI_1663d7ad-68dc-4fd1-af9b-6a5773cd77c2">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjAtMS0xLTEtODIwOTI_c2ce459c-0c3b-4faf-b266-e405fffcd711">26.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjAtMy0xLTEtODIwOTI_f17b1095-6f39-4afa-b5de-65dd673e5ae3">49.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjEtMS0xLTEtODIwOTI_9dfdb921-7ba6-4cb8-b126-b639233cdcff">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjEtMy0xLTEtODIwOTI_a2b4cc5c-d527-4b7d-a8b4-8113a4da3485">10.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjItMS0xLTEtODIwOTI_c57d3520-a7bb-433a-b41c-9b3d31503c6f">20.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjItMy0xLTEtODIwOTI_0c8a2cf2-8245-419d-839c-4a21a362477c">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjMtMS0xLTEtODIwOTI_9ae67346-a8b1-48b4-bd37-f7310004fb30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjMtMy0xLTEtODIwOTI_171442de-5996-46a7-b245-5551279431f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjQtMS0xLTEtODIwOTI_5f391c8a-9ace-4598-995b-958f92fac755">20.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjQtMy0xLTEtODIwOTI_7c29eedd-5b2f-41bf-b5b0-57fb734c8599">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjYtMS0xLTEtODIwOTI_13451a5c-49b1-4a98-9705-e3f92a8868e5"><ix:nonFraction unitRef="usdPerShare" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjYtMS0xLTEtODIwOTI_e8fffc03-6389-482c-99ad-3f55a6d46649">0.26</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjYtMy0xLTEtODIwOTI_8887a53e-08e5-45c3-9074-e16e0640c45d"><ix:nonFraction unitRef="usdPerShare" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjYtMy0xLTEtODIwOTI_c1b39c4f-1930-4a08-88b5-8dc1cf74fb5e">0.52</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjktMS0xLTEtODIwOTI_af71815d-3ccb-4714-8e2b-f6bd59454000"><ix:nonFraction unitRef="shares" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjktMS0xLTEtODIwOTI_fd404326-9514-4e7e-9689-de4a9e2260e4">80.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjktMy0xLTEtODIwOTI_c744fdb1-4046-4388-b699-6cdf6380381b"><ix:nonFraction unitRef="shares" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjktMy0xLTEtODIwOTI_d8758162-f924-4531-85ab-d1accb62099a">76.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.605%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfMi0xLTEtMS04MjA5Mg_2efcaca7-e788-43b4-8d19-6398e802a72a">20.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfMi0zLTEtMS04MjA5Mg_08bc693d-af35-4494-b2c0-cd148d138198">39.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss on available-for-sale debt securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfMy0xLTEtMS04MjA5Mg_7f10f61f-f203-4342-891d-56bd76c98f48">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfMy0zLTEtMS04MjA5Mg_404c1106-c92a-4567-88ee-cc3942544490">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in foreign currency translation adjustment, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfNC0xLTEtMS04MjA5Mg_e1b7706b-6264-4a30-8476-5e91d443d29d">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfNC0zLTEtMS04MjA5Mg_72b6f733-baa2-4c5e-9770-3620f3b42b70">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfNS0xLTEtMS04MjA5Mg_c454c3c3-d770-4e2e-ae9a-323665067a32">23.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfNS0zLTEtMS04MjA5Mg_747d3e5f-a19a-4ff6-8ac6-65fa1f2006ec">40.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfNi0xLTEtMS04MjA5Mg_f60b186d-b5d9-4fc6-8f41-195762ab05f5">23.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfNi0zLTEtMS04MjA5Mg_6788cc16-fb3d-4f58-a9f4-b075fdf8f681">40.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common<br/>stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Myriad Genetics, Inc.<br/>Stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALANCES AT DECEMBER 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib08aef4ce0a84366ae13a13964bae0a2_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMS0xLTEtMS04MjA5Mg_a377bf1c-f56b-43ed-91e0-7812cfc78ab9">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i778ef826320848759f1d194633ed0c53_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMS0zLTEtMS04MjA5Mg_5a51f0eb-a026-45f1-9d67-670c0851c0d5">1,109.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i492d83c9f93f475893f5e08b0f651c9e_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMS01LTEtMS04MjA5Mg_696937dc-ed45-41d2-a6ef-42347a80176c">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1ea1b38b6fd442f28bbfc072c2cbbf70_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMS03LTEtMS04MjA5Mg_fd378e83-f485-4f18-b697-7e1f15125924">227.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i38f47e17df9c466eb0964b81d156f640_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMS0xMy0xLTEtODIwOTI_d7d26086-0c79-4d49-8a5b-3bff461d3f9d">881.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib5272217093641ce807e8a88daa1cdd8_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMi0zLTEtMS04MjA5Mg_8bb6bef7-3d2d-478e-b53b-026469d30fb5">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMi0xMy0xLTEtODIwOTI_63fc42d4-496c-46e4-bc02-60fb92bdea94">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5272217093641ce807e8a88daa1cdd8_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMy0zLTEtMS04MjA5Mg_6521326a-a477-49a5-a168-1f1f02c0293f">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMy0xMy0xLTEtODIwOTI_227efe68-d8fc-477d-a8d9-49a2e7ab4fd2">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i665db2c7846646668f3cef8865847df8_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfNS03LTEtMS04MjA5Mg_17520305-3ed6-4d92-b1f2-3ce815f5ac20">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfNS0xMy0xLTEtODIwOTI_04f23681-5f34-4e67-a13b-a4b3528889ee">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if3215774ecd84e0d9af76636f9dec725_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfNy01LTEtMS04MjA5Mg_50b3dac3-cbf7-489c-a4b4-1d3c38418b4e">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfNy0xMy0xLTEtODIwOTI_7c8f5e2a-84e3-48f2-8ec6-788f4e592ea1">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALANCES AT MARCH 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibca09dd596a045b28ee64d75c60c6fa3_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfOC0xLTEtMS04MjA5Mg_27ae5b22-1c0c-4fc2-bfbe-383c2acc22d3">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i51360db4a9f443ecb44b43e6f565af3c_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfOC0zLTEtMS04MjA5Mg_b335e4a7-f6a6-4ffa-bf13-a42847bdda88">1,144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i07d7d32725ac4f4c924775a73475ec21_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfOC01LTEtMS04MjA5Mg_67d8f633-f59a-406a-a06c-33fe3fa4e3e3">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i708aff24e984491496d2d81e7aeae298_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfOC03LTEtMS04MjA5Mg_b6f688c2-4bea-4629-b084-312803da49f5">266.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c1c491ce07b46bf981a8c437b57ebe5_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfOC0xMy0xLTEtODIwOTI_a4eba350-de88-4b27-b9ba-8f027ccef3dc">875.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALANCES AT DECEMBER 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65bcf7eb7d084073a1d31f6c3266039e_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjAtMS0xLTEtODIwOTI_d21ad9fe-5634-4de8-b7c6-23fbb544dadd">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib058dc224c7c47e98c2cf75604eea5f2_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjAtMy0xLTEtODIwOTI_244c529a-0fc4-4d4b-af54-5d34358fdfc7">1,226.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9fdbf8c5ce07414fae885bf9107824e7_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjAtNS0xLTEtODIwOTI_70b14a6c-52b2-457e-8503-f91ba1f8064a">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ca9e1f471d94034b7814953ffe2f26a_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjAtNy0xLTEtODIwOTI_f2ac1083-da27-49b5-a47a-22c8a8b3dd1b">254.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjAtMTMtMS0xLTgyMDky_e22fc215-b106-4f0b-aa01-03166d7eb1f6">967.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia8a8f0a93ffd45eb9e88163c16f0d327_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjEtMy0xLTEtODIwOTI_ec7a205a-eaf9-44c7-bd33-b989dd0780d6">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjEtMTMtMS0xLTgyMDky_3e9b72c9-adcc-44e6-b9d0-55269fd7a3e4">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8a8f0a93ffd45eb9e88163c16f0d327_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjItMy0xLTEtODIwOTI_d28285a2-e58f-4713-9218-91796a68f619">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjItMTMtMS0xLTgyMDky_218a83ec-0051-414c-bbac-97f56330447a">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i812ea76259f24a58ae8fc86475a6e3e3_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjMtNy0xLTEtODIwOTI_717db404-1b07-4a5b-8d39-14f8819b9dc9">20.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjMtMTMtMS0xLTgyMDky_305da53e-b7d7-4b72-aea5-ee09ebe0282e">20.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4a8239ce03e247a09242f5f72f3b8f29_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjQtNS0xLTEtODIwOTI_e703ee83-4482-4c16-b295-d173d6656ec4">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjQtMTMtMS0xLTgyMDky_3417bc3d-3d4c-4c75-9728-2e2a13a0be38">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALANCES AT MARCH 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib37c60806afc4e62a8fcc62ed49d169e_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjUtMS0xLTEtODIwOTI_7812ea20-b590-4573-b22a-33ab740ead86">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i652588d3da5a43d2b2cf4ef648e7a8e6_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjUtMy0xLTEtODIwOTI_0286c8f7-3fc3-4bed-b5eb-239bca8c4e54">1,231.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9bb1c337d99746fcab9d1d8cfad76b30_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjUtNS0xLTEtODIwOTI_30f0a1e3-6df4-4569-b9ac-c826d5cdff0e">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i048b28f83191461ca446a385004cd1f5_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjUtNy0xLTEtODIwOTI_0fe17720-3bf8-4283-820d-63bc455158cf">274.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjUtMTMtMS0xLTgyMDky_b274aa07-ffad-4604-adb6-5e06c00f8db7">950.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMy0xLTEtMS04MjA5Mg_3df0c53a-ac7e-46f8-a097-375fdd0ed7c6">20.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMy0zLTEtMS04MjA5Mg_d44b013b-fa0b-4678-9e89-05f91f061bd9">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNS0xLTEtMS04MjA5Mg_9779ffd8-518b-418e-86e0-fb352e5a799a">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNS0zLTEtMS04MjA5Mg_a87d437e-b6ac-4c00-ae65-db2a552da1c2">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="mygn:NonCashInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNi0xLTEtMS04MjA5Mg_6b867114-897c-4a36-9e5f-19fce19b8355">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="mygn:NonCashInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNi0zLTEtMS04MjA5Mg_275bdc52-61c6-4735-b834-9f5ce20e6305">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNy0xLTEtMS04MjA5Mg_53e8f2e8-45c6-4710-b86e-428fe7dbb45a">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNy0zLTEtMS04MjA5Mg_ff02dfe4-1b13-4c92-9451-bf8df7eff454">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfOC0xLTEtMS04MjA5Mg_9b776c2b-28cc-4540-b1ad-5bb969575d12">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfOC0zLTEtMS04MjA5Mg_4dc98e42-53a2-471e-841f-e0d2f9b1ecb4">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfOS0xLTEtMS04MjA5Mg_8e67dc01-84b3-402e-b653-9ebb54499bbe">5.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfOS0zLTEtMS04MjA5Mg_371d1794-872b-464b-baac-2b10bfd50d9f">11.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="mygn:IncreaseDecreaseInUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTAtMS0xLTEtODIwOTI_68dc6b3f-113c-450b-a797-0ce32ed262e0">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="mygn:IncreaseDecreaseInUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTAtMy0xLTEtODIwOTI_2c1d86e0-4083-41cb-bd00-b147a2eefd06">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impairment of goodwill and long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTMtMS0xLTEtODIwOTI_16de746d-9f5a-4d21-9206-399d243ddccf">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTMtMy0xLTEtODIwOTI_72152101-6a62-462c-b57e-5a47650e8143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTYtMS0xLTEtODIwOTI_43f7a7d4-e73d-4f9e-8a82-5f049bf10877">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTYtMy0xLTEtODIwOTI_4d56ca78-011a-49a8-aade-1de2af4a6dc3">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTctMS0xLTEtODIwOTI_174cff9b-77b5-4c3a-84bd-e30480ac6328">10.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTctMy0xLTEtODIwOTI_e39aa92a-8ab7-46bf-8109-172b137931b8">4.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTgtMS0xLTEtODIwOTI_d120422b-76c6-4e7f-8639-92d9eef17dfc">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTgtMy0xLTEtODIwOTI_210d1dbf-028a-4f0a-bab9-ee152fb5d1fb">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTktMS0xLTEtODIwOTI_e2ca456e-00a1-47e7-9e58-53252c816b6f">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTktMy0xLTEtODIwOTI_2b9b0531-3a44-4e98-8917-e622e0a05740">90.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjAtMS0xLTEtODIwOTI_f8dc46f0-d921-4ccd-a602-b2859f6909db">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjAtMy0xLTEtODIwOTI_92518aec-1025-4a4e-b5ce-8a9a6aff638f">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjEtMS0xLTEtODIwOTI_dae03076-719a-405d-81e0-bdc243aba168">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjEtMy0xLTEtODIwOTI_a4eeadf8-8cbe-426a-923a-ac3c7d233845">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjItMS0xLTEtODIwOTI_2a19942d-e4c2-4320-8e71-f49cf4144cd2">35.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjItMy0xLTEtODIwOTI_91780fc8-79cb-49f7-b2b4-1c49c1d31451">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjMtMS0xLTEtODIwOTI_5a626f11-cd0b-40de-8024-d59de8f9c533">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjMtMy0xLTEtODIwOTI_f2350c0f-de44-4d4d-b7a8-1e49947fbad9">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjQtMS0xLTEtODIwOTI_9a1c21eb-50e6-4c48-b856-9c5444e67c39">46.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjQtMy0xLTEtODIwOTI_8d56daeb-0789-4bd1-92d5-47dcc50f23ba">71.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjYtMS0xLTEtODIwOTI_f9a9e011-911b-477f-b232-4e6ccaea3544">6.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjYtMy0xLTEtODIwOTI_d0194c26-e80a-4f7c-872e-6c8bf7fc3f46">7.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of marketable investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjgtMS0xLTEtODIwOTI_df2dbf03-043b-4d86-84f6-48841910c7e2">52.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjgtMy0xLTEtODIwOTI_2810ebf7-dde3-4cac-9baf-5c28e94499d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from maturities and sales of marketable investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjktMS0xLTEtODIwOTI_c604fdbb-0c76-4e7f-97cb-5ac990fc6bed">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjktMy0xLTEtODIwOTI_05d718a0-3230-4efb-bda7-c834f4476082">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzAtMS0xLTEtODIwOTI_909e19c3-bead-491f-8849-6d35928579ee">41.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzAtMy0xLTEtODIwOTI_f79738f7-0459-4192-b314-64d8ef9d87cc">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from common stock issued under stock-based compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzItMS0xLTEtODIwOTI_15981347-d09a-433f-882c-72f4d4aeb23f">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzItMy0xLTEtODIwOTI_780abfed-e8b0-4c10-8cf7-15d7e3a5d8b1">26.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of tax withheld for common stock issued under stock-based compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzMtMS0xLTEtODIwOTI_2d96124f-6530-4611-80b7-e4550ccb006e">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzMtMy0xLTEtODIwOTI_adb0b948-d4ac-4022-b9a2-5ea148882883">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of contingent consideration recognized at acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzQtMS0xLTEtODIwOTI_861e59fe-31d5-4d28-a1ee-c3cab33a9a21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzQtMy0xLTEtODIwOTI_3d6eda91-8b44-4613-99e4-c5df47283757">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fees associated with refinancing of revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzUtMS0xLTEtODIwOTI_8f801b67-4722-459f-be0e-260f2d50c6dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzUtMy0xLTEtODIwOTI_dd6f533b-a4d8-4213-b633-e3700734eead">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Repayment of revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzYtMS0xLTEtODIwOTI_b3e904f0-5090-4179-9df4-0b6043025016">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzYtMy0xLTEtODIwOTI_d1e47115-a64f-4f10-ae7b-363d1ed6c4f0">70.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzctMS0xLTEtODIwOTI_8f264699-b278-4bb8-b189-cae543714089">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzctMy0xLTEtODIwOTI_65e7926e-6569-4e9e-bbbb-cd16ddcabcdf">48.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzgtMS0xLTEtODIwOTI_ceed73ba-f692-4f75-b880-bdbdba596847">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzgtMy0xLTEtODIwOTI_45c0b8c3-fd63-4912-97c4-244e629aa670">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNDAtMS0xLTEtODIwOTI_909bf367-0d27-434d-9c50-70c90527c1b2">93.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNDAtMy0xLTEtODIwOTI_a1ed847f-94a3-4f7c-8dd6-b44e2409e8af">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNDEtMS0xLTEtODIwOTI_39d908c5-8a4a-4206-8599-aa41e5a3caad">258.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i38f47e17df9c466eb0964b81d156f640_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNDEtMy0xLTEtODIwOTI_9236bd65-0309-4c14-b9f4-a6b62275bb88">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNDItMS0xLTEtODIwOTI_3d520b89-dbb3-4f2e-bd6a-9bf53b573e9b">165.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c1c491ce07b46bf981a8c437b57ebe5_I20210331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNDItMy0xLTEtODIwOTI_2447cf35-a9cd-4208-84d1-3e849ac927cd">148.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div id="ib6fee90945e74b97b833695fd82463c2_34"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNC9mcmFnOmJjZGU2YjlmOGNiNTQ2YjQ4MWE2ZGNkNDdiNDQ3YTMyL3RleHRyZWdpb246YmNkZTZiOWY4Y2I1NDZiNDgxYTZkY2Q0N2I0NDdhMzJfNDQ2Mw_d53acbb3-e7a0-4140-8b2c-945a3375b70f" continuedAt="ia2c7f295f07842a2a50a27e760b7c06b" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="ia2c7f295f07842a2a50a27e760b7c06b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad Genetics, Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;Myriad&#8221;) is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad develops and commercializes genetic tests that help assess the risk of developing disease or disease progression or guide treatment decisions across medical specialties.  The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021, by providing pharmaceutical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company currently operates as a single reporting segment. The Company&#8217;s corporate headquarters are located in Salt Lake City, Utah.</span></div><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNC9mcmFnOmJjZGU2YjlmOGNiNTQ2YjQ4MWE2ZGNkNDdiNDQ3YTMyL3RleHRyZWdpb246YmNkZTZiOWY4Y2I1NDZiNDgxYTZkY2Q0N2I0NDdhMzJfNDQ2MQ_411e7750-8004-4521-84e7-ace257ff1592" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company&#8217;s audited Consolidated Financial Statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;Form 10-K&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three months ended March&#160;31, 2022 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically experienced seasonality in its testing business. In the quarters ended March 31, the Company has  typically experienced a decrease in volumes due to the annual reset of patient deductibles. Additionally, the volume of testing is  negatively impacted by the summer season, which is generally reflected in the quarter ended September 30th. The quarter ended December 31 is generally strong as the Company typically experiences an increase in volumes from patients who have met their annual insurance deductible. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the ongoing COVID-19 global pandemic, including variants of COVID-19 (&#8220;COVID-19&#8221;), seasonality may not follow the same pattern as in prior years. Volumes and results of operations were impacted negatively in calendar year 2021 and early 2022 by COVID-19. As such, the Company&#8217;s year over year results may not be comparable. Management continues to monitor the impact of COVID-19 on the Company&#8217;s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the variants of COVID-19 that have surfaced around the world, the Company is not able to fully estimate the effects of COVID-19 on its results of operations, financial condition, or liquidity for future periods.</span></div><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNC9mcmFnOmJjZGU2YjlmOGNiNTQ2YjQ4MWE2ZGNkNDdiNDQ3YTMyL3RleHRyZWdpb246YmNkZTZiOWY4Y2I1NDZiNDgxYTZkY2Q0N2I0NDdhMzJfNDQ2NQ_8a229c41-9881-4b7c-87c5-c0d2ba7e8f24" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period's presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders&#8217; equity, cash flows from operations, or net loss for the period.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ib6fee90945e74b97b833695fd82463c2_37"></div><div style="padding-left:18pt;padding-right:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNzE5Nw_4d1f547c-138a-456f-9e99-6e45c999f2dc" continuedAt="ib416c9739f8c48b9bbbc9e462a4a9b51" escape="true">REVENUE</ix:nonNumeric></span></div><ix:continuation id="ib416c9739f8c48b9bbbc9e462a4a9b51" continuedAt="i0776e6c88a88476aa420aa3d84363787"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad primarily generates revenue by performing molecular diagnostic testing. Molecular diagnostic revenues are derived from the following categories of products: Hereditary Cancer (myRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, EndoPredict, and Precise), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp; Co. KG (the &#8220;Clinic&#8221;) in February 2020, respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Molecular diagnostic revenues. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.</span></div><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNzE5OQ_0c2ed63f-7b64-4a34-81d3-c1b2d551feba" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents detail regarding the composition of the Company&#8217;s total revenue by type and by U.S. versus rest of world (&#8220;RoW&#8221;):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.200%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia1519c8391b842399d132e8fd6ef21f2_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNC0xLTEtMS04MjA5Mg_ea0e18e2-3e40-4076-9084-39201755f4b8">60.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8eb5af63f8b8413cbb2c5ccef8a23335_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNC0zLTEtMS04MjA5Mg_3558dad1-8b98-490a-9e11-21671b82101e">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3a00625e25ad4bb19d387987d29c1b37_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNC01LTEtMS04MjA5Mg_52fcfb07-ddaa-4300-86c5-74774b45bfb8">70.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3a0861127f384074bea6194dcadccff8_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNC04LTEtMS04MjA5Mg_7bedba9f-c5bf-4c1c-9d7f-e9f21e94a46f">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i168a53dec81546e9841245e8c2ecad66_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNC0xMC0xLTEtODIwOTI_6b53c010-b3e1-47a9-8629-33cf99fb0bdc">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i71aaffb802404ab2bd2254ac4935374c_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNC0xMi0xLTEtODIwOTI_26b6073d-fc8b-4162-928a-e9e6165ad280">76.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic48d92006ed6462eaddb141061226da3_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNS0xLTEtMS04MjA5Mg_c2111cd8-6850-48ff-b2e9-c582cae66b24">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb41f2d374db4b62bf6fca7d3c8b87a7_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNS0zLTEtMS04MjA5Mg_bf5c7670-7127-44eb-89ce-f86764c0b7f4">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic124314e94e44fcfbb72df064864b2f6_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNS01LTEtMS04MjA5Mg_90801345-0306-45a8-bcc0-de7d43959bee">32.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5ef67c76df944005bcce30f068506e34_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNS04LTEtMS04MjA5Mg_2162cdd1-bada-4885-83df-d0bc5d4c5058">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f84ba2616749a88b3f961574d23e09_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNS0xMC0xLTEtODIwOTI_e0eb4474-c96c-4839-b645-3f7192c61d53">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie57f1eaf9e8d430c860af6b4ed687e97_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNS0xMi0xLTEtODIwOTI_e09abf0d-bfb8-4424-95c7-325841345185">31.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30c094758e7a4db5b59bcf76bcabd03f_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNi0xLTEtMS04MjA5Mg_e843e9dd-025f-48a1-bcb1-5597775fafbb">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f731ae454a94bd9a075b65ce61d8ee5_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNi0zLTEtMS04MjA5Mg_f31c0b6e-1d1a-4c08-9220-c28a41b8d4ea">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie79831c4c3804d78a024b6129000343b_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNi01LTEtMS04MjA5Mg_384dca7f-92cf-4b01-8c67-5063506a40ea">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifdf8e565250c4b04bab9ef9d5c4ff45f_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNi04LTEtMS04MjA5Mg_c8a76c9e-9be7-4f79-bde9-4520627926e7">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b03a6430a624a6b8f8e6bcd7cf82f56_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNi0xMC0xLTEtODIwOTI_3b37aac5-5453-4e72-9319-d7acbe4e82b6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i97fe976f531f43a09cf8064128efdc2f_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNi0xMi0xLTEtODIwOTI_4d96779d-62e6-4ead-9ae5-52888054085c">23.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i057ec40f04944ea984f6ecb96adffb38_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNy0xLTEtMS04MjA5Mg_70c6f157-66e7-45b4-b096-4d7c84ee49d5">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76e2445fd4247ce8565ace69a07cb58_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNy0zLTEtMS04MjA5Mg_a196ba17-8e38-48d3-be18-27faf4af176a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1b860be39e224a04a1a68674e503b529_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNy01LTEtMS04MjA5Mg_949a0184-8c85-40e9-8a35-9e31f976ea50">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i79ddeaedfccb40d88221e0e2d74fa96d_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNy04LTEtMS04MjA5Mg_4ace4cf3-a97b-4db1-a722-6aab3e1d059e">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87691cf56a19478eb1f6544cf57295c9_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNy0xMC0xLTEtODIwOTI_1d8acf4c-8227-4b7e-a5c3-ee9cef3b49b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e4cecae202247c880970efaf5f9ee3e_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNy0xMi0xLTEtODIwOTI_5d669252-07fc-42fe-88fa-bb8770bbdbbc">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3b19f57c78b44ad683bb1b4bd44e5f62_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOC0xLTEtMS04MjA5Mg_17fa574b-b9fc-4631-80c9-4a67415ab609">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82485441ef944386996ccf0d6e192050_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOC0zLTEtMS04MjA5Mg_03c2c3fa-a594-47ae-b181-c980ad566bb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i87f3f03808324e1b8cda4b6e447e0038_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOC01LTEtMS04MjA5Mg_5841c885-2cda-4494-a1ab-396e3904b9c2">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8a108bb0e4d641a9ba014a3fb5413714_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOC04LTEtMS04MjA5Mg_d70185bd-bcac-4d32-b0a3-ca72091c64cb">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea03d11e0304ccfb26dc185eac9a3d0_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOC0xMC0xLTEtODIwOTI_37369bb5-a680-47bb-a789-86f1886b1c7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3f29514d91043cb8814629006fe138c_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOC0xMi0xLTEtODIwOTI_447c2608-58e9-4106-addf-e92ae33123fc">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d668be165244dd1be2739e4bddd8d6b_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOS0xLTEtMS04MjA5Mg_80a6cacf-4553-4836-8c78-39766cd80c28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic1e28fc7eb7c417ca6677b3b6e228c4e_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOS0zLTEtMS04MjA5Mg_653a8435-7f85-4e7f-b0e8-2eab818f8a03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54fe3cc0d3b14d139aadd0a94943b49c_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOS01LTEtMS04MjA5Mg_a4bfa7fd-9fd4-43aa-911a-cd3fadb06d7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03a8be3329254025993297729bd21abe_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOS04LTEtMS04MjA5Mg_45e31eb6-d850-4ae9-b0ce-c16596c5cbf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if7b88a6e741b4f37bbb83847c7547ff3_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOS0xMC0xLTEtODIwOTI_8f72bc83-b850-4295-b166-3280845483d0">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i45649325d565477e9e05700b9cf7f061_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOS0xMi0xLTEtODIwOTI_a31f43f9-2b32-4739-8b7d-e584f65a8ea4">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i40fb715741a94f7e965b632953843495_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTAtMS0xLTEtODIwOTI_c5402ecf-6498-4f9b-9009-5346771c4c60">141.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i99e56a4a61a6448ca8284c81c5072352_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTAtMy0xLTEtODIwOTI_73dbd270-8cb2-448f-85b7-acc7bc5294ac">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icf33e5d604a449409285140d03ecf9c4_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTAtNS0xLTEtODIwOTI_4dfa7fac-0ad0-49f6-8287-f15b8d911bed">164.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i48867d19db404992b557cd1387f4e47f_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTAtOC0xLTEtODIwOTI_e8fe624b-6f64-4fdc-8d21-237c1a9a194b">141.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i87a32a4bbc484c8ab0294925b08b160c_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTAtMTAtMS0xLTgyMDky_231dd416-9265-412c-8b96-923b2930c03c">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if0028e3d51994bd79cb5c6bff0d75e18_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTAtMTItMS0xLTgyMDky_49783b57-4af3-42e3-b7fe-a3a935056960">159.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7abf3b2881464b55837ca122fffaf119_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTEtMS0xLTEtODIwOTI_7ad1592f-15c2-4d46-a36d-e785f43c2c82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3255bff47e5459f88724051e2d8e564_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTEtMy0xLTEtODIwOTI_ff19fd27-e7ca-4f75-bbd2-7c3d09d0e211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7a6fd51a77104485bed5515365b14f90_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTEtNS0xLTEtODIwOTI_fc3f7d6e-cb92-43dd-8092-37562ed373e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if3a1622be8904dc6a17e7260d663d789_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTEtOC0xLTEtODIwOTI_36ea3076-7869-43f1-b54c-6051ac5e786b">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba63cbfb3f734a24bab843e8ad4d779e_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTEtMTAtMS0xLTgyMDky_61e0f534-5cb9-45f9-a293-39dde388ac98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i51af4328f7a04a4b8cac37c1e5d162d6_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTEtMTItMS0xLTgyMDky_036f290c-b313-4453-b79e-59dff1c73858">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic8dbe812816b48cb830e84114c6d8f60_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTItMS0xLTEtODIwOTI_5ca16186-bde2-4c37-b607-53b36838bb83">141.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibda7b5c57b0c429db2fdc77635ae5e5c_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTItMy0xLTEtODIwOTI_70820630-c641-4610-bf13-2e7add94f5a0">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTItNS0xLTEtODIwOTI_9d4dab69-9ec2-4696-a335-fa65bc8ba6de">164.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ca0e6bc0455492dbe206a7d48a02709_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTItOC0xLTEtODIwOTI_80755018-c849-456f-adb9-47cca4bfb5fa">154.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29edbbeae1f74f208e45c112f01268c7_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTItMTAtMS0xLTgyMDky_55ed58d3-c760-4d5c-a34a-77ff501bc9cd">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTItMTItMS0xLTgyMDky_8df97989-cc32-45c5-a565-2e4df7a30954">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company&#8217;s performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During the fiscal year ended June 30, 2020, the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="ied55de41f92a4292af6d62bd5c0088d0_D20190701-20200630" decimals="-5" name="mygn:CARESActOf2020MedicarePaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfMjAzMA_d168fda2-96e4-4e2e-b49d-f83da40fe4ee">29.7</ix:nonFraction> million in advance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments were applied against services performed in April 2021 and continued until the funds previously received were fully earned, which occurred during the quarter ended March 31, 2022. <ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNzIwMA_e6eaf046-8db3-4a8f-89f3-13b59a51f7b9" continuedAt="i093fcdf1157549f8b7d4cd8c6be3a56e" escape="true">A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:</ix:nonNumeric></span></div><div><ix:continuation id="i093fcdf1157549f8b7d4cd8c6be3a56e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue - beginning balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfMi0xLTEtMS04MjA5Mg_91296977-c01d-40e6-84cc-951937d52eb5">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i38f47e17df9c466eb0964b81d156f640_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfMi00LTEtMS04MjA5Mg_7a6cfa80-8408-480a-bdc8-7b23d1de79d3">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfMy0xLTEtMS04MjA5Mg_6a64fbca-c486-46f5-8c7d-828a55e89d3e">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfMy00LTEtMS04MjA5Mg_43672aac-ca46-4c4a-83c7-ba913bdf853d">6.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="mygn:ContractWithCustomerLiabilityPrepayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfNC0xLTEtMS04MjA5Mg_73ba45c3-742b-4b4c-ada0-3084eb5241f3">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="mygn:ContractWithCustomerLiabilityPrepayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfNC00LTEtMS04MjA5Mg_20d902e2-15bc-4d36-a7ad-738fd2e3b1f3">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue - ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfNi0xLTEtMS04MjA5Mg_c3100a9a-eb91-4eba-aa13-c1f6c9e9fa44">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c1c491ce07b46bf981a8c437b57ebe5_I20210331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfNi00LTEtMS04MjA5Mg_bb4e5448-a36c-4c83-9c4a-88e6389e055e">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 606, Revenue from Contracts with Customers, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#8217;s right to payment is in an amount that directly corresponds with the value of the Company&#8217;s performance to date. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><ix:continuation id="i0776e6c88a88476aa420aa3d84363787"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third party payors. During the three months ended March 31, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNDkzOA_f9f95db5-1f23-4c6e-9440-8352383dccb3">12.4</ix:nonFraction> million in revenue, which resulted in a $<ix:nonFraction unitRef="usdPerShare" contextRef="i9bc19c6cc66c4ff9a3b4c1f8519220c4_D20220101-20220331" decimals="2" name="mygn:IncreaseDecreaseInEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNDk5NA_811795fe-6a5e-44b9-adfa-a503c8487fc0">0.12</ix:nonFraction> impact to earnings per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, <ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="INF" name="us-gaap:CapitalizedContractCostGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNTYxMw_7558f6df-0067-4ded-af8a-6bce73332c15">no</ix:nonFraction> costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare which represents greater than 10% of its revenues. Revenues received from Medicare represented <ix:nonFraction unitRef="number" contextRef="if788ce35f1a7443780443d8285c4dabf_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNjc4Nw_bea6fae0-229d-4cea-8745-6aa79cbffbaf">13</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="icb95dc894d0d4604b1d478d160dbf2ce_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfMTA5OTUxMTYzNTAwMg_a6647bc0-f832-4736-b78f-9c19a77e0996">19</ix:nonFraction>% of total revenue for the three months ended March&#160;31, 2022 and March&#160;31, 2021, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#8217;s customers as well as their dispersion across many geographic regions. No payor accounted for more than 10% of accounts receivable at March&#160;31, 2022 or December&#160;31, 2021. The Company does not require collateral from its customers.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div id="ib6fee90945e74b97b833695fd82463c2_40"></div><div style="margin-top:12pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RleHRyZWdpb246N2Y3M2E2OTllZmNiNGYzZmFjMjExYTQ1MGIxNDUwMzdfNjEz_b777aa53-b722-416c-9205-c22c6fa3dc2b" continuedAt="i93be6acd7dc44af284ecf578331d567a" escape="true">MARKETABLE INVESTMENT SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i93be6acd7dc44af284ecf578331d567a"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RleHRyZWdpb246N2Y3M2E2OTllZmNiNGYzZmFjMjExYTQ1MGIxNDUwMzdfNjE0_4df01f4f-fcb5-4004-99c8-6b5e74598f71" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i136db30e02474345827ada253c52a3dc_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMy0xLTEtMS04MjA5Mg_fea13666-4e6b-4fd0-ac5e-22335fce02e1">138.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i136db30e02474345827ada253c52a3dc_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMy03LTEtMS04MjA5Mg_4361d3b3-1136-4819-a843-1f4c2e4a86e2">138.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a42c624b75245bcac04b9a7d1f99fdd_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNC0xLTEtMS04MjA5Mg_caee01ae-b2d7-4512-b273-9307ea4c5a23">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a42c624b75245bcac04b9a7d1f99fdd_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNC03LTEtMS04MjA5Mg_778c7ee2-32ba-4b1f-afcf-21358ec281c0">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNS0xLTEtMS04MjA5Mg_b5375a03-9e39-4a3e-81b4-b6705eb60952">165.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNS03LTEtMS04MjA5Mg_f32955a7-f705-4803-bb4e-db246281d012">165.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i079b9de7e87d46e9bcccd402328b76f2_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNy0xLTEtMS04MjA5Mg_69eb14e3-3fd2-4387-97e2-73b5950f5869">109.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i079b9de7e87d46e9bcccd402328b76f2_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNy0zLTEtMS04MjA5Mg_7bec30cb-8833-49d0-ab43-d9a04f814b03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i079b9de7e87d46e9bcccd402328b76f2_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNy01LTEtMS04MjA5Mg_7bad139e-19f5-4f07-8ae7-cfd2e0b08a5b">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i079b9de7e87d46e9bcccd402328b76f2_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNy03LTEtMS04MjA5Mg_4bd0d83e-d940-422f-aa5b-cd26b8170f6b">108.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3979e6cb59c140e695831c1612356572_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOC0xLTEtMS04MjA5Mg_70e8541d-2237-4277-b37d-a251286503fe">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3979e6cb59c140e695831c1612356572_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOC0zLTEtMS04MjA5Mg_2bffcf82-d148-45d5-a812-7796f0159bb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3979e6cb59c140e695831c1612356572_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOC01LTEtMS04MjA5Mg_3e0bb531-0375-4dd6-991d-ac9e73bf8b8e">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3979e6cb59c140e695831c1612356572_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOC03LTEtMS04MjA5Mg_af512f17-0daf-4ca5-92d4-5194b5a012e6">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i33295928e5bd414aada50cf100d5946c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOS0xLTEtMS04MjA5Mg_c8f9af94-29d3-4f48-9ec4-795e41dfa82e">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i33295928e5bd414aada50cf100d5946c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOS0zLTEtMS04MjA5Mg_ab0d236a-07de-472c-aafb-544e3b760d37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i33295928e5bd414aada50cf100d5946c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOS01LTEtMS04MjA5Mg_1676a00a-937b-4ab7-8f2b-e60ff754a965">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i33295928e5bd414aada50cf100d5946c_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOS03LTEtMS04MjA5Mg_e26435e8-916c-47fe-9c93-79d97e42f3b4">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29a7ee8981794d99b60509cd1fbedcf6_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTAtMS0xLTEtODIwOTI_3a5906a3-3af8-411d-9e0a-267a258259df">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29a7ee8981794d99b60509cd1fbedcf6_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTAtMy0xLTEtODIwOTI_a7ec0aba-e8d1-4adf-bba6-f2a0d99ab5e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i29a7ee8981794d99b60509cd1fbedcf6_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTAtNS0xLTEtODIwOTI_ebc2b779-a53f-4bb6-b323-fad3a47da6c2">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29a7ee8981794d99b60509cd1fbedcf6_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTAtNy0xLTEtODIwOTI_9ac5dd0a-fcec-4826-b409-62eef0e236e6">26.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="mygn:InvestmentsAndCashAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTEtMS0xLTEtODIwOTI_a7ddb3b0-33c5-4fd4-abd8-ea476d2989d3">340.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTEtMy0xLTEtODIwOTI_82b97f91-af4f-4ea5-addd-4ecdba66ad47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTEtNS0xLTEtODIwOTI_8db1f971-fbbc-48a7-b193-35ef9945df80">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTEtNy0xLTEtODIwOTI_7b3d5473-dcc5-4432-b303-e08e3f33cd38">339.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3bd84c1ecd394413b497049a3d8c0482_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMy0xLTEtMS04MjA5Mg_84fac36f-c64a-4ba9-bc34-8139b1d0e637">195.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3bd84c1ecd394413b497049a3d8c0482_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMy03LTEtMS04MjA5Mg_5694e26b-94dc-42e8-9f55-847a6c40b04c">195.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i11689e851c8f4f9a9804225d7cafc5bd_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNC0xLTEtMS04MjA5Mg_79f33b6b-f272-4aad-9ca6-2a56d6f64c7a">63.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i11689e851c8f4f9a9804225d7cafc5bd_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNC03LTEtMS04MjA5Mg_7b552155-d21f-4836-b447-0a77252463ca">63.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNS0xLTEtMS04MjA5Mg_e269f4fb-7a1e-4331-829f-62449918bbac">258.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNS03LTEtMS04MjA5Mg_67d22d2c-af5f-42d2-822b-2f054886cc02">258.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i353c741ab7484eb590076cce6cf8785f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNy0xLTEtMS04MjA5Mg_0490738b-aa91-4df0-872d-f570e72668f0">105.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i353c741ab7484eb590076cce6cf8785f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNy0zLTEtMS04MjA5Mg_4dd6a7e3-95bb-4c12-80b8-6529b562e5b5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i353c741ab7484eb590076cce6cf8785f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNy01LTEtMS04MjA5Mg_13da0aee-9f41-4b7f-a3e1-0b9cd303be9d">0.2</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i353c741ab7484eb590076cce6cf8785f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNy03LTEtMS04MjA5Mg_5104bb2e-acdd-4a99-974e-009b78edff99">105.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia61c6cbe23264dc3937f411e7be9e941_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOC0xLTEtMS04MjA5Mg_0ac25e4c-c340-489b-a1ab-18301e20cabe">16.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia61c6cbe23264dc3937f411e7be9e941_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOC0zLTEtMS04MjA5Mg_9e630074-16e0-441e-aa85-9e375c86a307">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia61c6cbe23264dc3937f411e7be9e941_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOC01LTEtMS04MjA5Mg_796514f9-d0ae-4bd2-924c-6859ba13a112">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia61c6cbe23264dc3937f411e7be9e941_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOC03LTEtMS04MjA5Mg_bb5c075a-d987-4ee6-9ad1-6aa281f36191">16.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i14b1f730f55149ffb4bc95c14af1afd4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOS0xLTEtMS04MjA5Mg_b40e3764-6d39-4ca8-b901-c046c107f77a">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i14b1f730f55149ffb4bc95c14af1afd4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOS0zLTEtMS04MjA5Mg_0a76d501-80cc-4561-96c2-55c301b3e415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i14b1f730f55149ffb4bc95c14af1afd4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOS01LTEtMS04MjA5Mg_2a6414c4-774b-4ee9-b511-263ef687c2ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i14b1f730f55149ffb4bc95c14af1afd4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOS03LTEtMS04MjA5Mg_c028c996-5240-4234-b2d6-265967cedef9">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i357d6b9001eb4f34ab4e5759c25bafad_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTAtMS0xLTEtODIwOTI_85aa8004-3a99-4465-baaa-20799395752e">11.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i357d6b9001eb4f34ab4e5759c25bafad_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTAtMy0xLTEtODIwOTI_554e05a0-4bf5-4a22-9742-8b3f3af89b1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i357d6b9001eb4f34ab4e5759c25bafad_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTAtNS0xLTEtODIwOTI_0465cddf-abd0-4ae3-87ab-6b9496310228">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i357d6b9001eb4f34ab4e5759c25bafad_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTAtNy0xLTEtODIwOTI_083fa7c3-2075-4235-b2b6-5697556791bb">11.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="mygn:InvestmentsAndCashAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTEtMS0xLTEtODIwOTI_5db3c9b5-f06e-40b0-98ca-f4c6f22d4df4">398.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTEtMy0xLTEtODIwOTI_ec60b5d5-95f5-4f21-bfac-ed87662ab26a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTEtNS0xLTEtODIwOTI_1bc5060d-5906-487c-a8eb-83f5a278698f">0.2</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTEtNy0xLTEtODIwOTI_4dbfd2c1-5eb2-4b8c-b2a2-ca8dc47b2c5d">398.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RleHRyZWdpb246N2Y3M2E2OTllZmNiNGYzZmFjMjExYTQ1MGIxNDUwMzdfNjE1_68d7fda0-76df-40f5-b91e-85ca50bfa3fa" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at March&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136db30e02474345827ada253c52a3dc_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfMS0xLTEtMS04MjA5Mg_c2116633-3cb1-4922-9eac-3341840b1597">138.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136db30e02474345827ada253c52a3dc_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfMS0zLTEtMS04MjA5Mg_cbd0add2-afee-49d6-bcd9-84f6f7545693">138.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a42c624b75245bcac04b9a7d1f99fdd_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfMi0xLTEtMS04MjA5Mg_acba532b-f12d-482e-ac0c-b2985f419281">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a42c624b75245bcac04b9a7d1f99fdd_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfMi0zLTEtMS04MjA5Mg_97cbf2c9-8d29-462d-af95-7aa7c98a2e46">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNC0xLTEtMS04MjA5Mg_b4fca1d6-73b2-4ec4-b325-592d871efb2b">103.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNC0zLTEtMS04MjA5Mg_e4edd363-25ff-4fa7-9de4-1cb2d1db2f70">103.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNS0xLTEtMS04MjA5Mg_74f7bc41-7d4f-4685-8f54-50c17fbb203e">72.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNS0zLTEtMS04MjA5Mg_33f6eb6e-0ef0-46e0-a0ca-437c9da6366c">70.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNi0xLTEtMS04MjA5Mg_575c88e5-9488-40c5-9dcc-d3b244005741">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNi0zLTEtMS04MjA5Mg_f355d1eb-57f2-45b5-86ce-9fe18605388d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="mygn:InvestmentsAndCashAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNy0xLTEtMS04MjA5Mg_32a1cee9-4b7e-412d-8b2d-c05b702a9262">340.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNy0zLTEtMS04MjA5Mg_ef3da600-3901-482b-b16c-431f1af9a83d">339.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information relating to fair value of marketable investment securities can be found in Note 4.</span></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RleHRyZWdpb246MGYyZmY3NGM4M2Y3NDhhZTg2MDM0ZWEyYmY4ZmYyMjFfMzEzMw_aa56e58e-d083-4211-8941-208f9a71049b" continuedAt="i833030015b704740b483f515854a6f44" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i833030015b704740b483f515854a6f44" continuedAt="i1aabb3e888a24136b8d210974e5980f5"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;&#160;Some of the Company&#8217;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;unobservable inputs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability.&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement period of approximately <ix:nonNumeric contextRef="id6ed914040924d00942b5531f455cea3_D20220101-20220331" name="mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RleHRyZWdpb246MGYyZmY3NGM4M2Y3NDhhZTg2MDM0ZWEyYmY4ZmYyMjFfMTg3MQ_7096af37-0bc4-4650-8796-6db0c20e9a51">13.3</ix:nonNumeric> years, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business.&#160;The contingent earn-out liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets.&#160;&#160;Changes to contingent consideration liabilities are reflected in Selling, general and administrative expense in the Company&#8217;s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#8217;s financial statements.</span></div><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RleHRyZWdpb246MGYyZmY3NGM4M2Y3NDhhZTg2MDM0ZWEyYmY4ZmYyMjFfMzEzNA_ed5bdbb2-1df7-4ed5-a5fe-6bf64dbed715" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i08e3194cd9264422920009833989a9f4_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMi0xLTEtMS04MjA5Mg_46475e38-2880-4c43-a7c5-79e98e4907eb">27.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i45e4529dc74b46368324bb8e8304fae6_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMi0zLTEtMS04MjA5Mg_4c2e91fc-409b-4b86-8019-09bef765b4c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic383f28c706e43be88cc15989d93d8bf_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMi01LTEtMS04MjA5Mg_edd21aa2-45da-4410-a6c2-c5a1cd511fd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1149c109c7944153bce0f07495ff3516_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMi03LTEtMS04MjA5Mg_86207f18-45b3-4352-aa89-bcb01bca4a97">27.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4683011548b54f0d9ebf8e148ae0cb58_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMy0xLTEtMS04MjA5Mg_03a50a4b-0068-44f6-9005-9d1210ba7e32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib523b385ec3e473889798b06a5b0e42c_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMy0zLTEtMS04MjA5Mg_f5f264fa-c22e-4d5e-af24-91c601ad72bd">108.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i093a64b69b8c4abeaf4706d4a48aced8_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMy01LTEtMS04MjA5Mg_0d8e062a-bd37-40a2-b25d-f6206d25b221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i079b9de7e87d46e9bcccd402328b76f2_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMy03LTEtMS04MjA5Mg_440dd62b-e08a-4f31-b227-b5a01646d609">108.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0db6ed20d3b7496abd3bc2149d9f0911_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNC0xLTEtMS04MjA5Mg_89ff6f3f-da3c-45cc-818f-385205257d2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib288a6a85cb34b21a1848dd46ede7ea7_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNC0zLTEtMS04MjA5Mg_6d993bc8-0e18-4f97-a5ba-1ce149230a8e">21.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0a9e29a9d23b4534a84fb267bb955273_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNC01LTEtMS04MjA5Mg_11384512-4bb4-477b-bfd4-0d280d522814">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3979e6cb59c140e695831c1612356572_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNC03LTEtMS04MjA5Mg_9f265cb3-cce0-4b49-94b7-02a5cecae938">21.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i73ec880d0b0e4b1ca8cf3ae965faa17a_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNS0xLTEtMS04MjA5Mg_c5f483c7-e0ae-403f-baa9-04dfb08fc920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i57812bb46fe444018878a29051cb790e_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNS0zLTEtMS04MjA5Mg_521085f6-454e-49c1-9de9-9c2138278556">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0d28eeea16924dc8b5cbe6c78890f671_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNS01LTEtMS04MjA5Mg_2b711ccc-df85-4ac6-96b0-9e4b94203f05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i33295928e5bd414aada50cf100d5946c_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNS03LTEtMS04MjA5Mg_1d89d325-a22e-4823-bfac-c6c7e9e297d8">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icc4b68d2f71a40e0873b52510f156925_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNi0xLTEtMS04MjA5Mg_e2010772-f7ba-4027-9001-0485b23b1345">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e850fa3529c440d8963459b76c7b82e_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNi0zLTEtMS04MjA5Mg_86fcec14-0967-40d3-851f-fdd7d9f8d832">26.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifcb86fc367024853965b38c7d1144948_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNi01LTEtMS04MjA5Mg_c94c394e-2424-4886-9303-37095853bec1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29a7ee8981794d99b60509cd1fbedcf6_I20220331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNi03LTEtMS04MjA5Mg_9f0c69c6-7112-4812-8f86-b122e7c37230">26.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idfe95fe4dd354dbd98eabe24039da4d9_I20220331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNy0xLTEtMS04MjA5Mg_40329c36-186f-4428-accb-4dc8f90b87f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29cf1314b6ca487490b61e18b013ff26_I20220331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNy0zLTEtMS04MjA5Mg_653fa26d-0dad-420c-b741-5e9d79825747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2604abe8133848178f910dd24f6b3462_I20220331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNy01LTEtMS04MjA5Mg_ee6414f3-c7be-4ae1-a5d7-09233c205087">7.9</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if8170fc4406e43bdbb3216785308da75_I20220331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNy03LTEtMS04MjA5Mg_655fa52e-a78f-4529-8ce8-dc4870f907e3">7.9</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1e05e765ecae4061bff51a2cb034aa20_I20220331" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfOC0xLTEtMS04MjA5Mg_02e295ae-713c-45d8-a41b-2414b43e79a5">27.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9035568ac69b433da12c2f4a2affbff1_I20220331" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfOC0zLTEtMS04MjA5Mg_e3e6cba1-088d-4462-8f35-4d2dbefa79b3">174.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iab78bf60a5c942cc87ccc71b20df6a27_I20220331" decimals="-5" sign="-" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfOC01LTEtMS04MjA5Mg_95d93284-f9a5-4c01-b084-4e23ccfecee8">7.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfOC03LTEtMS04MjA5Mg_a179523a-d2be-4ff8-9ebb-97359b782962">193.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaf0f4b68da2b4515afa573f19f88ff4e_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMi0xLTEtMS04MjA5Mg_e7ce93fa-7179-48ce-8d63-63f16462ca20">63.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if4ae2273e9614043945b8f236bd47dfd_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMi0zLTEtMS04MjA5Mg_cff42b6d-a2d0-4744-8076-d8206d943a81">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id72e536fe9d14ae6ab7cb34094bb9d39_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMi01LTEtMS04MjA5Mg_f0a01537-9b3b-4275-b372-3db14a802900">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6bb9b95d87db4378a84eed47d440eb40_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMi03LTEtMS04MjA5Mg_564e980f-de4e-466e-985a-9962a98117d1">63.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6de004c7a5244c518e0a748f1c208172_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMy0xLTEtMS04MjA5Mg_f40de04e-d82e-457d-91b3-12e00b8c117e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i528dc644c9ff4943b02b055e4f0985a4_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMy0zLTEtMS04MjA5Mg_70febf95-2919-4b23-9bbb-98633f73c0c1">105.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e871c32c4824df6aba031d957b820f7_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMy01LTEtMS04MjA5Mg_d37f75b8-3798-4c26-ad58-e42a16f8d6a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i353c741ab7484eb590076cce6cf8785f_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMy03LTEtMS04MjA5Mg_3980381b-337f-4328-aa52-3c4df8ba7eb3">105.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idf97501434e045bdbec15630658c5c1b_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNC0xLTEtMS04MjA5Mg_a004dd89-84d6-4a45-95ad-deadf70df812">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i07615525c7da4600a164f6377287dda5_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNC0zLTEtMS04MjA5Mg_4ec8da18-1575-4c34-a856-d9960ca6fc47">16.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e2f08fba40d4ba3af31fe0475b3de3e_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNC01LTEtMS04MjA5Mg_456359f8-056b-4450-9d5c-c968771e82d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia61c6cbe23264dc3937f411e7be9e941_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNC03LTEtMS04MjA5Mg_7df52aaa-19e1-4bda-8967-022b0906ac1c">16.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0bc70dfe49e04a118a51198b256f8dae_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNS0xLTEtMS04MjA5Mg_8b232315-82f6-435a-94fe-3c79de74a393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic5de6b4aac9841a5b074aec661dd7e40_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNS0zLTEtMS04MjA5Mg_02216fd2-e30d-4e17-be32-623ee1ad9de1">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i78479d9de84a4fa987db5df225bb0dc9_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNS01LTEtMS04MjA5Mg_a54a1d61-e427-4c04-ba3d-2e2a4fdc7db0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i14b1f730f55149ffb4bc95c14af1afd4_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNS03LTEtMS04MjA5Mg_b84a1944-fe74-4aa0-b239-7f16696944fa">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if9714eb29e60483d97d657c738112562_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNi0xLTEtMS04MjA5Mg_b5735577-2fe1-4b5c-87b1-922ea62a87bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia84c478ac57b495fa98f396e489b0dfd_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNi0zLTEtMS04MjA5Mg_fceb7761-e7ca-45a1-b27d-e4538c7a40cc">11.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i859a42bcc97943128dc28bd68082557d_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNi01LTEtMS04MjA5Mg_943d2704-4120-4c40-8f0f-46b204f9a514">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i357d6b9001eb4f34ab4e5759c25bafad_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNi03LTEtMS04MjA5Mg_88c9b116-df81-481c-bf73-aaedea50a75c">11.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0e3c14443da2478fbd20257901c8b17d_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNy0xLTEtMS04MjA5Mg_8dee661c-9efd-4599-bf11-8c3e3067e9da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i10f83fadc928439aae7775e2a66e9369_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNy0zLTEtMS04MjA5Mg_463a49b8-99bc-4256-a0c0-80708802ceed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia71dcd4c9af541eead967fd44feac0ee_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNy01LTEtMS04MjA5Mg_3c5fffa4-42a7-42eb-a388-9d08e561a556">8.6</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5990b598e2d1460597cd94495019968d_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNy03LTEtMS04MjA5Mg_e496c011-4775-4400-9408-b83ae8786f7d">8.6</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i51f0f49e3b5045d5b1be9e63528af3ce_I20211231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfOC0xLTEtMS04MjA5Mg_dfd8d1b5-49cf-4c6c-97c0-5325b757e97f">63.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic9a60ca8f13e4a989f4559d73febd0b9_I20211231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfOC0zLTEtMS04MjA5Mg_8ef99fae-6faa-45c3-919b-0be9edccef1e">140.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8b8d4e9c04da414c897ed06bbbf510d4_I20211231" decimals="-5" sign="-" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfOC01LTEtMS04MjA5Mg_3637cf5a-339a-48d5-916f-01e9ba19a92c">8.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfOC03LTEtMS04MjA5Mg_38ea86b4-8518-409f-99de-47c21c16bf29">195.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><ix:continuation id="i1aabb3e888a24136b8d210974e5980f5"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RleHRyZWdpb246MGYyZmY3NGM4M2Y3NDhhZTg2MDM0ZWEyYmY4ZmYyMjFfMzEzNQ_3c807972-0714-4328-bb48-751bcc6825d4" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjNhZmRjZmJmNjE4MzQ5Y2ZhYTk5NDBmNTFkM2E4MjZiL3RhYmxlcmFuZ2U6M2FmZGNmYmY2MTgzNDljZmFhOTk0MGY1MWQzYTgyNmJfMS0xLTEtMS04MjA5Mg_654f1a25-89cb-4786-b39f-8065fe93f20e">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value recognized in the Statement of Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjNhZmRjZmJmNjE4MzQ5Y2ZhYTk5NDBmNTFkM2E4MjZiL3RhYmxlcmFuZ2U6M2FmZGNmYmY2MTgzNDljZmFhOTk0MGY1MWQzYTgyNmJfMy0xLTEtMS04MjA5Mg_e1b569dd-31c1-4f81-886c-51a74c294ee4">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translation adjustments recognized in Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjNhZmRjZmJmNjE4MzQ5Y2ZhYTk5NDBmNTFkM2E4MjZiL3RhYmxlcmFuZ2U6M2FmZGNmYmY2MTgzNDljZmFhOTk0MGY1MWQzYTgyNmJfNC0xLTEtMS04MjA5Mg_e057bd6a-7fa5-43bb-9abf-7678e0dadca2">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjNhZmRjZmJmNjE4MzQ5Y2ZhYTk5NDBmNTFkM2E4MjZiL3RhYmxlcmFuZ2U6M2FmZGNmYmY2MTgzNDljZmFhOTk0MGY1MWQzYTgyNmJfNS0xLTEtMS04MjA5Mg_5ecf0b69-4c64-4d15-8b47-bd80f5ade910">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib6fee90945e74b97b833695fd82463c2_46"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RleHRyZWdpb246ODRjOGJmNjEzYTRmNDAwNWIwMDk4ZTI2NTNkZWZlNWJfMjc4_55423821-dc14-48aa-8376-43bb96a34d3e" continuedAt="i59ac60c42c4a435caa688a2725f8f51c" escape="true">PROPERTY, PLANT AND EQUIPMENT, NET</ix:nonNumeric></span></div><ix:continuation id="i59ac60c42c4a435caa688a2725f8f51c"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RleHRyZWdpb246ODRjOGJmNjEzYTRmNDAwNWIwMDk4ZTI2NTNkZWZlNWJfMjc3_e31d93cf-f0ae-4121-86b5-dcf87fd412bc" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic5028f46356f458f8cd14be716668ff9_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfMS0xLTEtMS04MjA5Mg_62bf4852-4dbb-4421-b20b-2bf14722ebf5">34.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i93acac9c7ae94d1aa34a4be6c6c75cfe_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfMS00LTEtMS04MjA5Mg_12a7a1b6-d61f-4895-a589-a29a41de58c3">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8fe2de508784dd7a2055d130fa36acb_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfMi0xLTEtMS04MjA5Mg_c55ed863-c503-4bf6-8a25-d1e56dba610a">114.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i174cf853880a4694890b201c320822fa_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfMi00LTEtMS04MjA5Mg_70359e62-568c-4e44-8deb-22ed66145fa6">112.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfMy0xLTEtMS04MjA5Mg_2e7e902f-e532-4f17-be8d-5a1388978ada">149.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfMy00LTEtMS04MjA5Mg_cc43cbde-5009-4230-870e-505d07e8c273">150.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfNC0xLTEtMS04MjA5Mg_e18f103e-45ff-4f2d-a3df-8eaf588c6608">103.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfNC00LTEtMS04MjA5Mg_2b2aa635-bdd6-4239-8881-f323c355bc36">106.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfNS0xLTEtMS04MjA5Mg_cbec9b5d-500b-4ec9-839f-2f1c96e8b4c1">45.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfNS00LTEtMS04MjA5Mg_20e17f62-37e0-4a4b-91da-65349b56f78d">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company ceased the use of one of its leased Salt Lake City facilities. As a result, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i49163efc76014827a31448fd386b5085_D20220101-20220331" decimals="-5" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RleHRyZWdpb246ODRjOGJmNjEzYTRmNDAwNWIwMDk4ZTI2NTNkZWZlNWJfMTA5OTUxMTYyOTA0OQ_f87163a7-256e-43b3-ad91-5ab877827bec">2.1</ix:nonFraction> million impairment on the property, plant and equipment associated with the lease, which consisted primarily of leasehold improvements. See Note 15 for further discussion.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOmQ1YTJlNTRiMDY4YTQ5YWY5ZTYyMTAxN2U2NGI4OGI0L3RhYmxlcmFuZ2U6ZDVhMmU1NGIwNjhhNDlhZjllNjIxMDE3ZTY0Yjg4YjRfMi0xLTEtMS04MjA5Mg_3bfbf4f5-4878-4c1e-b870-5abc59b73958">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOmQ1YTJlNTRiMDY4YTQ5YWY5ZTYyMTAxN2U2NGI4OGI0L3RhYmxlcmFuZ2U6ZDVhMmU1NGIwNjhhNDlhZjllNjIxMDE3ZTY0Yjg4YjRfMi0zLTEtMS04MjA5Mg_740268f1-4be4-421a-bb38-9a7f3cd95b47">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib6fee90945e74b97b833695fd82463c2_49"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RleHRyZWdpb246YmRlYmY1ZDEyYTMzNDM4NWI3ZGY2Yjc0ZTVhMjRiOTlfMTU0Mw_d8fde79d-9351-44e9-ab38-440b900ba00e" continuedAt="i95788a5f7ce748f9bedc2f00cfab5f34" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="i95788a5f7ce748f9bedc2f00cfab5f34" continuedAt="i69032146ed23493d9af9e633cc152499"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RleHRyZWdpb246YmRlYmY1ZDEyYTMzNDM4NWI3ZGY2Yjc0ZTVhMjRiOTlfMTU0NA_d58718c6-70f7-4f0e-8e7a-23316f4d0ab2" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill for the three months ended March&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOmYzNGJlZDZjMjJjZDQ3N2Q4ZGRkMTYxYjIzZjgyMDgyL3RhYmxlcmFuZ2U6ZjM0YmVkNmMyMmNkNDc3ZDhkZGQxNjFiMjNmODIwODJfMS01LTEtMS04MjA5Mg_d563ef14-8b0c-479c-a51c-8edf0b1e4576">239.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOmYzNGJlZDZjMjJjZDQ3N2Q4ZGRkMTYxYjIzZjgyMDgyL3RhYmxlcmFuZ2U6ZjM0YmVkNmMyMmNkNDc3ZDhkZGQxNjFiMjNmODIwODJfMy01LTEtMS04MjA5Mg_bfdd2f46-3fe1-490b-a66b-32f74fb19cc1">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOmYzNGJlZDZjMjJjZDQ3N2Q4ZGRkMTYxYjIzZjgyMDgyL3RhYmxlcmFuZ2U6ZjM0YmVkNmMyMmNkNDc3ZDhkZGQxNjFiMjNmODIwODJfNC01LTEtMS04MjA5Mg_f71e4011-6a0c-4729-8a84-c8da7fa49e4f">238.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consists of purchased licenses and technologies. <ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RleHRyZWdpb246YmRlYmY1ZDEyYTMzNDM4NWI3ZGY2Yjc0ZTVhMjRiOTlfMTU0NQ_22f005ab-b28e-4707-b4fe-a099e319ba78" continuedAt="i0ec7b2bd37ee4a829cfb6dd3158acd8f" escape="true"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RleHRyZWdpb246YmRlYmY1ZDEyYTMzNDM4NWI3ZGY2Yjc0ZTVhMjRiOTlfMTU0NQ_9311598c-8da8-46cd-9920-a6f974ad0729" continuedAt="i76cb821fd67e4fe4bffea753466b5059" escape="true">The following summarizes the amounts reported as intangible assets:</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i0ec7b2bd37ee4a829cfb6dd3158acd8f"><ix:continuation id="i76cb821fd67e4fe4bffea753466b5059"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i48dce0415e7b4acd9af7a58cea440e09_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjUwZGVhYjBmOTZhZDQ4MjhhNzQwYjg5MzkwNDM0MThmL3RhYmxlcmFuZ2U6NTBkZWFiMGY5NmFkNDgyOGE3NDBiODkzOTA0MzQxOGZfMi0xLTEtMS04MjA5Mg_f01983c6-0e33-4052-a521-a4157a525662">616.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i48dce0415e7b4acd9af7a58cea440e09_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjUwZGVhYjBmOTZhZDQ4MjhhNzQwYjg5MzkwNDM0MThmL3RhYmxlcmFuZ2U6NTBkZWFiMGY5NmFkNDgyOGE3NDBiODkzOTA0MzQxOGZfMi0zLTEtMS04MjA5Mg_f2016c4d-b375-4fbd-b357-6cebd58ccfa8">222.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i48dce0415e7b4acd9af7a58cea440e09_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjUwZGVhYjBmOTZhZDQ4MjhhNzQwYjg5MzkwNDM0MThmL3RhYmxlcmFuZ2U6NTBkZWFiMGY5NmFkNDgyOGE3NDBiODkzOTA0MzQxOGZfMi01LTEtMS04MjA5Mg_1d0fba74-c6d3-47f3-aede-f01ce64b9714">393.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjUwZGVhYjBmOTZhZDQ4MjhhNzQwYjg5MzkwNDM0MThmL3RhYmxlcmFuZ2U6NTBkZWFiMGY5NmFkNDgyOGE3NDBiODkzOTA0MzQxOGZfNC0xLTEtMS04MjA5Mg_fa1cc2a3-4f57-4032-9220-80493c226f13">616.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjUwZGVhYjBmOTZhZDQ4MjhhNzQwYjg5MzkwNDM0MThmL3RhYmxlcmFuZ2U6NTBkZWFiMGY5NmFkNDgyOGE3NDBiODkzOTA0MzQxOGZfNC0zLTEtMS04MjA5Mg_f111c6fb-d43b-4909-b74c-6a8056441a1f">222.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjUwZGVhYjBmOTZhZDQ4MjhhNzQwYjg5MzkwNDM0MThmL3RhYmxlcmFuZ2U6NTBkZWFiMGY5NmFkNDgyOGE3NDBiODkzOTA0MzQxOGZfNC01LTEtMS04MjA5Mg_bbbdac26-2c0b-40cb-bff8-5cf966776fcc">393.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1016b9209b0844a8a1fe882aaf69c3fe_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjE5ZmE1ZjgxZDA3YTQ4YjJhNDU5MWMwM2QxZTgwOTA2L3RhYmxlcmFuZ2U6MTlmYTVmODFkMDdhNDhiMmE0NTkxYzAzZDFlODA5MDZfMi0xLTEtMS04MjA5Mg_a7831469-9883-404a-91cd-ebe122a7962f">616.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1016b9209b0844a8a1fe882aaf69c3fe_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjE5ZmE1ZjgxZDA3YTQ4YjJhNDU5MWMwM2QxZTgwOTA2L3RhYmxlcmFuZ2U6MTlmYTVmODFkMDdhNDhiMmE0NTkxYzAzZDFlODA5MDZfMi0zLTEtMS04MjA5Mg_e425421e-35dc-4f4a-b611-40d7c19f6bda">212.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1016b9209b0844a8a1fe882aaf69c3fe_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjE5ZmE1ZjgxZDA3YTQ4YjJhNDU5MWMwM2QxZTgwOTA2L3RhYmxlcmFuZ2U6MTlmYTVmODFkMDdhNDhiMmE0NTkxYzAzZDFlODA5MDZfMi01LTEtMS04MjA5Mg_bbe3a4e8-8dd8-4c7d-b0be-289d3eafdf57">404.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjE5ZmE1ZjgxZDA3YTQ4YjJhNDU5MWMwM2QxZTgwOTA2L3RhYmxlcmFuZ2U6MTlmYTVmODFkMDdhNDhiMmE0NTkxYzAzZDFlODA5MDZfOC0xLTEtMS04MjA5Mg_325cce9c-2b77-4409-a43a-d746da1e7cd6">616.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjE5ZmE1ZjgxZDA3YTQ4YjJhNDU5MWMwM2QxZTgwOTA2L3RhYmxlcmFuZ2U6MTlmYTVmODFkMDdhNDhiMmE0NTkxYzAzZDFlODA5MDZfOC0zLTEtMS04MjA5Mg_3b642965-a618-41c9-bb0e-8a30cb9ab2af">212.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjE5ZmE1ZjgxZDA3YTQ4YjJhNDU5MWMwM2QxZTgwOTA2L3RhYmxlcmFuZ2U6MTlmYTVmODFkMDdhNDhiMmE0NTkxYzAzZDFlODA5MDZfOC01LTEtMS04MjA5Mg_3e24a394-031a-4fe7-9928-1449b9da559a">404.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><ix:continuation id="i69032146ed23493d9af9e633cc152499"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RleHRyZWdpb246YmRlYmY1ZDEyYTMzNDM4NWI3ZGY2Yjc0ZTVhMjRiOTlfMTU0Ng_1771fa83-13b6-485a-83d0-c63fe9f46688" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization expense during the respective periods for these intangible assets as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOmE3MzA1ODM5MDBjMDRiYzBiOGExYzJiMzFkZWNkNTY3L3RhYmxlcmFuZ2U6YTczMDU4MzkwMGMwNGJjMGI4YTFjMmIzMWRlY2Q1NjdfMi0xLTEtMS04MjA5Mg_4556dd73-8903-40d0-b0f9-6d464578e8b0">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOmE3MzA1ODM5MDBjMDRiYzBiOGExYzJiMzFkZWNkNTY3L3RhYmxlcmFuZ2U6YTczMDU4MzkwMGMwNGJjMGI4YTFjMmIzMWRlY2Q1NjdfMi00LTEtMS04MjA5Mg_785c6462-b1a0-4742-ae43-01bb020e333f">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib6fee90945e74b97b833695fd82463c2_52"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RleHRyZWdpb246ZmFmYTE4ZmEwZmFhNGZlMTkxODljYmRiNjQ1ODVhNDNfMjQw_f10a6727-765b-4776-a12e-f0da5983fd15" continuedAt="idbf11d1f8bf94519bcfa85617ad25155" escape="true">ACCRUED LIABILITIES</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="idbf11d1f8bf94519bcfa85617ad25155"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RleHRyZWdpb246ZmFmYTE4ZmEwZmFhNGZlMTkxODljYmRiNjQ1ODVhNDNfMjQx_f47d18c0-caed-4320-ab5f-9211dc5f708a" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfMS0xLTEtMS04MjA5Mg_7d3bb20c-963d-49a4-a08a-665898f796e3">37.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfMS00LTEtMS04MjA5Mg_bd8e3ffa-7630-4806-a81a-686874f5543f">52.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal charges pending settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfMi0xLTEtMS04MjA5Mg_f4fdcbb0-43a3-47c2-84e2-b2c204f486a0">48.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfMi00LTEtMS04MjA5Mg_8b3600b9-24f0-4c28-9ff5-7ab38ec91041">62.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfMy0xLTEtMS04MjA5Mg_eccad45d-6854-488d-8fa2-da1327ed7ba9">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfMy00LTEtMS04MjA5Mg_95738364-abd6-402a-b219-d6d6a3ebafd8">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds payable and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="mygn:RefundsPayableAndReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfNC0xLTEtMS04MjA5Mg_a78abc4b-d914-4271-9228-ecf81e3aaa53">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="mygn:RefundsPayableAndReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfNC00LTEtMS04MjA5Mg_7109e48e-950e-454d-9bce-d7f76c40cdb1">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfNS0xLTEtMS04MjA5Mg_c3fca526-755c-4723-9bc9-951241e4f13b">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfNS00LTEtMS04MjA5Mg_1607d06a-06f5-42b1-beff-160b84d1dde8">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfNi0xLTEtMS04MjA5Mg_ac7a31da-95b6-4175-bdab-9743391a93ef">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfNi00LTEtMS04MjA5Mg_23e8c434-000b-4e86-8f56-2d4df7953d33">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfOC0xLTEtMS04MjA5Mg_d2907e10-d762-4a0e-ade0-1f5c02d73d06">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfOC00LTEtMS04MjA5Mg_7c87b954-ace8-42d5-a0c2-fbce7b00cd87">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfOS0xLTEtMS04MjA5Mg_c8ce3cd2-872c-4e3d-a76b-1da0e58d5cc8">124.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfOS00LTEtMS04MjA5Mg_76f89aa7-ffc3-4b4b-80f6-96d79d1d74e8">156.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="ib6fee90945e74b97b833695fd82463c2_55"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfNDczNQ_fc45478b-735c-40fc-a50c-2cbbb30b6c92" continuedAt="i180f82175de84fa0839f70f4708554e4" escape="true">LONG-TERM DEBT</ix:nonNumeric></span></div><ix:continuation id="i180f82175de84fa0839f70f4708554e4" continuedAt="i5f23d367a44149f2bc148e2b1355bb67"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2016, the Company entered into a senior secured revolving credit facility (the &#8220;Facility&#8221;) as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 to the Facility, which effected an &#8220;amend and extend&#8221; transaction with respect to the Facility by which the maturity date thereof was extended to <ix:nonNumeric contextRef="i9f00404949054a39b7ce601ba38532bd_D20180731-20180731" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMzk4_30bb9c15-35d1-4c29-abed-52e2250f059f">July 31, 2023</ix:nonNumeric> and the maximum aggregate principal commitment was increased from $<ix:nonFraction unitRef="usd" contextRef="i0837431576cf4579a0f3ff1238105f8f_I20161223" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfNDY3_8b9f0b6f-8a2d-4727-a163-62ad8a1f1b6b">300.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i1c833d35617e45489ec45fd17d8b7885_I20180731" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfNDcz_adba1fa7-a5b8-4a96-90d3-66cf641f225a">350.0</ix:nonFraction> million.&#160;On May 1, 2020, the Company entered into Amendment No. 2 to the Facility, which waived the Company&#8217;s compliance with certain covenants and modified the interest rate and other terms during the modification period from March 31, 2020 through June 30, 2021 (&#8220;Modification Period&#8221;). This included a modification to the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021, as well as revision to certain negative covenants of the Amended Facility during the Modification Period. On February 22, 2021, the Company entered into Amendment No. 3 (the &#8220;Amended Facility&#8221;), which waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ended March 31, 2022 and also lowered the minimum liquidity covenant, which was added by Amendment No. 2, to $<ix:nonFraction unitRef="usd" contextRef="iab8dc65629934bb09610a94e1585f5e2_I20210221" decimals="-5" name="mygn:DebtCovenantLiquidityCovenantMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMTA5OTUxMTY0MDU0MQ_dde07b89-e4d9-4524-b62d-84e345740f96">150.0</ix:nonFraction>&#160;million, and made it applicable through such quarter. Amendment No. 3 also restricted the Company from borrowing under the Amended Facility if unrestricted cash, cash equivalents and marketable investment securities exceed $<ix:nonFraction unitRef="usd" contextRef="iab8dc65629934bb09610a94e1585f5e2_I20210221" decimals="-5" name="mygn:DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMTA5OTUxMTY0MDkwNw_6095d72f-b959-4044-aaf6-27efa0b6b92e">150.0</ix:nonFraction>&#160;million, unless such borrowings are in connection with permitted acquisitions, decreased the maximum aggregate principal commitment from $<ix:nonFraction unitRef="usd" contextRef="i41e34ef04eda424fb7d05a478f98d582_I20201231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfOTgx_1c490843-b000-4b96-afde-0b828a5a90b4">350.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="iab8dc65629934bb09610a94e1585f5e2_I20210221" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfOTg3_4908e230-3443-48ec-8a2d-951033184639">300.0</ix:nonFraction>&#160;million, with a further reduction in the maximum aggregate principal commitment from $<ix:nonFraction unitRef="usd" contextRef="iab8dc65629934bb09610a94e1585f5e2_I20210221" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMTA2Nw_1cd6a50d-2c10-44d8-b217-b60c4dad0b9c">300.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i71d2eeb4225b4d9581fbf31f410c3194_I20210930" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMTA3Mw_9fa6dbbd-7fe5-48b2-8cfa-defe9610d878">250.0</ix:nonFraction>&#160;million by September 30, 2021, extended the Modification Period for an additional year through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company&#8217;s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company&#8217;s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. The Company was in compliance with all applicable financial covenants at March&#160;31, 2022. It is possible that the Company could be in violation of certain financial covenants contained in the Amended Facility in the future. If the Company is unable to comply with certain covenants and ratios in the Amended Facility, the Company may be in default under the Amended Facility, which could impact the Company's ability to borrow under the facility or result in the termination of the commitments under the Amended Facility or the Company being required to pay off any outstanding loans or fees and cash collateralize any outstanding letters of credit. In the future, the Company may seek waivers or amendments from lenders in order to avoid a future covenant violation, in addition to taking other potential actions. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><ix:continuation id="i5f23d367a44149f2bc148e2b1355bb67"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Amended Facility to increase the interest rate to be fixed at a spread of LIBOR plus <ix:nonFraction unitRef="number" contextRef="i2304a6ab41d9426daa1dd160660afb17_D20200401-20220630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMTkyMw_903f8805-18f5-4146-ab81-275109ce1cca">350</ix:nonFraction> basis points on drawn balances and the undrawn fee was increased to <ix:nonFraction unitRef="number" contextRef="i5b494a8f5d504446b284a79c8608ed05_D20200401-20220630" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMTk5Mw_33b5a1ad-a2fb-4d78-bfae-2da2ad28b469">50</ix:nonFraction> basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR plus <ix:nonFraction unitRef="number" contextRef="i65072d8099784761bad742b663d1ac97_D20220701-20220701" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMjE1OA_7b0976cc-c6c3-4cf8-8630-a4fa1829acff">150</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i29e8864078c14a39bc3142c044233017_D20220701-20220701" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMjE2MQ_2a1e555d-ffe4-470b-9f11-b4ac4162e994">250</ix:nonFraction> basis points on drawn balances and an undrawn fee ranging from <ix:nonFraction unitRef="number" contextRef="i9856b6ac715043c4aba22142b3f40f4f_D20220701-20220701" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMjIyNw_74779be9-1823-41a5-a9ca-fdc3d5a7dd23">25</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i2c4a4127b1ac49719e15e702d9dbb3e4_D20220701-20220701" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMjIzMw_55520d15-9fb3-4f32-88f5-895dca5f9299">45</ix:nonFraction> basis points, in each case, based on the Company's leverage ratio. The LIBOR floor was also increased to <ix:nonFraction unitRef="number" contextRef="i5b494a8f5d504446b284a79c8608ed05_D20200401-20220630" decimals="INF" name="mygn:DebtInstrumentLIBORFloorPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMjM0MQ_d09f4e5b-08dc-4138-86bc-fad320aa2828">1.0</ix:nonFraction>% during the Modification Period. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company made principal repayments totaling $<ix:nonFraction unitRef="usd" contextRef="i1e2100574367494095bfa2718fab642f_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfNDAwMg_64618a16-b436-49ad-be8a-d2b25e95bfe6">226.4</ix:nonFraction>&#160;million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had <ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfNDE5Mw_520bd3d2-c66b-4ad1-bd7d-c4dcb17bfe29"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfNDE5Mw_ac7a3c40-8dbb-4e33-8f3a-50641745361e">no</ix:nonFraction></ix:nonFraction> outstanding balances under the Amended Facility as of March 31, 2022 and December 31, 2021. The Company's maximum aggregate principal commitment on its Amended Facility is $<ix:nonFraction unitRef="usd" contextRef="i4d18f4068d394dcfba0bad4c86c8ef8a_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMjE5OTAyMzI2MTM1OA_eaebfd5c-e46a-4685-9a7c-08d331a56dae">250.0</ix:nonFraction>&#160;million as of March&#160;31, 2022.</span></div></ix:continuation><div id="ib6fee90945e74b97b833695fd82463c2_58"></div><div style="margin-top:9pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RleHRyZWdpb246ZjQ4Njk1ZTQyNmI0NGQ1YzliZDkzZjI4YzI0MGI1ZTdfMzI2_1fad4a04-9e17-447b-a174-af924d78a412" continuedAt="i2e1be50f50134c2bb163750b293bbc8f" escape="true">OTHER LONG-TERM LIABILITIES</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i2e1be50f50134c2bb163750b293bbc8f" continuedAt="ia90bb28969ed4b7ca30ba1515851b50c"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RleHRyZWdpb246ZjQ4Njk1ZTQyNmI0NGQ1YzliZDkzZjI4YzI0MGI1ZTdfMzI1_10d1b052-41e7-4e37-b67a-d370e6eca359" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RhYmxlOmRjZjFmYmY0Njc2NjQ3Zjc5YmQwMzI2MTQwYzBhYTQwL3RhYmxlcmFuZ2U6ZGNmMWZiZjQ2NzY2NDdmNzliZDAzMjYxNDBjMGFhNDBfMS0xLTEtMS04MjA5Mg_8607a68a-7b08-446f-82b3-d33e3edcc964">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RhYmxlOmRjZjFmYmY0Njc2NjQ3Zjc5YmQwMzI2MTQwYzBhYTQwL3RhYmxlcmFuZ2U6ZGNmMWZiZjQ2NzY2NDdmNzliZDAzMjYxNDBjMGFhNDBfMS00LTEtMS04MjA5Mg_7b85575d-1517-411d-9660-c58a5c3050b2">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RhYmxlOmRjZjFmYmY0Njc2NjQ3Zjc5YmQwMzI2MTQwYzBhYTQwL3RhYmxlcmFuZ2U6ZGNmMWZiZjQ2NzY2NDdmNzliZDAzMjYxNDBjMGFhNDBfMi0xLTEtMS04MjA5Mg_0b0842b4-0cfc-426c-a92c-1e5dbb3da3d6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RhYmxlOmRjZjFmYmY0Njc2NjQ3Zjc5YmQwMzI2MTQwYzBhYTQwL3RhYmxlcmFuZ2U6ZGNmMWZiZjQ2NzY2NDdmNzliZDAzMjYxNDBjMGFhNDBfMi00LTEtMS04MjA5Mg_82a48d2c-9739-4832-9823-2e2cb61e269f">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RhYmxlOmRjZjFmYmY0Njc2NjQ3Zjc5YmQwMzI2MTQwYzBhYTQwL3RhYmxlcmFuZ2U6ZGNmMWZiZjQ2NzY2NDdmNzliZDAzMjYxNDBjMGFhNDBfMy0xLTEtMS04MjA5Mg_b3a0dd7b-c8fb-4513-a5b2-1be2c97acde0">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RhYmxlOmRjZjFmYmY0Njc2NjQ3Zjc5YmQwMzI2MTQwYzBhYTQwL3RhYmxlcmFuZ2U6ZGNmMWZiZjQ2NzY2NDdmNzliZDAzMjYxNDBjMGFhNDBfMy00LTEtMS04MjA5Mg_aa6426e3-d588-4468-a475-647038e4a5a6">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia90bb28969ed4b7ca30ba1515851b50c">The Company's balance of other long-term liabilities as of March&#160;31, 2022 and December&#160;31, 2021 consists primarily of the long-term portion of contingent consideration related to the acquisition of Sividon Diagnostics.</ix:continuation> </span></div><div id="ib6fee90945e74b97b833695fd82463c2_61"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTkwMQ_68c045b0-397b-42e5-8c8c-1cff4b7f9153" continuedAt="ifaa5b75a145742e68a0918bae57423af" escape="true">PREFERRED AND COMMON STOCKHOLDERS' EQUITY</ix:nonNumeric></span></div><ix:continuation id="ifaa5b75a145742e68a0918bae57423af" continuedAt="i239786a8554545e09cdf2507ce1e7773"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfODg_2c277fd1-d941-47f6-a0a9-c6204f0b9965">5.0</ix:nonFraction> million shares of preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTI4_92c8531c-622e-48dd-8bab-506bc756b295">0.01</ix:nonFraction> per share. There were <ix:nonFraction unitRef="shares" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTUz_69d568e2-2187-4871-a3e3-0b2e2b6e6810">no</ix:nonFraction> preferred shares outstanding at March&#160;31, 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMjMz_397a1ad6-bb52-4263-8d0a-282602e19b9f">150.0</ix:nonFraction> million shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMjcw_e889d93b-2515-4a47-b551-8999c7ded323">0.01</ix:nonFraction> per share. There were <ix:nonFraction unitRef="shares" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMjk1_0d4be9bd-86ab-4f5f-b80d-26d3a2366d43"><ix:nonFraction unitRef="shares" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMjk1_142afe39-018b-41fb-98a8-4920ac2325f3">80.3</ix:nonFraction></ix:nonFraction> million shares issued and outstanding at March&#160;31, 2022.</span></div><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTkwMg_8f0b597e-c7ea-4683-897c-fa301e7e95b5" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common shares issued and outstanding</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfMi0xLTEtMS04MjA5Mg_17577d83-0e12-4cd4-8618-c3147c70c0ae"><ix:nonFraction unitRef="shares" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfMi0xLTEtMS04MjA5Mg_6245a253-89a1-443c-a6f5-f8a7bb9c522b">80.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i38f47e17df9c466eb0964b81d156f640_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfMi00LTEtMS04MjA5Mg_bc8195a2-c167-495f-9584-1b3f027ccdbb"><ix:nonFraction unitRef="shares" contextRef="i38f47e17df9c466eb0964b81d156f640_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfMi00LTEtMS04MjA5Mg_eb2d9cd5-4a45-4846-82f4-2efef7744c79">75.4</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfMy0xLTEtMS04MjA5Mg_eca7f7e2-55d2-442b-b473-515a95998a36">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfMy00LTEtMS04MjA5Mg_e2a76696-a055-4587-9740-b8c5db8e1167">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued and outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfNS0xLTEtMS04MjA5Mg_c2f7784a-8c2b-4f4a-b4a0-d0b0816caaff"><ix:nonFraction unitRef="shares" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfNS0xLTEtMS04MjA5Mg_e8653be1-2614-4a5e-adf6-d43ee48d470a">80.3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5c1c491ce07b46bf981a8c437b57ebe5_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfNS00LTEtMS04MjA5Mg_76605dfe-767f-417b-a1a6-c672b1a8cf7a"><ix:nonFraction unitRef="shares" contextRef="i5c1c491ce07b46bf981a8c437b57ebe5_I20210331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfNS00LTEtMS04MjA5Mg_81134be2-80fc-45ab-99ae-7d6027d7ba4f">76.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.</span></div><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTkwMw_155da76a-5aca-46d2-9265-b088ed5244de" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share (&#8220;EPS&#8221;) computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOjhmYmZiNDlhZmQwYjRkODZhNDgzNWQ3MWNhNmRhMzQxL3RhYmxlcmFuZ2U6OGZiZmI0OWFmZDBiNGQ4NmE0ODM1ZDcxY2E2ZGEzNDFfMy0xLTEtMS04MjA5Mg_65c40374-c7a6-408a-be04-caf714255bc1">80.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOjhmYmZiNDlhZmQwYjRkODZhNDgzNWQ3MWNhNmRhMzQxL3RhYmxlcmFuZ2U6OGZiZmI0OWFmZDBiNGQ4NmE0ODM1ZDcxY2E2ZGEzNDFfMy00LTEtMS04MjA5Mg_fecab163-b08c-4d8c-b17a-404063ba1654">76.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive shares</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOjhmYmZiNDlhZmQwYjRkODZhNDgzNWQ3MWNhNmRhMzQxL3RhYmxlcmFuZ2U6OGZiZmI0OWFmZDBiNGQ4NmE0ODM1ZDcxY2E2ZGEzNDFfNC0xLTEtMS04MjA5Mg_1e5c696c-532f-46ef-9306-ed3df33b1d37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOjhmYmZiNDlhZmQwYjRkODZhNDgzNWQ3MWNhNmRhMzQxL3RhYmxlcmFuZ2U6OGZiZmI0OWFmZDBiNGQ4NmE0ODM1ZDcxY2E2ZGEzNDFfNC00LTEtMS04MjA5Mg_d83e75ae-e56b-4e3a-87e0-c1129e63aa1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOjhmYmZiNDlhZmQwYjRkODZhNDgzNWQ3MWNhNmRhMzQxL3RhYmxlcmFuZ2U6OGZiZmI0OWFmZDBiNGQ4NmE0ODM1ZDcxY2E2ZGEzNDFfNS0xLTEtMS04MjA5Mg_80faab47-5e2e-405f-9dba-b19ab082c4e6">80.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOjhmYmZiNDlhZmQwYjRkODZhNDgzNWQ3MWNhNmRhMzQxL3RhYmxlcmFuZ2U6OGZiZmI0OWFmZDBiNGQ4NmE0ODM1ZDcxY2E2ZGEzNDFfNS00LTEtMS04MjA5Mg_9e4aade1-0781-4304-97fe-7651d3fbaf45">76.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><ix:continuation id="i239786a8554545e09cdf2507ce1e7773"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain outstanding options and restricted stock units (&#8220;RSUs&#8221;) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. <ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTkwNA_eb0b3c43-da65-4573-8d03-daf7b9f665b0" continuedAt="i2717282cc82b4b81a32b46982e872c4c" escape="true">These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i2717282cc82b4b81a32b46982e872c4c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.453%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmMxYzg3ZDYxZDkzZTRmZTNhMjVhOTFkODljNmZhMWU2L3RhYmxlcmFuZ2U6YzFjODdkNjFkOTNlNGZlM2EyNWE5MWQ4OWM2ZmExZTZfMi0xLTEtMS04MjA5Mg_48fc8964-f6d3-4723-98da-10415b3a19ac">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmMxYzg3ZDYxZDkzZTRmZTNhMjVhOTFkODljNmZhMWU2L3RhYmxlcmFuZ2U6YzFjODdkNjFkOTNlNGZlM2EyNWE5MWQ4OWM2ZmExZTZfMi00LTEtMS04MjA5Mg_96c307a8-5dbd-43d4-9fcf-b9269c39c4f8">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s Board of Directors authorized a share repurchase program of $<ix:nonFraction unitRef="usd" contextRef="i10eb9ab7fc8b46e6a64d2ef084755cf1_I20160630" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTM3MQ_227c26d5-9911-4182-a20a-7b8ad1d1435a">200.0</ix:nonFraction> million of the Company&#8217;s outstanding common stock. The Company may repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company's management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of March&#160;31, 2022, the Company has $<ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTgxNA_29df9c15-11c8-4af0-8c40-3baaac236ba1">110.7</ix:nonFraction> million remaining under its current share repurchase authorization. <ix:nonFraction unitRef="shares" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTg1Mw_e383a0eb-c09c-4ba0-96b0-98652427809f"><ix:nonFraction unitRef="shares" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTg1Mw_f5bb4140-68d2-4ca8-bb6f-96ebdcdd9443">No</ix:nonFraction></ix:nonFraction> shares were repurchased during the three months ended March 31, 2022 or 2021.</span></div></ix:continuation><div id="ib6fee90945e74b97b833695fd82463c2_64"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMzk2NQ_c283d445-41d0-4378-9724-70b3d702a28a" continuedAt="iaa9f2f172ace478e86559ec28dc1d0ee" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="iaa9f2f172ace478e86559ec28dc1d0ee" continuedAt="i11b91f7fb1c24cfabb1218331229cff6"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2017, the Company&#8217;s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the &#8220;2017 Plan&#8221;). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants, and directors. Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant.  As of March&#160;31, 2022, the Company has <ix:nonFraction unitRef="shares" contextRef="ic7e4a2bcdad04bc89e6ef5fbff976fec_I20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfNTU0_f994a8d8-5684-4e96-8513-9b80b592f491">2.0</ix:nonFraction>&#160;million shares of common stock available for grant under the 2017 Plan.  If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they also will be available for issuance pursuant to the 2017 Plan. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares, terms, and vesting periods are generally determined by the Company&#8217;s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over <ix:nonNumeric contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMTI5MA_6b714d55-0235-42ad-a277-a91355af2556">four years</ix:nonNumeric> either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of performance-based RSUs ("PSUs") awarded to certain employees may be increased or may be reduced based on certain additional performance and market metrics. Options and RSUs granted to non-employee directors vest in full upon the earlier of the completion of <ix:nonNumeric contextRef="i7bad2fadc9ee42ca9a12a98237615f28_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjE5OTAyMzI2MzY3Ng_105290e3-7faa-4645-90a9-1697886cecec">one year</ix:nonNumeric> of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options granted generally expire <ix:nonNumeric contextRef="ife4ee7239ab34cb7986b1613a6ea4129_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMTg4Mw_60d2990b-3f66-43f9-b698-4cd2c60aa690">ten years</ix:nonNumeric> from the date of grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire <ix:nonNumeric contextRef="ibdb73b76a7ef4b6192ddf53020f1bfc4_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjE5OTAyMzI2MTQ5Mg_db9e0d3e-9b0b-4ffa-b1f8-4e06ff18098f">seven years</ix:nonNumeric> from the grant date.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance and market conditions associated with PSU awards granted during the quarter ended March 31, 2022 include vesting that is based on revenue growth targets (<ix:nonFraction unitRef="number" contextRef="i9d16553d025b4028aa1658a83e5f4561_D20220101-20220331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjE5OTAyMzI2MzY2Mg_3a71d99a-1866-4958-b3b9-9268418b030e">34</ix:nonFraction>% weighting), adjusted earnings per share targets (<ix:nonFraction unitRef="number" contextRef="i17685ad6b9cf47d5a2539fde84607b3c_D20220101-20220331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjE5OTAyMzI2MzY2Nw_84c3746c-dc41-4f69-94a2-f352212aa6e3">33</ix:nonFraction>% weighting), and relative total stockholder return (<ix:nonFraction unitRef="number" contextRef="i425eb7ec3ba04e4d97719f260b166abb_D20220101-20220331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjE5OTAyMzI2MzY3Mg_fc667561-5f09-4e82-90d0-b6c87ddb2d91">33</ix:nonFraction>% weighting) measured against the Nasdaq Health Care Index (IXHC) using the 20-trading day averages at the beginning and end of the measurement period. The measurement period for the PSUs is January 1, 2022 through December 31, 2024. The Company estimates the likelihood of achievement of performance conditions at the end of each period. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><ix:continuation id="i11b91f7fb1c24cfabb1218331229cff6" continuedAt="i83e34348d7444ef581904f7c7f63beb6"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMzk2Mg_68fcefff-563e-4c13-b2af-451599aff31e" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company&#8217;s equity plans and inducement awards, for the three months ended March&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfMS0xLTEtMS04MjA5Mg_6d5eb6b8-3b9b-4024-8563-3352554ca046">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfMS0zLTEtMS04MjA5Mg_51e5054e-7bc9-49b9-904d-ddf3f7c90375">20.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNC0xLTEtMS04MjA5Mg_115c89ec-58ed-4ae4-85cc-9fe870d927d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNC0zLTEtMS04MjA5Mg_9e0bd915-86ff-494b-9b9c-4a8ea2bd16a2">23.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNS0xLTEtMS04MjA5Mg_88084377-3242-4252-8c5c-4be93624fed2">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNS0zLTEtMS04MjA5Mg_2dae1fe8-1f8f-4d55-8ca5-924ffe9fbc7b">24.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNi0xLTEtMS04MjA5Mg_40b0fcd9-e197-423f-8546-05e02a560757">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNi0zLTEtMS04MjA5Mg_10b4d2b1-f706-47d1-be30-d4e78c0c37db">20.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNy0xLTEtMS04MjA5Mg_006ba448-3ea0-4c69-9914-7c128f76f747">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNy0zLTEtMS04MjA5Mg_577d89f4-d603-4a6d-ba27-09e42ec7550d">22.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjA4NA_602830a6-7f38-49e1-906a-b2d9d748c6ed">2.0</ix:nonFraction> million of total unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of <ix:nonNumeric contextRef="ife4ee7239ab34cb7986b1613a6ea4129_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjIyNQ_3175e9ac-1d6e-4d07-bfa5-b81c56e66e70">1.8</ix:nonNumeric> years. There were no options granted during the three months ended March 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMzk2Mw_a52cae2f-d6af-4104-b6a3-cf4314af574d" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU awards activity under the Company&#8217;s equity plans and inducement awards, including RSU awards with performance metrics, for the three months ended March&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6d5670611ac54c00895e101571e289ec_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfMS0xLTEtMS04MjA5Mg_97e479e9-5882-44f4-a29d-8181e4f19373">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6d5670611ac54c00895e101571e289ec_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfMS0zLTEtMS04MjA5Mg_79abfe23-f3e7-499d-8d59-1f8b345ef807">24.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfMi0xLTEtMS04MjA5Mg_bfd090bd-ca93-4593-a2ed-e7b534f0458d">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfMi0zLTEtMS04MjA5Mg_758d862f-dc14-43a9-ac9a-c4f43d115bf8">27.17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfNC0xLTEtMS04MjA5Mg_945593e1-e54e-4230-8438-4f0c21f5b637">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfNC0zLTEtMS04MjA5Mg_a3e4a2b6-aed3-4983-9981-d8f7636c3d33">28.24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs canceled</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfNS0xLTEtMS04MjA5Mg_60dd1383-704f-42ec-803d-6ad09360ac6e">0.1</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfNS0zLTEtMS04MjA5Mg_0c80bcb5-cf6f-411c-894b-7975c88feb75">24.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at March 31, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7e88ace7ed394a94800fdca61421e851_I20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfNi0xLTEtMS04MjA5Mg_825dafd1-62ae-4823-b17f-3bc9af6c9a70">4.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e88ace7ed394a94800fdca61421e851_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfNi0zLTEtMS04MjA5Mg_ef21a422-1eb1-4986-a1e7-8a86ed2ccf92">25.43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i7e88ace7ed394a94800fdca61421e851_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjQ1MA_680c986b-8711-43f1-aaf7-91c6cd8bef6e">90.8</ix:nonFraction> million of total unrecognized stock-based compensation expense related to RSUs that will be recognized over a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weighted-average period of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjU4Mg_a7ecd20a-46ef-4bf8-b354-dbdbdc4cf392">2.7</ix:nonNumeric> years.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the &#8220;2012 Purchase Plan&#8221;), under which <ix:nonFraction unitRef="shares" contextRef="i83a6571b146e482389af3212034e29e0_I20121231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjc1MQ_5fdb62a7-dc6a-492d-9dff-efcd2c25acdd">2.0</ix:nonFraction> million shares of common stock have been authorized.&#160;&#160;On September 23, 2021, the Board of Directors of the Company approved an Amended and Restated 2012 Employee Stock Purchase Plan, which authorizes an additional <ix:nonFraction unitRef="shares" contextRef="iaac367b814414abc8b2dc1fcfc86625f_D20210923-20210923" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjk2MA_0d697e6c-7c73-45c1-a253-8a9f1b456844">2.0</ix:nonFraction>&#160;million shares of common stock and extends the term of the 2012 Purchase Plan to November 30, 2032, subject in each case to obtaining stockholder approval. The Company is seeking stockholder approval of the Amended and Restated 2012 Employee Stock Purchase Plan at its 2022 Annual Meeting of Stockholders to be held on June 2, 2022. The Amended and Restated 2012 Employee Stock Purchase Plan also amended certain provisions of the 2012 Purchase Plan effective upon approval by the Board of Directors, including expanding the definition of "offering period" to provide that the Board of Directors may determine the period in accordance with the terms of the plan, and capping the number of shares that may be purchased by any participant during an offering period at <ix:nonFraction unitRef="shares" contextRef="iaac367b814414abc8b2dc1fcfc86625f_D20210923-20210923" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMzU0NA_187ecb7f-6765-4717-aa75-998fd38641de">5,000</ix:nonFraction> shares. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period.&#160;As of March&#160;31, 2022, a total of approximately <ix:nonFraction unitRef="shares" contextRef="i5030a2b3d82c4d60868c0b2191a2d4a0_D20211205-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMTA5OTUxMTYzMTc1Ng_ee19406d-b37a-4745-9f46-5a279357f812">2.0</ix:nonFraction>&#160;million shares of common stock had been purchased under the 2012 Purchase Plan.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><ix:continuation id="i83e34348d7444ef581904f7c7f63beb6"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMzk2NA_6038c83f-3b2f-486e-9113-f8348548577a" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.009%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i86d71b985caa4964a6e254ec96cb87cd_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfMi0xLTEtMS04MjA5Mg_6b74e18f-cbb1-48e4-9890-c3a9af0d2f3e">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iafba3568c8f8479caf7ae3e55c4f2129_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfMi00LTEtMS04MjA5Mg_b465f4e0-b0b5-44b8-b675-06e7c3405a3f">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2566e34ad9de42d492126a12c9a969e8_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfMy0xLTEtMS04MjA5Mg_5b589763-a61a-4b50-b03c-ef423345841e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i72551335efb84f1dacbfab6e1f4b32f2_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfMy00LTEtMS04MjA5Mg_322286e2-085c-4d23-be5b-444dbb288d41">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0e442b7e778a40d0b0ea4e18405b7a44_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfNC0xLTEtMS04MjA5Mg_f4e7e32e-1310-41a7-9824-6e2c6fe92312">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5ccf0e5050c9430eba39a50029c3c70e_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfNC00LTEtMS04MjA5Mg_c7e6b343-1ec1-42da-9e4a-253613cc0c54">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1114d9d3200747a2a214afd2bfab8814_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfNS0xLTEtMS04MjA5Mg_5ceef722-01fb-4e99-a6a2-4e6e26ef06ea">7.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie78cb4d47d2f4c79b9717d147044b377_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfNS00LTEtMS04MjA5Mg_6a2fd02b-a85e-49c2-a2fe-3ec2e89a0684">7.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfNi0xLTEtMS04MjA5Mg_62c4694b-350b-4556-8cb0-6e1ca448975d">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfNi00LTEtMS04MjA5Mg_120557a1-1ece-4427-b9fd-8bfc39ed40ad">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib6fee90945e74b97b833695fd82463c2_67"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMjIxNA_1cb9896b-080c-4cf4-93db-94bf31bb62ac" continuedAt="iacc4695d4643464eb319b3cfe3c4f8db" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="iacc4695d4643464eb319b3cfe3c4f8db"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the Company&#8217;s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates.&#160;Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit for the three months ended March&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfNTE0_7133bee9-7f1f-4319-944f-7efcc341839d">5.9</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfNTM1_c84fd19a-7ec6-4a60-85f6-c4d333451868">22.3</ix:nonFraction>% of pre-tax income compared to an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfNTkz_bd1f438c-4c67-4303-9d68-09c47b53fe9c">10.1</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfNjE0_eeb0d306-c739-4a35-be8b-7875c076cd2a">20.4</ix:nonFraction>% of pre-tax loss, for the three months ended March&#160;31, 2021.&#160;Income tax expense for the three months ended March&#160;31, 2022 is based on the Company&#8217;s estimated annualized effective tax rate for the fiscal year ending December 31, 2022, adjusted for discrete items recognized during the respective periods.&#160;&#160;For the three months ended March&#160;31, 2022, the Company&#8217;s recognized effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, stock compensation expenses, and asset impairment expenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations.&#160;&#160;The Company is currently under audit by the State of California for the fiscal years ended June 30, <ix:nonNumeric contextRef="i4c40a24632bf4346946172c6e98b52fc_D20220101-20220331" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMTc2NA_92d9c9c1-7ac4-49e5-971f-c66c4cc017b8">2017</ix:nonNumeric>-<ix:nonNumeric contextRef="i2b99c5119ccf4bec978689998d8156c9_D20220101-20220331" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMTc2Nw_6dd773cd-a5bb-4c9a-b31f-a807b33afdf4">2018</ix:nonNumeric>, the State of New Jersey for the fiscal years ended June 30, <ix:nonNumeric contextRef="iddf2e4709d4e4f3c8f8de9d3848531a3_D20220101-20220331" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMTgzMQ_ca09b83c-4d60-4941-9db6-e56c04455df8">2013</ix:nonNumeric>-<ix:nonNumeric contextRef="i165aceb443f54911b03d14bf7fa31bef_D20220101-20220331" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMTgzNA_3f9a4d51-7f42-4726-b6b2-72b716e65940">2017</ix:nonNumeric>; and Switzerland for the fiscal years ended June 30, <ix:nonNumeric contextRef="i0f49e0371ac14b658fae67bfe038cf32_D20220101-20220331" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMTk0NQ_b6a6e00a-0bd1-4ef8-9723-5647fcaa57ed">2015</ix:nonNumeric>-<ix:nonNumeric contextRef="i9b97c328c10c4fa3b4b35d35fc41de1f_D20220101-20220331" name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMTk0OA_c653d01b-bf90-443c-9a74-93b231dc600c">2016</ix:nonNumeric>. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.</span></div></ix:continuation><div id="ib6fee90945e74b97b833695fd82463c2_70"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83MC9mcmFnOmViNzMxNzc2YTA3MDRhNDg4ZGJkMGUzOTAzMDllZDY3L3RleHRyZWdpb246ZWI3MzE3NzZhMDcwNGE0ODhkYmQwZTM5MDMwOWVkNjdfNzcwNw_733783bb-410e-41c9-811c-3aa9caf706f9" continuedAt="iade7c54a34ed4c8fac33f19cc85e4c30" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="iade7c54a34ed4c8fac33f19cc85e4c30" continuedAt="i655969111e984f2caacf381ec03efc5b"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved from time to time in various disputes, claims and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amount of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company is involved, and has received subpoenas, from time to time, related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to vigorously defend its current litigation matters, but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><ix:continuation id="i655969111e984f2caacf381ec03efc5b" continuedAt="id8c4e25d44734a40ba74e56b4c1af15a"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the proceedings may be in early stages, there may be uncertainty as to the outcome of pending appeals or motions, there may be significant factual issues to be resolved, and there may be complex or novel legal theories to be presented. In addition, damages may not be specified or the damage amounts claimed may be unsupported, exaggerated or unrelated to possible outcomes, and therefore, such amounts are not a reliable indicator of potential liability. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as noted below, as of March 31, 2022, the Company has not recorded any accrual for loss contingencies associated with legal proceedings or other matters or determined that an unfavorable outcome is probable and reasonably estimable in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, it is possible that the ultimate resolution of legal proceedings or other matters, if unfavorable, may be material to the Company's results of operations, financial condition or cash flows.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qui Tam Lawsuit</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company's wholly owned subsidiary, Crescendo Bioscience, LLC (formerly known as Crescendo Biosciences, Inc. (&#8220;CBI&#8221;), received a subpoena from the Office of Inspector General of the Department of Health and Human Services (the "Office of Inspector General") requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act ("CIFPA").  On January 22, 2020, after a multi-year investigation into CBI&#8217;s and the Company&#8217;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company&#8217;s motion to dismiss. As of March 31, 2022, the Company has accrued $<ix:nonFraction unitRef="usd" contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331" decimals="-5" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83MC9mcmFnOmViNzMxNzc2YTA3MDRhNDg4ZGJkMGUzOTAzMDllZDY3L3RleHRyZWdpb246ZWI3MzE3NzZhMDcwNGE0ODhkYmQwZTM5MDMwOWVkNjdfMTcwMg_77ab569c-eae0-46df-9ec3-701ea14b3def">48.0</ix:nonFraction> million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in accrued liabilities in the Company's Condensed Consolidated Balance Sheet as of March 31, 2022. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, the Company settled the qui tam lawsuit with the relator, STF, LLC (the "Relator"). Pursuant to the terms of the settlement agreements, the Company agreed to pay a total of $<ix:nonFraction unitRef="usd" contextRef="idd3dfbf88a4f49d29528546627f27aa0_D20220401-20220401" decimals="-4" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83MC9mcmFnOmViNzMxNzc2YTA3MDRhNDg4ZGJkMGUzOTAzMDllZDY3L3RleHRyZWdpb246ZWI3MzE3NzZhMDcwNGE0ODhkYmQwZTM5MDMwOWVkNjdfMjE5OTAyMzMwMTEwMQ_03d5aebc-c710-4f94-ae0e-85b1a6b89ead">45.25</ix:nonFraction>&#160;million to the United States and the State of California and $<ix:nonFraction unitRef="usd" contextRef="i725231d93b934c6d91bff94381a504dd_D20220401-20220401" decimals="-4" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83MC9mcmFnOmViNzMxNzc2YTA3MDRhNDg4ZGJkMGUzOTAzMDllZDY3L3RleHRyZWdpb246ZWI3MzE3NzZhMDcwNGE0ODhkYmQwZTM5MDMwOWVkNjdfMjE5OTAyMzMwMTExNw_7b19b52c-5064-46e8-82b4-bb2cfe3645d2">2.75</ix:nonFraction>&#160;million to Relator&#8217;s counsel. The Relator agreed to the dismissal of the lawsuit with prejudice as to the Relator and fully released all claims against the defendants and their affiliates, directors, officers, and employees. The State of California agreed to the dismissal of the lawsuit with prejudice as to the State of California and released the defendants from any claims submitted to the State&#8217;s Medicaid program or under the CIFPA as a result of certain alleged conduct. The United States Department of Justice approved the settlement of federal claims, including dismissal of the lawsuit without prejudice as to the United States. The settlement agreements contain no admission of liability, wrongdoing or responsibility on the part of the defendants. The Company expressly denies any and all liability for claims alleged in the lawsuit. On May 4, 2022, the qui tam lawsuit was formally dismissed by the United States District Court for the Northern District of California.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Class Action</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2019, a class action complaint was filed in the United States District Court for the District of Utah against the Company, its former President and Chief Executive Officer, Mark C. Capone, and its Chief Financial Officer, R. Bryan Riggsbee (the &#8220;Defendants&#8221;). On February 21, 2020, the plaintiff filed an amended class action complaint, which added the Company's former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Myriad Genetics, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding the Company's business, operations, and acquisitions.  The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees. On March 16, 2021, the United States District Court for the District of Utah denied the Company's motion to dismiss. On December 1, 2021, the United States District Court for the District of Utah granted plaintiff's motion for class certification. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><ix:continuation id="id8c4e25d44734a40ba74e56b4c1af15a" continuedAt="ieba3ec9232754f3e9eb2bf54dcbfde5d"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Derivative Actions</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's  former President and Chief Executive Officer, Mark C. Capone, its Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of its current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, a  stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and the Hickock stockholder derivative action. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2022, the Delaware Court of Chancery consolidated the Hickock and Kogus derivative actions and stayed the consolidated action. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, a stockholder derivative complaint was filed in the United States District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the United States District Court for the District of Delaware pending the resolution of the securities class action lawsuit. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Legal Matters</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2022, a purported class action lawsuit was filed against the Company in the United States District Court in the Northern District of California by Ashley Carroll. Plaintiff alleges, among other things, that the Company made false statements about the accuracy of its Prequel prenatal screening test. The complaint seeks unspecified monetary damages and injunctive relief. On April 1, 2022, the Company filed a motion to dismiss the lawsuit.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieba3ec9232754f3e9eb2bf54dcbfde5d">From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.</ix:continuation> </span></div><div id="ib6fee90945e74b97b833695fd82463c2_76"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RleHRyZWdpb246ZjRjYTliY2Y0YzljNDdkMDgzZTY2Y2JmZWIzYThlYTNfNDM_05bfe11b-8bed-48f4-adb7-2ac17f6c5522" continuedAt="i4ffc0256599b4c2b86ba9750f6017c2c" escape="true">SUPPLEMENTAL CASH FLOW INFORMATION</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i4ffc0256599b4c2b86ba9750f6017c2c"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RleHRyZWdpb246ZjRjYTliY2Y0YzljNDdkMDgzZTY2Y2JmZWIzYThlYTNfNDI_89b235bc-b65c-4e0b-b47d-6ca3afd885f3" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid during the period for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfMi0xLTEtMS04MjA5Mg_dc0f707d-cc10-43cb-93e0-4cfcb3579ec4">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfMi00LTEtMS04MjA5Mg_9c4bdbce-8beb-42eb-ae58-42b37a0d9d79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfMy0xLTEtMS04MjA5Mg_ddbe1a7a-54e8-4e3f-9648-39fda5a173d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfMy00LTEtMS04MjA5Mg_d063da9c-bfea-4b14-848e-d67a7aadc88b">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfNi0xLTEtMS04MjA5Mg_13857e2d-8235-4df6-8043-12a60d51e6c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfNi00LTEtMS04MjA5Mg_468389be-6157-4d65-86d8-5b304de56ec5">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="mygn:OperatingLeaseLiabilityEstablished" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfNy0xLTEtMS04MjA5Mg_b4a6a443-0bd4-44a6-8b2b-e4120ef0dc1e">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="mygn:OperatingLeaseLiabilityEstablished" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfNy00LTEtMS04MjA5Mg_4563f83b-0b32-4a90-8963-b7e16e4c604f">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property, plant and equipment in accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfOC0xLTEtMS05MTczNA_a768581b-172e-4b9b-95d6-8cd4466edab9">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfOC00LTEtMS05MTc0MQ_97edb5f0-2670-439f-9705-099ac773bbe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="padding-left:36pt"><span><br/></span></div><div id="ib6fee90945e74b97b833695fd82463c2_1133"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8yMTk5MDIzMjU2NzEx_7b805759-02b6-4457-8919-acd158fc80dc" continuedAt="i7ffe5700d6d74fbab0123e9891b77edd" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i7ffe5700d6d74fbab0123e9891b77edd"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from one to fourteen years. During the quarter ended March 31, 2022, in an effort to reduce its real estate footprint, the Company ceased the use of one of its leased Salt Lake City facilities. As a result, the Company recorded an impairment charge on right-of-use assets of $<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8xMDk5NTExNjI5NTc0_031b24d3-d63c-4bc0-b663-4d6715d56149">8.6</ix:nonFraction> million and an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i49163efc76014827a31448fd386b5085_D20220101-20220331" decimals="-5" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8xMDk5NTExNjMxNzc5_f87163a7-256e-43b3-ad91-5ab877827bec">2.1</ix:nonFraction> million on the related leasehold improvements. The total $<ix:nonFraction unitRef="usd" contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8xMDk5NTExNjMyOTM1_bcb5d5a6-4834-4634-b2be-5a98adf6d95c">10.7</ix:nonFraction> million impairment is included in Goodwill and long-lived asset impairment charges in the Condensed Consolidated Statement of Operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022, we entered into a non-cancelable operating lease for approximately <ix:nonFraction unitRef="sqft" contextRef="i04e805b5f43a48c59b3233b51bbc2f4c_D20220101-20220331" decimals="-3" name="mygn:LesseeOperatingLeaseAreaOfLeasedSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8yMTk5MDIzMjYxNTE4_37b20754-a8e8-41e7-84f8-35f66be958be">230,000</ix:nonFraction> square feet in west Salt Lake City, Utah. The lease has a term of <ix:nonNumeric contextRef="i9b97b4edf342400a89726e31b3e19c6c_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8yMTk5MDIzMjYxNTEx_855afee6-896f-4343-92a7-9a6746211651">15</ix:nonNumeric> years, which, along with rent payments, are expected to commence in the third quarter of 2023. Total future rent payments under the lease is approximately $<ix:nonFraction unitRef="usd" contextRef="i9b97b4edf342400a89726e31b3e19c6c_I20220331" decimals="-5" name="mygn:LesseeOperatingLeaseExpectedFutureRentPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8yMTk5MDIzMjYxNTI3_03414902-4c62-45ae-8a4e-2f7c1752be2f">77.8</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="ib6fee90945e74b97b833695fd82463c2_82"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl84Mi9mcmFnOjIzZjFkNWNjMjM5NTQyYjE4MjBiNTFmNDQxNGU3NDRjL3RleHRyZWdpb246MjNmMWQ1Y2MyMzk1NDJiMTgyMGI1MWY0NDE0ZTc0NGNfMjk5_669a77a6-7260-4080-bdbc-3aa72321af30" continuedAt="ia1b389c2cb834059ab22d57f9604c4c0" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia1b389c2cb834059ab22d57f9604c4c0">As previously noted, on April 1, 2022, the Company settled the qui tam lawsuit with the Relator. Pursuant to the terms of the settlement agreements, the Company agreed to pay a total of $<ix:nonFraction unitRef="usd" contextRef="idd3dfbf88a4f49d29528546627f27aa0_D20220401-20220401" decimals="-4" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl84Mi9mcmFnOjIzZjFkNWNjMjM5NTQyYjE4MjBiNTFmNDQxNGU3NDRjL3RleHRyZWdpb246MjNmMWQ1Y2MyMzk1NDJiMTgyMGI1MWY0NDE0ZTc0NGNfMjE5OTAyMzI1OTc2Mw_d639d749-c48f-4605-9a09-028af6296c3b">45.25</ix:nonFraction>&#160;million to the United States and the State of California and $<ix:nonFraction unitRef="usd" contextRef="i725231d93b934c6d91bff94381a504dd_D20220401-20220401" decimals="-4" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl84Mi9mcmFnOjIzZjFkNWNjMjM5NTQyYjE4MjBiNTFmNDQxNGU3NDRjL3RleHRyZWdpb246MjNmMWQ1Y2MyMzk1NDJiMTgyMGI1MWY0NDE0ZTc0NGNfMjE5OTAyMzI1OTc3OQ_1c2faa88-4ea9-43fd-b905-8dcf93b0c4c6">2.75</ix:nonFraction>&#160;million to Relator&#8217;s counsel. On April 7, 2022, the Company paid the settlement amounts in full. On May 4, 2022, the qui tam lawsuit was formally dismissed by the United States District Court for the Northern District of California.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Dollars and shares in millions, except per share data)</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the related notes thereto included in this Quarterly Report on Form 10-Q and the audited Consolidated Financial Statements and notes thereto and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2021 included in our Annual Report on Form 10-K filed with the SEC on February 25, 2022. &#8220;We,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Myriad&#8221; and the &#8220;Company&#8221; as used in this Quarterly Report on Form 10&#8209;Q refer to Myriad Genetics, Inc., a Delaware corporation, and its subsidiaries.</span></div><div id="ib6fee90945e74b97b833695fd82463c2_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC encourages companies to disclose forward-looking information so that investors can better understand a company&#8217;s future prospects and make informed investment decisions. This Quarterly Report on Form 10&#8209;Q contains such &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Words such as &#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seek,&#8221; &#8220;could,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;strategy&#8221; and &#8220;goal&#8221; and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. All forward-looking statements are management&#8217;s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services and on our ability to efficiently and flexibly manage our business; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that sales and profit margins of our existing molecular diagnostic tests may decline or that we may not be able to operate our business on a profitable basis; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our ability to generate sufficient revenue from our existing product portfolio or in launching and commercializing new tests; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to changes in governmental or private insurers&#8217; coverage and reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to increased competition and the development of new competing tests and services; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests in a timely manner, or at all; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that we may not successfully develop new markets for our molecular diagnostic tests, including our ability to successfully generate revenue outside the United States; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that licenses to the technology underlying our molecular diagnostic tests and any future tests are terminated or cannot be maintained on satisfactory terms; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to delays or other problems with operating and constructing our laboratory testing facilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to public concern over genetic testing in general or our tests in particular;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license, acquire, or develop; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to our projections about the potential market opportunity for our current and future products; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk of patent-infringement claims or challenges to the validity of our patents; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to changes in intellectual property laws covering our molecular diagnostic tests, or patents or enforcement, in the United States and foreign countries; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">risks related to security breaches, loss of data and other disruptions, including from cyberattacks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks of new, changing and competitive technologies and regulations in the United States and internationally; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the material weakness related to our general information technology controls, including the impact thereof and our remediation plan, and our inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to current and future lawsuits, including product or professional liability claims; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on February 25, 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report, or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements in this Quarterly Report attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.</span></div><div id="ib6fee90945e74b97b833695fd82463c2_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. We provide insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. We develop and commercialize genetic tests that help assess the risk of developing disease or disease progression or guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower health care costs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personalized genetic data and digital and virtual consumer trends are converging to change traditional models of care. Significant growth opportunities exist to help patient populations with pressing health care needs through innovative solutions and services. We are currently executing a strategic transformation and growth plan that aims to capitalize on those trends by focusing on three strategic priorities: (1) innovation that improves clinical outcomes, ease of use, and access, (2) enterprise capabilities to accelerate growth and scale to market opportunity; and (3) a focus on execution and delivery of consistent results. In connection with these strategic priorities, we are focusing our efforts in three key areas where we have specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In each of these areas, we intend to develop and enhance best-in-class products to support growth, improve patient and provider experience, and reach more patients of all backgrounds. By investing in tech-enabled commercial tools, we believe we will be able to drive increased engagement, improve revenue cycle management, and reduce complexity and cost. We are committed to disciplined management of a key set of initiatives to fulfill our mission and drive long-term growth and profitability. With a foundation of financial, commercial, operational and technological strength, we expect to accelerate growth as we launch a new enterprise commercial model, launch a unified ordering portal, invest in new sequencing technologies, further develop direct-to-consumer channels, and build commercial capabilities to support new products and offerings.</span></div><div id="ib6fee90945e74b97b833695fd82463c2_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the quarter ended March 31, 2022, we continued to take meaningful steps to fulfill our mission and execute our strategic transformation and growth plan. We have also made the following recent announcements:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">On February 23, 2022, we announced that peer-reviewed journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Psychiatry Research</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> published a new analysis of GeneSight Psychotropic showing that the combinatorial approach available in the GeneSight&#174; Psychotropic test is more effective than single-gene testing at predicting setraline metabolism in patients with major depressive disorder.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">On March 8, 2022, we announced that Myriad Genetics, Inc. was recognized on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fast Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">'s annual list of the World's Most Innovative Companies for 2022.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">On March 11, 2022, we received FDA approval of BRACAnalysis CDx as a companion diagnostic for Lynparza in early breast cancer.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">On March 14, 2022, we announced the launch of Precise Oncology Solutions, a comprehensive offering designed to help oncologists determine effective and personalized treatment plans for individual patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three Months Ended March 31, 2022 and 2021</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The results of operations for the three months ended March 31, 2022 and 2021 are discussed below.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of total revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues increased $5.3&#160;million for the three months ended March 31, 2022 compared to the same period in the prior year. Revenues from Pharmacogenomics increased $11.7&#160;million compared to the same period in the prior year due primarily to a 49% increase in volume. Prenatal revenues increased $8.2&#160;million compared to the same period in the prior year due primarily to a 23% increase in average reimbursement per test and revenue related to tests performed in prior periods. Hereditary Cancer revenues decreased $5.2&#160;million compared to the same period in the prior year due to a 13% decrease in volume, partially offset by a 4% increase in average reimbursement per test. Tumor profiling revenues increased $1.5&#160;million compared to the same period in the prior year. Autoimmune revenues decreased $10.4&#160;million due to the sale of the Myriad Autoimmune business on September 13, 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenues were $13.5&#160;million in the prior period. As a result of the sale of Myriad RBM, Inc. on July 1, 2021, there were no Pharmaceutical and clinical services revenues during the current period. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of molecular diagnostic testing as a % of revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of pharmaceutical and clinical services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.2)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of pharmaceutical and clinical services as a % of revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of molecular diagnostic testing as a percentage of revenue increased from 27.6% to 29.1% during the three months ended March&#160;31, 2022 compared to the same period in the prior year. The increase was primarily driven by the shift in the product mix for the current period.&#160;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of pharmaceutical and clinical services as a percentage of revenue was 45.9% for the three months ended March 31, 2021. The sale of Myriad RBM, Inc. was completed on July 1, 2021, and as a result there were no corresponding costs during the current period.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.9)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense as a % of total revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense for the three months ended March&#160;31, 2022 decreased compared to the same period in the prior year primarily due to a decrease in costs incurred in the current period as a result of certain costs related to the Company&#8217;s strategic transformation initiatives not recurring in the current period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35.8)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense as a % of total revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense decreased for the three months ended March&#160;31, 2022 compared to the same period in the prior year primarily due to an $11.0 million decrease in costs incurred in the current period as part of the Company's strategic transformation initiatives, the receipt of $11.4 million from insurers to offset the previously accrued Abelli settlement and other legal expenses, an $8.7 million decrease in compensation-related expenses due to lower headcount as a result of the divestitures in the prior year, a $2.9 million decrease in amortization expense due to intangible assets sold in the divestitures in the prior year, and a $2.7 million decrease in general legal expenses, partially offset by a $3.0 million increase in marketing expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and long-lived asset impairment charges</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and long-lived asset impairment charges</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and long-lived asset impairment charges as a % of total revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and long-lived asset impairment charges increased for the three months ended March&#160;31, 2022 compared to the same period in the prior year primarily due to the Company recognizing an $8.6 million impairment to right-of-use assets and a $2.1 million impairment to the related leasehold improvements in the current period as a result of its decision to no longer use one of its facilities in order to consolidate space. There were no impairments recognized in the prior period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.9)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net decreased for the three months ended March&#160;31, 2022 compared to the same period in the prior year due primarily to a $2.1 million decrease in interest expense in the current period. The interest expense in the prior period is related to the debt outstanding at that time with no corresponding debt outstanding in the current period, as the debt was repaid in full on July 30, 2021.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Benefit  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.9)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.1)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tax rate is the product of a blended U.S. federal effective rate of 21.0% and a blended state income tax rate of approximately 4.2%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax benefit for the three months ended March&#160;31, 2022 was $5.9 million, and our effective tax rate was 22.3%.&#160;&#160;For the three months ended March 31, 2022, our recognized effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, stock compensation expenses and asset impairment expenses. For the three months ended March 31, 2021, our recognized effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, and stock compensation expenses.</span></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ib6fee90945e74b97b833695fd82463c2_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash, cash equivalents and marketable investment securities, our cash flows from operations, our cash flows from investing activities, and, in certain circumstances, as discussed below, amounts available for borrowing under our Amended Facility. Our capital deployment strategy focuses on use of resources in the key areas of research and development, technology and acquisitions. We believe that investing organically through research and development or acquisitively to support business strategy provides the best return on invested capital. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources will be sufficient to meet our projected operating requirements for the foreseeable future. In addition, our capital resources and cash on hand may be used for acquisitions or other strategic investments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All previously outstanding borrowings under our Amended Facility, which matures on July 31, 2023, were repaid on July 30, 2021 using cash generated from our recent divestitures and as such, we have no outstanding borrowings as of March 31, 2022. Our available capital resources, however, may be consumed more rapidly than currently expected, and we may need or want to raise additional financing. We may not be able to secure such financing in a timely manner or on favorable terms, if at all, and the current rising interest rate environment could make any potential financing more difficult or expensive to obtain. In addition, we are subject to financial covenants under our Amended Facility that could limit our ability to incur additional indebtedness or impact our decision to pursue other financing. Without additional funds, we may be forced to delay, scale back or eliminate some of our sales and marketing efforts, research and development activities, or other operations, and potentially delay development of our diagnostic tests in an effort to provide sufficient funds to continue our operations. If any of these events occurs, our ability to achieve our development and commercialization goals could be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility restricts our ability to make future borrowings if unrestricted cash, cash equivalents and marketable securities exceed $150.0 million, unless such borrowings are used in connection with certain permitted acquisitions. Unrestricted cash, cash equivalents and marketable securities totaled $339.2&#160;million as of March 31, 2022. Our revolving commitment amount is $250.0 million as of March 31, 2022. As the Company's total unrestricted cash, cash equivalents, and marketable securities exceeded $150.0 million as of March 31, 2022, we are unable to make future borrowings unless related to a permitted acquisition. In addition, following the expiration of the waiver of the leverage ratio and interest coverage ratio covenants, which waiver was effective until March 31, 2022, our ability to borrow under the Amended Facility will be limited if we are unable to comply with those financial covenants.  If we are unable to comply with certain covenants and ratios in the Amended Facility, we may be in default under the Amended Facility, which could impact our ability to borrow under the facility or result in the termination of the commitments under the Amended Facility or the Company being required to pay off any outstanding loans or fees and cash collateralize any outstanding letters of credit. In the future, we may seek waivers or amendments from our lenders in order to avoid a future covenant violation, in addition to taking other potential actions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into purchase commitments or other agreements that may materially impact our liquidity position in future periods. In February 2022, we entered into a non-cancelable operating lease for approximately 230,000 square feet in west Salt Lake City, Utah. The lease has a term of 15 years, which, along with rent payments, are expected to commence in the third quarter of 2023. Total future rent payments under the lease is approximately $77.8 million. In addition, we have accrued $48.0 million for the settlement of the qui tam lawsuit against Crescendo Bioscience, LLC and the Company, which is included in Accrued liabilities in our Condensed Consolidated Balance Sheet as of March 31, 2022. The $48.0 million settlement was subsequently paid in April 2022. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the continually evolving global situation from the COVID-19 pandemic, it is not possible to predict whether ongoing consequences of the pandemic are reasonably likely to materially affect our liquidity and capital resources in the future. Because of the technical nature of our business and our focus on science, research and development, we are highly dependent upon our ability to attract and retain highly qualified and experienced management, scientific, and technical personnel. Competition and compensation for such personnel and other qualified personnel increased as employment vacancies surged during the year ended December 31, 2021 and into the quarter ended March 31, 2022, which has increased the difficulty and cost of hiring and retaining qualified personnel. Loss of the services of or failure to recruit additional key management, scientific and technical personnel and other qualified personnel who are necessary to operate our business would adversely affect our business, and it may have a material adverse effect on our business as a whole. Additionally, disruptions to our supply chain could cause shortages of critical materials required to conduct our business, which may have a material adverse effect on our business as a whole. In addition, inflation has had, and we expect it will continue to have, an impact on the costs we incur to attract and retain qualified personnel, costs to generate sales and produce diagnostic testing results, and costs of lab supplies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the balances of cash, cash equivalents and marketable investment securities:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, <br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(93.2)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable investment securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term marketable investment securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable investment securities</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">398.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in cash, cash equivalents, and marketable investment securities was primarily driven by $46.5 million in cash used by operations, $6.3 million used for capital expenditures, and $4.8 million used for the payment of withholding tax for the issuance of common stock, net of proceeds from the issuance of common stock.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Condensed Consolidated Cash Flow Statement:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in cash flows from operating activities for the three months ended March 31, 2022, compared to the same period in the prior year, was primarily due to the change in the balance of prepaid taxes due to the receipt of an $89.6&#160;million U.S. federal tax refund in the prior period and a $35.3&#160;million decrease in accrued liabilities for the current period, which was  primarily driven by a legal settlement payment of $14.0&#160;million and a decrease of $14.6&#160;million in accrued bonuses due to payout of prior year bonuses, as compared to an $8.4&#160;million increase in accrued liabilities for the prior period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in cash flows from investing activities for the three months ended March 31, 2022, compared to the same period in the prior year, was primarily due to an increase of $52.1&#160;million in purchases of marketable investments securities in the current period as compared to the prior period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows used in Financing Activities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in cash flows used in financing activities for the three months ended March 31, 2022, compared to the same period in the prior year, was primarily due to the use of $70.0&#160;million in cash for repayments of the Amended Facility during the three months ended March 31, 2021, partially offset by a decrease of $30.8&#160;million in proceeds from the exercise of stock options, net of shares exchanged for payroll withholding tax, compared to the same period in the prior year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effects of Inflation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that inflation has had a material impact on our business, sales, or operating results during the periods presented. However, inflation, led by supply constraints, federal stimulus funding, increases to household savings, and the sudden macroeconomic shift in activity levels arising from the loosening or removal of many government restrictions and the broader availability of COVID-19 vaccines, has had, and may continue to have, an impact on the labor costs we incur to attract and retain qualified personnel, costs to generate sales and produce diagnostic testing results, and costs of lab supplies. Inflationary costs may impact our profitability and could adversely affect our business, financial condition and results of operations. In addition, increased inflation has had, and may continue to have, an effect on interest rates. Increased interest rates may adversely affect our borrowing rate and our ability to obtain, or the terms under which we can obtain, any potential additional funding. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those policies which are both important to the presentation of a company&#8217;s financial condition and results and require management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a further discussion of our critical accounting policies, see our Annual Report on Form&#160;10-K. No significant changes to our accounting policies took place during the three months ended March 31, 2022.</span></div><div id="ib6fee90945e74b97b833695fd82463c2_106"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our market risk during the three months ended March 31, 2022 compared to the disclosures in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/899923/000089992322000033/mygn-20211231.htm#ifead9d28cda549c1af769d1d50d95807_64">Part II, Item&#160;7A of our Annual Report on Form 10-K</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> filed with the SEC on February 25, 2022, which are incorporated by reference herein.</span></div><div id="ib6fee90945e74b97b833695fd82463c2_109"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures (&#8220;Disclosure Controls&#8221;) within the meaning of Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our Disclosure Controls are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Our Disclosure Controls are also designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our Disclosure Controls, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily applied its judgment in evaluating and implementing possible controls and procedures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this Quarterly Report on Form 10-Q, we evaluated the effectiveness of the design and operation of our Disclosure Controls, which was done under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on the evaluation of our Disclosure Controls, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2022, our Disclosure Controls are not effective.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management concluded that, as of December 31, 2021, a material weakness in internal control over financial reporting exists related to general information technology controls for information systems that are relevant to the preparation of the financial statements. Specifically, the material weakness resulted from the aggregation of control deficiencies related to systems supporting the Company's internal control processes. This material weakness has not been remediated as of March 31, 2022. Our IT-dependent business process controls were also deemed ineffective because they could have been adversely impacted. While the aggregation of these deficiencies did not result in any misstatement of the consolidated financial statements, the material weakness could have resulted in a misstatement impacting account balances or disclosures that would have resulted in a material misstatement to the consolidated financial statements that would not have been prevented or detected on a timely basis. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan to Remediate Material Weakness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is committed to the remediation of the material weakness described above, as well as the continued improvement of our internal control over financial reporting. Management has been implementing, and will continue to implement, measures designed to ensure that our controls are designed, implemented, and operating effectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have begun the process of, and we are focused on, designing and implementing effective internal control measures to improve our internal control over financial reporting and remediate the material weaknesses identified above. Our efforts include the following actions:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Information Technology General Controls ("ITGCs")</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have conducted and will continue to conduct additional training for our IT personnel to ensure a clear understanding of risk assessment, controls and monitoring activities related to automated processes and systems and ITGCs related to financial reporting.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are implementing improved IT policies, procedures and control activities for key systems which impact our financial reporting.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are increasing resources dedicated to monitoring ITGCs related to financial reporting, including additional personnel with the appropriate level of knowledge, experience and training, to ensure compliance with policies and procedures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to remediate this material weakness as soon as possible. We will continue to monitor the effectiveness of our controls and will make any further changes that management determines are appropriate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remediation of Previously Reported Material Weakness</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material weakness in our internal control over financial reporting related to our income tax provision process identified in connection with the preparation of our condensed consolidated quarterly financial statements as of September 30, 2021 has been remediated. Specifically, we did not provide adequate review and control with respect to the completeness and accuracy of inputs used in the income tax provision and related accrual. While the control deficiency did not result in a misstatement of our previously issued consolidated financial statements, the control deficiency could have resulted in a misstatement of the income tax related accounts or disclosures that would have resulted in a material misstatement of our annual or interim consolidated financial statements that would not have been prevented or detected on a timely basis. This material weakness has been remediated as of March 31, 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To improve our internal control over financial reporting and remediate this prior period material weakness, we designed and implemented enhanced controls over the review of information underlying discrete transactions in the income tax provision.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Controls&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - Other Information</span></div><div id="ib6fee90945e74b97b833695fd82463c2_115"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding certain current legal proceedings, see Note 13, "Commitments and Contingencies - Legal Proceedings" in Notes to Condensed Consolidated Financial Statements, which are included herein. </span></div><div id="ib6fee90945e74b97b833695fd82463c2_118"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this Quarterly Report, you should carefully consider the risk factors and other cautionary statements described under the heading &#8220;Item 1A. Risk Factors&#8221; included in our Annual Report on Form 10-K, which could materially affect our business, financial condition or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition or future results. There have been no material changes in our risk factors from those described in our Annual Report on Form 10-K. We may disclose changes to risk factors or additional risk factors from time to time in our future filings with the SEC.</span></div><div id="ib6fee90945e74b97b833695fd82463c2_121"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has previously authorized us to repurchase up to $200.0 million of our outstanding common stock, of which $110.7 million is still available to repurchase as of March&#160;31, 2022. We are authorized to complete the repurchase through open market transactions or through an accelerated share repurchase program, in each case to be executed at management&#8217;s discretion based on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;The repurchase program may be suspended or discontinued at any time without prior notice.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock repurchases were made under our stock repurchase program during the three months ended March 31, 2022.</span></div><div id="ib6fee90945e74b97b833695fd82463c2_124"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ib6fee90945e74b97b833695fd82463c2_127"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ib6fee90945e74b97b833695fd82463c2_130"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992322000014/separationandconsultingagr.htm">Separation and Consulting Agreement, dated February 7, 2022, by and between Myriad Genetics, Inc. and Jerry Lanchbury (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, File No. 000-26642, filed with the SEC on February 9, 2022) +</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-certificationof.htm">Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-certificationof.htm">Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-certificationpu.htm">Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 has been formatted in Inline XBRL.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(+) Management contract or compensatory plan arrangement</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ib6fee90945e74b97b833695fd82463c2_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6fee90945e74b97b833695fd82463c2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MYRIAD GENETICS, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May 6, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Paul J. Diaz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paul J. Diaz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal executive officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May 6, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ R. Bryan Riggsbee</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R. Bryan Riggsbee</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal financial and accounting officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311-certificationof.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i612845c48563483fa8941b4320ee7993_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY SECTION 302(a) CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul J. Diaz, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this quarterly report on Form 10-Q of Myriad Genetics, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.695%"><tr><td style="width:1.0%"></td><td style="width:5.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 6, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312-certificationof.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib2997a496d6641eaa6593766ea8fbace_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY SECTION 302(a) CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, R. Bryan Riggsbee, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this quarterly report on Form 10-Q of Myriad Genetics, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.421%"><tr><td style="width:1.0%"></td><td style="width:5.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 6, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; R. Bryan Riggsbee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Bryan Riggsbee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321-certificationpu.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1878e6600c5b4a8bb1798e41564b9b97_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Myriad Genetics, Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:2.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.463%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 6, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 6, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R. Bryan Riggsbee</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Bryan Riggsbee</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Financial and Accounting Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mygn-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6c4a3a2c-b656-4a66-b2d1-1ba9bc2e559c,g:c641d519-fa56-4157-9313-b107a5eea025-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mygn="http://www.myriad.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.myriad.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.myriad.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.myriad.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.myriad.com/role/BasisofPresentation">
        <link:definition>2101101 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.myriad.com/role/BasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.myriad.com/role/Revenue">
        <link:definition>2103102 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.myriad.com/role/RevenueTables">
        <link:definition>2304301 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails" roleURI="http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails">
        <link:definition>2405401 - Disclosure - Revenue - Total Revenue by Category and by US versus Rest of World (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReconciliationofDeferredRevenueBalancesDetails" roleURI="http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails">
        <link:definition>2406402 - Disclosure - Revenue - Reconciliation of Deferred Revenue Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.myriad.com/role/RevenueNarrativeDetails">
        <link:definition>2407403 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecurities" roleURI="http://www.myriad.com/role/MarketableInvestmentSecurities">
        <link:definition>2108103 - Disclosure - Marketable Investment Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesTables" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesTables">
        <link:definition>2309302 - Disclosure - Marketable Investment Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails">
        <link:definition>2410404 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails">
        <link:definition>2411405 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.myriad.com/role/FairValueMeasurements">
        <link:definition>2112104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.myriad.com/role/FairValueMeasurementsTables">
        <link:definition>2313303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2414406 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails">
        <link:definition>2415407 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" roleURI="http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails">
        <link:definition>2416408 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNet" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNet">
        <link:definition>2117105 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetTables" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetTables">
        <link:definition>2318304 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetBalancesDetails" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails">
        <link:definition>2419409 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetDepreciationExpenseDetails" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails">
        <link:definition>2420410 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetNarrativeDetails" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails">
        <link:definition>2421411 - Disclosure - Property, Plant and Equipment, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssets">
        <link:definition>2122106 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2323305 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails">
        <link:definition>2424412 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails">
        <link:definition>2425413 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails">
        <link:definition>2426414 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.myriad.com/role/AccruedLiabilities">
        <link:definition>2127107 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.myriad.com/role/AccruedLiabilitiesTables">
        <link:definition>2328306 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.myriad.com/role/AccruedLiabilitiesDetails">
        <link:definition>2429415 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.myriad.com/role/LongTermDebt">
        <link:definition>2130108 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNarrativeDetails" roleURI="http://www.myriad.com/role/LongTermDebtNarrativeDetails">
        <link:definition>2431416 - Disclosure - Long-Term Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLongTermLiabilities" roleURI="http://www.myriad.com/role/OtherLongTermLiabilities">
        <link:definition>2132109 - Disclosure - Other Long-Term Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLongTermLiabilitiesTables" roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesTables">
        <link:definition>2333307 - Disclosure - Other Long-Term Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLongTermLiabilitiesDetails" roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails">
        <link:definition>2434417 - Disclosure - Other Long-Term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquity" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquity">
        <link:definition>2135110 - Disclosure - Preferred and Common Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityTables" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables">
        <link:definition>2336308 - Disclosure - Preferred and Common Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityNarrativeDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails">
        <link:definition>2437418 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails">
        <link:definition>2438419 - Disclosure - Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails">
        <link:definition>2439420 - Disclosure - Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails">
        <link:definition>2440421 - Disclosure - Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.myriad.com/role/StockBasedCompensation">
        <link:definition>2141111 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.myriad.com/role/StockBasedCompensationTables">
        <link:definition>2342309 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2443422 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2444423 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRSUActivityDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails">
        <link:definition>2445424 - Disclosure - Stock-Based Compensation - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2446425 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.myriad.com/role/IncomeTaxes">
        <link:definition>2147112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.myriad.com/role/IncomeTaxesDetails">
        <link:definition>2448426 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.myriad.com/role/CommitmentsandContingencies">
        <link:definition>2149113 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.myriad.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2450427 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.myriad.com/role/SupplementalCashFlowInformation">
        <link:definition>2151114 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationTables">
        <link:definition>2352310 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>2453428 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.myriad.com/role/Leases">
        <link:definition>2154115 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.myriad.com/role/LeasesDetails">
        <link:definition>2455429 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.myriad.com/role/SubsequentEvents">
        <link:definition>2156116 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.myriad.com/role/SubsequentEventsDetails">
        <link:definition>2457430 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mygn_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_PurchasedLicensesAndTechnologiesMember" abstract="true" name="PurchasedLicensesAndTechnologiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_LesseeOperatingLeaseExpectedFutureRentPayments" abstract="false" name="LesseeOperatingLeaseExpectedFutureRentPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ContractWithCustomerLiabilityPrepayments" abstract="false" name="ContractWithCustomerLiabilityPrepayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" abstract="false" name="DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_RefundsPayableAndReserveCurrent" abstract="false" name="RefundsPayableAndReserveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" abstract="false" name="IncreaseDecreaseInUnrecognizedTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MolecularDiagnosticHereditaryCancerTestingMember" abstract="true" name="MolecularDiagnosticHereditaryCancerTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_PerformanceObligationEstimatedTransactionPriceMember" abstract="true" name="PerformanceObligationEstimatedTransactionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OperatingLeaseLiabilityEstablished" abstract="false" name="OperatingLeaseLiabilityEstablished" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DebtInstrumentLIBORFloorPercentage" abstract="false" name="DebtInstrumentLIBORFloorPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_CBICIFPASettlementMember" abstract="true" name="CBICIFPASettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OptionsAndRestrictedStockUnitsMember" abstract="true" name="OptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_AmendmentToCreditAgreementMember" abstract="true" name="AmendmentToCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_IncreaseDecreaseInEarningsLossPerShare" abstract="false" name="IncreaseDecreaseInEarningsLossPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mygn_DebtCovenantLiquidityCovenantMinimum" abstract="false" name="DebtCovenantLiquidityCovenantMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MolecularDiagnosticAutoimmuneMember" abstract="true" name="MolecularDiagnosticAutoimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_IntangibleAssetsLineItems" abstract="true" name="IntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_RelatorMember" abstract="true" name="RelatorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MolecularDiagnosticOtherTestingMember" abstract="true" name="MolecularDiagnosticOtherTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_CostOfPharmaceuticalAndClinicalServicesMember" abstract="true" name="CostOfPharmaceuticalAndClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_LesseeOperatingLeaseAreaOfLeasedSpace" abstract="false" name="LesseeOperatingLeaseAreaOfLeasedSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mygn_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MolecularDiagnosticPrenatalTestingMember" abstract="true" name="MolecularDiagnosticPrenatalTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ScheduleOfIntangibleAssetsTable" abstract="true" name="ScheduleOfIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mygn_InvestmentsAndCashAmortizedCost" abstract="false" name="InvestmentsAndCashAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_LeaseArrangementDomain" abstract="true" name="LeaseArrangementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_CostOfMolecularDiagnosticTestingMember" abstract="true" name="CostOfMolecularDiagnosticTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_NonEmployeeDirectorMember" abstract="true" name="NonEmployeeDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_CARESActOf2020MedicarePaymentAmount" abstract="false" name="CARESActOf2020MedicarePaymentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" abstract="false" name="StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mygn_WestSaltLakeCityLeaseMember" abstract="true" name="WestSaltLakeCityLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MolecularDiagnosticPharmacogenomicsMember" abstract="true" name="MolecularDiagnosticPharmacogenomicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_UnitedStatesAndStateOfCaliforniaMember" abstract="true" name="UnitedStatesAndStateOfCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_PharmaceuticalAndClinicalServicesMember" abstract="true" name="PharmaceuticalAndClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_EmployeeStockPurchasePlanTwentyTwelveMember" abstract="true" name="EmployeeStockPurchasePlanTwentyTwelveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MolecularDiagnosticTumorProfilingMember" abstract="true" name="MolecularDiagnosticTumorProfilingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_LeaseArrangementAxis" abstract="true" name="LeaseArrangementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="mygn_MolecularDiagnosticTestingMember" abstract="true" name="MolecularDiagnosticTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>mygn-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6c4a3a2c-b656-4a66-b2d1-1ba9bc2e559c,g:c641d519-fa56-4157-9313-b107a5eea025-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mygn-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2f49b31d-cc61-4dd6-a982-017f0936001a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ec3912b1-e79d-4bbc-940b-a0b977dd22d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2f49b31d-cc61-4dd6-a982-017f0936001a" xlink:to="loc_us-gaap_Liabilities_ec3912b1-e79d-4bbc-940b-a0b977dd22d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9fe531a0-918b-4b02-a720-54c8ef58790f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2f49b31d-cc61-4dd6-a982-017f0936001a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9fe531a0-918b-4b02-a720-54c8ef58790f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e517062-6eda-4472-bb6e-930b4e660dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2f49b31d-cc61-4dd6-a982-017f0936001a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e517062-6eda-4472-bb6e-930b4e660dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5acfea9-dc04-4acb-a80d-78eaca77d3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_52bf8719-ffea-4229-aef3-da8c679de3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5acfea9-dc04-4acb-a80d-78eaca77d3f8" xlink:to="loc_us-gaap_StockholdersEquity_52bf8719-ffea-4229-aef3-da8c679de3fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_fb5f4128-49ec-4576-bb7b-ea29092e7f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5acfea9-dc04-4acb-a80d-78eaca77d3f8" xlink:to="loc_us-gaap_MinorityInterest_fb5f4128-49ec-4576-bb7b-ea29092e7f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_be572e30-06c7-481e-83c9-8515ef9fd595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0962dcd1-ae1b-4349-94f8-f18d8b7dfe47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be572e30-06c7-481e-83c9-8515ef9fd595" xlink:to="loc_us-gaap_AssetsCurrent_0962dcd1-ae1b-4349-94f8-f18d8b7dfe47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_625008a3-48fb-421e-8903-6afbf33d7482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be572e30-06c7-481e-83c9-8515ef9fd595" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_625008a3-48fb-421e-8903-6afbf33d7482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_c5c8dca6-038f-4f47-aa49-b300bdf397dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be572e30-06c7-481e-83c9-8515ef9fd595" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_c5c8dca6-038f-4f47-aa49-b300bdf397dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ee9e2302-1651-4cb1-a7da-be39f27501ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be572e30-06c7-481e-83c9-8515ef9fd595" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ee9e2302-1651-4cb1-a7da-be39f27501ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_471159ac-b25d-451c-a624-7c83c392cf66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be572e30-06c7-481e-83c9-8515ef9fd595" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_471159ac-b25d-451c-a624-7c83c392cf66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_04216766-7ec8-4813-bf3d-1eaedb25cdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be572e30-06c7-481e-83c9-8515ef9fd595" xlink:to="loc_us-gaap_Goodwill_04216766-7ec8-4813-bf3d-1eaedb25cdb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_98c42f21-13a7-43a8-8be2-34dff244c663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be572e30-06c7-481e-83c9-8515ef9fd595" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_98c42f21-13a7-43a8-8be2-34dff244c663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_55fb3b7f-2806-4753-860e-59ee570b3b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b77192d8-8d37-4977-abbc-bbb60da00319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_55fb3b7f-2806-4753-860e-59ee570b3b9a" xlink:to="loc_us-gaap_AccountsPayableCurrent_b77192d8-8d37-4977-abbc-bbb60da00319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_261c3328-9cb1-4f63-808e-afe77b11b091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_55fb3b7f-2806-4753-860e-59ee570b3b9a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_261c3328-9cb1-4f63-808e-afe77b11b091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ada95892-a3cf-454e-b464-cf230fa8c967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_55fb3b7f-2806-4753-860e-59ee570b3b9a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ada95892-a3cf-454e-b464-cf230fa8c967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_be789639-b8cd-4a82-8497-3c1db4bab2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_55fb3b7f-2806-4753-860e-59ee570b3b9a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_be789639-b8cd-4a82-8497-3c1db4bab2f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a6c53b4d-6cb0-406b-a357-a5ec4e270de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2e77f711-64e2-481f-af54-0be92f16aa50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6c53b4d-6cb0-406b-a357-a5ec4e270de2" xlink:to="loc_us-gaap_CommonStockValue_2e77f711-64e2-481f-af54-0be92f16aa50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_354a5256-4c0e-4397-8c44-b16f7febee86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6c53b4d-6cb0-406b-a357-a5ec4e270de2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_354a5256-4c0e-4397-8c44-b16f7febee86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_895505f0-83dd-4a86-a4bd-c936e69397eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6c53b4d-6cb0-406b-a357-a5ec4e270de2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_895505f0-83dd-4a86-a4bd-c936e69397eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df40b5db-a8d7-4864-9396-9a995503d2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6c53b4d-6cb0-406b-a357-a5ec4e270de2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df40b5db-a8d7-4864-9396-9a995503d2d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_75d62750-3c60-4fe3-a110-ace9574ab99c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_491393da-c2d8-4726-9378-230cf857d3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_75d62750-3c60-4fe3-a110-ace9574ab99c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_491393da-c2d8-4726-9378-230cf857d3d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_75396cd0-95c9-41cc-a4b0-177d86870cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_75d62750-3c60-4fe3-a110-ace9574ab99c" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_75396cd0-95c9-41cc-a4b0-177d86870cc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8f78c9a8-32c6-4b9e-94e5-9218c16c3a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_75d62750-3c60-4fe3-a110-ace9574ab99c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8f78c9a8-32c6-4b9e-94e5-9218c16c3a49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_907768b1-b2d4-4824-9b4b-962a93924a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_75d62750-3c60-4fe3-a110-ace9574ab99c" xlink:to="loc_us-gaap_InventoryNet_907768b1-b2d4-4824-9b4b-962a93924a16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_ca82acbc-e428-4d7b-a1ae-1f5812a0f7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_75d62750-3c60-4fe3-a110-ace9574ab99c" xlink:to="loc_us-gaap_PrepaidTaxes_ca82acbc-e428-4d7b-a1ae-1f5812a0f7fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_192813c6-9bec-4641-8e46-1bf1acc5d028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_75d62750-3c60-4fe3-a110-ace9574ab99c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_192813c6-9bec-4641-8e46-1bf1acc5d028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8941a976-c34c-416e-b510-720614ef6435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4d538b9f-6069-4c9f-b60d-527f2279a4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8941a976-c34c-416e-b510-720614ef6435" xlink:to="loc_us-gaap_LiabilitiesCurrent_4d538b9f-6069-4c9f-b60d-527f2279a4e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3c3f5065-d331-4d94-a31b-476c57408cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8941a976-c34c-416e-b510-720614ef6435" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3c3f5065-d331-4d94-a31b-476c57408cd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eaf5be3f-0e67-4ffc-a783-8bd68ffd7ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8941a976-c34c-416e-b510-720614ef6435" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eaf5be3f-0e67-4ffc-a783-8bd68ffd7ed7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3597cfe1-01c8-4139-b3e7-85543507779e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8941a976-c34c-416e-b510-720614ef6435" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3597cfe1-01c8-4139-b3e7-85543507779e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_742e8a80-1dd9-4ff5-a555-b7b2ae354ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8941a976-c34c-416e-b510-720614ef6435" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_742e8a80-1dd9-4ff5-a555-b7b2ae354ed5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="mygn-20220331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4eed72af-dc52-40e4-86d6-09cbc2bb2b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_49da6fbb-6943-4f5a-b1d9-bc0dd70b50e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4eed72af-dc52-40e4-86d6-09cbc2bb2b0c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_49da6fbb-6943-4f5a-b1d9-bc0dd70b50e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_82422565-80bb-4e24-bd00-4d9d084e1eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4eed72af-dc52-40e4-86d6-09cbc2bb2b0c" xlink:to="loc_us-gaap_InterestExpense_82422565-80bb-4e24-bd00-4d9d084e1eda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_24925f14-5ef0-4b3d-9f70-26ad64691cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4eed72af-dc52-40e4-86d6-09cbc2bb2b0c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_24925f14-5ef0-4b3d-9f70-26ad64691cfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf5544f7-6d02-4c9c-b4ab-94f88f3a838c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c1d36508-2bf4-4306-9d00-39322830531a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf5544f7-6d02-4c9c-b4ab-94f88f3a838c" xlink:to="loc_us-gaap_OperatingIncomeLoss_c1d36508-2bf4-4306-9d00-39322830531a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8f315b87-4dd6-4ffa-b439-27784a48aa64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf5544f7-6d02-4c9c-b4ab-94f88f3a838c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8f315b87-4dd6-4ffa-b439-27784a48aa64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_654b2014-6716-40cc-9103-cff0057fdcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_22c11b6e-3035-4dd8-855c-5bc03a464d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_654b2014-6716-40cc-9103-cff0057fdcfd" xlink:to="loc_us-gaap_ProfitLoss_22c11b6e-3035-4dd8-855c-5bc03a464d8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_30fd808c-66cc-49aa-906f-68c62bc1f6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_654b2014-6716-40cc-9103-cff0057fdcfd" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_30fd808c-66cc-49aa-906f-68c62bc1f6b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_54738dd6-f3da-4062-b314-f258abcc5433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e228d258-124e-4685-a3f4-490f3ddc3558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_54738dd6-f3da-4062-b314-f258abcc5433" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e228d258-124e-4685-a3f4-490f3ddc3558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4dacd3e7-2d2c-4ca3-9392-2ec94554443b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_54738dd6-f3da-4062-b314-f258abcc5433" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4dacd3e7-2d2c-4ca3-9392-2ec94554443b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dff93d69-451b-4790-9858-8db4e5805417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_54738dd6-f3da-4062-b314-f258abcc5433" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dff93d69-451b-4790-9858-8db4e5805417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_30d7e1bb-923a-462d-913f-18fbf1b9cfb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_54738dd6-f3da-4062-b314-f258abcc5433" xlink:to="loc_us-gaap_AssetImpairmentCharges_30d7e1bb-923a-462d-913f-18fbf1b9cfb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b2907e28-7efd-4a7f-a783-06f670c3b37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_823536ea-fb7d-4f7a-8511-9324f6fccef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b2907e28-7efd-4a7f-a783-06f670c3b37b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_823536ea-fb7d-4f7a-8511-9324f6fccef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2b236a0d-a25b-414b-b8a8-24f76a9bc8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b2907e28-7efd-4a7f-a783-06f670c3b37b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2b236a0d-a25b-414b-b8a8-24f76a9bc8a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e270ad25-4044-4210-b890-934de9bd1bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b0e3bf70-82e5-49d5-a4d0-5020a6ce7cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e270ad25-4044-4210-b890-934de9bd1bdf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b0e3bf70-82e5-49d5-a4d0-5020a6ce7cf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1f449c60-e779-441b-83e3-c8b33ef30629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e270ad25-4044-4210-b890-934de9bd1bdf" xlink:to="loc_us-gaap_CostsAndExpenses_1f449c60-e779-441b-83e3-c8b33ef30629" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="mygn-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d5b5da9c-e05d-441b-b1e0-0516dbbfbdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d2162124-7f7d-4137-a535-79ec952f7c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d5b5da9c-e05d-441b-b1e0-0516dbbfbdb9" xlink:to="loc_us-gaap_NetIncomeLoss_d2162124-7f7d-4137-a535-79ec952f7c2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c34f3015-a531-4ad9-a71b-0d7a66f9a173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d5b5da9c-e05d-441b-b1e0-0516dbbfbdb9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c34f3015-a531-4ad9-a71b-0d7a66f9a173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_95484ffc-e4c0-4bef-81a8-fd41a4893586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d5b5da9c-e05d-441b-b1e0-0516dbbfbdb9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_95484ffc-e4c0-4bef-81a8-fd41a4893586" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c79524b5-b4f6-4f97-81ea-77f0cfbc56ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1f68238c-e7eb-429a-8352-71f6a2caa30e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c79524b5-b4f6-4f97-81ea-77f0cfbc56ad" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1f68238c-e7eb-429a-8352-71f6a2caa30e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mygn-20220331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8766aa9-d4cc-4b08-8628-d5a2fc488cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2d922ab9-1700-4f11-85b7-a91916f12cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8766aa9-d4cc-4b08-8628-d5a2fc488cee" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2d922ab9-1700-4f11-85b7-a91916f12cf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_38e589aa-04c0-4522-b189-782722223c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8766aa9-d4cc-4b08-8628-d5a2fc488cee" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_38e589aa-04c0-4522-b189-782722223c0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_892b5b49-3821-4a3c-bc34-69af5a263b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8766aa9-d4cc-4b08-8628-d5a2fc488cee" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_892b5b49-3821-4a3c-bc34-69af5a263b89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_89e8a30b-c210-46bb-8bec-cde0f1fe8a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8766aa9-d4cc-4b08-8628-d5a2fc488cee" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_89e8a30b-c210-46bb-8bec-cde0f1fe8a6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_fa81e511-6272-4c5c-b66a-ae14de617c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8766aa9-d4cc-4b08-8628-d5a2fc488cee" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_fa81e511-6272-4c5c-b66a-ae14de617c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_22a57e1f-e4b3-42ba-87a0-1b226e4adf80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_NetIncomeLoss_22a57e1f-e4b3-42ba-87a0-1b226e4adf80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_67de2632-9512-4b1b-a315-44779b0f3d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_DepreciationAndAmortization_67de2632-9512-4b1b-a315-44779b0f3d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonCashInterestExpense_007b3989-6584-4f6c-a1cf-26fa091163a0" xlink:href="mygn-20220331.xsd#mygn_NonCashInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_mygn_NonCashInterestExpense_007b3989-6584-4f6c-a1cf-26fa091163a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4553e33a-743a-4570-92ad-0cc58bd3c842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4553e33a-743a-4570-92ad-0cc58bd3c842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1717b2f2-f23e-46b6-b62d-5193c46e8da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_ShareBasedCompensation_1717b2f2-f23e-46b6-b62d-5193c46e8da1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_04c26d22-5edb-48b5-b865-fbd32a6fe55a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_04c26d22-5edb-48b5-b865-fbd32a6fe55a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_9d0953ee-e7b0-40ea-92b9-44c0d0b1cfed" xlink:href="mygn-20220331.xsd#mygn_IncreaseDecreaseInUnrecognizedTaxBenefits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_9d0953ee-e7b0-40ea-92b9-44c0d0b1cfed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_9a6edd76-a400-4d2d-8e65-9e714e257da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_AssetImpairmentCharges_9a6edd76-a400-4d2d-8e65-9e714e257da1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_d7d2c0d9-ba92-447e-aee8-e4e37a534782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_d7d2c0d9-ba92-447e-aee8-e4e37a534782" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8466860d-bfa1-4e05-b977-b3bf0ccc3ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8466860d-bfa1-4e05-b977-b3bf0ccc3ffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_315c2cdd-9401-47d5-a5a3-8c13e74eff29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_315c2cdd-9401-47d5-a5a3-8c13e74eff29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_04ecdf18-59a1-4ddc-a39e-b8846e24ee35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_04ecdf18-59a1-4ddc-a39e-b8846e24ee35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_fc5d4500-775f-4198-bf2b-a347f7044d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_fc5d4500-775f-4198-bf2b-a347f7044d1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4d7a46b3-d5ab-46e3-99c5-df97acd69dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4d7a46b3-d5ab-46e3-99c5-df97acd69dbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3c60d4fb-db3a-4526-b911-43ceba177675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3c60d4fb-db3a-4526-b911-43ceba177675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_49fbfef1-79fd-4fe3-8fe5-6d7f511e64fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2161b14-30a0-462e-a288-02b236c75bb9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_49fbfef1-79fd-4fe3-8fe5-6d7f511e64fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d33aae9f-2a92-4ffd-8e02-b21aa7831923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b2066d2-5a93-482e-b328-2f9908c9a287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d33aae9f-2a92-4ffd-8e02-b21aa7831923" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b2066d2-5a93-482e-b328-2f9908c9a287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c2e819dc-d189-432c-a372-b9968f0dad8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d33aae9f-2a92-4ffd-8e02-b21aa7831923" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c2e819dc-d189-432c-a372-b9968f0dad8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c2aca40-d4e3-4946-8774-b88be09e8693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d33aae9f-2a92-4ffd-8e02-b21aa7831923" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c2aca40-d4e3-4946-8774-b88be09e8693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd4cfada-ed29-457c-b20f-5f79227f6388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d33aae9f-2a92-4ffd-8e02-b21aa7831923" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd4cfada-ed29-457c-b20f-5f79227f6388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b042c43-b836-44e1-8474-2a8780a44336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_7ff71c7c-c7bb-4ca2-908d-a846f0ad7ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b042c43-b836-44e1-8474-2a8780a44336" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_7ff71c7c-c7bb-4ca2-908d-a846f0ad7ab8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_dac2aad9-b740-4bd8-bbce-6989f446f468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b042c43-b836-44e1-8474-2a8780a44336" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_dac2aad9-b740-4bd8-bbce-6989f446f468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_404e34e9-6537-4c31-985c-86c62d870c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b042c43-b836-44e1-8474-2a8780a44336" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_404e34e9-6537-4c31-985c-86c62d870c74" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d40bb59b-91df-44d6-81f0-a47cf13a506d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4765a0b1-5cc3-47bc-ae12-27437a77f827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d40bb59b-91df-44d6-81f0-a47cf13a506d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4765a0b1-5cc3-47bc-ae12-27437a77f827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3e210091-93de-4314-813f-37b65f44d347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d40bb59b-91df-44d6-81f0-a47cf13a506d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3e210091-93de-4314-813f-37b65f44d347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_945b5c88-2a54-4004-b7f9-b15b5f1398c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d40bb59b-91df-44d6-81f0-a47cf13a506d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_945b5c88-2a54-4004-b7f9-b15b5f1398c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_eeaa14e1-ee52-4285-92a5-91df78fcfc43" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_4e46427a-c596-4a8e-bc29-d81653a7a223" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_eeaa14e1-ee52-4285-92a5-91df78fcfc43" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_4e46427a-c596-4a8e-bc29-d81653a7a223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_e8cdef7f-5016-4917-80a8-a91d08bcc737" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_eeaa14e1-ee52-4285-92a5-91df78fcfc43" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_e8cdef7f-5016-4917-80a8-a91d08bcc737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_d584a2ae-3f7f-4903-9305-eb05e6478f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_eeaa14e1-ee52-4285-92a5-91df78fcfc43" xlink:to="loc_us-gaap_InvestmentsAndCash_d584a2ae-3f7f-4903-9305-eb05e6478f06" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_eae2f203-2e5c-44f3-90aa-eae5f3bed1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9d8d313f-0bf1-40ee-9aa1-d65d6da3c934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_eae2f203-2e5c-44f3-90aa-eae5f3bed1b8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9d8d313f-0bf1-40ee-9aa1-d65d6da3c934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f93e079e-7765-4be8-a49e-89263afcb255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_eae2f203-2e5c-44f3-90aa-eae5f3bed1b8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f93e079e-7765-4be8-a49e-89263afcb255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d950a03b-fa80-4fe3-93ce-998aa8eab6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_eae2f203-2e5c-44f3-90aa-eae5f3bed1b8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d950a03b-fa80-4fe3-93ce-998aa8eab6ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_2881953c-a439-47bc-b39f-d528987ff420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_eae2f203-2e5c-44f3-90aa-eae5f3bed1b8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_2881953c-a439-47bc-b39f-d528987ff420" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_5152e555-5e62-4d92-9739-89efcda03cde" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f7483b96-9726-4723-a9b2-062a307fb84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_5152e555-5e62-4d92-9739-89efcda03cde" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f7483b96-9726-4723-a9b2-062a307fb84c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_df94ae14-9b32-4540-a1e5-acc5c35123de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_5152e555-5e62-4d92-9739-89efcda03cde" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_df94ae14-9b32-4540-a1e5-acc5c35123de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_f1ac6f5b-ab86-446f-91d5-2b18302f820e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_5152e555-5e62-4d92-9739-89efcda03cde" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_f1ac6f5b-ab86-446f-91d5-2b18302f820e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_771fddc0-fc23-4bd1-9cdd-2ab0c55e9510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_5152e555-5e62-4d92-9739-89efcda03cde" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_771fddc0-fc23-4bd1-9cdd-2ab0c55e9510" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_584e961d-4096-476d-8c0e-a2aa0248568b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6ae9c7a3-1f87-4d5e-ab65-69c4ddbb0518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueNetAssetLiability_584e961d-4096-476d-8c0e-a2aa0248568b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6ae9c7a3-1f87-4d5e-ab65-69c4ddbb0518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_14b2344c-1b92-4cad-8968-26426ffcb9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueNetAssetLiability_584e961d-4096-476d-8c0e-a2aa0248568b" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_14b2344c-1b92-4cad-8968-26426ffcb9b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#PropertyPlantandEquipmentNetBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d2b47687-bc04-4085-8b36-d54ff64aa1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a95dec63-210d-4f54-a72e-11ade5c19614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d2b47687-bc04-4085-8b36-d54ff64aa1e7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a95dec63-210d-4f54-a72e-11ade5c19614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d4a94ed0-b2aa-4de2-82e8-4d7754c79c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d2b47687-bc04-4085-8b36-d54ff64aa1e7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d4a94ed0-b2aa-4de2-82e8-4d7754c79c75" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b972f8f0-43c2-4248-8fc9-b0121b710963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9edfa1b2-7073-433b-96e3-1948d6a77851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b972f8f0-43c2-4248-8fc9-b0121b710963" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9edfa1b2-7073-433b-96e3-1948d6a77851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9b026765-3c69-40d4-ada7-75094fa0fba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b972f8f0-43c2-4248-8fc9-b0121b710963" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9b026765-3c69-40d4-ada7-75094fa0fba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_77d5255d-2387-41da-9343-5f53c5c38ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_db33c44d-5a56-4e91-aa65-7bf4ee212926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_77d5255d-2387-41da-9343-5f53c5c38ec1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_db33c44d-5a56-4e91-aa65-7bf4ee212926" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3e040a23-4331-4d33-8596-a854f59dedec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_65491c5e-4e6f-414e-852c-f388af41b325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3e040a23-4331-4d33-8596-a854f59dedec" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_65491c5e-4e6f-414e-852c-f388af41b325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_848ac14d-c517-4853-9e3d-3f47ead41732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3e040a23-4331-4d33-8596-a854f59dedec" xlink:to="loc_us-gaap_LitigationReserveCurrent_848ac14d-c517-4853-9e3d-3f47ead41732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_d47c0440-4f85-4978-b371-7c3588afe18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3e040a23-4331-4d33-8596-a854f59dedec" xlink:to="loc_us-gaap_TaxesPayableCurrent_d47c0440-4f85-4978-b371-7c3588afe18e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RefundsPayableAndReserveCurrent_2f86f10a-e75c-4c08-91da-e1928d4e02a7" xlink:href="mygn-20220331.xsd#mygn_RefundsPayableAndReserveCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3e040a23-4331-4d33-8596-a854f59dedec" xlink:to="loc_mygn_RefundsPayableAndReserveCurrent_2f86f10a-e75c-4c08-91da-e1928d4e02a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c6bf6872-ec17-4996-8895-4c6b9c791561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3e040a23-4331-4d33-8596-a854f59dedec" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c6bf6872-ec17-4996-8895-4c6b9c791561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_08e7d572-762d-49ac-883d-9114f6d62186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3e040a23-4331-4d33-8596-a854f59dedec" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_08e7d572-762d-49ac-883d-9114f6d62186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e20d7cdf-4879-491d-9065-4f1927cc853d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3e040a23-4331-4d33-8596-a854f59dedec" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e20d7cdf-4879-491d-9065-4f1927cc853d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#OtherLongTermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_751f5581-dcc2-48f2-b23d-8a370b597e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3cefe07c-716b-499d-9a15-1cac41a54eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_751f5581-dcc2-48f2-b23d-8a370b597e75" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3cefe07c-716b-499d-9a15-1cac41a54eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_18c7a25c-1980-4f43-bf5f-6df5c019ef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_751f5581-dcc2-48f2-b23d-8a370b597e75" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_18c7a25c-1980-4f43-bf5f-6df5c019ef9d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_30711f40-15c7-44d3-b8fb-ac1ffbd77ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fc073b43-105d-42fb-89bb-2f11db0ded18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_30711f40-15c7-44d3-b8fb-ac1ffbd77ac5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fc073b43-105d-42fb-89bb-2f11db0ded18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a14a52a6-217c-4222-9d00-a04178c9f01a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_30711f40-15c7-44d3-b8fb-ac1ffbd77ac5" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a14a52a6-217c-4222-9d00-a04178c9f01a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>mygn-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6c4a3a2c-b656-4a66-b2d1-1ba9bc2e559c,g:c641d519-fa56-4157-9313-b107a5eea025-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="mygn-20220331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i75dd427b35ec4325bc47ba19d7bef02c_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b39ee543-3d86-4361-9846-539e42562e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_RevenuesAbstract_b39ee543-3d86-4361-9846-539e42562e0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_af92ed39-62c6-4d51-9261-a4d6bba67374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_b39ee543-3d86-4361-9846-539e42562e0f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_af92ed39-62c6-4d51-9261-a4d6bba67374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_34aabf62-d64f-4fe0-bf6a-d792ed8f6f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_34aabf62-d64f-4fe0-bf6a-d792ed8f6f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a05b6875-d0f9-4b20-ac86-91af1dfa93e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a05b6875-d0f9-4b20-ac86-91af1dfa93e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_770d7c99-f7e8-4f5d-80b1-97839092cdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_770d7c99-f7e8-4f5d-80b1-97839092cdf0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_8c411fce-3070-4094-8563-96e8eb17993f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:to="loc_us-gaap_AssetImpairmentCharges_8c411fce-3070-4094-8563-96e8eb17993f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fd4feedd-4722-4cc0-a57c-e2831f3e9ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:to="loc_us-gaap_CostsAndExpenses_fd4feedd-4722-4cc0-a57c-e2831f3e9ad6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7f8fa25c-cf7a-4863-9f42-7c2bd93c8e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_OperatingIncomeLoss_7f8fa25c-cf7a-4863-9f42-7c2bd93c8e37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6c863c8e-487f-448e-8987-f12703391acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6c863c8e-487f-448e-8987-f12703391acd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_88cb9f77-3fa7-4523-95a4-936616d72bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6c863c8e-487f-448e-8987-f12703391acd" xlink:to="loc_us-gaap_InvestmentIncomeInterest_88cb9f77-3fa7-4523-95a4-936616d72bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fc608a27-4a3c-41d4-b8e0-c57e6b6944a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6c863c8e-487f-448e-8987-f12703391acd" xlink:to="loc_us-gaap_InterestExpense_fc608a27-4a3c-41d4-b8e0-c57e6b6944a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5e604fb0-a924-4120-881e-430d03f6618c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6c863c8e-487f-448e-8987-f12703391acd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5e604fb0-a924-4120-881e-430d03f6618c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_716c316f-420d-466c-b298-050c6b37e76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6c863c8e-487f-448e-8987-f12703391acd" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_716c316f-420d-466c-b298-050c6b37e76e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9426a646-104e-4543-9dff-af4aeed995e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9426a646-104e-4543-9dff-af4aeed995e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c9dd262b-c568-48e1-9254-7a9936f1b783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c9dd262b-c568-48e1-9254-7a9936f1b783" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dd6c6453-e73e-4244-b4c0-24e074652bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_ProfitLoss_dd6c6453-e73e-4244-b4c0-24e074652bd2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6c2e4b28-6143-4102-ac2d-7483feee2b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6c2e4b28-6143-4102-ac2d-7483feee2b4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0a60e5f1-09f6-43e4-a036-b208781b65ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_NetIncomeLoss_0a60e5f1-09f6-43e4-a036-b208781b65ad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3bf51aab-47e5-464f-b2b7-67d3ff009032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3bf51aab-47e5-464f-b2b7-67d3ff009032" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1155b7be-2ddf-47f0-8917-bb044379703d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3bf51aab-47e5-464f-b2b7-67d3ff009032" xlink:to="loc_us-gaap_EarningsPerShareBasic_1155b7be-2ddf-47f0-8917-bb044379703d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_44938d15-7506-4786-8997-a161fdad8557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3bf51aab-47e5-464f-b2b7-67d3ff009032" xlink:to="loc_us-gaap_EarningsPerShareDiluted_44938d15-7506-4786-8997-a161fdad8557" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_f223302a-f526-464c-8cd4-ec8a9ecf9493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_f223302a-f526-464c-8cd4-ec8a9ecf9493" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6e2b53d-cbb3-447c-b792-6ffea33d3abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_f223302a-f526-464c-8cd4-ec8a9ecf9493" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6e2b53d-cbb3-447c-b792-6ffea33d3abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca8dae3e-a61e-4dca-8c35-f9d08574ea41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_f223302a-f526-464c-8cd4-ec8a9ecf9493" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca8dae3e-a61e-4dca-8c35-f9d08574ea41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6dad1d2d-d378-47c6-a3e2-6b090f523c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_StatementTable_6dad1d2d-d378-47c6-a3e2-6b090f523c13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_af038744-a0f6-4acb-bd93-cde9268021f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6dad1d2d-d378-47c6-a3e2-6b090f523c13" xlink:to="loc_srt_ProductOrServiceAxis_af038744-a0f6-4acb-bd93-cde9268021f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af038744-a0f6-4acb-bd93-cde9268021f8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_af038744-a0f6-4acb-bd93-cde9268021f8" xlink:to="loc_srt_ProductsAndServicesDomain_af038744-a0f6-4acb-bd93-cde9268021f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_55ba3bd7-141b-4a2f-9694-01f2dbd09d99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_af038744-a0f6-4acb-bd93-cde9268021f8" xlink:to="loc_srt_ProductsAndServicesDomain_55ba3bd7-141b-4a2f-9694-01f2dbd09d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_d4f77b6b-6862-47be-ac49-dd245eb0d3eb" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_55ba3bd7-141b-4a2f-9694-01f2dbd09d99" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_d4f77b6b-6862-47be-ac49-dd245eb0d3eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_c6b39a47-c59e-4aef-bc9e-c0efd3ba37ef" xlink:href="mygn-20220331.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_55ba3bd7-141b-4a2f-9694-01f2dbd09d99" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_c6b39a47-c59e-4aef-bc9e-c0efd3ba37ef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mygn-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i52731911aa3e41359c8637685add2592_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02498b11-8a67-4c82-9510-4d83b84eb8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02498b11-8a67-4c82-9510-4d83b84eb8d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0f04a3de-233a-4982-ab1b-3e8071526532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0f04a3de-233a-4982-ab1b-3e8071526532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3f22f4c7-9715-4a2a-af5d-78f250eac2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3f22f4c7-9715-4a2a-af5d-78f250eac2c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21046b9a-0a26-4967-bc36-bcc053fae6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:to="loc_us-gaap_NetIncomeLoss_21046b9a-0a26-4967-bc36-bcc053fae6b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2862a931-dd59-4706-8239-f8d77e8f6952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2862a931-dd59-4706-8239-f8d77e8f6952" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_feff4d0d-39ab-49aa-afe1-28dc572fd4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_05e3fa7b-ac74-4cf9-ad23-b87d7d84c460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:to="loc_us-gaap_StatementTable_05e3fa7b-ac74-4cf9-ad23-b87d7d84c460" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_54b3d1e7-47d6-4627-8303-3829474ad764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_05e3fa7b-ac74-4cf9-ad23-b87d7d84c460" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_54b3d1e7-47d6-4627-8303-3829474ad764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_54b3d1e7-47d6-4627-8303-3829474ad764_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_54b3d1e7-47d6-4627-8303-3829474ad764" xlink:to="loc_us-gaap_EquityComponentDomain_54b3d1e7-47d6-4627-8303-3829474ad764_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aa764f75-3bbc-4f20-b3a7-5d17a35d6168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_54b3d1e7-47d6-4627-8303-3829474ad764" xlink:to="loc_us-gaap_EquityComponentDomain_aa764f75-3bbc-4f20-b3a7-5d17a35d6168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_59991b42-310e-4d29-8ada-52390c110914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aa764f75-3bbc-4f20-b3a7-5d17a35d6168" xlink:to="loc_us-gaap_CommonStockMember_59991b42-310e-4d29-8ada-52390c110914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ddd666c6-e432-4390-96a7-55ed2a7af648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aa764f75-3bbc-4f20-b3a7-5d17a35d6168" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ddd666c6-e432-4390-96a7-55ed2a7af648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28e7a722-b71e-46e4-b3b9-7c1172154b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aa764f75-3bbc-4f20-b3a7-5d17a35d6168" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28e7a722-b71e-46e4-b3b9-7c1172154b9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6ade8081-3082-48b9-a72b-dee2dc1d8a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aa764f75-3bbc-4f20-b3a7-5d17a35d6168" xlink:to="loc_us-gaap_RetainedEarningsMember_6ade8081-3082-48b9-a72b-dee2dc1d8a45" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails" xlink:type="extended" id="i65f8b11372a24c5ea40b0263392f2102_RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_345ccac9-6a41-4233-b067-681c3d4f06e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dff8ba2d-8f85-4cea-a10f-7f2472f1aff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_345ccac9-6a41-4233-b067-681c3d4f06e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dff8ba2d-8f85-4cea-a10f-7f2472f1aff9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b0c46dd7-72ba-4f59-bb21-a2112b29f970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_345ccac9-6a41-4233-b067-681c3d4f06e4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b0c46dd7-72ba-4f59-bb21-a2112b29f970" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d924c888-e232-448e-b54a-ce777afd821b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b0c46dd7-72ba-4f59-bb21-a2112b29f970" xlink:to="loc_srt_ProductOrServiceAxis_d924c888-e232-448e-b54a-ce777afd821b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d924c888-e232-448e-b54a-ce777afd821b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d924c888-e232-448e-b54a-ce777afd821b" xlink:to="loc_srt_ProductsAndServicesDomain_d924c888-e232-448e-b54a-ce777afd821b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3f27ee31-c086-40e8-ae8a-9573c9832eae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d924c888-e232-448e-b54a-ce777afd821b" xlink:to="loc_srt_ProductsAndServicesDomain_3f27ee31-c086-40e8-ae8a-9573c9832eae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3f27ee31-c086-40e8-ae8a-9573c9832eae" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_0a2339f5-006d-42f3-a519-25572958c76a" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticHereditaryCancerTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:to="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_0a2339f5-006d-42f3-a519-25572958c76a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTumorProfilingMember_a842a8bf-e940-413c-bdab-4df9fade3d80" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticTumorProfilingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:to="loc_mygn_MolecularDiagnosticTumorProfilingMember_a842a8bf-e940-413c-bdab-4df9fade3d80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPrenatalTestingMember_9bd01025-8d5d-4443-9fb9-305ddb62d99e" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticPrenatalTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:to="loc_mygn_MolecularDiagnosticPrenatalTestingMember_9bd01025-8d5d-4443-9fb9-305ddb62d99e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_0db3f54a-fa4f-4b64-941d-7ef647509879" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticPharmacogenomicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:to="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_0db3f54a-fa4f-4b64-941d-7ef647509879" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticAutoimmuneMember_055628d0-da64-4f98-ab49-1617e63d1840" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticAutoimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:to="loc_mygn_MolecularDiagnosticAutoimmuneMember_055628d0-da64-4f98-ab49-1617e63d1840" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticOtherTestingMember_1742c97f-e31e-4c43-9ffb-149ba7ee88f2" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticOtherTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:to="loc_mygn_MolecularDiagnosticOtherTestingMember_1742c97f-e31e-4c43-9ffb-149ba7ee88f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_763ce027-5c72-4277-849c-afcf2acb087d" xlink:href="mygn-20220331.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3f27ee31-c086-40e8-ae8a-9573c9832eae" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_763ce027-5c72-4277-849c-afcf2acb087d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0d04efc8-fefc-4514-91b4-bafe3fdb9aaf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b0c46dd7-72ba-4f59-bb21-a2112b29f970" xlink:to="loc_srt_StatementGeographicalAxis_0d04efc8-fefc-4514-91b4-bafe3fdb9aaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0d04efc8-fefc-4514-91b4-bafe3fdb9aaf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0d04efc8-fefc-4514-91b4-bafe3fdb9aaf" xlink:to="loc_srt_SegmentGeographicalDomain_0d04efc8-fefc-4514-91b4-bafe3fdb9aaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_14dff1d4-c631-4833-90eb-167fe6275741" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0d04efc8-fefc-4514-91b4-bafe3fdb9aaf" xlink:to="loc_srt_SegmentGeographicalDomain_14dff1d4-c631-4833-90eb-167fe6275741" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_964cdb8b-3c92-434e-a5bb-febcd7a680e5" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_14dff1d4-c631-4833-90eb-167fe6275741" xlink:to="loc_country_US_964cdb8b-3c92-434e-a5bb-febcd7a680e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_323f732d-8256-46e3-83f8-7e462fd6ed15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_14dff1d4-c631-4833-90eb-167fe6275741" xlink:to="loc_us-gaap_NonUsMember_323f732d-8256-46e3-83f8-7e462fd6ed15" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/RevenueNarrativeDetails" xlink:type="extended" id="i7cd05818d6cd4612aafad281465cdf9b_RevenueNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_f2b8fbe0-0a8c-4e90-acbf-be04cf0f1f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_bda6b650-3763-466b-b5e8-f008f0e65fba" xlink:href="mygn-20220331.xsd#mygn_IncreaseDecreaseInEarningsLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f2b8fbe0-0a8c-4e90-acbf-be04cf0f1f5b" xlink:to="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_bda6b650-3763-466b-b5e8-f008f0e65fba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c9d9f7c8-32de-4622-abe2-51d1ebb50d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f2b8fbe0-0a8c-4e90-acbf-be04cf0f1f5b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c9d9f7c8-32de-4622-abe2-51d1ebb50d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f2b8fbe0-0a8c-4e90-acbf-be04cf0f1f5b" xlink:to="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_78e48a03-7231-40d5-966d-9b983bb4ad89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_78e48a03-7231-40d5-966d-9b983bb4ad89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_78e48a03-7231-40d5-966d-9b983bb4ad89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_78e48a03-7231-40d5-966d-9b983bb4ad89" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_78e48a03-7231-40d5-966d-9b983bb4ad89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3a1d7a88-90bf-42b0-adc4-6d0364918ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_78e48a03-7231-40d5-966d-9b983bb4ad89" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3a1d7a88-90bf-42b0-adc4-6d0364918ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_2b7fcc6f-620d-4929-b6c8-396fdffe04a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3a1d7a88-90bf-42b0-adc4-6d0364918ec4" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_2b7fcc6f-620d-4929-b6c8-396fdffe04a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_385f5a91-29a9-48b4-9dfc-c8ddcf2254ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:to="loc_srt_MajorCustomersAxis_385f5a91-29a9-48b4-9dfc-c8ddcf2254ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_385f5a91-29a9-48b4-9dfc-c8ddcf2254ad_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_385f5a91-29a9-48b4-9dfc-c8ddcf2254ad" xlink:to="loc_srt_NameOfMajorCustomerDomain_385f5a91-29a9-48b4-9dfc-c8ddcf2254ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9e80bbec-ec11-4e8d-a663-16a48f658492" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_385f5a91-29a9-48b4-9dfc-c8ddcf2254ad" xlink:to="loc_srt_NameOfMajorCustomerDomain_9e80bbec-ec11-4e8d-a663-16a48f658492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MedicareMember_a844bdc9-8f64-427e-a47c-3889251cd0ea" xlink:href="mygn-20220331.xsd#mygn_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9e80bbec-ec11-4e8d-a663-16a48f658492" xlink:to="loc_mygn_MedicareMember_a844bdc9-8f64-427e-a47c-3889251cd0ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c07f19e8-da71-4dc1-902b-e79695847985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c07f19e8-da71-4dc1-902b-e79695847985" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c07f19e8-da71-4dc1-902b-e79695847985_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c07f19e8-da71-4dc1-902b-e79695847985" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c07f19e8-da71-4dc1-902b-e79695847985_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ff02e90-4bc0-47ad-be02-5aa27a361c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c07f19e8-da71-4dc1-902b-e79695847985" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ff02e90-4bc0-47ad-be02-5aa27a361c31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_dffc8df5-a2e3-4b35-a73c-7d829be6f86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ff02e90-4bc0-47ad-be02-5aa27a361c31" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_dffc8df5-a2e3-4b35-a73c-7d829be6f86b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_85b2c4ed-d327-43cc-9472-69a7c27656c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_85b2c4ed-d327-43cc-9472-69a7c27656c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_85b2c4ed-d327-43cc-9472-69a7c27656c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_85b2c4ed-d327-43cc-9472-69a7c27656c8" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_85b2c4ed-d327-43cc-9472-69a7c27656c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_4e7336e1-abd9-41e0-9c1b-25769ced5302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_85b2c4ed-d327-43cc-9472-69a7c27656c8" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_4e7336e1-abd9-41e0-9c1b-25769ced5302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_6ded4b65-6087-477f-a228-6c89ba7bda7e" xlink:href="mygn-20220331.xsd#mygn_PerformanceObligationEstimatedTransactionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_4e7336e1-abd9-41e0-9c1b-25769ced5302" xlink:to="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_6ded4b65-6087-477f-a228-6c89ba7bda7e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="extended" id="i0c35d6adae9a49ce85983d39ca2b0ef6_MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16d39089-127f-41c5-90bc-23e1eb8e2a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_c278f4b0-6eda-4823-be54-e31545a6b999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16d39089-127f-41c5-90bc-23e1eb8e2a89" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_c278f4b0-6eda-4823-be54-e31545a6b999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7221e846-588f-44ac-9a23-8d00898f2295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_c278f4b0-6eda-4823-be54-e31545a6b999" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7221e846-588f-44ac-9a23-8d00898f2295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_72d662e3-34fe-4d8f-9570-f7dbfac68dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_c278f4b0-6eda-4823-be54-e31545a6b999" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_72d662e3-34fe-4d8f-9570-f7dbfac68dcf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43ff2183-1065-4968-878d-87dfa3c8a441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16d39089-127f-41c5-90bc-23e1eb8e2a89" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43ff2183-1065-4968-878d-87dfa3c8a441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_74c16695-2f9d-4d5e-a84b-93609b982d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43ff2183-1065-4968-878d-87dfa3c8a441" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_74c16695-2f9d-4d5e-a84b-93609b982d00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_edff7a49-891b-4164-bbec-a01a5e38a2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43ff2183-1065-4968-878d-87dfa3c8a441" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_edff7a49-891b-4164-bbec-a01a5e38a2cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_74e49842-51cb-4e7d-96ea-633f95731e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43ff2183-1065-4968-878d-87dfa3c8a441" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_74e49842-51cb-4e7d-96ea-633f95731e82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8dc86dbc-ce20-4f82-997a-1373d74b2693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43ff2183-1065-4968-878d-87dfa3c8a441" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8dc86dbc-ce20-4f82-997a-1373d74b2693" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCashAbstract_4f05d5fa-8f11-4f7b-a7a5-55c0ee39dd47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCashAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16d39089-127f-41c5-90bc-23e1eb8e2a89" xlink:to="loc_us-gaap_InvestmentsAndCashAbstract_4f05d5fa-8f11-4f7b-a7a5-55c0ee39dd47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_bf2a121d-43bf-411f-8916-3955843158ae" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_4f05d5fa-8f11-4f7b-a7a5-55c0ee39dd47" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_bf2a121d-43bf-411f-8916-3955843158ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_43941287-7847-4827-a464-7d83d78eb5fe" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_4f05d5fa-8f11-4f7b-a7a5-55c0ee39dd47" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_43941287-7847-4827-a464-7d83d78eb5fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_037c623c-f6be-4f5c-b93a-ab3f6755338d" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_4f05d5fa-8f11-4f7b-a7a5-55c0ee39dd47" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_037c623c-f6be-4f5c-b93a-ab3f6755338d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_65a054dc-8e34-4534-8982-e32d59e14572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_4f05d5fa-8f11-4f7b-a7a5-55c0ee39dd47" xlink:to="loc_us-gaap_InvestmentsAndCash_65a054dc-8e34-4534-8982-e32d59e14572" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5485cf9e-6840-49c0-a1c1-5d785d91b0af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16d39089-127f-41c5-90bc-23e1eb8e2a89" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5485cf9e-6840-49c0-a1c1-5d785d91b0af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_278fe0dc-eb9a-462a-a793-9f5eaaa50828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5485cf9e-6840-49c0-a1c1-5d785d91b0af" xlink:to="loc_us-gaap_InvestmentTypeAxis_278fe0dc-eb9a-462a-a793-9f5eaaa50828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_278fe0dc-eb9a-462a-a793-9f5eaaa50828_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_278fe0dc-eb9a-462a-a793-9f5eaaa50828" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_278fe0dc-eb9a-462a-a793-9f5eaaa50828_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_55949e9f-ad8c-40f5-819f-d8d4f4e58374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_278fe0dc-eb9a-462a-a793-9f5eaaa50828" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_55949e9f-ad8c-40f5-819f-d8d4f4e58374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e7947a2b-d0cc-431b-8b93-29aec12157a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55949e9f-ad8c-40f5-819f-d8d4f4e58374" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e7947a2b-d0cc-431b-8b93-29aec12157a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_c68a8631-341f-4446-8228-5224d6dee388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55949e9f-ad8c-40f5-819f-d8d4f4e58374" xlink:to="loc_us-gaap_MunicipalBondsMember_c68a8631-341f-4446-8228-5224d6dee388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_bc5bdf94-9978-4da9-83be-1085fed97a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55949e9f-ad8c-40f5-819f-d8d4f4e58374" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_bc5bdf94-9978-4da9-83be-1085fed97a6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ee00e113-9a0d-4068-9b4e-244346f9c296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55949e9f-ad8c-40f5-819f-d8d4f4e58374" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ee00e113-9a0d-4068-9b4e-244346f9c296" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_6f197944-8910-41ed-b6b7-e0f2b172f117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5485cf9e-6840-49c0-a1c1-5d785d91b0af" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_6f197944-8910-41ed-b6b7-e0f2b172f117" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6f197944-8910-41ed-b6b7-e0f2b172f117_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6f197944-8910-41ed-b6b7-e0f2b172f117" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6f197944-8910-41ed-b6b7-e0f2b172f117_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00874087-b9c3-4f11-9c1f-befcad6205f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6f197944-8910-41ed-b6b7-e0f2b172f117" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00874087-b9c3-4f11-9c1f-befcad6205f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_241335d0-f365-4449-98c1-7bc54d391557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00874087-b9c3-4f11-9c1f-befcad6205f6" xlink:to="loc_us-gaap_CashMember_241335d0-f365-4449-98c1-7bc54d391557" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_f39073f3-cf7f-48f1-b5e1-34e902ee4566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00874087-b9c3-4f11-9c1f-befcad6205f6" xlink:to="loc_us-gaap_CashEquivalentsMember_f39073f3-cf7f-48f1-b5e1-34e902ee4566" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="extended" id="id412a1c377aa4b66b3cb05efa80fe7da_MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3657de04-e2d1-4632-9f8a-3e7bc2086fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3657de04-e2d1-4632-9f8a-3e7bc2086fc6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_952c97ad-3b51-48dd-967b-75d88f04a038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_952c97ad-3b51-48dd-967b-75d88f04a038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c4b82450-e1f7-4529-8afb-5748be10f279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c4b82450-e1f7-4529-8afb-5748be10f279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_657a230f-7a46-4f5d-9789-1fea63cb0653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_657a230f-7a46-4f5d-9789-1fea63cb0653" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_92a9ed40-a3e6-4ab3-9111-5905a870721b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_92a9ed40-a3e6-4ab3-9111-5905a870721b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_b95c8a95-5c16-4598-b97d-a55aaf694b74" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_b95c8a95-5c16-4598-b97d-a55aaf694b74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3657de04-e2d1-4632-9f8a-3e7bc2086fc6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1c8dad87-0300-4256-a22b-d78795e7ac2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1c8dad87-0300-4256-a22b-d78795e7ac2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1b3ec93e-e60e-46e4-8a23-7178eeb10766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1b3ec93e-e60e-46e4-8a23-7178eeb10766" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_01c09980-ac84-487c-aea0-e779871584cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_01c09980-ac84-487c-aea0-e779871584cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_deb74bba-3950-4cce-94d9-f21cef18f3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_deb74bba-3950-4cce-94d9-f21cef18f3f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_f0018735-1cb4-4973-b2bb-8976b02cdc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:to="loc_us-gaap_InvestmentsAndCash_f0018735-1cb4-4973-b2bb-8976b02cdc3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_912e9935-2eda-4de5-954a-60ae75ed8204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3657de04-e2d1-4632-9f8a-3e7bc2086fc6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_912e9935-2eda-4de5-954a-60ae75ed8204" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_b0281b6a-910a-45d6-8c36-99981c6af9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_912e9935-2eda-4de5-954a-60ae75ed8204" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_b0281b6a-910a-45d6-8c36-99981c6af9d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b0281b6a-910a-45d6-8c36-99981c6af9d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_b0281b6a-910a-45d6-8c36-99981c6af9d0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b0281b6a-910a-45d6-8c36-99981c6af9d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4746fa34-fdf1-4029-b19f-2581ebea0569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_b0281b6a-910a-45d6-8c36-99981c6af9d0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4746fa34-fdf1-4029-b19f-2581ebea0569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_3046cd12-d783-4efe-a31c-49cf9015dc62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4746fa34-fdf1-4029-b19f-2581ebea0569" xlink:to="loc_us-gaap_CashMember_3046cd12-d783-4efe-a31c-49cf9015dc62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_d4ce81a1-4168-4bb3-906a-3ea3306323a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4746fa34-fdf1-4029-b19f-2581ebea0569" xlink:to="loc_us-gaap_CashEquivalentsMember_d4ce81a1-4168-4bb3-906a-3ea3306323a9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="idf340ada069f4d13b4c6671d5be95227_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7b8d2682-eb46-440b-9c9b-674e39c5229e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_366ec8ef-c370-422c-8027-785b7be8445d" xlink:href="mygn-20220331.xsd#mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7b8d2682-eb46-440b-9c9b-674e39c5229e" xlink:to="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_366ec8ef-c370-422c-8027-785b7be8445d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_da2e2512-c3cb-489b-a03c-ba19b59ef5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7b8d2682-eb46-440b-9c9b-674e39c5229e" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_da2e2512-c3cb-489b-a03c-ba19b59ef5a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9bf65c86-1f6c-4ab0-ad95-98d45177975c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_da2e2512-c3cb-489b-a03c-ba19b59ef5a4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9bf65c86-1f6c-4ab0-ad95-98d45177975c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bf65c86-1f6c-4ab0-ad95-98d45177975c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9bf65c86-1f6c-4ab0-ad95-98d45177975c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bf65c86-1f6c-4ab0-ad95-98d45177975c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53be6862-27c3-4f58-bf71-c459e41d18e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9bf65c86-1f6c-4ab0-ad95-98d45177975c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53be6862-27c3-4f58-bf71-c459e41d18e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_51dc0129-3686-478c-ab65-47a54fd2efe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53be6862-27c3-4f58-bf71-c459e41d18e2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_51dc0129-3686-478c-ab65-47a54fd2efe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_95134d5a-6bc5-46f3-a13c-398ba6b46404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_da2e2512-c3cb-489b-a03c-ba19b59ef5a4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_95134d5a-6bc5-46f3-a13c-398ba6b46404" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_95134d5a-6bc5-46f3-a13c-398ba6b46404_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_95134d5a-6bc5-46f3-a13c-398ba6b46404" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_95134d5a-6bc5-46f3-a13c-398ba6b46404_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1026263d-5a13-455b-b324-c28a447c8536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_95134d5a-6bc5-46f3-a13c-398ba6b46404" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1026263d-5a13-455b-b324-c28a447c8536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_54e5f90f-b20f-4313-8fa6-8ff78c170839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1026263d-5a13-455b-b324-c28a447c8536" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_54e5f90f-b20f-4313-8fa6-8ff78c170839" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended" id="if5bcc55e86744f6eb08220e8564d6e15_FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e7a82e1-a9d9-402d-802c-8d10e8fa08e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_cf58f55b-7a56-4e73-b594-865cb8dd09df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e7a82e1-a9d9-402d-802c-8d10e8fa08e2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_cf58f55b-7a56-4e73-b594-865cb8dd09df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c2cecca1-e690-4a94-9e3e-6368fbc37d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e7a82e1-a9d9-402d-802c-8d10e8fa08e2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_c2cecca1-e690-4a94-9e3e-6368fbc37d3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_56e9e375-2ec8-4f33-b87d-81fda7299f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e7a82e1-a9d9-402d-802c-8d10e8fa08e2" xlink:to="loc_us-gaap_FairValueNetAssetLiability_56e9e375-2ec8-4f33-b87d-81fda7299f1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921e26e5-5256-4469-9e2d-79d87a40ce6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e7a82e1-a9d9-402d-802c-8d10e8fa08e2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921e26e5-5256-4469-9e2d-79d87a40ce6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652b1dca-52bb-48cc-b55c-26a24f6bcd67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921e26e5-5256-4469-9e2d-79d87a40ce6d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652b1dca-52bb-48cc-b55c-26a24f6bcd67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_652b1dca-52bb-48cc-b55c-26a24f6bcd67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652b1dca-52bb-48cc-b55c-26a24f6bcd67" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_652b1dca-52bb-48cc-b55c-26a24f6bcd67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa1dcdc9-b1b5-458f-aa04-f1c1d0beb859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652b1dca-52bb-48cc-b55c-26a24f6bcd67" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa1dcdc9-b1b5-458f-aa04-f1c1d0beb859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8eff48df-7c71-4d17-8b0b-e17871df58fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa1dcdc9-b1b5-458f-aa04-f1c1d0beb859" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8eff48df-7c71-4d17-8b0b-e17871df58fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_575e5b37-7fc6-4dc0-82ac-676265a0f4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa1dcdc9-b1b5-458f-aa04-f1c1d0beb859" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_575e5b37-7fc6-4dc0-82ac-676265a0f4a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2f13a110-a4a3-4409-b4a1-610c95941126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa1dcdc9-b1b5-458f-aa04-f1c1d0beb859" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2f13a110-a4a3-4409-b4a1-610c95941126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_b016eb8f-ce9e-44c7-bec8-8243293c72e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921e26e5-5256-4469-9e2d-79d87a40ce6d" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_b016eb8f-ce9e-44c7-bec8-8243293c72e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b016eb8f-ce9e-44c7-bec8-8243293c72e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b016eb8f-ce9e-44c7-bec8-8243293c72e9" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b016eb8f-ce9e-44c7-bec8-8243293c72e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2894283d-d324-45d8-bc4a-5cc2e89e31a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b016eb8f-ce9e-44c7-bec8-8243293c72e9" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2894283d-d324-45d8-bc4a-5cc2e89e31a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContingentConsiderationMember_38106861-352a-48fa-8d4c-a19cc611f1c0" xlink:href="mygn-20220331.xsd#mygn_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2894283d-d324-45d8-bc4a-5cc2e89e31a3" xlink:to="loc_mygn_ContingentConsiderationMember_38106861-352a-48fa-8d4c-a19cc611f1c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4af11f23-133c-4d25-96fa-5849ec9a5878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921e26e5-5256-4469-9e2d-79d87a40ce6d" xlink:to="loc_us-gaap_InvestmentTypeAxis_4af11f23-133c-4d25-96fa-5849ec9a5878" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4af11f23-133c-4d25-96fa-5849ec9a5878_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4af11f23-133c-4d25-96fa-5849ec9a5878" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4af11f23-133c-4d25-96fa-5849ec9a5878_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4af11f23-133c-4d25-96fa-5849ec9a5878" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_234b00db-a670-4413-8ebb-0c321cb29f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:to="loc_us-gaap_MoneyMarketFundsMember_234b00db-a670-4413-8ebb-0c321cb29f1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8d594ef6-b5c7-49df-b1b0-8b4e120321bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8d594ef6-b5c7-49df-b1b0-8b4e120321bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_c4a7cd2c-3beb-450c-94bb-762da59f8d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:to="loc_us-gaap_MunicipalBondsMember_c4a7cd2c-3beb-450c-94bb-762da59f8d79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8145abeb-feaa-45bf-ba33-9fa4f19dc9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8145abeb-feaa-45bf-ba33-9fa4f19dc9fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_740c2bdd-a811-4613-86a0-cc3b582f60a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_740c2bdd-a811-4613-86a0-cc3b582f60a0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#PropertyPlantandEquipmentNetBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="extended" id="i080d4e851f174157b8184cc44a1b2ab1_PropertyPlantandEquipmentNetBalancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_111318c1-9e25-4fc8-b38a-58d9a3f64e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f389f502-2424-4ac5-ae13-c10c8eba4611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_111318c1-9e25-4fc8-b38a-58d9a3f64e06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f389f502-2424-4ac5-ae13-c10c8eba4611" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cad08fae-de1c-4002-b6e6-9c4357d609ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_111318c1-9e25-4fc8-b38a-58d9a3f64e06" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cad08fae-de1c-4002-b6e6-9c4357d609ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_798c756e-5276-41f3-96cf-fc104dcd2e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_111318c1-9e25-4fc8-b38a-58d9a3f64e06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_798c756e-5276-41f3-96cf-fc104dcd2e8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb2aad42-c7b6-4f53-86d5-fae45010d1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_111318c1-9e25-4fc8-b38a-58d9a3f64e06" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb2aad42-c7b6-4f53-86d5-fae45010d1ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a567bf3-430b-4792-8e2f-5274de9cb256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb2aad42-c7b6-4f53-86d5-fae45010d1ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a567bf3-430b-4792-8e2f-5274de9cb256" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a567bf3-430b-4792-8e2f-5274de9cb256_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a567bf3-430b-4792-8e2f-5274de9cb256" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a567bf3-430b-4792-8e2f-5274de9cb256_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_997ecfc3-d6cf-4e2f-ae6f-9c935524785b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a567bf3-430b-4792-8e2f-5274de9cb256" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_997ecfc3-d6cf-4e2f-ae6f-9c935524785b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_656b1201-800e-4b50-bbda-da7ed73d2e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_997ecfc3-d6cf-4e2f-ae6f-9c935524785b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_656b1201-800e-4b50-bbda-da7ed73d2e6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_6b1ba58b-fa32-4b89-bed9-c50d89bc05ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_997ecfc3-d6cf-4e2f-ae6f-9c935524785b" xlink:to="loc_us-gaap_EquipmentMember_6b1ba58b-fa32-4b89-bed9-c50d89bc05ec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#PropertyPlantandEquipmentNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails" xlink:type="extended" id="ibf2c4e61a53d47c9aa25c6cceb745dfb_PropertyPlantandEquipmentNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77c61599-1a44-4059-8184-ea4e44b3256a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_6b9a696e-2ddc-4022-abf5-8f72765fe50b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77c61599-1a44-4059-8184-ea4e44b3256a" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_6b9a696e-2ddc-4022-abf5-8f72765fe50b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c30be1c-7b3a-449a-b9cf-f02934f603d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77c61599-1a44-4059-8184-ea4e44b3256a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c30be1c-7b3a-449a-b9cf-f02934f603d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_06281b80-285b-406f-a308-8212181bbad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c30be1c-7b3a-449a-b9cf-f02934f603d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_06281b80-285b-406f-a308-8212181bbad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06281b80-285b-406f-a308-8212181bbad4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_06281b80-285b-406f-a308-8212181bbad4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_06281b80-285b-406f-a308-8212181bbad4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4789a7e1-2827-4009-86ba-508d46692f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_06281b80-285b-406f-a308-8212181bbad4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4789a7e1-2827-4009-86ba-508d46692f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_995a5602-e91b-4a91-8264-457f7df2e2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4789a7e1-2827-4009-86ba-508d46692f37" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_995a5602-e91b-4a91-8264-457f7df2e2e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended" id="idcb3603dd8044dd1a4fcd4fbf12fcc80_GoodwillandIntangibleAssetsIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:href="mygn-20220331.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f04cfbb8-f886-43af-9600-c91ab4adad04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f04cfbb8-f886-43af-9600-c91ab4adad04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_760a86e4-fde4-4056-be33-a0eec7581fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_760a86e4-fde4-4056-be33-a0eec7581fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b236d895-87b0-42bf-b22c-61191426c4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b236d895-87b0-42bf-b22c-61191426c4dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_662c763e-6804-4d99-b8ce-430e6c1ef5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_662c763e-6804-4d99-b8ce-430e6c1ef5d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cb70c476-f46a-4323-8112-b713ba146298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cb70c476-f46a-4323-8112-b713ba146298" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable_98b4077c-8d35-4ed3-878d-287347bb1ac1" xlink:href="mygn-20220331.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:to="loc_mygn_ScheduleOfIntangibleAssetsTable_98b4077c-8d35-4ed3-878d-287347bb1ac1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f5c080c-f7a0-4e05-abdc-037d91be7e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_98b4077c-8d35-4ed3-878d-287347bb1ac1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f5c080c-f7a0-4e05-abdc-037d91be7e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f5c080c-f7a0-4e05-abdc-037d91be7e27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f5c080c-f7a0-4e05-abdc-037d91be7e27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f5c080c-f7a0-4e05-abdc-037d91be7e27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a949569-accd-40ec-89cf-f1c3576fbba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f5c080c-f7a0-4e05-abdc-037d91be7e27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a949569-accd-40ec-89cf-f1c3576fbba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember_01de789a-de08-41b4-a5c5-a9117e3b54ce" xlink:href="mygn-20220331.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a949569-accd-40ec-89cf-f1c3576fbba2" xlink:to="loc_mygn_PurchasedLicensesAndTechnologiesMember_01de789a-de08-41b4-a5c5-a9117e3b54ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#LongTermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/LongTermDebtNarrativeDetails" xlink:type="extended" id="i430da5afab8e4db49d89fc004488eff2_LongTermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1c7c391c-7978-4c30-8274-4765db5a9c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1c7c391c-7978-4c30-8274-4765db5a9c13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_af3a7956-e4be-414f-8fcd-fbdc501e96a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_af3a7956-e4be-414f-8fcd-fbdc501e96a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantLiquidityCovenantMinimum_eaf367e6-f382-471d-aa86-c35e07e70cf6" xlink:href="mygn-20220331.xsd#mygn_DebtCovenantLiquidityCovenantMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_mygn_DebtCovenantLiquidityCovenantMinimum_eaf367e6-f382-471d-aa86-c35e07e70cf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_8d11ecd8-ba61-4f6c-a633-ebf37bffe50b" xlink:href="mygn-20220331.xsd#mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_8d11ecd8-ba61-4f6c-a633-ebf37bffe50b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_30e7dfce-d0b7-4dbb-8ceb-da529442bdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_30e7dfce-d0b7-4dbb-8ceb-da529442bdb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_ead024e2-e179-43f9-806c-bf09a29c9c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_ead024e2-e179-43f9-806c-bf09a29c9c18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtInstrumentLIBORFloorPercentage_b6b6def4-20af-4bcd-b8eb-aa2f4bbdfb9c" xlink:href="mygn-20220331.xsd#mygn_DebtInstrumentLIBORFloorPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_mygn_DebtInstrumentLIBORFloorPercentage_b6b6def4-20af-4bcd-b8eb-aa2f4bbdfb9c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_e63fc801-be9a-44ea-a7f9-625bef57354f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_e63fc801-be9a-44ea-a7f9-625bef57354f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_114529e3-a3bf-4f3e-892b-292769b05133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_LongTermDebt_114529e3-a3bf-4f3e-892b-292769b05133" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7bc6c5e5-5d8e-4c6f-aaba-c2adb885024e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:to="loc_us-gaap_CreditFacilityAxis_7bc6c5e5-5d8e-4c6f-aaba-c2adb885024e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7bc6c5e5-5d8e-4c6f-aaba-c2adb885024e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7bc6c5e5-5d8e-4c6f-aaba-c2adb885024e" xlink:to="loc_us-gaap_CreditFacilityDomain_7bc6c5e5-5d8e-4c6f-aaba-c2adb885024e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_48f070ec-6e20-4a01-b267-afb3e63d0faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7bc6c5e5-5d8e-4c6f-aaba-c2adb885024e" xlink:to="loc_us-gaap_CreditFacilityDomain_48f070ec-6e20-4a01-b267-afb3e63d0faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1cca3f65-6c2d-4ba6-a9d1-87dd2991850e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_48f070ec-6e20-4a01-b267-afb3e63d0faa" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1cca3f65-6c2d-4ba6-a9d1-87dd2991850e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7915ccce-2d29-4ee3-ac93-845c98afe09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:to="loc_us-gaap_DebtInstrumentAxis_7915ccce-2d29-4ee3-ac93-845c98afe09a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7915ccce-2d29-4ee3-ac93-845c98afe09a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7915ccce-2d29-4ee3-ac93-845c98afe09a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7915ccce-2d29-4ee3-ac93-845c98afe09a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_72e47c4b-1e20-4657-beb5-2d812c9dfc11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7915ccce-2d29-4ee3-ac93-845c98afe09a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_72e47c4b-1e20-4657-beb5-2d812c9dfc11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmendmentToCreditAgreementMember_00046835-2ade-4b01-90bd-f32344dbc91b" xlink:href="mygn-20220331.xsd#mygn_AmendmentToCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_72e47c4b-1e20-4657-beb5-2d812c9dfc11" xlink:to="loc_mygn_AmendmentToCreditAgreementMember_00046835-2ade-4b01-90bd-f32344dbc91b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_0b3cf901-bdae-459f-94b1-0aaa901aad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:to="loc_us-gaap_VariableRateAxis_0b3cf901-bdae-459f-94b1-0aaa901aad3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0b3cf901-bdae-459f-94b1-0aaa901aad3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_0b3cf901-bdae-459f-94b1-0aaa901aad3c" xlink:to="loc_us-gaap_VariableRateDomain_0b3cf901-bdae-459f-94b1-0aaa901aad3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_62f57b90-f111-4a4c-9880-db53f62601f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_0b3cf901-bdae-459f-94b1-0aaa901aad3c" xlink:to="loc_us-gaap_VariableRateDomain_62f57b90-f111-4a4c-9880-db53f62601f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_788c03d8-06d3-4958-a096-d9638351127e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_62f57b90-f111-4a4c-9880-db53f62601f5" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_788c03d8-06d3-4958-a096-d9638351127e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e7a29127-fa4a-453e-904f-6cfad2ea7a74" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:to="loc_srt_StatementScenarioAxis_e7a29127-fa4a-453e-904f-6cfad2ea7a74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e7a29127-fa4a-453e-904f-6cfad2ea7a74_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_e7a29127-fa4a-453e-904f-6cfad2ea7a74" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e7a29127-fa4a-453e-904f-6cfad2ea7a74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e72ea47f-64d5-4f7d-8c94-bf17f80ea7a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_e7a29127-fa4a-453e-904f-6cfad2ea7a74" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e72ea47f-64d5-4f7d-8c94-bf17f80ea7a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a2950dee-e9e4-4a5d-919b-9226da6702e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e72ea47f-64d5-4f7d-8c94-bf17f80ea7a7" xlink:to="loc_srt_ScenarioForecastMember_a2950dee-e9e4-4a5d-919b-9226da6702e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4af0efa6-46c3-418a-a10c-80ec06bd63f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:to="loc_srt_RangeAxis_4af0efa6-46c3-418a-a10c-80ec06bd63f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4af0efa6-46c3-418a-a10c-80ec06bd63f9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4af0efa6-46c3-418a-a10c-80ec06bd63f9" xlink:to="loc_srt_RangeMember_4af0efa6-46c3-418a-a10c-80ec06bd63f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f08acfa-4da4-4b30-ba52-bcf888b244e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4af0efa6-46c3-418a-a10c-80ec06bd63f9" xlink:to="loc_srt_RangeMember_9f08acfa-4da4-4b30-ba52-bcf888b244e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_152769b8-1e9a-478d-acdf-b97f745bd5cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f08acfa-4da4-4b30-ba52-bcf888b244e5" xlink:to="loc_srt_MinimumMember_152769b8-1e9a-478d-acdf-b97f745bd5cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_00338b9c-0f0d-4554-8df2-f66b273febed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f08acfa-4da4-4b30-ba52-bcf888b244e5" xlink:to="loc_srt_MaximumMember_00338b9c-0f0d-4554-8df2-f66b273febed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i1ececefedd034453b8750ed15a7ad9e5_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ac493793-cae8-47be-ac95-b40ca616bdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ac493793-cae8-47be-ac95-b40ca616bdf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d413dc1d-fc32-47cd-9b6e-fee65d60961a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d413dc1d-fc32-47cd-9b6e-fee65d60961a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1bb9f595-1ec1-486d-812d-75d6b0d5e68c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1bb9f595-1ec1-486d-812d-75d6b0d5e68c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1c3f7a91-26f2-4b30-89b2-1e85faa4edf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1c3f7a91-26f2-4b30-89b2-1e85faa4edf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86bf1d2e-8e76-4a08-9ef3-69fafecee1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86bf1d2e-8e76-4a08-9ef3-69fafecee1a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fce5e925-9cba-4203-971c-2405335b00ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fce5e925-9cba-4203-971c-2405335b00ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6b274129-dc01-4d56-95cc-e9edfdafeefd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6b274129-dc01-4d56-95cc-e9edfdafeefd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f4b172ce-b7e5-4784-b595-d5825f571671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f4b172ce-b7e5-4784-b595-d5825f571671" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_5b1babf6-b353-45b4-bc0e-b87c76c1184c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_5b1babf6-b353-45b4-bc0e-b87c76c1184c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_de2aaaf9-d896-4748-81ae-377668774ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_de2aaaf9-d896-4748-81ae-377668774ea7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ec306851-137b-4b00-8963-ad0d4f988ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ec306851-137b-4b00-8963-ad0d4f988ef1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc34eb71-0cc8-405f-9e0a-677dd7c83d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:to="loc_us-gaap_AwardTypeAxis_dc34eb71-0cc8-405f-9e0a-677dd7c83d98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc34eb71-0cc8-405f-9e0a-677dd7c83d98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dc34eb71-0cc8-405f-9e0a-677dd7c83d98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc34eb71-0cc8-405f-9e0a-677dd7c83d98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5b11331-a5a6-431c-a675-31982620a787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dc34eb71-0cc8-405f-9e0a-677dd7c83d98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5b11331-a5a6-431c-a675-31982620a787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsAndRestrictedStockUnitsMember_9c273e24-0a19-4298-84ea-b3e02f48c928" xlink:href="mygn-20220331.xsd#mygn_OptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5b11331-a5a6-431c-a675-31982620a787" xlink:to="loc_mygn_OptionsAndRestrictedStockUnitsMember_9c273e24-0a19-4298-84ea-b3e02f48c928" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8eb8c182-a298-4422-b239-268b1546102d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_9c273e24-0a19-4298-84ea-b3e02f48c928" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8eb8c182-a298-4422-b239-268b1546102d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7656d553-d2d9-452c-b2e7-ba5012dfe540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_9c273e24-0a19-4298-84ea-b3e02f48c928" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7656d553-d2d9-452c-b2e7-ba5012dfe540" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_52bca56f-73ee-44d7-b8ea-db22a4ca8dff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:to="loc_srt_TitleOfIndividualAxis_52bca56f-73ee-44d7-b8ea-db22a4ca8dff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_52bca56f-73ee-44d7-b8ea-db22a4ca8dff_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_52bca56f-73ee-44d7-b8ea-db22a4ca8dff" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_52bca56f-73ee-44d7-b8ea-db22a4ca8dff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_525a309a-c2c9-482f-9cb4-2f10b7930f46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_52bca56f-73ee-44d7-b8ea-db22a4ca8dff" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_525a309a-c2c9-482f-9cb4-2f10b7930f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonEmployeeDirectorMember_2e9c3aab-7747-4334-ba03-bc164767c538" xlink:href="mygn-20220331.xsd#mygn_NonEmployeeDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_525a309a-c2c9-482f-9cb4-2f10b7930f46" xlink:to="loc_mygn_NonEmployeeDirectorMember_2e9c3aab-7747-4334-ba03-bc164767c538" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_fccb1f3f-af1b-4c6a-9b70-49c850585726" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_525a309a-c2c9-482f-9cb4-2f10b7930f46" xlink:to="loc_srt_ChiefExecutiveOfficerMember_fccb1f3f-af1b-4c6a-9b70-49c850585726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d4239239-1d79-4e0e-8651-43f011ea82fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:to="loc_us-gaap_VestingAxis_d4239239-1d79-4e0e-8651-43f011ea82fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d4239239-1d79-4e0e-8651-43f011ea82fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_d4239239-1d79-4e0e-8651-43f011ea82fe" xlink:to="loc_us-gaap_VestingDomain_d4239239-1d79-4e0e-8651-43f011ea82fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e89d1a8e-2fee-4131-9885-2478b3ef0d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_d4239239-1d79-4e0e-8651-43f011ea82fe" xlink:to="loc_us-gaap_VestingDomain_e89d1a8e-2fee-4131-9885-2478b3ef0d51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b37cb20f-1dc8-4839-8740-dd662c5c0148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_e89d1a8e-2fee-4131-9885-2478b3ef0d51" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b37cb20f-1dc8-4839-8740-dd662c5c0148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_472881c9-54f0-4b28-aca2-6fed5a76b971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_e89d1a8e-2fee-4131-9885-2478b3ef0d51" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_472881c9-54f0-4b28-aca2-6fed5a76b971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c7ecfc36-d193-4ff5-8969-c63ad5ea1501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_e89d1a8e-2fee-4131-9885-2478b3ef0d51" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c7ecfc36-d193-4ff5-8969-c63ad5ea1501" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a8fa607c-2fc2-4c68-a832-45b0e1e330ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:to="loc_us-gaap_PlanNameAxis_a8fa607c-2fc2-4c68-a832-45b0e1e330ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a8fa607c-2fc2-4c68-a832-45b0e1e330ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a8fa607c-2fc2-4c68-a832-45b0e1e330ee" xlink:to="loc_us-gaap_PlanNameDomain_a8fa607c-2fc2-4c68-a832-45b0e1e330ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e1c5e0e5-51d5-4556-8477-2aeea9fb2193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a8fa607c-2fc2-4c68-a832-45b0e1e330ee" xlink:to="loc_us-gaap_PlanNameDomain_e1c5e0e5-51d5-4556-8477-2aeea9fb2193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_ab0d0a3f-c7d5-4738-8efc-444f88430669" xlink:href="mygn-20220331.xsd#mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e1c5e0e5-51d5-4556-8477-2aeea9fb2193" xlink:to="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_ab0d0a3f-c7d5-4738-8efc-444f88430669" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_b1ce8770-1edf-453f-8952-45f8ed7b62f7" xlink:href="mygn-20220331.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e1c5e0e5-51d5-4556-8477-2aeea9fb2193" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_b1ce8770-1edf-453f-8952-45f8ed7b62f7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#StockBasedCompensationRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" xlink:type="extended" id="ic99122a9c29e43ae9f6acdc23721971f_StockBasedCompensationRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0dfc097-f6c9-4598-a20e-b37b485d4279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0dfc097-f6c9-4598-a20e-b37b485d4279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ef8af0e-b3b4-41dc-b311-fff2d2b220ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ef8af0e-b3b4-41dc-b311-fff2d2b220ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0e2f9f06-1140-4b9e-8dca-eaeeea123ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0e2f9f06-1140-4b9e-8dca-eaeeea123ef8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b3af0c5-f6d9-45ce-98ff-5515c439a674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b3af0c5-f6d9-45ce-98ff-5515c439a674" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_66587320-f2c8-4b1b-a44a-baad9c9f30d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_66587320-f2c8-4b1b-a44a-baad9c9f30d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_972a4c34-270e-4d5a-9492-327942392378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0dfc097-f6c9-4598-a20e-b37b485d4279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_22f2a325-ed6a-418c-a6e8-6d2d9ba39dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_22f2a325-ed6a-418c-a6e8-6d2d9ba39dfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cf570035-75a5-44ad-ab78-c1bf139c3031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cf570035-75a5-44ad-ab78-c1bf139c3031" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9e8aa8b4-ce91-4fdf-9a4d-3bce34dd599e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9e8aa8b4-ce91-4fdf-9a4d-3bce34dd599e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f2d9cd76-211a-44bb-9e31-44cb33574b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f2d9cd76-211a-44bb-9e31-44cb33574b0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9f22dc02-314a-4560-bdef-224356da392c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e480b8d-30e8-4e5a-b166-96958ee21cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0dfc097-f6c9-4598-a20e-b37b485d4279" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e480b8d-30e8-4e5a-b166-96958ee21cc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a9605edf-c8b3-48c9-a8c5-d2a23c2e8ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e480b8d-30e8-4e5a-b166-96958ee21cc3" xlink:to="loc_us-gaap_AwardTypeAxis_a9605edf-c8b3-48c9-a8c5-d2a23c2e8ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9605edf-c8b3-48c9-a8c5-d2a23c2e8ff8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a9605edf-c8b3-48c9-a8c5-d2a23c2e8ff8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9605edf-c8b3-48c9-a8c5-d2a23c2e8ff8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_209daaaa-32e0-4f93-a525-d294b04a9e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a9605edf-c8b3-48c9-a8c5-d2a23c2e8ff8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_209daaaa-32e0-4f93-a525-d294b04a9e37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_10ba278f-6905-4902-969d-e57a006815fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_209daaaa-32e0-4f93-a525-d294b04a9e37" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_10ba278f-6905-4902-969d-e57a006815fc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i1ac137d17d18481f81bcb7b7bf52ef8d_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_582a0bf7-cf56-47a2-bad8-9ea48fc7fced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a4c4efae-29b8-4a70-9c39-93d9e8a75c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_582a0bf7-cf56-47a2-bad8-9ea48fc7fced" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a4c4efae-29b8-4a70-9c39-93d9e8a75c74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c7498787-ce17-4bb9-9a18-687aa7ca6fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_582a0bf7-cf56-47a2-bad8-9ea48fc7fced" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c7498787-ce17-4bb9-9a18-687aa7ca6fd7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5ec40fee-c80b-413a-8243-bfecfce727f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c7498787-ce17-4bb9-9a18-687aa7ca6fd7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5ec40fee-c80b-413a-8243-bfecfce727f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5ec40fee-c80b-413a-8243-bfecfce727f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5ec40fee-c80b-413a-8243-bfecfce727f9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5ec40fee-c80b-413a-8243-bfecfce727f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0f2387ef-ae80-4a3d-9664-087bc18ebdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5ec40fee-c80b-413a-8243-bfecfce727f9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0f2387ef-ae80-4a3d-9664-087bc18ebdcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfMolecularDiagnosticTestingMember_7a66bd84-2413-449b-b33e-7ce89c118561" xlink:href="mygn-20220331.xsd#mygn_CostOfMolecularDiagnosticTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f2387ef-ae80-4a3d-9664-087bc18ebdcd" xlink:to="loc_mygn_CostOfMolecularDiagnosticTestingMember_7a66bd84-2413-449b-b33e-7ce89c118561" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember_47175ac2-fa03-4c2a-b0a6-529fecc4879e" xlink:href="mygn-20220331.xsd#mygn_CostOfPharmaceuticalAndClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f2387ef-ae80-4a3d-9664-087bc18ebdcd" xlink:to="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember_47175ac2-fa03-4c2a-b0a6-529fecc4879e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5c7d7c5b-3743-42b2-998f-37daa9f3c250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f2387ef-ae80-4a3d-9664-087bc18ebdcd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5c7d7c5b-3743-42b2-998f-37daa9f3c250" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_043dad85-5401-4130-a758-531c6b82100d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f2387ef-ae80-4a3d-9664-087bc18ebdcd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_043dad85-5401-4130-a758-531c6b82100d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/IncomeTaxesDetails" xlink:type="extended" id="i067caa4f90fa4c90a174c872c5171bd3_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_3355324b-79f0-4a82-b6f6-6c50afb5b78f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_32b2c18e-2004-4e8e-8fcd-041f12fce962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3355324b-79f0-4a82-b6f6-6c50afb5b78f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_32b2c18e-2004-4e8e-8fcd-041f12fce962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7bdfe63f-03bf-4764-bb80-ade0c3f0d680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3355324b-79f0-4a82-b6f6-6c50afb5b78f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7bdfe63f-03bf-4764-bb80-ade0c3f0d680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_90731fa1-4e9c-46d1-984f-8b667ca6e04b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3355324b-79f0-4a82-b6f6-6c50afb5b78f" xlink:to="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_90731fa1-4e9c-46d1-984f-8b667ca6e04b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_25c513c6-5421-4619-bc44-63c7f9703882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3355324b-79f0-4a82-b6f6-6c50afb5b78f" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_25c513c6-5421-4619-bc44-63c7f9703882" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2beee6e3-fbe2-4ac9-8bb3-451a642fcc40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_25c513c6-5421-4619-bc44-63c7f9703882" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2beee6e3-fbe2-4ac9-8bb3-451a642fcc40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2beee6e3-fbe2-4ac9-8bb3-451a642fcc40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2beee6e3-fbe2-4ac9-8bb3-451a642fcc40" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2beee6e3-fbe2-4ac9-8bb3-451a642fcc40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_bb2cf8a6-6816-4d0e-940a-9b87d8d7fde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2beee6e3-fbe2-4ac9-8bb3-451a642fcc40" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_bb2cf8a6-6816-4d0e-940a-9b87d8d7fde8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f4f1e534-53e1-41cc-ab0c-ef7531616425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bb2cf8a6-6816-4d0e-940a-9b87d8d7fde8" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f4f1e534-53e1-41cc-ab0c-ef7531616425" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_2d5f76de-30f7-491b-b525-21aa16fd4a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bb2cf8a6-6816-4d0e-940a-9b87d8d7fde8" xlink:to="loc_us-gaap_ForeignCountryMember_2d5f76de-30f7-491b-b525-21aa16fd4a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_b403f7c7-6156-4269-ac50-f20ef146be79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_25c513c6-5421-4619-bc44-63c7f9703882" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_b403f7c7-6156-4269-ac50-f20ef146be79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_b403f7c7-6156-4269-ac50-f20ef146be79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_b403f7c7-6156-4269-ac50-f20ef146be79" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_b403f7c7-6156-4269-ac50-f20ef146be79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_e444a5b7-63c4-4ead-a35f-d3d1a2adea2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_b403f7c7-6156-4269-ac50-f20ef146be79" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_e444a5b7-63c4-4ead-a35f-d3d1a2adea2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_1c20820b-edf0-47df-af6a-0abe420b9ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_e444a5b7-63c4-4ead-a35f-d3d1a2adea2e" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_1c20820b-edf0-47df-af6a-0abe420b9ffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_ce351d7c-d18e-44d4-9105-2756b9d3bb66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_e444a5b7-63c4-4ead-a35f-d3d1a2adea2e" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_ce351d7c-d18e-44d4-9105-2756b9d3bb66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_79ebe458-803f-41d5-9908-199ff804a85c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_e444a5b7-63c4-4ead-a35f-d3d1a2adea2e" xlink:to="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_79ebe458-803f-41d5-9908-199ff804a85c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_c665186d-413f-4467-a2b0-7872200bfe3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_25c513c6-5421-4619-bc44-63c7f9703882" xlink:to="loc_us-gaap_TaxPeriodAxis_c665186d-413f-4467-a2b0-7872200bfe3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_c665186d-413f-4467-a2b0-7872200bfe3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_c665186d-413f-4467-a2b0-7872200bfe3a" xlink:to="loc_us-gaap_TaxPeriodDomain_c665186d-413f-4467-a2b0-7872200bfe3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_20ae63e9-98f4-4525-aed3-fac0bd468e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_c665186d-413f-4467-a2b0-7872200bfe3a" xlink:to="loc_us-gaap_TaxPeriodDomain_20ae63e9-98f4-4525-aed3-fac0bd468e80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember_bec0f2af-4374-4b98-9e3b-021516dd9637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_20ae63e9-98f4-4525-aed3-fac0bd468e80" xlink:to="loc_us-gaap_EarliestTaxYearMember_bec0f2af-4374-4b98-9e3b-021516dd9637" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember_e83ba632-609c-42ce-afbc-9ed298b3ef65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_20ae63e9-98f4-4525-aed3-fac0bd468e80" xlink:to="loc_us-gaap_LatestTaxYearMember_e83ba632-609c-42ce-afbc-9ed298b3ef65" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="if2b4c8b388cc4c1ca0196cb2234ef887_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5ccedaad-2413-425d-b703-a1da0e44e13f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_4c9ad2c9-3b0d-4d9a-81f0-3ba19a0a0604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5ccedaad-2413-425d-b703-a1da0e44e13f" xlink:to="loc_us-gaap_LitigationReserveCurrent_4c9ad2c9-3b0d-4d9a-81f0-3ba19a0a0604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a8c57847-d6dd-4a91-b4c0-f512826045a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5ccedaad-2413-425d-b703-a1da0e44e13f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a8c57847-d6dd-4a91-b4c0-f512826045a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b5c765b2-e96e-4eb5-9e78-6331fc9244f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_5ccedaad-2413-425d-b703-a1da0e44e13f" xlink:to="loc_us-gaap_LossContingenciesTable_b5c765b2-e96e-4eb5-9e78-6331fc9244f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_28430a24-dc19-4acf-b1b9-7b50b80a0bfc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b5c765b2-e96e-4eb5-9e78-6331fc9244f1" xlink:to="loc_srt_LitigationCaseAxis_28430a24-dc19-4acf-b1b9-7b50b80a0bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_28430a24-dc19-4acf-b1b9-7b50b80a0bfc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_28430a24-dc19-4acf-b1b9-7b50b80a0bfc" xlink:to="loc_srt_LitigationCaseTypeDomain_28430a24-dc19-4acf-b1b9-7b50b80a0bfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4fba1d05-8721-4f5f-99ae-158d8a9c2961" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_28430a24-dc19-4acf-b1b9-7b50b80a0bfc" xlink:to="loc_srt_LitigationCaseTypeDomain_4fba1d05-8721-4f5f-99ae-158d8a9c2961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CBICIFPASettlementMember_f9e437d0-8e56-4777-a41f-0a811316872c" xlink:href="mygn-20220331.xsd#mygn_CBICIFPASettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4fba1d05-8721-4f5f-99ae-158d8a9c2961" xlink:to="loc_mygn_CBICIFPASettlementMember_f9e437d0-8e56-4777-a41f-0a811316872c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c681e9f8-2272-44cc-a39b-d43d27aea684" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b5c765b2-e96e-4eb5-9e78-6331fc9244f1" xlink:to="loc_srt_CounterpartyNameAxis_c681e9f8-2272-44cc-a39b-d43d27aea684" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c681e9f8-2272-44cc-a39b-d43d27aea684_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c681e9f8-2272-44cc-a39b-d43d27aea684" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c681e9f8-2272-44cc-a39b-d43d27aea684_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9af4699a-2ad7-4b60-a740-785bea6766f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c681e9f8-2272-44cc-a39b-d43d27aea684" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9af4699a-2ad7-4b60-a740-785bea6766f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_UnitedStatesAndStateOfCaliforniaMember_fd4c12fc-422a-408c-931a-a48211e4645d" xlink:href="mygn-20220331.xsd#mygn_UnitedStatesAndStateOfCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9af4699a-2ad7-4b60-a740-785bea6766f5" xlink:to="loc_mygn_UnitedStatesAndStateOfCaliforniaMember_fd4c12fc-422a-408c-931a-a48211e4645d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RelatorMember_c13e6afa-1622-43a2-86f2-11321b726892" xlink:href="mygn-20220331.xsd#mygn_RelatorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9af4699a-2ad7-4b60-a740-785bea6766f5" xlink:to="loc_mygn_RelatorMember_c13e6afa-1622-43a2-86f2-11321b726892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_63e5dd60-745d-4b76-9793-4c26d10abb68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b5c765b2-e96e-4eb5-9e78-6331fc9244f1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_63e5dd60-745d-4b76-9793-4c26d10abb68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_63e5dd60-745d-4b76-9793-4c26d10abb68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_63e5dd60-745d-4b76-9793-4c26d10abb68" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_63e5dd60-745d-4b76-9793-4c26d10abb68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_feaedf0a-d940-4f80-93b4-6a254bad5003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_63e5dd60-745d-4b76-9793-4c26d10abb68" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_feaedf0a-d940-4f80-93b4-6a254bad5003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cf63e308-19ad-4f3c-b87d-23efb7e85920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_feaedf0a-d940-4f80-93b4-6a254bad5003" xlink:to="loc_us-gaap_SubsequentEventMember_cf63e308-19ad-4f3c-b87d-23efb7e85920" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#LeasesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/LeasesDetails" xlink:type="extended" id="ib9aad7fb55c84748ad0ecb2567035766_LeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_6cafbd91-052e-46c9-be83-4d483e6fb007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_6cafbd91-052e-46c9-be83-4d483e6fb007" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_e161b9a8-8d22-4e99-b365-bcefb1e281f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_e161b9a8-8d22-4e99-b365-bcefb1e281f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_d6ee78a3-10b9-482c-895a-04c33e51af64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_us-gaap_AssetImpairmentCharges_d6ee78a3-10b9-482c-895a-04c33e51af64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_87aa046e-0e74-4d51-b852-bc2770a5a777" xlink:href="mygn-20220331.xsd#mygn_LesseeOperatingLeaseAreaOfLeasedSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_87aa046e-0e74-4d51-b852-bc2770a5a777" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_26883f72-91c8-4a8a-b3a6-17df10a70850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_26883f72-91c8-4a8a-b3a6-17df10a70850" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseExpectedFutureRentPayments_19a91448-14d7-4eac-9177-4110ac89019e" xlink:href="mygn-20220331.xsd#mygn_LesseeOperatingLeaseExpectedFutureRentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_mygn_LesseeOperatingLeaseExpectedFutureRentPayments_19a91448-14d7-4eac-9177-4110ac89019e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b2d4b07c-4c85-4f68-b32e-4f4d85ecfe8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b2d4b07c-4c85-4f68-b32e-4f4d85ecfe8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementAxis_a5bd0b7a-df02-4516-bebf-c8dc06619457" xlink:href="mygn-20220331.xsd#mygn_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b2d4b07c-4c85-4f68-b32e-4f4d85ecfe8f" xlink:to="loc_mygn_LeaseArrangementAxis_a5bd0b7a-df02-4516-bebf-c8dc06619457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain_a5bd0b7a-df02-4516-bebf-c8dc06619457_default" xlink:href="mygn-20220331.xsd#mygn_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mygn_LeaseArrangementAxis_a5bd0b7a-df02-4516-bebf-c8dc06619457" xlink:to="loc_mygn_LeaseArrangementDomain_a5bd0b7a-df02-4516-bebf-c8dc06619457_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain_d29cf244-de2a-4666-a7d7-78eb1e187c30" xlink:href="mygn-20220331.xsd#mygn_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mygn_LeaseArrangementAxis_a5bd0b7a-df02-4516-bebf-c8dc06619457" xlink:to="loc_mygn_LeaseArrangementDomain_d29cf244-de2a-4666-a7d7-78eb1e187c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_WestSaltLakeCityLeaseMember_9aeab01d-17ac-480a-852b-fa14d19bfc88" xlink:href="mygn-20220331.xsd#mygn_WestSaltLakeCityLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_LeaseArrangementDomain_d29cf244-de2a-4666-a7d7-78eb1e187c30" xlink:to="loc_mygn_WestSaltLakeCityLeaseMember_9aeab01d-17ac-480a-852b-fa14d19bfc88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d721179-4bc4-43ea-8f43-23d820d5095d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b2d4b07c-4c85-4f68-b32e-4f4d85ecfe8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d721179-4bc4-43ea-8f43-23d820d5095d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d721179-4bc4-43ea-8f43-23d820d5095d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d721179-4bc4-43ea-8f43-23d820d5095d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d721179-4bc4-43ea-8f43-23d820d5095d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_945fecf5-cc6e-411f-a3ae-e967a0987434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d721179-4bc4-43ea-8f43-23d820d5095d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_945fecf5-cc6e-411f-a3ae-e967a0987434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bcc60063-4f1e-4134-9c4c-242b7bfcb527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_945fecf5-cc6e-411f-a3ae-e967a0987434" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bcc60063-4f1e-4134-9c4c-242b7bfcb527" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/SubsequentEventsDetails" xlink:type="extended" id="i1b9340e0d3ee469daab53284fa97a3d3_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_34da9552-7165-4b03-912e-fcfc07fb1ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_0e0540f7-2660-49b1-89f8-55f1dd6c7546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_34da9552-7165-4b03-912e-fcfc07fb1ad0" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_0e0540f7-2660-49b1-89f8-55f1dd6c7546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_6d1284f5-3650-46c9-ab1f-111fcffd320c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_34da9552-7165-4b03-912e-fcfc07fb1ad0" xlink:to="loc_us-gaap_SubsequentEventTable_6d1284f5-3650-46c9-ab1f-111fcffd320c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bf30f504-4033-4643-a835-5a983ce09232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_6d1284f5-3650-46c9-ab1f-111fcffd320c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bf30f504-4033-4643-a835-5a983ce09232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bf30f504-4033-4643-a835-5a983ce09232_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bf30f504-4033-4643-a835-5a983ce09232" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bf30f504-4033-4643-a835-5a983ce09232_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_85625cae-f930-4749-be9b-8f8051e85fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bf30f504-4033-4643-a835-5a983ce09232" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_85625cae-f930-4749-be9b-8f8051e85fa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3d4d7fa4-f616-40db-af09-d55d03404aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_85625cae-f930-4749-be9b-8f8051e85fa8" xlink:to="loc_us-gaap_SubsequentEventMember_3d4d7fa4-f616-40db-af09-d55d03404aa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_64628f6d-3090-415a-9f03-3374a4a638f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_6d1284f5-3650-46c9-ab1f-111fcffd320c" xlink:to="loc_srt_CounterpartyNameAxis_64628f6d-3090-415a-9f03-3374a4a638f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_64628f6d-3090-415a-9f03-3374a4a638f5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_64628f6d-3090-415a-9f03-3374a4a638f5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_64628f6d-3090-415a-9f03-3374a4a638f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7f99fe0-063b-4dfc-ace3-81ca67703cbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_64628f6d-3090-415a-9f03-3374a4a638f5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7f99fe0-063b-4dfc-ace3-81ca67703cbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_UnitedStatesAndStateOfCaliforniaMember_91dd668d-f7a7-4520-a2e1-863230d7e00e" xlink:href="mygn-20220331.xsd#mygn_UnitedStatesAndStateOfCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7f99fe0-063b-4dfc-ace3-81ca67703cbf" xlink:to="loc_mygn_UnitedStatesAndStateOfCaliforniaMember_91dd668d-f7a7-4520-a2e1-863230d7e00e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RelatorMember_a1f66663-d3e6-4943-b188-7f9678e6c7fc" xlink:href="mygn-20220331.xsd#mygn_RelatorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7f99fe0-063b-4dfc-ace3-81ca67703cbf" xlink:to="loc_mygn_RelatorMember_a1f66663-d3e6-4943-b188-7f9678e6c7fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4cca4c86-144c-435f-b968-45fa4c7b8f6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_6d1284f5-3650-46c9-ab1f-111fcffd320c" xlink:to="loc_srt_LitigationCaseAxis_4cca4c86-144c-435f-b968-45fa4c7b8f6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4cca4c86-144c-435f-b968-45fa4c7b8f6b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_4cca4c86-144c-435f-b968-45fa4c7b8f6b" xlink:to="loc_srt_LitigationCaseTypeDomain_4cca4c86-144c-435f-b968-45fa4c7b8f6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_240c5d35-fe25-46c1-addb-604620237054" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_4cca4c86-144c-435f-b968-45fa4c7b8f6b" xlink:to="loc_srt_LitigationCaseTypeDomain_240c5d35-fe25-46c1-addb-604620237054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CBICIFPASettlementMember_50ed57b3-abc9-4cd5-b452-e1ab9766f243" xlink:href="mygn-20220331.xsd#mygn_CBICIFPASettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_240c5d35-fe25-46c1-addb-604620237054" xlink:to="loc_mygn_CBICIFPASettlementMember_50ed57b3-abc9-4cd5-b452-e1ab9766f243" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>mygn-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6c4a3a2c-b656-4a66-b2d1-1ba9bc2e559c,g:c641d519-fa56-4157-9313-b107a5eea025-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_2786ee63-8099-47a5-9a4e-039a697c3c3f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9a54b97e-8ed8-409f-bb6c-b3c622375728_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8994a612-4bd0-4dbf-a5a1-b11042f566b1_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8fe9726d-bbcf-4e32-97bf-12e61c91917c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_57404d90-ccb5-494e-8be8-d183a2c259ac_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_edf89161-8376-4ad0-a931-babc4fc96f0d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9a5b2897-5120-4561-bfbe-47cdfbe04078_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Myriad Genetics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f4111b4e-3d26-4823-a41f-02b11b8ca04f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Myriad Genetics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1e8c02d3-1bf5-491b-8157-ea41818d3367_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_585e4d7b-962a-4519-aea9-38964b3fa2ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_b061a7c9-a8aa-4e52-81d6-f48c7f463640_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_63b8716d-95e1-4b96-996f-fca391f29f02_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_83a5c85e-2070-42e0-841e-8513632bada0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_522a507d-5fc6-401a-9035-93c9befc3313_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e46db20b-16c9-457c-9447-56c04d5a5e45_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LeaseArrangementAxis_c9d2dde7-0e4a-44ed-8a22-093089eb1f0a_terseLabel_en-US" xlink:label="lab_mygn_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_mygn_LeaseArrangementAxis_label_en-US" xlink:label="lab_mygn_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_mygn_LeaseArrangementAxis_documentation_en-US" xlink:label="lab_mygn_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementAxis" xlink:href="mygn-20220331.xsd#mygn_LeaseArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LeaseArrangementAxis" xlink:to="lab_mygn_LeaseArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_db561309-1f9c-4a21-badd-743f617d86cf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4c3250bf-c01d-4032-bc05-16d4446f6b05_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_16e7f0c8-2882-4bb6-9b89-3765609613c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs canceled (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_da0875de-7b72-45f3-8dae-9847ca26138d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares per participant per offering period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_f56a383f-fab2-4d1e-8b72-9ef3ee94d750_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_5cd6bb05-9405-4e22-a757-58f67cfef285_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Deferred Revenue Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_59eb40d3-de3a-4a29-990a-f48276e1af98_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration recognized at acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_36cf1a5f-fb04-457c-80fd-eb96aee3f157_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_bf4e21d0-abf5-4705-b850-15a3124d34f2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1a41bd81-74b9-4928-816d-f2826d8deba5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cd66f870-7652-4f6d-ad42-849d1aa28a43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3fc82a08-53ec-4cb7-a923-174418fac5d6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4d979382-3cf9-4ebf-9481-d33561181125_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d2cea756-6369-4751-893c-d8c43bef2d95_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3fa222cb-87e5-43dc-80ad-bad53aa9f571_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based payment expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_849ac2e3-45ec-414d-941d-1c6f78ee870a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value recognized in the Statement of Operations</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_22354842-1110-4bfe-acfe-4d867437d9fe_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled or expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember_525706d2-0afc-4d4d-a9bf-ac91b4bb978a_terseLabel_en-US" xlink:label="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of pharmaceutical and clinical services</link:label>
    <link:label id="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember_label_en-US" xlink:label="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Pharmaceutical And Clinical Services [Member]</link:label>
    <link:label id="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember_documentation_en-US" xlink:label="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary financial statement caption in which the reported facts about the cost of pharmaceutical and clinical services expense have been included.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:href="mygn-20220331.xsd#mygn_CostOfPharmaceuticalAndClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:to="lab_mygn_CostOfPharmaceuticalAndClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_b0e05441-37f8-4314-9fb0-e505054453c2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_33904762-779a-4a3e-8c80-1f29a6a093e7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_202f95d1-f366-4c94-9d32-e827c0621874_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_48f07f7b-9ab1-495c-b1f7-9434d85e7036_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_ef5834fd-6af9-4db9-89be-b884f8cbc3cb_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program, remaining repurchase authorization</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_caf255f5-f4f7-419c-85b0-b4666d2f9a6c_terseLabel_en-US" xlink:label="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease area (sq ft)</link:label>
    <link:label id="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_label_en-US" xlink:label="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Leased Space</link:label>
    <link:label id="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_documentation_en-US" xlink:label="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Leased Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace" xlink:href="mygn-20220331.xsd#mygn_LesseeOperatingLeaseAreaOfLeasedSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace" xlink:to="lab_mygn_LesseeOperatingLeaseAreaOfLeasedSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e33602d2-1b12-43f7-ad87-b03e99d4ed20_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive options and RSUs excluded from EPS computation</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_250a43b6-bd58-4970-b1e2-a7cd90058973_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_8abfde09-0d2e-4341-9aee-36990a46d1d9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_b33c5f72-e5ab-44fd-8748-8c6dbbfe7d7c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa851977-f798-4334-89a2-5f3206e39982_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_29f85dde-1c5c-4917-b3cc-4e2439086fa2_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_17e4e3c4-626a-4687-9efc-d754ae15601c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b06ce416-aed9-4d75-8475-948a4f4ead99_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale debt securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_4c066ae9-835e-41fd-9322-d32c0733e4a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_2722f84c-19bf-4e5d-b7c2-6d2b8451ba3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-amortizable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a980bfd6-4cb5-45f3-b19c-d3780e6ecdac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b85779e9-7c3d-49ab-a676-45c37d4e491d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_5090ea9a-fa48-4779-9505-ec208273baba_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_23576f3d-8abd-4a59-961e-f30ebc51a2fe_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_67da9ff4-70bf-46ad-acba-55e992b9da67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_72090684-f610-4593-94b9-bbfa0ccca39b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OperatingLeaseLiabilityEstablished_3ba4b9a7-319e-48ac-8a64-94fe93a89d14_terseLabel_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityEstablished_label_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Established</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityEstablished_documentation_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Established</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityEstablished" xlink:href="mygn-20220331.xsd#mygn_OperatingLeaseLiabilityEstablished"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OperatingLeaseLiabilityEstablished" xlink:to="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_2a5df3fa-0740-481c-bdf3-8c4cc5701c60_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_86c3d2d4-da1e-495a-958d-50eeb1e97a23_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_59388216-427a-412c-b41b-e663fd8d0c9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_d11c5d10-61da-44d4-a990-de4a2375eb7d_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f8109c7b-505d-4348-8328-1a9896f7698c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a033a899-bfba-44ed-917e-c4c1df60d204_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f9dcb788-05f5-464c-9f02-857c8611ebd7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1a11b920-bb33-46f8-8129-b7994c73c8f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7b807496-5234-48a9-94d1-7536a2331362_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2e01ca3f-3287-4db3-9a20-6ffba5a32ffb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2d7fe09f-fdd3-450a-a07c-7e2a6373b82a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_6db92809-e385-47b0-b2a5-618aba154423_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_788c1336-b8b1-4f8f-a3e0-6b3645209fe0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LesseeOperatingLeaseExpectedFutureRentPayments_2d7ac388-51ee-4e80-9641-35a7914dc6e4_terseLabel_en-US" xlink:label="lab_mygn_LesseeOperatingLeaseExpectedFutureRentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expected future rent payments</link:label>
    <link:label id="lab_mygn_LesseeOperatingLeaseExpectedFutureRentPayments_label_en-US" xlink:label="lab_mygn_LesseeOperatingLeaseExpectedFutureRentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Expected Future Rent Payments</link:label>
    <link:label id="lab_mygn_LesseeOperatingLeaseExpectedFutureRentPayments_documentation_en-US" xlink:label="lab_mygn_LesseeOperatingLeaseExpectedFutureRentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Expected Future Rent Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseExpectedFutureRentPayments" xlink:href="mygn-20220331.xsd#mygn_LesseeOperatingLeaseExpectedFutureRentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LesseeOperatingLeaseExpectedFutureRentPayments" xlink:to="lab_mygn_LesseeOperatingLeaseExpectedFutureRentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3a461316-e3a7-4134-94a8-75d6d8dbb425_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember_b8d83174-2021-4f11-9f84-c0e6fe47be9b_terseLabel_en-US" xlink:label="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation estimate</link:label>
    <link:label id="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember_label_en-US" xlink:label="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Obligation Estimated Transaction Price [Member]</link:label>
    <link:label id="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember_documentation_en-US" xlink:label="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Obligation Estimated Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:href="mygn-20220331.xsd#mygn_PerformanceObligationEstimatedTransactionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:to="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_248acdb4-228e-440b-8706-af023062c525_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c5847797-c20f-4733-a7e4-b0f181f642ec_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c9ce24a7-8bc5-4485-b1c7-706361c1587b_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_f541ae91-3e93-4376-9d03-bcbc4ca1e9d6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2b890e29-eb6d-4cd6-81e9-adbf4cad50d7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting weight (percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_93721049-fd55-455c-a3a2-18e1932ba0d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustments recognized in Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d4ec00a-0958-4f5b-8021-4ee0b8f02971_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f63ab86c-5f67-4a5c-a179-65a464e10eec_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_91c1629f-f01c-4c74-84a0-d033e80acff6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_736d2346-2d56-45c6-8cdd-6ba4e888d239_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_36740af7-aa26-4313-822a-3dd74aae76fc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2c55ee63-0e97-4c07-83a1-3e4365dfd0e7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0d45457c-4726-4ac1-9076-b3362920f1fc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_8ecfa9de-c0ee-44ec-922f-dab883b27f93_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal agency issues</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_05c1436b-4f2e-43e8-902e-90f48960a8ea_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LatestTaxYearMember_a8f50a2a-f22d-4ca0-b39b-c26355164288_terseLabel_en-US" xlink:label="lab_us-gaap_LatestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latest tax year</link:label>
    <link:label id="lab_us-gaap_LatestTaxYearMember_label_en-US" xlink:label="lab_us-gaap_LatestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latest Tax Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LatestTaxYearMember" xlink:to="lab_us-gaap_LatestTaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fe62da80-500a-40df-a537-2dbb5880304f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d073225b-2705-4dff-8a17-babb24be1670_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eec684e1-45de-4e1a-a7ea-35c2f862e10b_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4e0ce961-c5c7-40a9-bbcf-3e57d07d9426_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_110b171b-d8e8-4574-9703-1c5042b55882_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1deeff3b-baf3-42d2-8af7-ff13b727c364_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Revenue by Category and by U.S versus Rest of World</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a70766ab-c891-4ceb-9f52-4fc9833455d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs, Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_AmendmentToCreditAgreementMember_109dd3f6-ad16-47bf-87c8-966e9209bca1_terseLabel_en-US" xlink:label="lab_mygn_AmendmentToCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended facility</link:label>
    <link:label id="lab_mygn_AmendmentToCreditAgreementMember_label_en-US" xlink:label="lab_mygn_AmendmentToCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment To Credit Agreement [Member]</link:label>
    <link:label id="lab_mygn_AmendmentToCreditAgreementMember_documentation_en-US" xlink:label="lab_mygn_AmendmentToCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment to Credit Agreement [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmendmentToCreditAgreementMember" xlink:href="mygn-20220331.xsd#mygn_AmendmentToCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_AmendmentToCreditAgreementMember" xlink:to="lab_mygn_AmendmentToCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8ff5ef6d-2308-4e88-ac67-ace5d2e96a96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_bb879db7-bbf5-4461-a231-0ed101a6b8ea_negatedTerseLabel_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Gross unrealized holding losses</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_49945e7d-44b8-4010-92d9-b9d292d0ce33_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7c98887b-7a22-4b84-9df9-2e1901436b8c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_1948e436-99a5-4d0e-af41-9e61af581eae_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balances</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_0c8ec766-e2d9-4178-9187-4581db968c01_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_199df143-72cf-400b-b4a4-fa1c0e19e83c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55988728-0fac-492e-a5ed-b55c8a8f10bb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_f1d49b04-0a46-44c3-88fe-bdc9a2e2b11e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_35fd9e84-c412-4266-9859-4df0208e39a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c8eb09f4-43c1-4f70-93f8-7cc67e99c9f5_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CostOfMolecularDiagnosticTestingMember_cf77f3c9-63e2-4e1a-8a5c-8798b6060222_terseLabel_en-US" xlink:label="lab_mygn_CostOfMolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of molecular diagnostic testing</link:label>
    <link:label id="lab_mygn_CostOfMolecularDiagnosticTestingMember_label_en-US" xlink:label="lab_mygn_CostOfMolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Molecular Diagnostic Testing [Member]</link:label>
    <link:label id="lab_mygn_CostOfMolecularDiagnosticTestingMember_documentation_en-US" xlink:label="lab_mygn_CostOfMolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary financial statement caption in which the reported facts about the cost of molecular diagnostic testing expense have been included.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfMolecularDiagnosticTestingMember" xlink:href="mygn-20220331.xsd#mygn_CostOfMolecularDiagnosticTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CostOfMolecularDiagnosticTestingMember" xlink:to="lab_mygn_CostOfMolecularDiagnosticTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_31cc517f-8fb3-456a-b23e-b16a759bc2bb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_32cf0334-75e0-4388-b23e-781fbb53fbf6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_38dc9d83-2648-487e-9c92-5191e404f1e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_47170877-ed4b-4858-8ecd-9fa429d1ce57_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5a9c700e-9304-4ce9-a6c8-c8b950706a71_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement levels based on EPS targets</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_5014f372-814e-4122-92b5-bf40f35cea97_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c4248e9f-3923-46af-b278-10fa5fc927b8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_01f4cec3-d107-493a-a828-b94f6be9970d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_098475f6-6659-41d4-a4a8-7867945a9ff0_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_31290990-f5e6-4d42-b2ba-e62a033ab4ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_709135b2-1c2a-4a17-bb14-fb7cf15b17f7_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c449d8f0-5213-45c0-97ac-1bf9e92c7c5e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_67ea3b59-399b-4a09-ac48-cd18f0421c2f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_0a92993d-0169-44ff-867d-35567e0172af_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue and Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42a98e27-994e-4598-a4b7-930f6916d73f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9f2b8a71-017a-4d4d-9976-4b770c9ff4bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_a830b76c-bcca-4ec4-84ff-cb3400d1abfc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_a72c5e3e-83fc-48b6-b1a5-7a132823dd85_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss due to abandonment of facility</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_63c82a87-c69c-42d6-85ee-23c384c22aca_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_11235260-ae87-45e1-83a2-13e8d0219ac8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_06d4350d-e448-4503-a4d2-ffc3ef89e288_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_832ec0de-b35f-44c3-b7a8-0734a9772bce_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_dccee00b-7cc4-4ac3-a82e-b0cfef6effd2_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable investment securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e8d4ec2-4ae5-4bd9-bc6c-9f094065f0b4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_549dbbd0-9a7a-4756-b6dd-4560a2b48335_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_810218d0-d77d-4883-a2bb-bb234f08793c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_681dc7be-b758-4d77-9dd9-902c3bb5213d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled or expired (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_502a5e6e-0f08-4665-94bf-dcf3967e5fb9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_33fa0c11-8f2d-4971-b4cc-d1948acd3122_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_5be0cf52-b213-424c-b4fa-239c970cb332_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_9817d27a-8c14-4ffa-bb17-c0ec2388e8d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0586db0b-8415-4e12-bdf4-211350a5c1b2_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b6cb2f26-d4b7-4b77-ac52-185ee7b9ca53_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Gross unrealized holding gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_5290d013-1492-4bff-9c0f-5c25eb32863c_totalLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_217c5bf4-d22a-4226-86af-c8a2d0c2fd60_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e4d68b90-3a92-41b6-9ca9-65b27e3fa003_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_0c992862-0614-45f1-bf57-7f4b52df1465_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_615b4f82-6a1c-4b49-adcb-02c0f642b32e_negatedLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract, Revenue Recognized</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="mygn-20220331.xsd#mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_403c3832-b455-4aba-aa9f-a2000a6cc052_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cd389ac3-c1ad-4176-a1e0-97a5aabb40b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6e1cade8-75d7-4d93-b477-0363d65d9c59_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_fd3d6767-ff5d-42cc-a0b9-4e89d30aeee9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5c5814d7-e196-4a44-b4be-9e11e5e272f3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_efe91092-5b53-4684-9f85-7c568d0fc154_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, 80.3 million and 80.0 million shares outstanding at March&#160;31, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_5a2e6035-3557-4f57-9123-a6115d0d48e0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_043afc16-a402-4dd9-a808-4bb98345aa49_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_28b6490e-a54c-42bb-8f90-aa5a34165166_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_309187a1-203f-4b30-aab1-08264929b8eb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding, beginning (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4871bd2a-4632-42fb-8d88-cb14330512d3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding, ending (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0142dd25-f330-42e1-9dc8-5ec2eb258c86_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9b555f77-6755-4293-892e-1f73784ea7c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticPharmacogenomicsMember_e53b0198-de3e-48bc-8551-928afa56101a_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic - Pharmacogenomics</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticPharmacogenomicsMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Pharmacogenomics [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticPharmacogenomicsMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Pharmacogenomics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticPharmacogenomicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:to="lab_mygn_MolecularDiagnosticPharmacogenomicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_2ce44bbe-4a5f-4085-b5a2-9c2b25d910c3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_08d93dce-798c-463c-b4ec-422241644480_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1e39de70-6edf-4183-9c30-3d639e668bda_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a16e63ac-cabc-4e0a-928c-2d720245a17a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_RefundsPayableAndReserveCurrent_483c24ce-d15f-4be0-bcf0-c86c72c24f70_terseLabel_en-US" xlink:label="lab_mygn_RefundsPayableAndReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds payable and reserves</link:label>
    <link:label id="lab_mygn_RefundsPayableAndReserveCurrent_label_en-US" xlink:label="lab_mygn_RefundsPayableAndReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds Payable And Reserve, Current</link:label>
    <link:label id="lab_mygn_RefundsPayableAndReserveCurrent_documentation_en-US" xlink:label="lab_mygn_RefundsPayableAndReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds Payable And Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RefundsPayableAndReserveCurrent" xlink:href="mygn-20220331.xsd#mygn_RefundsPayableAndReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_RefundsPayableAndReserveCurrent" xlink:to="lab_mygn_RefundsPayableAndReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MedicareMember_aaad3d6c-5868-4d7e-849a-d485e8b17fdf_terseLabel_en-US" xlink:label="lab_mygn_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_mygn_MedicareMember_label_en-US" xlink:label="lab_mygn_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_mygn_MedicareMember_documentation_en-US" xlink:label="lab_mygn_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MedicareMember" xlink:href="mygn-20220331.xsd#mygn_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MedicareMember" xlink:to="lab_mygn_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_5ed28fe7-50e6-4c04-b8f3-8ec8680cf3a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees associated with refinancing of revolving credit facility</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_c21aeeb4-0cef-4f4a-82f6-3dc8cf527325_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_93a1ead2-b054-4b86-9752-cde4faae8862_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_4ec6fadc-fe98-45d8-b43c-1d799b7db291_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_1c1aa8da-fd3d-4274-9700-f05bccdf3242_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_88fd4d15-5dc6-46da-98bc-6c30ee00bf65_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Investment Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ea2f248b-03d2-42a0-8656-f9a015155c94_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_9c083460-6e79-4f1b-aa69-b14dc0361698_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_3b5d4182-78a2-40ed-a5ea-e89b88db946a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_bae44987-8ab9-4dd1-82ff-d3535c28569a_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_cf6f6dc4-3fc0-4fc8-9ad6-bd41a94fdd2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_d11f27c9-bdc0-4d2c-a15f-f96c4fa5a0c2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ada1b7a1-e9f7-42f1-99a4-b0144348be2b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_663ec0f1-3b10-4f63-bae2-c574aa225272_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_38a18b4b-626b-4171-837a-832f1b98ae13_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ea7f6c94-72c4-4b02-95b1-fa9339cc9086_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d21f5c75-0f21-4508-8dba-6e1a08717147_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f03fc482-009b-4b89-a025-a5cce76b8a6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_824cb7e6-956c-4f9c-bf96-73f59f85473a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c9c9631f-ecdb-4e28-98cc-c35c7ebe7819_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4979b2cf-0633-44b9-a7c6-4c900025be2f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a82eb346-0f5d-4ec5-b03f-8bfdf029973b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_8ae2b317-6329-4e75-9660-10c25813e197_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_cd9c85b0-8cd1-4dba-919c-a735844dea16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1b058e4c-5557-4d8c-9a8a-8a10dd323088_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_3be3297d-ad8f-4659-8491-4fa93d090895_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_64a25cf4-ae9b-4713-af0b-14cd5ca004d7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CARESActOf2020MedicarePaymentAmount_9c4cbe1c-c920-4166-b513-64eff7246fc5_terseLabel_en-US" xlink:label="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Medicare payments to provide relief from economic impacts of COVID-19</link:label>
    <link:label id="lab_mygn_CARESActOf2020MedicarePaymentAmount_label_en-US" xlink:label="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Of 2020 Medicare Payment Amount</link:label>
    <link:label id="lab_mygn_CARESActOf2020MedicarePaymentAmount_documentation_en-US" xlink:label="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act of 2020 Medicare payment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020MedicarePaymentAmount" xlink:href="mygn-20220331.xsd#mygn_CARESActOf2020MedicarePaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CARESActOf2020MedicarePaymentAmount" xlink:to="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_33b75e3d-edac-4129-ac5b-85ae280c1539_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9502395b-8284-4a5b-a771-9d44bb84e207_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_45ad94e6-21e5-4d60-a739-991813a1d2bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5d3bfb02-ac1f-4bae-a23c-c6bafac95e35_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0ff4fa36-7944-469b-a94f-ece10b91a623_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f2be3f5b-6644-468d-9f01-624c4d859635_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Gross unrealized holding losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29c307dd-02a0-4330-8adb-f1b100b32ffc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_de8181bb-0997-4144-8120-1822377a1682_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_4a366169-1240-4c62-a5f8-bffae6bf6f67_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_cfbf8a0f-ea8e-41db-92d9-45a1d7be5788_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3b185f01-91fb-4e51-be49-0f260c9e2f3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_fcf166b8-b90a-4331-a8d2-24f8f0d8c6d5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_769dabff-5a8d-4146-981f-d6af14944d06_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2666fedf-be9d-44b1-9d0a-19dcce80d345_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e103a648-8c3d-4801-b883-6260942b400d_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Amortized cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_3c15fba1-6737-46a6-9144-936bf081d7de_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_9fe5e4c9-a058-4d37-89ae-20b7fa19d2a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_56edf7aa-0a2c-483c-b913-71539124663e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable investment securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_5180d32a-6447-4ad7-8a0d-46ebd81cc5ce_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_276f8015-b2cd-45af-95c2-c1bddc1f1851_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCashAbstract_6fc995e2-d28e-424b-b79b-b02a87027d88_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total:</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCashAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCashAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract" xlink:to="lab_us-gaap_InvestmentsAndCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_32ef682d-57d3-4aeb-b3e8-893cf56eb23a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and long-lived asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_684bae49-a945-4fc8-a013-67ac4771e004_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill and long-lived assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticPrenatalTestingMember_695f3948-4c81-4f51-bf5e-33be96b319b6_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Prenatal</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticPrenatalTestingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Prenatal Testing [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticPrenatalTestingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic Prenatal testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticPrenatalTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:to="lab_mygn_MolecularDiagnosticPrenatalTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_fdab96b7-3c12-43c7-aef3-54e09c336264_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_WestSaltLakeCityLeaseMember_d5f1e0d8-8231-47df-a249-88c436c83e4e_terseLabel_en-US" xlink:label="lab_mygn_WestSaltLakeCityLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">West Salt Lake City</link:label>
    <link:label id="lab_mygn_WestSaltLakeCityLeaseMember_label_en-US" xlink:label="lab_mygn_WestSaltLakeCityLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">West Salt Lake City Lease [Member]</link:label>
    <link:label id="lab_mygn_WestSaltLakeCityLeaseMember_documentation_en-US" xlink:label="lab_mygn_WestSaltLakeCityLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">West Salt Lake City Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_WestSaltLakeCityLeaseMember" xlink:href="mygn-20220331.xsd#mygn_WestSaltLakeCityLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_WestSaltLakeCityLeaseMember" xlink:to="lab_mygn_WestSaltLakeCityLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_bc18ad80-7e07-48fa-9cd2-ffcf9d184bf0_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_8d9028fd-6f1d-4937-a4e4-4a40afbe6e49_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_b7b39995-4f25-49b1-98f3-e15cac1acd3c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_dd90d990-ed20-4362-a14c-c02284e147ce_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7097237-5f47-40e9-ab3c-2b563edfdf7b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f494a57f-fa9f-4d6b-a54e-8601d692a660_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a08f49bd-560c-48b6-b2e3-651b57410ccb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0c731dff-37ba-41f9-a1a8-20f6992c44f4_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53628679-f18c-4f11-b57d-2ce1a10b65af_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_91962d26-183b-4c75-afb1-8045ae40c6f8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a57420ba-b6c1-4162-b761-e2c2dfaf552d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Myriad Genetics, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0d8694f3-b14c-4440-9551-19df8f429378_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_31360102-2a46-4142-b7f5-a2728004e4fc_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning common stock issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_eeaf8171-5196-4bc3-b932-5fc92219fc6f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued at end of period</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_500971c3-9492-4ea3-9dec-ce6f9eb37672_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_ba456aa7-69ef-4a48-9bd8-0e807453d077_terseLabel_en-US" xlink:label="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_label_en-US" xlink:label="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Unrecognized Tax Benefits</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_documentation_en-US" xlink:label="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in unrecognized tax benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:href="mygn-20220331.xsd#mygn_IncreaseDecreaseInUnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:to="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_5bec95e3-cebe-426d-87f9-63906be2ebce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa19287b-8785-4ef0-bdb7-39c4f82c2a41_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_5056c257-4b08-4183-9004-5632427f021f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input, expected term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_680c1e0f-5056-41c3-a139-b46471e67737_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_NonEmployeeDirectorMember_8772b0ea-b1e1-46ed-97dc-aa51db3057c4_terseLabel_en-US" xlink:label="lab_mygn_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee director</link:label>
    <link:label id="lab_mygn_NonEmployeeDirectorMember_label_en-US" xlink:label="lab_mygn_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Director [Member]</link:label>
    <link:label id="lab_mygn_NonEmployeeDirectorMember_documentation_en-US" xlink:label="lab_mygn_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee director.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonEmployeeDirectorMember" xlink:href="mygn-20220331.xsd#mygn_NonEmployeeDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_NonEmployeeDirectorMember" xlink:to="lab_mygn_NonEmployeeDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticTumorProfilingMember_18f37e53-b70f-4aa2-a7fc-02d634056041_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticTumorProfilingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Tumor Profiling</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticTumorProfilingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticTumorProfilingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Tumor Profiling [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticTumorProfilingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticTumorProfilingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Tumor Profiling</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTumorProfilingMember" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticTumorProfilingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticTumorProfilingMember" xlink:to="lab_mygn_MolecularDiagnosticTumorProfilingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0aed65d6-592f-4ef3-a2fd-3044d2cc1d51_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_66da07f2-178b-42be-bcc4-55db0089003d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c0f1a969-ee8b-495b-ba53-e06337965df1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_dfa8fa5a-148e-4c68-b022-55dfb02e5f7e_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_PurchasedLicensesAndTechnologiesMember_bf4f6c0b-6151-4b15-b07b-0e01d545267b_terseLabel_en-US" xlink:label="lab_mygn_PurchasedLicensesAndTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased licenses and technologies</link:label>
    <link:label id="lab_mygn_PurchasedLicensesAndTechnologiesMember_label_en-US" xlink:label="lab_mygn_PurchasedLicensesAndTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased Licenses And Technologies [Member]</link:label>
    <link:label id="lab_mygn_PurchasedLicensesAndTechnologiesMember_documentation_en-US" xlink:label="lab_mygn_PurchasedLicensesAndTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased licenses and technologies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember" xlink:href="mygn-20220331.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_PurchasedLicensesAndTechnologiesMember" xlink:to="lab_mygn_PurchasedLicensesAndTechnologiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_6dcb5087-79f9-4e6a-93a5-cba14a443eec_terseLabel_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Gross unrealized holding gains</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_eec1fdf9-631f-4499-b44a-36207da8538a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_3ab15fc9-fae8-4654-a8e1-ba57aa27346a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_9e96bb7f-fdaf-481b-8dac-a26ce70bdfa4_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_86df28df-bd35-467c-8f13-84b462b10930_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d4bd868d-40ca-4979-9773-1cc1629cf88f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_b0e713ae-9a7d-45e8-9be3-b67ee8e4a704_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undrawn fee (percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f7edde0b-5b6f-4962-aff2-cb24444a6fea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_916ae540-793a-45db-8b73-6ce71c71b72a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_14c595df-0355-418f-ab46-ebe7e8bad0df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance based on Nasdaq Healthcare Provider Index</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_3fab4590-448e-42e0-b126-4d28c52aac2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_36030142-1f0e-409b-8eee-9ad1472711e7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6e4afab0-a99c-4f35-88cf-241e7ec8d69c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_671cb30c-4111-45db-9ecc-e52e2bbc7908_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_6751efb5-9074-4c81-a880-d1c2c5451e32_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_53d63286-c90f-415b-aae3-30b4fc8cbafa_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal repayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3afbfba4-8216-433b-90b9-c4def7e38012_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f872a38a-118d-4d04-a5e6-40dd4366dc0f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85dda31d-9a83-40ee-8247-5830fb88d123_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee7db5b6-012c-4c27-a879-35dd4ce3631d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_01716e7a-72c2-42ad-b71d-e0a4a7826a34_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b6f7d75c-12f9-4ff2-b009-a8f42291b0e2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2da5a032-0b98-4827-81b9-bf7675be744e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticAutoimmuneMember_4f1e71e4-10d3-445e-9083-7f9c1c7dd9c2_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticAutoimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic - Autoimmune</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticAutoimmuneMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticAutoimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Autoimmune [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticAutoimmuneMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticAutoimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Autoimmune</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticAutoimmuneMember" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticAutoimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticAutoimmuneMember" xlink:to="lab_mygn_MolecularDiagnosticAutoimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ed67402f-e3cc-4d32-ab34-9e0725494369_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5af7ce83-572c-4c71-9c83-09da4b0e8b01_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b00a0f85-801a-4d02-a576-a7d94745e54e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_280b870c-b416-4ea1-ace4-85442c7d6cea_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_eaea7ba5-b929-4937-9a68-a759197594a5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncreaseDecreaseInEarningsLossPerShare_119076fa-f129-46a2-ae61-77110d9d5043_terseLabel_en-US" xlink:label="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in earnings per share (dollars per share)</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInEarningsLossPerShare_label_en-US" xlink:label="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Earnings Loss Per Share</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInEarningsLossPerShare_documentation_en-US" xlink:label="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in earnings (loss) per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:href="mygn-20220331.xsd#mygn_IncreaseDecreaseInEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:to="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a1211e40-18eb-43c9-92a0-e03f8c20ab5e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_1659c0e6-a0e6-4c33-a44d-9b9a0335a794_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_35d9e546-6dd5-49b0-a46a-9d2e84962653_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_af16772c-b296-41ab-b9d1-3ded10114a3b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs canceled (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_0a6d3df9-c060-43ae-b5ba-31c2aa34a928_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DebtCovenantLiquidityCovenantMinimum_2d2cbf49-d4b7-414c-9269-8b2cfca331b6_terseLabel_en-US" xlink:label="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum liquidity covenant</link:label>
    <link:label id="lab_mygn_DebtCovenantLiquidityCovenantMinimum_label_en-US" xlink:label="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Liquidity Covenant Minimum</link:label>
    <link:label id="lab_mygn_DebtCovenantLiquidityCovenantMinimum_documentation_en-US" xlink:label="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Liquidity Covenant Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:href="mygn-20220331.xsd#mygn_DebtCovenantLiquidityCovenantMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:to="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CBICIFPASettlementMember_01449536-0706-4457-bced-b97b88270cdb_terseLabel_en-US" xlink:label="lab_mygn_CBICIFPASettlementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CBI CIFPA</link:label>
    <link:label id="lab_mygn_CBICIFPASettlementMember_label_en-US" xlink:label="lab_mygn_CBICIFPASettlementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CBI CIFPA Settlement [Member]</link:label>
    <link:label id="lab_mygn_CBICIFPASettlementMember_documentation_en-US" xlink:label="lab_mygn_CBICIFPASettlementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CBI CIFPA Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CBICIFPASettlementMember" xlink:href="mygn-20220331.xsd#mygn_CBICIFPASettlementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CBICIFPASettlementMember" xlink:to="lab_mygn_CBICIFPASettlementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f07bd5bc-0519-4c76-8aca-34320d6bbafa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3bc4af93-102e-40c3-aa8d-ad9d19029c85_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3c2d770e-5559-4923-a447-92342c606455_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2e51f98f-216d-4c5d-9904-847c740f1913_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense related to stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_41b4de5f-1e4b-42d5-aa60-673c3718e176_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_08de3fd2-cc7d-4d51-855d-f7aee806e05a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_49e79750-f204-4eb0-8faa-c95ff50d637b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_7cf47235-58dc-4711-8cbf-d2db5fb64eb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_54cb0599-067b-4831-9fc6-27d994160be2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityPrepayments_42de4e03-8532-44aa-8527-31d0459ba810_terseLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityPrepayments_label_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Prepayments</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityPrepayments_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability, prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityPrepayments" xlink:href="mygn-20220331.xsd#mygn_ContractWithCustomerLiabilityPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerLiabilityPrepayments" xlink:to="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_27bd11d0-896d-4ea3-a3ae-67a175af2183_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense related to RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_78ea7887-b60a-4cc7-afa4-d268bbf04482_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President and Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_86acd6e9-a5ac-4cdf-b48c-c421f2067700_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_a6ec2c66-c670-455d-9735-a4138fef3119_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Rolling Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c9cd1c82-bca4-45de-9c76-fdf0557a6570_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_9d881c59-ca38-4bd9-9d48-a3e68e27f619_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under the Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_3f561ecb-8a8a-4d19-9cb5-55739249e276_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable investment securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6d8d7024-4c34-4a99-9c5e-d484cd0c324e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_9d80cbbb-99d0-4efe-a6d1-6fbf0b052cb0_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_662f2264-52db-4ca5-a05f-9291d65c4a6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f3868dc2-e34f-4048-9d18-b83a5a1babd8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_9dabf406-a1f6-4464-ab07-375717feeccd_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5765f47-59e0-45ed-a73c-0c0abce431c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_88f26561-208d-432f-bcb8-250c88f0c21b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ab91d06-e9ae-4675-8708-a6cbb8c14fab_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9a4f803e-4723-4db4-8635-e644dd3ae06c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5c89f619-58b9-429b-9c59-c90058f0d73e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount, total</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_84f6c7a2-c802-4717-9738-def19bc83b09_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_c02cc366-ebf3-4857-af32-98c6ee32f67d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticOtherTestingMember_ad795401-893d-4fc6-a635-0ed8ca03f0e9_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticOtherTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Other</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticOtherTestingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticOtherTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Other Testing [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticOtherTestingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticOtherTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic other testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticOtherTestingMember" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticOtherTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticOtherTestingMember" xlink:to="lab_mygn_MolecularDiagnosticOtherTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c2708d71-84c1-48da-9e8f-cc4ffeeac11e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_cf85bdf7-868f-4f55-8684-d773170f852f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c8025cf6-f513-4846-9565-60e19a6c42d1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f763465a-1988-46e3-a919-d6b4f639728d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a4640b56-6737-4263-923e-7c8ea29a87b9_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IntangibleAssetsLineItems_e6f4472a-6f1e-4c8c-9cc7-d5ab75ea94e5_terseLabel_en-US" xlink:label="lab_mygn_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_mygn_IntangibleAssetsLineItems_label_en-US" xlink:label="lab_mygn_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_mygn_IntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_mygn_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems" xlink:href="mygn-20220331.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IntangibleAssetsLineItems" xlink:to="lab_mygn_IntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_4fbaf184-c0d9-4ed4-8755-f4ce2f9c5ff7_terseLabel_en-US" xlink:label="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Purchase Plan</link:label>
    <link:label id="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_label_en-US" xlink:label="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Twenty Twelve [Member]</link:label>
    <link:label id="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_documentation_en-US" xlink:label="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Twenty Twelve [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:href="mygn-20220331.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:to="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d54b2e2d-48e3-4751-8b0f-3222f7ac8eb8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8d735c0b-9cca-4795-b977-b38650346feb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_3a1046b7-0d85-400d-a2e4-f982ede4ab9f_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_f1aec21a-cda7-4a77-8afa-22f9e681c07a_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_9a46b736-02ef-4de4-ad45-c9332705d343_terseLabel_en-US" xlink:label="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Plan</link:label>
    <link:label id="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_label_en-US" xlink:label="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:href="mygn-20220331.xsd#mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:to="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b3f51515-ca14-4450-8832-e3bbf12e5f61_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationYearUnderExamination_1dd57ab8-85f8-42e7-bb30-4ed908453887_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax year being audited in income tax examination</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationYearUnderExamination_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Year under Examination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:to="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_RelatorMember_76d601ff-720b-499a-b380-889bbc5efed9_terseLabel_en-US" xlink:label="lab_mygn_RelatorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relator's counsel</link:label>
    <link:label id="lab_mygn_RelatorMember_label_en-US" xlink:label="lab_mygn_RelatorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relator [Member]</link:label>
    <link:label id="lab_mygn_RelatorMember_documentation_en-US" xlink:label="lab_mygn_RelatorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RelatorMember" xlink:href="mygn-20220331.xsd#mygn_RelatorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_RelatorMember" xlink:to="lab_mygn_RelatorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_fa1299a0-3ec7-4baa-8634-d70eefaaead1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_c555902b-bb5b-405a-bf66-75d5f448277a_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_9b8f044a-1532-44c1-becb-22ee9587d060_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d7679029-ea36-4da8-acee-9cd533f4a10c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_ad6107f8-c366-4320-a830-6c27796720b8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_67136583-6a5a-4f91-876a-aa4b92d0d7ce_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_6975b4ed-7a99-4896-9db6-497fada79623_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ae420b7d-804d-4452-a30a-5ba36c6eb5d9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContingentConsiderationMember_2d637890-deef-484d-ad11-f586ad2fdfe0_terseLabel_en-US" xlink:label="lab_mygn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_mygn_ContingentConsiderationMember_label_en-US" xlink:label="lab_mygn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_mygn_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_mygn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContingentConsiderationMember" xlink:href="mygn-20220331.xsd#mygn_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContingentConsiderationMember" xlink:to="lab_mygn_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3a63c5aa-16ac-4a30-b83a-04b867118825_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_78066fc0-05ad-4c70-bbc3-d33cf2184c4b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InvestmentsAndCashAmortizedCost_f9519e00-7e05-49bb-8236-b50825300e09_totalLabel_en-US" xlink:label="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Amortized cost</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAmortizedCost_label_en-US" xlink:label="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAmortizedCost_documentation_en-US" xlink:label="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost" xlink:to="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_b1ae7f33-5a7f-4641-8650-c9ed5aa5dbfe_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0fd07198-e103-4a8d-aee9-278ba18e9c28_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8b637e3-e4bf-4af0-addd-a8dfa2314b8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_baf51268-da2f-416c-9962-94bcde1efafe_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_f0474b92-b6e2-469c-a0ae-0fe005554643_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4f0c3f6-c1da-407b-859b-7f071e0163b2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fdd55f4-d3a4-4937-9353-5bd17f782c18_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_431277ae-633a-4262-a607-fcf8dd81608e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_c406eccc-abf0-4324-aca5-4c10b60274f3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_2a455e80-eb97-46a1-8a26-3f821e70541c_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_64f9780a-a58e-4928-84af-58edd91dedc4_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. [Member]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_207f8777-6680-4905-ae8f-954e5408c692_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dac64a00-5605-43e0-986f-bd829e056403_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding used to compute basic EPS</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_397924af-2d2c-42fa-8fe1-bda5ef2df608_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_71288df0-8ef0-4825-90a4-ab4205ffd636_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b638c302-ff84-4d08-bfdd-7d54bbaa6354_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_e18211da-2dd0-4321-bd4f-fccb3f93c3b0_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e4d52878-0f99-4a1a-9d03-f0e62254256a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_ebba66d5-7e68-4f30-b5c3-0fb33799d7ee_terseLabel_en-US" xlink:label="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period for earn out liability</link:label>
    <link:label id="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_label_en-US" xlink:label="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input, Term</link:label>
    <link:label id="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_documentation_en-US" xlink:label="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:href="mygn-20220331.xsd#mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:to="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_838e5fa8-3b8f-4cdf-b206-ac9ffedf34b0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized costs incurred to obtain or fulfill contract</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostGross" xlink:to="lab_us-gaap_CapitalizedContractCostGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_28c813a9-bac6-4f18-bdfd-5f44aa2f4332_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RoW</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_7922e0d8-02c9-4df6-9341-3e80f442e057_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_d13e2721-6f63-469e-99e6-eab1a0930cf1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recorded Amortization Expense for Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6fb12799-ec1c-44c6-940c-328295bc66f3_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Myriad Genetics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2614acc3-865b-499c-9f20-1e79c8da8bfa_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9fae7e59-8633-4690-a4bc-ad47950078a8_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net, total</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3da2ff62-c29c-4071-8a63-d3df4cd1a9cb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_03fc6dd5-ef00-405d-ac7e-9e229ab8246d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3eeb032f-e775-4901-a6d0-45daca73f465_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period for award vesting (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_abbbf5c0-70c2-469c-b90f-aab7b41c5a1c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds and notes</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_9b700f03-154f-4f2a-bfff-36081270953b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_PharmaceuticalAndClinicalServicesMember_f4ec0412-c511-428d-9644-8eb5b5e0807e_terseLabel_en-US" xlink:label="lab_mygn_PharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical and clinical services</link:label>
    <link:label id="lab_mygn_PharmaceuticalAndClinicalServicesMember_label_en-US" xlink:label="lab_mygn_PharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical And Clinical Services [Member]</link:label>
    <link:label id="lab_mygn_PharmaceuticalAndClinicalServicesMember_documentation_en-US" xlink:label="lab_mygn_PharmaceuticalAndClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical and clinical services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember" xlink:href="mygn-20220331.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_PharmaceuticalAndClinicalServicesMember" xlink:to="lab_mygn_PharmaceuticalAndClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_13e10227-ea64-4ae8-9eb6-e7e324757754_terseLabel_en-US" xlink:label="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum unrestricted cash and cash equivalents threshold per covenant</link:label>
    <link:label id="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_label_en-US" xlink:label="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum</link:label>
    <link:label id="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_documentation_en-US" xlink:label="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:href="mygn-20220331.xsd#mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:to="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d40c2ace-6764-40f7-9803-cbdba64f537f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_65b109ab-24a4-4600-93d1-d89171d1a650_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_NonCashInterestExpense_8e4091c0-8eea-41de-85ba-6b9d490edf2d_terseLabel_en-US" xlink:label="lab_mygn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_mygn_NonCashInterestExpense_label_en-US" xlink:label="lab_mygn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense</link:label>
    <link:label id="lab_mygn_NonCashInterestExpense_documentation_en-US" xlink:label="lab_mygn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonCashInterestExpense" xlink:href="mygn-20220331.xsd#mygn_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_NonCashInterestExpense" xlink:to="lab_mygn_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_8fd3257b-3500-44e7-93f9-80f9f7d6196a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_6a4f4c94-2a11-4823-af4e-5dd6089aeb29_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal charges pending settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_234b7234-da6f-4a84-897e-4433b8cef918_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential settlement accrual</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_173de40b-95e0-4a49-b2e6-58eff53826cb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4dac4fe9-ab4a-494b-bbe0-1e7ee398a972_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_180d2fed-5db6-4ff6-abde-959cf5d80cb4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0bb23dfc-814b-40dd-98fc-cd9a68b621a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c87bf2c0-566d-40bc-bd3f-e72943ed0bee_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fa9478f7-de95-41ac-ae5b-caaed7cc9b4f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning common stock outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7ecfbbf0-cb49-4f57-acd5-c71875400316_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_9b0da3c3-5208-4a8c-84b8-a961f16ed567_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f4517688-2011-4703-af01-d70c9a1675c2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_e71422cf-ea1c-43a8-8330-c14f5a935674_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_e84ace8b-234d-4e15-ac73-bd54fae3974f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7a0a39ec-0cbf-4d77-b795-f45af2ffd814_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b7e12517-4c68-4063-9bdc-63f6b6f44ede_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_4510334a-763a-4d73-87d4-1edeb68579a6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_318afbbe-f7fb-4e9d-870e-6eb4fddfa77b_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a8f7f2c-6851-45ef-87bb-7f06e0d10017_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OptionsAndRestrictedStockUnitsMember_175e8568-d3fc-471f-8922-2a37f5b11715_terseLabel_en-US" xlink:label="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and RSUs</link:label>
    <link:label id="lab_mygn_OptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_mygn_OptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and Restricted Stock Units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsAndRestrictedStockUnitsMember" xlink:href="mygn-20220331.xsd#mygn_OptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember" xlink:to="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9b586877-3bcb-4770-a570-ce0f64a4446c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_be7567d4-8c7d-424f-aeaf-8c38039ba5b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_01a2a9ac-59b1-41b9-89e3-caa201fa1799_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_632be58e-d335-4b82-9b9c-274bd183e51b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_393bcce2-8338-4ded-9baa-26b78b70927f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_35d720ae-15ee-4d8f-8698-1cec3d4b7447_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e59de431-a08f-4c76-91d7-168f25658a5b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_21055119-b05d-4fe4-988a-da2a67542e0f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c7b08b6a-2896-4bc4-8fe3-4ac82769f68f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_56d94b3b-7f75-42d1-ae39-45cc68efed80_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ce23c1d3-24cf-4e66-86be-217710f97d09_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_7c2d29a6-16e1-4613-973b-4c57b29db914_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_16226eb8-ad3a-4759-b53c-22a4f96be5d6_totalLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e122490f-e616-4734-ba45-ead318b6b3ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_f77097e1-f7c4-424f-b2bc-f12c65df0efa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_83728bf4-acd7-41b4-b29b-70a8e55dc5ec_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_bd13c58a-64a4-4cd8-93cc-3323c351b2d8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6ecb749e-f3dc-4290-b62a-611090025441_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_390ac8ff-6136-48ef-afbd-6ca1bfde38b3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_3a794563-fd67-4af3-8770-b7317c1ecef1_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_79fc7241-7d67-4a4a-ba96-e023c3436a62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative total stockholders return</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DebtInstrumentLIBORFloorPercentage_0a0ce6a1-73f4-4a63-bb54-e8d2582e30df_terseLabel_en-US" xlink:label="lab_mygn_DebtInstrumentLIBORFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR floor (percent)</link:label>
    <link:label id="lab_mygn_DebtInstrumentLIBORFloorPercentage_label_en-US" xlink:label="lab_mygn_DebtInstrumentLIBORFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, LIBOR Floor, Percentage</link:label>
    <link:label id="lab_mygn_DebtInstrumentLIBORFloorPercentage_documentation_en-US" xlink:label="lab_mygn_DebtInstrumentLIBORFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, LIBOR Floor, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtInstrumentLIBORFloorPercentage" xlink:href="mygn-20220331.xsd#mygn_DebtInstrumentLIBORFloorPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DebtInstrumentLIBORFloorPercentage" xlink:to="lab_mygn_DebtInstrumentLIBORFloorPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18f50026-7566-463c-b02c-22acab383f8c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_965b886c-c7b2-4122-90a6-7e909ce9d39a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a451d022-da7b-4734-9219-012f4386c760_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember_33193dfa-0387-431b-9b87-8104afad0c71_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic - Hereditary Cancer</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Hereditary Cancer Testing [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic hereditary cancer testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticHereditaryCancerTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:to="lab_mygn_MolecularDiagnosticHereditaryCancerTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f3e188b2-7a15-44d8-81a8-deaf28406a7b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1da1997e-8a16-448c-9b5e-ecd83e979654_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b37a20e-8457-4ff5-8494-53584b85a0f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs, Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SwissFederalTaxAdministrationFTAMember_22f7c9c9-d564-4091-beb7-8610d04da6cd_terseLabel_en-US" xlink:label="lab_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland</link:label>
    <link:label id="lab_us-gaap_SwissFederalTaxAdministrationFTAMember_label_en-US" xlink:label="lab_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss Federal Tax Administration (FTA) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:to="lab_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_891aee57-2429-4019-9919-bc4ee1768851_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_1547d4c5-b7e5-4b86-8bff-7dd195cabf54_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_6d1e0903-d549-4b28-814b-488ca0e52343_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_0914eb30-e649-40d6-a528-4dc4799b679c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_19107de6-13e5-4087-91af-4a22a610ce40_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of marketable investment securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_d2711d9d-415e-4839-a40a-2e563cf8be35_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_UnitedStatesAndStateOfCaliforniaMember_f8a93633-9534-47ed-b4b4-45924cea0b2b_terseLabel_en-US" xlink:label="lab_mygn_UnitedStatesAndStateOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and State of California</link:label>
    <link:label id="lab_mygn_UnitedStatesAndStateOfCaliforniaMember_label_en-US" xlink:label="lab_mygn_UnitedStatesAndStateOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States And State Of California [Member]</link:label>
    <link:label id="lab_mygn_UnitedStatesAndStateOfCaliforniaMember_documentation_en-US" xlink:label="lab_mygn_UnitedStatesAndStateOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States And State Of California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_UnitedStatesAndStateOfCaliforniaMember" xlink:href="mygn-20220331.xsd#mygn_UnitedStatesAndStateOfCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_UnitedStatesAndStateOfCaliforniaMember" xlink:to="lab_mygn_UnitedStatesAndStateOfCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f5b6e263-e929-43ef-8b23-5b26eefaa0e8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73e556aa-3b85-4a71-aff2-197bca227cea_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1fd56720-0a13-496f-a866-61386d9cc94b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_dc742297-4571-4368-9575-f9c0f784a8d9_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_e96052d5-2349-44a0-a863-e1cb15552224_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a600f003-8735-4352-815a-0adf3f0ef5a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d28df0c9-1281-4027-8602-ae1e5d903cd1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6391d43a-d718-416c-a315-3a71f7af29e2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount, amortizable</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_259a1155-5ee0-4f2c-bedf-b266acd3fa47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amortizable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_ad861bfe-eee8-42c7-bd06-3eae1c6e2b89_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_02a9d645-0234-409d-a82a-e5e42452df28_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97d4f90a-530f-41b4-93ba-a4060ba12677_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5c09ea65-6070-439a-890f-36a2c52f3d68_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_17198e0e-ad33-4a65-b766-cd8eb3e5e5a4_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_34e80023-7937-40d1-9db1-5b543eb9771a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7b856a7f-d589-4e4d-93f3-40b13dd80ecb_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarliestTaxYearMember_0f7467ae-57d3-4526-b202-5a67e622bb10_terseLabel_en-US" xlink:label="lab_us-gaap_EarliestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earliest tax year</link:label>
    <link:label id="lab_us-gaap_EarliestTaxYearMember_label_en-US" xlink:label="lab_us-gaap_EarliestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earliest Tax Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarliestTaxYearMember" xlink:to="lab_us-gaap_EarliestTaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_2f5ec042-e7d1-450d-abee-24ff29c7b5df_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_16a1a5af-083b-4100-a37b-dd8f081bae02_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_35986a93-c047-429a-b01d-9ad2f48a1f99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_78b07dc7-59c9-4718-b9c1-6043734c1f48_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a3620df7-7194-4ae9-91b8-960abe70df4e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred and Common Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6331676c-ecb2-4bbc-8895-e7166a6ffb52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Dilutive Common Shares</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5c3f7a3c-5a39-4339-9ae5-9513b5e0fa4e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_8f932b4e-be16-4a5d-930a-ff6fa7be91aa_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_1ab0af05-2ea0-48cb-95a6-27c1b9d52c3c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81fb396b-34a9-44ea-a8a3-9bb307a54d01_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_58ff4532-af8d-4c52-a0c9-78877c7b944b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ba8f7a83-291a-46ac-b860-63ac5f079a2d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a135732e-f3a4-491b-9a53-3b184e5a8dd8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8a2ad5c1-b908-4be7-a7c9-1e9796972644_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e8a481a0-c696-4fff-82da-280f310aa555_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e67de72f-cef1-4273-850e-dcd114303200_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5a285d21-7376-4465-9dea-d5d246fea65f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_87bc0078-4351-4657-9361-c5f7e8d99624_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_85985848-a999-4ce6-a6c1-5b2412919ed9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of tax withheld for common stock issued under stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_3c07d626-ec4b-4b5e-9516-0c49a8fcc6f7_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Establishment of operating lease right-of-use assets and lease liabilities</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_701614fe-8ed8-4a74-bd88-52a3aef14fdb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate principal commitment</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_b52cf0c6-1404-4781-9ef4-2ea535d047b4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_025a6481-056c-42a4-a250-b9a91f840cd1_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_230d74a1-1e21-492d-8f6b-2672ba0e651e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_062dd1bf-99f4-45e2-8a93-dea31f80cc4a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ScheduleOfIntangibleAssetsTable_bb80a076-e81c-4e92-a54a-2814550775d5_terseLabel_en-US" xlink:label="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets [Table]</link:label>
    <link:label id="lab_mygn_ScheduleOfIntangibleAssetsTable_label_en-US" xlink:label="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets [Table]</link:label>
    <link:label id="lab_mygn_ScheduleOfIntangibleAssetsTable_documentation_en-US" xlink:label="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable" xlink:href="mygn-20220331.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable" xlink:to="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_6c321bd8-8cac-4c79-b47b-8d1c20f623fb_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f8d9e6ec-c50f-4ddf-be10-f0377a231b17_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_a06a8e7e-9da3-4e61-ad1b-50d0e53ccc15_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government contracts concentration risk</link:label>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contracts Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:to="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_448e32f2-3e72-4163-9cdb-e0847a41f8a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_896eb0c6-8b80-41f7-b6e1-8886d3ef05b7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_bfb0ba39-4089-4915-9c47-d9982e97800e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_6e379f00-750b-4e20-89fb-4b9f6f807e55_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_c0ca2ac0-5aed-43a8-a8dc-8a912f0478c5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_82a107a9-5b07-4b80-bdf6-95fe7a59d23c_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net, amortizable</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_3764c851-d175-44d5-b9dc-3c1f3e309476_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_3a979b17-5829-4d99-9918-72b0a3a2e691_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_49596aab-4338-40a7-85ec-2311486a44c8_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_61514009-f5fc-4030-aaf0-c62ecfdc896e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_b44786fb-6c89-41d1-af40-b458c7f54c1b_terseLabel_en-US" xlink:label="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan</link:label>
    <link:label id="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans</link:label>
    <link:label id="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_documentation_en-US" xlink:label="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:href="mygn-20220331.xsd#mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:to="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_a85e9e6f-5f3f-4fb8-a586-2db4603ff6f8_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_bb8dbdf6-3f9b-4554-87dc-d24fdeba7a80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0f4ef2a-5f29-4238-a692-e3ba01929713_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_154dcf44-e221-49c9-84ea-271a3a7a4c09_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c96d6271-470f-467b-84d2-2afa4e5154c6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LeaseArrangementDomain_b8dd97df-9b0c-4f5c-8091-d253509dbe43_terseLabel_en-US" xlink:label="lab_mygn_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_mygn_LeaseArrangementDomain_label_en-US" xlink:label="lab_mygn_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_mygn_LeaseArrangementDomain_documentation_en-US" xlink:label="lab_mygn_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain" xlink:href="mygn-20220331.xsd#mygn_LeaseArrangementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LeaseArrangementDomain" xlink:to="lab_mygn_LeaseArrangementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_d56224b9-fc55-4add-a322-9eb2139e57b6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_969f2a4c-e1f7-405c-8658-304dd7bb0e96_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_da87eba4-cde1-4fc2-9a13-e184d895564f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Common Shares Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MolecularDiagnosticTestingMember_2f7c58a4-a3f8-4dce-854b-0347de312700_terseLabel_en-US" xlink:label="lab_mygn_MolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic testing</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticTestingMember_label_en-US" xlink:label="lab_mygn_MolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular Diagnostic Testing [Member]</link:label>
    <link:label id="lab_mygn_MolecularDiagnosticTestingMember_documentation_en-US" xlink:label="lab_mygn_MolecularDiagnosticTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MolecularDiagnosticTestingMember" xlink:to="lab_mygn_MolecularDiagnosticTestingMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>mygn-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6c4a3a2c-b656-4a66-b2d1-1ba9bc2e559c,g:c641d519-fa56-4157-9313-b107a5eea025-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.myriad.com/role/Cover" xlink:type="simple" xlink:href="mygn-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_539b7d71-acca-4a07-983e-1295429b0814" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_DocumentType_539b7d71-acca-4a07-983e-1295429b0814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_835154a0-a4d5-4428-8db9-6b5e469a3ea0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_DocumentQuarterlyReport_835154a0-a4d5-4428-8db9-6b5e469a3ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9a1c5035-982a-4702-b05e-232e27f86f72" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_DocumentPeriodEndDate_9a1c5035-982a-4702-b05e-232e27f86f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b27bfdde-4e5a-46e2-bb65-d3f34f6aaea7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_DocumentTransitionReport_b27bfdde-4e5a-46e2-bb65-d3f34f6aaea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1c6bd0cd-6c14-40f7-8779-1f81b118bd8b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityFileNumber_1c6bd0cd-6c14-40f7-8779-1f81b118bd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fb56f0ee-aaf3-479d-89b2-547d916e4145" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityRegistrantName_fb56f0ee-aaf3-479d-89b2-547d916e4145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_17aec9a3-3b6f-43c9-922d-fde2a9f20bec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityCentralIndexKey_17aec9a3-3b6f-43c9-922d-fde2a9f20bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c8262453-f51b-4a11-bd4b-2bd6cc2b0de5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_CurrentFiscalYearEndDate_c8262453-f51b-4a11-bd4b-2bd6cc2b0de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8e2cdba4-c674-4025-8838-280e28f4fbce" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_DocumentFiscalYearFocus_8e2cdba4-c674-4025-8838-280e28f4fbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_64456825-c554-4185-8ebe-682756aa9c11" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_DocumentFiscalPeriodFocus_64456825-c554-4185-8ebe-682756aa9c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_22e6fd6a-1e98-493e-ba7c-c8ad7d248d43" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_AmendmentFlag_22e6fd6a-1e98-493e-ba7c-c8ad7d248d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d9c2a134-628f-4d90-b74b-54c941064aac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d9c2a134-628f-4d90-b74b-54c941064aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d8258825-28a8-4907-9157-cff4644f0941" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityTaxIdentificationNumber_d8258825-28a8-4907-9157-cff4644f0941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1c8795b6-1409-4c86-ad77-d0fd26334b1a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityAddressAddressLine1_1c8795b6-1409-4c86-ad77-d0fd26334b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_28815da9-4d14-4339-b100-85c859f4584e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityAddressCityOrTown_28815da9-4d14-4339-b100-85c859f4584e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9e2d23f9-4d00-4e68-8c68-e158e01bc84b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityAddressStateOrProvince_9e2d23f9-4d00-4e68-8c68-e158e01bc84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_55c50d4f-dcf3-4b52-b764-40070857a101" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityAddressPostalZipCode_55c50d4f-dcf3-4b52-b764-40070857a101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6f1f9cd0-2de5-4fa1-a296-75ae1cc62f16" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_CityAreaCode_6f1f9cd0-2de5-4fa1-a296-75ae1cc62f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b2d3b016-8893-451b-ba66-24000dce26cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_LocalPhoneNumber_b2d3b016-8893-451b-ba66-24000dce26cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4f4db998-c88e-454d-8ae5-500c64fc667e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_Security12bTitle_4f4db998-c88e-454d-8ae5-500c64fc667e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cbc2c521-1122-4cb3-bc31-9d93df8aaf1c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_TradingSymbol_cbc2c521-1122-4cb3-bc31-9d93df8aaf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_874f0e45-6c8b-4bfb-bdf1-ca5bf8189572" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_SecurityExchangeName_874f0e45-6c8b-4bfb-bdf1-ca5bf8189572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_dbe60a40-ed0c-4b67-b278-6de476a55561" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityCurrentReportingStatus_dbe60a40-ed0c-4b67-b278-6de476a55561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4b52d756-04c6-4860-90de-2b4b509ad6d3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityInteractiveDataCurrent_4b52d756-04c6-4860-90de-2b4b509ad6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_cb918fba-ce8c-4f86-9518-67f7a807834f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityFilerCategory_cb918fba-ce8c-4f86-9518-67f7a807834f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5617bf65-b568-4206-ac79-dd07f39e5b0c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntitySmallBusiness_5617bf65-b568-4206-ac79-dd07f39e5b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_15324f76-9e28-49a3-af72-1ebffc0dca69" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityEmergingGrowthCompany_15324f76-9e28-49a3-af72-1ebffc0dca69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8d762ee8-40df-4554-8b29-4afa646e0434" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityShellCompany_8d762ee8-40df-4554-8b29-4afa646e0434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bca25c2d-a1fc-417e-9cbb-cc4fb714de43" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e90bdcd1-b6c5-4167-adab-3e986c5ffa98" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bca25c2d-a1fc-417e-9cbb-cc4fb714de43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mygn-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fb7792b2-728a-4826-9181-83c857038820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8a330ed1-cb5e-4547-b25a-f627221850e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb7792b2-728a-4826-9181-83c857038820" xlink:to="loc_us-gaap_AssetsAbstract_8a330ed1-cb5e-4547-b25a-f627221850e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_668c6602-f971-4467-b16c-39e738e5d815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a330ed1-cb5e-4547-b25a-f627221850e0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_668c6602-f971-4467-b16c-39e738e5d815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b7957059-c0b3-4622-8759-f3a242d53d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_668c6602-f971-4467-b16c-39e738e5d815" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b7957059-c0b3-4622-8759-f3a242d53d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_6bd8b439-e15d-4c60-b259-261c077acd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_668c6602-f971-4467-b16c-39e738e5d815" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_6bd8b439-e15d-4c60-b259-261c077acd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fd1a8dd9-6071-49b0-b6fa-2384e6fd1e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_668c6602-f971-4467-b16c-39e738e5d815" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fd1a8dd9-6071-49b0-b6fa-2384e6fd1e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7e926401-8eff-46ec-8e34-6696e3228857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_668c6602-f971-4467-b16c-39e738e5d815" xlink:to="loc_us-gaap_InventoryNet_7e926401-8eff-46ec-8e34-6696e3228857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_bf884a99-163e-4ee5-9a59-b031195b071c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_668c6602-f971-4467-b16c-39e738e5d815" xlink:to="loc_us-gaap_PrepaidTaxes_bf884a99-163e-4ee5-9a59-b031195b071c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b2e220de-95d1-4cb9-8548-691b336b6912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_668c6602-f971-4467-b16c-39e738e5d815" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b2e220de-95d1-4cb9-8548-691b336b6912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_385d3ca8-44d4-44e7-a2e5-2d14703316e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_668c6602-f971-4467-b16c-39e738e5d815" xlink:to="loc_us-gaap_AssetsCurrent_385d3ca8-44d4-44e7-a2e5-2d14703316e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ac23787f-18b5-41ef-9130-4e12e171cd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a330ed1-cb5e-4547-b25a-f627221850e0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ac23787f-18b5-41ef-9130-4e12e171cd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_a7266ae8-92c5-45de-9c87-f711799f16a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a330ed1-cb5e-4547-b25a-f627221850e0" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_a7266ae8-92c5-45de-9c87-f711799f16a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_90088577-d4fb-4560-a04a-9c811f813693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a330ed1-cb5e-4547-b25a-f627221850e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_90088577-d4fb-4560-a04a-9c811f813693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e29c3be9-e9e5-4d74-a66e-fe25e305ab9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a330ed1-cb5e-4547-b25a-f627221850e0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e29c3be9-e9e5-4d74-a66e-fe25e305ab9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9a988a62-e668-4e62-9ef2-9bda4255c345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a330ed1-cb5e-4547-b25a-f627221850e0" xlink:to="loc_us-gaap_Goodwill_9a988a62-e668-4e62-9ef2-9bda4255c345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c2e8bba2-d0c2-44e5-8fca-020485087791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a330ed1-cb5e-4547-b25a-f627221850e0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c2e8bba2-d0c2-44e5-8fca-020485087791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e9eb3d86-14a3-46d0-8297-f5849f7d2f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8a330ed1-cb5e-4547-b25a-f627221850e0" xlink:to="loc_us-gaap_Assets_e9eb3d86-14a3-46d0-8297-f5849f7d2f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a71e44c-0a2d-4626-9216-237ec34f1c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb7792b2-728a-4826-9181-83c857038820" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a71e44c-0a2d-4626-9216-237ec34f1c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d593a232-608f-4814-8834-ca1dc2fdbc94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a71e44c-0a2d-4626-9216-237ec34f1c29" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d593a232-608f-4814-8834-ca1dc2fdbc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ae05600c-0463-4e01-8de8-b212ee7e58aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d593a232-608f-4814-8834-ca1dc2fdbc94" xlink:to="loc_us-gaap_AccountsPayableCurrent_ae05600c-0463-4e01-8de8-b212ee7e58aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_02ea4b6e-b18e-4f95-8524-d7fad2175d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d593a232-608f-4814-8834-ca1dc2fdbc94" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_02ea4b6e-b18e-4f95-8524-d7fad2175d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7f44558f-4617-47b1-b52a-44cbe5124b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d593a232-608f-4814-8834-ca1dc2fdbc94" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7f44558f-4617-47b1-b52a-44cbe5124b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_eddfa64e-4e9a-42b3-80db-4a2c15bb1719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d593a232-608f-4814-8834-ca1dc2fdbc94" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_eddfa64e-4e9a-42b3-80db-4a2c15bb1719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f8b55a47-e2cb-4840-9e5e-cae9d749dce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d593a232-608f-4814-8834-ca1dc2fdbc94" xlink:to="loc_us-gaap_LiabilitiesCurrent_f8b55a47-e2cb-4840-9e5e-cae9d749dce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_780d13bf-dc5b-4a54-853c-f92e0cb40be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a71e44c-0a2d-4626-9216-237ec34f1c29" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_780d13bf-dc5b-4a54-853c-f92e0cb40be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c06d753c-7572-4798-944c-fef04fb11f59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a71e44c-0a2d-4626-9216-237ec34f1c29" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c06d753c-7572-4798-944c-fef04fb11f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_98d0fa88-8434-4e62-839f-edf46914e111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a71e44c-0a2d-4626-9216-237ec34f1c29" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_98d0fa88-8434-4e62-839f-edf46914e111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5df11604-922e-4ae3-b4dc-47de63b73d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a71e44c-0a2d-4626-9216-237ec34f1c29" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5df11604-922e-4ae3-b4dc-47de63b73d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_44e55d17-959b-4ba4-8a44-c3c186d8708d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a71e44c-0a2d-4626-9216-237ec34f1c29" xlink:to="loc_us-gaap_Liabilities_44e55d17-959b-4ba4-8a44-c3c186d8708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6599e934-7aeb-4e51-8c0b-3a2f0d63c21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a71e44c-0a2d-4626-9216-237ec34f1c29" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6599e934-7aeb-4e51-8c0b-3a2f0d63c21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5c2d04f7-6e68-42e3-af73-108a3d04984e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a71e44c-0a2d-4626-9216-237ec34f1c29" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5c2d04f7-6e68-42e3-af73-108a3d04984e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6e4d393c-7d39-4422-a567-f0dfdb2055e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c2d04f7-6e68-42e3-af73-108a3d04984e" xlink:to="loc_us-gaap_CommonStockValue_6e4d393c-7d39-4422-a567-f0dfdb2055e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_654b637a-9042-455b-9395-9bdb25f43bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c2d04f7-6e68-42e3-af73-108a3d04984e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_654b637a-9042-455b-9395-9bdb25f43bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e961194e-c445-4ca9-9945-1fa77de465d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c2d04f7-6e68-42e3-af73-108a3d04984e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e961194e-c445-4ca9-9945-1fa77de465d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bfb0ff6e-3dfc-4230-b9ed-15fed5ea7170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c2d04f7-6e68-42e3-af73-108a3d04984e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bfb0ff6e-3dfc-4230-b9ed-15fed5ea7170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fede2a34-b0d5-4833-aa28-7ed759135b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c2d04f7-6e68-42e3-af73-108a3d04984e" xlink:to="loc_us-gaap_StockholdersEquity_fede2a34-b0d5-4833-aa28-7ed759135b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_13c7e4f5-26c8-47e0-96af-61bbeeb4964e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c2d04f7-6e68-42e3-af73-108a3d04984e" xlink:to="loc_us-gaap_MinorityInterest_13c7e4f5-26c8-47e0-96af-61bbeeb4964e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3838fbeb-73b5-4429-8be2-9bd1810bc515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5c2d04f7-6e68-42e3-af73-108a3d04984e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3838fbeb-73b5-4429-8be2-9bd1810bc515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_278a1b7d-ddc1-4b74-bbfe-c6d96a42f960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a71e44c-0a2d-4626-9216-237ec34f1c29" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_278a1b7d-ddc1-4b74-bbfe-c6d96a42f960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mygn-20220331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a63c9093-195b-40b6-8d3c-a69ceecab990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_97d9def1-e7cd-44ab-baa7-590f392dcbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a63c9093-195b-40b6-8d3c-a69ceecab990" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_97d9def1-e7cd-44ab-baa7-590f392dcbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="mygn-20220331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c4287ad2-90d3-40ab-abac-658914996be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6dad1d2d-d378-47c6-a3e2-6b090f523c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c4287ad2-90d3-40ab-abac-658914996be0" xlink:to="loc_us-gaap_StatementTable_6dad1d2d-d378-47c6-a3e2-6b090f523c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_af038744-a0f6-4acb-bd93-cde9268021f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6dad1d2d-d378-47c6-a3e2-6b090f523c13" xlink:to="loc_srt_ProductOrServiceAxis_af038744-a0f6-4acb-bd93-cde9268021f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_55ba3bd7-141b-4a2f-9694-01f2dbd09d99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_af038744-a0f6-4acb-bd93-cde9268021f8" xlink:to="loc_srt_ProductsAndServicesDomain_55ba3bd7-141b-4a2f-9694-01f2dbd09d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_d4f77b6b-6862-47be-ac49-dd245eb0d3eb" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_55ba3bd7-141b-4a2f-9694-01f2dbd09d99" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_d4f77b6b-6862-47be-ac49-dd245eb0d3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_c6b39a47-c59e-4aef-bc9e-c0efd3ba37ef" xlink:href="mygn-20220331.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_55ba3bd7-141b-4a2f-9694-01f2dbd09d99" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_c6b39a47-c59e-4aef-bc9e-c0efd3ba37ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6dad1d2d-d378-47c6-a3e2-6b090f523c13" xlink:to="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b39ee543-3d86-4361-9846-539e42562e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_RevenuesAbstract_b39ee543-3d86-4361-9846-539e42562e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_af92ed39-62c6-4d51-9261-a4d6bba67374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b39ee543-3d86-4361-9846-539e42562e0f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_af92ed39-62c6-4d51-9261-a4d6bba67374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_34aabf62-d64f-4fe0-bf6a-d792ed8f6f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_34aabf62-d64f-4fe0-bf6a-d792ed8f6f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a05b6875-d0f9-4b20-ac86-91af1dfa93e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a05b6875-d0f9-4b20-ac86-91af1dfa93e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_770d7c99-f7e8-4f5d-80b1-97839092cdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_770d7c99-f7e8-4f5d-80b1-97839092cdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_8c411fce-3070-4094-8563-96e8eb17993f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:to="loc_us-gaap_AssetImpairmentCharges_8c411fce-3070-4094-8563-96e8eb17993f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fd4feedd-4722-4cc0-a57c-e2831f3e9ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2a7fc60f-5bc8-4485-af25-e30d892952a9" xlink:to="loc_us-gaap_CostsAndExpenses_fd4feedd-4722-4cc0-a57c-e2831f3e9ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7f8fa25c-cf7a-4863-9f42-7c2bd93c8e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_OperatingIncomeLoss_7f8fa25c-cf7a-4863-9f42-7c2bd93c8e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6c863c8e-487f-448e-8987-f12703391acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6c863c8e-487f-448e-8987-f12703391acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_88cb9f77-3fa7-4523-95a4-936616d72bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6c863c8e-487f-448e-8987-f12703391acd" xlink:to="loc_us-gaap_InvestmentIncomeInterest_88cb9f77-3fa7-4523-95a4-936616d72bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fc608a27-4a3c-41d4-b8e0-c57e6b6944a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6c863c8e-487f-448e-8987-f12703391acd" xlink:to="loc_us-gaap_InterestExpense_fc608a27-4a3c-41d4-b8e0-c57e6b6944a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5e604fb0-a924-4120-881e-430d03f6618c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6c863c8e-487f-448e-8987-f12703391acd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5e604fb0-a924-4120-881e-430d03f6618c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_716c316f-420d-466c-b298-050c6b37e76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6c863c8e-487f-448e-8987-f12703391acd" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_716c316f-420d-466c-b298-050c6b37e76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9426a646-104e-4543-9dff-af4aeed995e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9426a646-104e-4543-9dff-af4aeed995e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c9dd262b-c568-48e1-9254-7a9936f1b783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c9dd262b-c568-48e1-9254-7a9936f1b783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dd6c6453-e73e-4244-b4c0-24e074652bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_ProfitLoss_dd6c6453-e73e-4244-b4c0-24e074652bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6c2e4b28-6143-4102-ac2d-7483feee2b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6c2e4b28-6143-4102-ac2d-7483feee2b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0a60e5f1-09f6-43e4-a036-b208781b65ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_NetIncomeLoss_0a60e5f1-09f6-43e4-a036-b208781b65ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3bf51aab-47e5-464f-b2b7-67d3ff009032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3bf51aab-47e5-464f-b2b7-67d3ff009032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1155b7be-2ddf-47f0-8917-bb044379703d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3bf51aab-47e5-464f-b2b7-67d3ff009032" xlink:to="loc_us-gaap_EarningsPerShareBasic_1155b7be-2ddf-47f0-8917-bb044379703d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_44938d15-7506-4786-8997-a161fdad8557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3bf51aab-47e5-464f-b2b7-67d3ff009032" xlink:to="loc_us-gaap_EarningsPerShareDiluted_44938d15-7506-4786-8997-a161fdad8557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_f223302a-f526-464c-8cd4-ec8a9ecf9493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88849a9f-3efe-465a-8ce0-e6aba59053c0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_f223302a-f526-464c-8cd4-ec8a9ecf9493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6e2b53d-cbb3-447c-b792-6ffea33d3abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_f223302a-f526-464c-8cd4-ec8a9ecf9493" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6e2b53d-cbb3-447c-b792-6ffea33d3abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca8dae3e-a61e-4dca-8c35-f9d08574ea41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_f223302a-f526-464c-8cd4-ec8a9ecf9493" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca8dae3e-a61e-4dca-8c35-f9d08574ea41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="mygn-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_87b3eb9c-a513-4d8d-9b79-02693a93d3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3b751b6c-adc7-489a-b6a6-e79c076d4bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_87b3eb9c-a513-4d8d-9b79-02693a93d3eb" xlink:to="loc_us-gaap_NetIncomeLoss_3b751b6c-adc7-489a-b6a6-e79c076d4bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_311e5154-c4c7-4959-ad4f-af5d6a6f658e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_87b3eb9c-a513-4d8d-9b79-02693a93d3eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_311e5154-c4c7-4959-ad4f-af5d6a6f658e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e309d5a8-0d37-4306-b519-4e4ca1479704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_87b3eb9c-a513-4d8d-9b79-02693a93d3eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e309d5a8-0d37-4306-b519-4e4ca1479704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3f90a331-f5d5-43e1-8bfc-75d8f1744378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_87b3eb9c-a513-4d8d-9b79-02693a93d3eb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3f90a331-f5d5-43e1-8bfc-75d8f1744378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_dd6e7e77-9183-490b-a8d2-3d8de70e215b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_87b3eb9c-a513-4d8d-9b79-02693a93d3eb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_dd6e7e77-9183-490b-a8d2-3d8de70e215b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mygn-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ee3b8db3-2b92-4a23-b953-7e1f224d8bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_05e3fa7b-ac74-4cf9-ad23-b87d7d84c460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ee3b8db3-2b92-4a23-b953-7e1f224d8bac" xlink:to="loc_us-gaap_StatementTable_05e3fa7b-ac74-4cf9-ad23-b87d7d84c460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_54b3d1e7-47d6-4627-8303-3829474ad764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_05e3fa7b-ac74-4cf9-ad23-b87d7d84c460" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_54b3d1e7-47d6-4627-8303-3829474ad764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aa764f75-3bbc-4f20-b3a7-5d17a35d6168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_54b3d1e7-47d6-4627-8303-3829474ad764" xlink:to="loc_us-gaap_EquityComponentDomain_aa764f75-3bbc-4f20-b3a7-5d17a35d6168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_59991b42-310e-4d29-8ada-52390c110914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aa764f75-3bbc-4f20-b3a7-5d17a35d6168" xlink:to="loc_us-gaap_CommonStockMember_59991b42-310e-4d29-8ada-52390c110914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ddd666c6-e432-4390-96a7-55ed2a7af648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aa764f75-3bbc-4f20-b3a7-5d17a35d6168" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ddd666c6-e432-4390-96a7-55ed2a7af648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28e7a722-b71e-46e4-b3b9-7c1172154b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aa764f75-3bbc-4f20-b3a7-5d17a35d6168" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_28e7a722-b71e-46e4-b3b9-7c1172154b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6ade8081-3082-48b9-a72b-dee2dc1d8a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aa764f75-3bbc-4f20-b3a7-5d17a35d6168" xlink:to="loc_us-gaap_RetainedEarningsMember_6ade8081-3082-48b9-a72b-dee2dc1d8a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_05e3fa7b-ac74-4cf9-ad23-b87d7d84c460" xlink:to="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02498b11-8a67-4c82-9510-4d83b84eb8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02498b11-8a67-4c82-9510-4d83b84eb8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0f04a3de-233a-4982-ab1b-3e8071526532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0f04a3de-233a-4982-ab1b-3e8071526532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3f22f4c7-9715-4a2a-af5d-78f250eac2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3f22f4c7-9715-4a2a-af5d-78f250eac2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21046b9a-0a26-4967-bc36-bcc053fae6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:to="loc_us-gaap_NetIncomeLoss_21046b9a-0a26-4967-bc36-bcc053fae6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2862a931-dd59-4706-8239-f8d77e8f6952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2862a931-dd59-4706-8239-f8d77e8f6952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_feff4d0d-39ab-49aa-afe1-28dc572fd4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42478976-8ebe-41c7-a072-c5d3163450d7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_feff4d0d-39ab-49aa-afe1-28dc572fd4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mygn-20220331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_563aa0bb-192d-4382-a09e-a429ab3c3967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d5d3d9b-7221-4f51-b1cf-52b5751ed385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_563aa0bb-192d-4382-a09e-a429ab3c3967" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d5d3d9b-7221-4f51-b1cf-52b5751ed385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_acccd8a4-b632-40eb-82c4-168f92a67cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d5d3d9b-7221-4f51-b1cf-52b5751ed385" xlink:to="loc_us-gaap_NetIncomeLoss_acccd8a4-b632-40eb-82c4-168f92a67cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0360bb38-4756-4c22-af67-12b5eae59780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d5d3d9b-7221-4f51-b1cf-52b5751ed385" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0360bb38-4756-4c22-af67-12b5eae59780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_3d9496e1-bc5b-423a-a2f3-752ae56f8697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0360bb38-4756-4c22-af67-12b5eae59780" xlink:to="loc_us-gaap_DepreciationAndAmortization_3d9496e1-bc5b-423a-a2f3-752ae56f8697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonCashInterestExpense_aecd2f2d-ad45-44f4-878f-9991ecd97351" xlink:href="mygn-20220331.xsd#mygn_NonCashInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0360bb38-4756-4c22-af67-12b5eae59780" xlink:to="loc_mygn_NonCashInterestExpense_aecd2f2d-ad45-44f4-878f-9991ecd97351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_fed83e10-4cd1-4eed-8c4e-d82708016ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0360bb38-4756-4c22-af67-12b5eae59780" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_fed83e10-4cd1-4eed-8c4e-d82708016ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_249ee865-5a48-4e05-89be-90de5deb4bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0360bb38-4756-4c22-af67-12b5eae59780" xlink:to="loc_us-gaap_ShareBasedCompensation_249ee865-5a48-4e05-89be-90de5deb4bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_564092b1-afd5-4930-835c-1d20f1e06e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0360bb38-4756-4c22-af67-12b5eae59780" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_564092b1-afd5-4930-835c-1d20f1e06e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_4e4cb855-2a63-430b-9095-21074d0f1727" xlink:href="mygn-20220331.xsd#mygn_IncreaseDecreaseInUnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0360bb38-4756-4c22-af67-12b5eae59780" xlink:to="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_4e4cb855-2a63-430b-9095-21074d0f1727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c84271f3-2f2f-4a08-b734-cf47d9554b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0360bb38-4756-4c22-af67-12b5eae59780" xlink:to="loc_us-gaap_AssetImpairmentCharges_c84271f3-2f2f-4a08-b734-cf47d9554b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24fe9233-9c67-4039-b420-bb8673e9ca36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0360bb38-4756-4c22-af67-12b5eae59780" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24fe9233-9c67-4039-b420-bb8673e9ca36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_9008006a-92be-4e8e-a796-310274c75ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24fe9233-9c67-4039-b420-bb8673e9ca36" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_9008006a-92be-4e8e-a796-310274c75ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a096f6e0-032c-4cfe-9958-ff77cf7df6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24fe9233-9c67-4039-b420-bb8673e9ca36" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a096f6e0-032c-4cfe-9958-ff77cf7df6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7a4fe52e-eea6-419d-a9c4-2f11fbf15ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24fe9233-9c67-4039-b420-bb8673e9ca36" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7a4fe52e-eea6-419d-a9c4-2f11fbf15ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_90f08ee2-9d80-4539-b44b-a017f44087bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24fe9233-9c67-4039-b420-bb8673e9ca36" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_90f08ee2-9d80-4539-b44b-a017f44087bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_10559254-866d-4566-b545-6194e7e9002e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24fe9233-9c67-4039-b420-bb8673e9ca36" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_10559254-866d-4566-b545-6194e7e9002e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5b99ef52-3aa8-47d8-a319-67834aaf49da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24fe9233-9c67-4039-b420-bb8673e9ca36" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5b99ef52-3aa8-47d8-a319-67834aaf49da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_95744a94-88e3-4a8a-8479-2c4b110ef980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24fe9233-9c67-4039-b420-bb8673e9ca36" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_95744a94-88e3-4a8a-8479-2c4b110ef980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a2dcf32a-527e-4ced-a9dd-82440a6d61eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24fe9233-9c67-4039-b420-bb8673e9ca36" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a2dcf32a-527e-4ced-a9dd-82440a6d61eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6db68cad-45e7-43d8-a9e2-a339bf8b00ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d5d3d9b-7221-4f51-b1cf-52b5751ed385" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6db68cad-45e7-43d8-a9e2-a339bf8b00ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0472d71a-4666-47b7-b217-956bf79f5def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_563aa0bb-192d-4382-a09e-a429ab3c3967" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0472d71a-4666-47b7-b217-956bf79f5def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_f41a59df-ee68-487a-b58d-ca3da7268b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0472d71a-4666-47b7-b217-956bf79f5def" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_f41a59df-ee68-487a-b58d-ca3da7268b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_77da8005-a822-465e-af5a-7caab049d3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0472d71a-4666-47b7-b217-956bf79f5def" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_77da8005-a822-465e-af5a-7caab049d3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_cf6be7df-2524-4e1f-8c69-3362dfd69ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0472d71a-4666-47b7-b217-956bf79f5def" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_cf6be7df-2524-4e1f-8c69-3362dfd69ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7fa4b6e1-bb82-4ba8-b508-e8e5c02e52c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0472d71a-4666-47b7-b217-956bf79f5def" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7fa4b6e1-bb82-4ba8-b508-e8e5c02e52c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9077c23-b0da-4d68-8091-5ea3355540ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_563aa0bb-192d-4382-a09e-a429ab3c3967" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9077c23-b0da-4d68-8091-5ea3355540ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8f4c9e58-3801-4225-84dd-2135d3af10c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9077c23-b0da-4d68-8091-5ea3355540ca" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8f4c9e58-3801-4225-84dd-2135d3af10c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_20d1d775-6f07-4a6a-84ce-b6f241ff00cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9077c23-b0da-4d68-8091-5ea3355540ca" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_20d1d775-6f07-4a6a-84ce-b6f241ff00cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_17239948-0fe1-4f06-a503-b32819cfa1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9077c23-b0da-4d68-8091-5ea3355540ca" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_17239948-0fe1-4f06-a503-b32819cfa1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_984eae05-2347-47d9-9814-450c23fc2814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9077c23-b0da-4d68-8091-5ea3355540ca" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_984eae05-2347-47d9-9814-450c23fc2814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_bc4fce8c-95b6-498d-abe2-c70f38b70b66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9077c23-b0da-4d68-8091-5ea3355540ca" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_bc4fce8c-95b6-498d-abe2-c70f38b70b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d81d93fb-f831-49fd-928d-55bcd6894e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9077c23-b0da-4d68-8091-5ea3355540ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d81d93fb-f831-49fd-928d-55bcd6894e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2498a404-85d4-4d19-ab0f-21a38db23a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_563aa0bb-192d-4382-a09e-a429ab3c3967" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2498a404-85d4-4d19-ab0f-21a38db23a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_274335a2-f770-4a26-a3ec-b7feab0f4f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_563aa0bb-192d-4382-a09e-a429ab3c3967" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_274335a2-f770-4a26-a3ec-b7feab0f4f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dae1bff1-bdfc-4fa4-afb0-9d55d2b779ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_563aa0bb-192d-4382-a09e-a429ab3c3967" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dae1bff1-bdfc-4fa4-afb0-9d55d2b779ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df3fce15-fbf6-43ac-9758-06eab7001567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_563aa0bb-192d-4382-a09e-a429ab3c3967" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df3fce15-fbf6-43ac-9758-06eab7001567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BasisofPresentation" xlink:type="simple" xlink:href="mygn-20220331.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_06f47595-20cd-49de-8858-5d519e7933e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_551e5702-8421-4833-ae25-9df88b3b91b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_06f47595-20cd-49de-8858-5d519e7933e3" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_551e5702-8421-4833-ae25-9df88b3b91b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="mygn-20220331.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fa517af8-efdf-4e2b-a5c9-cc6fcf8ee358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e42d496d-93e0-40ae-923c-4493b4e33ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fa517af8-efdf-4e2b-a5c9-cc6fcf8ee358" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e42d496d-93e0-40ae-923c-4493b4e33ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2b573867-d2d1-45f6-8a8e-6bdeee4f154c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fa517af8-efdf-4e2b-a5c9-cc6fcf8ee358" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2b573867-d2d1-45f6-8a8e-6bdeee4f154c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/Revenue" xlink:type="simple" xlink:href="mygn-20220331.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_01e4b799-e741-4dc4-b40f-10104e6c68f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_fbcc61ef-1fdf-4386-b169-74692d20899f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_01e4b799-e741-4dc4-b40f-10104e6c68f2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_fbcc61ef-1fdf-4386-b169-74692d20899f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/RevenueTables" xlink:type="simple" xlink:href="mygn-20220331.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3f7fee19-8ef2-491a-9145-e3dac9eba182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_94d7e557-ba2e-4be6-b64d-2f2916100546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3f7fee19-8ef2-491a-9145-e3dac9eba182" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_94d7e557-ba2e-4be6-b64d-2f2916100546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_24f52a80-1ec2-4cd9-a1c6-acd10d532ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3f7fee19-8ef2-491a-9145-e3dac9eba182" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_24f52a80-1ec2-4cd9-a1c6-acd10d532ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d0a5f7be-4ea0-4938-910a-3a6f646f0ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b0c46dd7-72ba-4f59-bb21-a2112b29f970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d0a5f7be-4ea0-4938-910a-3a6f646f0ead" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b0c46dd7-72ba-4f59-bb21-a2112b29f970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d924c888-e232-448e-b54a-ce777afd821b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b0c46dd7-72ba-4f59-bb21-a2112b29f970" xlink:to="loc_srt_ProductOrServiceAxis_d924c888-e232-448e-b54a-ce777afd821b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3f27ee31-c086-40e8-ae8a-9573c9832eae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d924c888-e232-448e-b54a-ce777afd821b" xlink:to="loc_srt_ProductsAndServicesDomain_3f27ee31-c086-40e8-ae8a-9573c9832eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3f27ee31-c086-40e8-ae8a-9573c9832eae" xlink:to="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_0a2339f5-006d-42f3-a519-25572958c76a" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticHereditaryCancerTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:to="loc_mygn_MolecularDiagnosticHereditaryCancerTestingMember_0a2339f5-006d-42f3-a519-25572958c76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticTumorProfilingMember_a842a8bf-e940-413c-bdab-4df9fade3d80" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticTumorProfilingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:to="loc_mygn_MolecularDiagnosticTumorProfilingMember_a842a8bf-e940-413c-bdab-4df9fade3d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPrenatalTestingMember_9bd01025-8d5d-4443-9fb9-305ddb62d99e" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticPrenatalTestingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:to="loc_mygn_MolecularDiagnosticPrenatalTestingMember_9bd01025-8d5d-4443-9fb9-305ddb62d99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_0db3f54a-fa4f-4b64-941d-7ef647509879" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticPharmacogenomicsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:to="loc_mygn_MolecularDiagnosticPharmacogenomicsMember_0db3f54a-fa4f-4b64-941d-7ef647509879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticAutoimmuneMember_055628d0-da64-4f98-ab49-1617e63d1840" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticAutoimmuneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:to="loc_mygn_MolecularDiagnosticAutoimmuneMember_055628d0-da64-4f98-ab49-1617e63d1840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MolecularDiagnosticOtherTestingMember_1742c97f-e31e-4c43-9ffb-149ba7ee88f2" xlink:href="mygn-20220331.xsd#mygn_MolecularDiagnosticOtherTestingMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_MolecularDiagnosticTestingMember_6b181961-f119-43e2-95de-9f3ded570d3f" xlink:to="loc_mygn_MolecularDiagnosticOtherTestingMember_1742c97f-e31e-4c43-9ffb-149ba7ee88f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmaceuticalAndClinicalServicesMember_763ce027-5c72-4277-849c-afcf2acb087d" xlink:href="mygn-20220331.xsd#mygn_PharmaceuticalAndClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3f27ee31-c086-40e8-ae8a-9573c9832eae" xlink:to="loc_mygn_PharmaceuticalAndClinicalServicesMember_763ce027-5c72-4277-849c-afcf2acb087d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0d04efc8-fefc-4514-91b4-bafe3fdb9aaf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b0c46dd7-72ba-4f59-bb21-a2112b29f970" xlink:to="loc_srt_StatementGeographicalAxis_0d04efc8-fefc-4514-91b4-bafe3fdb9aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_14dff1d4-c631-4833-90eb-167fe6275741" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0d04efc8-fefc-4514-91b4-bafe3fdb9aaf" xlink:to="loc_srt_SegmentGeographicalDomain_14dff1d4-c631-4833-90eb-167fe6275741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_964cdb8b-3c92-434e-a5bb-febcd7a680e5" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_14dff1d4-c631-4833-90eb-167fe6275741" xlink:to="loc_country_US_964cdb8b-3c92-434e-a5bb-febcd7a680e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_323f732d-8256-46e3-83f8-7e462fd6ed15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_14dff1d4-c631-4833-90eb-167fe6275741" xlink:to="loc_us-gaap_NonUsMember_323f732d-8256-46e3-83f8-7e462fd6ed15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_345ccac9-6a41-4233-b067-681c3d4f06e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b0c46dd7-72ba-4f59-bb21-a2112b29f970" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_345ccac9-6a41-4233-b067-681c3d4f06e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dff8ba2d-8f85-4cea-a10f-7f2472f1aff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_345ccac9-6a41-4233-b067-681c3d4f06e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dff8ba2d-8f85-4cea-a10f-7f2472f1aff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#RevenueReconciliationofDeferredRevenueBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_822dee5e-9cbb-4272-9354-f92520d7d9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_69672c43-21a6-4217-8736-b09245aa8e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_822dee5e-9cbb-4272-9354-f92520d7d9f4" xlink:to="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_69672c43-21a6-4217-8736-b09245aa8e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2510cd8d-aee9-49d6-867e-66a8ccc18616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_69672c43-21a6-4217-8736-b09245aa8e41" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2510cd8d-aee9-49d6-867e-66a8ccc18616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_2276b79a-53f1-49b2-b962-4d40ecb87ff6" xlink:href="mygn-20220331.xsd#mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_69672c43-21a6-4217-8736-b09245aa8e41" xlink:to="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_2276b79a-53f1-49b2-b962-4d40ecb87ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityPrepayments_2f0ce3e9-56e2-46dd-963b-2aeb4cdbb09d" xlink:href="mygn-20220331.xsd#mygn_ContractWithCustomerLiabilityPrepayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_69672c43-21a6-4217-8736-b09245aa8e41" xlink:to="loc_mygn_ContractWithCustomerLiabilityPrepayments_2f0ce3e9-56e2-46dd-963b-2aeb4cdbb09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bcf2547e-9df6-41c1-a9bf-93b9bc6dd25f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_69672c43-21a6-4217-8736-b09245aa8e41" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bcf2547e-9df6-41c1-a9bf-93b9bc6dd25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_290729e0-6975-42ae-98c5-21f432a13be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020MedicarePaymentAmount_fd47ef22-3559-4fae-80a5-87055b74d524" xlink:href="mygn-20220331.xsd#mygn_CARESActOf2020MedicarePaymentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_290729e0-6975-42ae-98c5-21f432a13be0" xlink:to="loc_mygn_CARESActOf2020MedicarePaymentAmount_fd47ef22-3559-4fae-80a5-87055b74d524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_2e922f80-a803-47a9-bb21-dc21974fdaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_290729e0-6975-42ae-98c5-21f432a13be0" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_2e922f80-a803-47a9-bb21-dc21974fdaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_33f06d7f-8b5f-4ba7-adfd-7feeaeebb812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_290729e0-6975-42ae-98c5-21f432a13be0" xlink:to="loc_us-gaap_CapitalizedContractCostGross_33f06d7f-8b5f-4ba7-adfd-7feeaeebb812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_290729e0-6975-42ae-98c5-21f432a13be0" xlink:to="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_78e48a03-7231-40d5-966d-9b983bb4ad89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_78e48a03-7231-40d5-966d-9b983bb4ad89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3a1d7a88-90bf-42b0-adc4-6d0364918ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_78e48a03-7231-40d5-966d-9b983bb4ad89" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3a1d7a88-90bf-42b0-adc4-6d0364918ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_2b7fcc6f-620d-4929-b6c8-396fdffe04a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3a1d7a88-90bf-42b0-adc4-6d0364918ec4" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_2b7fcc6f-620d-4929-b6c8-396fdffe04a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_385f5a91-29a9-48b4-9dfc-c8ddcf2254ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:to="loc_srt_MajorCustomersAxis_385f5a91-29a9-48b4-9dfc-c8ddcf2254ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9e80bbec-ec11-4e8d-a663-16a48f658492" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_385f5a91-29a9-48b4-9dfc-c8ddcf2254ad" xlink:to="loc_srt_NameOfMajorCustomerDomain_9e80bbec-ec11-4e8d-a663-16a48f658492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MedicareMember_a844bdc9-8f64-427e-a47c-3889251cd0ea" xlink:href="mygn-20220331.xsd#mygn_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9e80bbec-ec11-4e8d-a663-16a48f658492" xlink:to="loc_mygn_MedicareMember_a844bdc9-8f64-427e-a47c-3889251cd0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c07f19e8-da71-4dc1-902b-e79695847985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c07f19e8-da71-4dc1-902b-e79695847985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ff02e90-4bc0-47ad-be02-5aa27a361c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c07f19e8-da71-4dc1-902b-e79695847985" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ff02e90-4bc0-47ad-be02-5aa27a361c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_dffc8df5-a2e3-4b35-a73c-7d829be6f86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ff02e90-4bc0-47ad-be02-5aa27a361c31" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_dffc8df5-a2e3-4b35-a73c-7d829be6f86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_85b2c4ed-d327-43cc-9472-69a7c27656c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_85b2c4ed-d327-43cc-9472-69a7c27656c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_4e7336e1-abd9-41e0-9c1b-25769ced5302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_85b2c4ed-d327-43cc-9472-69a7c27656c8" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_4e7336e1-abd9-41e0-9c1b-25769ced5302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_6ded4b65-6087-477f-a228-6c89ba7bda7e" xlink:href="mygn-20220331.xsd#mygn_PerformanceObligationEstimatedTransactionPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_4e7336e1-abd9-41e0-9c1b-25769ced5302" xlink:to="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_6ded4b65-6087-477f-a228-6c89ba7bda7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_f2b8fbe0-0a8c-4e90-acbf-be04cf0f1f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_47a93656-cede-48ce-a53e-50c42f3262b2" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_f2b8fbe0-0a8c-4e90-acbf-be04cf0f1f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_bda6b650-3763-466b-b5e8-f008f0e65fba" xlink:href="mygn-20220331.xsd#mygn_IncreaseDecreaseInEarningsLossPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f2b8fbe0-0a8c-4e90-acbf-be04cf0f1f5b" xlink:to="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_bda6b650-3763-466b-b5e8-f008f0e65fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c9d9f7c8-32de-4622-abe2-51d1ebb50d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f2b8fbe0-0a8c-4e90-acbf-be04cf0f1f5b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c9d9f7c8-32de-4622-abe2-51d1ebb50d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecurities" xlink:type="simple" xlink:href="mygn-20220331.xsd#MarketableInvestmentSecurities"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_580f4d29-727c-4335-9a27-9e3fc86bf4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_814ffd04-7d00-4bb0-8640-18754884d310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_580f4d29-727c-4335-9a27-9e3fc86bf4ac" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_814ffd04-7d00-4bb0-8640-18754884d310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesTables" xlink:type="simple" xlink:href="mygn-20220331.xsd#MarketableInvestmentSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b0a83977-4385-4649-9d4f-fab184347c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_5b36177e-06b4-445b-80f0-40f1ee882486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b0a83977-4385-4649-9d4f-fab184347c6c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_5b36177e-06b4-445b-80f0-40f1ee882486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e10a7683-ffa1-4df7-baca-24728f312a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b0a83977-4385-4649-9d4f-fab184347c6c" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e10a7683-ffa1-4df7-baca-24728f312a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3624a7c4-e08f-486b-8f93-37891083a6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5485cf9e-6840-49c0-a1c1-5d785d91b0af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3624a7c4-e08f-486b-8f93-37891083a6a2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5485cf9e-6840-49c0-a1c1-5d785d91b0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_278fe0dc-eb9a-462a-a793-9f5eaaa50828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5485cf9e-6840-49c0-a1c1-5d785d91b0af" xlink:to="loc_us-gaap_InvestmentTypeAxis_278fe0dc-eb9a-462a-a793-9f5eaaa50828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_55949e9f-ad8c-40f5-819f-d8d4f4e58374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_278fe0dc-eb9a-462a-a793-9f5eaaa50828" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_55949e9f-ad8c-40f5-819f-d8d4f4e58374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e7947a2b-d0cc-431b-8b93-29aec12157a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55949e9f-ad8c-40f5-819f-d8d4f4e58374" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e7947a2b-d0cc-431b-8b93-29aec12157a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_c68a8631-341f-4446-8228-5224d6dee388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55949e9f-ad8c-40f5-819f-d8d4f4e58374" xlink:to="loc_us-gaap_MunicipalBondsMember_c68a8631-341f-4446-8228-5224d6dee388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_bc5bdf94-9978-4da9-83be-1085fed97a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55949e9f-ad8c-40f5-819f-d8d4f4e58374" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_bc5bdf94-9978-4da9-83be-1085fed97a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ee00e113-9a0d-4068-9b4e-244346f9c296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55949e9f-ad8c-40f5-819f-d8d4f4e58374" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ee00e113-9a0d-4068-9b4e-244346f9c296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_6f197944-8910-41ed-b6b7-e0f2b172f117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5485cf9e-6840-49c0-a1c1-5d785d91b0af" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_6f197944-8910-41ed-b6b7-e0f2b172f117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00874087-b9c3-4f11-9c1f-befcad6205f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6f197944-8910-41ed-b6b7-e0f2b172f117" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00874087-b9c3-4f11-9c1f-befcad6205f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_241335d0-f365-4449-98c1-7bc54d391557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00874087-b9c3-4f11-9c1f-befcad6205f6" xlink:to="loc_us-gaap_CashMember_241335d0-f365-4449-98c1-7bc54d391557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_f39073f3-cf7f-48f1-b5e1-34e902ee4566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00874087-b9c3-4f11-9c1f-befcad6205f6" xlink:to="loc_us-gaap_CashEquivalentsMember_f39073f3-cf7f-48f1-b5e1-34e902ee4566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16d39089-127f-41c5-90bc-23e1eb8e2a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5485cf9e-6840-49c0-a1c1-5d785d91b0af" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16d39089-127f-41c5-90bc-23e1eb8e2a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_c278f4b0-6eda-4823-be54-e31545a6b999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16d39089-127f-41c5-90bc-23e1eb8e2a89" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_c278f4b0-6eda-4823-be54-e31545a6b999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7221e846-588f-44ac-9a23-8d00898f2295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_c278f4b0-6eda-4823-be54-e31545a6b999" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7221e846-588f-44ac-9a23-8d00898f2295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_72d662e3-34fe-4d8f-9570-f7dbfac68dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_c278f4b0-6eda-4823-be54-e31545a6b999" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_72d662e3-34fe-4d8f-9570-f7dbfac68dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43ff2183-1065-4968-878d-87dfa3c8a441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16d39089-127f-41c5-90bc-23e1eb8e2a89" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43ff2183-1065-4968-878d-87dfa3c8a441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_74c16695-2f9d-4d5e-a84b-93609b982d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43ff2183-1065-4968-878d-87dfa3c8a441" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_74c16695-2f9d-4d5e-a84b-93609b982d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_edff7a49-891b-4164-bbec-a01a5e38a2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43ff2183-1065-4968-878d-87dfa3c8a441" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_edff7a49-891b-4164-bbec-a01a5e38a2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_74e49842-51cb-4e7d-96ea-633f95731e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43ff2183-1065-4968-878d-87dfa3c8a441" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_74e49842-51cb-4e7d-96ea-633f95731e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8dc86dbc-ce20-4f82-997a-1373d74b2693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_43ff2183-1065-4968-878d-87dfa3c8a441" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8dc86dbc-ce20-4f82-997a-1373d74b2693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCashAbstract_4f05d5fa-8f11-4f7b-a7a5-55c0ee39dd47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCashAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16d39089-127f-41c5-90bc-23e1eb8e2a89" xlink:to="loc_us-gaap_InvestmentsAndCashAbstract_4f05d5fa-8f11-4f7b-a7a5-55c0ee39dd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_bf2a121d-43bf-411f-8916-3955843158ae" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_4f05d5fa-8f11-4f7b-a7a5-55c0ee39dd47" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_bf2a121d-43bf-411f-8916-3955843158ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_43941287-7847-4827-a464-7d83d78eb5fe" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_4f05d5fa-8f11-4f7b-a7a5-55c0ee39dd47" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_43941287-7847-4827-a464-7d83d78eb5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_037c623c-f6be-4f5c-b93a-ab3f6755338d" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_4f05d5fa-8f11-4f7b-a7a5-55c0ee39dd47" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_037c623c-f6be-4f5c-b93a-ab3f6755338d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_65a054dc-8e34-4534-8982-e32d59e14572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_4f05d5fa-8f11-4f7b-a7a5-55c0ee39dd47" xlink:to="loc_us-gaap_InvestmentsAndCash_65a054dc-8e34-4534-8982-e32d59e14572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a2d1a5fc-8e8b-43fd-a6ac-bb82d5b4cd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_912e9935-2eda-4de5-954a-60ae75ed8204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a2d1a5fc-8e8b-43fd-a6ac-bb82d5b4cd8a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_912e9935-2eda-4de5-954a-60ae75ed8204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_b0281b6a-910a-45d6-8c36-99981c6af9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_912e9935-2eda-4de5-954a-60ae75ed8204" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_b0281b6a-910a-45d6-8c36-99981c6af9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4746fa34-fdf1-4029-b19f-2581ebea0569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_b0281b6a-910a-45d6-8c36-99981c6af9d0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4746fa34-fdf1-4029-b19f-2581ebea0569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_3046cd12-d783-4efe-a31c-49cf9015dc62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4746fa34-fdf1-4029-b19f-2581ebea0569" xlink:to="loc_us-gaap_CashMember_3046cd12-d783-4efe-a31c-49cf9015dc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_d4ce81a1-4168-4bb3-906a-3ea3306323a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4746fa34-fdf1-4029-b19f-2581ebea0569" xlink:to="loc_us-gaap_CashEquivalentsMember_d4ce81a1-4168-4bb3-906a-3ea3306323a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3657de04-e2d1-4632-9f8a-3e7bc2086fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_912e9935-2eda-4de5-954a-60ae75ed8204" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3657de04-e2d1-4632-9f8a-3e7bc2086fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3657de04-e2d1-4632-9f8a-3e7bc2086fc6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_952c97ad-3b51-48dd-967b-75d88f04a038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_952c97ad-3b51-48dd-967b-75d88f04a038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c4b82450-e1f7-4529-8afb-5748be10f279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c4b82450-e1f7-4529-8afb-5748be10f279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_657a230f-7a46-4f5d-9789-1fea63cb0653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_657a230f-7a46-4f5d-9789-1fea63cb0653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_92a9ed40-a3e6-4ab3-9111-5905a870721b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_92a9ed40-a3e6-4ab3-9111-5905a870721b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_b95c8a95-5c16-4598-b97d-a55aaf694b74" xlink:href="mygn-20220331.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ca320111-e201-4637-8a85-d9e79dbb7cc9" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_b95c8a95-5c16-4598-b97d-a55aaf694b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3657de04-e2d1-4632-9f8a-3e7bc2086fc6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1c8dad87-0300-4256-a22b-d78795e7ac2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1c8dad87-0300-4256-a22b-d78795e7ac2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1b3ec93e-e60e-46e4-8a23-7178eeb10766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1b3ec93e-e60e-46e4-8a23-7178eeb10766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_01c09980-ac84-487c-aea0-e779871584cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_01c09980-ac84-487c-aea0-e779871584cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_deb74bba-3950-4cce-94d9-f21cef18f3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_deb74bba-3950-4cce-94d9-f21cef18f3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_f0018735-1cb4-4973-b2bb-8976b02cdc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_f7aed4e8-9fa3-497b-8613-ce87d894279a" xlink:to="loc_us-gaap_InvestmentsAndCash_f0018735-1cb4-4973-b2bb-8976b02cdc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="mygn-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6c496bf1-a3f8-44c0-95a7-bb0f5a2e0e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_161d283b-29e4-4c80-ae3e-572b484dac75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6c496bf1-a3f8-44c0-95a7-bb0f5a2e0e01" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_161d283b-29e4-4c80-ae3e-572b484dac75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="mygn-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_eccfa249-1c65-4cd3-9fb6-365d4765daf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0fed245c-96a2-42e2-9177-3cf380c334cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eccfa249-1c65-4cd3-9fb6-365d4765daf1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0fed245c-96a2-42e2-9177-3cf380c334cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a742c41d-b5e9-4548-9d63-285f82aa52e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eccfa249-1c65-4cd3-9fb6-365d4765daf1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a742c41d-b5e9-4548-9d63-285f82aa52e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ba4420b9-d444-4a34-8691-0298917b6afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_da2e2512-c3cb-489b-a03c-ba19b59ef5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ba4420b9-d444-4a34-8691-0298917b6afa" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_da2e2512-c3cb-489b-a03c-ba19b59ef5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9bf65c86-1f6c-4ab0-ad95-98d45177975c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_da2e2512-c3cb-489b-a03c-ba19b59ef5a4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9bf65c86-1f6c-4ab0-ad95-98d45177975c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53be6862-27c3-4f58-bf71-c459e41d18e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9bf65c86-1f6c-4ab0-ad95-98d45177975c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53be6862-27c3-4f58-bf71-c459e41d18e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_51dc0129-3686-478c-ab65-47a54fd2efe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53be6862-27c3-4f58-bf71-c459e41d18e2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_51dc0129-3686-478c-ab65-47a54fd2efe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_95134d5a-6bc5-46f3-a13c-398ba6b46404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_da2e2512-c3cb-489b-a03c-ba19b59ef5a4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_95134d5a-6bc5-46f3-a13c-398ba6b46404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1026263d-5a13-455b-b324-c28a447c8536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_95134d5a-6bc5-46f3-a13c-398ba6b46404" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1026263d-5a13-455b-b324-c28a447c8536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_54e5f90f-b20f-4313-8fa6-8ff78c170839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1026263d-5a13-455b-b324-c28a447c8536" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_54e5f90f-b20f-4313-8fa6-8ff78c170839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7b8d2682-eb46-440b-9c9b-674e39c5229e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_da2e2512-c3cb-489b-a03c-ba19b59ef5a4" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7b8d2682-eb46-440b-9c9b-674e39c5229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_366ec8ef-c370-422c-8027-785b7be8445d" xlink:href="mygn-20220331.xsd#mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7b8d2682-eb46-440b-9c9b-674e39c5229e" xlink:to="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_366ec8ef-c370-422c-8027-785b7be8445d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_84b21f51-3376-486e-9966-f1c50938d529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921e26e5-5256-4469-9e2d-79d87a40ce6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_84b21f51-3376-486e-9966-f1c50938d529" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921e26e5-5256-4469-9e2d-79d87a40ce6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652b1dca-52bb-48cc-b55c-26a24f6bcd67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921e26e5-5256-4469-9e2d-79d87a40ce6d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652b1dca-52bb-48cc-b55c-26a24f6bcd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa1dcdc9-b1b5-458f-aa04-f1c1d0beb859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_652b1dca-52bb-48cc-b55c-26a24f6bcd67" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa1dcdc9-b1b5-458f-aa04-f1c1d0beb859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8eff48df-7c71-4d17-8b0b-e17871df58fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa1dcdc9-b1b5-458f-aa04-f1c1d0beb859" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8eff48df-7c71-4d17-8b0b-e17871df58fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_575e5b37-7fc6-4dc0-82ac-676265a0f4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa1dcdc9-b1b5-458f-aa04-f1c1d0beb859" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_575e5b37-7fc6-4dc0-82ac-676265a0f4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2f13a110-a4a3-4409-b4a1-610c95941126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa1dcdc9-b1b5-458f-aa04-f1c1d0beb859" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2f13a110-a4a3-4409-b4a1-610c95941126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_b016eb8f-ce9e-44c7-bec8-8243293c72e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921e26e5-5256-4469-9e2d-79d87a40ce6d" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_b016eb8f-ce9e-44c7-bec8-8243293c72e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2894283d-d324-45d8-bc4a-5cc2e89e31a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b016eb8f-ce9e-44c7-bec8-8243293c72e9" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2894283d-d324-45d8-bc4a-5cc2e89e31a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContingentConsiderationMember_38106861-352a-48fa-8d4c-a19cc611f1c0" xlink:href="mygn-20220331.xsd#mygn_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2894283d-d324-45d8-bc4a-5cc2e89e31a3" xlink:to="loc_mygn_ContingentConsiderationMember_38106861-352a-48fa-8d4c-a19cc611f1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4af11f23-133c-4d25-96fa-5849ec9a5878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921e26e5-5256-4469-9e2d-79d87a40ce6d" xlink:to="loc_us-gaap_InvestmentTypeAxis_4af11f23-133c-4d25-96fa-5849ec9a5878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4af11f23-133c-4d25-96fa-5849ec9a5878" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_234b00db-a670-4413-8ebb-0c321cb29f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:to="loc_us-gaap_MoneyMarketFundsMember_234b00db-a670-4413-8ebb-0c321cb29f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8d594ef6-b5c7-49df-b1b0-8b4e120321bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8d594ef6-b5c7-49df-b1b0-8b4e120321bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_c4a7cd2c-3beb-450c-94bb-762da59f8d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:to="loc_us-gaap_MunicipalBondsMember_c4a7cd2c-3beb-450c-94bb-762da59f8d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8145abeb-feaa-45bf-ba33-9fa4f19dc9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8145abeb-feaa-45bf-ba33-9fa4f19dc9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_740c2bdd-a811-4613-86a0-cc3b582f60a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4b4047e1-597b-488f-986e-85e1625a2666" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_740c2bdd-a811-4613-86a0-cc3b582f60a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e7a82e1-a9d9-402d-802c-8d10e8fa08e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921e26e5-5256-4469-9e2d-79d87a40ce6d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e7a82e1-a9d9-402d-802c-8d10e8fa08e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_cf58f55b-7a56-4e73-b594-865cb8dd09df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e7a82e1-a9d9-402d-802c-8d10e8fa08e2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_cf58f55b-7a56-4e73-b594-865cb8dd09df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c2cecca1-e690-4a94-9e3e-6368fbc37d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e7a82e1-a9d9-402d-802c-8d10e8fa08e2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_c2cecca1-e690-4a94-9e3e-6368fbc37d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_56e9e375-2ec8-4f33-b87d-81fda7299f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e7a82e1-a9d9-402d-802c-8d10e8fa08e2" xlink:to="loc_us-gaap_FairValueNetAssetLiability_56e9e375-2ec8-4f33-b87d-81fda7299f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e22e3eff-dfd6-4195-98ef-47cea3338f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_325caab2-9ac2-4259-b37a-bf09a0a7614d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e22e3eff-dfd6-4195-98ef-47cea3338f86" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_325caab2-9ac2-4259-b37a-bf09a0a7614d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e6ed4a08-f33a-4123-9e36-310f07704f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_325caab2-9ac2-4259-b37a-bf09a0a7614d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e6ed4a08-f33a-4123-9e36-310f07704f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2ada5a0e-654c-46ea-8dc8-9c7dabe0b4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_325caab2-9ac2-4259-b37a-bf09a0a7614d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2ada5a0e-654c-46ea-8dc8-9c7dabe0b4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_2f135004-dfdf-47f9-83a2-ad264bee825c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_325caab2-9ac2-4259-b37a-bf09a0a7614d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_2f135004-dfdf-47f9-83a2-ad264bee825c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_85f084f7-2acb-4ac4-af7e-adc57cf5928c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_325caab2-9ac2-4259-b37a-bf09a0a7614d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_85f084f7-2acb-4ac4-af7e-adc57cf5928c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNet" xlink:type="simple" xlink:href="mygn-20220331.xsd#PropertyPlantandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bde03fac-6714-4711-8355-52994e5c97fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d70ab1a4-3de8-4235-8ee3-3b2ce9c1a4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bde03fac-6714-4711-8355-52994e5c97fd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d70ab1a4-3de8-4235-8ee3-3b2ce9c1a4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetTables" xlink:type="simple" xlink:href="mygn-20220331.xsd#PropertyPlantandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_83793996-c395-4bc0-a039-36e5c37feade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_49d720e6-fa50-44c8-9504-81a7d2f96685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_83793996-c395-4bc0-a039-36e5c37feade" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_49d720e6-fa50-44c8-9504-81a7d2f96685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#PropertyPlantandEquipmentNetBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cce3e3b8-9a3d-4365-bb32-550197671430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb2aad42-c7b6-4f53-86d5-fae45010d1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cce3e3b8-9a3d-4365-bb32-550197671430" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb2aad42-c7b6-4f53-86d5-fae45010d1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a567bf3-430b-4792-8e2f-5274de9cb256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb2aad42-c7b6-4f53-86d5-fae45010d1ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a567bf3-430b-4792-8e2f-5274de9cb256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_997ecfc3-d6cf-4e2f-ae6f-9c935524785b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a567bf3-430b-4792-8e2f-5274de9cb256" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_997ecfc3-d6cf-4e2f-ae6f-9c935524785b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_656b1201-800e-4b50-bbda-da7ed73d2e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_997ecfc3-d6cf-4e2f-ae6f-9c935524785b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_656b1201-800e-4b50-bbda-da7ed73d2e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_6b1ba58b-fa32-4b89-bed9-c50d89bc05ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_997ecfc3-d6cf-4e2f-ae6f-9c935524785b" xlink:to="loc_us-gaap_EquipmentMember_6b1ba58b-fa32-4b89-bed9-c50d89bc05ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_111318c1-9e25-4fc8-b38a-58d9a3f64e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb2aad42-c7b6-4f53-86d5-fae45010d1ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_111318c1-9e25-4fc8-b38a-58d9a3f64e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f389f502-2424-4ac5-ae13-c10c8eba4611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_111318c1-9e25-4fc8-b38a-58d9a3f64e06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f389f502-2424-4ac5-ae13-c10c8eba4611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cad08fae-de1c-4002-b6e6-9c4357d609ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_111318c1-9e25-4fc8-b38a-58d9a3f64e06" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cad08fae-de1c-4002-b6e6-9c4357d609ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_798c756e-5276-41f3-96cf-fc104dcd2e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_111318c1-9e25-4fc8-b38a-58d9a3f64e06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_798c756e-5276-41f3-96cf-fc104dcd2e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#PropertyPlantandEquipmentNetDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a26330fa-09bd-48da-bf30-f9342971425a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0417b225-3a48-43d7-a49b-433413907d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a26330fa-09bd-48da-bf30-f9342971425a" xlink:to="loc_us-gaap_Depreciation_0417b225-3a48-43d7-a49b-433413907d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#PropertyPlantandEquipmentNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5cdb50f2-2036-4cf6-8dc6-2862b464c199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c30be1c-7b3a-449a-b9cf-f02934f603d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5cdb50f2-2036-4cf6-8dc6-2862b464c199" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c30be1c-7b3a-449a-b9cf-f02934f603d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_06281b80-285b-406f-a308-8212181bbad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c30be1c-7b3a-449a-b9cf-f02934f603d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_06281b80-285b-406f-a308-8212181bbad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4789a7e1-2827-4009-86ba-508d46692f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_06281b80-285b-406f-a308-8212181bbad4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4789a7e1-2827-4009-86ba-508d46692f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_995a5602-e91b-4a91-8264-457f7df2e2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4789a7e1-2827-4009-86ba-508d46692f37" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_995a5602-e91b-4a91-8264-457f7df2e2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77c61599-1a44-4059-8184-ea4e44b3256a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c30be1c-7b3a-449a-b9cf-f02934f603d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77c61599-1a44-4059-8184-ea4e44b3256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_6b9a696e-2ddc-4022-abf5-8f72765fe50b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77c61599-1a44-4059-8184-ea4e44b3256a" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_6b9a696e-2ddc-4022-abf5-8f72765fe50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="mygn-20220331.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7e5bd6da-5bdb-4283-afee-8b028a0b490b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_61b6660f-dc82-49c7-b139-1cd2b6d6329c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7e5bd6da-5bdb-4283-afee-8b028a0b490b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_61b6660f-dc82-49c7-b139-1cd2b6d6329c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="mygn-20220331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50f5bdc4-5271-42df-9025-1fd27a86350a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_59c9bd02-efb4-4c13-a9ca-e9b6f2fafda9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50f5bdc4-5271-42df-9025-1fd27a86350a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_59c9bd02-efb4-4c13-a9ca-e9b6f2fafda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2d2499eb-58e5-44e3-94e9-a5c917afe498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50f5bdc4-5271-42df-9025-1fd27a86350a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2d2499eb-58e5-44e3-94e9-a5c917afe498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_023f5676-83fb-4bb0-986f-579d46c554a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50f5bdc4-5271-42df-9025-1fd27a86350a" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_023f5676-83fb-4bb0-986f-579d46c554a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_855dd1b7-5ac3-42d9-88c5-c86e4f7b5bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50f5bdc4-5271-42df-9025-1fd27a86350a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_855dd1b7-5ac3-42d9-88c5-c86e4f7b5bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_23f20cdf-b067-4477-a9e3-51fc984dc8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_f6dd26c1-1b74-421f-901f-5b71b09713bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_23f20cdf-b067-4477-a9e3-51fc984dc8c8" xlink:to="loc_us-gaap_GoodwillRollForward_f6dd26c1-1b74-421f-901f-5b71b09713bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_474b6361-0b97-4885-b363-55ba10ce3ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f6dd26c1-1b74-421f-901f-5b71b09713bc" xlink:to="loc_us-gaap_Goodwill_474b6361-0b97-4885-b363-55ba10ce3ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_27c115e0-d805-45c3-8193-d931d5763092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f6dd26c1-1b74-421f-901f-5b71b09713bc" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_27c115e0-d805-45c3-8193-d931d5763092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1eb96216-e2e3-46b2-8cee-96a6bd7a70c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f6dd26c1-1b74-421f-901f-5b71b09713bc" xlink:to="loc_us-gaap_Goodwill_1eb96216-e2e3-46b2-8cee-96a6bd7a70c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a7afcb6c-9df3-4992-b00c-bf7fc2884f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable_98b4077c-8d35-4ed3-878d-287347bb1ac1" xlink:href="mygn-20220331.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a7afcb6c-9df3-4992-b00c-bf7fc2884f29" xlink:to="loc_mygn_ScheduleOfIntangibleAssetsTable_98b4077c-8d35-4ed3-878d-287347bb1ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f5c080c-f7a0-4e05-abdc-037d91be7e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_98b4077c-8d35-4ed3-878d-287347bb1ac1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f5c080c-f7a0-4e05-abdc-037d91be7e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a949569-accd-40ec-89cf-f1c3576fbba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f5c080c-f7a0-4e05-abdc-037d91be7e27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a949569-accd-40ec-89cf-f1c3576fbba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PurchasedLicensesAndTechnologiesMember_01de789a-de08-41b4-a5c5-a9117e3b54ce" xlink:href="mygn-20220331.xsd#mygn_PurchasedLicensesAndTechnologiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a949569-accd-40ec-89cf-f1c3576fbba2" xlink:to="loc_mygn_PurchasedLicensesAndTechnologiesMember_01de789a-de08-41b4-a5c5-a9117e3b54ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:href="mygn-20220331.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_98b4077c-8d35-4ed3-878d-287347bb1ac1" xlink:to="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f04cfbb8-f886-43af-9600-c91ab4adad04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f04cfbb8-f886-43af-9600-c91ab4adad04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_760a86e4-fde4-4056-be33-a0eec7581fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_760a86e4-fde4-4056-be33-a0eec7581fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b236d895-87b0-42bf-b22c-61191426c4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b236d895-87b0-42bf-b22c-61191426c4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_662c763e-6804-4d99-b8ce-430e6c1ef5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_662c763e-6804-4d99-b8ce-430e6c1ef5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cb70c476-f46a-4323-8112-b713ba146298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_a1b0d296-8c06-44a2-936e-4dfb2f4a338d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cb70c476-f46a-4323-8112-b713ba146298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b438903a-f4d1-410e-9511-9383e2a6b571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_420e5893-361b-4872-b38c-3c93490c3882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b438903a-f4d1-410e-9511-9383e2a6b571" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_420e5893-361b-4872-b38c-3c93490c3882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="mygn-20220331.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5ddbfeed-9924-4bc1-a50c-c7c900cc0f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_915a001e-395a-4667-98c8-a15dcfb4cdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5ddbfeed-9924-4bc1-a50c-c7c900cc0f7a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_915a001e-395a-4667-98c8-a15dcfb4cdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="mygn-20220331.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_22575966-06c9-4da4-9542-16ac4837b916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_45dcad7e-b3e9-4c87-b1c1-0db5b73e3682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_22575966-06c9-4da4-9542-16ac4837b916" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_45dcad7e-b3e9-4c87-b1c1-0db5b73e3682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_736daccc-05a8-4217-a98b-a24647aa5843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c2a9c8bb-0be7-4cb4-b4f7-984ba0e537cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_736daccc-05a8-4217-a98b-a24647aa5843" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c2a9c8bb-0be7-4cb4-b4f7-984ba0e537cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_8bff318e-79ed-44f3-8648-680fadd57b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_736daccc-05a8-4217-a98b-a24647aa5843" xlink:to="loc_us-gaap_LitigationReserveCurrent_8bff318e-79ed-44f3-8648-680fadd57b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_e5663429-7ea4-4b68-8f76-ad42f4e6c168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_736daccc-05a8-4217-a98b-a24647aa5843" xlink:to="loc_us-gaap_TaxesPayableCurrent_e5663429-7ea4-4b68-8f76-ad42f4e6c168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RefundsPayableAndReserveCurrent_fc6bd920-d55b-430e-8281-6dff86e203f3" xlink:href="mygn-20220331.xsd#mygn_RefundsPayableAndReserveCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_736daccc-05a8-4217-a98b-a24647aa5843" xlink:to="loc_mygn_RefundsPayableAndReserveCurrent_fc6bd920-d55b-430e-8281-6dff86e203f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4fe2d199-6c99-4ab8-a519-813b2b1d42dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_736daccc-05a8-4217-a98b-a24647aa5843" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4fe2d199-6c99-4ab8-a519-813b2b1d42dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_c9338ef5-4968-417c-b070-4e21aab4524f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_736daccc-05a8-4217-a98b-a24647aa5843" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_c9338ef5-4968-417c-b070-4e21aab4524f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7eabbc24-13cd-477f-a5fa-a2129d77cc27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_736daccc-05a8-4217-a98b-a24647aa5843" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7eabbc24-13cd-477f-a5fa-a2129d77cc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5b67f87b-40ee-46b9-a574-bee63283c10f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_736daccc-05a8-4217-a98b-a24647aa5843" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5b67f87b-40ee-46b9-a574-bee63283c10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LongTermDebt" xlink:type="simple" xlink:href="mygn-20220331.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5f003680-7e0a-41e1-aa92-2cb2a18098dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_bb9d1e79-b959-405a-9254-3b9b685cd883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f003680-7e0a-41e1-aa92-2cb2a18098dd" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_bb9d1e79-b959-405a-9254-3b9b685cd883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#LongTermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ea452947-1649-4edd-b273-615b0acb3f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ea452947-1649-4edd-b273-615b0acb3f72" xlink:to="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7bc6c5e5-5d8e-4c6f-aaba-c2adb885024e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:to="loc_us-gaap_CreditFacilityAxis_7bc6c5e5-5d8e-4c6f-aaba-c2adb885024e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_48f070ec-6e20-4a01-b267-afb3e63d0faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7bc6c5e5-5d8e-4c6f-aaba-c2adb885024e" xlink:to="loc_us-gaap_CreditFacilityDomain_48f070ec-6e20-4a01-b267-afb3e63d0faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1cca3f65-6c2d-4ba6-a9d1-87dd2991850e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_48f070ec-6e20-4a01-b267-afb3e63d0faa" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1cca3f65-6c2d-4ba6-a9d1-87dd2991850e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7915ccce-2d29-4ee3-ac93-845c98afe09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:to="loc_us-gaap_DebtInstrumentAxis_7915ccce-2d29-4ee3-ac93-845c98afe09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_72e47c4b-1e20-4657-beb5-2d812c9dfc11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7915ccce-2d29-4ee3-ac93-845c98afe09a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_72e47c4b-1e20-4657-beb5-2d812c9dfc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmendmentToCreditAgreementMember_00046835-2ade-4b01-90bd-f32344dbc91b" xlink:href="mygn-20220331.xsd#mygn_AmendmentToCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_72e47c4b-1e20-4657-beb5-2d812c9dfc11" xlink:to="loc_mygn_AmendmentToCreditAgreementMember_00046835-2ade-4b01-90bd-f32344dbc91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_0b3cf901-bdae-459f-94b1-0aaa901aad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:to="loc_us-gaap_VariableRateAxis_0b3cf901-bdae-459f-94b1-0aaa901aad3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_62f57b90-f111-4a4c-9880-db53f62601f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_0b3cf901-bdae-459f-94b1-0aaa901aad3c" xlink:to="loc_us-gaap_VariableRateDomain_62f57b90-f111-4a4c-9880-db53f62601f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_788c03d8-06d3-4958-a096-d9638351127e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_62f57b90-f111-4a4c-9880-db53f62601f5" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_788c03d8-06d3-4958-a096-d9638351127e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e7a29127-fa4a-453e-904f-6cfad2ea7a74" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:to="loc_srt_StatementScenarioAxis_e7a29127-fa4a-453e-904f-6cfad2ea7a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e72ea47f-64d5-4f7d-8c94-bf17f80ea7a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_e7a29127-fa4a-453e-904f-6cfad2ea7a74" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e72ea47f-64d5-4f7d-8c94-bf17f80ea7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a2950dee-e9e4-4a5d-919b-9226da6702e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e72ea47f-64d5-4f7d-8c94-bf17f80ea7a7" xlink:to="loc_srt_ScenarioForecastMember_a2950dee-e9e4-4a5d-919b-9226da6702e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4af0efa6-46c3-418a-a10c-80ec06bd63f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:to="loc_srt_RangeAxis_4af0efa6-46c3-418a-a10c-80ec06bd63f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f08acfa-4da4-4b30-ba52-bcf888b244e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4af0efa6-46c3-418a-a10c-80ec06bd63f9" xlink:to="loc_srt_RangeMember_9f08acfa-4da4-4b30-ba52-bcf888b244e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_152769b8-1e9a-478d-acdf-b97f745bd5cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f08acfa-4da4-4b30-ba52-bcf888b244e5" xlink:to="loc_srt_MinimumMember_152769b8-1e9a-478d-acdf-b97f745bd5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_00338b9c-0f0d-4554-8df2-f66b273febed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f08acfa-4da4-4b30-ba52-bcf888b244e5" xlink:to="loc_srt_MaximumMember_00338b9c-0f0d-4554-8df2-f66b273febed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57acebf3-897a-4a6d-89fb-6a66b4f8bd6f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1c7c391c-7978-4c30-8274-4765db5a9c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1c7c391c-7978-4c30-8274-4765db5a9c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_af3a7956-e4be-414f-8fcd-fbdc501e96a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_af3a7956-e4be-414f-8fcd-fbdc501e96a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantLiquidityCovenantMinimum_eaf367e6-f382-471d-aa86-c35e07e70cf6" xlink:href="mygn-20220331.xsd#mygn_DebtCovenantLiquidityCovenantMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_mygn_DebtCovenantLiquidityCovenantMinimum_eaf367e6-f382-471d-aa86-c35e07e70cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_8d11ecd8-ba61-4f6c-a633-ebf37bffe50b" xlink:href="mygn-20220331.xsd#mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_8d11ecd8-ba61-4f6c-a633-ebf37bffe50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_30e7dfce-d0b7-4dbb-8ceb-da529442bdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_30e7dfce-d0b7-4dbb-8ceb-da529442bdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_ead024e2-e179-43f9-806c-bf09a29c9c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_ead024e2-e179-43f9-806c-bf09a29c9c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtInstrumentLIBORFloorPercentage_b6b6def4-20af-4bcd-b8eb-aa2f4bbdfb9c" xlink:href="mygn-20220331.xsd#mygn_DebtInstrumentLIBORFloorPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_mygn_DebtInstrumentLIBORFloorPercentage_b6b6def4-20af-4bcd-b8eb-aa2f4bbdfb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_e63fc801-be9a-44ea-a7f9-625bef57354f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_e63fc801-be9a-44ea-a7f9-625bef57354f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_114529e3-a3bf-4f3e-892b-292769b05133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_394b1d0f-d581-4b6e-883e-d37486e14913" xlink:to="loc_us-gaap_LongTermDebt_114529e3-a3bf-4f3e-892b-292769b05133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilities" xlink:type="simple" xlink:href="mygn-20220331.xsd#OtherLongTermLiabilities"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8e3908bf-b517-433f-830b-db6ac24880f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_620c9a63-da51-49be-8109-a4ccc7cbeb96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8e3908bf-b517-433f-830b-db6ac24880f1" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_620c9a63-da51-49be-8109-a4ccc7cbeb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesTables" xlink:type="simple" xlink:href="mygn-20220331.xsd#OtherLongTermLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_c71815fd-e098-46a8-aefc-c888b0979635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_220fd035-ed81-44b5-870a-c859543962a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_c71815fd-e098-46a8-aefc-c888b0979635" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_220fd035-ed81-44b5-870a-c859543962a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#OtherLongTermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_418d768e-b541-4a83-997b-eaa1c42af3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6ad0f37d-f40c-471a-9f4b-0a29702e662f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_418d768e-b541-4a83-997b-eaa1c42af3eb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6ad0f37d-f40c-471a-9f4b-0a29702e662f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_a7223cc8-1680-4ff4-b056-8a5ea8b11a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_418d768e-b541-4a83-997b-eaa1c42af3eb" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_a7223cc8-1680-4ff4-b056-8a5ea8b11a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c94dbffd-87bf-4004-b9f9-f0661ecf6b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_418d768e-b541-4a83-997b-eaa1c42af3eb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c94dbffd-87bf-4004-b9f9-f0661ecf6b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquity" xlink:type="simple" xlink:href="mygn-20220331.xsd#PreferredandCommonStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_91ef421c-bc24-4bbf-afb8-a4cf5e938c04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8d1e86c5-a105-4c90-a3d1-35d1a206dcda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_91ef421c-bc24-4bbf-afb8-a4cf5e938c04" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8d1e86c5-a105-4c90-a3d1-35d1a206dcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables" xlink:type="simple" xlink:href="mygn-20220331.xsd#PreferredandCommonStockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_afcbf027-1e2d-4e25-ba56-efe85489bdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_8f11f009-210e-4327-a0ad-007aab246c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_afcbf027-1e2d-4e25-ba56-efe85489bdf8" xlink:to="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_8f11f009-210e-4327-a0ad-007aab246c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_9cb9e130-574d-490b-a3b8-f98f10454ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_afcbf027-1e2d-4e25-ba56-efe85489bdf8" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_9cb9e130-574d-490b-a3b8-f98f10454ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_85770408-9cad-4034-9208-0adb88b9fd59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_afcbf027-1e2d-4e25-ba56-efe85489bdf8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_85770408-9cad-4034-9208-0adb88b9fd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#PreferredandCommonStockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_94f7b1e8-f24a-4a19-898d-ca35d152f990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3921c6b9-cc96-4a5b-8f18-32bab4d79ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94f7b1e8-f24a-4a19-898d-ca35d152f990" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3921c6b9-cc96-4a5b-8f18-32bab4d79ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c13f36dd-d83b-4474-b0e5-6bd18365b508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94f7b1e8-f24a-4a19-898d-ca35d152f990" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c13f36dd-d83b-4474-b0e5-6bd18365b508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_957efc35-71e9-47e7-b32c-bc4c413aa008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94f7b1e8-f24a-4a19-898d-ca35d152f990" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_957efc35-71e9-47e7-b32c-bc4c413aa008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_09593a80-0a4d-46fd-860e-34eaec5fcf0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94f7b1e8-f24a-4a19-898d-ca35d152f990" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_09593a80-0a4d-46fd-860e-34eaec5fcf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_781049cb-0f0b-4bfa-9ac4-9ceda5548c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94f7b1e8-f24a-4a19-898d-ca35d152f990" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_781049cb-0f0b-4bfa-9ac4-9ceda5548c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9930244f-93f9-4aae-999f-a2036ab716d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94f7b1e8-f24a-4a19-898d-ca35d152f990" xlink:to="loc_us-gaap_CommonStockSharesIssued_9930244f-93f9-4aae-999f-a2036ab716d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_aa519cf9-8094-49f7-befb-a31c12e4658c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94f7b1e8-f24a-4a19-898d-ca35d152f990" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_aa519cf9-8094-49f7-befb-a31c12e4658c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d69c0f22-d794-4031-a1f2-76d622644196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94f7b1e8-f24a-4a19-898d-ca35d152f990" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d69c0f22-d794-4031-a1f2-76d622644196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_88008db3-9757-4997-823e-a2feb4df897b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94f7b1e8-f24a-4a19-898d-ca35d152f990" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_88008db3-9757-4997-823e-a2feb4df897b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_b3c0a302-9c55-428b-9b6f-085f98922999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94f7b1e8-f24a-4a19-898d-ca35d152f990" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_b3c0a302-9c55-428b-9b6f-085f98922999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4affd7ca-bf80-43af-9797-fa26e789c7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c6b470a9-bde8-4b3d-b05b-b25eb84f4db4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4affd7ca-bf80-43af-9797-fa26e789c7c8" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c6b470a9-bde8-4b3d-b05b-b25eb84f4db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f71f115d-f071-4d56-99ca-c0b27e3596d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c6b470a9-bde8-4b3d-b05b-b25eb84f4db4" xlink:to="loc_us-gaap_CommonStockSharesIssued_f71f115d-f071-4d56-99ca-c0b27e3596d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_07a2d1e4-3732-4381-a3d3-d29de6aec072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c6b470a9-bde8-4b3d-b05b-b25eb84f4db4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_07a2d1e4-3732-4381-a3d3-d29de6aec072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_8877a95b-7e97-4bdb-b09c-e4ea60c2d3b2" xlink:href="mygn-20220331.xsd#mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c6b470a9-bde8-4b3d-b05b-b25eb84f4db4" xlink:to="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_8877a95b-7e97-4bdb-b09c-e4ea60c2d3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3f174f91-abe6-4f6c-91ad-e2e3e3ab5f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c6b470a9-bde8-4b3d-b05b-b25eb84f4db4" xlink:to="loc_us-gaap_CommonStockSharesIssued_3f174f91-abe6-4f6c-91ad-e2e3e3ab5f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d135a423-8d0a-49ec-98ed-7045cd685925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c6b470a9-bde8-4b3d-b05b-b25eb84f4db4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d135a423-8d0a-49ec-98ed-7045cd685925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fb2b53a7-f440-44e0-a05b-bf7f7d0420f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_34ab5a3a-9df3-42e2-a754-1f5a60f802ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fb2b53a7-f440-44e0-a05b-bf7f7d0420f9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_34ab5a3a-9df3-42e2-a754-1f5a60f802ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_922cd19a-ca35-4bab-9acf-2414bbbaf095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fb2b53a7-f440-44e0-a05b-bf7f7d0420f9" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_922cd19a-ca35-4bab-9acf-2414bbbaf095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_51ec0a07-e639-42bd-aeb4-5cd6cde655ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fb2b53a7-f440-44e0-a05b-bf7f7d0420f9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_51ec0a07-e639-42bd-aeb4-5cd6cde655ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e895c1d6-0c26-4b6c-95f6-ec7c47a4f3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3b7af31c-becc-40c7-926e-8b00350ae6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e895c1d6-0c26-4b6c-95f6-ec7c47a4f3cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3b7af31c-becc-40c7-926e-8b00350ae6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mygn-20220331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a8cba6b-ae55-49c4-bc5d-392561498035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aedd1b91-3c10-4c4c-97b3-f566df7196b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a8cba6b-ae55-49c4-bc5d-392561498035" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aedd1b91-3c10-4c4c-97b3-f566df7196b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mygn-20220331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cdef954-6e9c-407b-b6b9-a07b4e3790c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_913c12c9-08c4-4c34-82d0-2eb116d8e596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cdef954-6e9c-407b-b6b9-a07b4e3790c8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_913c12c9-08c4-4c34-82d0-2eb116d8e596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e312db1b-b6b5-48d1-a1f6-b3969900d871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cdef954-6e9c-407b-b6b9-a07b4e3790c8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e312db1b-b6b5-48d1-a1f6-b3969900d871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9cd2bb08-6c67-4521-ad52-f36ad32e968f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cdef954-6e9c-407b-b6b9-a07b4e3790c8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9cd2bb08-6c67-4521-ad52-f36ad32e968f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a1d0393-7770-4d6a-ab6c-5c38ff36e40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a1d0393-7770-4d6a-ab6c-5c38ff36e40b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc34eb71-0cc8-405f-9e0a-677dd7c83d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:to="loc_us-gaap_AwardTypeAxis_dc34eb71-0cc8-405f-9e0a-677dd7c83d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5b11331-a5a6-431c-a675-31982620a787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dc34eb71-0cc8-405f-9e0a-677dd7c83d98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5b11331-a5a6-431c-a675-31982620a787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsAndRestrictedStockUnitsMember_9c273e24-0a19-4298-84ea-b3e02f48c928" xlink:href="mygn-20220331.xsd#mygn_OptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5b11331-a5a6-431c-a675-31982620a787" xlink:to="loc_mygn_OptionsAndRestrictedStockUnitsMember_9c273e24-0a19-4298-84ea-b3e02f48c928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8eb8c182-a298-4422-b239-268b1546102d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_9c273e24-0a19-4298-84ea-b3e02f48c928" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8eb8c182-a298-4422-b239-268b1546102d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7656d553-d2d9-452c-b2e7-ba5012dfe540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_9c273e24-0a19-4298-84ea-b3e02f48c928" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7656d553-d2d9-452c-b2e7-ba5012dfe540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_52bca56f-73ee-44d7-b8ea-db22a4ca8dff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:to="loc_srt_TitleOfIndividualAxis_52bca56f-73ee-44d7-b8ea-db22a4ca8dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_525a309a-c2c9-482f-9cb4-2f10b7930f46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_52bca56f-73ee-44d7-b8ea-db22a4ca8dff" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_525a309a-c2c9-482f-9cb4-2f10b7930f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonEmployeeDirectorMember_2e9c3aab-7747-4334-ba03-bc164767c538" xlink:href="mygn-20220331.xsd#mygn_NonEmployeeDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_525a309a-c2c9-482f-9cb4-2f10b7930f46" xlink:to="loc_mygn_NonEmployeeDirectorMember_2e9c3aab-7747-4334-ba03-bc164767c538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_fccb1f3f-af1b-4c6a-9b70-49c850585726" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_525a309a-c2c9-482f-9cb4-2f10b7930f46" xlink:to="loc_srt_ChiefExecutiveOfficerMember_fccb1f3f-af1b-4c6a-9b70-49c850585726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d4239239-1d79-4e0e-8651-43f011ea82fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:to="loc_us-gaap_VestingAxis_d4239239-1d79-4e0e-8651-43f011ea82fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e89d1a8e-2fee-4131-9885-2478b3ef0d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_d4239239-1d79-4e0e-8651-43f011ea82fe" xlink:to="loc_us-gaap_VestingDomain_e89d1a8e-2fee-4131-9885-2478b3ef0d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b37cb20f-1dc8-4839-8740-dd662c5c0148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_e89d1a8e-2fee-4131-9885-2478b3ef0d51" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b37cb20f-1dc8-4839-8740-dd662c5c0148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_472881c9-54f0-4b28-aca2-6fed5a76b971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_e89d1a8e-2fee-4131-9885-2478b3ef0d51" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_472881c9-54f0-4b28-aca2-6fed5a76b971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c7ecfc36-d193-4ff5-8969-c63ad5ea1501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_e89d1a8e-2fee-4131-9885-2478b3ef0d51" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c7ecfc36-d193-4ff5-8969-c63ad5ea1501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a8fa607c-2fc2-4c68-a832-45b0e1e330ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:to="loc_us-gaap_PlanNameAxis_a8fa607c-2fc2-4c68-a832-45b0e1e330ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e1c5e0e5-51d5-4556-8477-2aeea9fb2193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a8fa607c-2fc2-4c68-a832-45b0e1e330ee" xlink:to="loc_us-gaap_PlanNameDomain_e1c5e0e5-51d5-4556-8477-2aeea9fb2193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_ab0d0a3f-c7d5-4738-8efc-444f88430669" xlink:href="mygn-20220331.xsd#mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e1c5e0e5-51d5-4556-8477-2aeea9fb2193" xlink:to="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_ab0d0a3f-c7d5-4738-8efc-444f88430669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_b1ce8770-1edf-453f-8952-45f8ed7b62f7" xlink:href="mygn-20220331.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e1c5e0e5-51d5-4556-8477-2aeea9fb2193" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_b1ce8770-1edf-453f-8952-45f8ed7b62f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a80e512-1382-4c95-b15b-07d7d51a22c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ac493793-cae8-47be-ac95-b40ca616bdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ac493793-cae8-47be-ac95-b40ca616bdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d413dc1d-fc32-47cd-9b6e-fee65d60961a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d413dc1d-fc32-47cd-9b6e-fee65d60961a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1bb9f595-1ec1-486d-812d-75d6b0d5e68c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1bb9f595-1ec1-486d-812d-75d6b0d5e68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1c3f7a91-26f2-4b30-89b2-1e85faa4edf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1c3f7a91-26f2-4b30-89b2-1e85faa4edf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86bf1d2e-8e76-4a08-9ef3-69fafecee1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86bf1d2e-8e76-4a08-9ef3-69fafecee1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fce5e925-9cba-4203-971c-2405335b00ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fce5e925-9cba-4203-971c-2405335b00ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6b274129-dc01-4d56-95cc-e9edfdafeefd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6b274129-dc01-4d56-95cc-e9edfdafeefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f4b172ce-b7e5-4784-b595-d5825f571671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f4b172ce-b7e5-4784-b595-d5825f571671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_5b1babf6-b353-45b4-bc0e-b87c76c1184c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_5b1babf6-b353-45b4-bc0e-b87c76c1184c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_de2aaaf9-d896-4748-81ae-377668774ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_de2aaaf9-d896-4748-81ae-377668774ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ec306851-137b-4b00-8963-ad0d4f988ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d41eb8e-5e40-4cfd-85c0-bf59e4a1ec4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ec306851-137b-4b00-8963-ad0d4f988ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5388341-89e8-442b-bf0f-1e35a9ae8818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_498a3f02-a2a1-4721-9fd2-27c8a4c5de4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5388341-89e8-442b-bf0f-1e35a9ae8818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_498a3f02-a2a1-4721-9fd2-27c8a4c5de4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6fb023db-9bbe-408d-b314-1134712b4861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_498a3f02-a2a1-4721-9fd2-27c8a4c5de4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6fb023db-9bbe-408d-b314-1134712b4861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d0a983de-f61b-47a7-b540-50a1a57b3490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_498a3f02-a2a1-4721-9fd2-27c8a4c5de4f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d0a983de-f61b-47a7-b540-50a1a57b3490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_26cf01f4-3d1f-4bef-aba3-b33a8005019d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_498a3f02-a2a1-4721-9fd2-27c8a4c5de4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_26cf01f4-3d1f-4bef-aba3-b33a8005019d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3215e177-5713-4329-9564-e1a75dff3b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_498a3f02-a2a1-4721-9fd2-27c8a4c5de4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3215e177-5713-4329-9564-e1a75dff3b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_dc09e0da-db33-4369-bbf0-671e18a4193a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5388341-89e8-442b-bf0f-1e35a9ae8818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_dc09e0da-db33-4369-bbf0-671e18a4193a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_84d9c069-50ca-40e3-88e3-d66891aed307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5388341-89e8-442b-bf0f-1e35a9ae8818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_84d9c069-50ca-40e3-88e3-d66891aed307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d4ec3481-f423-41f4-a9a1-311b69fd006b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_84d9c069-50ca-40e3-88e3-d66891aed307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d4ec3481-f423-41f4-a9a1-311b69fd006b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9bcfb383-d667-41c9-83e8-def712e6003a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_84d9c069-50ca-40e3-88e3-d66891aed307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9bcfb383-d667-41c9-83e8-def712e6003a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c73ef664-b102-448f-b66b-9e8f841abca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_84d9c069-50ca-40e3-88e3-d66891aed307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c73ef664-b102-448f-b66b-9e8f841abca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_834bce22-94bc-4b96-92d0-4b1f4734df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_84d9c069-50ca-40e3-88e3-d66891aed307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_834bce22-94bc-4b96-92d0-4b1f4734df0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fd8c4714-70ad-493a-831c-e9e3640e1686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5388341-89e8-442b-bf0f-1e35a9ae8818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fd8c4714-70ad-493a-831c-e9e3640e1686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#StockBasedCompensationRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e36735a6-dba1-4af2-a4ce-ed4928e327c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e480b8d-30e8-4e5a-b166-96958ee21cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e36735a6-dba1-4af2-a4ce-ed4928e327c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e480b8d-30e8-4e5a-b166-96958ee21cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a9605edf-c8b3-48c9-a8c5-d2a23c2e8ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e480b8d-30e8-4e5a-b166-96958ee21cc3" xlink:to="loc_us-gaap_AwardTypeAxis_a9605edf-c8b3-48c9-a8c5-d2a23c2e8ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_209daaaa-32e0-4f93-a525-d294b04a9e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a9605edf-c8b3-48c9-a8c5-d2a23c2e8ff8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_209daaaa-32e0-4f93-a525-d294b04a9e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_10ba278f-6905-4902-969d-e57a006815fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_209daaaa-32e0-4f93-a525-d294b04a9e37" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_10ba278f-6905-4902-969d-e57a006815fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0dfc097-f6c9-4598-a20e-b37b485d4279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e480b8d-30e8-4e5a-b166-96958ee21cc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0dfc097-f6c9-4598-a20e-b37b485d4279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0dfc097-f6c9-4598-a20e-b37b485d4279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ef8af0e-b3b4-41dc-b311-fff2d2b220ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ef8af0e-b3b4-41dc-b311-fff2d2b220ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0e2f9f06-1140-4b9e-8dca-eaeeea123ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0e2f9f06-1140-4b9e-8dca-eaeeea123ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b3af0c5-f6d9-45ce-98ff-5515c439a674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b3af0c5-f6d9-45ce-98ff-5515c439a674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_66587320-f2c8-4b1b-a44a-baad9c9f30d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_66587320-f2c8-4b1b-a44a-baad9c9f30d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_972a4c34-270e-4d5a-9492-327942392378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a4b5ecc3-f7e3-40c3-81f0-0a9d903313e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_972a4c34-270e-4d5a-9492-327942392378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0dfc097-f6c9-4598-a20e-b37b485d4279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_22f2a325-ed6a-418c-a6e8-6d2d9ba39dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_22f2a325-ed6a-418c-a6e8-6d2d9ba39dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cf570035-75a5-44ad-ab78-c1bf139c3031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cf570035-75a5-44ad-ab78-c1bf139c3031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9e8aa8b4-ce91-4fdf-9a4d-3bce34dd599e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9e8aa8b4-ce91-4fdf-9a4d-3bce34dd599e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f2d9cd76-211a-44bb-9e31-44cb33574b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f2d9cd76-211a-44bb-9e31-44cb33574b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9f22dc02-314a-4560-bdef-224356da392c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37373ca4-fdea-49b6-badd-29c7c8ff0911" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9f22dc02-314a-4560-bdef-224356da392c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a8a5fc2-ff69-4582-aee5-42b4480affd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c7498787-ce17-4bb9-9a18-687aa7ca6fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a8a5fc2-ff69-4582-aee5-42b4480affd1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c7498787-ce17-4bb9-9a18-687aa7ca6fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5ec40fee-c80b-413a-8243-bfecfce727f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c7498787-ce17-4bb9-9a18-687aa7ca6fd7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5ec40fee-c80b-413a-8243-bfecfce727f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0f2387ef-ae80-4a3d-9664-087bc18ebdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5ec40fee-c80b-413a-8243-bfecfce727f9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0f2387ef-ae80-4a3d-9664-087bc18ebdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfMolecularDiagnosticTestingMember_7a66bd84-2413-449b-b33e-7ce89c118561" xlink:href="mygn-20220331.xsd#mygn_CostOfMolecularDiagnosticTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f2387ef-ae80-4a3d-9664-087bc18ebdcd" xlink:to="loc_mygn_CostOfMolecularDiagnosticTestingMember_7a66bd84-2413-449b-b33e-7ce89c118561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember_47175ac2-fa03-4c2a-b0a6-529fecc4879e" xlink:href="mygn-20220331.xsd#mygn_CostOfPharmaceuticalAndClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f2387ef-ae80-4a3d-9664-087bc18ebdcd" xlink:to="loc_mygn_CostOfPharmaceuticalAndClinicalServicesMember_47175ac2-fa03-4c2a-b0a6-529fecc4879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5c7d7c5b-3743-42b2-998f-37daa9f3c250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f2387ef-ae80-4a3d-9664-087bc18ebdcd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5c7d7c5b-3743-42b2-998f-37daa9f3c250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_043dad85-5401-4130-a758-531c6b82100d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f2387ef-ae80-4a3d-9664-087bc18ebdcd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_043dad85-5401-4130-a758-531c6b82100d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_582a0bf7-cf56-47a2-bad8-9ea48fc7fced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c7498787-ce17-4bb9-9a18-687aa7ca6fd7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_582a0bf7-cf56-47a2-bad8-9ea48fc7fced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a4c4efae-29b8-4a70-9c39-93d9e8a75c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_582a0bf7-cf56-47a2-bad8-9ea48fc7fced" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a4c4efae-29b8-4a70-9c39-93d9e8a75c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mygn-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_45eeab28-377d-4417-9e59-54061ab60c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f673181d-4bda-4e0b-acfd-e738739ee3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_45eeab28-377d-4417-9e59-54061ab60c0e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f673181d-4bda-4e0b-acfd-e738739ee3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_269f2156-0b6d-494e-9a66-08b8ca0e9727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_25c513c6-5421-4619-bc44-63c7f9703882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_269f2156-0b6d-494e-9a66-08b8ca0e9727" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_25c513c6-5421-4619-bc44-63c7f9703882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2beee6e3-fbe2-4ac9-8bb3-451a642fcc40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_25c513c6-5421-4619-bc44-63c7f9703882" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2beee6e3-fbe2-4ac9-8bb3-451a642fcc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_bb2cf8a6-6816-4d0e-940a-9b87d8d7fde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2beee6e3-fbe2-4ac9-8bb3-451a642fcc40" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_bb2cf8a6-6816-4d0e-940a-9b87d8d7fde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f4f1e534-53e1-41cc-ab0c-ef7531616425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bb2cf8a6-6816-4d0e-940a-9b87d8d7fde8" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f4f1e534-53e1-41cc-ab0c-ef7531616425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_2d5f76de-30f7-491b-b525-21aa16fd4a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bb2cf8a6-6816-4d0e-940a-9b87d8d7fde8" xlink:to="loc_us-gaap_ForeignCountryMember_2d5f76de-30f7-491b-b525-21aa16fd4a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_b403f7c7-6156-4269-ac50-f20ef146be79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_25c513c6-5421-4619-bc44-63c7f9703882" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_b403f7c7-6156-4269-ac50-f20ef146be79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_e444a5b7-63c4-4ead-a35f-d3d1a2adea2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_b403f7c7-6156-4269-ac50-f20ef146be79" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_e444a5b7-63c4-4ead-a35f-d3d1a2adea2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_1c20820b-edf0-47df-af6a-0abe420b9ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_e444a5b7-63c4-4ead-a35f-d3d1a2adea2e" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_1c20820b-edf0-47df-af6a-0abe420b9ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_ce351d7c-d18e-44d4-9105-2756b9d3bb66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_e444a5b7-63c4-4ead-a35f-d3d1a2adea2e" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_ce351d7c-d18e-44d4-9105-2756b9d3bb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_79ebe458-803f-41d5-9908-199ff804a85c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_e444a5b7-63c4-4ead-a35f-d3d1a2adea2e" xlink:to="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_79ebe458-803f-41d5-9908-199ff804a85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_c665186d-413f-4467-a2b0-7872200bfe3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_25c513c6-5421-4619-bc44-63c7f9703882" xlink:to="loc_us-gaap_TaxPeriodAxis_c665186d-413f-4467-a2b0-7872200bfe3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_20ae63e9-98f4-4525-aed3-fac0bd468e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_c665186d-413f-4467-a2b0-7872200bfe3a" xlink:to="loc_us-gaap_TaxPeriodDomain_20ae63e9-98f4-4525-aed3-fac0bd468e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember_bec0f2af-4374-4b98-9e3b-021516dd9637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_20ae63e9-98f4-4525-aed3-fac0bd468e80" xlink:to="loc_us-gaap_EarliestTaxYearMember_bec0f2af-4374-4b98-9e3b-021516dd9637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember_e83ba632-609c-42ce-afbc-9ed298b3ef65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_20ae63e9-98f4-4525-aed3-fac0bd468e80" xlink:to="loc_us-gaap_LatestTaxYearMember_e83ba632-609c-42ce-afbc-9ed298b3ef65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_3355324b-79f0-4a82-b6f6-6c50afb5b78f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_25c513c6-5421-4619-bc44-63c7f9703882" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_3355324b-79f0-4a82-b6f6-6c50afb5b78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_32b2c18e-2004-4e8e-8fcd-041f12fce962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3355324b-79f0-4a82-b6f6-6c50afb5b78f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_32b2c18e-2004-4e8e-8fcd-041f12fce962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7bdfe63f-03bf-4764-bb80-ade0c3f0d680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3355324b-79f0-4a82-b6f6-6c50afb5b78f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7bdfe63f-03bf-4764-bb80-ade0c3f0d680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_90731fa1-4e9c-46d1-984f-8b667ca6e04b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3355324b-79f0-4a82-b6f6-6c50afb5b78f" xlink:to="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_90731fa1-4e9c-46d1-984f-8b667ca6e04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mygn-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a554def9-19e2-49cf-b08f-1e5b68839994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b9ab85e1-346a-401a-bb9a-d8ad098430c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a554def9-19e2-49cf-b08f-1e5b68839994" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b9ab85e1-346a-401a-bb9a-d8ad098430c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ca8998ca-9dda-4587-a726-377a723723b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b5c765b2-e96e-4eb5-9e78-6331fc9244f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ca8998ca-9dda-4587-a726-377a723723b0" xlink:to="loc_us-gaap_LossContingenciesTable_b5c765b2-e96e-4eb5-9e78-6331fc9244f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_28430a24-dc19-4acf-b1b9-7b50b80a0bfc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b5c765b2-e96e-4eb5-9e78-6331fc9244f1" xlink:to="loc_srt_LitigationCaseAxis_28430a24-dc19-4acf-b1b9-7b50b80a0bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4fba1d05-8721-4f5f-99ae-158d8a9c2961" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_28430a24-dc19-4acf-b1b9-7b50b80a0bfc" xlink:to="loc_srt_LitigationCaseTypeDomain_4fba1d05-8721-4f5f-99ae-158d8a9c2961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CBICIFPASettlementMember_f9e437d0-8e56-4777-a41f-0a811316872c" xlink:href="mygn-20220331.xsd#mygn_CBICIFPASettlementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4fba1d05-8721-4f5f-99ae-158d8a9c2961" xlink:to="loc_mygn_CBICIFPASettlementMember_f9e437d0-8e56-4777-a41f-0a811316872c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c681e9f8-2272-44cc-a39b-d43d27aea684" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b5c765b2-e96e-4eb5-9e78-6331fc9244f1" xlink:to="loc_srt_CounterpartyNameAxis_c681e9f8-2272-44cc-a39b-d43d27aea684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9af4699a-2ad7-4b60-a740-785bea6766f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c681e9f8-2272-44cc-a39b-d43d27aea684" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9af4699a-2ad7-4b60-a740-785bea6766f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_UnitedStatesAndStateOfCaliforniaMember_fd4c12fc-422a-408c-931a-a48211e4645d" xlink:href="mygn-20220331.xsd#mygn_UnitedStatesAndStateOfCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9af4699a-2ad7-4b60-a740-785bea6766f5" xlink:to="loc_mygn_UnitedStatesAndStateOfCaliforniaMember_fd4c12fc-422a-408c-931a-a48211e4645d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RelatorMember_c13e6afa-1622-43a2-86f2-11321b726892" xlink:href="mygn-20220331.xsd#mygn_RelatorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9af4699a-2ad7-4b60-a740-785bea6766f5" xlink:to="loc_mygn_RelatorMember_c13e6afa-1622-43a2-86f2-11321b726892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_63e5dd60-745d-4b76-9793-4c26d10abb68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b5c765b2-e96e-4eb5-9e78-6331fc9244f1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_63e5dd60-745d-4b76-9793-4c26d10abb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_feaedf0a-d940-4f80-93b4-6a254bad5003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_63e5dd60-745d-4b76-9793-4c26d10abb68" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_feaedf0a-d940-4f80-93b4-6a254bad5003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cf63e308-19ad-4f3c-b87d-23efb7e85920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_feaedf0a-d940-4f80-93b4-6a254bad5003" xlink:to="loc_us-gaap_SubsequentEventMember_cf63e308-19ad-4f3c-b87d-23efb7e85920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5ccedaad-2413-425d-b703-a1da0e44e13f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b5c765b2-e96e-4eb5-9e78-6331fc9244f1" xlink:to="loc_us-gaap_LossContingenciesLineItems_5ccedaad-2413-425d-b703-a1da0e44e13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_4c9ad2c9-3b0d-4d9a-81f0-3ba19a0a0604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5ccedaad-2413-425d-b703-a1da0e44e13f" xlink:to="loc_us-gaap_LitigationReserveCurrent_4c9ad2c9-3b0d-4d9a-81f0-3ba19a0a0604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a8c57847-d6dd-4a91-b4c0-f512826045a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5ccedaad-2413-425d-b703-a1da0e44e13f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a8c57847-d6dd-4a91-b4c0-f512826045a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="mygn-20220331.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_b70e6ff1-ef74-4930-8d0f-bf39e6358c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_5df87f57-d4d1-4d06-99bd-b824ed57f2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_b70e6ff1-ef74-4930-8d0f-bf39e6358c3e" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_5df87f57-d4d1-4d06-99bd-b824ed57f2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="mygn-20220331.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_e3c9bbd7-0eb3-43da-88bf-d7c301a8745b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_b48928ff-fc08-447e-8cae-0ec9deb6870d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_e3c9bbd7-0eb3-43da-88bf-d7c301a8745b" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_b48928ff-fc08-447e-8cae-0ec9deb6870d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_900a4cb8-4ca3-4eb6-ae8b-59a7dda19458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_30902b7c-c1bc-4bc3-9909-f2df50879bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_900a4cb8-4ca3-4eb6-ae8b-59a7dda19458" xlink:to="loc_us-gaap_IncomeTaxesPaid_30902b7c-c1bc-4bc3-9909-f2df50879bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b9864c76-7232-46bb-bc91-cdb9cf8b114d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_900a4cb8-4ca3-4eb6-ae8b-59a7dda19458" xlink:to="loc_us-gaap_InterestPaidNet_b9864c76-7232-46bb-bc91-cdb9cf8b114d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_84483b41-8e36-4648-9015-fbdab66d416f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_900a4cb8-4ca3-4eb6-ae8b-59a7dda19458" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_84483b41-8e36-4648-9015-fbdab66d416f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d7fe0b4d-6acb-48c3-bd93-30cd774a9ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_84483b41-8e36-4648-9015-fbdab66d416f" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d7fe0b4d-6acb-48c3-bd93-30cd774a9ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityEstablished_12a718c2-5331-49ac-bac0-580d0e71609f" xlink:href="mygn-20220331.xsd#mygn_OperatingLeaseLiabilityEstablished"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_84483b41-8e36-4648-9015-fbdab66d416f" xlink:to="loc_mygn_OperatingLeaseLiabilityEstablished_12a718c2-5331-49ac-bac0-580d0e71609f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3be60c7f-78e6-4764-9911-badcf9ef9893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_900a4cb8-4ca3-4eb6-ae8b-59a7dda19458" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3be60c7f-78e6-4764-9911-badcf9ef9893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/Leases" xlink:type="simple" xlink:href="mygn-20220331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5e79987c-949b-482d-abe9-fe4e7a4028d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_358c5e83-dc6e-4f9c-a4fc-eb0c3819de0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5e79987c-949b-482d-abe9-fe4e7a4028d4" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_358c5e83-dc6e-4f9c-a4fc-eb0c3819de0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#LeasesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5b17530c-0e51-437f-9841-2b019c3fefeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b2d4b07c-4c85-4f68-b32e-4f4d85ecfe8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5b17530c-0e51-437f-9841-2b019c3fefeb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b2d4b07c-4c85-4f68-b32e-4f4d85ecfe8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementAxis_a5bd0b7a-df02-4516-bebf-c8dc06619457" xlink:href="mygn-20220331.xsd#mygn_LeaseArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b2d4b07c-4c85-4f68-b32e-4f4d85ecfe8f" xlink:to="loc_mygn_LeaseArrangementAxis_a5bd0b7a-df02-4516-bebf-c8dc06619457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain_d29cf244-de2a-4666-a7d7-78eb1e187c30" xlink:href="mygn-20220331.xsd#mygn_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_LeaseArrangementAxis_a5bd0b7a-df02-4516-bebf-c8dc06619457" xlink:to="loc_mygn_LeaseArrangementDomain_d29cf244-de2a-4666-a7d7-78eb1e187c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_WestSaltLakeCityLeaseMember_9aeab01d-17ac-480a-852b-fa14d19bfc88" xlink:href="mygn-20220331.xsd#mygn_WestSaltLakeCityLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_LeaseArrangementDomain_d29cf244-de2a-4666-a7d7-78eb1e187c30" xlink:to="loc_mygn_WestSaltLakeCityLeaseMember_9aeab01d-17ac-480a-852b-fa14d19bfc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d721179-4bc4-43ea-8f43-23d820d5095d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b2d4b07c-4c85-4f68-b32e-4f4d85ecfe8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d721179-4bc4-43ea-8f43-23d820d5095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_945fecf5-cc6e-411f-a3ae-e967a0987434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d721179-4bc4-43ea-8f43-23d820d5095d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_945fecf5-cc6e-411f-a3ae-e967a0987434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bcc60063-4f1e-4134-9c4c-242b7bfcb527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_945fecf5-cc6e-411f-a3ae-e967a0987434" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bcc60063-4f1e-4134-9c4c-242b7bfcb527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b2d4b07c-4c85-4f68-b32e-4f4d85ecfe8f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_6cafbd91-052e-46c9-be83-4d483e6fb007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_6cafbd91-052e-46c9-be83-4d483e6fb007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_e161b9a8-8d22-4e99-b365-bcefb1e281f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_e161b9a8-8d22-4e99-b365-bcefb1e281f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_d6ee78a3-10b9-482c-895a-04c33e51af64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_us-gaap_AssetImpairmentCharges_d6ee78a3-10b9-482c-895a-04c33e51af64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_87aa046e-0e74-4d51-b852-bc2770a5a777" xlink:href="mygn-20220331.xsd#mygn_LesseeOperatingLeaseAreaOfLeasedSpace"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_mygn_LesseeOperatingLeaseAreaOfLeasedSpace_87aa046e-0e74-4d51-b852-bc2770a5a777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_26883f72-91c8-4a8a-b3a6-17df10a70850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_26883f72-91c8-4a8a-b3a6-17df10a70850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LesseeOperatingLeaseExpectedFutureRentPayments_19a91448-14d7-4eac-9177-4110ac89019e" xlink:href="mygn-20220331.xsd#mygn_LesseeOperatingLeaseExpectedFutureRentPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f9aeb3d1-2245-4c80-a8b7-91729b1ab901" xlink:to="loc_mygn_LesseeOperatingLeaseExpectedFutureRentPayments_19a91448-14d7-4eac-9177-4110ac89019e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mygn-20220331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_37ba67cd-f469-4f99-a93d-e3d81303a9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_876b1fc9-f3da-4b20-bb69-508b14e7ae25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_37ba67cd-f469-4f99-a93d-e3d81303a9b3" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_876b1fc9-f3da-4b20-bb69-508b14e7ae25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mygn-20220331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_4761cd83-48fb-41aa-8afd-433ff38f9947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_6d1284f5-3650-46c9-ab1f-111fcffd320c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_4761cd83-48fb-41aa-8afd-433ff38f9947" xlink:to="loc_us-gaap_SubsequentEventTable_6d1284f5-3650-46c9-ab1f-111fcffd320c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bf30f504-4033-4643-a835-5a983ce09232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6d1284f5-3650-46c9-ab1f-111fcffd320c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bf30f504-4033-4643-a835-5a983ce09232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_85625cae-f930-4749-be9b-8f8051e85fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bf30f504-4033-4643-a835-5a983ce09232" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_85625cae-f930-4749-be9b-8f8051e85fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3d4d7fa4-f616-40db-af09-d55d03404aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_85625cae-f930-4749-be9b-8f8051e85fa8" xlink:to="loc_us-gaap_SubsequentEventMember_3d4d7fa4-f616-40db-af09-d55d03404aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_64628f6d-3090-415a-9f03-3374a4a638f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6d1284f5-3650-46c9-ab1f-111fcffd320c" xlink:to="loc_srt_CounterpartyNameAxis_64628f6d-3090-415a-9f03-3374a4a638f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7f99fe0-063b-4dfc-ace3-81ca67703cbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_64628f6d-3090-415a-9f03-3374a4a638f5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7f99fe0-063b-4dfc-ace3-81ca67703cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_UnitedStatesAndStateOfCaliforniaMember_91dd668d-f7a7-4520-a2e1-863230d7e00e" xlink:href="mygn-20220331.xsd#mygn_UnitedStatesAndStateOfCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7f99fe0-063b-4dfc-ace3-81ca67703cbf" xlink:to="loc_mygn_UnitedStatesAndStateOfCaliforniaMember_91dd668d-f7a7-4520-a2e1-863230d7e00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RelatorMember_a1f66663-d3e6-4943-b188-7f9678e6c7fc" xlink:href="mygn-20220331.xsd#mygn_RelatorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7f99fe0-063b-4dfc-ace3-81ca67703cbf" xlink:to="loc_mygn_RelatorMember_a1f66663-d3e6-4943-b188-7f9678e6c7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4cca4c86-144c-435f-b968-45fa4c7b8f6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6d1284f5-3650-46c9-ab1f-111fcffd320c" xlink:to="loc_srt_LitigationCaseAxis_4cca4c86-144c-435f-b968-45fa4c7b8f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_240c5d35-fe25-46c1-addb-604620237054" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_4cca4c86-144c-435f-b968-45fa4c7b8f6b" xlink:to="loc_srt_LitigationCaseTypeDomain_240c5d35-fe25-46c1-addb-604620237054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CBICIFPASettlementMember_50ed57b3-abc9-4cd5-b452-e1ab9766f243" xlink:href="mygn-20220331.xsd#mygn_CBICIFPASettlementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_240c5d35-fe25-46c1-addb-604620237054" xlink:to="loc_mygn_CBICIFPASettlementMember_50ed57b3-abc9-4cd5-b452-e1ab9766f243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_34da9552-7165-4b03-912e-fcfc07fb1ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6d1284f5-3650-46c9-ab1f-111fcffd320c" xlink:to="loc_us-gaap_SubsequentEventLineItems_34da9552-7165-4b03-912e-fcfc07fb1ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_0e0540f7-2660-49b1-89f8-55f1dd6c7546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_34da9552-7165-4b03-912e-fcfc07fb1ad0" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_0e0540f7-2660-49b1-89f8-55f1dd6c7546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725395724680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-26642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MYRIAD GENETICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000899923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0494517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">320 Wakara Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt Lake City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">584-3600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MYGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,343,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725398384024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 165.2<span></span>
</td>
<td class="nump">$ 258.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable investment securities</a></td>
<td class="nump">103.2<span></span>
</td>
<td class="nump">81.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable</a></td>
<td class="nump">101.7<span></span>
</td>
<td class="nump">91.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">15.6<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">22.9<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">427.4<span></span>
</td>
<td class="nump">484.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">70.9<span></span>
</td>
<td class="nump">81.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable investment securities</a></td>
<td class="nump">70.8<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">45.7<span></span>
</td>
<td class="nump">43.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">393.6<span></span>
</td>
<td class="nump">404.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">238.8<span></span>
</td>
<td class="nump">239.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">8.2<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,255.4<span></span>
</td>
<td class="nump">1,320.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">27.1<span></span>
</td>
<td class="nump">29.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">124.8<span></span>
</td>
<td class="nump">156.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating lease liabilities</a></td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">166.0<span></span>
</td>
<td class="nump">204.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">28.0<span></span>
</td>
<td class="nump">27.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Long-term deferred taxes</a></td>
<td class="nump">29.9<span></span>
</td>
<td class="nump">35.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">76.5<span></span>
</td>
<td class="nump">79.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">305.3<span></span>
</td>
<td class="nump">352.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, 80.3 million and 80.0 million shares outstanding at March&#160;31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,231.6<span></span>
</td>
<td class="nump">1,226.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(7.6)<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(274.7)<span></span>
</td>
<td class="num">(254.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Myriad Genetics, Inc. stockholders&#8217; equity</a></td>
<td class="nump">950.1<span></span>
</td>
<td class="nump">967.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">950.1<span></span>
</td>
<td class="nump">967.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,255.4<span></span>
</td>
<td class="nump">$ 1,320.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725404230584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">80.3<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">76.7<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402886616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 164.9<span></span>
</td>
<td class="nump">$ 173.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="nump">110.6<span></span>
</td>
<td class="nump">146.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Goodwill and long-lived asset impairment charges</a></td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">190.5<span></span>
</td>
<td class="nump">219.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(25.6)<span></span>
</td>
<td class="num">(46.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(26.4)<span></span>
</td>
<td class="num">(49.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(5.9)<span></span>
</td>
<td class="num">(10.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(20.5)<span></span>
</td>
<td class="num">(39.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="num">$ (20.5)<span></span>
</td>
<td class="num">$ (39.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">80.1<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">80.1<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember', window );">Molecular diagnostic testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 164.9<span></span>
</td>
<td class="nump">$ 159.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">48.0<span></span>
</td>
<td class="nump">44.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember', window );">Pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725395708744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="num">$ (20.5)<span></span>
</td>
<td class="num">$ (39.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale debt securities, net of tax</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Change in foreign currency translation adjustment, net of tax</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(23.0)<span></span>
</td>
<td class="num">(40.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="num">$ (23.0)<span></span>
</td>
<td class="num">$ (40.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725398368440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 881.0<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1,109.5<span></span>
</td>
<td class="num">$ (2.3)<span></span>
</td>
<td class="num">$ (227.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="nump">26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(39.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">875.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,144.5<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="num">(266.5)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">967.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,226.3<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(254.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(20.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 950.1<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1,231.6<span></span>
</td>
<td class="num">$ (7.6)<span></span>
</td>
<td class="num">$ (274.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725399285384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="num">$ (20.5)<span></span>
</td>
<td class="num">$ (39.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(5.9)<span></span>
</td>
<td class="num">(11.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of goodwill and long-lived assets</a></td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="num">(10.5)<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">90.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3.2)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(35.3)<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="num">(4.5)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(46.5)<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(6.3)<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable investment securities</a></td>
<td class="num">(52.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities and sales of marketable investment securities</a></td>
<td class="nump">17.1<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(41.3)<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of tax withheld for common stock issued under stock-based compensation plans</a></td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration recognized at acquisition</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Fees associated with refinancing of revolving credit facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of revolving credit facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(70.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">(48.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(93.2)<span></span>
</td>
<td class="nump">31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">258.4<span></span>
</td>
<td class="nump">117.0<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">$ 165.2<span></span>
</td>
<td class="nump">$ 148.9<span></span>
</td>
<td class="nump">$ 258.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncreaseDecreaseInUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401864600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text">BASIS OF PRESENTATION<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad Genetics, Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;Myriad&#8221;) is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad develops and commercializes genetic tests that help assess the risk of developing disease or disease progression or guide treatment decisions across medical specialties.  The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021, by providing pharmaceutical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company currently operates as a single reporting segment. The Company&#8217;s corporate headquarters are located in Salt Lake City, Utah.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company&#8217;s audited Consolidated Financial Statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;Form 10-K&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three months ended March&#160;31, 2022 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically experienced seasonality in its testing business. In the quarters ended March 31, the Company has  typically experienced a decrease in volumes due to the annual reset of patient deductibles. Additionally, the volume of testing is  negatively impacted by the summer season, which is generally reflected in the quarter ended September 30th. The quarter ended December 31 is generally strong as the Company typically experiences an increase in volumes from patients who have met their annual insurance deductible. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the ongoing COVID-19 global pandemic, including variants of COVID-19 (&#8220;COVID-19&#8221;), seasonality may not follow the same pattern as in prior years. Volumes and results of operations were impacted negatively in calendar year 2021 and early 2022 by COVID-19. As such, the Company&#8217;s year over year results may not be comparable. Management continues to monitor the impact of COVID-19 on the Company&#8217;s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the variants of COVID-19 that have surfaced around the world, the Company is not able to fully estimate the effects of COVID-19 on its results of operations, financial condition, or liquidity for future periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period's presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders&#8217; equity, cash flows from operations, or net loss for the period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402089912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">REVENUE<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad primarily generates revenue by performing molecular diagnostic testing. Molecular diagnostic revenues are derived from the following categories of products: Hereditary Cancer (myRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, EndoPredict, and Precise), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp; Co. KG (the &#8220;Clinic&#8221;) in February 2020, respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Molecular diagnostic revenues. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents detail regarding the composition of the Company&#8217;s total revenue by type and by U.S. versus rest of world (&#8220;RoW&#8221;):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company&#8217;s performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During the fiscal year ended June 30, 2020, the Company received approximately $29.7 million in advance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments were applied against services performed in April 2021 and continued until the funds previously received were fully earned, which occurred during the quarter ended March 31, 2022. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue - beginning balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue - ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 606, Revenue from Contracts with Customers, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#8217;s right to payment is in an amount that directly corresponds with the value of the Company&#8217;s performance to date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third party payors. During the three months ended March 31, 2022, the Company recognized $12.4 million in revenue, which resulted in a $0.12 impact to earnings per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare which represents greater than 10% of its revenues. Revenues received from Medicare represented 13% and 19% of total revenue for the three months ended March&#160;31, 2022 and March&#160;31, 2021, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#8217;s customers as well as their dispersion across many geographic regions. No payor accounted for more than 10% of accounts receivable at March&#160;31, 2022 or December&#160;31, 2021. The Company does not require collateral from its customers.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401963688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Investment Securities</a></td>
<td class="text">MARKETABLE INVESTMENT SECURITIES<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">398.9&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">398.8&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at March&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information relating to fair value of marketable investment securities can be found in Note 4.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402977560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;&#160;Some of the Company&#8217;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;unobservable inputs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability.&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement period of approximately 13.3 years, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business.&#160;The contingent earn-out liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company&#8217;s Condensed Consolidated Balance Sheets.&#160;&#160;Changes to contingent consideration liabilities are reflected in Selling, general and administrative expense in the Company&#8217;s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.6)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.6)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value recognized in the Statement of Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translation adjustments recognized in Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402055848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment, Net</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT, NET<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(103.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(106.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.5&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company ceased the use of one of its leased Salt Lake City facilities. As a result, the Company recognized a $2.1 million impairment on the property, plant and equipment associated with the lease, which consisted primarily of leasehold improvements. See Note 15 for further discussion.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401975480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill for the three months ended March&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consists of purchased licenses and technologies. The following summarizes the amounts reported as intangible assets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">616.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(222.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">616.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(222.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">616.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(212.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">404.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">616.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(212.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">404.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization expense during the respective periods for these intangible assets as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402085848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">ACCRUED LIABILITIES<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal charges pending settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds payable and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725407696312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">LONG-TERM DEBT<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2016, the Company entered into a senior secured revolving credit facility (the &#8220;Facility&#8221;) as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 to the Facility, which effected an &#8220;amend and extend&#8221; transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million.&#160;On May 1, 2020, the Company entered into Amendment No. 2 to the Facility, which waived the Company&#8217;s compliance with certain covenants and modified the interest rate and other terms during the modification period from March 31, 2020 through June 30, 2021 (&#8220;Modification Period&#8221;). This included a modification to the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021, as well as revision to certain negative covenants of the Amended Facility during the Modification Period. On February 22, 2021, the Company entered into Amendment No. 3 (the &#8220;Amended Facility&#8221;), which waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ended March 31, 2022 and also lowered the minimum liquidity covenant, which was added by Amendment No. 2, to $150.0&#160;million, and made it applicable through such quarter. Amendment No. 3 also restricted the Company from borrowing under the Amended Facility if unrestricted cash, cash equivalents and marketable investment securities exceed $150.0&#160;million, unless such borrowings are in connection with permitted acquisitions, decreased the maximum aggregate principal commitment from $350.0&#160;million to $300.0&#160;million, with a further reduction in the maximum aggregate principal commitment from $300.0&#160;million to $250.0&#160;million by September 30, 2021, extended the Modification Period for an additional year through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company&#8217;s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company&#8217;s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. The Company was in compliance with all applicable financial covenants at March&#160;31, 2022. It is possible that the Company could be in violation of certain financial covenants contained in the Amended Facility in the future. If the Company is unable to comply with certain covenants and ratios in the Amended Facility, the Company may be in default under the Amended Facility, which could impact the Company's ability to borrow under the facility or result in the termination of the commitments under the Amended Facility or the Company being required to pay off any outstanding loans or fees and cash collateralize any outstanding letters of credit. In the future, the Company may seek waivers or amendments from lenders in order to avoid a future covenant violation, in addition to taking other potential actions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Amended Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balances and the undrawn fee was increased to 50 basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR plus 150-250 basis points on drawn balances and an undrawn fee ranging from 25 to 45 basis points, in each case, based on the Company's leverage ratio. The LIBOR floor was also increased to 1.0% during the Modification Period. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company made principal repayments totaling $226.4&#160;million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had no outstanding balances under the Amended Facility as of March 31, 2022 and December 31, 2021. The Company's maximum aggregate principal commitment on its Amended Facility is $250.0&#160;million as of March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725406643928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Long-Term Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Long-Term Liabilities</a></td>
<td class="text">OTHER LONG-TERM LIABILITIES<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The Company's balance of other long-term liabilities as of March&#160;31, 2022 and December&#160;31, 2021 consists primarily of the long-term portion of contingent consideration related to the acquisition of Sividon Diagnostics.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401993240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Preferred and Common Stockholders' Equity</a></td>
<td class="text">PREFERRED AND COMMON STOCKHOLDERS' EQUITY<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at March&#160;31, 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 80.3 million shares issued and outstanding at March&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common shares issued and outstanding</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued and outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share (&#8220;EPS&#8221;) computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive shares</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain outstanding options and restricted stock units (&#8220;RSUs&#8221;) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.453%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s Board of Directors authorized a share repurchase program of $200.0 million of the Company&#8217;s outstanding common stock. The Company may repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company's management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of March&#160;31, 2022, the Company has $110.7 million remaining under its current share repurchase authorization. No shares were repurchased during the three months ended March 31, 2022 or 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401905432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2017, the Company&#8217;s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the &#8220;2017 Plan&#8221;). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants, and directors. Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant.  As of March&#160;31, 2022, the Company has 2.0&#160;million shares of common stock available for grant under the 2017 Plan.  If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they also will be available for issuance pursuant to the 2017 Plan. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares, terms, and vesting periods are generally determined by the Company&#8217;s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over four years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of performance-based RSUs ("PSUs") awarded to certain employees may be increased or may be reduced based on certain additional performance and market metrics. Options and RSUs granted to non-employee directors vest in full upon the earlier of the completion of one year of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options granted generally expire ten years from the date of grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire seven years from the grant date.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance and market conditions associated with PSU awards granted during the quarter ended March 31, 2022 include vesting that is based on revenue growth targets (34% weighting), adjusted earnings per share targets (33% weighting), and relative total stockholder return (33% weighting) measured against the Nasdaq Health Care Index (IXHC) using the 20-trading day averages at the beginning and end of the measurement period. The measurement period for the PSUs is January 1, 2022 through December 31, 2024. The Company estimates the likelihood of achievement of performance conditions at the end of each period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company&#8217;s equity plans and inducement awards, for the three months ended March&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there was $2.0 million of total unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of 1.8 years. There were no options granted during the three months ended March 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU awards activity under the Company&#8217;s equity plans and inducement awards, including RSU awards with performance metrics, for the three months ended March&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.96&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs canceled</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.26&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at March 31, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there was $90.8 million of total unrecognized stock-based compensation expense related to RSUs that will be recognized over a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weighted-average period of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2.7 years.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the &#8220;2012 Purchase Plan&#8221;), under which 2.0 million shares of common stock have been authorized.&#160;&#160;On September 23, 2021, the Board of Directors of the Company approved an Amended and Restated 2012 Employee Stock Purchase Plan, which authorizes an additional 2.0&#160;million shares of common stock and extends the term of the 2012 Purchase Plan to November 30, 2032, subject in each case to obtaining stockholder approval. The Company is seeking stockholder approval of the Amended and Restated 2012 Employee Stock Purchase Plan at its 2022 Annual Meeting of Stockholders to be held on June 2, 2022. The Amended and Restated 2012 Employee Stock Purchase Plan also amended certain provisions of the 2012 Purchase Plan effective upon approval by the Board of Directors, including expanding the definition of "offering period" to provide that the Board of Directors may determine the period in accordance with the terms of the plan, and capping the number of shares that may be purchased by any participant during an offering period at 5,000 shares. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period.&#160;As of March&#160;31, 2022, a total of approximately 2.0&#160;million shares of common stock had been purchased under the 2012 Purchase Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401949416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the Company&#8217;s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates.&#160;Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit for the three months ended March&#160;31, 2022 was $5.9 million, or approximately 22.3% of pre-tax income compared to an income tax benefit of $10.1 million, or approximately 20.4% of pre-tax loss, for the three months ended March&#160;31, 2021.&#160;Income tax expense for the three months ended March&#160;31, 2022 is based on the Company&#8217;s estimated annualized effective tax rate for the fiscal year ending December 31, 2022, adjusted for discrete items recognized during the respective periods.&#160;&#160;For the three months ended March&#160;31, 2022, the Company&#8217;s recognized effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, stock compensation expenses, and asset impairment expenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations.&#160;&#160;The Company is currently under audit by the State of California for the fiscal years ended June 30, 2017-2018, the State of New Jersey for the fiscal years ended June 30, 2013-2017; and Switzerland for the fiscal years ended June 30, 2015-2016. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401977144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved from time to time in various disputes, claims and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amount of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company is involved, and has received subpoenas, from time to time, related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to vigorously defend its current litigation matters, but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the proceedings may be in early stages, there may be uncertainty as to the outcome of pending appeals or motions, there may be significant factual issues to be resolved, and there may be complex or novel legal theories to be presented. In addition, damages may not be specified or the damage amounts claimed may be unsupported, exaggerated or unrelated to possible outcomes, and therefore, such amounts are not a reliable indicator of potential liability. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as noted below, as of March 31, 2022, the Company has not recorded any accrual for loss contingencies associated with legal proceedings or other matters or determined that an unfavorable outcome is probable and reasonably estimable in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, it is possible that the ultimate resolution of legal proceedings or other matters, if unfavorable, may be material to the Company's results of operations, financial condition or cash flows.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qui Tam Lawsuit</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company's wholly owned subsidiary, Crescendo Bioscience, LLC (formerly known as Crescendo Biosciences, Inc. (&#8220;CBI&#8221;), received a subpoena from the Office of Inspector General of the Department of Health and Human Services (the "Office of Inspector General") requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act ("CIFPA").  On January 22, 2020, after a multi-year investigation into CBI&#8217;s and the Company&#8217;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company&#8217;s motion to dismiss. As of March 31, 2022, the Company has accrued $48.0 million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in accrued liabilities in the Company's Condensed Consolidated Balance Sheet as of March 31, 2022. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, the Company settled the qui tam lawsuit with the relator, STF, LLC (the "Relator"). Pursuant to the terms of the settlement agreements, the Company agreed to pay a total of $45.25&#160;million to the United States and the State of California and $2.75&#160;million to Relator&#8217;s counsel. The Relator agreed to the dismissal of the lawsuit with prejudice as to the Relator and fully released all claims against the defendants and their affiliates, directors, officers, and employees. The State of California agreed to the dismissal of the lawsuit with prejudice as to the State of California and released the defendants from any claims submitted to the State&#8217;s Medicaid program or under the CIFPA as a result of certain alleged conduct. The United States Department of Justice approved the settlement of federal claims, including dismissal of the lawsuit without prejudice as to the United States. The settlement agreements contain no admission of liability, wrongdoing or responsibility on the part of the defendants. The Company expressly denies any and all liability for claims alleged in the lawsuit. On May 4, 2022, the qui tam lawsuit was formally dismissed by the United States District Court for the Northern District of California.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Class Action</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2019, a class action complaint was filed in the United States District Court for the District of Utah against the Company, its former President and Chief Executive Officer, Mark C. Capone, and its Chief Financial Officer, R. Bryan Riggsbee (the &#8220;Defendants&#8221;). On February 21, 2020, the plaintiff filed an amended class action complaint, which added the Company's former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Myriad Genetics, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding the Company's business, operations, and acquisitions.  The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees. On March 16, 2021, the United States District Court for the District of Utah denied the Company's motion to dismiss. On December 1, 2021, the United States District Court for the District of Utah granted plaintiff's motion for class certification. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Derivative Actions</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's  former President and Chief Executive Officer, Mark C. Capone, its Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of its current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, a  stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and the Hickock stockholder derivative action. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2022, the Delaware Court of Chancery consolidated the Hickock and Kogus derivative actions and stayed the consolidated action. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, a stockholder derivative complaint was filed in the United States District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the United States District Court for the District of Delaware pending the resolution of the securities class action lawsuit. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Legal Matters</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2022, a purported class action lawsuit was filed against the Company in the United States District Court in the Northern District of California by Ashley Carroll. Plaintiff alleges, among other things, that the Company made false statements about the accuracy of its Prequel prenatal screening test. The complaint seeks unspecified monetary damages and injunctive relief. On April 1, 2022, the Company filed a motion to dismiss the lawsuit.</span></div>From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401919736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">SUPPLEMENTAL CASH FLOW INFORMATION<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid during the period for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property, plant and equipment in accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401975480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from one to fourteen years. During the quarter ended March 31, 2022, in an effort to reduce its real estate footprint, the Company ceased the use of one of its leased Salt Lake City facilities. As a result, the Company recorded an impairment charge on right-of-use assets of $8.6 million and an impairment charge of $2.1 million on the related leasehold improvements. The total $10.7 million impairment is included in Goodwill and long-lived asset impairment charges in the Condensed Consolidated Statement of Operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022, we entered into a non-cancelable operating lease for approximately 230,000 square feet in west Salt Lake City, Utah. The lease has a term of 15 years, which, along with rent payments, are expected to commence in the third quarter of 2023. Total future rent payments under the lease is approximately $77.8&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401866440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTSAs previously noted, on April 1, 2022, the Company settled the qui tam lawsuit with the Relator. Pursuant to the terms of the settlement agreements, the Company agreed to pay a total of $45.25&#160;million to the United States and the State of California and $2.75&#160;million to Relator&#8217;s counsel. On April 7, 2022, the Company paid the settlement amounts in full. On May 4, 2022, the qui tam lawsuit was formally dismissed by the United States District Court for the Northern District of California.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725404164664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company&#8217;s audited Consolidated Financial Statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;Form 10-K&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three months ended March&#160;31, 2022 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period's presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders&#8217; equity, cash flows from operations, or net loss for the period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402105624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Total Revenue by Category and by U.S versus Rest of World</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents detail regarding the composition of the Company&#8217;s total revenue by type and by U.S. versus rest of world (&#8220;RoW&#8221;):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Reconciliation of Deferred Revenue Balances</a></td>
<td class="text">A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue - beginning balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue - ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402948328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">398.9&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">398.8&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at March&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402965976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2022</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.6)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.6)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Change in Fair Value of Contingent Consideration</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value recognized in the Statement of Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translation adjustments recognized in Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402086408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment, Net</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(103.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(106.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.5&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company ceased the use of one of its leased Salt Lake City facilities. As a result, the Company recognized a $2.1 million impairment on the property, plant and equipment associated with the lease, which consisted primarily of leasehold improvements. See Note 15 for further discussion.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725404144408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in Carrying Amount of Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill for the three months ended March&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Amortizable Intangible Assets</a></td>
<td class="text">The following summarizes the amounts reported as intangible assets:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">616.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(222.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">616.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(222.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">616.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(212.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">404.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">616.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(212.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">404.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Non-amortizable Intangible Assets</a></td>
<td class="text">The following summarizes the amounts reported as intangible assets:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">616.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(222.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">616.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(222.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">616.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(212.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">404.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">616.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(212.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">404.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Recorded Amortization Expense for Intangible Assets</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization expense during the respective periods for these intangible assets as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402968408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal charges pending settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds payable and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401955848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Long-Term Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Long-Term Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725405012872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Summary of Common Shares Issued and Outstanding</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common shares issued and outstanding</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued and outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share (&#8220;EPS&#8221;) computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive shares</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Common Shares</a></td>
<td class="text">These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.453%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725407692280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company&#8217;s equity plans and inducement awards, for the three months ended March&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU awards activity under the Company&#8217;s equity plans and inducement awards, including RSU awards with performance metrics, for the three months ended March&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.96&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs canceled</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.26&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at March 31, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725404149544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid during the period for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property, plant and equipment in accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725400557560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Total Revenue by Category and by US versus Rest of World (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 164.9<span></span>
</td>
<td class="nump">$ 173.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">141.7<span></span>
</td>
<td class="nump">154.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">23.2<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember', window );">Molecular diagnostic testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">164.9<span></span>
</td>
<td class="nump">159.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember', window );">Molecular diagnostic testing | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">141.7<span></span>
</td>
<td class="nump">141.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember', window );">Molecular diagnostic testing | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">23.2<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember', window );">Molecular diagnostic - Hereditary Cancer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">70.9<span></span>
</td>
<td class="nump">76.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember', window );">Molecular diagnostic - Hereditary Cancer | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">60.7<span></span>
</td>
<td class="nump">65.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember', window );">Molecular diagnostic - Hereditary Cancer | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember', window );">Molecular diagnostic - Tumor Profiling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">32.5<span></span>
</td>
<td class="nump">31.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember', window );">Molecular diagnostic - Tumor Profiling | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">19.7<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember', window );">Molecular diagnostic - Tumor Profiling | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">12.8<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember', window );">Molecular diagnostic - Prenatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">31.9<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember', window );">Molecular diagnostic - Prenatal | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">31.7<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember', window );">Molecular diagnostic - Prenatal | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember', window );">Molecular Diagnostic - Pharmacogenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">29.3<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember', window );">Molecular Diagnostic - Pharmacogenomics | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">29.3<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember', window );">Molecular Diagnostic - Pharmacogenomics | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember', window );">Molecular Diagnostic - Autoimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember', window );">Molecular Diagnostic - Autoimmune | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember', window );">Molecular Diagnostic - Autoimmune | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember', window );">Molecular diagnostic - Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember', window );">Molecular diagnostic - Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember', window );">Molecular diagnostic - Other | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember', window );">Pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember', window );">Pharmaceutical and clinical services | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember', window );">Pharmaceutical and clinical services | RoW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticHereditaryCancerTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticTumorProfilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPrenatalTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticPharmacogenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticAutoimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_MolecularDiagnosticOtherTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_PharmaceuticalAndClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725398371896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Reconciliation of Deferred Revenue Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Reconciliation of Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue - beginning balance</a></td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 32.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Revenue recognized</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_ContractWithCustomerLiabilityPrepayments', window );">Prepayments</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue - ending balance</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 31.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerLiabilityPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer, liability, prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerLiabilityPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725395666568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_CARESActOf2020MedicarePaymentAmount', window );">Advance Medicare payments to provide relief from economic impacts of COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments</a></td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Capitalized costs incurred to obtain or fulfill contract</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=mygn_PerformanceObligationEstimatedTransactionPriceMember', window );">Performance obligation estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Revenue and Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IncreaseDecreaseInEarningsLossPerShare', window );">Change in earnings per share (dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember', window );">Government contracts concentration risk | Medicare | Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Revenue and Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_CARESActOf2020MedicarePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act of 2020 Medicare payment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_CARESActOf2020MedicarePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncreaseDecreaseInEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in earnings (loss) per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncreaseDecreaseInEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=mygn_PerformanceObligationEstimatedTransactionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=mygn_PerformanceObligationEstimatedTransactionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mygn_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mygn_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725395233832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized cost</a></td>
<td class="nump">$ 165.2<span></span>
</td>
<td class="nump">$ 258.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Estimated fair value</a></td>
<td class="nump">165.2<span></span>
</td>
<td class="nump">258.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCashAbstract', window );"><strong>Total:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_InvestmentsAndCashAmortizedCost', window );">Total, Amortized cost</a></td>
<td class="nump">340.9<span></span>
</td>
<td class="nump">398.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax', window );">Total, Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax', window );">Total, Gross unrealized holding losses</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total, Estimated fair value</a></td>
<td class="nump">339.2<span></span>
</td>
<td class="nump">398.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized cost</a></td>
<td class="nump">138.0<span></span>
</td>
<td class="nump">195.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Estimated fair value</a></td>
<td class="nump">138.0<span></span>
</td>
<td class="nump">195.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized cost</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Estimated fair value</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized cost</a></td>
<td class="nump">109.1<span></span>
</td>
<td class="nump">105.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross unrealized holding losses</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Estimated fair value</a></td>
<td class="nump">108.1<span></span>
</td>
<td class="nump">105.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized cost</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross unrealized holding losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Estimated fair value</a></td>
<td class="nump">21.4<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized cost</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross unrealized holding losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Estimated fair value</a></td>
<td class="nump">17.7<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized cost</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross unrealized holding losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Estimated fair value</a></td>
<td class="nump">$ 26.8<span></span>
</td>
<td class="nump">$ 11.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Accumulated Gross Unrealized Loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725395222120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 165.2<span></span>
</td>
<td class="nump">$ 258.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Available-for-sale, Due within one year</a></td>
<td class="nump">103.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Available-for-sale, Due after one year through five years</a></td>
<td class="nump">72.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Available-for-sale, Due after five years</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_InvestmentsAndCashAmortizedCost', window );">Total, Amortized cost</a></td>
<td class="nump">340.9<span></span>
</td>
<td class="nump">398.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">165.2<span></span>
</td>
<td class="nump">258.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale, Due within one year</a></td>
<td class="nump">103.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale, Due after one year through five years</a></td>
<td class="nump">70.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Available-for-sale, Due after five years</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total, Estimated fair value</a></td>
<td class="nump">339.2<span></span>
</td>
<td class="nump">398.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">138.0<span></span>
</td>
<td class="nump">195.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">138.0<span></span>
</td>
<td class="nump">195.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 27.2<span></span>
</td>
<td class="nump">$ 63.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402965976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Measurement input, expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm', window );">Measurement period for earn out liability</a></td>
<td class="text">13 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Measurement Input, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401206856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">$ 193.3<span></span>
</td>
<td class="nump">$ 195.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">108.1<span></span>
</td>
<td class="nump">105.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">21.4<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">17.7<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">26.8<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">174.0<span></span>
</td>
<td class="nump">140.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">108.1<span></span>
</td>
<td class="nump">105.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">21.4<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">17.7<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">26.8<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | US government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="num">$ (7.9)<span></span>
</td>
<td class="num">$ (8.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725398281880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Reconciliation of change in fair value of contingent consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 8.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recognized in the Statement of Operations</a></td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Translation adjustments recognized in Other comprehensive loss</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 7.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725399780936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 149.1<span></span>
</td>
<td class="nump">$ 150.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(103.4)<span></span>
</td>
<td class="num">(106.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">45.7<span></span>
</td>
<td class="nump">43.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">34.2<span></span>
</td>
<td class="nump">38.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 114.9<span></span>
</td>
<td class="nump">$ 112.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401913816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Depreciation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725409419096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725409433464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 239.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation adjustments</a></td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 238.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401123576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (222.5)<span></span>
</td>
<td class="num">$ (212.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount, total</a></td>
<td class="nump">616.1<span></span>
</td>
<td class="nump">616.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net, total</a></td>
<td class="nump">393.6<span></span>
</td>
<td class="nump">404.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember', window );">Purchased licenses and technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount, amortizable</a></td>
<td class="nump">616.1<span></span>
</td>
<td class="nump">616.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(222.5)<span></span>
</td>
<td class="num">(212.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net, amortizable</a></td>
<td class="nump">$ 393.6<span></span>
</td>
<td class="nump">$ 404.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_PurchasedLicensesAndTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402858232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Amortization on Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725400492376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">$ 37.9<span></span>
</td>
<td class="nump">$ 52.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Legal charges pending settlement</a></td>
<td class="nump">48.0<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Accrued taxes payable</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_RefundsPayableAndReserveCurrent', window );">Refunds payable and reserves</a></td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Short-term contingent consideration</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">17.5<span></span>
</td>
<td class="nump">19.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 124.8<span></span>
</td>
<td class="nump">$ 156.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_RefundsPayableAndReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refunds Payable And Reserve, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_RefundsPayableAndReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725400183288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Feb. 21, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 23, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum aggregate principal commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum aggregate principal commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DebtCovenantLiquidityCovenantMinimum', window );">Minimum liquidity covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum', window );">Minimum unrestricted cash and cash equivalents threshold per covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Undrawn fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_DebtInstrumentLIBORFloorPercentage', window );">LIBOR floor (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | Forecast | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Undrawn fee (percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | Forecast | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Undrawn fee (percent)</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | LIBOR | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | LIBOR | Forecast | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on rate (percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Amended facility | LIBOR | Forecast | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on rate (percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DebtCovenantLiquidityCovenantMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Liquidity Covenant Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DebtCovenantLiquidityCovenantMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DebtInstrumentLIBORFloorPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, LIBOR Floor, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DebtInstrumentLIBORFloorPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mygn_AmendmentToCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mygn_AmendmentToCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725399317848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Long-Term Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401196168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (shares)</a></td>
<td class="nump">80,300,000<span></span>
</td>
<td class="nump">76,700,000<span></span>
</td>
<td class="nump">80,000,000.0<span></span>
</td>
<td class="nump">75,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (shares)</a></td>
<td class="nump">80,300,000<span></span>
</td>
<td class="nump">76,700,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">75,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Share repurchase program, remaining repurchase authorization</a></td>
<td class="nump">$ 110,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725404080120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common shares issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning common stock issued</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning common stock outstanding</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans', window );">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued at end of period</a></td>
<td class="nump">80.3<span></span>
</td>
<td class="nump">76.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding at end of period</a></td>
<td class="nump">80.3<span></span>
</td>
<td class="nump">76.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725399318008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding used to compute basic EPS</a></td>
<td class="nump">80.1<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive shares</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</a></td>
<td class="nump">80.1<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725402098904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive options and RSUs excluded from EPS computation</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725400974792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 23, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember', window );">2012 Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per participant per offering period</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember', window );">Options and RSUs | Non-employee director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Service period for award vesting (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | President and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Service period for award vesting (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense related to RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.8<span></span>
</td>
<td class="nump">$ 90.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Achievement levels based on EPS targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting weight (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Relative total stockholders return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting weight (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Performance based on Nasdaq Healthcare Provider Index</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting weight (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mygn_NonEmployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mygn_NonEmployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401173800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options, Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning (shares) | shares</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (shares) | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled or expired (shares) | shares</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending (shares) | shares</a></td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at end of period (shares) | shares</a></td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Options, Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning (dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (dollars per share) | $ / shares</a></td>
<td class="nump">23.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled or expired (dollars per share) | $ / shares</a></td>
<td class="nump">24.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending (dollars per share) | $ / shares</a></td>
<td class="nump">20.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at end of period (dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725395678088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSU Activity (Details) - RSUs<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs, Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding, beginning (shares) | shares</a></td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (shares) | shares</a></td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested (shares) | shares</a></td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs canceled (shares) | shares</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding, ending (shares) | shares</a></td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>RSUs, Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs outstanding, beginning (dollars per share) | $ / shares</a></td>
<td class="nump">$ 24.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted (dollars per share) | $ / shares</a></td>
<td class="nump">27.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSUs vested (dollars per share) | $ / shares</a></td>
<td class="nump">28.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs canceled (dollars per share) | $ / shares</a></td>
<td class="nump">24.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs outstanding, ending (dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725398307576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfMolecularDiagnosticTestingMember', window );">Cost of molecular diagnostic testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfPharmaceuticalAndClinicalServicesMember', window );">Cost of pharmaceutical and clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfMolecularDiagnosticTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=mygn_CostOfMolecularDiagnosticTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfPharmaceuticalAndClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=mygn_CostOfPharmaceuticalAndClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725395352520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (5.9)<span></span>
</td>
<td class="num">$ (10.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Approximate tax rate</a></td>
<td class="nump">22.30%<span></span>
</td>
<td class="nump">20.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | Earliest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | Latest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey | Earliest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey | Latest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Switzerland | Earliest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Switzerland | Latest tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax year being audited in income tax examination</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationYearUnderExamination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year being audited in the income tax examination, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationYearUnderExamination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725398220440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Potential settlement accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=mygn_CBICIFPASettlementMember', window );">CBI CIFPA | United States and State of California | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement agreement</a></td>
<td class="nump">$ 45,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=mygn_CBICIFPASettlementMember', window );">CBI CIFPA | Relator's counsel | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement agreement</a></td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mygn_CBICIFPASettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mygn_CBICIFPASettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mygn_UnitedStatesAndStateOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mygn_UnitedStatesAndStateOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mygn_RelatorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mygn_RelatorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725401104904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Establishment of operating lease right-of-use assets and lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_OperatingLeaseLiabilityEstablished', window );">Operating lease liabilities</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment in accounts payable</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OperatingLeaseLiabilityEstablished">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability Established</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OperatingLeaseLiabilityEstablished</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725398311192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Loss due to abandonment of facility</a></td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Goodwill and long-lived asset impairment charges</a></td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_LeaseArrangementAxis=mygn_WestSaltLakeCityLeaseMember', window );">West Salt Lake City</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_LesseeOperatingLeaseAreaOfLeasedSpace', window );">Operating lease area (sq ft) | ft&#178;</a></td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mygn_LesseeOperatingLeaseExpectedFutureRentPayments', window );">Total expected future rent payments</a></td>
<td class="nump">$ 77.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_LesseeOperatingLeaseAreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Of Leased Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_LesseeOperatingLeaseAreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_LesseeOperatingLeaseExpectedFutureRentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Expected Future Rent Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_LesseeOperatingLeaseExpectedFutureRentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_LeaseArrangementAxis=mygn_WestSaltLakeCityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_LeaseArrangementAxis=mygn_WestSaltLakeCityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139725400506280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent event - CBI CIFPA<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">United States and State of California</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement agreement</a></td>
<td class="nump">$ 45,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Relator's counsel</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement agreement</a></td>
<td class="nump">$ 2,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mygn_UnitedStatesAndStateOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mygn_UnitedStatesAndStateOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mygn_CBICIFPASettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mygn_CBICIFPASettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mygn_RelatorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mygn_RelatorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>mygn-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mygn="http://www.myriad.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mygn-20220331.xsd" xlink:type="simple"/>
    <context id="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie26f4d836b8c43f3a81066cbd86c0c0a_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="i9ac025088f904137a68dd99ae7162c5e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i56db6c3d57e14c2b8658a385a44e3603_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf33e5d604a449409285140d03ecf9c4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if0028e3d51994bd79cb5c6bff0d75e18_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7a6fd51a77104485bed5515365b14f90_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i51af4328f7a04a4b8cac37c1e5d162d6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib08aef4ce0a84366ae13a13964bae0a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i778ef826320848759f1d194633ed0c53_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i492d83c9f93f475893f5e08b0f651c9e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ea1b38b6fd442f28bbfc072c2cbbf70_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38f47e17df9c466eb0964b81d156f640_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5272217093641ce807e8a88daa1cdd8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i665db2c7846646668f3cef8865847df8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if3215774ecd84e0d9af76636f9dec725_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibca09dd596a045b28ee64d75c60c6fa3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i51360db4a9f443ecb44b43e6f565af3c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i07d7d32725ac4f4c924775a73475ec21_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i708aff24e984491496d2d81e7aeae298_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5c1c491ce07b46bf981a8c437b57ebe5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i65bcf7eb7d084073a1d31f6c3266039e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib058dc224c7c47e98c2cf75604eea5f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fdbf8c5ce07414fae885bf9107824e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ca9e1f471d94034b7814953ffe2f26a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8a8f0a93ffd45eb9e88163c16f0d327_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i812ea76259f24a58ae8fc86475a6e3e3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4a8239ce03e247a09242f5f72f3b8f29_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib37c60806afc4e62a8fcc62ed49d169e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i652588d3da5a43d2b2cf4ef648e7a8e6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9bb1c337d99746fcab9d1d8cfad76b30_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i048b28f83191461ca446a385004cd1f5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia1519c8391b842399d132e8fd6ef21f2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8eb5af63f8b8413cbb2c5ccef8a23335_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3a00625e25ad4bb19d387987d29c1b37_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3a0861127f384074bea6194dcadccff8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i168a53dec81546e9841245e8c2ecad66_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i71aaffb802404ab2bd2254ac4935374c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticHereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic48d92006ed6462eaddb141061226da3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibb41f2d374db4b62bf6fca7d3c8b87a7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic124314e94e44fcfbb72df064864b2f6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5ef67c76df944005bcce30f068506e34_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i96f84ba2616749a88b3f961574d23e09_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie57f1eaf9e8d430c860af6b4ed687e97_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i30c094758e7a4db5b59bcf76bcabd03f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8f731ae454a94bd9a075b65ce61d8ee5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie79831c4c3804d78a024b6129000343b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifdf8e565250c4b04bab9ef9d5c4ff45f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1b03a6430a624a6b8f8e6bcd7cf82f56_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i97fe976f531f43a09cf8064128efdc2f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i057ec40f04944ea984f6ecb96adffb38_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia76e2445fd4247ce8565ace69a07cb58_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1b860be39e224a04a1a68674e503b529_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i79ddeaedfccb40d88221e0e2d74fa96d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i87691cf56a19478eb1f6544cf57295c9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4e4cecae202247c880970efaf5f9ee3e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticPharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3b19f57c78b44ad683bb1b4bd44e5f62_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i82485441ef944386996ccf0d6e192050_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i87f3f03808324e1b8cda4b6e447e0038_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a108bb0e4d641a9ba014a3fb5413714_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7ea03d11e0304ccfb26dc185eac9a3d0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id3f29514d91043cb8814629006fe138c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticAutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5d668be165244dd1be2739e4bddd8d6b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic1e28fc7eb7c417ca6677b3b6e228c4e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i54fe3cc0d3b14d139aadd0a94943b49c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i03a8be3329254025993297729bd21abe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if7b88a6e741b4f37bbb83847c7547ff3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i45649325d565477e9e05700b9cf7f061_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticOtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i40fb715741a94f7e965b632953843495_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i99e56a4a61a6448ca8284c81c5072352_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i48867d19db404992b557cd1387f4e47f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i87a32a4bbc484c8ab0294925b08b160c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:MolecularDiagnosticTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7abf3b2881464b55837ca122fffaf119_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id3255bff47e5459f88724051e2d8e564_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if3a1622be8904dc6a17e7260d663d789_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iba63cbfb3f734a24bab843e8ad4d779e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic8dbe812816b48cb830e84114c6d8f60_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibda7b5c57b0c429db2fdc77635ae5e5c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7ca0e6bc0455492dbe206a7d48a02709_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i29edbbeae1f74f208e45c112f01268c7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ied55de41f92a4292af6d62bd5c0088d0_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9bc19c6cc66c4ff9a3b4c1f8519220c4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if788ce35f1a7443780443d8285c4dabf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icb95dc894d0d4604b1d478d160dbf2ce_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i136db30e02474345827ada253c52a3dc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5a42c624b75245bcac04b9a7d1f99fdd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i079b9de7e87d46e9bcccd402328b76f2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3979e6cb59c140e695831c1612356572_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i33295928e5bd414aada50cf100d5946c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i29a7ee8981794d99b60509cd1fbedcf6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3bd84c1ecd394413b497049a3d8c0482_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11689e851c8f4f9a9804225d7cafc5bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i353c741ab7484eb590076cce6cf8785f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia61c6cbe23264dc3937f411e7be9e941_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14b1f730f55149ffb4bc95c14af1afd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i357d6b9001eb4f34ab4e5759c25bafad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6ed914040924d00942b5531f455cea3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i08e3194cd9264422920009833989a9f4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i45e4529dc74b46368324bb8e8304fae6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic383f28c706e43be88cc15989d93d8bf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1149c109c7944153bce0f07495ff3516_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4683011548b54f0d9ebf8e148ae0cb58_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib523b385ec3e473889798b06a5b0e42c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i093a64b69b8c4abeaf4706d4a48aced8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0db6ed20d3b7496abd3bc2149d9f0911_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib288a6a85cb34b21a1848dd46ede7ea7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0a9e29a9d23b4534a84fb267bb955273_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i73ec880d0b0e4b1ca8cf3ae965faa17a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i57812bb46fe444018878a29051cb790e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0d28eeea16924dc8b5cbe6c78890f671_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icc4b68d2f71a40e0873b52510f156925_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3e850fa3529c440d8963459b76c7b82e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifcb86fc367024853965b38c7d1144948_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idfe95fe4dd354dbd98eabe24039da4d9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i29cf1314b6ca487490b61e18b013ff26_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2604abe8133848178f910dd24f6b3462_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if8170fc4406e43bdbb3216785308da75_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1e05e765ecae4061bff51a2cb034aa20_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9035568ac69b433da12c2f4a2affbff1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iab78bf60a5c942cc87ccc71b20df6a27_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaf0f4b68da2b4515afa573f19f88ff4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4ae2273e9614043945b8f236bd47dfd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id72e536fe9d14ae6ab7cb34094bb9d39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bb9b95d87db4378a84eed47d440eb40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6de004c7a5244c518e0a748f1c208172_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i528dc644c9ff4943b02b055e4f0985a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e871c32c4824df6aba031d957b820f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf97501434e045bdbec15630658c5c1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07615525c7da4600a164f6377287dda5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e2f08fba40d4ba3af31fe0475b3de3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bc70dfe49e04a118a51198b256f8dae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5de6b4aac9841a5b074aec661dd7e40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78479d9de84a4fa987db5df225bb0dc9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9714eb29e60483d97d657c738112562_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia84c478ac57b495fa98f396e489b0dfd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i859a42bcc97943128dc28bd68082557d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e3c14443da2478fbd20257901c8b17d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10f83fadc928439aae7775e2a66e9369_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia71dcd4c9af541eead967fd44feac0ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5990b598e2d1460597cd94495019968d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51f0f49e3b5045d5b1be9e63528af3ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9a60ca8f13e4a989f4559d73febd0b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b8d4e9c04da414c897ed06bbbf510d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5028f46356f458f8cd14be716668ff9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i93acac9c7ae94d1aa34a4be6c6c75cfe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8fe2de508784dd7a2055d130fa36acb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i174cf853880a4694890b201c320822fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49163efc76014827a31448fd386b5085_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i48dce0415e7b4acd9af7a58cea440e09_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1016b9209b0844a8a1fe882aaf69c3fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mygn:PurchasedLicensesAndTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f00404949054a39b7ce601ba38532bd_D20180731-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-31</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i0837431576cf4579a0f3ff1238105f8f_I20161223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-23</instant>
        </period>
    </context>
    <context id="i1c833d35617e45489ec45fd17d8b7885_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="iab8dc65629934bb09610a94e1585f5e2_I20210221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-21</instant>
        </period>
    </context>
    <context id="i41e34ef04eda424fb7d05a478f98d582_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71d2eeb4225b4d9581fbf31f410c3194_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2304a6ab41d9426daa1dd160660afb17_D20200401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5b494a8f5d504446b284a79c8608ed05_D20200401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i65072d8099784761bad742b663d1ac97_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i29e8864078c14a39bc3142c044233017_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i9856b6ac715043c4aba22142b3f40f4f_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i2c4a4127b1ac49719e15e702d9dbb3e4_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="i1e2100574367494095bfa2718fab642f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d18f4068d394dcfba0bad4c86c8ef8a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i10eb9ab7fc8b46e6a64d2ef084755cf1_I20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="ic7e4a2bcdad04bc89e6ef5fbff976fec_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7bad2fadc9ee42ca9a12a98237615f28_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mygn:NonEmployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mygn:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ife4ee7239ab34cb7986b1613a6ea4129_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibdb73b76a7ef4b6192ddf53020f1bfc4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9d16553d025b4028aa1658a83e5f4561_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i17685ad6b9cf47d5a2539fde84607b3c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i425eb7ec3ba04e4d97719f260b166abb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6d5670611ac54c00895e101571e289ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e88ace7ed394a94800fdca61421e851_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i83a6571b146e482389af3212034e29e0_I20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="iaac367b814414abc8b2dc1fcfc86625f_D20210923-20210923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-23</startDate>
            <endDate>2021-09-23</endDate>
        </period>
    </context>
    <context id="i5030a2b3d82c4d60868c0b2191a2d4a0_D20211205-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-05</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i86d71b985caa4964a6e254ec96cb87cd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iafba3568c8f8479caf7ae3e55c4f2129_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfMolecularDiagnosticTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2566e34ad9de42d492126a12c9a969e8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i72551335efb84f1dacbfab6e1f4b32f2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfPharmaceuticalAndClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0e442b7e778a40d0b0ea4e18405b7a44_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5ccf0e5050c9430eba39a50029c3c70e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1114d9d3200747a2a214afd2bfab8814_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie78cb4d47d2f4c79b9717d147044b377_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4c40a24632bf4346946172c6e98b52fc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2b99c5119ccf4bec978689998d8156c9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iddf2e4709d4e4f3c8f8de9d3848531a3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i165aceb443f54911b03d14bf7fa31bef_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0f49e0371ac14b658fae67bfe038cf32_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9b97c328c10c4fa3b4b35d35fc41de1f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idd3dfbf88a4f49d29528546627f27aa0_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mygn:UnitedStatesAndStateOfCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mygn:CBICIFPASettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i725231d93b934c6d91bff94381a504dd_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mygn:RelatorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mygn:CBICIFPASettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i04e805b5f43a48c59b3233b51bbc2f4c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:WestSaltLakeCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9b97b4edf342400a89726e31b3e19c6c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:WestSaltLakeCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80L2ZyYWc6MGVhYTU0MDVkNzRlNDdmZDk2YzM1MTdhN2U4OTM1YzcvdGFibGU6MmI1MTAzNjRhOTZmNDI2YmFlMjJjZWM2YzUzNTViOTEvdGFibGVyYW5nZToyYjUxMDM2NGE5NmY0MjZiYWUyMmNlYzZjNTM1NWI5MV8xLTEtMS0xLTgyMDky_c528dd38-e7da-4dfe-8415-731268e71924">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80L2ZyYWc6MGVhYTU0MDVkNzRlNDdmZDk2YzM1MTdhN2U4OTM1YzcvdGFibGU6MmI1MTAzNjRhOTZmNDI2YmFlMjJjZWM2YzUzNTViOTEvdGFibGVyYW5nZToyYjUxMDM2NGE5NmY0MjZiYWUyMmNlYzZjNTM1NWI5MV8yLTEtMS0xLTgyMDky_b022a6f1-a418-4dc6-85f7-fe5af47db679">0000899923</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80L2ZyYWc6MGVhYTU0MDVkNzRlNDdmZDk2YzM1MTdhN2U4OTM1YzcvdGFibGU6MmI1MTAzNjRhOTZmNDI2YmFlMjJjZWM2YzUzNTViOTEvdGFibGVyYW5nZToyYjUxMDM2NGE5NmY0MjZiYWUyMmNlYzZjNTM1NWI5MV8zLTEtMS0xLTgyMDky_5666b331-c172-4cb7-89e9-1b85bffc1b62">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80L2ZyYWc6MGVhYTU0MDVkNzRlNDdmZDk2YzM1MTdhN2U4OTM1YzcvdGFibGU6MmI1MTAzNjRhOTZmNDI2YmFlMjJjZWM2YzUzNTViOTEvdGFibGVyYW5nZToyYjUxMDM2NGE5NmY0MjZiYWUyMmNlYzZjNTM1NWI5MV80LTEtMS0xLTgyMDky_7be0842b-c680-4cb2-bbd4-aef014f913af">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80L2ZyYWc6MGVhYTU0MDVkNzRlNDdmZDk2YzM1MTdhN2U4OTM1YzcvdGFibGU6MmI1MTAzNjRhOTZmNDI2YmFlMjJjZWM2YzUzNTViOTEvdGFibGVyYW5nZToyYjUxMDM2NGE5NmY0MjZiYWUyMmNlYzZjNTM1NWI5MV81LTEtMS0xLTgyMDky_4f14f016-fa3f-4603-9bee-a9150e68f42a">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzc5_08aae016-c111-45a7-9dfd-b98b637c76f1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6MjdlZTczZDgzMTBlNDYzZmEwYTgyOWUyYTIyYWMzNjAvdGFibGVyYW5nZToyN2VlNzNkODMxMGU0NjNmYTBhODI5ZTJhMjJhYzM2MF8wLTAtMS0xLTgyMDky_312fd540-7365-4797-a17e-3816a28ee3ee">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV83MTQ2ODI1NTgyOTUw_7237849f-b83c-4b3e-9922-9292e80a97da">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6NjMyYzRhOGRiOGNiNGIxOTg0M2E1ZjFhOTRhMzYxZDMvdGFibGVyYW5nZTo2MzJjNGE4ZGI4Y2I0YjE5ODQzYTVmMWE5NGEzNjFkM18wLTAtMS0xLTgyMDky_afda960b-34a9-41f9-bf32-f52ef8e60e62">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzgw_90070082-c125-4e77-8bfd-7c160fb350f2">0-26642</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzgx_19af4560-3e67-43a1-9f55-e0b71d18c005">MYRIAD GENETICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzcx_c048f429-f4bd-486d-9c0d-20d451eca5c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzgy_faa73ebc-bb6f-4a3c-aa70-fd5ed8c94b91">320 Wakara Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzcy_b9391e86-21b3-4040-bdea-540535b3451b">Salt Lake City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzcz_377422ee-1301-4a60-abe3-2cf55d9e9268">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityTaxIdentificationNumber
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzc1_33f91159-ec65-4f9c-8b04-5b85a0a82af0">87-0494517</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzc2_abd421fc-3214-440c-8616-32627ca4f6f0">84108</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzc0_0703c19b-f90b-4ba3-8226-7389b6c68cdd">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzgz_77429f4f-01d2-4f7b-bb63-741f77c1f7e8">584-3600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6ODhjMWZjZTU4N2U1NGEzZWFiMTkxYzJmZWY1YWQxZjEvdGFibGVyYW5nZTo4OGMxZmNlNTg3ZTU0YTNlYWIxOTFjMmZlZjVhZDFmMV8xLTAtMS0xLTgyMDky_0c7e8a10-fe39-4dae-8f1a-f259be7c32ea">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6ODhjMWZjZTU4N2U1NGEzZWFiMTkxYzJmZWY1YWQxZjEvdGFibGVyYW5nZTo4OGMxZmNlNTg3ZTU0YTNlYWIxOTFjMmZlZjVhZDFmMV8xLTItMS0xLTgyMDky_a7f81fe6-b5dc-40b0-8d4a-34dbe83a6c24">MYGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6ODhjMWZjZTU4N2U1NGEzZWFiMTkxYzJmZWY1YWQxZjEvdGFibGVyYW5nZTo4OGMxZmNlNTg3ZTU0YTNlYWIxOTFjMmZlZjVhZDFmMV8xLTQtMS0xLTgyMDky_f2322ca4-a058-4686-8622-09dc52bc7222">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzg0_9fb65da9-4dad-4532-a6e3-84e44eef5478">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzc4_115b0fe2-02d5-4b49-8a61-7ebd706f804a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6NzRlNzU4NThiMzk4NDkyYmJjNjQ3NjZkZjQwZjE3ODQvdGFibGVyYW5nZTo3NGU3NTg1OGIzOTg0OTJiYmM2NDc2NmRmNDBmMTc4NF8wLTAtMS0xLTgyMDky_851a9c77-6758-4b0c-8e4b-2b771efdc69d">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6NzRlNzU4NThiMzk4NDkyYmJjNjQ3NjZkZjQwZjE3ODQvdGFibGVyYW5nZTo3NGU3NTg1OGIzOTg0OTJiYmM2NDc2NmRmNDBmMTc4NF8xLTQtMS0xLTgyMDky_7561e536-fb32-40ba-b6d9-8b2e48cb9020">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGFibGU6NzRlNzU4NThiMzk4NDkyYmJjNjQ3NjZkZjQwZjE3ODQvdGFibGVyYW5nZTo3NGU3NTg1OGIzOTg0OTJiYmM2NDc2NmRmNDBmMTc4NF8yLTQtMS0xLTgyMDky_676c92a1-d679-4365-8d35-b3d975b57e76">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzc3_31e2a2df-11e6-4f1f-b2d6-ef291b6f3c03">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie26f4d836b8c43f3a81066cbd86c0c0a_I20220429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xL2ZyYWc6N2JhYTUyMTM1ZmYwNDYzNzgwNTFlN2VhMThjNDhkMjUvdGV4dHJlZ2lvbjo3YmFhNTIxMzVmZjA0NjM3ODA1MWU3ZWExOGM0OGQyNV8yMzE4_38a403d0-31b0-47a4-9d62-e5b50f496f33"
      unitRef="shares">80343165</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNC0xLTEtMS04MjA5Mg_efd9ff0d-16e6-4f02-901a-51b106b98ed7"
      unitRef="usd">165200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNC0zLTEtMS04MjA5Mg_4425a626-34ee-4919-854f-79bf59c0dfdb"
      unitRef="usd">258400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNS0xLTEtMS04MjA5Mg_d2035172-1151-4bfd-9bef-07f36c332cab"
      unitRef="usd">103200000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNS0zLTEtMS04MjA5Mg_7303663c-4556-4dfc-ac45-3cb884904153"
      unitRef="usd">81400000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNi0xLTEtMS04MjA5Mg_aa798d60-ce82-49c3-8cf5-d729a99e192e"
      unitRef="usd">101700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNi0zLTEtMS04MjA5Mg_dde02d49-474b-4976-8f45-b514d7983c6c"
      unitRef="usd">91300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNy0xLTEtMS04MjA5Mg_365d07e6-a05a-44ca-be60-d14a19f06b46"
      unitRef="usd">15600000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNy0zLTEtMS04MjA5Mg_5f93c88e-aa1c-429e-9a24-4110b7534db9"
      unitRef="usd">15300000</us-gaap:InventoryNet>
    <us-gaap:PrepaidTaxes
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfOC0xLTEtMS04MjA5Mg_acdeeed4-53f7-422a-b768-882607b9235c"
      unitRef="usd">18800000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfOC0zLTEtMS04MjA5Mg_11dc6499-7d46-4a89-bd00-4b02e9386140"
      unitRef="usd">18400000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfOS0xLTEtMS04MjA5Mg_0bfab051-1159-4f4d-b833-11729f333e6a"
      unitRef="usd">22900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfOS0zLTEtMS04MjA5Mg_858d6e06-4cbf-4030-9dcd-df6eeb08f83d"
      unitRef="usd">20000000.0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTAtMS0xLTEtODIwOTI_7d15b95b-6f69-49d7-9f9c-0eed72709999"
      unitRef="usd">427400000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTAtMy0xLTEtODIwOTI_cb4ff5b6-d7cb-4902-ac07-0b575c5fd786"
      unitRef="usd">484800000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTEtMS0xLTEtODIwOTI_06e15c0e-cd19-4730-b619-8060329d428b"
      unitRef="usd">70900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTEtMy0xLTEtODIwOTI_44ccb1d3-c75b-4f64-b77f-aec6147e0452"
      unitRef="usd">81800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTItMS0xLTEtODIwOTI_97de2313-44b7-4efb-b7d0-d2c7d1c0ca61"
      unitRef="usd">70800000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTItMy0xLTEtODIwOTI_82007a54-a257-4986-bac1-807028c96af9"
      unitRef="usd">59000000.0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTMtMS0xLTEtODIwOTI_3219d0ff-9aff-4405-acbc-27ab987b5191"
      unitRef="usd">45700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTMtMy0xLTEtODIwOTI_1aae7e30-091d-4e3c-be8a-e2e524726051"
      unitRef="usd">43500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTQtMS0xLTEtODIwOTI_e25ca4c3-a0b4-400d-bc14-7a8551c723f6"
      unitRef="usd">393600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTQtMy0xLTEtODIwOTI_2bbde91e-0fc6-419a-8c38-a5ecfdc10402"
      unitRef="usd">404100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTUtMS0xLTEtODIwOTI_13aee6e7-c086-4917-b34a-0005b9df2142"
      unitRef="usd">238800000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTUtMy0xLTEtODIwOTI_1f5a9561-a8f3-488c-8ab8-3a85ec5200df"
      unitRef="usd">239200000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTYtMS0xLTEtODIwOTI_306ad407-6473-4c3e-81ce-e2519bc54ebb"
      unitRef="usd">8200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTYtMy0xLTEtODIwOTI_ed85fc16-4186-4ab5-a652-ca1253a8f67a"
      unitRef="usd">8300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTctMS0xLTEtODIwOTI_10d91772-7a6c-4d63-a3a5-f49450ceacf3"
      unitRef="usd">1255400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMTctMy0xLTEtODIwOTI_ed92aecc-d072-4d56-abf9-de1b904013dd"
      unitRef="usd">1320700000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjAtMS0xLTEtODIwOTI_8499419a-842c-47c0-acbd-3accdc1b8e73"
      unitRef="usd">27100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjAtMy0xLTEtODIwOTI_f44ab0a0-ee47-471e-9cb8-e7b4ba21fcd1"
      unitRef="usd">29600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjEtMS0xLTEtODIwOTI_d727c76c-3398-4ac6-a464-d4d277c24629"
      unitRef="usd">124800000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjEtMy0xLTEtODIwOTI_5f378c96-f0ef-4836-b7c6-ea74181e293b"
      unitRef="usd">156500000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjItMS0xLTEtODIwOTI_2e1a2c02-fcf4-4302-8344-47b84ea1cb75"
      unitRef="usd">13400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjItMy0xLTEtODIwOTI_d1775fa9-37be-4751-97d7-a86fea68fbc9"
      unitRef="usd">13000000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjMtMS0xLTEtODIwOTI_b413ada5-aec4-4788-aee3-446dd7075630"
      unitRef="usd">700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjMtMy0xLTEtODIwOTI_2c01b1e4-906f-4bd8-a721-a9491c1b0e2d"
      unitRef="usd">5200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjQtMS0xLTEtODIwOTI_a6a61645-ea31-4ab6-8542-bde79e9e0688"
      unitRef="usd">166000000.0</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjQtMy0xLTEtODIwOTI_50747cf8-0842-49e8-8ac3-2594e41f256e"
      unitRef="usd">204300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjUtMS0xLTEtODIwOTI_d8f973fd-8117-45a8-bd2a-1d5a9cd952ee"
      unitRef="usd">28000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjUtMy0xLTEtODIwOTI_b31e2e60-65c0-4ca2-aae5-5b375afb4998"
      unitRef="usd">27900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjYtMS0xLTEtODIwOTI_5358c939-0a41-480f-8fb6-b94bc8779865"
      unitRef="usd">29900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjYtMy0xLTEtODIwOTI_0195304c-b5d5-4cf9-b7b0-2703cd2a5ceb"
      unitRef="usd">35800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjctMS0xLTEtODIwOTI_08c16d6e-1d63-474c-86e7-ee89a30e09b7"
      unitRef="usd">76500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjctMy0xLTEtODIwOTI_40f1c782-984e-4a90-9b76-d9a7ba8d1b29"
      unitRef="usd">79300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjktMS0xLTEtODIwOTI_f1e97d09-aed8-4f0f-a025-0778b10a311b"
      unitRef="usd">4900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMjktMy0xLTEtODIwOTI_cef5496a-a952-463e-a08f-407b4b88c2e0"
      unitRef="usd">5600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzAtMS0xLTEtODIwOTI_63432da5-9ffa-42ce-81d1-fddf230830a9"
      unitRef="usd">305300000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzAtMy0xLTEtODIwOTI_f437db7c-d9a9-41ca-984c-d5f1ac040b87"
      unitRef="usd">352900000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzEtMS0xLTEtODIwOTI_be44953c-3a04-4377-b6bd-95440bc26ea9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzEtMy0xLTEtODIwOTI_83b2f149-33f7-45b8-bb43-48ac5aa81d6f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzMtMC0xLTEtODIwOTIvdGV4dHJlZ2lvbjo5NDNhZjk4MGRiMmU0MWViOTZkOTg2NzJhYTc5ZTM1Nl8xOA_c6c5afa9-55d2-458f-9a9f-a6bf5b2780b4"
      unitRef="shares">80300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzMtMC0xLTEtODIwOTIvdGV4dHJlZ2lvbjo5NDNhZjk4MGRiMmU0MWViOTZkOTg2NzJhYTc5ZTM1Nl8yNQ_e560e107-5087-4832-b970-3e8b7194ba57"
      unitRef="shares">80000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzMtMS0xLTEtODIwOTI_f3c7cba5-0f13-4af8-b356-4d6921612045"
      unitRef="usd">800000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzMtMy0xLTEtODIwOTI_ee756ea2-0c34-4911-912b-05ac5f18c960"
      unitRef="usd">800000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzQtMS0xLTEtODIwOTI_6203842a-e1ac-4f4e-9e81-3a1f618c5061"
      unitRef="usd">1231600000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzQtMy0xLTEtODIwOTI_2f5e8258-e391-4cd1-8962-721f5b8ce276"
      unitRef="usd">1226300000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzUtMS0xLTEtODIwOTI_4cbfa476-c16d-4482-a6d8-838750a5aab8"
      unitRef="usd">-7600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzUtMy0xLTEtODIwOTI_9f9edcb2-8714-402f-837e-e71d5d4c08cb"
      unitRef="usd">-5100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzYtMS0xLTEtODIwOTI_584490f6-d5bd-45e1-91a1-d529ec744694"
      unitRef="usd">-274700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzYtMy0xLTEtODIwOTI_53ec25fa-968e-421e-ad59-82a2d6b56dcc"
      unitRef="usd">-254200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzctMS0xLTEtODIwOTI_6966b4b3-45c5-4ed2-848a-2424fd612edf"
      unitRef="usd">950100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzctMy0xLTEtODIwOTI_46708cab-fa17-4cb2-b323-7cb4aa5f512e"
      unitRef="usd">967800000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzgtMS0xLTEtODIwOTI_211178e5-83d1-413d-ba45-219c7e3b473a"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzgtMy0xLTEtODIwOTI_5618484f-78f8-4756-8d7a-04edb8beff4f"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzktMS0xLTEtODIwOTI_ccbd7f67-62f7-44eb-bdc9-2ff5f0583f85"
      unitRef="usd">950100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfMzktMy0xLTEtODIwOTI_f4b5cf3a-0e0c-431d-b8c4-5b979273095d"
      unitRef="usd">967800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNDAtMS0xLTEtODIwOTI_99cc4121-a4ff-44ba-a557-2289e6446310"
      unitRef="usd">1255400000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xNi9mcmFnOjBlNDljODk1YjQ5ZjQyMDE4ODE4OGJjYmFjYTE3ODM4L3RhYmxlOmVhODJiMjc0Y2MyMDRhMDhiNzVjZGVmYTY3YjM3YzA3L3RhYmxlcmFuZ2U6ZWE4MmIyNzRjYzIwNGEwOGI3NWNkZWZhNjdiMzdjMDdfNDAtMy0xLTEtODIwOTI_d4b21085-6ee6-4ede-9a34-359a8be940b7"
      unitRef="usd">1320700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf33e5d604a449409285140d03ecf9c4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMy0xLTEtMS04MjA5Mg_72d245ac-4f00-4a58-9a35-0ab7c8749752"
      unitRef="usd">164900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0028e3d51994bd79cb5c6bff0d75e18_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMy0zLTEtMS04MjA5Mg_f687c43d-0364-4704-b528-c24ce1d1a0df"
      unitRef="usd">159600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a6fd51a77104485bed5515365b14f90_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfNC0xLTEtMS04MjA5Mg_c5c3c2da-1fab-402e-afec-3501fdf60387"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51af4328f7a04a4b8cac37c1e5d162d6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfNC0zLTEtMS04MjA5Mg_35ea64cf-6e72-4266-8e79-015ac600238a"
      unitRef="usd">13500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfNS0xLTEtMS04MjA5Mg_a92ffcba-e909-4542-b2e1-b6898b31c3f4"
      unitRef="usd">164900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfNS0zLTEtMS04MjA5Mg_3db83525-7b5e-47b5-a102-e0a4d06666cb"
      unitRef="usd">173100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icf33e5d604a449409285140d03ecf9c4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfNy0xLTEtMS04MjA5Mg_6481e913-5fd1-4037-8542-5cad98659866"
      unitRef="usd">48000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if0028e3d51994bd79cb5c6bff0d75e18_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfNy0zLTEtMS04MjA5Mg_ee06d912-ee1f-423c-ba61-2807cb2e7816"
      unitRef="usd">44100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7a6fd51a77104485bed5515365b14f90_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfOC0xLTEtMS04MjA5Mg_0ce44e0b-825b-4abe-b05b-b59930ea9631"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i51af4328f7a04a4b8cac37c1e5d162d6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfOC0zLTEtMS04MjA5Mg_f630e04e-87f0-4f43-a972-1aea7f53a50b"
      unitRef="usd">6200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfOS0xLTEtMS04MjA5Mg_b0722e66-1764-4d17-bd45-1cfca1d29839"
      unitRef="usd">21200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfOS0zLTEtMS04MjA5Mg_ef49d763-7e7c-41b6-8ce8-9f3e9b8d6d23"
      unitRef="usd">23100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTAtMS0xLTEtODIwOTI_e9e01cde-f4de-4094-a3b5-c0a202c18223"
      unitRef="usd">110600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTAtMy0xLTEtODIwOTI_265f57db-1572-4122-be81-f85f0a3e0690"
      unitRef="usd">146400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AssetImpairmentCharges
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTItMS0xLTEtODIwOTI_f9bd8f9a-a2d5-42ce-a8e1-6638acc7c05d"
      unitRef="usd">10700000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTItMy0xLTEtODIwOTI_24301a75-1f4b-4455-a83b-68fcd52f0aed"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:CostsAndExpenses
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTMtMS0xLTEtODIwOTI_e893476f-7680-4dde-994c-af3daed10ece"
      unitRef="usd">190500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTMtMy0xLTEtODIwOTI_d3171718-b73e-4b6a-ac35-3d0a6cb1628d"
      unitRef="usd">219800000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTQtMS0xLTEtODIwOTI_eabae140-31a1-422b-b140-c2a41e9a411f"
      unitRef="usd">-25600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTQtMy0xLTEtODIwOTI_e51a44bf-a5e7-44b4-b010-bda83c65bf4b"
      unitRef="usd">-46700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTYtMS0xLTEtODIwOTI_53c97875-704d-4a79-954a-4e7ada3697da"
      unitRef="usd">100000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTYtMy0xLTEtODIwOTI_ac4ab547-133b-41bf-894c-15281b796d30"
      unitRef="usd">200000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTctMS0xLTEtODIwOTI_89327339-88de-43af-a306-fe04b3f54400"
      unitRef="usd">900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTctMy0xLTEtODIwOTI_ed0a80c4-6742-48ad-8d44-aec4b2a345ff"
      unitRef="usd">3000000.0</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTgtMS0xLTEtODIwOTI_1a0e98cd-b2f5-4635-98d1-3ca5b4a46f90"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTgtMy0xLTEtODIwOTI_998dad7f-1161-4e9a-8763-33bc598e6397"
      unitRef="usd">-100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTktMS0xLTEtODIwOTI_de03e54b-bb13-405b-9dde-e4b2edb49a06"
      unitRef="usd">-800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMTktMy0xLTEtODIwOTI_1663d7ad-68dc-4fd1-af9b-6a5773cd77c2"
      unitRef="usd">-2900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjAtMS0xLTEtODIwOTI_c2ce459c-0c3b-4faf-b266-e405fffcd711"
      unitRef="usd">-26400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjAtMy0xLTEtODIwOTI_f17b1095-6f39-4afa-b5de-65dd673e5ae3"
      unitRef="usd">-49600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjEtMS0xLTEtODIwOTI_9dfdb921-7ba6-4cb8-b126-b639233cdcff"
      unitRef="usd">-5900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjEtMy0xLTEtODIwOTI_a2b4cc5c-d527-4b7d-a8b4-8113a4da3485"
      unitRef="usd">-10100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjItMS0xLTEtODIwOTI_c57d3520-a7bb-433a-b41c-9b3d31503c6f"
      unitRef="usd">-20500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjItMy0xLTEtODIwOTI_0c8a2cf2-8245-419d-839c-4a21a362477c"
      unitRef="usd">-39500000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjMtMS0xLTEtODIwOTI_9ae67346-a8b1-48b4-bd37-f7310004fb30"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjMtMy0xLTEtODIwOTI_171442de-5996-46a7-b245-5551279431f7"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjQtMS0xLTEtODIwOTI_5f391c8a-9ace-4598-995b-958f92fac755"
      unitRef="usd">-20500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjQtMy0xLTEtODIwOTI_7c29eedd-5b2f-41bf-b5b0-57fb734c8599"
      unitRef="usd">-39500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjYtMS0xLTEtODIwOTI_13451a5c-49b1-4a98-9705-e3f92a8868e5"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjYtMS0xLTEtODIwOTI_e8fffc03-6389-482c-99ad-3f55a6d46649"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjYtMy0xLTEtODIwOTI_8887a53e-08e5-45c3-9074-e16e0640c45d"
      unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjYtMy0xLTEtODIwOTI_c1b39c4f-1930-4a08-88b5-8dc1cf74fb5e"
      unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjktMS0xLTEtODIwOTI_af71815d-3ccb-4714-8e2b-f6bd59454000"
      unitRef="shares">80100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjktMS0xLTEtODIwOTI_fd404326-9514-4e7e-9689-de4a9e2260e4"
      unitRef="shares">80100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjktMy0xLTEtODIwOTI_c744fdb1-4046-4388-b699-6cdf6380381b"
      unitRef="shares">76000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xOS9mcmFnOjk5MWU3ZjhiYWU0ZjQ2YTQ5NzU0MTk2NzI1ODhjMDJhL3RhYmxlOjc5ZjY3OTE0Y2ZiMDQzOWFiNDY1OGQ1N2MxMWRhZTdmL3RhYmxlcmFuZ2U6NzlmNjc5MTRjZmIwNDM5YWI0NjU4ZDU3YzExZGFlN2ZfMjktMy0xLTEtODIwOTI_d8758162-f924-4531-85ab-d1accb62099a"
      unitRef="shares">76000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfMi0xLTEtMS04MjA5Mg_2efcaca7-e788-43b4-8d19-6398e802a72a"
      unitRef="usd">-20500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfMi0zLTEtMS04MjA5Mg_08bc693d-af35-4494-b2c0-cd148d138198"
      unitRef="usd">-39500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfMy0xLTEtMS04MjA5Mg_7f10f61f-f203-4342-891d-56bd76c98f48"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfMy0zLTEtMS04MjA5Mg_404c1106-c92a-4567-88ee-cc3942544490"
      unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfNC0xLTEtMS04MjA5Mg_e1b7706b-6264-4a30-8476-5e91d443d29d"
      unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfNC0zLTEtMS04MjA5Mg_72b6f733-baa2-4c5e-9770-3620f3b42b70"
      unitRef="usd">-1100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfNS0xLTEtMS04MjA5Mg_c454c3c3-d770-4e2e-ae9a-323665067a32"
      unitRef="usd">-23000000.0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfNS0zLTEtMS04MjA5Mg_747d3e5f-a19a-4ff6-8ac6-65fa1f2006ec"
      unitRef="usd">-40800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfNi0xLTEtMS04MjA5Mg_f60b186d-b5d9-4fc6-8f41-195762ab05f5"
      unitRef="usd">-23000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yMi9mcmFnOjMwMTBkNmRhNDExMzRmY2RhMWEwZGFiOTJhMmZlYTEzL3RhYmxlOjFmYjQzMTFjZDNjNjQyMmQ5YjgyN2E1ZmM4YTgzYTY1L3RhYmxlcmFuZ2U6MWZiNDMxMWNkM2M2NDIyZDliODI3YTVmYzhhODNhNjVfNi0zLTEtMS04MjA5Mg_6788cc16-fb3d-4f58-a9f4-b075fdf8f681"
      unitRef="usd">-40800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib08aef4ce0a84366ae13a13964bae0a2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMS0xLTEtMS04MjA5Mg_a377bf1c-f56b-43ed-91e0-7812cfc78ab9"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i778ef826320848759f1d194633ed0c53_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMS0zLTEtMS04MjA5Mg_5a51f0eb-a026-45f1-9d67-670c0851c0d5"
      unitRef="usd">1109500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i492d83c9f93f475893f5e08b0f651c9e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMS01LTEtMS04MjA5Mg_696937dc-ed45-41d2-a6ef-42347a80176c"
      unitRef="usd">-2300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ea1b38b6fd442f28bbfc072c2cbbf70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMS03LTEtMS04MjA5Mg_fd378e83-f485-4f18-b697-7e1f15125924"
      unitRef="usd">-227000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38f47e17df9c466eb0964b81d156f640_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMS0xMy0xLTEtODIwOTI_d7d26086-0c79-4d49-8a5b-3bff461d3f9d"
      unitRef="usd">881000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib5272217093641ce807e8a88daa1cdd8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMi0zLTEtMS04MjA5Mg_8bb6bef7-3d2d-478e-b53b-026469d30fb5"
      unitRef="usd">26000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMi0xMy0xLTEtODIwOTI_63fc42d4-496c-46e4-bc02-60fb92bdea94"
      unitRef="usd">26000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib5272217093641ce807e8a88daa1cdd8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMy0zLTEtMS04MjA5Mg_6521326a-a477-49a5-a168-1f1f02c0293f"
      unitRef="usd">9000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMy0xMy0xLTEtODIwOTI_227efe68-d8fc-477d-a8d9-49a2e7ab4fd2"
      unitRef="usd">9000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i665db2c7846646668f3cef8865847df8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfNS03LTEtMS04MjA5Mg_17520305-3ed6-4d92-b1f2-3ce815f5ac20"
      unitRef="usd">-39500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfNS0xMy0xLTEtODIwOTI_04f23681-5f34-4e67-a13b-a4b3528889ee"
      unitRef="usd">-39500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if3215774ecd84e0d9af76636f9dec725_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfNy01LTEtMS04MjA5Mg_50b3dac3-cbf7-489c-a4b4-1d3c38418b4e"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfNy0xMy0xLTEtODIwOTI_7c8f5e2a-84e3-48f2-8ec6-788f4e592ea1"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibca09dd596a045b28ee64d75c60c6fa3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfOC0xLTEtMS04MjA5Mg_27ae5b22-1c0c-4fc2-bfbe-383c2acc22d3"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51360db4a9f443ecb44b43e6f565af3c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfOC0zLTEtMS04MjA5Mg_b335e4a7-f6a6-4ffa-bf13-a42847bdda88"
      unitRef="usd">1144500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07d7d32725ac4f4c924775a73475ec21_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfOC01LTEtMS04MjA5Mg_67d8f633-f59a-406a-a06c-33fe3fa4e3e3"
      unitRef="usd">-3600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i708aff24e984491496d2d81e7aeae298_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfOC03LTEtMS04MjA5Mg_b6f688c2-4bea-4629-b084-312803da49f5"
      unitRef="usd">-266500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c1c491ce07b46bf981a8c437b57ebe5_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfOC0xMy0xLTEtODIwOTI_a4eba350-de88-4b27-b9ba-8f027ccef3dc"
      unitRef="usd">875200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65bcf7eb7d084073a1d31f6c3266039e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjAtMS0xLTEtODIwOTI_d21ad9fe-5634-4de8-b7c6-23fbb544dadd"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib058dc224c7c47e98c2cf75604eea5f2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjAtMy0xLTEtODIwOTI_244c529a-0fc4-4d4b-af54-5d34358fdfc7"
      unitRef="usd">1226300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fdbf8c5ce07414fae885bf9107824e7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjAtNS0xLTEtODIwOTI_70b14a6c-52b2-457e-8503-f91ba1f8064a"
      unitRef="usd">-5100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ca9e1f471d94034b7814953ffe2f26a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjAtNy0xLTEtODIwOTI_f2ac1083-da27-49b5-a47a-22c8a8b3dd1b"
      unitRef="usd">-254200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjAtMTMtMS0xLTgyMDky_e22fc215-b106-4f0b-aa01-03166d7eb1f6"
      unitRef="usd">967800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia8a8f0a93ffd45eb9e88163c16f0d327_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjEtMy0xLTEtODIwOTI_ec7a205a-eaf9-44c7-bd33-b989dd0780d6"
      unitRef="usd">-4800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjEtMTMtMS0xLTgyMDky_3e9b72c9-adcc-44e6-b9d0-55269fd7a3e4"
      unitRef="usd">-4800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia8a8f0a93ffd45eb9e88163c16f0d327_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjItMy0xLTEtODIwOTI_d28285a2-e58f-4713-9218-91796a68f619"
      unitRef="usd">10100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjItMTMtMS0xLTgyMDky_218a83ec-0051-414c-bbac-97f56330447a"
      unitRef="usd">10100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i812ea76259f24a58ae8fc86475a6e3e3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjMtNy0xLTEtODIwOTI_717db404-1b07-4a5b-8d39-14f8819b9dc9"
      unitRef="usd">-20500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjMtMTMtMS0xLTgyMDky_305da53e-b7d7-4b72-aea5-ee09ebe0282e"
      unitRef="usd">-20500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4a8239ce03e247a09242f5f72f3b8f29_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjQtNS0xLTEtODIwOTI_e703ee83-4482-4c16-b295-d173d6656ec4"
      unitRef="usd">-2500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjQtMTMtMS0xLTgyMDky_3417bc3d-3d4c-4c75-9728-2e2a13a0be38"
      unitRef="usd">-2500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib37c60806afc4e62a8fcc62ed49d169e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjUtMS0xLTEtODIwOTI_7812ea20-b590-4573-b22a-33ab740ead86"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i652588d3da5a43d2b2cf4ef648e7a8e6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjUtMy0xLTEtODIwOTI_0286c8f7-3fc3-4bed-b5eb-239bca8c4e54"
      unitRef="usd">1231600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9bb1c337d99746fcab9d1d8cfad76b30_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjUtNS0xLTEtODIwOTI_30f0a1e3-6df4-4569-b9ac-c826d5cdff0e"
      unitRef="usd">-7600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i048b28f83191461ca446a385004cd1f5_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjUtNy0xLTEtODIwOTI_0fe17720-3bf8-4283-820d-63bc455158cf"
      unitRef="usd">-274700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yNS9mcmFnOjkwYWY5NWZmYTgzNjRkM2FhMzc3Nzk2NGZjZjM5ZGIzL3RhYmxlOjY1ZTYyMGRlMTViMTQzZTA5OTI4M2E2Y2E0YjI4ODcwL3RhYmxlcmFuZ2U6NjVlNjIwZGUxNWIxNDNlMDk5MjgzYTZjYTRiMjg4NzBfMjUtMTMtMS0xLTgyMDky_b274aa07-ffad-4604-adb6-5e06c00f8db7"
      unitRef="usd">950100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMy0xLTEtMS04MjA5Mg_3df0c53a-ac7e-46f8-a097-375fdd0ed7c6"
      unitRef="usd">-20500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMy0zLTEtMS04MjA5Mg_d44b013b-fa0b-4678-9e89-05f91f061bd9"
      unitRef="usd">-39500000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNS0xLTEtMS04MjA5Mg_9779ffd8-518b-418e-86e0-fb352e5a799a"
      unitRef="usd">13000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNS0zLTEtMS04MjA5Mg_a87d437e-b6ac-4c00-ae65-db2a552da1c2"
      unitRef="usd">18400000</us-gaap:DepreciationAndAmortization>
    <mygn:NonCashInterestExpense
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNi0xLTEtMS04MjA5Mg_6b867114-897c-4a36-9e5f-19fce19b8355"
      unitRef="usd">200000</mygn:NonCashInterestExpense>
    <mygn:NonCashInterestExpense
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNi0zLTEtMS04MjA5Mg_275bdc52-61c6-4735-b834-9f5ce20e6305"
      unitRef="usd">500000</mygn:NonCashInterestExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNy0xLTEtMS04MjA5Mg_53e8f2e8-45c6-4710-b86e-428fe7dbb45a"
      unitRef="usd">3100000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNy0zLTEtMS04MjA5Mg_ff02dfe4-1b13-4c92-9451-bf8df7eff454"
      unitRef="usd">3500000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfOC0xLTEtMS04MjA5Mg_9b776c2b-28cc-4540-b1ad-5bb969575d12"
      unitRef="usd">10100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfOC0zLTEtMS04MjA5Mg_4dc98e42-53a2-471e-841f-e0d2f9b1ecb4"
      unitRef="usd">9000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfOS0xLTEtMS04MjA5Mg_8e67dc01-84b3-402e-b653-9ebb54499bbe"
      unitRef="usd">-5900000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfOS0zLTEtMS04MjA5Mg_371d1794-872b-464b-baac-2b10bfd50d9f"
      unitRef="usd">-11800000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <mygn:IncreaseDecreaseInUnrecognizedTaxBenefits
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTAtMS0xLTEtODIwOTI_68dc6b3f-113c-450b-a797-0ce32ed262e0"
      unitRef="usd">200000</mygn:IncreaseDecreaseInUnrecognizedTaxBenefits>
    <mygn:IncreaseDecreaseInUnrecognizedTaxBenefits
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTAtMy0xLTEtODIwOTI_2c1d86e0-4083-41cb-bd00-b147a2eefd06"
      unitRef="usd">300000</mygn:IncreaseDecreaseInUnrecognizedTaxBenefits>
    <us-gaap:AssetImpairmentCharges
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTMtMS0xLTEtODIwOTI_16de746d-9f5a-4d21-9206-399d243ddccf"
      unitRef="usd">10700000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTMtMy0xLTEtODIwOTI_72152101-6a62-462c-b57e-5a47650e8143"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTYtMS0xLTEtODIwOTI_43f7a7d4-e73d-4f9e-8a82-5f049bf10877"
      unitRef="usd">3000000.0</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTYtMy0xLTEtODIwOTI_4d56ca78-011a-49a8-aade-1de2af4a6dc3"
      unitRef="usd">2500000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTctMS0xLTEtODIwOTI_174cff9b-77b5-4c3a-84bd-e30480ac6328"
      unitRef="usd">10500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTctMy0xLTEtODIwOTI_e39aa92a-8ab7-46bf-8109-172b137931b8"
      unitRef="usd">4700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTgtMS0xLTEtODIwOTI_d120422b-76c6-4e7f-8639-92d9eef17dfc"
      unitRef="usd">200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTgtMy0xLTEtODIwOTI_210d1dbf-028a-4f0a-bab9-ee152fb5d1fb"
      unitRef="usd">-2400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTktMS0xLTEtODIwOTI_e2ca456e-00a1-47e7-9e58-53252c816b6f"
      unitRef="usd">400000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMTktMy0xLTEtODIwOTI_2b9b0531-3a44-4e98-8917-e622e0a05740"
      unitRef="usd">-90300000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjAtMS0xLTEtODIwOTI_f8dc46f0-d921-4ccd-a602-b2859f6909db"
      unitRef="usd">300000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjAtMy0xLTEtODIwOTI_92518aec-1025-4a4e-b5ce-8a9a6aff638f"
      unitRef="usd">1200000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjEtMS0xLTEtODIwOTI_dae03076-719a-405d-81e0-bdc243aba168"
      unitRef="usd">-3200000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjEtMy0xLTEtODIwOTI_a4eeadf8-8cbe-426a-923a-ac3c7d233845"
      unitRef="usd">300000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjItMS0xLTEtODIwOTI_2a19942d-e4c2-4320-8e71-f49cf4144cd2"
      unitRef="usd">-35300000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjItMy0xLTEtODIwOTI_91780fc8-79cb-49f7-b2b4-1c49c1d31451"
      unitRef="usd">8400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjMtMS0xLTEtODIwOTI_5a626f11-cd0b-40de-8024-d59de8f9c533"
      unitRef="usd">-4500000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjMtMy0xLTEtODIwOTI_f2350c0f-de44-4d4d-b7a8-1e49947fbad9"
      unitRef="usd">-1600000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjQtMS0xLTEtODIwOTI_9a1c21eb-50e6-4c48-b856-9c5444e67c39"
      unitRef="usd">-46500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjQtMy0xLTEtODIwOTI_8d56daeb-0789-4bd1-92d5-47dcc50f23ba"
      unitRef="usd">71800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjYtMS0xLTEtODIwOTI_f9a9e011-911b-477f-b232-4e6ccaea3544"
      unitRef="usd">6300000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjYtMy0xLTEtODIwOTI_d0194c26-e80a-4f7c-872e-6c8bf7fc3f46"
      unitRef="usd">7100000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjgtMS0xLTEtODIwOTI_df2dbf03-043b-4d86-84f6-48841910c7e2"
      unitRef="usd">52100000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjgtMy0xLTEtODIwOTI_2810ebf7-dde3-4cac-9baf-5c28e94499d2"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjktMS0xLTEtODIwOTI_c604fdbb-0c76-4e7f-97cb-5ac990fc6bed"
      unitRef="usd">17100000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMjktMy0xLTEtODIwOTI_05d718a0-3230-4efb-bda7-c834f4476082"
      unitRef="usd">15300000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzAtMS0xLTEtODIwOTI_909e19c3-bead-491f-8849-6d35928579ee"
      unitRef="usd">-41300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzAtMy0xLTEtODIwOTI_f79738f7-0459-4192-b314-64d8ef9d87cc"
      unitRef="usd">8200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzItMS0xLTEtODIwOTI_15981347-d09a-433f-882c-72f4d4aeb23f"
      unitRef="usd">300000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzItMy0xLTEtODIwOTI_780abfed-e8b0-4c10-8cf7-15d7e3a5d8b1"
      unitRef="usd">26500000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzMtMS0xLTEtODIwOTI_2d96124f-6530-4611-80b7-e4550ccb006e"
      unitRef="usd">5100000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzMtMy0xLTEtODIwOTI_adb0b948-d4ac-4022-b9a2-5ea148882883"
      unitRef="usd">500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzQtMS0xLTEtODIwOTI_861e59fe-31d5-4d28-a1ee-c3cab33a9a21"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzQtMy0xLTEtODIwOTI_3d6eda91-8b44-4613-99e4-c5df47283757"
      unitRef="usd">3300000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzUtMS0xLTEtODIwOTI_8f801b67-4722-459f-be0e-260f2d50c6dd"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzUtMy0xLTEtODIwOTI_dd6f533b-a4d8-4213-b633-e3700734eead"
      unitRef="usd">1200000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzYtMS0xLTEtODIwOTI_b3e904f0-5090-4179-9df4-0b6043025016"
      unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzYtMy0xLTEtODIwOTI_d1e47115-a64f-4f10-ae7b-363d1ed6c4f0"
      unitRef="usd">70000000.0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzctMS0xLTEtODIwOTI_8f264699-b278-4bb8-b189-cae543714089"
      unitRef="usd">-4800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzctMy0xLTEtODIwOTI_65e7926e-6569-4e9e-bbbb-cd16ddcabcdf"
      unitRef="usd">-48500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzgtMS0xLTEtODIwOTI_ceed73ba-f692-4f75-b880-bdbdba596847"
      unitRef="usd">-600000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfMzgtMy0xLTEtODIwOTI_45c0b8c3-fd63-4912-97c4-244e629aa670"
      unitRef="usd">400000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNDAtMS0xLTEtODIwOTI_909bf367-0d27-434d-9c50-70c90527c1b2"
      unitRef="usd">-93200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNDAtMy0xLTEtODIwOTI_a1ed847f-94a3-4f7c-8dd6-b44e2409e8af"
      unitRef="usd">31900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNDEtMS0xLTEtODIwOTI_39d908c5-8a4a-4206-8599-aa41e5a3caad"
      unitRef="usd">258400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i38f47e17df9c466eb0964b81d156f640_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNDEtMy0xLTEtODIwOTI_9236bd65-0309-4c14-b9f4-a6b62275bb88"
      unitRef="usd">117000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNDItMS0xLTEtODIwOTI_3d520b89-dbb3-4f2e-bd6a-9bf53b573e9b"
      unitRef="usd">165200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5c1c491ce07b46bf981a8c437b57ebe5_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8yOC9mcmFnOjc1NjU3YjdhMTRiYTRlYzJiNDg3ZjA4MWIzODkwM2RlL3RhYmxlOjJjNzAyNDczYTU3YTRlMTY5MWEyNWFhYTIwMWRhNWZkL3RhYmxlcmFuZ2U6MmM3MDI0NzNhNTdhNGUxNjkxYTI1YWFhMjAxZGE1ZmRfNDItMy0xLTEtODIwOTI_2447cf35-a9cd-4208-84d1-3e849ac927cd"
      unitRef="usd">148900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNC9mcmFnOmJjZGU2YjlmOGNiNTQ2YjQ4MWE2ZGNkNDdiNDQ3YTMyL3RleHRyZWdpb246YmNkZTZiOWY4Y2I1NDZiNDgxYTZkY2Q0N2I0NDdhMzJfNDQ2Mw_d53acbb3-e7a0-4140-8b2c-945a3375b70f">BASIS OF PRESENTATION&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Myriad Genetics, Inc. and its subsidiaries (collectively, the &#x201c;Company&#x201d; or &#x201c;Myriad&#x201d;) is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad develops and commercializes genetic tests that help assess the risk of developing disease or disease progression or guide treatment decisions across medical specialties.  The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021, by providing pharmaceutical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company currently operates as a single reporting segment. The Company&#x2019;s corporate headquarters are located in Salt Lake City, Utah.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company&#x2019;s audited Consolidated Financial Statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#x201c;Form 10-K&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three months ended March&#160;31, 2022 may not necessarily be indicative of results to be expected for any other interim period or for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically experienced seasonality in its testing business. In the quarters ended March 31, the Company has  typically experienced a decrease in volumes due to the annual reset of patient deductibles. Additionally, the volume of testing is  negatively impacted by the summer season, which is generally reflected in the quarter ended September 30th. The quarter ended December 31 is generally strong as the Company typically experiences an increase in volumes from patients who have met their annual insurance deductible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the ongoing COVID-19 global pandemic, including variants of COVID-19 (&#x201c;COVID-19&#x201d;), seasonality may not follow the same pattern as in prior years. Volumes and results of operations were impacted negatively in calendar year 2021 and early 2022 by COVID-19. As such, the Company&#x2019;s year over year results may not be comparable. Management continues to monitor the impact of COVID-19 on the Company&#x2019;s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the variants of COVID-19 that have surfaced around the world, the Company is not able to fully estimate the effects of COVID-19 on its results of operations, financial condition, or liquidity for future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform with the current period's presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders&#x2019; equity, cash flows from operations, or net loss for the period.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNC9mcmFnOmJjZGU2YjlmOGNiNTQ2YjQ4MWE2ZGNkNDdiNDQ3YTMyL3RleHRyZWdpb246YmNkZTZiOWY4Y2I1NDZiNDgxYTZkY2Q0N2I0NDdhMzJfNDQ2MQ_411e7750-8004-4521-84e7-ace257ff1592">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&#160;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company&#x2019;s audited Consolidated Financial Statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#x201c;Form 10-K&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three months ended March&#160;31, 2022 may not necessarily be indicative of results to be expected for any other interim period or for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNC9mcmFnOmJjZGU2YjlmOGNiNTQ2YjQ4MWE2ZGNkNDdiNDQ3YTMyL3RleHRyZWdpb246YmNkZTZiOWY4Y2I1NDZiNDgxYTZkY2Q0N2I0NDdhMzJfNDQ2NQ_8a229c41-9881-4b7c-87c5-c0d2ba7e8f24">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform with the current period's presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders&#x2019; equity, cash flows from operations, or net loss for the period.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNzE5Nw_4d1f547c-138a-456f-9e99-6e45c999f2dc">REVENUE&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Myriad primarily generates revenue by performing molecular diagnostic testing. Molecular diagnostic revenues are derived from the following categories of products: Hereditary Cancer (myRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, EndoPredict, and Precise), Prenatal (Foresight and Prequel), Pharmacogenomics (GeneSight), Autoimmune (Vectra), and Other. The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp;amp; Co. KG (the &#x201c;Clinic&#x201d;) in February 2020, respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Molecular diagnostic revenues. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents detail regarding the composition of the Company&#x2019;s total revenue by type and by U.S. versus rest of world (&#x201c;RoW&#x201d;):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;141.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;141.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical and clinical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;141.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company&#x2019;s performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During the fiscal year ended June 30, 2020, the Company received approximately $29.7 million in advance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments were applied against services performed in April 2021 and continued until the funds previously received were fully earned, which occurred during the quarter ended March 31, 2022. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC Topic 606, Revenue from Contracts with Customers, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#x2019;s right to payment is in an amount that directly corresponds with the value of the Company&#x2019;s performance to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company&#x2019;s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third party payors. During the three months ended March 31, 2022, the Company recognized $12.4 million in revenue, which resulted in a $0.12 impact to earnings per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#x2019;s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare which represents greater than 10% of its revenues. Revenues received from Medicare represented 13% and 19% of total revenue for the three months ended March&#160;31, 2022 and March&#160;31, 2021, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#x2019;s customers as well as their dispersion across many geographic regions. No payor accounted for more than 10% of accounts receivable at March&#160;31, 2022 or December&#160;31, 2021. The Company does not require collateral from its customers.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNzE5OQ_0c2ed63f-7b64-4a34-81d3-c1b2d551feba">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents detail regarding the composition of the Company&#x2019;s total revenue by type and by U.S. versus rest of world (&#x201c;RoW&#x201d;):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molecular diagnostic revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total molecular diagnostic revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;141.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;141.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical and clinical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;141.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1519c8391b842399d132e8fd6ef21f2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNC0xLTEtMS04MjA5Mg_ea0e18e2-3e40-4076-9084-39201755f4b8"
      unitRef="usd">60700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eb5af63f8b8413cbb2c5ccef8a23335_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNC0zLTEtMS04MjA5Mg_3558dad1-8b98-490a-9e11-21671b82101e"
      unitRef="usd">10200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a00625e25ad4bb19d387987d29c1b37_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNC01LTEtMS04MjA5Mg_52fcfb07-ddaa-4300-86c5-74774b45bfb8"
      unitRef="usd">70900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a0861127f384074bea6194dcadccff8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNC04LTEtMS04MjA5Mg_7bedba9f-c5bf-4c1c-9d7f-e9f21e94a46f"
      unitRef="usd">65100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i168a53dec81546e9841245e8c2ecad66_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNC0xMC0xLTEtODIwOTI_6b53c010-b3e1-47a9-8629-33cf99fb0bdc"
      unitRef="usd">11000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71aaffb802404ab2bd2254ac4935374c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNC0xMi0xLTEtODIwOTI_26b6073d-fc8b-4162-928a-e9e6165ad280"
      unitRef="usd">76100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic48d92006ed6462eaddb141061226da3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNS0xLTEtMS04MjA5Mg_c2111cd8-6850-48ff-b2e9-c582cae66b24"
      unitRef="usd">19700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb41f2d374db4b62bf6fca7d3c8b87a7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNS0zLTEtMS04MjA5Mg_bf5c7670-7127-44eb-89ce-f86764c0b7f4"
      unitRef="usd">12800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic124314e94e44fcfbb72df064864b2f6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNS01LTEtMS04MjA5Mg_90801345-0306-45a8-bcc0-de7d43959bee"
      unitRef="usd">32500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ef67c76df944005bcce30f068506e34_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNS04LTEtMS04MjA5Mg_2162cdd1-bada-4885-83df-d0bc5d4c5058"
      unitRef="usd">24200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96f84ba2616749a88b3f961574d23e09_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNS0xMC0xLTEtODIwOTI_e0eb4474-c96c-4839-b645-3f7192c61d53"
      unitRef="usd">6800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie57f1eaf9e8d430c860af6b4ed687e97_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNS0xMi0xLTEtODIwOTI_e09abf0d-bfb8-4424-95c7-325841345185"
      unitRef="usd">31000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30c094758e7a4db5b59bcf76bcabd03f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNi0xLTEtMS04MjA5Mg_e843e9dd-025f-48a1-bcb1-5597775fafbb"
      unitRef="usd">31700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f731ae454a94bd9a075b65ce61d8ee5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNi0zLTEtMS04MjA5Mg_f31c0b6e-1d1a-4c08-9220-c28a41b8d4ea"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie79831c4c3804d78a024b6129000343b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNi01LTEtMS04MjA5Mg_384dca7f-92cf-4b01-8c67-5063506a40ea"
      unitRef="usd">31900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdf8e565250c4b04bab9ef9d5c4ff45f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNi04LTEtMS04MjA5Mg_c8a76c9e-9be7-4f79-bde9-4520627926e7"
      unitRef="usd">23600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b03a6430a624a6b8f8e6bcd7cf82f56_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNi0xMC0xLTEtODIwOTI_3b37aac5-5453-4e72-9319-d7acbe4e82b6"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97fe976f531f43a09cf8064128efdc2f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNi0xMi0xLTEtODIwOTI_4d96779d-62e6-4ead-9ae5-52888054085c"
      unitRef="usd">23700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i057ec40f04944ea984f6ecb96adffb38_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNy0xLTEtMS04MjA5Mg_70c6f157-66e7-45b4-b096-4d7c84ee49d5"
      unitRef="usd">29300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia76e2445fd4247ce8565ace69a07cb58_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNy0zLTEtMS04MjA5Mg_a196ba17-8e38-48d3-be18-27faf4af176a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b860be39e224a04a1a68674e503b529_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNy01LTEtMS04MjA5Mg_949a0184-8c85-40e9-8a35-9e31f976ea50"
      unitRef="usd">29300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79ddeaedfccb40d88221e0e2d74fa96d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNy04LTEtMS04MjA5Mg_4ace4cf3-a97b-4db1-a722-6aab3e1d059e"
      unitRef="usd">17600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87691cf56a19478eb1f6544cf57295c9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNy0xMC0xLTEtODIwOTI_1d8acf4c-8227-4b7e-a5c3-ee9cef3b49b6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e4cecae202247c880970efaf5f9ee3e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfNy0xMi0xLTEtODIwOTI_5d669252-07fc-42fe-88fa-bb8770bbdbbc"
      unitRef="usd">17600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b19f57c78b44ad683bb1b4bd44e5f62_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOC0xLTEtMS04MjA5Mg_17fa574b-b9fc-4631-80c9-4a67415ab609"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82485441ef944386996ccf0d6e192050_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOC0zLTEtMS04MjA5Mg_03c2c3fa-a594-47ae-b181-c980ad566bb2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87f3f03808324e1b8cda4b6e447e0038_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOC01LTEtMS04MjA5Mg_5841c885-2cda-4494-a1ab-396e3904b9c2"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a108bb0e4d641a9ba014a3fb5413714_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOC04LTEtMS04MjA5Mg_d70185bd-bcac-4d32-b0a3-ca72091c64cb"
      unitRef="usd">10700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ea03d11e0304ccfb26dc185eac9a3d0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOC0xMC0xLTEtODIwOTI_37369bb5-a680-47bb-a789-86f1886b1c7e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3f29514d91043cb8814629006fe138c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOC0xMi0xLTEtODIwOTI_447c2608-58e9-4106-addf-e92ae33123fc"
      unitRef="usd">10700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d668be165244dd1be2739e4bddd8d6b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOS0xLTEtMS04MjA5Mg_80a6cacf-4553-4836-8c78-39766cd80c28"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1e28fc7eb7c417ca6677b3b6e228c4e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOS0zLTEtMS04MjA5Mg_653a8435-7f85-4e7f-b0e8-2eab818f8a03"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54fe3cc0d3b14d139aadd0a94943b49c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOS01LTEtMS04MjA5Mg_a4bfa7fd-9fd4-43aa-911a-cd3fadb06d7c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03a8be3329254025993297729bd21abe_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOS04LTEtMS04MjA5Mg_45e31eb6-d850-4ae9-b0ce-c16596c5cbf6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7b88a6e741b4f37bbb83847c7547ff3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOS0xMC0xLTEtODIwOTI_8f72bc83-b850-4295-b166-3280845483d0"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45649325d565477e9e05700b9cf7f061_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfOS0xMi0xLTEtODIwOTI_a31f43f9-2b32-4739-8b7d-e584f65a8ea4"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40fb715741a94f7e965b632953843495_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTAtMS0xLTEtODIwOTI_c5402ecf-6498-4f9b-9009-5346771c4c60"
      unitRef="usd">141700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99e56a4a61a6448ca8284c81c5072352_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTAtMy0xLTEtODIwOTI_73dbd270-8cb2-448f-85b7-acc7bc5294ac"
      unitRef="usd">23200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf33e5d604a449409285140d03ecf9c4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTAtNS0xLTEtODIwOTI_4dfa7fac-0ad0-49f6-8287-f15b8d911bed"
      unitRef="usd">164900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48867d19db404992b557cd1387f4e47f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTAtOC0xLTEtODIwOTI_e8fe624b-6f64-4fdc-8d21-237c1a9a194b"
      unitRef="usd">141200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87a32a4bbc484c8ab0294925b08b160c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTAtMTAtMS0xLTgyMDky_231dd416-9265-412c-8b96-923b2930c03c"
      unitRef="usd">18400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0028e3d51994bd79cb5c6bff0d75e18_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTAtMTItMS0xLTgyMDky_49783b57-4af3-42e3-b7fe-a3a935056960"
      unitRef="usd">159600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7abf3b2881464b55837ca122fffaf119_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTEtMS0xLTEtODIwOTI_7ad1592f-15c2-4d46-a36d-e785f43c2c82"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3255bff47e5459f88724051e2d8e564_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTEtMy0xLTEtODIwOTI_ff19fd27-e7ca-4f75-bbd2-7c3d09d0e211"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a6fd51a77104485bed5515365b14f90_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTEtNS0xLTEtODIwOTI_fc3f7d6e-cb92-43dd-8092-37562ed373e0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3a1622be8904dc6a17e7260d663d789_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTEtOC0xLTEtODIwOTI_36ea3076-7869-43f1-b54c-6051ac5e786b"
      unitRef="usd">13500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba63cbfb3f734a24bab843e8ad4d779e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTEtMTAtMS0xLTgyMDky_61e0f534-5cb9-45f9-a293-39dde388ac98"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51af4328f7a04a4b8cac37c1e5d162d6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTEtMTItMS0xLTgyMDky_036f290c-b313-4453-b79e-59dff1c73858"
      unitRef="usd">13500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8dbe812816b48cb830e84114c6d8f60_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTItMS0xLTEtODIwOTI_5ca16186-bde2-4c37-b607-53b36838bb83"
      unitRef="usd">141700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibda7b5c57b0c429db2fdc77635ae5e5c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTItMy0xLTEtODIwOTI_70820630-c641-4610-bf13-2e7add94f5a0"
      unitRef="usd">23200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTItNS0xLTEtODIwOTI_9d4dab69-9ec2-4696-a335-fa65bc8ba6de"
      unitRef="usd">164900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ca0e6bc0455492dbe206a7d48a02709_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTItOC0xLTEtODIwOTI_80755018-c849-456f-adb9-47cca4bfb5fa"
      unitRef="usd">154700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29edbbeae1f74f208e45c112f01268c7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTItMTAtMS0xLTgyMDky_55ed58d3-c760-4d5c-a34a-77ff501bc9cd"
      unitRef="usd">18400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOjU4N2Q5Yjk2MWNjOTRmM2NiYTRhYWY2ZWY0NmM0OWU5L3RhYmxlcmFuZ2U6NTg3ZDliOTYxY2M5NGYzY2JhNGFhZjZlZjQ2YzQ5ZTlfMTItMTItMS0xLTgyMDky_8df97989-cc32-45c5-a565-2e4df7a30954"
      unitRef="usd">173100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mygn:CARESActOf2020MedicarePaymentAmount
      contextRef="ied55de41f92a4292af6d62bd5c0088d0_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfMjAzMA_d168fda2-96e4-4e2e-b49d-f83da40fe4ee"
      unitRef="usd">29700000</mygn:CARESActOf2020MedicarePaymentAmount>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNzIwMA_e6eaf046-8db3-4a8f-89f3-13b59a51f7b9">A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfMi0xLTEtMS04MjA5Mg_91296977-c01d-40e6-84cc-951937d52eb5"
      unitRef="usd">5200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i38f47e17df9c466eb0964b81d156f640_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfMi00LTEtMS04MjA5Mg_7a6cfa80-8408-480a-bdc8-7b23d1de79d3"
      unitRef="usd">32700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfMy0xLTEtMS04MjA5Mg_6a64fbca-c486-46f5-8c7d-828a55e89d3e"
      unitRef="usd">4800000</mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfMy00LTEtMS04MjA5Mg_43672aac-ca46-4c4a-83c7-ba913bdf853d"
      unitRef="usd">6700000</mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <mygn:ContractWithCustomerLiabilityPrepayments
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfNC0xLTEtMS04MjA5Mg_73ba45c3-742b-4b4c-ada0-3084eb5241f3"
      unitRef="usd">300000</mygn:ContractWithCustomerLiabilityPrepayments>
    <mygn:ContractWithCustomerLiabilityPrepayments
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfNC00LTEtMS04MjA5Mg_20d902e2-15bc-4d36-a7ad-738fd2e3b1f3"
      unitRef="usd">5100000</mygn:ContractWithCustomerLiabilityPrepayments>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfNi0xLTEtMS04MjA5Mg_c3100a9a-eb91-4eba-aa13-c1f6c9e9fa44"
      unitRef="usd">700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5c1c491ce07b46bf981a8c437b57ebe5_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RhYmxlOmMxMmM2ODJjNzRkZDQ2YzI5ODAwZDlkZGVjNDVmYjEzL3RhYmxlcmFuZ2U6YzEyYzY4MmM3NGRkNDZjMjk4MDBkOWRkZWM0NWZiMTNfNi00LTEtMS04MjA5Mg_bb4e5448-a36c-4c83-9c4a-88e6389e055e"
      unitRef="usd">31100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNDkzOA_f9f95db5-1f23-4c6e-9440-8352383dccb3"
      unitRef="usd">12400000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <mygn:IncreaseDecreaseInEarningsLossPerShare
      contextRef="i9bc19c6cc66c4ff9a3b4c1f8519220c4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNDk5NA_811795fe-6a5e-44b9-adfa-a503c8487fc0"
      unitRef="usdPerShare">0.12</mygn:IncreaseDecreaseInEarningsLossPerShare>
    <us-gaap:CapitalizedContractCostGross
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNTYxMw_7558f6df-0067-4ded-af8a-6bce73332c15"
      unitRef="usd">0</us-gaap:CapitalizedContractCostGross>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if788ce35f1a7443780443d8285c4dabf_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfNjc4Nw_bea6fae0-229d-4cea-8745-6aa79cbffbaf"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icb95dc894d0d4604b1d478d160dbf2ce_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8zNy9mcmFnOmQ3YzZkNmJkNDI2YTRiMzc4NzQ0YWFhZTFmZTVkODAzL3RleHRyZWdpb246ZDdjNmQ2YmQ0MjZhNGIzNzg3NDRhYWFlMWZlNWQ4MDNfMTA5OTUxMTYzNTAwMg_a6647bc0-f832-4736-b78f-9c19a77e0996"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RleHRyZWdpb246N2Y3M2E2OTllZmNiNGYzZmFjMjExYTQ1MGIxNDUwMzdfNjEz_b777aa53-b722-416c-9205-c22c6fa3dc2b">MARKETABLE INVESTMENT SECURITIES&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March&#160;31, 2022 and December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;165.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;165.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;258.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;258.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;398.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information relating to fair value of marketable investment securities can be found in Note 4.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RleHRyZWdpb246N2Y3M2E2OTllZmNiNGYzZmFjMjExYTQ1MGIxNDUwMzdfNjE0_4df01f4f-fcb5-4004-99c8-6b5e74598f71">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at March&#160;31, 2022 and December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;165.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;165.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;258.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;258.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;398.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i136db30e02474345827ada253c52a3dc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMy0xLTEtMS04MjA5Mg_fea13666-4e6b-4fd0-ac5e-22335fce02e1"
      unitRef="usd">138000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i136db30e02474345827ada253c52a3dc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMy03LTEtMS04MjA5Mg_4361d3b3-1136-4819-a843-1f4c2e4a86e2"
      unitRef="usd">138000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a42c624b75245bcac04b9a7d1f99fdd_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNC0xLTEtMS04MjA5Mg_caee01ae-b2d7-4512-b273-9307ea4c5a23"
      unitRef="usd">27200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5a42c624b75245bcac04b9a7d1f99fdd_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNC03LTEtMS04MjA5Mg_778c7ee2-32ba-4b1f-afcf-21358ec281c0"
      unitRef="usd">27200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNS0xLTEtMS04MjA5Mg_b5375a03-9e39-4a3e-81b4-b6705eb60952"
      unitRef="usd">165200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNS03LTEtMS04MjA5Mg_f32955a7-f705-4803-bb4e-db246281d012"
      unitRef="usd">165200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i079b9de7e87d46e9bcccd402328b76f2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNy0xLTEtMS04MjA5Mg_69eb14e3-3fd2-4387-97e2-73b5950f5869"
      unitRef="usd">109100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i079b9de7e87d46e9bcccd402328b76f2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNy0zLTEtMS04MjA5Mg_7bec30cb-8833-49d0-ab43-d9a04f814b03"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i079b9de7e87d46e9bcccd402328b76f2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNy01LTEtMS04MjA5Mg_7bad139e-19f5-4f07-8ae7-cfd2e0b08a5b"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i079b9de7e87d46e9bcccd402328b76f2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfNy03LTEtMS04MjA5Mg_4bd0d83e-d940-422f-aa5b-cd26b8170f6b"
      unitRef="usd">108100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3979e6cb59c140e695831c1612356572_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOC0xLTEtMS04MjA5Mg_70e8541d-2237-4277-b37d-a251286503fe"
      unitRef="usd">21600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3979e6cb59c140e695831c1612356572_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOC0zLTEtMS04MjA5Mg_2bffcf82-d148-45d5-a812-7796f0159bb7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3979e6cb59c140e695831c1612356572_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOC01LTEtMS04MjA5Mg_3e0bb531-0375-4dd6-991d-ac9e73bf8b8e"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3979e6cb59c140e695831c1612356572_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOC03LTEtMS04MjA5Mg_af512f17-0daf-4ca5-92d4-5194b5a012e6"
      unitRef="usd">21400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i33295928e5bd414aada50cf100d5946c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOS0xLTEtMS04MjA5Mg_c8f9af94-29d3-4f48-9ec4-795e41dfa82e"
      unitRef="usd">18000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i33295928e5bd414aada50cf100d5946c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOS0zLTEtMS04MjA5Mg_ab0d236a-07de-472c-aafb-544e3b760d37"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i33295928e5bd414aada50cf100d5946c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOS01LTEtMS04MjA5Mg_1676a00a-937b-4ab7-8f2b-e60ff754a965"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33295928e5bd414aada50cf100d5946c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfOS03LTEtMS04MjA5Mg_e26435e8-916c-47fe-9c93-79d97e42f3b4"
      unitRef="usd">17700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i29a7ee8981794d99b60509cd1fbedcf6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTAtMS0xLTEtODIwOTI_3a5906a3-3af8-411d-9e0a-267a258259df"
      unitRef="usd">27000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i29a7ee8981794d99b60509cd1fbedcf6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTAtMy0xLTEtODIwOTI_a7ec0aba-e8d1-4adf-bba6-f2a0d99ab5e0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i29a7ee8981794d99b60509cd1fbedcf6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTAtNS0xLTEtODIwOTI_ebc2b779-a53f-4bb6-b323-fad3a47da6c2"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i29a7ee8981794d99b60509cd1fbedcf6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTAtNy0xLTEtODIwOTI_9ac5dd0a-fcec-4826-b409-62eef0e236e6"
      unitRef="usd">26800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <mygn:InvestmentsAndCashAmortizedCost
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTEtMS0xLTEtODIwOTI_a7ddb3b0-33c5-4fd4-abd8-ea476d2989d3"
      unitRef="usd">340900000</mygn:InvestmentsAndCashAmortizedCost>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTEtMy0xLTEtODIwOTI_82b97f91-af4f-4ea5-addd-4ecdba66ad47"
      unitRef="usd">0</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTEtNS0xLTEtODIwOTI_8db1f971-fbbc-48a7-b193-35ef9945df80"
      unitRef="usd">1700000</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsAndCash
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjVkOThiOTM4Njg5YTQ4ZDRhMzYyMTQ3NDUwYjc5ZDEzL3RhYmxlcmFuZ2U6NWQ5OGI5Mzg2ODlhNDhkNGEzNjIxNDc0NTBiNzlkMTNfMTEtNy0xLTEtODIwOTI_7b3d5473-dcc5-4432-b303-e08e3f33cd38"
      unitRef="usd">339200000</us-gaap:InvestmentsAndCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3bd84c1ecd394413b497049a3d8c0482_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMy0xLTEtMS04MjA5Mg_84fac36f-c64a-4ba9-bc34-8139b1d0e637"
      unitRef="usd">195200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3bd84c1ecd394413b497049a3d8c0482_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMy03LTEtMS04MjA5Mg_5694e26b-94dc-42e8-9f55-847a6c40b04c"
      unitRef="usd">195200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i11689e851c8f4f9a9804225d7cafc5bd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNC0xLTEtMS04MjA5Mg_79f33b6b-f272-4aad-9ca6-2a56d6f64c7a"
      unitRef="usd">63200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i11689e851c8f4f9a9804225d7cafc5bd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNC03LTEtMS04MjA5Mg_7b552155-d21f-4836-b447-0a77252463ca"
      unitRef="usd">63200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNS0xLTEtMS04MjA5Mg_e269f4fb-7a1e-4331-829f-62449918bbac"
      unitRef="usd">258400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNS03LTEtMS04MjA5Mg_67d22d2c-af5f-42d2-822b-2f054886cc02"
      unitRef="usd">258400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i353c741ab7484eb590076cce6cf8785f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNy0xLTEtMS04MjA5Mg_0490738b-aa91-4df0-872d-f570e72668f0"
      unitRef="usd">105700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i353c741ab7484eb590076cce6cf8785f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNy0zLTEtMS04MjA5Mg_4dd6a7e3-95bb-4c12-80b8-6529b562e5b5"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i353c741ab7484eb590076cce6cf8785f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNy01LTEtMS04MjA5Mg_13da0aee-9f41-4b7f-a3e1-0b9cd303be9d"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i353c741ab7484eb590076cce6cf8785f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfNy03LTEtMS04MjA5Mg_5104bb2e-acdd-4a99-974e-009b78edff99"
      unitRef="usd">105600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia61c6cbe23264dc3937f411e7be9e941_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOC0xLTEtMS04MjA5Mg_0ac25e4c-c340-489b-a1ab-18301e20cabe"
      unitRef="usd">16100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia61c6cbe23264dc3937f411e7be9e941_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOC0zLTEtMS04MjA5Mg_9e630074-16e0-441e-aa85-9e375c86a307"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia61c6cbe23264dc3937f411e7be9e941_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOC01LTEtMS04MjA5Mg_796514f9-d0ae-4bd2-924c-6859ba13a112"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia61c6cbe23264dc3937f411e7be9e941_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOC03LTEtMS04MjA5Mg_bb5c075a-d987-4ee6-9ad1-6aa281f36191"
      unitRef="usd">16100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i14b1f730f55149ffb4bc95c14af1afd4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOS0xLTEtMS04MjA5Mg_b40e3764-6d39-4ca8-b901-c046c107f77a"
      unitRef="usd">6800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i14b1f730f55149ffb4bc95c14af1afd4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOS0zLTEtMS04MjA5Mg_0a76d501-80cc-4561-96c2-55c301b3e415"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i14b1f730f55149ffb4bc95c14af1afd4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOS01LTEtMS04MjA5Mg_2a6414c4-774b-4ee9-b511-263ef687c2ed"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i14b1f730f55149ffb4bc95c14af1afd4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfOS03LTEtMS04MjA5Mg_c028c996-5240-4234-b2d6-265967cedef9"
      unitRef="usd">6800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i357d6b9001eb4f34ab4e5759c25bafad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTAtMS0xLTEtODIwOTI_85aa8004-3a99-4465-baaa-20799395752e"
      unitRef="usd">11900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i357d6b9001eb4f34ab4e5759c25bafad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTAtMy0xLTEtODIwOTI_554e05a0-4bf5-4a22-9742-8b3f3af89b1f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i357d6b9001eb4f34ab4e5759c25bafad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTAtNS0xLTEtODIwOTI_0465cddf-abd0-4ae3-87ab-6b9496310228"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i357d6b9001eb4f34ab4e5759c25bafad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTAtNy0xLTEtODIwOTI_083fa7c3-2075-4235-b2b6-5697556791bb"
      unitRef="usd">11900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <mygn:InvestmentsAndCashAmortizedCost
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTEtMS0xLTEtODIwOTI_5db3c9b5-f06e-40b0-98ca-f4c6f22d4df4"
      unitRef="usd">398900000</mygn:InvestmentsAndCashAmortizedCost>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTEtMy0xLTEtODIwOTI_ec60b5d5-95f5-4f21-bfac-ed87662ab26a"
      unitRef="usd">100000</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTEtNS0xLTEtODIwOTI_1bc5060d-5906-487c-a8eb-83f5a278698f"
      unitRef="usd">200000</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsAndCash
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjhjODMxNTMxNzRmZDQ5OWVhZjcxZTQ0NjE1OTY4MmMxL3RhYmxlcmFuZ2U6OGM4MzE1MzE3NGZkNDk5ZWFmNzFlNDQ2MTU5NjgyYzFfMTEtNy0xLTEtODIwOTI_4dbfd2c1-5eb2-4b8c-b2a2-ca8dc47b2c5d"
      unitRef="usd">398800000</us-gaap:InvestmentsAndCash>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RleHRyZWdpb246N2Y3M2E2OTllZmNiNGYzZmFjMjExYTQ1MGIxNDUwMzdfNjE1_68d7fda0-76df-40f5-b91e-85ca50bfa3fa">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i136db30e02474345827ada253c52a3dc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfMS0xLTEtMS04MjA5Mg_c2116633-3cb1-4922-9eac-3341840b1597"
      unitRef="usd">138000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i136db30e02474345827ada253c52a3dc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfMS0zLTEtMS04MjA5Mg_cbd0add2-afee-49d6-bcd9-84f6f7545693"
      unitRef="usd">138000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a42c624b75245bcac04b9a7d1f99fdd_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfMi0xLTEtMS04MjA5Mg_acba532b-f12d-482e-ac0c-b2985f419281"
      unitRef="usd">27200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5a42c624b75245bcac04b9a7d1f99fdd_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfMi0zLTEtMS04MjA5Mg_97cbf2c9-8d29-462d-af95-7aa7c98a2e46"
      unitRef="usd">27200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNC0xLTEtMS04MjA5Mg_b4fca1d6-73b2-4ec4-b325-592d871efb2b"
      unitRef="usd">103400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNC0zLTEtMS04MjA5Mg_e4edd363-25ff-4fa7-9de4-1cb2d1db2f70"
      unitRef="usd">103200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNS0xLTEtMS04MjA5Mg_74f7bc41-7d4f-4685-8f54-50c17fbb203e"
      unitRef="usd">72300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNS0zLTEtMS04MjA5Mg_33f6eb6e-0ef0-46e0-a0ca-437c9da6366c"
      unitRef="usd">70800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNi0xLTEtMS04MjA5Mg_575c88e5-9488-40c5-9dcc-d3b244005741"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNi0zLTEtMS04MjA5Mg_f355d1eb-57f2-45b5-86ce-9fe18605388d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <mygn:InvestmentsAndCashAmortizedCost
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNy0xLTEtMS04MjA5Mg_32a1cee9-4b7e-412d-8b2d-c05b702a9262"
      unitRef="usd">340900000</mygn:InvestmentsAndCashAmortizedCost>
    <us-gaap:InvestmentsAndCash
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80MC9mcmFnOjdmNzNhNjk5ZWZjYjRmM2ZhYzIxMWE0NTBiMTQ1MDM3L3RhYmxlOjAzNmRiZDA3N2FiMjRlNWVhMjBkMjQyNzFmNjJhNTJkL3RhYmxlcmFuZ2U6MDM2ZGJkMDc3YWIyNGU1ZWEyMGQyNDI3MWY2MmE1MmRfNy0zLTEtMS04MjA5Mg_ef3da600-3901-482b-b16c-431f1af9a83d"
      unitRef="usd">339200000</us-gaap:InvestmentsAndCash>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RleHRyZWdpb246MGYyZmY3NGM4M2Y3NDhhZTg2MDM0ZWEyYmY4ZmYyMjFfMzEzMw_aa56e58e-d083-4211-8941-208f9a71049b">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;&#160;Some of the Company&#x2019;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability.&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement period of approximately 13.3 years, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business.&#160;The contingent earn-out liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company&#x2019;s Condensed Consolidated Balance Sheets.&#160;&#160;Changes to contingent consideration liabilities are reflected in Selling, general and administrative expense in the Company&#x2019;s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;193.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table reconciles the change in the fair value of the contingent consideration during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value recognized in the Statement of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Translation adjustments recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm
      contextRef="id6ed914040924d00942b5531f455cea3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RleHRyZWdpb246MGYyZmY3NGM4M2Y3NDhhZTg2MDM0ZWEyYmY4ZmYyMjFfMTg3MQ_7096af37-0bc4-4650-8796-6db0c20e9a51">P13Y3M18D</mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RleHRyZWdpb246MGYyZmY3NGM4M2Y3NDhhZTg2MDM0ZWEyYmY4ZmYyMjFfMzEzNA_ed5bdbb2-1df7-4ed5-a5fe-6bf64dbed715">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;193.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i08e3194cd9264422920009833989a9f4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMi0xLTEtMS04MjA5Mg_46475e38-2880-4c43-a7c5-79e98e4907eb"
      unitRef="usd">27200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i45e4529dc74b46368324bb8e8304fae6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMi0zLTEtMS04MjA5Mg_4c2e91fc-409b-4b86-8019-09bef765b4c3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic383f28c706e43be88cc15989d93d8bf_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMi01LTEtMS04MjA5Mg_edd21aa2-45da-4410-a6c2-c5a1cd511fd4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1149c109c7944153bce0f07495ff3516_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMi03LTEtMS04MjA5Mg_86207f18-45b3-4352-aa89-bcb01bca4a97"
      unitRef="usd">27200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4683011548b54f0d9ebf8e148ae0cb58_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMy0xLTEtMS04MjA5Mg_03a50a4b-0068-44f6-9005-9d1210ba7e32"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib523b385ec3e473889798b06a5b0e42c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMy0zLTEtMS04MjA5Mg_f5f264fa-c22e-4d5e-af24-91c601ad72bd"
      unitRef="usd">108100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i093a64b69b8c4abeaf4706d4a48aced8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMy01LTEtMS04MjA5Mg_0d8e062a-bd37-40a2-b25d-f6206d25b221"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i079b9de7e87d46e9bcccd402328b76f2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfMy03LTEtMS04MjA5Mg_440dd62b-e08a-4f31-b227-b5a01646d609"
      unitRef="usd">108100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0db6ed20d3b7496abd3bc2149d9f0911_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNC0xLTEtMS04MjA5Mg_89ff6f3f-da3c-45cc-818f-385205257d2b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib288a6a85cb34b21a1848dd46ede7ea7_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNC0zLTEtMS04MjA5Mg_6d993bc8-0e18-4f97-a5ba-1ce149230a8e"
      unitRef="usd">21400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0a9e29a9d23b4534a84fb267bb955273_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNC01LTEtMS04MjA5Mg_11384512-4bb4-477b-bfd4-0d280d522814"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3979e6cb59c140e695831c1612356572_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNC03LTEtMS04MjA5Mg_9f265cb3-cce0-4b49-94b7-02a5cecae938"
      unitRef="usd">21400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i73ec880d0b0e4b1ca8cf3ae965faa17a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNS0xLTEtMS04MjA5Mg_c5f483c7-e0ae-403f-baa9-04dfb08fc920"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i57812bb46fe444018878a29051cb790e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNS0zLTEtMS04MjA5Mg_521085f6-454e-49c1-9de9-9c2138278556"
      unitRef="usd">17700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d28eeea16924dc8b5cbe6c78890f671_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNS01LTEtMS04MjA5Mg_2b711ccc-df85-4ac6-96b0-9e4b94203f05"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i33295928e5bd414aada50cf100d5946c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNS03LTEtMS04MjA5Mg_1d89d325-a22e-4823-bfac-c6c7e9e297d8"
      unitRef="usd">17700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icc4b68d2f71a40e0873b52510f156925_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNi0xLTEtMS04MjA5Mg_e2010772-f7ba-4027-9001-0485b23b1345"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3e850fa3529c440d8963459b76c7b82e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNi0zLTEtMS04MjA5Mg_86fcec14-0967-40d3-851f-fdd7d9f8d832"
      unitRef="usd">26800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifcb86fc367024853965b38c7d1144948_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNi01LTEtMS04MjA5Mg_c94c394e-2424-4886-9303-37095853bec1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i29a7ee8981794d99b60509cd1fbedcf6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNi03LTEtMS04MjA5Mg_9f0c69c6-7112-4812-8f86-b122e7c37230"
      unitRef="usd">26800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idfe95fe4dd354dbd98eabe24039da4d9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNy0xLTEtMS04MjA5Mg_40329c36-186f-4428-accb-4dc8f90b87f0"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i29cf1314b6ca487490b61e18b013ff26_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNy0zLTEtMS04MjA5Mg_653fa26d-0dad-420c-b741-5e9d79825747"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2604abe8133848178f910dd24f6b3462_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNy01LTEtMS04MjA5Mg_ee6414f3-c7be-4ae1-a5d7-09233c205087"
      unitRef="usd">7900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if8170fc4406e43bdbb3216785308da75_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfNy03LTEtMS04MjA5Mg_655fa52e-a78f-4529-8ce8-dc4870f907e3"
      unitRef="usd">7900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i1e05e765ecae4061bff51a2cb034aa20_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfOC0xLTEtMS04MjA5Mg_02e295ae-713c-45d8-a41b-2414b43e79a5"
      unitRef="usd">27200000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i9035568ac69b433da12c2f4a2affbff1_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfOC0zLTEtMS04MjA5Mg_e3e6cba1-088d-4462-8f35-4d2dbefa79b3"
      unitRef="usd">174000000.0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="iab78bf60a5c942cc87ccc71b20df6a27_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfOC01LTEtMS04MjA5Mg_95d93284-f9a5-4c01-b084-4e23ccfecee8"
      unitRef="usd">-7900000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjAyOWViNzFjMWJkNDRiYzc4ZDcwNWFiOWEwNmQwYmYyL3RhYmxlcmFuZ2U6MDI5ZWI3MWMxYmQ0NGJjNzhkNzA1YWI5YTA2ZDBiZjJfOC03LTEtMS04MjA5Mg_a179523a-d2be-4ff8-9ebb-97359b782962"
      unitRef="usd">193300000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaf0f4b68da2b4515afa573f19f88ff4e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMi0xLTEtMS04MjA5Mg_e7ce93fa-7179-48ce-8d63-63f16462ca20"
      unitRef="usd">63200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if4ae2273e9614043945b8f236bd47dfd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMi0zLTEtMS04MjA5Mg_cff42b6d-a2d0-4744-8076-d8206d943a81"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id72e536fe9d14ae6ab7cb34094bb9d39_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMi01LTEtMS04MjA5Mg_f0a01537-9b3b-4275-b372-3db14a802900"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6bb9b95d87db4378a84eed47d440eb40_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMi03LTEtMS04MjA5Mg_564e980f-de4e-466e-985a-9962a98117d1"
      unitRef="usd">63200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6de004c7a5244c518e0a748f1c208172_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMy0xLTEtMS04MjA5Mg_f40de04e-d82e-457d-91b3-12e00b8c117e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i528dc644c9ff4943b02b055e4f0985a4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMy0zLTEtMS04MjA5Mg_70febf95-2919-4b23-9bbb-98633f73c0c1"
      unitRef="usd">105600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3e871c32c4824df6aba031d957b820f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMy01LTEtMS04MjA5Mg_d37f75b8-3798-4c26-ad58-e42a16f8d6a6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i353c741ab7484eb590076cce6cf8785f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfMy03LTEtMS04MjA5Mg_3980381b-337f-4328-aa52-3c4df8ba7eb3"
      unitRef="usd">105600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idf97501434e045bdbec15630658c5c1b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNC0xLTEtMS04MjA5Mg_a004dd89-84d6-4a45-95ad-deadf70df812"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i07615525c7da4600a164f6377287dda5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNC0zLTEtMS04MjA5Mg_4ec8da18-1575-4c34-a856-d9960ca6fc47"
      unitRef="usd">16100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3e2f08fba40d4ba3af31fe0475b3de3e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNC01LTEtMS04MjA5Mg_456359f8-056b-4450-9d5c-c968771e82d8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia61c6cbe23264dc3937f411e7be9e941_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNC03LTEtMS04MjA5Mg_7df52aaa-19e1-4bda-8967-022b0906ac1c"
      unitRef="usd">16100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0bc70dfe49e04a118a51198b256f8dae_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNS0xLTEtMS04MjA5Mg_8b232315-82f6-435a-94fe-3c79de74a393"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic5de6b4aac9841a5b074aec661dd7e40_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNS0zLTEtMS04MjA5Mg_02216fd2-e30d-4e17-be32-623ee1ad9de1"
      unitRef="usd">6800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i78479d9de84a4fa987db5df225bb0dc9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNS01LTEtMS04MjA5Mg_a54a1d61-e427-4c04-ba3d-2e2a4fdc7db0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i14b1f730f55149ffb4bc95c14af1afd4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNS03LTEtMS04MjA5Mg_b84a1944-fe74-4aa0-b239-7f16696944fa"
      unitRef="usd">6800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if9714eb29e60483d97d657c738112562_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNi0xLTEtMS04MjA5Mg_b5735577-2fe1-4b5c-87b1-922ea62a87bb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia84c478ac57b495fa98f396e489b0dfd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNi0zLTEtMS04MjA5Mg_fceb7761-e7ca-45a1-b27d-e4538c7a40cc"
      unitRef="usd">11900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i859a42bcc97943128dc28bd68082557d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNi01LTEtMS04MjA5Mg_943d2704-4120-4c40-8f0f-46b204f9a514"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i357d6b9001eb4f34ab4e5759c25bafad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNi03LTEtMS04MjA5Mg_88c9b116-df81-481c-bf73-aaedea50a75c"
      unitRef="usd">11900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0e3c14443da2478fbd20257901c8b17d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNy0xLTEtMS04MjA5Mg_8dee661c-9efd-4599-bf11-8c3e3067e9da"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i10f83fadc928439aae7775e2a66e9369_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNy0zLTEtMS04MjA5Mg_463a49b8-99bc-4256-a0c0-80708802ceed"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia71dcd4c9af541eead967fd44feac0ee_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNy01LTEtMS04MjA5Mg_3c5fffa4-42a7-42eb-a388-9d08e561a556"
      unitRef="usd">8600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5990b598e2d1460597cd94495019968d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfNy03LTEtMS04MjA5Mg_e496c011-4775-4400-9408-b83ae8786f7d"
      unitRef="usd">8600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i51f0f49e3b5045d5b1be9e63528af3ce_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfOC0xLTEtMS04MjA5Mg_dfd8d1b5-49cf-4c6c-97c0-5325b757e97f"
      unitRef="usd">63200000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="ic9a60ca8f13e4a989f4559d73febd0b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfOC0zLTEtMS04MjA5Mg_8ef99fae-6faa-45c3-919b-0be9edccef1e"
      unitRef="usd">140400000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i8b8d4e9c04da414c897ed06bbbf510d4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfOC01LTEtMS04MjA5Mg_3637cf5a-339a-48d5-916f-01e9ba19a92c"
      unitRef="usd">-8600000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjU0ZGE5MDk3MjIzNjRlYzliZTg2OTBmMGNlZGUyNjNjL3RhYmxlcmFuZ2U6NTRkYTkwOTcyMjM2NGVjOWJlODY5MGYwY2VkZTI2M2NfOC03LTEtMS04MjA5Mg_38ea86b4-8518-409f-99de-47c21c16bf29"
      unitRef="usd">195000000.0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RleHRyZWdpb246MGYyZmY3NGM4M2Y3NDhhZTg2MDM0ZWEyYmY4ZmYyMjFfMzEzNQ_3c807972-0714-4328-bb48-751bcc6825d4">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table reconciles the change in the fair value of the contingent consideration during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value recognized in the Statement of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Translation adjustments recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjNhZmRjZmJmNjE4MzQ5Y2ZhYTk5NDBmNTFkM2E4MjZiL3RhYmxlcmFuZ2U6M2FmZGNmYmY2MTgzNDljZmFhOTk0MGY1MWQzYTgyNmJfMS0xLTEtMS04MjA5Mg_654f1a25-89cb-4786-b39f-8065fe93f20e"
      unitRef="usd">8600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjNhZmRjZmJmNjE4MzQ5Y2ZhYTk5NDBmNTFkM2E4MjZiL3RhYmxlcmFuZ2U6M2FmZGNmYmY2MTgzNDljZmFhOTk0MGY1MWQzYTgyNmJfMy0xLTEtMS04MjA5Mg_e1b569dd-31c1-4f81-886c-51a74c294ee4"
      unitRef="usd">500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjNhZmRjZmJmNjE4MzQ5Y2ZhYTk5NDBmNTFkM2E4MjZiL3RhYmxlcmFuZ2U6M2FmZGNmYmY2MTgzNDljZmFhOTk0MGY1MWQzYTgyNmJfNC0xLTEtMS04MjA5Mg_e057bd6a-7fa5-43bb-9abf-7678e0dadca2"
      unitRef="usd">200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80My9mcmFnOjBmMmZmNzRjODNmNzQ4YWU4NjAzNGVhMmJmOGZmMjIxL3RhYmxlOjNhZmRjZmJmNjE4MzQ5Y2ZhYTk5NDBmNTFkM2E4MjZiL3RhYmxlcmFuZ2U6M2FmZGNmYmY2MTgzNDljZmFhOTk0MGY1MWQzYTgyNmJfNS0xLTEtMS04MjA5Mg_5ecf0b69-4c64-4d15-8b47-bd80f5ade910"
      unitRef="usd">7900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RleHRyZWdpb246ODRjOGJmNjEzYTRmNDAwNWIwMDk4ZTI2NTNkZWZlNWJfMjc4_55423821-dc14-48aa-8376-43bb96a34d3e">PROPERTY, PLANT AND EQUIPMENT, NET&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;150.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(103.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(106.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, the Company ceased the use of one of its leased Salt Lake City facilities. As a result, the Company recognized a $2.1 million impairment on the property, plant and equipment associated with the lease, which consisted primarily of leasehold improvements. See Note 15 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RleHRyZWdpb246ODRjOGJmNjEzYTRmNDAwNWIwMDk4ZTI2NTNkZWZlNWJfMjc3_e31d93cf-f0ae-4121-86b5-dcf87fd412bc">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;150.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(103.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(106.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, the Company ceased the use of one of its leased Salt Lake City facilities. As a result, the Company recognized a $2.1 million impairment on the property, plant and equipment associated with the lease, which consisted primarily of leasehold improvements. See Note 15 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic5028f46356f458f8cd14be716668ff9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfMS0xLTEtMS04MjA5Mg_62bf4852-4dbb-4421-b20b-2bf14722ebf5"
      unitRef="usd">34200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i93acac9c7ae94d1aa34a4be6c6c75cfe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfMS00LTEtMS04MjA5Mg_12a7a1b6-d61f-4895-a589-a29a41de58c3"
      unitRef="usd">38000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia8fe2de508784dd7a2055d130fa36acb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfMi0xLTEtMS04MjA5Mg_c55ed863-c503-4bf6-8a25-d1e56dba610a"
      unitRef="usd">114900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i174cf853880a4694890b201c320822fa_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfMi00LTEtMS04MjA5Mg_70359e62-568c-4e44-8deb-22ed66145fa6"
      unitRef="usd">112400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfMy0xLTEtMS04MjA5Mg_2e7e902f-e532-4f17-be8d-5a1388978ada"
      unitRef="usd">149100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfMy00LTEtMS04MjA5Mg_cc43cbde-5009-4230-870e-505d07e8c273"
      unitRef="usd">150400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfNC0xLTEtMS04MjA5Mg_e18f103e-45ff-4f2d-a3df-8eaf588c6608"
      unitRef="usd">103400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfNC00LTEtMS04MjA5Mg_2b2aa635-bdd6-4239-8881-f323c355bc36"
      unitRef="usd">106900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfNS0xLTEtMS04MjA5Mg_cbec9b5d-500b-4ec9-839f-2f1c96e8b4c1"
      unitRef="usd">45700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOjEzY2FhZjM4NzQ5NjRmODhiOWNmMWMxZTBkZDc3YjFhL3RhYmxlcmFuZ2U6MTNjYWFmMzg3NDk2NGY4OGI5Y2YxYzFlMGRkNzdiMWFfNS00LTEtMS04MjA5Mg_20e17f62-37e0-4a4b-91da-65349b56f78d"
      unitRef="usd">43500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i49163efc76014827a31448fd386b5085_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RleHRyZWdpb246ODRjOGJmNjEzYTRmNDAwNWIwMDk4ZTI2NTNkZWZlNWJfMTA5OTUxMTYyOTA0OQ_f87163a7-256e-43b3-ad91-5ab877827bec"
      unitRef="usd">2100000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:Depreciation
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOmQ1YTJlNTRiMDY4YTQ5YWY5ZTYyMTAxN2U2NGI4OGI0L3RhYmxlcmFuZ2U6ZDVhMmU1NGIwNjhhNDlhZjllNjIxMDE3ZTY0Yjg4YjRfMi0xLTEtMS04MjA5Mg_3bfbf4f5-4878-4c1e-b870-5abc59b73958"
      unitRef="usd">2800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80Ni9mcmFnOjg0YzhiZjYxM2E0ZjQwMDViMDA5OGUyNjUzZGVmZTViL3RhYmxlOmQ1YTJlNTRiMDY4YTQ5YWY5ZTYyMTAxN2U2NGI4OGI0L3RhYmxlcmFuZ2U6ZDVhMmU1NGIwNjhhNDlhZjllNjIxMDE3ZTY0Yjg4YjRfMi0zLTEtMS04MjA5Mg_740268f1-4be4-421a-bb38-9a7f3cd95b47"
      unitRef="usd">2900000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RleHRyZWdpb246YmRlYmY1ZDEyYTMzNDM4NWI3ZGY2Yjc0ZTVhMjRiOTlfMTU0Mw_d8fde79d-9351-44e9-ab38-440b900ba00e">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consists of purchased licenses and technologies. The following summarizes the amounts reported as intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;616.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(222.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;393.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;616.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(222.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;393.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded amortization expense during the respective periods for these intangible assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RleHRyZWdpb246YmRlYmY1ZDEyYTMzNDM4NWI3ZGY2Yjc0ZTVhMjRiOTlfMTU0NA_d58718c6-70f7-4f0e-8e7a-23316f4d0ab2">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOmYzNGJlZDZjMjJjZDQ3N2Q4ZGRkMTYxYjIzZjgyMDgyL3RhYmxlcmFuZ2U6ZjM0YmVkNmMyMmNkNDc3ZDhkZGQxNjFiMjNmODIwODJfMS01LTEtMS04MjA5Mg_d563ef14-8b0c-479c-a51c-8edf0b1e4576"
      unitRef="usd">239200000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOmYzNGJlZDZjMjJjZDQ3N2Q4ZGRkMTYxYjIzZjgyMDgyL3RhYmxlcmFuZ2U6ZjM0YmVkNmMyMmNkNDc3ZDhkZGQxNjFiMjNmODIwODJfMy01LTEtMS04MjA5Mg_bfdd2f46-3fe1-490b-a66b-32f74fb19cc1"
      unitRef="usd">-400000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOmYzNGJlZDZjMjJjZDQ3N2Q4ZGRkMTYxYjIzZjgyMDgyL3RhYmxlcmFuZ2U6ZjM0YmVkNmMyMmNkNDc3ZDhkZGQxNjFiMjNmODIwODJfNC01LTEtMS04MjA5Mg_f71e4011-6a0c-4729-8a84-c8da7fa49e4f"
      unitRef="usd">238800000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RleHRyZWdpb246YmRlYmY1ZDEyYTMzNDM4NWI3ZGY2Yjc0ZTVhMjRiOTlfMTU0NQ_22f005ab-b28e-4707-b4fe-a099e319ba78">The following summarizes the amounts reported as intangible assets:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;616.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(222.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;393.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;616.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(222.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;393.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RleHRyZWdpb246YmRlYmY1ZDEyYTMzNDM4NWI3ZGY2Yjc0ZTVhMjRiOTlfMTU0NQ_9311598c-8da8-46cd-9920-a6f974ad0729">The following summarizes the amounts reported as intangible assets:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;616.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(222.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;393.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;616.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(222.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;393.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchased licenses and technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i48dce0415e7b4acd9af7a58cea440e09_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjUwZGVhYjBmOTZhZDQ4MjhhNzQwYjg5MzkwNDM0MThmL3RhYmxlcmFuZ2U6NTBkZWFiMGY5NmFkNDgyOGE3NDBiODkzOTA0MzQxOGZfMi0xLTEtMS04MjA5Mg_f01983c6-0e33-4052-a521-a4157a525662"
      unitRef="usd">616100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i48dce0415e7b4acd9af7a58cea440e09_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjUwZGVhYjBmOTZhZDQ4MjhhNzQwYjg5MzkwNDM0MThmL3RhYmxlcmFuZ2U6NTBkZWFiMGY5NmFkNDgyOGE3NDBiODkzOTA0MzQxOGZfMi0zLTEtMS04MjA5Mg_f2016c4d-b375-4fbd-b357-6cebd58ccfa8"
      unitRef="usd">222500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i48dce0415e7b4acd9af7a58cea440e09_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjUwZGVhYjBmOTZhZDQ4MjhhNzQwYjg5MzkwNDM0MThmL3RhYmxlcmFuZ2U6NTBkZWFiMGY5NmFkNDgyOGE3NDBiODkzOTA0MzQxOGZfMi01LTEtMS04MjA5Mg_1d0fba74-c6d3-47f3-aede-f01ce64b9714"
      unitRef="usd">393600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjUwZGVhYjBmOTZhZDQ4MjhhNzQwYjg5MzkwNDM0MThmL3RhYmxlcmFuZ2U6NTBkZWFiMGY5NmFkNDgyOGE3NDBiODkzOTA0MzQxOGZfNC0xLTEtMS04MjA5Mg_fa1cc2a3-4f57-4032-9220-80493c226f13"
      unitRef="usd">616100000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjUwZGVhYjBmOTZhZDQ4MjhhNzQwYjg5MzkwNDM0MThmL3RhYmxlcmFuZ2U6NTBkZWFiMGY5NmFkNDgyOGE3NDBiODkzOTA0MzQxOGZfNC0zLTEtMS04MjA5Mg_f111c6fb-d43b-4909-b74c-6a8056441a1f"
      unitRef="usd">222500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjUwZGVhYjBmOTZhZDQ4MjhhNzQwYjg5MzkwNDM0MThmL3RhYmxlcmFuZ2U6NTBkZWFiMGY5NmFkNDgyOGE3NDBiODkzOTA0MzQxOGZfNC01LTEtMS04MjA5Mg_bbbdac26-2c0b-40cb-bff8-5cf966776fcc"
      unitRef="usd">393600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1016b9209b0844a8a1fe882aaf69c3fe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjE5ZmE1ZjgxZDA3YTQ4YjJhNDU5MWMwM2QxZTgwOTA2L3RhYmxlcmFuZ2U6MTlmYTVmODFkMDdhNDhiMmE0NTkxYzAzZDFlODA5MDZfMi0xLTEtMS04MjA5Mg_a7831469-9883-404a-91cd-ebe122a7962f"
      unitRef="usd">616600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1016b9209b0844a8a1fe882aaf69c3fe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjE5ZmE1ZjgxZDA3YTQ4YjJhNDU5MWMwM2QxZTgwOTA2L3RhYmxlcmFuZ2U6MTlmYTVmODFkMDdhNDhiMmE0NTkxYzAzZDFlODA5MDZfMi0zLTEtMS04MjA5Mg_e425421e-35dc-4f4a-b611-40d7c19f6bda"
      unitRef="usd">212500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1016b9209b0844a8a1fe882aaf69c3fe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjE5ZmE1ZjgxZDA3YTQ4YjJhNDU5MWMwM2QxZTgwOTA2L3RhYmxlcmFuZ2U6MTlmYTVmODFkMDdhNDhiMmE0NTkxYzAzZDFlODA5MDZfMi01LTEtMS04MjA5Mg_bbe3a4e8-8dd8-4c7d-b0be-289d3eafdf57"
      unitRef="usd">404100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjE5ZmE1ZjgxZDA3YTQ4YjJhNDU5MWMwM2QxZTgwOTA2L3RhYmxlcmFuZ2U6MTlmYTVmODFkMDdhNDhiMmE0NTkxYzAzZDFlODA5MDZfOC0xLTEtMS04MjA5Mg_325cce9c-2b77-4409-a43a-d746da1e7cd6"
      unitRef="usd">616600000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjE5ZmE1ZjgxZDA3YTQ4YjJhNDU5MWMwM2QxZTgwOTA2L3RhYmxlcmFuZ2U6MTlmYTVmODFkMDdhNDhiMmE0NTkxYzAzZDFlODA5MDZfOC0zLTEtMS04MjA5Mg_3b642965-a618-41c9-bb0e-8a30cb9ab2af"
      unitRef="usd">212500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOjE5ZmE1ZjgxZDA3YTQ4YjJhNDU5MWMwM2QxZTgwOTA2L3RhYmxlcmFuZ2U6MTlmYTVmODFkMDdhNDhiMmE0NTkxYzAzZDFlODA5MDZfOC01LTEtMS04MjA5Mg_3e24a394-031a-4fe7-9928-1449b9da559a"
      unitRef="usd">404100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RleHRyZWdpb246YmRlYmY1ZDEyYTMzNDM4NWI3ZGY2Yjc0ZTVhMjRiOTlfMTU0Ng_1771fa83-13b6-485a-83d0-c63fe9f46688">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded amortization expense during the respective periods for these intangible assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOmE3MzA1ODM5MDBjMDRiYzBiOGExYzJiMzFkZWNkNTY3L3RhYmxlcmFuZ2U6YTczMDU4MzkwMGMwNGJjMGI4YTFjMmIzMWRlY2Q1NjdfMi0xLTEtMS04MjA5Mg_4556dd73-8903-40d0-b0f9-6d464578e8b0"
      unitRef="usd">10200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl80OS9mcmFnOmJkZWJmNWQxMmEzMzQzODViN2RmNmI3NGU1YTI0Yjk5L3RhYmxlOmE3MzA1ODM5MDBjMDRiYzBiOGExYzJiMzFkZWNkNTY3L3RhYmxlcmFuZ2U6YTczMDU4MzkwMGMwNGJjMGI4YTFjMmIzMWRlY2Q1NjdfMi00LTEtMS04MjA5Mg_785c6462-b1a0-4742-ae43-01bb020e333f"
      unitRef="usd">15500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RleHRyZWdpb246ZmFmYTE4ZmEwZmFhNGZlMTkxODljYmRiNjQ1ODVhNDNfMjQw_f10a6727-765b-4776-a12e-f0da5983fd15">ACCRUED LIABILITIES&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal charges pending settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refunds payable and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;124.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;156.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RleHRyZWdpb246ZmFmYTE4ZmEwZmFhNGZlMTkxODljYmRiNjQ1ODVhNDNfMjQx_f47d18c0-caed-4320-ab5f-9211dc5f708a">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal charges pending settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refunds payable and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;124.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;156.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfMS0xLTEtMS04MjA5Mg_7d3bb20c-963d-49a4-a08a-665898f796e3"
      unitRef="usd">37900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfMS00LTEtMS04MjA5Mg_bd8e3ffa-7630-4806-a81a-686874f5543f"
      unitRef="usd">52800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfMi0xLTEtMS04MjA5Mg_f4fdcbb0-43a3-47c2-84e2-b2c204f486a0"
      unitRef="usd">48000000.0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfMi00LTEtMS04MjA5Mg_8b3600b9-24f0-4c28-9ff5-7ab38ec91041"
      unitRef="usd">62000000.0</us-gaap:LitigationReserveCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfMy0xLTEtMS04MjA5Mg_eccad45d-6854-488d-8fa2-da1327ed7ba9"
      unitRef="usd">4100000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfMy00LTEtMS04MjA5Mg_95738364-abd6-402a-b219-d6d6a3ebafd8"
      unitRef="usd">4000000.0</us-gaap:TaxesPayableCurrent>
    <mygn:RefundsPayableAndReserveCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfNC0xLTEtMS04MjA5Mg_a78abc4b-d914-4271-9228-ecf81e3aaa53"
      unitRef="usd">9200000</mygn:RefundsPayableAndReserveCurrent>
    <mygn:RefundsPayableAndReserveCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfNC00LTEtMS04MjA5Mg_7109e48e-950e-454d-9bce-d7f76c40cdb1"
      unitRef="usd">9800000</mygn:RefundsPayableAndReserveCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfNS0xLTEtMS04MjA5Mg_c3fca526-755c-4723-9bc9-951241e4f13b"
      unitRef="usd">3100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfNS00LTEtMS04MjA5Mg_1607d06a-06f5-42b1-beff-160b84d1dde8"
      unitRef="usd">3200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfNi0xLTEtMS04MjA5Mg_ac7a31da-95b6-4175-bdab-9743391a93ef"
      unitRef="usd">5000000.0</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfNi00LTEtMS04MjA5Mg_23e8c434-000b-4e86-8f56-2d4df7953d33"
      unitRef="usd">5400000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfOC0xLTEtMS04MjA5Mg_d2907e10-d762-4a0e-ade0-1f5c02d73d06"
      unitRef="usd">17500000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfOC00LTEtMS04MjA5Mg_7c87b954-ace8-42d5-a0c2-fbce7b00cd87"
      unitRef="usd">19300000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfOS0xLTEtMS04MjA5Mg_c8ce3cd2-872c-4e3d-a76b-1da0e58d5cc8"
      unitRef="usd">124800000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81Mi9mcmFnOmZhZmExOGZhMGZhYTRmZTE5MTg5Y2JkYjY0NTg1YTQzL3RhYmxlOjFiMDNhYmMxMDAwYjQwMWNhZGViNjU1MmU1MmEwZDJiL3RhYmxlcmFuZ2U6MWIwM2FiYzEwMDBiNDAxY2FkZWI2NTUyZTUyYTBkMmJfOS00LTEtMS04MjA5Mg_76f89aa7-ffc3-4b4b-80f6-96d79d1d74e8"
      unitRef="usd">156500000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfNDczNQ_fc45478b-735c-40fc-a50c-2cbbb30b6c92">LONG-TERM DEBT&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 23, 2016, the Company entered into a senior secured revolving credit facility (the &#x201c;Facility&#x201d;) as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 to the Facility, which effected an &#x201c;amend and extend&#x201d; transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million.&#160;On May 1, 2020, the Company entered into Amendment No. 2 to the Facility, which waived the Company&#x2019;s compliance with certain covenants and modified the interest rate and other terms during the modification period from March 31, 2020 through June 30, 2021 (&#x201c;Modification Period&#x201d;). This included a modification to the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021, as well as revision to certain negative covenants of the Amended Facility during the Modification Period. On February 22, 2021, the Company entered into Amendment No. 3 (the &#x201c;Amended Facility&#x201d;), which waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ended March 31, 2022 and also lowered the minimum liquidity covenant, which was added by Amendment No. 2, to $150.0&#160;million, and made it applicable through such quarter. Amendment No. 3 also restricted the Company from borrowing under the Amended Facility if unrestricted cash, cash equivalents and marketable investment securities exceed $150.0&#160;million, unless such borrowings are in connection with permitted acquisitions, decreased the maximum aggregate principal commitment from $350.0&#160;million to $300.0&#160;million, with a further reduction in the maximum aggregate principal commitment from $300.0&#160;million to $250.0&#160;million by September 30, 2021, extended the Modification Period for an additional year through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company&#x2019;s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company&#x2019;s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. The Company was in compliance with all applicable financial covenants at March&#160;31, 2022. It is possible that the Company could be in violation of certain financial covenants contained in the Amended Facility in the future. If the Company is unable to comply with certain covenants and ratios in the Amended Facility, the Company may be in default under the Amended Facility, which could impact the Company's ability to borrow under the facility or result in the termination of the commitments under the Amended Facility or the Company being required to pay off any outstanding loans or fees and cash collateralize any outstanding letters of credit. In the future, the Company may seek waivers or amendments from lenders in order to avoid a future covenant violation, in addition to taking other potential actions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Amended Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balances and the undrawn fee was increased to 50 basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR plus 150-250 basis points on drawn balances and an undrawn fee ranging from 25 to 45 basis points, in each case, based on the Company's leverage ratio. The LIBOR floor was also increased to 1.0% during the Modification Period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, the Company made principal repayments totaling $226.4&#160;million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had no outstanding balances under the Amended Facility as of March 31, 2022 and December 31, 2021. The Company's maximum aggregate principal commitment on its Amended Facility is $250.0&#160;million as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i9f00404949054a39b7ce601ba38532bd_D20180731-20180731"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMzk4_30bb9c15-35d1-4c29-abed-52e2250f059f">2023-07-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0837431576cf4579a0f3ff1238105f8f_I20161223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfNDY3_8b9f0b6f-8a2d-4727-a163-62ad8a1f1b6b"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i1c833d35617e45489ec45fd17d8b7885_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfNDcz_adba1fa7-a5b8-4a96-90d3-66cf641f225a"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <mygn:DebtCovenantLiquidityCovenantMinimum
      contextRef="iab8dc65629934bb09610a94e1585f5e2_I20210221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMTA5OTUxMTY0MDU0MQ_dde07b89-e4d9-4524-b62d-84e345740f96"
      unitRef="usd">150000000</mygn:DebtCovenantLiquidityCovenantMinimum>
    <mygn:DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum
      contextRef="iab8dc65629934bb09610a94e1585f5e2_I20210221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMTA5OTUxMTY0MDkwNw_6095d72f-b959-4044-aaf6-27efa0b6b92e"
      unitRef="usd">150000000</mygn:DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i41e34ef04eda424fb7d05a478f98d582_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfOTgx_1c490843-b000-4b96-afde-0b828a5a90b4"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iab8dc65629934bb09610a94e1585f5e2_I20210221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfOTg3_4908e230-3443-48ec-8a2d-951033184639"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iab8dc65629934bb09610a94e1585f5e2_I20210221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMTA2Nw_1cd6a50d-2c10-44d8-b217-b60c4dad0b9c"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i71d2eeb4225b4d9581fbf31f410c3194_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMTA3Mw_9fa6dbbd-7fe5-48b2-8cfa-defe9610d878"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2304a6ab41d9426daa1dd160660afb17_D20200401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMTkyMw_903f8805-18f5-4146-ab81-275109ce1cca"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i5b494a8f5d504446b284a79c8608ed05_D20200401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMTk5Mw_33b5a1ad-a2fb-4d78-bfae-2da2ad28b469"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i65072d8099784761bad742b663d1ac97_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMjE1OA_7b0976cc-c6c3-4cf8-8630-a4fa1829acff"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i29e8864078c14a39bc3142c044233017_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMjE2MQ_2a1e555d-ffe4-470b-9f11-b4ac4162e994"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i9856b6ac715043c4aba22142b3f40f4f_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMjIyNw_74779be9-1823-41a5-a9ca-fdc3d5a7dd23"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i2c4a4127b1ac49719e15e702d9dbb3e4_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMjIzMw_55520d15-9fb3-4f32-88f5-895dca5f9299"
      unitRef="number">0.0045</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <mygn:DebtInstrumentLIBORFloorPercentage
      contextRef="i5b494a8f5d504446b284a79c8608ed05_D20200401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMjM0MQ_d09f4e5b-08dc-4138-86bc-fad320aa2828"
      unitRef="number">0.010</mygn:DebtInstrumentLIBORFloorPercentage>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i1e2100574367494095bfa2718fab642f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfNDAwMg_64618a16-b436-49ad-be8a-d2b25e95bfe6"
      unitRef="usd">226400000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:LongTermDebt
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfNDE5Mw_520bd3d2-c66b-4ad1-bd7d-c4dcb17bfe29"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfNDE5Mw_ac7a3c40-8dbb-4e33-8f3a-50641745361e"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i4d18f4068d394dcfba0bad4c86c8ef8a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81NS9mcmFnOjUyZmRjODE5ZDJjZDQzMjQ5OTRkMWEzNTBjMjdjMjczL3RleHRyZWdpb246NTJmZGM4MTlkMmNkNDMyNDk5NGQxYTM1MGMyN2MyNzNfMjE5OTAyMzI2MTM1OA_eaebfd5c-e46a-4685-9a7c-08d331a56dae"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RleHRyZWdpb246ZjQ4Njk1ZTQyNmI0NGQ1YzliZDkzZjI4YzI0MGI1ZTdfMzI2_1fad4a04-9e17-447b-a174-af924d78a412">OTHER LONG-TERM LIABILITIES&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The Company's balance of other long-term liabilities as of March&#160;31, 2022 and December&#160;31, 2021 consists primarily of the long-term portion of contingent consideration related to the acquisition of Sividon Diagnostics.</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RleHRyZWdpb246ZjQ4Njk1ZTQyNmI0NGQ1YzliZDkzZjI4YzI0MGI1ZTdfMzI1_10d1b052-41e7-4e37-b67a-d370e6eca359">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RhYmxlOmRjZjFmYmY0Njc2NjQ3Zjc5YmQwMzI2MTQwYzBhYTQwL3RhYmxlcmFuZ2U6ZGNmMWZiZjQ2NzY2NDdmNzliZDAzMjYxNDBjMGFhNDBfMS0xLTEtMS04MjA5Mg_8607a68a-7b08-446f-82b3-d33e3edcc964"
      unitRef="usd">4800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RhYmxlOmRjZjFmYmY0Njc2NjQ3Zjc5YmQwMzI2MTQwYzBhYTQwL3RhYmxlcmFuZ2U6ZGNmMWZiZjQ2NzY2NDdmNzliZDAzMjYxNDBjMGFhNDBfMS00LTEtMS04MjA5Mg_7b85575d-1517-411d-9660-c58a5c3050b2"
      unitRef="usd">5400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RhYmxlOmRjZjFmYmY0Njc2NjQ3Zjc5YmQwMzI2MTQwYzBhYTQwL3RhYmxlcmFuZ2U6ZGNmMWZiZjQ2NzY2NDdmNzliZDAzMjYxNDBjMGFhNDBfMi0xLTEtMS04MjA5Mg_0b0842b4-0cfc-426c-a92c-1e5dbb3da3d6"
      unitRef="usd">100000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RhYmxlOmRjZjFmYmY0Njc2NjQ3Zjc5YmQwMzI2MTQwYzBhYTQwL3RhYmxlcmFuZ2U6ZGNmMWZiZjQ2NzY2NDdmNzliZDAzMjYxNDBjMGFhNDBfMi00LTEtMS04MjA5Mg_82a48d2c-9739-4832-9823-2e2cb61e269f"
      unitRef="usd">200000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RhYmxlOmRjZjFmYmY0Njc2NjQ3Zjc5YmQwMzI2MTQwYzBhYTQwL3RhYmxlcmFuZ2U6ZGNmMWZiZjQ2NzY2NDdmNzliZDAzMjYxNDBjMGFhNDBfMy0xLTEtMS04MjA5Mg_b3a0dd7b-c8fb-4513-a5b2-1be2c97acde0"
      unitRef="usd">4900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl81OC9mcmFnOmY0ODY5NWU0MjZiNDRkNWM5YmQ5M2YyOGMyNDBiNWU3L3RhYmxlOmRjZjFmYmY0Njc2NjQ3Zjc5YmQwMzI2MTQwYzBhYTQwL3RhYmxlcmFuZ2U6ZGNmMWZiZjQ2NzY2NDdmNzliZDAzMjYxNDBjMGFhNDBfMy00LTEtMS04MjA5Mg_aa6426e3-d588-4468-a475-647038e4a5a6"
      unitRef="usd">5600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTkwMQ_68c045b0-397b-42e5-8c8c-1cff4b7f9153">PREFERRED AND COMMON STOCKHOLDERS' EQUITY&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 80.3 million shares issued and outstanding at March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common shares issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock issued and outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the denominators of the basic and diluted earnings per share (&#x201c;EPS&#x201d;) computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding used to compute basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effect of dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding and dilutive securities used to compute diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain outstanding options and restricted stock units (&#x201c;RSUs&#x201d;) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive options and RSUs excluded from EPS computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company&#x2019;s Board of Directors authorized a share repurchase program of $200.0 million of the Company&#x2019;s outstanding common stock. The Company may repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company's management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of March&#160;31, 2022, the Company has $110.7 million remaining under its current share repurchase authorization. No shares were repurchased during the three months ended March 31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfODg_2c277fd1-d941-47f6-a0a9-c6204f0b9965"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTI4_92c8531c-622e-48dd-8bab-506bc756b295"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTUz_69d568e2-2187-4871-a3e3-0b2e2b6e6810"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMjMz_397a1ad6-bb52-4263-8d0a-282602e19b9f"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMjcw_e889d93b-2515-4a47-b551-8999c7ded323"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMjk1_0d4be9bd-86ab-4f5f-b80d-26d3a2366d43"
      unitRef="shares">80300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMjk1_142afe39-018b-41fb-98a8-4920ac2325f3"
      unitRef="shares">80300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTkwMg_8f0b597e-c7ea-4683-897c-fa301e7e95b5">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common shares issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock issued and outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfMi0xLTEtMS04MjA5Mg_17577d83-0e12-4cd4-8618-c3147c70c0ae"
      unitRef="shares">80000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfMi0xLTEtMS04MjA5Mg_6245a253-89a1-443c-a6f5-f8a7bb9c522b"
      unitRef="shares">80000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i38f47e17df9c466eb0964b81d156f640_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfMi00LTEtMS04MjA5Mg_bc8195a2-c167-495f-9584-1b3f027ccdbb"
      unitRef="shares">75400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i38f47e17df9c466eb0964b81d156f640_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfMi00LTEtMS04MjA5Mg_eb2d9cd5-4a45-4846-82f4-2efef7744c79"
      unitRef="shares">75400000</us-gaap:CommonStockSharesOutstanding>
    <mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfMy0xLTEtMS04MjA5Mg_eca7f7e2-55d2-442b-b473-515a95998a36"
      unitRef="shares">300000</mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans>
    <mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfMy00LTEtMS04MjA5Mg_e2a76696-a055-4587-9740-b8c5db8e1167"
      unitRef="shares">1300000</mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfNS0xLTEtMS04MjA5Mg_c2f7784a-8c2b-4f4a-b4a0-d0b0816caaff"
      unitRef="shares">80300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfNS0xLTEtMS04MjA5Mg_e8653be1-2614-4a5e-adf6-d43ee48d470a"
      unitRef="shares">80300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5c1c491ce07b46bf981a8c437b57ebe5_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfNS00LTEtMS04MjA5Mg_76605dfe-767f-417b-a1a6-c672b1a8cf7a"
      unitRef="shares">76700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5c1c491ce07b46bf981a8c437b57ebe5_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmI5ZjQzZGQ3NGNlZTQwZjhiYWQ5ZDM5OWQxNGFiYTNiL3RhYmxlcmFuZ2U6YjlmNDNkZDc0Y2VlNDBmOGJhZDlkMzk5ZDE0YWJhM2JfNS00LTEtMS04MjA5Mg_81134be2-80fc-45ab-99ae-7d6027d7ba4f"
      unitRef="shares">76700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTkwMw_155da76a-5aca-46d2-9265-b088ed5244de">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the denominators of the basic and diluted earnings per share (&#x201c;EPS&#x201d;) computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding used to compute basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effect of dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding and dilutive securities used to compute diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOjhmYmZiNDlhZmQwYjRkODZhNDgzNWQ3MWNhNmRhMzQxL3RhYmxlcmFuZ2U6OGZiZmI0OWFmZDBiNGQ4NmE0ODM1ZDcxY2E2ZGEzNDFfMy0xLTEtMS04MjA5Mg_65c40374-c7a6-408a-be04-caf714255bc1"
      unitRef="shares">80100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOjhmYmZiNDlhZmQwYjRkODZhNDgzNWQ3MWNhNmRhMzQxL3RhYmxlcmFuZ2U6OGZiZmI0OWFmZDBiNGQ4NmE0ODM1ZDcxY2E2ZGEzNDFfMy00LTEtMS04MjA5Mg_fecab163-b08c-4d8c-b17a-404063ba1654"
      unitRef="shares">76000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOjhmYmZiNDlhZmQwYjRkODZhNDgzNWQ3MWNhNmRhMzQxL3RhYmxlcmFuZ2U6OGZiZmI0OWFmZDBiNGQ4NmE0ODM1ZDcxY2E2ZGEzNDFfNC0xLTEtMS04MjA5Mg_1e5c696c-532f-46ef-9306-ed3df33b1d37"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOjhmYmZiNDlhZmQwYjRkODZhNDgzNWQ3MWNhNmRhMzQxL3RhYmxlcmFuZ2U6OGZiZmI0OWFmZDBiNGQ4NmE0ODM1ZDcxY2E2ZGEzNDFfNC00LTEtMS04MjA5Mg_d83e75ae-e56b-4e3a-87e0-c1129e63aa1f"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOjhmYmZiNDlhZmQwYjRkODZhNDgzNWQ3MWNhNmRhMzQxL3RhYmxlcmFuZ2U6OGZiZmI0OWFmZDBiNGQ4NmE0ODM1ZDcxY2E2ZGEzNDFfNS0xLTEtMS04MjA5Mg_80faab47-5e2e-405f-9dba-b19ab082c4e6"
      unitRef="shares">80100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOjhmYmZiNDlhZmQwYjRkODZhNDgzNWQ3MWNhNmRhMzQxL3RhYmxlcmFuZ2U6OGZiZmI0OWFmZDBiNGQ4NmE0ODM1ZDcxY2E2ZGEzNDFfNS00LTEtMS04MjA5Mg_9e4aade1-0781-4304-97fe-7651d3fbaf45"
      unitRef="shares">76000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTkwNA_eb0b3c43-da65-4573-8d03-daf7b9f665b0">These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive options and RSUs excluded from EPS computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmMxYzg3ZDYxZDkzZTRmZTNhMjVhOTFkODljNmZhMWU2L3RhYmxlcmFuZ2U6YzFjODdkNjFkOTNlNGZlM2EyNWE5MWQ4OWM2ZmExZTZfMi0xLTEtMS04MjA5Mg_48fc8964-f6d3-4723-98da-10415b3a19ac"
      unitRef="shares">5500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RhYmxlOmMxYzg3ZDYxZDkzZTRmZTNhMjVhOTFkODljNmZhMWU2L3RhYmxlcmFuZ2U6YzFjODdkNjFkOTNlNGZlM2EyNWE5MWQ4OWM2ZmExZTZfMi00LTEtMS04MjA5Mg_96c307a8-5dbd-43d4-9fcf-b9269c39c4f8"
      unitRef="shares">300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i10eb9ab7fc8b46e6a64d2ef084755cf1_I20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTM3MQ_227c26d5-9911-4182-a20a-7b8ad1d1435a"
      unitRef="usd">200000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTgxNA_29df9c15-11c8-4af0-8c40-3baaac236ba1"
      unitRef="usd">110700000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTg1Mw_e383a0eb-c09c-4ba0-96b0-98652427809f"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82MS9mcmFnOmY4YTE5ODFiZDMyODQxNDViNDAwMGM3MDJmM2M0MmI1L3RleHRyZWdpb246ZjhhMTk4MWJkMzI4NDE0NWI0MDAwYzcwMmYzYzQyYjVfMTg1Mw_f5bb4140-68d2-4ca8-bb6f-96ebdcdd9443"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMzk2NQ_c283d445-41d0-4378-9724-70b3d702a28a">STOCK-BASED COMPENSATION&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 30, 2017, the Company&#x2019;s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the &#x201c;2017 Plan&#x201d;). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants, and directors. Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant.  As of March&#160;31, 2022, the Company has 2.0&#160;million shares of common stock available for grant under the 2017 Plan.  If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they also will be available for issuance pursuant to the 2017 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares, terms, and vesting periods are generally determined by the Company&#x2019;s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over four years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of performance-based RSUs ("PSUs") awarded to certain employees may be increased or may be reduced based on certain additional performance and market metrics. Options and RSUs granted to non-employee directors vest in full upon the earlier of the completion of one year of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options granted generally expire ten years from the date of grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire seven years from the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance and market conditions associated with PSU awards granted during the quarter ended March 31, 2022 include vesting that is based on revenue growth targets (34% weighting), adjusted earnings per share targets (33% weighting), and relative total stockholder return (33% weighting) measured against the Nasdaq Health Care Index (IXHC) using the 20-trading day averages at the beginning and end of the measurement period. The measurement period for the PSUs is January 1, 2022 through December 31, 2024. The Company estimates the likelihood of achievement of performance conditions at the end of each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the Company&#x2019;s equity plans and inducement awards, for the three months ended March&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options canceled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, there was $2.0 million of total unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of 1.8 years. There were no options granted during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU awards activity under the Company&#x2019;s equity plans and inducement awards, including RSU awards with performance metrics, for the three months ended March&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, there was $90.8 million of total unrecognized stock-based compensation expense related to RSUs that will be recognized over a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;weighted-average period of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2.7 years.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the &#x201c;2012 Purchase Plan&#x201d;), under which 2.0 million shares of common stock have been authorized.&#160;&#160;On September 23, 2021, the Board of Directors of the Company approved an Amended and Restated 2012 Employee Stock Purchase Plan, which authorizes an additional 2.0&#160;million shares of common stock and extends the term of the 2012 Purchase Plan to November 30, 2032, subject in each case to obtaining stockholder approval. The Company is seeking stockholder approval of the Amended and Restated 2012 Employee Stock Purchase Plan at its 2022 Annual Meeting of Stockholders to be held on June 2, 2022. The Amended and Restated 2012 Employee Stock Purchase Plan also amended certain provisions of the 2012 Purchase Plan effective upon approval by the Board of Directors, including expanding the definition of "offering period" to provide that the Board of Directors may determine the period in accordance with the terms of the plan, and capping the number of shares that may be purchased by any participant during an offering period at 5,000 shares. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period.&#160;As of March&#160;31, 2022, a total of approximately 2.0&#160;million shares of common stock had been purchased under the 2012 Purchase Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of molecular diagnostic testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of pharmaceutical and clinical services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic7e4a2bcdad04bc89e6ef5fbff976fec_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfNTU0_f994a8d8-5684-4e96-8513-9b80b592f491"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMTI5MA_6b714d55-0235-42ad-a277-a91355af2556">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7bad2fadc9ee42ca9a12a98237615f28_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjE5OTAyMzI2MzY3Ng_105290e3-7faa-4645-90a9-1697886cecec">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ife4ee7239ab34cb7986b1613a6ea4129_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMTg4Mw_60d2990b-3f66-43f9-b698-4cd2c60aa690">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ibdb73b76a7ef4b6192ddf53020f1bfc4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjE5OTAyMzI2MTQ5Mg_db9e0d3e-9b0b-4ffa-b1f8-4e06ff18098f">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i9d16553d025b4028aa1658a83e5f4561_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjE5OTAyMzI2MzY2Mg_3a71d99a-1866-4958-b3b9-9268418b030e"
      unitRef="number">0.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i17685ad6b9cf47d5a2539fde84607b3c_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjE5OTAyMzI2MzY2Nw_84c3746c-dc41-4f69-94a2-f352212aa6e3"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i425eb7ec3ba04e4d97719f260b166abb_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjE5OTAyMzI2MzY3Mg_fc667561-5f09-4e82-90d0-b6c87ddb2d91"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMzk2Mg_68fcefff-563e-4c13-b2af-451599aff31e">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the Company&#x2019;s equity plans and inducement awards, for the three months ended March&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options canceled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfMS0xLTEtMS04MjA5Mg_6d5eb6b8-3b9b-4024-8563-3352554ca046"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i56db6c3d57e14c2b8658a385a44e3603_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfMS0zLTEtMS04MjA5Mg_51e5054e-7bc9-49b9-904d-ddf3f7c90375"
      unitRef="usdPerShare">20.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNC0xLTEtMS04MjA5Mg_115c89ec-58ed-4ae4-85cc-9fe870d927d1"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNC0zLTEtMS04MjA5Mg_9e0bd915-86ff-494b-9b9c-4a8ea2bd16a2"
      unitRef="usdPerShare">23.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNS0xLTEtMS04MjA5Mg_88084377-3242-4252-8c5c-4be93624fed2"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNS0zLTEtMS04MjA5Mg_2dae1fe8-1f8f-4d55-8ca5-924ffe9fbc7b"
      unitRef="usdPerShare">24.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNi0xLTEtMS04MjA5Mg_40b0fcd9-e197-423f-8546-05e02a560757"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNi0zLTEtMS04MjA5Mg_10b4d2b1-f706-47d1-be30-d4e78c0c37db"
      unitRef="usdPerShare">20.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNy0xLTEtMS04MjA5Mg_006ba448-3ea0-4c69-9914-7c128f76f747"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOmU3M2YyNDIzZDExNDRiNDQ5ZGZkZjk4MDg5MjNjOWY2L3RhYmxlcmFuZ2U6ZTczZjI0MjNkMTE0NGI0NDlkZmRmOTgwODkyM2M5ZjZfNy0zLTEtMS04MjA5Mg_577d89f4-d603-4a6d-ba27-09e42ec7550d"
      unitRef="usdPerShare">22.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjA4NA_602830a6-7f38-49e1-906a-b2d9d748c6ed"
      unitRef="usd">2000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ife4ee7239ab34cb7986b1613a6ea4129_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjIyNQ_3175e9ac-1d6e-4d07-bfa5-b81c56e66e70">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMzk2Mw_a52cae2f-d6af-4104-b6a3-cf4314af574d">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU awards activity under the Company&#x2019;s equity plans and inducement awards, including RSU awards with performance metrics, for the three months ended March&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6d5670611ac54c00895e101571e289ec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfMS0xLTEtMS04MjA5Mg_97e479e9-5882-44f4-a29d-8181e4f19373"
      unitRef="shares">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6d5670611ac54c00895e101571e289ec_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfMS0zLTEtMS04MjA5Mg_79abfe23-f3e7-499d-8d59-1f8b345ef807"
      unitRef="usdPerShare">24.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfMi0xLTEtMS04MjA5Mg_bfd090bd-ca93-4593-a2ed-e7b534f0458d"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfMi0zLTEtMS04MjA5Mg_758d862f-dc14-43a9-ac9a-c4f43d115bf8"
      unitRef="usdPerShare">27.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfNC0xLTEtMS04MjA5Mg_945593e1-e54e-4230-8438-4f0c21f5b637"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfNC0zLTEtMS04MjA5Mg_a3e4a2b6-aed3-4983-9981-d8f7636c3d33"
      unitRef="usdPerShare">28.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfNS0xLTEtMS04MjA5Mg_60dd1383-704f-42ec-803d-6ad09360ac6e"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfNS0zLTEtMS04MjA5Mg_0c80bcb5-cf6f-411c-894b-7975c88feb75"
      unitRef="usdPerShare">24.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7e88ace7ed394a94800fdca61421e851_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfNi0xLTEtMS04MjA5Mg_825dafd1-62ae-4823-b17f-3bc9af6c9a70"
      unitRef="shares">4200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i7e88ace7ed394a94800fdca61421e851_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjdjM2U1NTY0N2QxOTQ0ODg5Y2VjYzc0MTg0NzBjNTFmL3RhYmxlcmFuZ2U6N2MzZTU1NjQ3ZDE5NDQ4ODljZWNjNzQxODQ3MGM1MWZfNi0zLTEtMS04MjA5Mg_ef21a422-1eb1-4986-a1e7-8a86ed2ccf92"
      unitRef="usdPerShare">25.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i7e88ace7ed394a94800fdca61421e851_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjQ1MA_680c986b-8711-43f1-aaf7-91c6cd8bef6e"
      unitRef="usd">90800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1a8f51a51835485d8efe2b192e258198_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjU4Mg_a7ecd20a-46ef-4bf8-b354-dbdbdc4cf392">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i83a6571b146e482389af3212034e29e0_I20121231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjc1MQ_5fdb62a7-dc6a-492d-9dff-efcd2c25acdd"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="iaac367b814414abc8b2dc1fcfc86625f_D20210923-20210923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMjk2MA_0d697e6c-7c73-45c1-a253-8a9f1b456844"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="iaac367b814414abc8b2dc1fcfc86625f_D20210923-20210923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMzU0NA_187ecb7f-6765-4717-aa75-998fd38641de"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i5030a2b3d82c4d60868c0b2191a2d4a0_D20211205-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMTA5OTUxMTYzMTc1Ng_ee19406d-b37a-4745-9f46-5a279357f812"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RleHRyZWdpb246ZmY3NjlhNjUxMjUzNDE2MTg2OGZmZmU5ZTUxZTNlZDBfMzk2NA_6038c83f-3b2f-486e-9113-f8348548577a">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of molecular diagnostic testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of pharmaceutical and clinical services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i86d71b985caa4964a6e254ec96cb87cd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfMi0xLTEtMS04MjA5Mg_6b74e18f-cbb1-48e4-9890-c3a9af0d2f3e"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iafba3568c8f8479caf7ae3e55c4f2129_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfMi00LTEtMS04MjA5Mg_b465f4e0-b0b5-44b8-b675-06e7c3405a3f"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2566e34ad9de42d492126a12c9a969e8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfMy0xLTEtMS04MjA5Mg_5b589763-a61a-4b50-b03c-ef423345841e"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i72551335efb84f1dacbfab6e1f4b32f2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfMy00LTEtMS04MjA5Mg_322286e2-085c-4d23-be5b-444dbb288d41"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0e442b7e778a40d0b0ea4e18405b7a44_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfNC0xLTEtMS04MjA5Mg_f4e7e32e-1310-41a7-9824-6e2c6fe92312"
      unitRef="usd">2400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ccf0e5050c9430eba39a50029c3c70e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfNC00LTEtMS04MjA5Mg_c7e6b343-1ec1-42da-9e4a-253613cc0c54"
      unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1114d9d3200747a2a214afd2bfab8814_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfNS0xLTEtMS04MjA5Mg_5ceef722-01fb-4e99-a6a2-4e6e26ef06ea"
      unitRef="usd">7400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie78cb4d47d2f4c79b9717d147044b377_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfNS00LTEtMS04MjA5Mg_6a2fd02b-a85e-49c2-a2fe-3ec2e89a0684"
      unitRef="usd">7100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfNi0xLTEtMS04MjA5Mg_62c4694b-350b-4556-8cb0-6e1ca448975d"
      unitRef="usd">10100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82NC9mcmFnOmZmNzY5YTY1MTI1MzQxNjE4NjhmZmZlOWU1MWUzZWQwL3RhYmxlOjE4YzdiMjk1YWU2MTRlZTBiM2JlODVlYmMzZWVmMzNjL3RhYmxlcmFuZ2U6MThjN2IyOTVhZTYxNGVlMGIzYmU4NWViYzNlZWYzM2NfNi00LTEtMS04MjA5Mg_120557a1-1ece-4427-b9fd-8bfc39ed40ad"
      unitRef="usd">9000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMjIxNA_1cb9896b-080c-4cf4-93db-94bf31bb62ac">INCOME TAXES &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to determine the Company&#x2019;s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates.&#160;Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit for the three months ended March&#160;31, 2022 was $5.9 million, or approximately 22.3% of pre-tax income compared to an income tax benefit of $10.1 million, or approximately 20.4% of pre-tax loss, for the three months ended March&#160;31, 2021.&#160;Income tax expense for the three months ended March&#160;31, 2022 is based on the Company&#x2019;s estimated annualized effective tax rate for the fiscal year ending December 31, 2022, adjusted for discrete items recognized during the respective periods.&#160;&#160;For the three months ended March&#160;31, 2022, the Company&#x2019;s recognized effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, stock compensation expenses, and asset impairment expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations.&#160;&#160;The Company is currently under audit by the State of California for the fiscal years ended June 30, 2017-2018, the State of New Jersey for the fiscal years ended June 30, 2013-2017; and Switzerland for the fiscal years ended June 30, 2015-2016. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfNTE0_7133bee9-7f1f-4319-944f-7efcc341839d"
      unitRef="usd">-5900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfNTM1_c84fd19a-7ec6-4a60-85f6-c4d333451868"
      unitRef="number">0.223</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfNTkz_bd1f438c-4c67-4303-9d68-09c47b53fe9c"
      unitRef="usd">-10100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfNjE0_eeb0d306-c739-4a35-be8b-7875c076cd2a"
      unitRef="number">0.204</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i4c40a24632bf4346946172c6e98b52fc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMTc2NA_92d9c9c1-7ac4-49e5-971f-c66c4cc017b8">2017</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i2b99c5119ccf4bec978689998d8156c9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMTc2Nw_6dd773cd-a5bb-4c9a-b31f-a807b33afdf4">2018</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="iddf2e4709d4e4f3c8f8de9d3848531a3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMTgzMQ_ca09b83c-4d60-4941-9db6-e56c04455df8">2013</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i165aceb443f54911b03d14bf7fa31bef_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMTgzNA_3f9a4d51-7f42-4726-b6b2-72b716e65940">2017</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i0f49e0371ac14b658fae67bfe038cf32_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMTk0NQ_b6a6e00a-0bd1-4ef8-9723-5647fcaa57ed">2015</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="i9b97c328c10c4fa3b4b35d35fc41de1f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl82Ny9mcmFnOjZlM2ZhNWI1NGNmZTQxYzRiMmUxNjA1MjdmZWM4NmE5L3RleHRyZWdpb246NmUzZmE1YjU0Y2ZlNDFjNGIyZTE2MDUyN2ZlYzg2YTlfMTk0OA_c653d01b-bf90-443c-9a74-93b231dc600c">2016</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83MC9mcmFnOmViNzMxNzc2YTA3MDRhNDg4ZGJkMGUzOTAzMDllZDY3L3RleHRyZWdpb246ZWI3MzE3NzZhMDcwNGE0ODhkYmQwZTM5MDMwOWVkNjdfNzcwNw_733783bb-410e-41c9-811c-3aa9caf706f9">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved from time to time in various disputes, claims and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amount of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company is involved, and has received subpoenas, from time to time, related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to vigorously defend its current litigation matters, but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the proceedings may be in early stages, there may be uncertainty as to the outcome of pending appeals or motions, there may be significant factual issues to be resolved, and there may be complex or novel legal theories to be presented. In addition, damages may not be specified or the damage amounts claimed may be unsupported, exaggerated or unrelated to possible outcomes, and therefore, such amounts are not a reliable indicator of potential liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except as noted below, as of March 31, 2022, the Company has not recorded any accrual for loss contingencies associated with legal proceedings or other matters or determined that an unfavorable outcome is probable and reasonably estimable in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;However, it is possible that the ultimate resolution of legal proceedings or other matters, if unfavorable, may be material to the Company's results of operations, financial condition or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Qui Tam Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company's wholly owned subsidiary, Crescendo Bioscience, LLC (formerly known as Crescendo Biosciences, Inc. (&#x201c;CBI&#x201d;), received a subpoena from the Office of Inspector General of the Department of Health and Human Services (the "Office of Inspector General") requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act ("CIFPA").  On January 22, 2020, after a multi-year investigation into CBI&#x2019;s and the Company&#x2019;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company&#x2019;s motion to dismiss. As of March 31, 2022, the Company has accrued $48.0 million for a potential settlement of this qui tam lawsuit against CBI and the Company, which is included in accrued liabilities in the Company's Condensed Consolidated Balance Sheet as of March 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2022, the Company settled the qui tam lawsuit with the relator, STF, LLC (the "Relator"). Pursuant to the terms of the settlement agreements, the Company agreed to pay a total of $45.25&#160;million to the United States and the State of California and $2.75&#160;million to Relator&#x2019;s counsel. The Relator agreed to the dismissal of the lawsuit with prejudice as to the Relator and fully released all claims against the defendants and their affiliates, directors, officers, and employees. The State of California agreed to the dismissal of the lawsuit with prejudice as to the State of California and released the defendants from any claims submitted to the State&#x2019;s Medicaid program or under the CIFPA as a result of certain alleged conduct. The United States Department of Justice approved the settlement of federal claims, including dismissal of the lawsuit without prejudice as to the United States. The settlement agreements contain no admission of liability, wrongdoing or responsibility on the part of the defendants. The Company expressly denies any and all liability for claims alleged in the lawsuit. On May 4, 2022, the qui tam lawsuit was formally dismissed by the United States District Court for the Northern District of California.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 27, 2019, a class action complaint was filed in the United States District Court for the District of Utah against the Company, its former President and Chief Executive Officer, Mark C. Capone, and its Chief Financial Officer, R. Bryan Riggsbee (the &#x201c;Defendants&#x201d;). On February 21, 2020, the plaintiff filed an amended class action complaint, which added the Company's former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Myriad Genetics, Inc. Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding the Company's business, operations, and acquisitions.  The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees. On March 16, 2021, the United States District Court for the District of Utah denied the Company's motion to dismiss. On December 1, 2021, the United States District Court for the District of Utah granted plaintiff's motion for class certification. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stockholder Derivative Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's  former President and Chief Executive Officer, Mark C. Capone, its Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of its current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, a  stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and the Hickock stockholder derivative action. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 3, 2022, the Delaware Court of Chancery consolidated the Hickock and Kogus derivative actions and stayed the consolidated action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 17, 2021, a stockholder derivative complaint was filed in the United States District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the United States District Court for the District of Delaware pending the resolution of the securities class action lawsuit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2022, a purported class action lawsuit was filed against the Company in the United States District Court in the Northern District of California by Ashley Carroll. Plaintiff alleges, among other things, that the Company made false statements about the accuracy of its Prequel prenatal screening test. The complaint seeks unspecified monetary damages and injunctive relief. On April 1, 2022, the Company filed a motion to dismiss the lawsuit.&lt;/span&gt;&lt;/div&gt;From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationReserveCurrent
      contextRef="i9ac025088f904137a68dd99ae7162c5e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83MC9mcmFnOmViNzMxNzc2YTA3MDRhNDg4ZGJkMGUzOTAzMDllZDY3L3RleHRyZWdpb246ZWI3MzE3NzZhMDcwNGE0ODhkYmQwZTM5MDMwOWVkNjdfMTcwMg_77ab569c-eae0-46df-9ec3-701ea14b3def"
      unitRef="usd">48000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="idd3dfbf88a4f49d29528546627f27aa0_D20220401-20220401"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83MC9mcmFnOmViNzMxNzc2YTA3MDRhNDg4ZGJkMGUzOTAzMDllZDY3L3RleHRyZWdpb246ZWI3MzE3NzZhMDcwNGE0ODhkYmQwZTM5MDMwOWVkNjdfMjE5OTAyMzMwMTEwMQ_03d5aebc-c710-4f94-ae0e-85b1a6b89ead"
      unitRef="usd">45250000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i725231d93b934c6d91bff94381a504dd_D20220401-20220401"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83MC9mcmFnOmViNzMxNzc2YTA3MDRhNDg4ZGJkMGUzOTAzMDllZDY3L3RleHRyZWdpb246ZWI3MzE3NzZhMDcwNGE0ODhkYmQwZTM5MDMwOWVkNjdfMjE5OTAyMzMwMTExNw_7b19b52c-5064-46e8-82b4-bb2cfe3645d2"
      unitRef="usd">2750000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RleHRyZWdpb246ZjRjYTliY2Y0YzljNDdkMDgzZTY2Y2JmZWIzYThlYTNfNDM_05bfe11b-8bed-48f4-adb7-2ac17f6c5522">SUPPLEMENTAL CASH FLOW INFORMATION&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid during the period for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Establishment of operating lease right-of-use assets and lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchases of property, plant and equipment in accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RleHRyZWdpb246ZjRjYTliY2Y0YzljNDdkMDgzZTY2Y2JmZWIzYThlYTNfNDI_89b235bc-b65c-4e0b-b47d-6ca3afd885f3">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid during the period for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Establishment of operating lease right-of-use assets and lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchases of property, plant and equipment in accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxesPaid
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfMi0xLTEtMS04MjA5Mg_dc0f707d-cc10-43cb-93e0-4cfcb3579ec4"
      unitRef="usd">300000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfMi00LTEtMS04MjA5Mg_9c4bdbce-8beb-42eb-ae58-42b37a0d9d79"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfMy0xLTEtMS04MjA5Mg_ddbe1a7a-54e8-4e3f-9648-39fda5a173d4"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfMy00LTEtMS04MjA5Mg_d063da9c-bfea-4b14-848e-d67a7aadc88b"
      unitRef="usd">2300000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfNi0xLTEtMS04MjA5Mg_13857e2d-8235-4df6-8043-12a60d51e6c3"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfNi00LTEtMS04MjA5Mg_468389be-6157-4d65-86d8-5b304de56ec5"
      unitRef="usd">2700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mygn:OperatingLeaseLiabilityEstablished
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfNy0xLTEtMS04MjA5Mg_b4a6a443-0bd4-44a6-8b2b-e4120ef0dc1e"
      unitRef="usd">800000</mygn:OperatingLeaseLiabilityEstablished>
    <mygn:OperatingLeaseLiabilityEstablished
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfNy00LTEtMS04MjA5Mg_4563f83b-0b32-4a90-8963-b7e16e4c604f"
      unitRef="usd">2700000</mygn:OperatingLeaseLiabilityEstablished>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfOC0xLTEtMS05MTczNA_a768581b-172e-4b9b-95d6-8cd4466edab9"
      unitRef="usd">900000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i3df7baeb0f1149ccbff1d325f5b10158_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl83Ni9mcmFnOmY0Y2E5YmNmNGM5YzQ3ZDA4M2U2NmNiZmViM2E4ZWEzL3RhYmxlOjE4NTA5NDRiZTBkYTQzZTI4ZTFhMzJiYmM1NTAxNzYzL3RhYmxlcmFuZ2U6MTg1MDk0NGJlMGRhNDNlMjhlMWEzMmJiYzU1MDE3NjNfOC00LTEtMS05MTc0MQ_97edb5f0-2670-439f-9705-099ac773bbe8"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8yMTk5MDIzMjU2NzEx_7b805759-02b6-4457-8919-acd158fc80dc">LEASES&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from one to fourteen years. During the quarter ended March 31, 2022, in an effort to reduce its real estate footprint, the Company ceased the use of one of its leased Salt Lake City facilities. As a result, the Company recorded an impairment charge on right-of-use assets of $8.6 million and an impairment charge of $2.1 million on the related leasehold improvements. The total $10.7 million impairment is included in Goodwill and long-lived asset impairment charges in the Condensed Consolidated Statement of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the first quarter of 2022, we entered into a non-cancelable operating lease for approximately 230,000 square feet in west Salt Lake City, Utah. The lease has a term of 15 years, which, along with rent payments, are expected to commence in the third quarter of 2023. Total future rent payments under the lease is approximately $77.8&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8xMDk5NTExNjI5NTc0_031b24d3-d63c-4bc0-b663-4d6715d56149"
      unitRef="usd">8600000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i49163efc76014827a31448fd386b5085_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8xMDk5NTExNjMxNzc5_f87163a7-256e-43b3-ad91-5ab877827bec"
      unitRef="usd">2100000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8xMDk5NTExNjMyOTM1_bcb5d5a6-4834-4634-b2be-5a98adf6d95c"
      unitRef="usd">10700000</us-gaap:AssetImpairmentCharges>
    <mygn:LesseeOperatingLeaseAreaOfLeasedSpace
      contextRef="i04e805b5f43a48c59b3233b51bbc2f4c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8yMTk5MDIzMjYxNTE4_37b20754-a8e8-41e7-84f8-35f66be958be"
      unitRef="sqft">230000</mygn:LesseeOperatingLeaseAreaOfLeasedSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i9b97b4edf342400a89726e31b3e19c6c_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8yMTk5MDIzMjYxNTEx_855afee6-896f-4343-92a7-9a6746211651">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mygn:LesseeOperatingLeaseExpectedFutureRentPayments
      contextRef="i9b97b4edf342400a89726e31b3e19c6c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl8xMTMzL2ZyYWc6ZmNmMjc4YzgwNTVhNDdmY2E4Njk2ZTE3ZGM5ZDcyY2YvdGV4dHJlZ2lvbjpmY2YyNzhjODA1NWE0N2ZjYTg2OTZlMTdkYzlkNzJjZl8yMTk5MDIzMjYxNTI3_03414902-4c62-45ae-8a4e-2f7c1752be2f"
      unitRef="usd">77800000</mygn:LesseeOperatingLeaseExpectedFutureRentPayments>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl84Mi9mcmFnOjIzZjFkNWNjMjM5NTQyYjE4MjBiNTFmNDQxNGU3NDRjL3RleHRyZWdpb246MjNmMWQ1Y2MyMzk1NDJiMTgyMGI1MWY0NDE0ZTc0NGNfMjk5_669a77a6-7260-4080-bdbc-3aa72321af30">SUBSEQUENT EVENTSAs previously noted, on April 1, 2022, the Company settled the qui tam lawsuit with the Relator. Pursuant to the terms of the settlement agreements, the Company agreed to pay a total of $45.25&#160;million to the United States and the State of California and $2.75&#160;million to Relator&#x2019;s counsel. On April 7, 2022, the Company paid the settlement amounts in full. On May 4, 2022, the qui tam lawsuit was formally dismissed by the United States District Court for the Northern District of California.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="idd3dfbf88a4f49d29528546627f27aa0_D20220401-20220401"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl84Mi9mcmFnOjIzZjFkNWNjMjM5NTQyYjE4MjBiNTFmNDQxNGU3NDRjL3RleHRyZWdpb246MjNmMWQ1Y2MyMzk1NDJiMTgyMGI1MWY0NDE0ZTc0NGNfMjE5OTAyMzI1OTc2Mw_d639d749-c48f-4605-9a09-028af6296c3b"
      unitRef="usd">45250000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i725231d93b934c6d91bff94381a504dd_D20220401-20220401"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2ZmVlOTA5NDVlNzRiOTdiODMzNjk1ZmQ4MjQ2M2MyL3NlYzpiNmZlZTkwOTQ1ZTc0Yjk3YjgzMzY5NWZkODI0NjNjMl84Mi9mcmFnOjIzZjFkNWNjMjM5NTQyYjE4MjBiNTFmNDQxNGU3NDRjL3RleHRyZWdpb246MjNmMWQ1Y2MyMzk1NDJiMTgyMGI1MWY0NDE0ZTc0NGNfMjE5OTAyMzI1OTc3OQ_1c2faa88-4ea9-43fd-b905-8dcf93b0c4c6"
      unitRef="usd">2750000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MG'E<Z@O@_%H(==K1-R@64D?_ E!+ P04    "  #@J94(IN:WY0&  !8&P
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MH[ #R@7@^TH(?1SD$]1WX_/_ %!+ P04    "  #@J94P--0.@P#  !B"
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M;\*6\UKP?T$J:$1/L"RMN/%+3=Z1F%XC$M")&YTXJG-1;"E7=@VRW%U+F;T
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M+SFU*QY0DE %DP:4) [*6V87(:VE?:4"6NV$V;?87%"1VLH%'X'R,G^V-RE
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M\B[-.2%=DRV[R7#FG2016=%0'*B.:?FG<AQ^B_(T55!F+,V4GE>E*BEY4>1
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M@<D"D3*PB X"R)3' (= KU_X+C J2F6#(N2BQ) "B#L2+=YMHJSNZZ TH=_
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M985;RIV"9C21:F]:/^.,H[/$-?"9:@<6 H&X2GMG''QJTQ)BXA:N.W]>@;T
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M*X#\F<0XUP?KH-J*!_\"4$L#!!0    (  ."IE3340L5W0<  -$4   9
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M!J<#5H@%;Y3_;%:_B.3/$>G+C7+A/UO%O=/# <L;YTV5A(&@DCK^\L<4AY[
MZ6B'P"0)3 +N:"B@_, ]OSRW9L4L[88VN@BN!FF DYJ2,O,63R7D_.5'+BW[
MQE4CV)W@KK$"$??N?.BAG+8,\Z3H.BJ:[% T97=&^]*Q6UV(8EM^"% =LDF+
M['KRJL([;C,V'1^PR6@R>47?M/-T&O1-?^SI!^ER9<A9Q_YU-7?>HCC^_8J-
MP\[&8;!Q^-]'\U5%U(IGKN:YN!B@UYRP#V)P^?'JU\_LV]5O7V_9W>W5[.OG
MV[O;?WR9L2^E8 NR_! LFP7SN'-CJIKK]=__=CH9G[QW;"$UU[GDBDD-CYN
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M*GZFVFR/'_M@<XDW%KP7+R ZRDZ.!A@RP@>TN/"F#A^MYL9[4X7+4J H+&W
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MWJ]4(0OOV.'<)#K5M0C-%C@O+'E-GPU!)_ V=R(!HL@\AHAWQ9*C4BJK38T
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MNK?0> <ZWVCM#H8/T-V$^1]02P,$%     @  X*F5,?Q-Y7/!0  -@\  !D
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M3<14E<J1I# @3 O+T/\Q)/NA]&>M19 +<N>M]MGG]"2O\0HF@W+1Y$=%&%*
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MRM$ /)]:&_(7VJ!YE?S%?P%02P,$%     @  X*F5"-<^(3* @  ( 8  !D
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MW*,+ >Q?6&['Q@@';'X@PS]02P,$%     @  X*F5(.X&7'J!   T0L  !D
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M=?A.^0F=SL>TF"T6C_@['5(^3?Y.'_#WWJ^5U?^F3,=TY6Q LF5.7-GR:R;
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MT@@0?R;H@F\.QD&]Z8_^ U!+ P04    "  #@J94F[XF'C$$  #Z"@  &0
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MSP%)6F2GFV5R+F8IQMLJ19X"%)/H/6<8O9:^[XA+JM3!<B\HQ]8+)ZKBBF!
MR9N?.D@LXJU@_[B8.(,K@U7@\@Y1?BIJ2%A'H3_$C%%4:%ZAI.E?.$A4__5C
M/9]0D:IR C([:>V X/_0*8E[]@]N :]KP.^Z]A7!=D-.)4;0F4=R4%LW=6FT
M4PI3C2;M:3O8W57SS!M[-16BS2W#5W'8H&CHCS$#5#5I5821A9MNUM+@K.2V
M&0ZGH"P#WF\D=H>:L ;:<7?^+U!+ P04    "  #@J94[&"]1$ #   C!P
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M^5155G")=QI,511,/RU1J/TL& 3MPCW?Y=8M1/-IR7;X@/:W\D[3+.JT9+Q
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MV=*%A38XT/G&&+\S0H#I"BS^ E!+ P04    "  #@J94H%[]B^ #  #@"0
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M7G2@?Z5-8]I<MK0&=7R+4L =[>M=KX\$WX8J"9=R(U*91,O,I@/0BXYL8"E
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M-?>)VN^4W)]H^51L-GR46LND.-R*<"54'F ^7TNI#R=Y!]5^U<5_4$L#!!0
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MB;55=3NN)T:N74=;28/]T0U+?,% 60/<SZ4T^XEUT+Z)R5]02P,$%     @
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MZ/#H5&2Z;C*[ ]LF3L/"LLQ6W%;RF)$+#G*_M)9WAQ"@?QZG?P!02P,$%
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M<LL"?PF@K '>9U*:_<8&Z'XR\1]02P,$%     @  X*F5"UV9%>\ @  X0@
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MLM2??EC2@XC:!=#^2BF[FSB![HE-WP!02P,$%     @  X*F5'*$9K#" @
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M8(5+JN[X]B/4 0T,7\JIM$^TK6T]!Z6E5+RHP5I!05CUQL]U(EH OW\ $-2
MX+V L :$-M!*F0UKCA5.8L&W2!AKS68&-C<6K:,AS'S&>R7T+M$XE5QSGFT)
MI0BS#-TPA=F:+"F@J92@)+KH6#N=@\*$RC.]^W _1Z<G9^@$$89N-8_^-#)V
ME59F^-VT5G%5J0@.J+C%HH="_QP%7A!TP&?'X7-(&[C_&N[J?#1)"9JD!)8O
M/,"W'_.W3]H$W2@HY/<C#L+&06@=] \XF*9I6904*\C0M.!"D9_85'57YBJF
MR#*90_F47 1!T!O$[E,[0UUF?MOLE=!^([1_5.BUX%*B&1;BA;"UT5HR=8X4
M5YAVB:W8ABT5D1_U_#^T=EM%W5('C=3!4:F?X9BPP9[+<!RV7%;"]JWZ7K\E
M_Y6PJ!$6'16V*$6:ZYLF0Y2D^@($:0^;@C1GG/(U 7FDI(:-E^'_J=E1XV#T
M-Z6 Z_+5CKOR/GI7071;'2B(<2-X_,\.V7A/0.<AZS([?,A\[_<E[+U=NV]D
MLJ:(WBCA#K.N&G9;+</T:WT#KPF3B,)*X[S>4!\%4;7 :J+XQG:1)5>Z)]EA
MKG\;0!@#O;_B7.TFIC$U/R+)+U!+ P04    "  #@J94;J)9_$@"  !:!0
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M;:">KQB3QXGNCLW7T.0_4$L#!!0    (  ."IE0A"Z%ELP0  +47   9
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;+5876_;-A1][GX%86Q "ZR62/FS
M< S4\=*X2=H@:;:'80^,1-M$*5$E*3L!^N-'2K+DQ!(EI'$>8DKB.3R\]^J0
MXF3+Q7>Y)D2!AY!%\J2S5BK^X#C27Y,0RRZ/2:2?++D(L=*78N7(6! <I*"0
M.<AU!TZ(:=293M)[UV(ZX8EB-"+7 L@D#+%XG!'&MR<=V-G=N*&KM3(WG.DD
MQBMR2]1=?"WTE5.P!#0DD:0\ H(L3SH?X8<+SS. M,??E&SE7AN8J=QS_MU<
M+(*3CFL4$49\92BP_MF04\*88=(Z?N2DG6), ]QO[]C/TLGKR=QC24XY^X<&
M:GW2&75 0)8X8>J&;\])/J&^X?,YD^E_L,WZ#GL=X"=2\3 ':P4AC;)?_) '
M8@\ ZP H!Z#G@$$-P,L!7ML1>CF@]QS0KP'T<T"_[0B#'#!H"QCF@&%;P"@'
MC-H"QCE@W!8 W5WFW-:0(ME9T655DI;8'"L\G0B^!<+TUWRFD=9IBM>512/S
M2MTJH9]2C5/32QZMWG\C(@1S<J_ >_ %"X%-F8.W<Z(P9?*=OGMW.P=O?W\W
M<90>TR =/^>?9?RHAO]SPKK A7\"Y")4 3]M ?=2.!Q5P.=V^!46.WCEZ'^U
MA\,*^)D=/B>^%?ZI:>Z1AKNUXL_M\%L2%_"JT1=V^!FY[P)4+_YS^[F[%?"+
M%G#DI7D?/(4[NL*+,D=%F:.4SZOET\6]B*02B5X/%/CW4G< "T5"^9^%WBOH
MO92^5T-_+6CDTQ@SO<K$^-$,456L&<DX)3%KW6:J0[/9K\?#'D,W^RLZ/A'8
M*P3VK *_)DHJ' 4T6ND5B.'()[)*8<;2KU=XUK/,X8FT?B&M;Y5V0S:<;8PP
M7Y" *K#$/F54/5KR,BBX!\=(^["@'UJE7^$'&B8AP*N5("NL"(B+0O!Y&%)5
M4PD7PX,H>JXUT:-"TN@5*O%L=# ^0H.>9?QQ,?[X9=D$/\%'K28@09L$0[=<
MO]QCI!CN+9"P(<DJ$68"@4YPY0IFQ^^6L-_>O-%>Z-DTE6X&T7$*[S0G?E)Y
M_>>5ER^MAUU1==?S]ET750(.2C]?8=IH?1K!TK"AW;&O:)1&D-$?"0U,>GV^
M(1&NC-HB)]OW1=B@I'1F:+?FG9(D$D17,?65?D5\+-= ^W76(%KC!C.=4@G4
M6G=;<Q: F B[Z$.K;A)=>C9\H6E7O.;ZEO[Z(7HFRE;\I:?#HY@Z+%T=VFW]
M+@H$WD9@2?0F6$?9UZ-4;7T_-?"XW;[[ATU1:>K0[NJ7B]G7&[!DG(L&178>
MV'7MBDJ;AZ_G\WL%H)MYO=LV=:7YHZ.8/RK-']G-NVTIS!IXW"[JVP*/]C:R
M=NO_A<!GBX9-16F?R#M*X$M71'97;!]X.X_;[=D#7UH>>E7+RU[95M:'2NM#
M1[$^5%H?LEO6#$LJ078Z!\RAF=E;6!VG@=!K\$!4>B"R>]<OQK^=\Y3^A\9'
M^: LK<US7S<3LP9"V) )KS1%SVYFKY")1BOR2D/TCO-IO_=M;]\JOB 3=D)4
MEPEG[QS/'&A?8;&BD02,+#61VQUJAQ+9&7%VH7B<'NW=<Z5XF#;76B41IH-^
MON1<[2[,:6%Q4C_]'U!+ P04    "  #@J94K&H*X5 "  "S!0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U,2YX;6R-5%UOFS 4_2L6ZD,KK4 (2;N*(+6)
MIDUJM:AIMX=I#PZY"5:-S>R;T/[[V88PFI)H+^!KWW/N.=<?2275B\X!D+P6
M7.B)ER.6-T&@LQP*JGU9@C K:ZD*BB94FT"7"NC*@0H>1&$X#@K*A)<F;FZN
MTD1ND3,!<T7TMBBH>KL#+JN)-_#V$X]LDZ.="-*DI!M8 #Z7<V6BH&59L0*$
M9E(0!>N)=SNXF8YLODOXP:#2G3&Q3I92OMC@VVKBA580<,C0,E#SV\$4.+=$
M1L:?AM-K2UI@=[QG_^*\&R]+JF$J^4^VPGSB77MD!6NZY?@HJZ_0^'$",\FU
M^Y*JSAU''LFV&F71@(V"@HGZ3U^;/G0 @_@((&H T?\"A@U@Z(S6RIRM&46:
M)DI61-ELPV8'KC<.;=PP87=Q@<JL,H/#]#OFH,B]%)O+)U %N6=TR3A#!IJ<
MSP IX_J"7)+GQ8R<GUV0,\($>6"<FSW028!&@B4*LJ;<75TN.E+N@2J?# >?
M2!1&40]\>AH^@ZR%#][# V.\=1^U[B/'-SSMON-YQG3&I=XJ(+]NEQJ5.6>_
M3U0:MI6&KE)\I-)4"F1B P))9CK'5J"H/<=]+:R9QH[)WL)=&OO72;#K]NEC
MSLB/VYQW$N-68GQ2HFM&GYX:=M6I%?J# SU].5&_GE&K9W12SY-$RHET6\3M
M 45[0/F_S>K3.NKIW><#K1]S1O[X0&O0N5+V.3,'=\.$)AS6!A7Z5X9$U4]$
M': LW2U;2C1WU@US\ZJ"L@EF?2TE[@-[<=MW.OT+4$L#!!0    (  ."IE0J
M#Q31;@,  ($,   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;)U776_:
M,!3]*U8T::W4D2^20 5(!5IMDSJAHFX/TQY,8DA4)\YL!]K]^ME."&DQ:2@/
M$#OW'!^?>^-<1CM"GUB,$ ?/*<[8V(@YSZ]-DX4Q2B'KD1QEXLZ:T!1R,:0;
MD^44P4B!4FPZEN6;*4PR8S)2<PLZ&9&"XR1#"PI8D::0ODP1)KNQ81O[B8=D
M$W,Y84Y&.=R@)>*/^8**D5FS1$F*,I:0#%"T'ALW]O6=[4J BOB9H!UK7 .Y
ME14A3W+P+1H;EE2$, JYI(#B9XMF"&/))'3\K4B->DT);%[OV>_4YL5F5I"A
M&<&_DHC'8V-@@ BM88'Y ]E]1=6&/,D7$LS4-]B5L4'? &'!.$DKL%"0)EGY
M"Y\K(QH P:,'.!7 >0LXM8); =RN@'X%Z'<%>!7 ZPKP*X"OO"_-4D[/(8>3
M$24[0&6T8),7*ET*+0Q.,EE92T[%W43@^&0A$HDH11& 601F)$U%NI><A$\Q
MP1&B[#.X_5LD_ 5\ 3\@I5 6 KB8(PX3S"[%[.-R#BX^78Y,+N1(4C.LEIZ6
M2SLGEG;!/<EXS,!M%J'H-=X4VZCWXNSW,G5:">\A[0'7O@*.Y3@:/;/N<%L#
MG[?#YRALA=]VAUL:^%T[_'N1";@EX;;?XJ5;UX6K^-P3?%72?]^L&*?B\?_3
MPMFO.?N*L_]NK3%98  6/"8T^2<F+E@,*6+:*BI)/44J#\KMQ+/49V1N-6J\
M6HUWCIHKD$,*MA 7HKPC@C&D#.1(',)2F598R3]H"+-ZEJU7Y=>J_+,\$B\#
MQL6CF62;5I/\(Y-.V!/40H)6(=51<%:F@B,1=I6J$V(&M9A!9S$?2-3@C$0-
M:TG#[OXDC!7O>#,\\F9@N:^M*0^IX\# #S2!<QVCI0F\U3!Z_9:LV-;AY6%U
M-Z%KJ5:<':S01)[P0LNI-4/'V>Y&XU5JM[JQE'L6[59>T# 6W0[(*=E0F%XU
MGQ^8DB+CN@.^8A\VE#E6Z^-C.P=IS@>E423[3YFSQMV]7BB[/VT.G2.MMFT%
M;5H/;Q[;?5\K:\B)M K<EA.O*I^VD%*<V>B<4D0WJL=E()0Y*AN/>K;NHV]4
M]_AF?FI?S\IN^$!3-N>BK=@D&0,8K06EU0N$'EKVN^6 DUSU9RO"1;>G+F/Q
M'P%1&2#NKPGA^X%<H/[7,?D/4$L#!!0    (  ."IE3N"S;:\P(  ) (   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;)U646_:,!#^*U9>MDD="0F0
MJ *D0CMM#]50JVW/;G(0JXZ=V@ZT_WYG)Z1I"8R5!V*?[[O[[K/CRW0GU:/.
M 0QY+KC0,R\WIKST?9WF4% ]D"4(7%E+55"#4[7Q=:F 9@Y4<#\,@HE?4":\
M^=395FH^E97A3,!*$5T5!54O"^!R-_.&WMYPQS:YL09_/BWI!N[!_"I7"F=^
M&R5C!0C-I" *UC/O:GBY3*R_<_C-8*<[8V(K>9#RT4Y^9#,OL(2 0VIL!(J/
M+2R!<QL(:3PU,;TVI05VQ_OHWUSM6,L#U;"4_ _+3#[S$H]DL*85-W=R]QV:
M>L8V7BJY=O]DU_@&'DDK;631@)%!P43]I,^-#AT QND'A T@? \8'0%$#2!R
MA=;,7%G7U-#Y5,D=4=8;H]F!T\:AL1HF["[>&X6K#'%FOD+50"G("!496<JB
M0&WOC4P?<\DS4/H3N7FJF'DA7]O5G"K0Y(?650/[61EM<,#$AGR^!D,9UU\0
MH&O/YL$$N66<X^;IJ6^0NV7@IPW/1<TS/,(S(K=2F%R3&Y%!]A;O8\UMX>&^
M\$5X,N M50,2#2](&(1A#Y_E^?#A"3I1NP^1BQ<=B==HNY?J55OYJNV)-*,V
MS<BE&1U)LX -$\+N4]HDM%O=Y.O;E3K<V(6S-\)VG@13?]L5JG:).R[Q># *
M.K]ABWA#>MR2'G^$]%%E:N;C?S,??Y3YI&4^.<E\>2@RJ4JTP#.HE&D@<DUD
M:2\T?4&VH(VM$FUX"(QBJ4'_&EP)9M#%GHBR4FF.-Y=&([ZA!(J2RQ> QG._
M3$I.19\PDX.J@T'T3IE#GV''YXT6<:M%_-]:4$/ GO$U*4$QV7L"XP,JR2'?
M0Z=X,HC["2<MX>1\PIW#=A;KY!S6ATX]K/W.Y5Z VKB>I_%5J(2IK[O6VK;5
M*]=-WMD7V&[K[O@:IN[5>)GA&Z8)AS6&# 8QOABJ[G_UQ,C2M9 ':; AN6&.
MGPR@K .NKZ4T^XE-T'Z$S/\"4$L#!!0    (  ."IE31BFG1S@(  "X'   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;*55VX[:,!#]%2LO;:4N">&R
MVQ4@+9>J?4!"B]I]J/I@D@FQUK%9>P*[?]^Q$[(L!=JJ/!!?9H[/F?&,!SMM
M'FT.@.RYD,H.@QQQ<QN&-LFAX+:E-Z!H)].FX$A3LP[MQ@!/O5,APSB*^F'!
MA0I& [^V,*.!+E$*!0O#;%D4W+R,0>K=,&@'^X5[L<[1+82CP8:O80GX;;,P
M- L;E%04H*S0BAG(AL%=^W;2=_;>X+N G3T8,Z=DI?6CFWQ-AT'D"(&$!!T"
MI\\6)B"E R(:3S5FT!SI' _'>_3/7CMI67$+$RT?1(KY,+@)6 H9+R7>Z]T7
MJ/7T'%ZBI?7_;%?;1@%+2HNZJ)V)02%4]>7/=1P.' CGM$-<.\3'#MTS#IW:
MH>.%5LR\K"E'/AH8O6/&61.:&_C8>&]2(Y3+XA(-[0KRP]&"H@;&0,JX2ME$
M%P7%=HDZ><RU3,'8=VSV5 I\85?L'A*M$B$%]QG0&9N"TD2*HS;6S<?<BL0C
M384LD5!GW"BAUI8MP+!ES@VX0S8E>@S+WD\!N9#V ^%;MVWW'Z'87$CIK 8A
MDE1'.$QJ6>-*5GQ&5H?-M<+<LIE*(7WK'U*(FCC%^SB-XXN <VY:K-/^R.(H
MCD_PF?R]>_L"G4Z3MH['ZYS!JW/RXVYET5 I_+R V6TPNQZS>P;SP5]Y2*_X
M%@Q5\#X15/L6*:>41E9:RBEJEO@<@JL@2OALL3R5HNJX:W^<ZR;;T4W4BCX=
M_@;A]C"(E4?OP..ZWYB\$=5K1/4NBIIE&34,=S=3=R.I9=2R3A'N_79\=$3P
MDL4;?OV&7_^_@^[JZ94])*41*,CF.!GION9.IZ/_S^GH_SD=X4'K*<"L?4>V
M1*E46%57L]HT_3O?ZX[6Q_085+W[%:9Z2:AVUH):A82,(*/6-1$R57>N)J@W
MOL&M-%*[],.<'C0PSH#V,ZUQ/W$'-$_DZ!=02P,$%     @  X*F5",4\]AI
M @  ?@4  !D   !X;"]W;W)K<VAE971S+W-H965T-34N>&ULC51-;]LP#/TK
M@B_;@#5V['0="L= DG;8#@6"!-T.PPZ*S<1"]>%*=-/^^U&RXV9M4^QB??$]
M\I$F\[VQ=ZX&0/:HI';3J$9L+N/8E34H[D:F 4TO6V,51SK:7>P:"[P*("7C
M-$F^Q(H+'15YN%O:(C<M2J%A:9EKE>+V:0[2[*?1.#I<K,2N1G\1%WG#=[ &
MO&V6ED[QP%()!=H)HYF%[32:C2\7$V\?#'X*V+NC/?-*-L;<^<./:AHE/B"0
M4*)GX+0\P *D]$04QGW/&0TN/?!X?V#_%K23E@UWL##REZBPGD9?(U;!EK<2
M5V;_'7H]YYZO--*%+]OWMDG$RM:A43V8(E!"=RM_[/-P!"">MP%I#TA? B8G
M %D/R(+0+K(@ZXHC+W)K]LQZ:V+SFY";@"8U0OLJKM'2JR <%DO*&E@+%>.Z
M8@NC%.5VC::\JXVLP+H/[/J^%?C$SMC2(&@47,HG=B5DZPLP0&INP;'KQU*V
M%;%MK5'L>KGV[TV+/-3LXQ4@%])](C+7 ?I%:'8CI"0CE\=(NGQT<=EKF'<:
MTA,:,G9C--;D79/K?_$QY6-(2GI(RCQ]E_"&VQ'+QI]9FJ3I&_$L_A\^?B><
M;*A1%OBR$WQ] 7[/-@XM_?=_WN&<#)R3P#DYP3FC0IY5AR*:QM?'A7]@M;YU
M#%[5L7RNXUL5ZKQ=!&]^<CP4YZ/S/'XXSMIKFV24#3:=C/CH5U9@=Z'#'7EO
M-78%'&Z'(3(+O?/B?D[#I9L%SS3=9*+R[ 2)E; ERF1T0:UINV[O#FB:T# ;
M@]1^85O3@ 3K#>A]:Z@1^H-W,(S<XB]02P,$%     @  X*F5 3VZP4&!0
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MZ&=0IJ5K5MQ$BX5M$"9"0[MAAP4T>$2:!?!^)H3>3,P&=<LX_ M02P,$%
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MH6%<Z&-(S9]_!-/97\ +N,EDI5F1Z!-X8^>77 C27L]]0ZXM@!\W;E:UF_"
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MS?@K;*\?=Z]8-A:7*5NR=-I.=3YKAH$=V*CM!0[[R%5S^1',QV%^!# L#J8
M\W%>6)S_:3]#=#\.P[0-O<@0]1FB/L[+ATR;#Q;'[Y/8R[_3)(FB.,8R.IUZ
M%4RQO,4Q?/ULF#;PP.) I#_+-5YMO$.>[P.LIL]U"+93O!.QG>*Y!L2?-_!(
M$G^UL3C@@54!ZQV([X\#/>7WB2*H*J8->X)Q)$DP!'K1WZ-QC&0GAH^_/MA3
M$D5)XD< \RN((@R!IQ%', 6@ 4.BJ#D']\ZC<'U.A9M??R:_ %!+ P04
M"  #@J94EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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MF/<(S'M:F"_</("7B01VI39@7;B>S:%JC7 BADQ&V%@]HL6\Y,*P.RY;8%^
MV]:$@<79& ]5";%+?%ZP]M9^>L-F?F!VC*N:??K1BG7XW9O8)0DFDX38)I^U
MKA^%E!W?E>\4ZCX0L _60C^8F$T28IU\J"K3^@'E6O NC1+00\,<DA!+Y%JK
M^]-;, V;PL+%5)@T$F)K?',K,.R%[4#@,&4DQ,[PH_ 2C/&M&AZ]B6X:K;PQ
M=/6PTK+N#3.8-!)B:W1$I]X=G=P:7Y-]+8X$,T="K(XK5>D&V"W_V6]:3" )
ML4%"8XI.&_:Y<97STPM05?_Y2S%_I,3^F+?KM>R<P26;<+MBEU(_^C%P6UN,
MB7DD)?;(M7=;/VCHW(-8%_-V8>%'&Q*"3YM7NDTQ0Z3$AMB;W+&3F<]%7S]T
MF"U28EL\)WKLY#;D5_:OF OS14KL"S3GZTV%4LP9*;$S#N1\NW#&F)@S4F)G
MH+E?/YJ8.E)B=>"Y7V^Y [-)2FR3/<G?OOZ383+)B&6"Y%N!-<;$9)*13TJ0
MG*N_=H19)J.VS(&<Z[G98TQTC8O8.6@&T8\FYISL?W+.*;O5@71WO'CRT*X7
M34Q!&;&"7C!OH-(^591BV^A>ZE-8QIB8@C)B!;U@?N7&\+"HSDZFWIU"]H<C
M3$ 9L8!PG<>+AADFH(Q80#AFO&R880+*B 5T*.MX?@3BQ6S,0?EQ%L0\9G<F
MQL0<E!,[Z##F9.4SD!@3<U!.[" \AXN[4(XY*"=V$(X9=Z$<W6DA=A".6<28
MF(-R8@>A&7'/Z#GFH)S803AF[]G$+)036PC'[#V;F(5R8@OMG5_L,7J..2@G
M=E!_F?FW["/>J\0<5!QS'C2-<\T"<U!QU'E0W($*S$$%N8,PS+@#%9B#"G('
M89CQX%Y@#BK('81AEC$FNM]/[*"#D]]MGX\Q,0<5Q Y",,.I&!-S4'&D[9LP
MS9Q_CY/B G-00>P@-)K]5U$P"Q7$%HHWF_8ZLL3D4Q++!]UV8B<Q)B:?DE@^
M^+)1[XT>3#XEL7RV&T_[6QFS34F^ZO9J"VH_(F::LC/-L+O87IS7L!0*ZJ^^
M>NO+*RZKF6'A8_MZ1EZ$W=1E*^7$EWU3UYK7NU<E=Z]Y7OP'4$L#!!0    (
M  ."IE322;QM$0(  !<F   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'/-V3MNVT 4A>&M"%R 1_<UM@/+51JW@3= R*,'+(D$AT'LW4>0"^D0*=(8
M/!4Q)'CY%\0'8OCTJQS:<=^=ZF[?U\7'\7"JJV8WCOV/E.IZ5XYMO>OZ<CI?
MV73#L1W/RV&;^G;]WFY+TN4RI^%V1O/\=#MS\?K9E_^9V&TV^W7YV:U_'\MI
M_,?@]*<;WNNNE+%9O+;#MHRK)GT<KJ=KNASD[CRY6;R\K9KAY4V:-'>00I#.
M'V009/,'.03Y_$$!03%_4(:@/'_0/03=SQ_T $$/\P<]0M#C_$&R1!F7!$D3
MK FT%N1:"+P6!%L(Q!8D6PC,%D1;"-069%L(W!:$6PCD%J1;".P6Q%L(]%;4
M6PGT5M1;"?36R<<V@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*
M>BN!WH9Z&X'>AGH;@=Z&>AN!WC;9+"'0VU!O(]#;4&\CT-M0;R/0VU!O(]#;
M4&\CT-M0;R/0VU%O)]#;46\GT-M1;R?0VU%O)]#;)YO=!'H[ZNT$>COJ[01Z
M.^KM!'H[ZNT$>COJ[01Z!^H=!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$>L?D9R6!
MWH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>&?7.!'IGU#L3Z)U1[TR@=T:],X'>&?7.
MWZEW'3\/I5Y[OM;X_.^D>CS?6ZZ/ORR_3D[>W@O.Z;:B/O\%4$L#!!0    (
M  ."IE3 B&UTZ0$  'XE   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:74_"
M,!0&X+]"=FM8Z=?\B'"CWJH7_H&Z'61A6YNV(/Q[NP$F&B4:3'QO6*#M><]Z
MDN>*ZZ>MHS#:M$T7IMDB1G?%6"@7U)J06T==6IE;WYJ8OOH7YDRY-"_$Q&12
ML-)VD;HXCGV-;'9]2W.S:N+H;I-^#K7MIIFG)F2CF]W&/FN:&>>:NC0QK;-U
M5WU*&>\3\G1RV!,6M0MG:4/&ODSH5[X/V)][6)/W=46C1^/CO6G3+K9I6(C;
MAD)^O,07/=KYO"ZILN6J34?RX#R9*BR(8MODNZ)GQY-CNF':??*3\X<RQP+3
MSD=O74@3\_3[N,-(^M-CEPJ1C_7Q5WQ/3*5/?C_JIUU1]</L=+VOUB^'>00V
M/$Z_XX\S?J__RSX$2!\2I \%TH<&Z:, Z>,<I(\+D#XN0?K@$Y1&4$3E**1R
M%%,Y"JH<156.PBI'<96CP,I19!4HL@H4606*K )%5H$BJT"15:#(*E!D%2BR
M"A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DEBJP215:%(JM"D56AR*I09%4H
MLBH4616*K I%5H4BJT*15:/(JE%DU2BR:A19-8JL&D56C2*K1I%5H\BJ460M
M4&0M4&0M4&0M4&0M_E/69VN7?QP_///6U-TAGPU_NYJ] 5!+ 0(4 Q0    (
M  ."IE0'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A
M<' N>&UL4$L! A0#%     @  X*F5%K^WD;N    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @  X*F5)E<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  #@J94\C!G2"P%  !4%0  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @  X*F5"*;FM^4
M!@  6!L  !@              ("!;PT  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    (  ."IE23R"L)2P(  ,T%   8              "
M@3D4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  #@J94
M?5;'89T%   G%P  &               @(&Z%@  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @  X*F5,#34#H, P  8@@  !@
M     ("!C1P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M  ."IE1:EIF)"P0  &D/   8              " @<\?  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    "  #@J94!J,0Y3\'  !_'0  &
M            @($0)   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @  X*F5,JFANB#"   )Q0  !@              ("!A2L  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (  ."IE15]]#[#0T  $ B
M   8              " @3XT  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    "  #@J94:?8#9DT$   A"P  &0              @(&!00
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (  ."IE3340L5
MW0<  -$4   9              " @05&  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @  X*F5.';_J!- P  ,0<  !D
M ("!&4X  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  #
M@J94:0L5U&X#   _"   &0              @(&=40  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  ."IE1<<78IQ0(  ,@%   9
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M970Q."YX;6Q02P$"% ,4    "  #@J94_SK#6-<$  "9"P  &0
M    @('L<P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M  ."IE0*;\3G2 \  %8N   9              " @?IX  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @  X*F5"-<^(3* @  ( 8  !D
M             ("!>8@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    "  #@J94+I(D\L@#   E"   &0              @(%ZBP  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  ."IE3-N_(FS@(
M $P&   9              " @7F/  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @  X*F5(.X&7'J!   T0L  !D              ("!
M?I(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  #@J94
M.4MJ72 $  !]"0  &0              @(&?EP  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    (  ."IE1H"!N68 0  /4+   9
M      " @?:;  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @  X*F5)N^)AXQ!   ^@H  !D              ("!C:   'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  #@J94[&"]1$ #   C!P
M&0              @('UI   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    (  ."IE2(-E["H@,  *<+   9              " @6RH  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @  X*F5-WQK+?"
M @  R04  !D              ("!1:P  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    "  #@J943@Z!G%4"   .!0  &0
M@($^KP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  ."
MIE2@7OV+X ,  . )   9              " @<JQ  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @  X*F5(Y,YQ-2!   ' L  !D
M         ("!X;4  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    "  #@J94HM_Q_KH"   2!@  &0              @(%JN@  >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  ."IE0RN\,79P8  +LJ
M   9              " @5N]  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @  X*F5(E8-K25 @  'P<  !D              ("!^<,
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  #@J94H2/\
M[9H#  !R"@  &0              @('%Q@  >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    (  ."IE3ZGH_Y+@4  %D;   9
M  " @9;*  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M X*F5 OG52VQ P  10\  !D              ("!^\\  'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    "  #@J94RT^$+5,"   J!0  &0
M            @('CTP  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    (  ."IE3**=PM7 8  &@P   9              " @6W6  !X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @  X*F5"032V2B @
M< 8  !D              ("! -T  'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    "  #@J94+79D5[P"  #A"   &0              @('9
MWP  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (  ."IE1$
MP.2D/P(  #8%   9              " @<SB  !X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @  X*F5& *O<DR @  U 0  !D
M     ("!0N4  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  ."IE0A"Z%ELP0  +47   9              "
M@?WR  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @  X*F
M5*QJ"N%0 @  LP4  !D              ("!Y_<  'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    "  #@J94*@\4T6X#  "!#   &0
M        @(%N^@  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   (  ."IE3N"S;:\P(  ) (   9              " @1/^  !X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @  X*F5-&*:='. @  +@<
M !D              ("!/0$! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    "  #@J94(Q3SV&D"  !^!0  &0              @(%"! $
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (  ."IE0$]NL%
M!@4  &46   9              " @>(& 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @  X*F5.[2L>4; P  H H  !D
M ("!'PP! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  #
M@J947"28T1 #   ^"@  &0              @(%Q#P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (  ."IE2^DW)!+P,  (T+   9
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M970V,RYX;6Q02P$"% ,4    "  #@J94VJT2H#X"  ""!0  &0
M    @(%0(P$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M  ."IE3F;/\1&@,   H2   -              "  <4E 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @  X*F5)>*NQS     $P(   L              ( !
M"BD! %]R96QS+RYR96QS4$L! A0#%     @  X*F5%!9AXCC!   :BH   \
M             ( !\RD! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  ."
MIE322;QM$0(  !<F   :              "  0,O 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  ."IE3 B&UTZ0$  'XE   3
M          "  4PQ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !( $@
*KQ,  &8S 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>197</ContextCount>
  <ElementCount>264</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Marketable Investment Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecurities</Role>
      <ShortName>Marketable Investment Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122106 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Other Long-Term Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OtherLongTermLiabilities</Role>
      <ShortName>Other Long-Term Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - Preferred and Common Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquity</Role>
      <ShortName>Preferred and Common Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2141111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2149113 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2151114 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2154115 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2156116 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/Revenue</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Marketable Investment Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesTables</Role>
      <ShortName>Marketable Investment Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/MarketableInvestmentSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/AccruedLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Other Long-Term Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OtherLongTermLiabilitiesTables</Role>
      <ShortName>Other Long-Term Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OtherLongTermLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2336308 - Disclosure - Preferred and Common Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables</Role>
      <ShortName>Preferred and Common Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/PreferredandCommonStockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2342309 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/StockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2352310 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Revenue - Total Revenue by Category and by US versus Rest of World (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails</Role>
      <ShortName>Revenue - Total Revenue by Category and by US versus Rest of World (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Revenue - Reconciliation of Deferred Revenue Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails</Role>
      <ShortName>Revenue - Reconciliation of Deferred Revenue Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails</Role>
      <ShortName>Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Depreciation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Property, Plant and Equipment, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Long-Term Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LongTermDebtNarrativeDetails</Role>
      <ShortName>Long-Term Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Other Long-Term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OtherLongTermLiabilitiesDetails</Role>
      <ShortName>Other Long-Term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OtherLongTermLiabilitiesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Stock-Based Compensation - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2448426 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/IncomeTaxes</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2450427 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/CommitmentsandContingencies</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2453428 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2455429 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/Leases</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="mygn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2457430 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SubsequentEvents</ParentRole>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mygn-20220331.htm">mygn-20220331.htm</File>
    <File>exhibit311-certificationof.htm</File>
    <File>exhibit312-certificationof.htm</File>
    <File>exhibit321-certificationpu.htm</File>
    <File>mygn-20220331.xsd</File>
    <File>mygn-20220331_cal.xml</File>
    <File>mygn-20220331_def.xml</File>
    <File>mygn-20220331_lab.xml</File>
    <File>mygn-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="602">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mygn-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 30,
   "contextCount": 197,
   "dts": {
    "calculationLink": {
     "local": [
      "mygn-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mygn-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mygn-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mygn-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mygn-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mygn-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 472,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 18,
   "keyStandard": 246,
   "memberCustom": 23,
   "memberStandard": 42,
   "nsprefix": "mygn",
   "nsuri": "http://www.myriad.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.myriad.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Marketable Investment Securities",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecurities",
     "shortName": "Marketable Investment Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Fair Value Measurements",
     "role": "http://www.myriad.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Property, Plant and Equipment, Net",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNet",
     "shortName": "Property, Plant and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122106 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - Accrued Liabilities",
     "role": "http://www.myriad.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Long-Term Debt",
     "role": "http://www.myriad.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Other Long-Term Liabilities",
     "role": "http://www.myriad.com/role/OtherLongTermLiabilities",
     "shortName": "Other Long-Term Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - Preferred and Common Stockholders' Equity",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquity",
     "shortName": "Preferred and Common Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141111 - Disclosure - Stock-Based Compensation",
     "role": "http://www.myriad.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147112 - Disclosure - Income Taxes",
     "role": "http://www.myriad.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149113 - Disclosure - Commitments and Contingencies",
     "role": "http://www.myriad.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151114 - Disclosure - Supplemental Cash Flow Information",
     "role": "http://www.myriad.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154115 - Disclosure - Leases",
     "role": "http://www.myriad.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156116 - Disclosure - Subsequent Events",
     "role": "http://www.myriad.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.myriad.com/role/BasisofPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Revenue (Tables)",
     "role": "http://www.myriad.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Marketable Investment Securities (Tables)",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables",
     "shortName": "Marketable Investment Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.myriad.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetTables",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.myriad.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Other Long-Term Liabilities (Tables)",
     "role": "http://www.myriad.com/role/OtherLongTermLiabilitiesTables",
     "shortName": "Other Long-Term Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336308 - Disclosure - Preferred and Common Stockholders' Equity (Tables)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables",
     "shortName": "Preferred and Common Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342309 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.myriad.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352310 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "role": "http://www.myriad.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Revenue - Total Revenue by Category and by US versus Rest of World (Details)",
     "role": "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails",
     "shortName": "Revenue - Total Revenue by Category and by US versus Rest of World (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "ic8dbe812816b48cb830e84114c6d8f60_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i56db6c3d57e14c2b8658a385a44e3603_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Revenue - Reconciliation of Deferred Revenue Balances (Details)",
     "role": "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails",
     "shortName": "Revenue - Reconciliation of Deferred Revenue Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i38f47e17df9c466eb0964b81d156f640_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "ied55de41f92a4292af6d62bd5c0088d0_D20190701-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mygn:CARESActOf2020MedicarePaymentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Revenue - Narrative (Details)",
     "role": "http://www.myriad.com/role/RevenueNarrativeDetails",
     "shortName": "Revenue - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "ied55de41f92a4292af6d62bd5c0088d0_D20190701-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mygn:CARESActOf2020MedicarePaymentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails",
     "shortName": "Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
     "shortName": "Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "id6ed914040924d00942b5531f455cea3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "id6ed914040924d00942b5531f455cea3_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)",
     "role": "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i56db6c3d57e14c2b8658a385a44e3603_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)",
     "role": "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails",
     "shortName": "Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i56db6c3d57e14c2b8658a385a44e3603_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
     "shortName": "Property, Plant and Equipment, Net - Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails",
     "shortName": "Property, Plant and Equipment, Net - Depreciation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i49163efc76014827a31448fd386b5085_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Property, Plant and Equipment, Net - Narrative (Details)",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails",
     "shortName": "Property, Plant and Equipment, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i56db6c3d57e14c2b8658a385a44e3603_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Accrued Liabilities (Details)",
     "role": "http://www.myriad.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLinesOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Long-Term Debt - Narrative (Details)",
     "role": "http://www.myriad.com/role/LongTermDebtNarrativeDetails",
     "shortName": "Long-Term Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebt",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Other Long-Term Liabilities (Details)",
     "role": "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails",
     "shortName": "Other Long-Term Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i56db6c3d57e14c2b8658a385a44e3603_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details)",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i83a6571b146e482389af3212034e29e0_I20121231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i56db6c3d57e14c2b8658a385a44e3603_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i56db6c3d57e14c2b8658a385a44e3603_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i6d5670611ac54c00895e101571e289ec_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Stock-Based Compensation - RSU Activity (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails",
     "shortName": "Stock-Based Compensation - RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i6d5670611ac54c00895e101571e289ec_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i38f47e17df9c466eb0964b81d156f640_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i38f47e17df9c466eb0964b81d156f640_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448426 - Disclosure - Income Taxes (Details)",
     "role": "http://www.myriad.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i9ac025088f904137a68dd99ae7162c5e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450427 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453428 - Disclosure - Supplemental Cash Flow Information (Details)",
     "role": "http://www.myriad.com/role/SupplementalCashFlowInformationDetails",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455429 - Disclosure - Leases (Details)",
     "role": "http://www.myriad.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "idd3dfbf88a4f49d29528546627f27aa0_D20220401-20220401",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457430 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.myriad.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation",
     "role": "http://www.myriad.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Revenue",
     "role": "http://www.myriad.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20220331.htm",
      "contextRef": "i91d207f7b7a04f9087ab7c35a54a9cc1_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mygn_AmendmentToCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to Credit Agreement [Member].",
        "label": "Amendment To Credit Agreement [Member]",
        "terseLabel": "Amended facility"
       }
      }
     },
     "localname": "AmendmentToCreditAgreementMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Measurement Input, Term",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input, Term",
        "terseLabel": "Measurement period for earn out liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mygn_CARESActOf2020MedicarePaymentAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act of 2020 Medicare payment amount.",
        "label": "CARES Act Of 2020 Medicare Payment Amount",
        "terseLabel": "Advance Medicare payments to provide relief from economic impacts of COVID-19"
       }
      }
     },
     "localname": "CARESActOf2020MedicarePaymentAmount",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_CBICIFPASettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CBI CIFPA Settlement",
        "label": "CBI CIFPA Settlement [Member]",
        "terseLabel": "CBI CIFPA"
       }
      }
     },
     "localname": "CBICIFPASettlementMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract, Revenue Recognized",
        "label": "Contract With Customer, Liability, Including New Contract, Revenue Recognized",
        "negatedLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ContractWithCustomerLiabilityPrepayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer, liability, prepayments.",
        "label": "Contract With Customer, Liability, Prepayments",
        "terseLabel": "Prepayments"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityPrepayments",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_CostOfMolecularDiagnosticTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about the cost of molecular diagnostic testing expense have been included.",
        "label": "Cost Of Molecular Diagnostic Testing [Member]",
        "terseLabel": "Cost of molecular diagnostic testing"
       }
      }
     },
     "localname": "CostOfMolecularDiagnosticTestingMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_CostOfPharmaceuticalAndClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about the cost of pharmaceutical and clinical services expense have been included.",
        "label": "Cost Of Pharmaceutical And Clinical Services [Member]",
        "terseLabel": "Cost of pharmaceutical and clinical services"
       }
      }
     },
     "localname": "CostOfPharmaceuticalAndClinicalServicesMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_DebtCovenantLiquidityCovenantMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Liquidity Covenant Minimum",
        "label": "Debt Covenant, Liquidity Covenant Minimum",
        "terseLabel": "Minimum liquidity covenant"
       }
      }
     },
     "localname": "DebtCovenantLiquidityCovenantMinimum",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum",
        "label": "Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum",
        "terseLabel": "Minimum unrestricted cash and cash equivalents threshold per covenant"
       }
      }
     },
     "localname": "DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DebtInstrumentLIBORFloorPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, LIBOR Floor, Percentage",
        "label": "Debt Instrument, LIBOR Floor, Percentage",
        "terseLabel": "LIBOR floor (percent)"
       }
      }
     },
     "localname": "DebtInstrumentLIBORFloorPercentage",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_EmployeeStockPurchasePlanTwentyTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan Twenty Twelve [Member]",
        "label": "Employee Stock Purchase Plan Twenty Twelve [Member]",
        "terseLabel": "2012 Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanTwentyTwelveMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_IncreaseDecreaseInEarningsLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in earnings (loss) per share.",
        "label": "Increase Decrease In Earnings Loss Per Share",
        "terseLabel": "Change in earnings per share (dollars per share)"
       }
      }
     },
     "localname": "IncreaseDecreaseInEarningsLossPerShare",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mygn_IncreaseDecreaseInUnrecognizedTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in unrecognized tax benefits.",
        "label": "Increase (Decrease) In Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInUnrecognizedTaxBenefits",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets.",
        "label": "Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IntangibleAssetsLineItems",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 1.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Accumulated Gross Unrealized Gain, before Tax",
        "label": "Investments And Cash, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Total, Gross unrealized holding gains"
       }
      }
     },
     "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 2.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Accumulated Gross Unrealized Loss, before Tax",
        "label": "Investments And Cash, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Total, Gross unrealized holding losses"
       }
      }
     },
     "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_InvestmentsAndCashAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Amortized Cost",
        "label": "Investments And Cash, Amortized Cost",
        "totalLabel": "Total, Amortized cost"
       }
      }
     },
     "localname": "InvestmentsAndCashAmortizedCost",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_LeaseArrangementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangement",
        "label": "Lease Arrangement [Axis]",
        "terseLabel": "Lease Arrangement [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementAxis",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_LeaseArrangementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangement [Domain]",
        "label": "Lease Arrangement [Domain]",
        "terseLabel": "Lease Arrangement [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementDomain",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_LesseeOperatingLeaseAreaOfLeasedSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area Of Leased Space",
        "label": "Lessee, Operating Lease, Area Of Leased Space",
        "terseLabel": "Operating lease area (sq ft)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaOfLeasedSpace",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "mygn_LesseeOperatingLeaseExpectedFutureRentPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Expected Future Rent Payments",
        "label": "Lessee, Operating Lease, Expected Future Rent Payments",
        "terseLabel": "Total expected future rent payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExpectedFutureRentPayments",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticAutoimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular Diagnostic Autoimmune",
        "label": "Molecular Diagnostic Autoimmune [Member]",
        "terseLabel": "Molecular Diagnostic - Autoimmune"
       }
      }
     },
     "localname": "MolecularDiagnosticAutoimmuneMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticHereditaryCancerTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic hereditary cancer testing.",
        "label": "Molecular Diagnostic Hereditary Cancer Testing [Member]",
        "terseLabel": "Molecular diagnostic - Hereditary Cancer"
       }
      }
     },
     "localname": "MolecularDiagnosticHereditaryCancerTestingMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticOtherTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic other testing.",
        "label": "Molecular Diagnostic Other Testing [Member]",
        "terseLabel": "Molecular diagnostic - Other"
       }
      }
     },
     "localname": "MolecularDiagnosticOtherTestingMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticPharmacogenomicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular Diagnostic Pharmacogenomics",
        "label": "Molecular Diagnostic Pharmacogenomics [Member]",
        "terseLabel": "Molecular Diagnostic - Pharmacogenomics"
       }
      }
     },
     "localname": "MolecularDiagnosticPharmacogenomicsMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticPrenatalTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic Prenatal testing.",
        "label": "Molecular Diagnostic Prenatal Testing [Member]",
        "terseLabel": "Molecular diagnostic - Prenatal"
       }
      }
     },
     "localname": "MolecularDiagnosticPrenatalTestingMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic testing.",
        "label": "Molecular Diagnostic Testing [Member]",
        "terseLabel": "Molecular diagnostic testing"
       }
      }
     },
     "localname": "MolecularDiagnosticTestingMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MolecularDiagnosticTumorProfilingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular Diagnostic Tumor Profiling",
        "label": "Molecular Diagnostic Tumor Profiling [Member]",
        "terseLabel": "Molecular diagnostic - Tumor Profiling"
       }
      }
     },
     "localname": "MolecularDiagnosticTumorProfilingMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash interest expense.",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_NonEmployeeDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee director.",
        "label": "Non Employee Director [Member]",
        "terseLabel": "Non-employee director"
       }
      }
     },
     "localname": "NonEmployeeDirectorMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_OperatingLeaseLiabilityEstablished": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability Established",
        "label": "Operating Lease Liability Established",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityEstablished",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_OptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and Restricted Stock Units.",
        "label": "Options And Restricted Stock Units [Member]",
        "terseLabel": "Options and RSUs"
       }
      }
     },
     "localname": "OptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_PerformanceObligationEstimatedTransactionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Obligation Estimated Transaction Price",
        "label": "Performance Obligation Estimated Transaction Price [Member]",
        "terseLabel": "Performance obligation estimate"
       }
      }
     },
     "localname": "PerformanceObligationEstimatedTransactionPriceMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_PharmaceuticalAndClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical and clinical services.",
        "label": "Pharmaceutical And Clinical Services [Member]",
        "terseLabel": "Pharmaceutical and clinical services"
       }
      }
     },
     "localname": "PharmaceuticalAndClinicalServicesMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_PurchasedLicensesAndTechnologiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased licenses and technologies.",
        "label": "Purchased Licenses And Technologies [Member]",
        "terseLabel": "Purchased licenses and technologies"
       }
      }
     },
     "localname": "PurchasedLicensesAndTechnologiesMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_RefundsPayableAndReserveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refunds Payable And Reserve, Current",
        "label": "Refunds Payable And Reserve, Current",
        "terseLabel": "Refunds payable and reserves"
       }
      }
     },
     "localname": "RefundsPayableAndReserveCurrent",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_RelatorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relator",
        "label": "Relator [Member]",
        "terseLabel": "Relator's counsel"
       }
      }
     },
     "localname": "RelatorMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ScheduleOfIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Intangible Assets [Table]",
        "label": "Schedule Of Intangible Assets [Table]",
        "terseLabel": "Schedule Of Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTable",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans",
        "label": "Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans",
        "terseLabel": "Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan",
        "label": "Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan [Member]",
        "terseLabel": "2017 Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_UnitedStatesAndStateOfCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States And State Of California",
        "label": "United States And State Of California [Member]",
        "terseLabel": "United States and State of California"
       }
      }
     },
     "localname": "UnitedStatesAndStateOfCaliforniaMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_WestSaltLakeCityLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "West Salt Lake City Lease",
        "label": "West Salt Lake City Lease [Member]",
        "terseLabel": "West Salt Lake City"
       }
      }
     },
     "localname": "WestSaltLakeCityLeaseMember",
     "nsuri": "http://www.myriad.com/20220331",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "President and Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r56",
      "r58",
      "r117",
      "r118",
      "r254",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r171",
      "r318",
      "r323",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r253",
      "r286",
      "r338",
      "r340",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r534",
      "r538",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r253",
      "r286",
      "r338",
      "r340",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r534",
      "r538",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r171",
      "r318",
      "r323",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r168",
      "r318",
      "r321",
      "r486",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r168",
      "r318",
      "r321",
      "r486",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r253",
      "r286",
      "r329",
      "r338",
      "r340",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r534",
      "r538",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r253",
      "r286",
      "r329",
      "r338",
      "r340",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r534",
      "r538",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r57",
      "r58",
      "r117",
      "r118",
      "r254",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r128",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r128",
      "r133",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r318",
      "r322",
      "r536",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r318",
      "r322",
      "r536",
      "r563",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "U.S. [Member]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r128",
      "r133",
      "r229",
      "r339",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r172",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39",
      "r469"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r7",
      "r25",
      "r173",
      "r174"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails",
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r45"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r37",
      "r219"
     ],
     "calculation": {
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r62",
      "r63",
      "r64",
      "r520",
      "r543",
      "r544"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r61",
      "r64",
      "r71",
      "r72",
      "r73",
      "r120",
      "r121",
      "r122",
      "r417",
      "r539",
      "r540",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r370",
      "r371",
      "r372",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r341",
      "r343",
      "r375",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based payment expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r343",
      "r366",
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r101",
      "r205",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive options and RSUs excluded from EPS computation"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r101",
      "r216"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Goodwill and long-lived asset impairment charges",
        "verboseLabel": "Impairment of goodwill and long-lived assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r113",
      "r157",
      "r160",
      "r166",
      "r193",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r411",
      "r418",
      "r443",
      "r467",
      "r469",
      "r492",
      "r517"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r12",
      "r55",
      "r113",
      "r193",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r411",
      "r418",
      "r443",
      "r467",
      "r469"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale, Gross unrealized holding gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Available-for-sale, Gross unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r178",
      "r195"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale, Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r186"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Available-for-sale, Due after five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r182",
      "r186",
      "r512"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Available-for-sale, Due after five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Available-for-sale, Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r182",
      "r185",
      "r511"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Available-for-sale, Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract]",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Rolling Maturity [Abstract]",
        "terseLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Available-for-sale, Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r182",
      "r184",
      "r510"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Available-for-sale, Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r176",
      "r179",
      "r195",
      "r498"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale, Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r345",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Short-term contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r105",
      "r106",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property, plant and equipment in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "terseLabel": "Capitalized costs incurred to obtain or fulfill contract"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r5",
      "r34",
      "r103"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents, Amortized cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, Estimated fair value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r96",
      "r103",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r96",
      "r444"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Establishment of operating lease right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r128",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r128",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Liability [Abstract]",
        "terseLabel": "Reconciliation of Deferred Revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r51",
      "r228",
      "r499",
      "r525"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r236",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Common stock issued at end of period",
        "periodStartLabel": "Beginning common stock issued",
        "terseLabel": "Common stock issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common stock outstanding at end of period",
        "periodStartLabel": "Beginning common stock outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24",
      "r469"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, 80.3 million and 80.0 million shares outstanding at March\u00a031, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r67",
      "r69",
      "r70",
      "r78",
      "r503",
      "r529"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Myriad Genetics, Inc. stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r69",
      "r77",
      "r409",
      "r422",
      "r502",
      "r528"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r171",
      "r440",
      "r441",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r171",
      "r440",
      "r441",
      "r546",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r171",
      "r440",
      "r441",
      "r546",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Revenue and Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r149",
      "r150",
      "r171",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r147",
      "r149",
      "r150",
      "r151",
      "r440",
      "r442",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r171",
      "r440",
      "r441",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Reconciliation of Deferred Revenue Balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r306",
      "r307",
      "r319"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Deferred revenue - ending balance",
        "periodStartLabel": "Deferred revenue - beginning balance",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r330",
      "r337",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds and notes"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r81",
      "r486"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r267",
      "r274",
      "r275",
      "r277",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r112",
      "r119",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r279",
      "r280",
      "r281",
      "r282",
      "r456",
      "r493",
      "r495",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r48",
      "r253",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r49",
      "r112",
      "r119",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r279",
      "r280",
      "r281",
      "r282",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r49",
      "r112",
      "r119",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r276",
      "r279",
      "r280",
      "r281",
      "r282",
      "r300",
      "r301",
      "r302",
      "r303",
      "r453",
      "r454",
      "r456",
      "r457",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Long-term deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "verboseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r101",
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r101",
      "r217"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r318",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Total Revenue by Category and by U.S versus Rest of World"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarliestTaxYearMember": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest identified tax year.",
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest tax year"
       }
      }
     },
     "localname": "EarliestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r79",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r134",
      "r136",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r425",
      "r426",
      "r504",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted average shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r79",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r136",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r425",
      "r426",
      "r504",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r444"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Approximate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-Based Compensation Expense [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense related to RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense related to stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r71",
      "r72",
      "r73",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r146",
      "r194",
      "r299",
      "r304",
      "r370",
      "r371",
      "r372",
      "r393",
      "r394",
      "r424",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r539",
      "r540",
      "r541",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r427",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r265",
      "r279",
      "r280",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r428",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r265",
      "r330",
      "r331",
      "r336",
      "r337",
      "r428",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r265",
      "r279",
      "r280",
      "r330",
      "r331",
      "r336",
      "r337",
      "r428",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r265",
      "r279",
      "r280",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r428",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Reconciliation of change in fair value of contingent consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r432",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Change in Fair Value of Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Change in fair value recognized in the Statement of Operations"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "negatedTerseLabel": "Translation adjustments recognized in Other comprehensive loss"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r265",
      "r279",
      "r280",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Recorded Amortization Expense for Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r210",
      "r213",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r210",
      "r488"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount, amortizable"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r206",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r210",
      "r487"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net, amortizable"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r199",
      "r200",
      "r469",
      "r491"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GovernmentContractsConcentrationRiskMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City.",
        "label": "Government Contracts Concentration Risk [Member]",
        "terseLabel": "Government contracts concentration risk"
       }
      }
     },
     "localname": "GovernmentContractsConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r75",
      "r157",
      "r159",
      "r162",
      "r165",
      "r167",
      "r489",
      "r500",
      "r506",
      "r531"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r222",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r386",
      "r388",
      "r390",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r384",
      "r389",
      "r391",
      "r395",
      "r397",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationYearUnderExamination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year being audited in the income tax examination, in YYYY format.",
        "label": "Income Tax Examination, Year under Examination",
        "terseLabel": "Tax year being audited in income tax examination"
       }
      }
     },
     "localname": "IncomeTaxExaminationYearUnderExamination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r131",
      "r132",
      "r156",
      "r382",
      "r396",
      "r398",
      "r532"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r98",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid during the period for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r100",
      "r484"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidTaxes": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Taxes",
        "negatedLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Common shares issued and outstanding"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Carrying Amount, total"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r204",
      "r208"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangibles, net",
        "totalLabel": "Net, total"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r74",
      "r155",
      "r452",
      "r455",
      "r505"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r94",
      "r97",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r6",
      "r54",
      "r469"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r83",
      "r154"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 3.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "terseLabel": "Total, Estimated fair value",
        "totalLabel": "Total, Estimated fair value"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments and Cash [Abstract]",
        "terseLabel": "Total:"
       }
      }
     },
     "localname": "InvestmentsAndCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r192",
      "r490",
      "r513",
      "r562",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Investment Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LatestTaxYearMember": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest identified tax year.",
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest tax year"
       }
      }
     },
     "localname": "LatestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r113",
      "r161",
      "r193",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r412",
      "r418",
      "r419",
      "r443",
      "r467",
      "r468"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r113",
      "r193",
      "r443",
      "r469",
      "r497",
      "r523"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r47",
      "r113",
      "r193",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r412",
      "r418",
      "r419",
      "r443",
      "r467",
      "r468",
      "r469"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "negatedTerseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum aggregate principal commitment"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Undrawn fee (percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r51",
      "r228",
      "r235"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Legal charges pending settlement",
        "verboseLabel": "Potential settlement accrual"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails",
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement agreement"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r21",
      "r264",
      "r278",
      "r279",
      "r280",
      "r495",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Outstanding balances"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r8",
      "r44"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable investment securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable investment securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement input, expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r53",
      "r113",
      "r193",
      "r239",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r443",
      "r496",
      "r522"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r96",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r3",
      "r65",
      "r68",
      "r73",
      "r76",
      "r102",
      "r113",
      "r123",
      "r125",
      "r126",
      "r127",
      "r128",
      "r131",
      "r132",
      "r137",
      "r157",
      "r159",
      "r162",
      "r165",
      "r167",
      "r193",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r426",
      "r443",
      "r501",
      "r527"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Myriad Genetics, Inc. stockholders",
        "totalLabel": "Net loss attributable to Myriad Genetics, Inc. stockholders",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r68",
      "r73",
      "r131",
      "r132",
      "r414",
      "r421"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New Jersey.",
        "label": "New Jersey Division of Taxation [Member]",
        "terseLabel": "New Jersey"
       }
      }
     },
     "localname": "NewJerseyDivisionOfTaxationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "RoW"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r157",
      "r159",
      "r162",
      "r165",
      "r167"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Loss due to abandonment of facility"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current maturities of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r4",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r45"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "auth_ref": [
      "r101",
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.",
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "OtherAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Change in foreign currency translation adjustment, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r66",
      "r69",
      "r409",
      "r410",
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r60",
      "r62"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on available-for-sale debt securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Long-Term Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Long-Term Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [
      "r22",
      "r494",
      "r518"
     ],
     "calculation": {
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.",
        "label": "Other Sundry Liabilities, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payment of contingent consideration recognized at acquisition"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Fees associated with refinancing of revolving credit facility"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Payment of tax withheld for common stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r86",
      "r87",
      "r177"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable investment securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r88",
      "r404",
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r345",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r9",
      "r11",
      "r196",
      "r197"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r89",
      "r369"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from common stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities and sales of marketable investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r3",
      "r65",
      "r68",
      "r73",
      "r95",
      "r113",
      "r123",
      "r131",
      "r132",
      "r157",
      "r159",
      "r162",
      "r165",
      "r167",
      "r193",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r409",
      "r413",
      "r415",
      "r421",
      "r422",
      "r426",
      "r443",
      "r506"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r37",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r223",
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r36",
      "r218"
     ],
     "calculation": {
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r220",
      "r469",
      "r514",
      "r524"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant, and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LeasesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r91",
      "r112"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Repayment of revolving credit facility",
        "terseLabel": "Principal repayment"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r378",
      "r485",
      "r580"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r304",
      "r373",
      "r469",
      "r521",
      "r542",
      "r544"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r194",
      "r370",
      "r371",
      "r372",
      "r393",
      "r394",
      "r424",
      "r539",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r152",
      "r153",
      "r158",
      "r163",
      "r164",
      "r168",
      "r169",
      "r171",
      "r317",
      "r318",
      "r486"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/RevenueTotalRevenuebyCategoryandbyUSversusRestofWorldDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r149",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r320",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r463",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Dilutive Common Shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r183",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in common stock outstanding.",
        "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Common Shares Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r343",
      "r365",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r343",
      "r365",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r206",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Amortizable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r212",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Non-amortizable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r37",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r345",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r350",
      "r361",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Service period for award vesting (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "RSUs canceled (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs canceled (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs granted (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "RSUs outstanding, ending (shares)",
        "periodStartLabel": "RSUs outstanding, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "RSUs, Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "RSUs outstanding, ending (dollars per share)",
        "periodStartLabel": "RSUs outstanding, beginning (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "RSUs, Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "RSUs vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs vested (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares per participant per offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable at end of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable at end of period (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options canceled or expired (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled or expired (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r352",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending (shares)",
        "periodStartLabel": "Options outstanding, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options, Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending (dollars per share)",
        "periodStartLabel": "Options outstanding, beginning (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Options, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued under the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r342",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Achievement levels based on EPS targets"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Relative total stockholders return"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Performance based on Nasdaq Healthcare Provider Index"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting weight (percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r52",
      "r71",
      "r72",
      "r73",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r146",
      "r194",
      "r299",
      "r304",
      "r370",
      "r371",
      "r372",
      "r393",
      "r394",
      "r424",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r539",
      "r540",
      "r541",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r146",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r24",
      "r299",
      "r304",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r304",
      "r344",
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Share repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Share repurchase program, remaining repurchase authorization"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r23",
      "r24",
      "r299",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Shares repurchased"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r29",
      "r30",
      "r113",
      "r175",
      "r193",
      "r443",
      "r469"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Myriad Genetics, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r72",
      "r113",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r193",
      "r194",
      "r304",
      "r370",
      "r371",
      "r372",
      "r393",
      "r394",
      "r407",
      "r408",
      "r420",
      "r424",
      "r443",
      "r445",
      "r446",
      "r450",
      "r540",
      "r541",
      "r588"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Preferred and Common Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r451",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r451",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r451",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r451",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
      "http://www.myriad.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r470",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SwissFederalTaxAdministrationFTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Switzerland.",
        "label": "Swiss Federal Tax Administration (FTA) [Member]",
        "terseLabel": "Switzerland"
       }
      }
     },
     "localname": "SwissFederalTaxAdministrationFTAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Accrued taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r116",
      "r330",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US government securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r330",
      "r507",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "Federal agency issues"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r379",
      "r387"
     ],
     "calculation": {
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Effect of dilutive shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r135",
      "r140"
     ],
     "calculation": {
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Weighted-average shares outstanding and dilutive securities used to compute diluted EPS"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r134",
      "r140"
     ],
     "calculation": {
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Weighted-average shares outstanding used to compute basic EPS"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e777-108305"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r581": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r582": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r583": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r584": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r585": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r586": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r587": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0000899923-22-000079-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000899923-22-000079-xbrl.zip
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MI09&TCJLZASC]##8C5965\!FY\9L6/M4\-;9.[P-UH+S_-E)*SH^LR6BRM*
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M-\&BZ;(;G@L$.T\'@L 2F6&0"2^+H%81?RB.S6:I768)L@BG(@JO8U4(U(G
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M'??EA/+"Y(AIZPN2.-9&> -\B3K$?9#!*F5*+9#3FB$1++\#?'%MR1S9^[D
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M.$T8DN!L6%L3J5#P+=2&((5FP\V/$>6Z$*0:\MQUV T:K6,ETABYM.%&IU;
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M)@N_3KOQD,RIO1>S)^9)QMD<S_!XGC?\E,'K^JWJU]5!3<C3\Q>,JPCYJ=3
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MP*J4)SZ3)Z[E>7=YXKO+$T]-G@#P$81II,2(,7"-@N<<<RJX320:5=\^W\%
MV#4NC$"0IK/2\ZM U]+'R:V#>313D&ADE*B8"*5A0(^,H])A@&(8Q[VHOID^
MMUB?Q5JI!Q_!!(LBQ@P< \!=["GA$:P58?X<Z#NK_7:1TX$?OIWH\'E?^/P8
MVG#QUM)W-,/^N:+>D_Y=>S[]N!9Z_6[>NZG8NY+T2T6\NES['[%/BY0)D;F
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MWA'"G'3@V&OE"(B*"\1",#R2N1'-\PS+TQ*3CMY&Y7@"$899-$&E.%B-D52
M_')^Q/3LP_+41.:,#C@RB;UFB#(K%8S-G,882"3"S(W(GGA8GI9\C#(J(J-!
M()[Q8#68%!;481%18L 5")V850A\_@ *A4DP4A"N@1@;K@ OHU,"G!@C @UT
M_H3[Q/-XSR)59A2A&L9 &L M-0B<4Q)YE"12JR+1\R?5YY_'>Q9!6RJ=0 H)
M$QT+@@!2.R=(\$Q[+/03AC'/B</PH/CJ*[X<X4IYZ@TWC'IBP5]@(0JF@C0J
MB+D1S7,X#-,3D[86.TJEUUHR$9VQ8#E>N6B\%):B^1'3,SL,TQ,98LH2%17%
M&C.!G6%,I-T&"#'G<>1S([(G=1BF)Q^#.=9.48VM8L!#P* H 5[I18@$1U(!
M]G'_V/G_A"( #IKB=#6E;RCN%DM_IXJ<:\N;T-\KS-%^&0E<UF:2RF+IP_9\
M\1H5+#=1T*A A3!U%D9/[E*$@2&44EX1%?J.Y,YLO-7O??B18<^,NE92EZA!
M"!S<0+CQ#$9[[:F26DE/M,- H"NB2[5\;Y>O$A@3&6E:-&$V&($U\\YXYV(E
M0I'JX>9YPV&P4(93'YS"G(FT/HP)XT$Y$D"+1%6V$=7#S0SHDL3&Q&@5(@PQ
M8XGUA'!F'-.44\E<172IEN]M.[V9\CHE_ M>,$&"\=YBAI' A AOJC!C_A,[
M@T?=?@&/Q+PS%Z/,\TS66@;>KP<0\)9906Q,\TW24P=>CC15(:*S.\K<2TLK
MJ4(.> G%+&@6&(LN6BN)CT@P)9@E451$A6JQ7HE\"U%()X6/FC&$N'4N4 1R
M51S&&<KFDC/,VYCR+&Q$BZB8-41@(9DV2ED:M< <QAA" ](5T9QZ3'D^%0I<
M1AQ,U$%Y1I%3 IDH+ -^JV30LB(J5(OURK08<DBGS=Q!&B"<W'*=@HN%=<9Z
M1.-<4H5W1>B9H>G,S738\ZR^1$FQ"2QE9636:X,DMX*[(+!7(=2K+T^KII74
MH2"UHM@Q1Q5B7BJ#"/B\F&@0,V745D2':KE>W2+LHPH\!3<AQRP"[FEUB-IS
MQV)D/,XE6YB[8>5Y5EDLHD8 Q32",".L DT".N*EBXI$7J^R5 M^GL??E1%<
M$A$YQ9%1@S3H#A(,$Q6B=Z2&GXK*%7$9'$,1,<U8,%JQ*(*S6A@?HZ5J/NG"
M.+=C?Z],?N>F@A@OT%TQ4@3"@'MX1IAT0:5,">"L)+_%65X5W9GA<>5^>EI)
M)<)6"60#U8$ .4',8".4D"QP1"VOQ):96K W"59J[X,)/CIG&?)*$8(#"L1+
M%HT6?CX9P]R-+,_"2I04&CMP30S63*I@<12<,?A%$LU=O;I2,0!Z%B5B@;G@
M3$BH!O1$*:0E"M%$'G4(-%1$B6K!7A4LM5@#$CBI+&/&"T6MQ999#QX,CV(^
M][FLC(;]O-L=]7ZT6ZP"8\KS+*X0IF ,P2'%>E EM!;.1>1%P)H@7I63*&9W
M3+FSAE93?62D$5&%%"4L@-?BO&%6!,9D0&A.)TKF7*0&(V4M"LP+AHVV!F%F
M:+0\G4R&YS/Z:Y[&D>?99Q ,HAZ#+TL1@Q'$$N$=5CP8IPWUJ"):4X\CSZ,^
MGD9P83'S&B-&G54*,Y%6YT4,F*KYW*8RWR+E7@AE Q:<,.8]MH%(J@,X)-XK
M+^8SY*+,93$WZ_+/M*D@$!5=RCOJ&);.""&EI4 J"5&.A8KHS>R.)/?0T4HJ
M$&<Q4.>0IQ8&%$RU,=XCHYEFU#+M*J) M5 OK<A3 X,)I403SA#A6L-'*8FV
MGF!CYW/:<KY&D^<Y0T0"ES0B2(8MBU1::Q553#K)F8R15D1OZM'DV=9+N&"
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MM6_3(><ANZ:3QW[1R\WK<O4E'Z0'_NJ;PD]K&0C*>U?V_Y7("@.M G\-+N_
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MCR65;U!0YM\L-^;42/#(@]FMZAGCTRG+Q1QU-RGN\]3E'MHKTI[SE%TGK4K
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MX) UWVSES>X'U/ST$?H)VMK>(ZVO?^_OM!W?;3=Q"]J\N?+9"<#3E.*%<T\
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ME9#1UT[FZ_.P,_*[5O<?W(#!=AA:@SL])[_]V$64'PFOVJKR'T>+<].]-SO
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M0+&WL]=T0E3'K/KG+/7WJ7#"SU(@QNNX\4_7^WVC)!!<V6KF]@2"D@NP4KD
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M1TZ:??% (6*2"A1&2(;#S03LL,@P( 7P0!D9+_Z$^@'%= B&YI;6(1#D;+!
MWK5 FH6$ G9>!.X%%GIM@_*'Y\34&"A63I+G)>]&)LV=I9)(Q8W5VK%D)!%
MYBF+V!1)KI\DS\0L(HZ.<\61-]*#*#.#G 0*P)(BAGI)@F!K&[*0]V62Y'EU
M<A0JD6B3B1J('O9:8INDXS%(K:)119+K*,FM:4DVUB4<4$[\ CN<<F3 ,D>,
MBIQ\S 71 MC[ J*/"Q3EA1Y28O5U\%>Z=5+P\5Z>_;O&49<:B ![L.%*Z*@L
M#TXXL#E]4M)YZP)FJ7@1Z@9$K=F3/)JS:$) F(H$C,*"F> =04(8I91(-CE7
MX= *GN1974F>USC023%B(\\5.+D+QF(EG!0^ J/4,9:C+S64Y&G/?F+$8R<C
M(H& F>^Q1@:6"GFJ+2<.N&*T:QLK>?)E=05Y;MM &0W[@'NF,0]*6TRYDX0:
M&"'CS!5!KI\@3SOVF<XI[BJ!^'I0R0[62GNID,"2P?\MQUF00267HR*/XMA_
M$4"10M)12$$%]K#%N+/.Q&2"\#PE+E)Q(M0/**8=^UY;);V)R+BH$$_*(!>B
MR5V\L:3*4!G5V@9EZW*%@6+E)'E>[DX<9E9RAJVDW$JG0;#!! _*)TV3*(<1
M:BC),XY]YIBRU@LDN&"(1T618<2@H*QWD4=-G<SDO4X9OT62%ZR3C4K1*)D$
M(XDSBPU(,):<4!U3\+3HY%I*\I1CGP<CE3(!21HE2+(-R-@(@DVUUEAPK(6O
ME'*='&HO+7E_NE53R=Z_#9.P4-%SG# W'#:ST3S)Z)V1-J3DF"X.A;IATOF,
MCU]A+Q,1"DF9[03A.'+8 #@!1]0\1@YF'T"266<UBC66M($%VPE@*T;*P;0/
MG'+EHP;KW_HHL[/?._%$DIP["-K<.?'[X'5J?8\!_8B];I'P^21\VO=OB9'.
M$H5T9!IQ'1ARD6A$5;*)VT24M&L;5=LK^D<1\N41\KDK$S@ML8O,1$JYQ=P2
M*[54/ K,G*"FJ.OZ"?-,8C\'2"::(^VU0!Q'@[1E ID(=B'8A]$*O/+JNB3V
M/W*A !-"M#$D[QW'0><NAA%'&A1/ULA0? WU XII_S\'^L9]8L@:Y8#-.X*L
MHA1):W--DX"%R<4NU</]_S4&BI63Y+ES=Y0TQ"<A@01RI:,C20H.^T(H:H1_
MHL3^PNL78KE/QP5(T-8G[A'@,YCN3D5DA6<H1N-C8HZ;'!<HQ'[II'Q>?<T!
MZ:.W,;-VL-ZUQD;A"-:=2"9&%HN^KJ,T3\4&1)#24$$15LDC3E-$6B>+G--*
M8>>"<[YV"ONE=2;9' ZZK=/382>6S/];,_\=,< OO-*.<QND9LZ1_Y^]-V]J
M*TG6A[^*PO=W(^9&N.A:LC;WA"-H8_MZW@%/VW0[S#^.6D%8"U<2MO&G?[..
M)!8);&0$2% =,QATCLZI[7DRLRH7#SX"))E5K>&Q:FST=KZ&!]/920V>>%O(
M2 E&# V6@%,:F'1>45M<#FZ\RU!=#E;8>.!@T%A@J<3W"Z.L52%D&E5BEE-)
MZZ' ^@!\]E" BL"#0/7"20LEP6DBGAE&@C741:F4]WQIMD,%^>I*:Z.SR%08
M:@2'Q+P)T8%7"4 G2NL9_BJ">:Y^A $62NH.'DH2#T!$.^8\$58E82EX&_A#
ME]8U)N"6><(Q:KRG":("YJQWE($3V4M@0K.:[&<%>6+V3"!JRHSTD?C@4*N/
M@A-/G2#!:4XM"PJ";PI@K9+[897X2U;K=7)41,82%110H?=<Q8#K(KE@G8BT
MG@FL#\+G8P6T4-9[29PR%/5Z[XG3IE0OR,P8Y5G0J>KU:XCR1>5U%)E;R2!:
M1D$$;PP#54)]54Y,F)KL?R71/!LO #IP10V1IH3N,:H(+MI2((F[A#/&10XK
M)[ ?6[S V]'!?(7RAWLXN:BZ4<ZUC$],20X0(_.):V$3^!BCB>J.L@Y4=>/F
M!#6?^M]0I]"4R 1DB4PT0A$3M"'":J5"-#1P4ST0UA#DB^<,3]QDU"V]#L!T
M<$II[857B7,3(%60KP_(9X\*E!3.@)!$Y^)RG'0FGB9#>'+>,),-FI,5Y(\
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MF:#X,02R]<12:HD4H+0N.:P5*A\,EE=ZX'IP62/WABL[]/ IP-HDE0.GF%,
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M"LA8Z;.42=&&=-RTJ.5ZV%6\J_D#'_FE'?!=-SE5N>C\]1CY33N?41(V@62
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M]U=Y>[[VB('L@E"9! 6ERK&SQ <!Q#!A/8LTJ9*8@-EE5"*[FL-N[:#AQ_I
MI:!UHJ!?K'A95UU==775U56W5JMN9=2MAUO\]<Y4KMDD%%)92%QY8B$& KRD
MH\A2$@/:J0#44PBKIW+]PN[&NEBFYS<UKI%DXF&'LS&FC$U&LF R9.NLH<"Y
MC#JX'*2/U7J[+RK9N:1^A,U">*22S#4G)?\0L<$IPIU4464%0;LGSY58E$EN
M3V]9()YT#7%V'66QCFT=VU4;VY61#U7=O+&,F%4WM9>2,]0O(V>9@!$EW!DT
MH4YK+CDH$>Y-1BSS'&0=SM*:J.;Q0=IE)VJ_EN)\@?/*ATE)J.MX%424.C$(
MW!LEC1-&NI)<5U%15=9[HZ/YI.=H^5H4')YHQQ(!(1@QW&:B.("US'A<X4^>
M<VEN7H%A463<\P[=8T;[C799ZP37":X37.5U-2&6)+-G30BE(^>QU"S($DT(
M_!5E-O>$9RK!&!4"Y6LFLQ^HL]YI$C&2^P,RQ$5_+9_7)3ED+N)W65]9/0/+
M^4M_<-0?N%$:E_ANS.)>?_2KY;ZN>9:]UN)32!$T,.<U&$A>6DHU4G!2(1MM
M9+ZN^'RDV;[O2(K.N]I1L%0+XXESEA&(F1*C>219:IHT5\KDD@J RB54'U@Y
M]Y,*WSN&[W4S*55,+X+IV;I>I>"OTTD0*[TG$!AJQM0;HB2W7BJ>I&\* +&*
MZ#5#]$(UO>X9T@\Q9<^=07JNII>(CKJ4B,V 8MKK3)Q(C%!O0Q14^&3C3?-Y
M5S0_/OG\P/-YWQE>Y]PI&07O>2(NE$R%SEIB-21"J?7:I)BSM6.U6JV0$'Z@
M[I3;"*S0/G*=L3G_Z+TIG6)!!9^XX IB$%9HE"HL:90BR0*KMOH*D,K;><=*
MZ@*7"0() B@!8]%J1Y% F!&4)4Z#\Z4TMUI4L:\.:@\%<C53\5WB<];NMDD)
MU,N ,)40G\!0_#LCB4U"RV"4$_17$Q57B#YXB,[8RQ6BRX#HK!VMK9(,LB41
MK6FTHR,GEJ-$549:[YAP.,$5HH\-HM4*7@[:9JU@[V6@6CH2K=$$4E+$NLB(
M<HX;EH5BEMV7POK8SK1?I9@&: *[_=0+)ZWV<'A<S[-_$%$"GF4M:)8H+VS.
M'GRP,C!PF;D<H=K(JT Y\Y[<'BAJVPJ(BL(2",X0;RDC@8(*C.JLF^##FY?1
MJ[OECQZ\U=J^2Z3/6MO4:14E0MO0$ A(Q8A5@1,I@Z#,BP1,+J\L4$5[17LU
MW.\.[;.&.W<*& 0@6H,OIH0E7C)&N!(I*Z,#3[&BO:+]E]%>]P"6 ]S9/8!
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M@]=TW8G)NCONS:V\:_5HI>34)JZ?A8136<<-.T>DW4*F/T,8K@+O"D&71=#
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MR6*99,$8V,"H#=KB@I/"AT0SU6!ESD*R96@6E106(04Q0PI&E8-P9DHN#4%
M2$Z<,Y;XX"GSP8$K];[NQ]9X#/N1+_J#H\;?M^7[95NE'/CVBB?MKV48G1^
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M55D9K> &2$9MC$"@C'B*?T+B(H2<0DIF02.X$EHEM#4@M$74,Q<HERCYLZ7
MA';*Q&BM2YHI'N2U?44KC2V+QF;W\AS35G+A2.1ERSUG0VSRGE@MBD^OX59Q
M5,^LV!#KIIXU^WZ_-76_G_^PJKC"93]Y(2ET\TSS*0>U>S'U1L^(4 WU+15N
ML[5/KU ?SHH7WOG;+XX*UQM,E&&XI,2B&Z36T0#Q.\ F( =T\8]ABJ58?/H6
M#EQO/[5& Q?QH\D7>K'E0A@<XR?M4F\V#4<;M03\=1^[;H7*:V-K"?C5*0$_
M?]R4F_]^Y).Y>E6QKU\;_J?]_:5JP^L[9K]63/MQC]EUZL_7,;OWBO6H(MV3
M6;B50NKZ-)A6K/\U8GK8==9K(U>S8OW]H::6JW] VUT.%W.3D\!Q#Y))EYW4
M(C.;C<D9QMM=C/'''D?V%]U[_5)N;WT6^#FVYQV^O]/>V]WG;W?Q>:]W.GNO
M_SHI[YK=[=K9???Y8]/&<+)]N,WQ'8=O/_RK\W;KH]Q^_?'K1_[WY[W=-]BO
MG<O*U2<=DA79$<VT)6!"(B8J011.D@+%@ROI_92HY>HK(RPGH!M<XER+9!4#
M"L*"]"9SH7P$'7-< B,\Z-"1.V.*6;<%5$R >Q6)XY$2T #$4*U(-*4LE07A
MS/H$=%>R6 NRB)HG*51.-C+D#>6\+B4VJ 7O;12VDL6*D,6L+T"FCC(I-+%>
M> )<2^*%YD1$CQ-I*+?T5\-%*UE4LKB4+!1R@K<R&AT]"&V<@92*4@% DP=:
M;8T[)H79DW6I(%E#,XFI)"A6*A%KI"/6*NZL84Q'=E^VQH/?C*RUZA<GE)@H
MA:"=Y !!,I.HTV R"YP:-JF!4K6/^R::^605&2A.'7(,VB9(-%)'8ID7A'&<
M4&\",DVJ4>Z/ ,&2FQ@4@M>B\8HFJJ?<4RD39%HD#U25X(Z1.KNIH&E./EM)
MN&66@.<"+8;B;&>4$%F+0$N6.$;EAJHX?;@X%<EH%@0/8#@4QW[OJ&#1RI(_
ME69=)>V*X'?6SH]"9RV](4);0R!P15R4AB3@CJELHG*J2MK'@& I@@;F/"K(
MD+RTE&H50E(A&VUDKI+VCI$Z:WP+M+R%89X(A"P!41*XH6%#1$#"-=[IU$0=
MKIBD?3!.#;50_4PR2*LE92  [33I8\D&+)6@2IH@ _-5X*\"C5Q2J-Y1"C$:
M2PQ$1<"!)%:Z2&)R,6N*5,+XVFSL/SK8H4QF4G(9='2@*$4=#;(26G.C8W2R
M2ND[AM>L/0PIF.B8(4SJ$D,K@#@C%8G6*AJ<RJ'D9V1J@U5LK1BV1.*9FNP=
MT C>"9<%RRC=T#P2,8EEN+I5D;8,S,W:L("*A[39$"J5)P"2$AME(,$JHS5+
MAI=R7E6DK2;LG&)!!9^XX IB$!;-&V L:9]LLL"J2+MC>,T:GCIFR9USA-G$
M"/CHB"EE>"CGGEJJ7&#AOD3:@S_UK57J%]./?2@V3 *+@MLQ9IQDS!K/9=G+
M=%6&KP;)S%>IQRD2."N2&%X*8(OB50(Y$1&TC4F#0[E0]Z$? 8*#C$EY<"Y8
M \Q)3W'R4U"*Q:A3=0*[<Z3.6K@H]IG*D9,D:"20F"8^"4X4%RDQ%Q&NQ0EL
MT;I%%:7KA%)M 'D9I]J @^QL<=F4,7,NO:<Q5+_N54'OK*WL)*I%4;%RP*M+
MCC<@WHE(>.(XD3'@/-8R0(\!P0P\RUK0+"4#F[,''ZP,#%QF+L?J67772)TU
MNSU2*[, )*/Z2U AH@1U9$MT9DI9A5>R6S4Y^U!.>VN!^JN"/ZUFD#RW25$P
M(EH=E=1!"X-4(57UJ%X--ID/$_=2"RFU)CPWFW@R$*,](Y;SY!1W^(>O>^2K
M"CMG(( V+DCMP<JB<&=A50)C4=U>2LQUA=<B\)HUBG-(7NNB5NO@"$C'4%CK
MB%JV+,7.'=!0]LC9);F3*[;N%UM&6@?<AV"U!<%*P $W/BI##4?&K/D,5@5S
M<^G*042NT8 %G',T98$2@YHL >4YA9+#G$$5::L*.X'04MY2RI*'+,!Y2%)+
M&[CT+KLJTNX:7K/VIS'!>L84*2Z!I4!](#YK09Q+,3E)G9;W)M(>_+%OK4Z_
M\,EO$H$!H$QP'%7E["/RA]26LF \N[X8?]1EK>^(;.8#?DU,22FD&)MR1/W9
M6B0;QH@)(@FJ=++1U6WI1P!C1K,1*/Z#Y0:$16&CM9:).Z62%>K:!TL5QG<!
MXSGO9R4<6&^(M3X0X%(11P,M><:H,92'E&*%\;K">*&R7YK%$"%8ER6PE%RT
M2N<(D),+-%W;$>M1E+V^,[S.FM BR)RS0Q.:.XT_DB=.&(1OI"9)Q9R4ZLES
M<TE$8:U._R!@BHH6]=*:Q",#1:75(5H *RFS5IFE:<T5IHO =-843V!5H*@.
M@RY!13CMQ (UQ!OADM%&91U7"*:U.GVM&%@K!IYQ+"LYU&T27E*047I6(EN4
MD-RX+,*U5:$'7S'P;OCUDNKT,4<3F4=JM2$3""H0%(242,&EUU(GJ_.OY#6\
M_X*!M?QI);/ENN=;5^*8368B@;/&9I#21BUR\I'Z:^_/5#);%IG-[L&8E*W-
M+A&577%%"()89CVA1>K$$%)FZ<ES!G0#*IM5-GMX;+:(_6N\B9!LH! =, C&
MZA2I\MYGR>B/O* ?:W7Z.^.UN;TJ)73(TA$A+/*:B1)Y365"6;+>,>LL#PL:
MP970*J&M :$M8FNJZ%40$6T69#/NC9+&B9(I%Y)05%3U[*YI;"Z-GTG.* _$
M2&8(4)N)M3$1T(&SP)3/W);J]'*#KIMZ5JO3KW=U^LERVSGN8M/#^._0."(=
M-\Y'%Z;S0DO/S=;S?_K!;\^O+'L_Z2SP#5WV>X_ZPW9Y]+-!ZN [OJ2S\O2%
M^,Y]<;*NZ=E7G,<E?#RZ^BMSY73OB;^9F!GG<S\/!F<#NI^('R3WF;B,C7WF
M.E_=R?#);Q=1A!":&</9[E_9R9QOK9-C\*)$Z8_]U)[AFDN#<A>VR:U,6UH'
M@R(F_ZOM54[)4@LR:?!6>R.$LC)'PT&)P#_I)\]W"Y$50!5G/%P_PW_^YIY?
M-I,S,!F+1>:<]R(98QP')A0:&IQ1JR')4D)%GHKU"=PNRG'+(J<Z:Z]=<66F
M1I?*64*6\%T; ONTA7*<4T89:7X11:!?(<+/G<UM)U?.X^+;WKL2TS9  /_A
MANWA7[V^Q['^4GK\IG=TC*W Y@3\5M.C76S7'YU^^+R>(K^3_O?=R=Z'>.1Q
M<E%$G^QU/XJ=U]NPS?'?K8.#(O:WM[;IWH>7)Q^['P&OHVA_E;>_O_R^\^<G
M$0S55G-"-8-QYEWOP1 MF0]!&2XC/&DEU(N."NL@Q3[YD>0[1TN'Q\-1.Y_<
M/2\Q7@ZT#E(K]SN=_E=<!ZU&;K<&DXG'MXSP\D22M'O-7QF75.M+65,%%LWU
M*_Q46_%XT#P4[SG"UO51 AVAR"DT')]=*1W.C91L),JX41<U'!R>CCL:IF?3
M7WZ/[>%1QYT\:_>:3C9?^GWRK(G<*$0YZ]U;YF%\^8Q#-^B81R?'EY,W3RYO
M-)=F]*[Q-:,W.(4K+],-=N6U'SV6T0UIU;4>N]S8VUNN--\\\%E[A"\+U]')
M< 'B>SJXLH9SUOQBG1UK G?<W4GG].6^WFXP.,'6-HK39K=_W!M=Z.+BSNXA
M)92O*S'CUU21_G =UPNIM95"ZOHT: GVM%5,U>O[+XP[_5CV/F[>_[KG<97"
M--&22NS_A_;H8$XY&E[4CH87=:G3G9+F60]DNV3G8*_[[G /K^T<OH3M[W_*
MCWSOX./N9VSK']V=W5>?MSE^?KC7GMTNV>:ONGNO=[JH5_'MW?WO.UL=?,ZK
M@[>[GRGJ8FS[PY_?/^[NG^QT_Y6WY_/"*0F9.2Z)L<$3T$81+VPFABJ92^%S
M3M/EN[Z+>A,OB)\["UW*S7]KQ>8O3K7&<QICT2SW>_B4.%4GWX_<J$%9T2;?
M'DU4QU_+;GG)*#U =\U?,@MO@_.NH+S7KMW[=W\X?-,+G>.8XIO>2S?HX6W#
MRH.+\.!\@%1B7BH;(Q$L, (E)-,8%8AD3J/0LY 2/'F.UL(-7$ O9YH["M!<
M/YUU=X!?[HS-71>+*5_0,YPANK?(=(/Q!FTZ2&@B?TFM#D+DUR(YYT>ILMP*
ML%PSR2_.SS%>ZW>K]K<(ZUU2K"91J7U4CNCL) %1"DLZGXE6VB0:70R.%]:;
M]\M<P/']4N:INMT50'[9*TUM^8G!ONT&X6!JK?-%1<T/SRP?KRV_Y-%9;<FP
MB&!P@7))C4&A $QHITR,UKJDF>)!CCWI;U$>5$M_:5P_;^G+%#+URA;_>R 0
M2RYX#YKX6([+7$R6T2?/]:+I1FX;74MTEKC>^7NSMGYZ?@GJR8_/5YB9=<)H
M/KG@A%$^N756N'Q37&[<BA/&M=X^,RQH5#7#<+O'M?\9](]PO9S\!^7J:+,7
M7_[?<?NH$--9&.6J',/NM*<$LT\_?C]H[QU^_(:D0/<.__RZO?5W>WMK4[YM
MO*?^^K[W^N_NWN[?[=ECV+=;2$JO&Y)!4GC7W=G:_+KSX0U^_S,4[ZF=W9W/
M>Q_V.CL?T!P^#/!)2N#"<$9B*(>PQCEBA%:-4FB5$Q!%>C(YCSQ.<7/41+>Z
MH&@ 'OY_]K[\J8TD6_=?47CNO#L3X61RSZR>&X[ !G/IUQ*-C=L/?B%R!8$6
M1HM9_OIWLDH20A*+0( $-1.-04M55N;)+\_Z'6XX$\[ @:$-551$'05QDT';
M/[_M_+GY;6__8^7//]9K>Y7UVD9E<_?']I_5S=K>QTIM<V]ZCXY',F<F MP[
MB%>3K'<L3^PPI/;DS$44L0F)0HX@+:T \8HZ$140:J?DXVV$JA5?H_1A,>5Y
M0]7D]J_>==F[WQ-4+-%5[YT"5D;KWW*T?F3PYN'Z64;O8U@?QYP$!7(4JL<-
MS?-^/HL5G=+QH/]P5LD34R >Q??WJG;P'V"+AN-VPU?JS;-.^U=NE4ZYB>][
MXG?K,YG[^=^,5\0)3'4$LT_(R(6.VGG";?*)2*ECS![J%;E53]SJM+O+$\![
MI+8X<&^ =DB_'A^<5'GM:E?43KXU=S:.ZSL_:\WJS^K%P=[GTX,-!_?^>CSE
MWMBKG>S__-JL7AVQVL8IK6WM\YVM;;%/]R_VK[XVJEO?3FM7OE[]^75F(@.U
MD6M!$?<V-:FEB2$<6P0O$ZXH#3;E!#,^-\? DW?"LK Q/> :CS@<2\ L 7/2
MC<R,,RYSRH2,>V(, \O<!NFD4\+%!Q.RE("Y2,#$$X!)J%&&6(F\)!%QG0ED
MA,Z0H9GAQ >A'0/ U'/7R;T:8*Z"S??0*.!0U-]]1R2C8Z @C5@KS;U7AF(A
M/&$X&B:-LZ7V]?)@,MW^R D1O)8,@;+,$+=1(IVR2CT)*7W82()-(K/G*]2@
M93$^@_>R3XGB+FK!M,:&RPS.$PSZ-W&,8DUI-.6A_QK[=/+05YB)+$B*A-0.
M\< YTCZ E42#EY)P$8U,^Y3.2UZT0ETG7G5'#<7[8^4L"7A>-AZ&(OZQ<M1Y
M=.KB(LRME4:@166OE BT. 2:3K2F084,TXB"8!3QF+<WUQX)0^#LR)0VJ1,%
MX=D:616[8S4<-26*O&BU6XDBBT2123W&.<Z<]0$)C#/$*<-(*YS^%!ZKH!U5
M#%!$S$_"6'HO%A%JZW83&4Z_V6^87O"P4<XZL%<>VF)K!1%FKOJ+!2DJZ]<S
MO#$VP?![(Z1? '76FVV8HZO\]5L1J02C.<!H5A4%T9%@%A"83Q%4&NJ183XB
M'4P46CLIL08PPFP&&-U61U'Z/59E-R]*82AW\^OLYDG5@EIJC&0"6>]E4BTR
MI+4F*#+*'!/".I9<)%C.<&4^YVY^\STY[W&-M,)4,.2!.EO)Y/H"$[3<@+Y,
M;J1:*#%Z+HR>3O9Q-KC,"I_,/XLX_(%T8BVAD;A,!FVY(Q\^<;&F%FO]+1V5
M];(YF4I$+A%Y]5QR)2+/C<A36C,.1$5)$5,!HY3OA3+B#9*"<4!J&97V@,AL
M!H'*JB+R@^FXLQ>H\IR]R3:N64)[QYT0*DWXRG&W$EJ)N/HFM\#'_&.)9,.T
M+BLN9<O[_*5^-Z<C;;?R?^J];J51O/G=-'J5/\PI?*O>NZQ$XP8TN&N5]6[%
M5#JAVV_T;EYWC+S%5/YK#A#@&9$L1*<D)EQ391CA7$?/4E49UF)NTI*<4R3G
MWM^&H=4["0B^',.JA>[-]M6M?A/Y=LYXG"ZVZDCQ^+(^>(Z=O1\7U;W]2W@F
MO+-[&#4HQ<PH1(4,J524(>,S@H2Q6BE8)=#3/GRB,T)YPP*F5(PQF'R0L(+/
M]BX[L&*ZW79RC8  G==[Q_DW<GG\6#D_KH,\YSRYW?3^-7\[R&UC9OG'6N4[
M[(I:NQ<J1*15K\1^)V<4\O6NZW>[,,0)%O>R1K&L45Q,C>)L=7PH';!;PG)\
M\H&1J5M-#3+;%[ST=7-[4T=F7CUW7:%X?V'BBTS\NRABO56=N\O!N7PR]<""
MUON?]FGAFT5>_PTLR10-]EO Y3=! CD>"JN$B[/0ZH:R9K<L07MIBLMQ.5QU
M"[#P%35WR?[>[XW:WC?XW#[?W]L5^S_WQ0%8=V#I7=3H#UK;VDX^(#SI*SK8
M2.QF/PB\?UX[.3ZN;32.#TX:C=K)]D5U8Y/!-6#<1WS_Y-NL8A%FHXT\"L2U
MTH@[$A"8BSA9C4YD5K%,Z&0UZE5)W7I3OOD2)M\/3#(/$&F"Q9$0#KAH8R2>
M41&%!6@4.H=),H1)4L+D<\+D9*-QQ3&5.A+$;>"(4V*0M4RCS*C(G,^$Y2K!
MY),)&U\7)I=4KWY&ZLALM:DCY7NCCMQJM_UYO=%8;_GM5L^TCNH@&7GDH+M\
MY)$[WP=@U_S]].#G[\W:S]V+:G,3/KM[M0-@5Z/?FK7F-JMM_0!@VT[7$I-1
M@?WFM\9^<Y\<;&Q>[N_!N#:JO/9SFQUL[=/]$X<!((^K)VG<C5C=^X&KYX=>
M1Q]4YE'&!" 6#QDR":PXQS;#V!J,I^@C,Z&T-B(J!SM%Q\P&[VC$V$5C1613
M/?^V=G8V?F[_\4?.&[E=VUL'8/W\QV9E_?OWS;WOCZ".O'\ -P<L,\PHX3)X
MRGC&?&9B%B1C($:"\BR[E<'P62. MSK>9F_?H31/S<\S[J#O[CCX?B/LQ.'=
MW_-VJ:T?>J$5T4XBA:-"/.* =% &49@\&;G'QM('LF.^7G1Y5G_+;K^98FY7
M-_I;=H<=B=R@%5_%Y&WX4ESN:" 0>?#MKD!UH=0,H]4/ZG$I5RLH5_:X7*J
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M!>XSQ 7ER$HXFS4/##0FL%&SE/XQ$XT+$!Y \L<" (T'H05(. ,)=WD5^U!
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M2.^:,?D:^1IOD<]BQH<#*Z)&4WXVDV;MVC$Q?76X9Z]PFQ70-O2=K56VX<X
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MO 2;9A7.V'HN;J U=<PYF,2FD;3/[BB<"Y"6OP$H-I':=)WS]D Y$99GW,!
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MK[AV,OC9Q-,W6H3EM#&)?GVX $5U\(!DU(V3OX>+]'LH.&<*.KOQ2N(AX?.
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M_ICT\-+ )-FR6V/C*,.&W'"WB0]@![(-P59,$H9QDTB;L"F9+TDB&G?G@X7
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MI&H]LU(Y^Q5W1U 3;AHQ )PD2*Y&S/P6-96 _\3%0]!, @E!>":*_7R!":R
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M%Z!63!TMS&K8"&Y;VQ-6CSX8=+8JF$XX\36*70DOX"X29&,VG6=3#$PXQY\
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M!.2MQ2[$J#?I29!H +8I7B6P2M'-4P$7_U5QII;V(4IR5 2"NO E:J+FP?P
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M7Z/6_:/6A[VW3PNU/C";!S56W2]6??I\^+2PZE-Y*%2-7/>(7-:.(=89-6+
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M+WBF]N+L\O7P5.0H@DXF3%GDFOI7&(3EC Z*T=9!RR%<6GCKD8UD QC..2V
M73Y=';1+=IK1SG#\R&^TI[U$GYM._K:M3U92,JN_M2&CMN2;),&-,DEZ-G%-
M<^Z4A&#H>\Q>+GTWIR<M1%H/5]X]%.C6=J53B"S-% 0'UR>X@Y'.G1=*_QU\
M>4.-S%ZA.F!P!X'.A,:8XU)[I6HA>=+-Y2O75?/M-.(ZZ#D"Z>YG8XB82V)2
M8&\2!P?-#D0P^#F!P2(DQ#F]=TDF== [;6YN"'W6_4S^M"8KT*34S%X*]1LJ
M"LV%%%#S\9D]+IB/&U\F^,E"CU+W\W+EL#6E5S8,AR%@#.6F&.$[V \%+^Q
M/XYOZSQ1/"A6C?TA:ZB#8USZ N*^$".VG.(K<\ ^XVL$FP%5[(L"-^[*]_!
MADS7.1C_-^J3(J*"$\,I<N?%"B51'5P@)7R/.>1U'G&JAO\,^CIH.S$7U/(=
M>C]+/1(W2\E<L@/H9GGGBS4.I_VIS,0J9D\I\\'!*8ZXMUQD3Y[FTM4TNP^[
M(XX?-L$G5](5LH#,*ET'WPP2BY3V5*@=%J6NAZ:*-3+H+!T?#P_X0I^C@K%/
M4P<SVM66WPJRKNTTX1>6R#;43J$@J(4?#!\^3X8F^&VOV^M&(Z-PC3@X83H;
MZ"*T=5WKD+-]P9$95SX&]K$4*7@W7/XMW\R)M-G&*PC-$:"21[31 !/+[-6A
MMZKNK68*@I--\LWX#4+;A#C>+?E.1]"^9717MP@E21W:1%H^%8PUV5R>;&'F
MC$]+,*B#OCCGC=/?Q).[9.2/^]F(./:,<=<F:F6+4M=!TS(K]3B#?-BU_SV.
M-<WF7CDW\Y>:E<F,K(_/4&X-?SM/.=&L%(LZZ)R6G_HPSAAS-H,4K<)@,YV\
M#KKNCS6&+W;F='QZV<.,*BT;.(IPEJ/BJ++JJ*1FXQ&YN57 8'Y)/OWT/U!+
M P04    "  $@J94*4TJ5.L>   %+@$ %0   &UY9VXM,C R,C S,S%?8V%L
M+GAM;-U]67-;.9+U>_\*C^=U4,:^5'3UA+?J<82K76&[IN=[8F!)2.RB2,TE
M:5OSZ[_$I791$D4"Y+4[JFV+I'A/(@^ S$1FXJ__^>UD\NP+=//Q;/K+<_83
M??X,IG&6QM.C7Y[_\?E78I__Y]_^\I>__ALA__/JX_MG;V9Q>0+3Q;/7'?@%
MI&=?QXOC9_],,/_S6>YF)\_^.>O^''_QA/RM_Z77L].S;GQTO'C&*>>WW^U^
MUE%ZX7DD02M-I->:!)X88<&[$#DHY>)_'/T<M61),4>R+Q]CRA GF""!4>,5
M@*=<]5\Z&4___+G\$?P<GJ%PTWG_XR_/CQ>+TY]?O/CZ]>M/WT(W^6G6';W@
ME(H7%Y]^?O[Q;W<^_U7TGV;.N1?]NY<?G8_7?1"_EKWXG]_>?XK'<.+)>#I?
M^&DL#YB/?Y[W+[Z?1;_HQ_Q17,_N_43YB5Q\C)27".-$L)^^S=/SO_WEV;/5
M<'2S"7R$_*S\_<?'=S<>>8+:\>FG.#MY4=Y^\7HV33"=0\)_S&>3<2I*?N4G
M!?^G8X#%'*7HOW5Q=@J_/)^/3TXG</':<0?YE^<G9T=34M1-Q0K+OV_PK2^N
M\$8_B<M)/SSO\>?S[R[PJD*';PO WUB-U,6S)[-XXT.3HJ=9=_&;$Q]@TK\Z
M6L[)D?>GH_=C'\:3\6(,\Y?3]&DQBW\>SR8)I]3;_UV.%V<CGJ4+@B42HV9$
MIJ2)=Y83RDRF3F@DB[\Y@$7(.4K9:SO[>>A5?OY 5#UG+V"RF%^\4L::X=>=
M:_[?-T6V&O,JDH\@"L=X8 2,2T2&$(F3-!!/@S,F)<Z3:RWD37FNL>AE%Y_-
M.A0<5[CGS[Y"68_.%[L5(M_%._2Z.=7./_%BOCPYZ;^3C!=P<O'[9>5KR(K%
MK,[ KQ2+HNRJ^=>SDY/QHNP#13J<;PO<+W#?*(!<!B68I\0Q&Q 0Y<0;3HF2
MT4)6UCB:FS#A 5";,(/_",RHI9AJ3+DKW[MIG"R+??'[K.M5L%ATX[!<^#"!
MS[-_S-#ZF"YP1/$;C]Y-%]#!?#%"0X 9JCG1D#R1TG 2@@8T FB0H#5-J<T:
M6@?_)OP3/P+_#J#NH5$U*1\S>$=2I!(MVHAKL:6)& L^>ER21;;?#55KC.)(
M\9"M*<8[C@N1G#OB(0N2O(T:=RT0.>UI1(9D(AR ;X]/UR<IJ]K4^VT\G77]
M )P+E8/*DG%+I(-(I#+H%@83"'CNJ.-@LN%-*',;R9 LAP$09B=%5:/+R_D<
MO;E1 &4X"$JHCH9(RX!8$1VQBBG(+B?E5!.2K)Y?1XK7RZY#<VU$G>8I)H:S
MC:%U)J1#.SY;DIE--IB409J&PIS#&-+ZN(66;]-U^R&NQM4/I]#Y8H6_!S^'
MCV7</N0_YM!#&VFN*+5>H%P9(?$BG*.":)]#%B(9:=NL<P_"&M*B5X$%]510
M;\/SW9_0+].?("Z[WAHOR_4Y4Z.*-D6O"14V$YFE(=XC78.@-*0L'#KV;;:_
M!W$-R8VIP(N*2JA&C-^[&;)U<?;[Q$\7Z)^5??ZT^//_0*H".. "_7:F%7IF
M,>!29M!!"B!<YD91!K$)+1Y"M0DIY/=#BFH*J$8)M+7\]&B,-%V)AT#>?CNW
M^_X^FZ6OX\ED) UCROE( E<)[3 6B==<$A-1<N%XS%HWH<8FZ#:AB/I^*%)=
M(=6H<OETBON8-EH3 ]$6\03!S2P1!AX2(HHIM G'/T7E^OM1^58#6\^&7!Q#
M=\ZUJ_W)V2AY1BTPX5$>X2VQ 3@1,N7,I8Q:BS:VXSHXFRC<?#\*WWW(JVG_
M6L#VPI-1*@<13";<4DVD48)838$H!R@SQ?=<\R/%M1[C%EYPC+/E=#'_W9\5
M2^Q"PF ,<SSA^":!(^T,&E_E;"N$H&GRR K69@%;CV=(?O&.?+CC(^^N@'J!
MG1B[):0U$G+-HA#<$E>,+IDU2D@M$)_!F,!8H(ZUXL-Z2$-RDNM3HH(:&H50
M+E"=76#RR3ME'2=>1/33E 02I)8D9C35L[?1Z3:1LX=Q#<E9KLR/B@JIF)(P
M770^+OXY7AR_7LX7LQ/H[B +8*S3 GUX&]$H]Y83BTL;$9&E((,//+?QDC9!
M-R1'NC)AJBNGX:'OR.NH1)")Z!@HD50')++"[4]!E, -3= F)EL_0ZND@\RF
M_??^MY\L8<1QF<[HF1*-DA23../2K22A 1S/3'NO:*,)<!/)D RJ'3FP+@=G
MZT&O9TJE-"ZR^\GO?IS>35_[T_'"3ZZ!&PDEO>(EGS;B/)8"YQKZ-Y($IK/)
M$ !LF]7P<6Q#,JXJTZ.R8FK:WLN3,LJ0>N<7 9UV< S3^?@+O)M&7+/?S^8E
MV/4A?_;?1M8I156FZ%.G?KG6Q,N02'1"@W8(&D(KB_PI0(=DA]6F4D.55>/5
M1UCX\1326]]-T62<7P/]!O(XCA>CE"4-*I4\A%0"-6@K(AA-G'<%L4@\M7'N
M'L<V)*.L,GLJ*Z9R=L>%56A4TN5D!<U C1)F$,0S1HF/X)21/CC7YLSK@;R(
M+0PQ/S\N";GX5]'<%S_I4W07KWW7G>'@KPP%Z9AP(GD22^!%&HXC+8PEZ#;%
M;)5)(C5R3S:!-R23;7N.W+'6JFNF:9+ E<@X#V.BQ*GHB&0QEJ6<$F9,LMH:
M&F.;X/\#H(9DM-4C2"TMU#34^H#M1XB ?$5@N,%?(++9V.B\)8)'M!^# ^(D
M*.(XLY'I*+QL&S=?AVI()E@]8E330\5,@2_X[%EW5G(5'#5&V\!*/:7$O9OC
MWAUD($YSCYLXEYZUR@BX0C$D\ZF>YK<>YXII0G"*WB,:]3 ?16^YCR$2D"41
M-QFTUY@'PK*RC'N*/F.;T\#K*(:7XU%#TUN/<VU-O_UV6FI;T5*Y=C)](2%S
MW#*4#HE7DK"U9,2"U(2%S'R,*E'>IN1D W##2P2IR(MJ6FF1+(#NOF3>&4VB
MD B :2!!H8"&4\TD9"U%F_SX>VMRJR0_R*2$#2X3334:71'_58ZDB>(F<VZ<
ME] F6K#=&? !T@*>I/D'BHNW&?%J3/YCVD&<'4W'_P=E_7T%4\CCQ7PDHLB*
M:D62$*4\T4GB1<GG-SKBM*4VIC;',_< &I+74XL#-<:^&A'>0 ;D85H%-!'.
M-2G[I%R?50"1"05M<!W/Z(09*X@-2=N<DX'4YOS_$6!#\GIJ$:.F+EKGAUS+
MVQ/*F9BA*+%D;;)RR"S $*L4"HL&O''0A"*/0AN2@U2+)'7U43>+]CI?K_ 8
MR<%Z2PE+R17:*N*54B28P#T()2&UL93NQS0D?ZH:,>IHX!8C_OKB]A"]QY\K
MMC_ZM, _^YX:LWS.;7SW)IH=^B#=\_6-&B)M(DRESDBHWMG%4K#:,,[]I9$$
MW >XSR1%Q8FD((G521/JT+WF(?! VQSJW NI1NAMWC=>67WM98&T=,GK' +1
M3@HDMO(D,*1XB#0E0X.BT,8ZN0_1D'R6.@Q9%Y[;61<UR[?ZIU](9KGD7*$-
M;2DBD< E"8G28DTG:M&3@D:M;&X!>:+?0KY+(FP_]'7-COOEX])QE9DD"C(B
M"2(1EPTE7/NDI78,[:1VIL>&Z^%AG9<VY*BHEXIKQ47.SJ\X"JOV74N$=K51
MOX(\Z^#2_8+YVV^+SJ-"QE/?G;W#<9S?T_8C9#2N939$)\I+$">2('WH6R#8
M++P5MLV>VU"H:I[C%<919$EH12WA(4LB!=7$E45".,&Y%;3T4&OK*UZ!&=)>
M/11NWNMM;JG#:I/W_K4$16 J6+-JIH;.#=H=$GU>;HR57EKOM3RDN7O8H.50
MB55'G_7H!8MK#-=*!DYQ>]*&(00:(W&,"A)SIE29G&*CGFHW8%3H=I''BUX@
MSB-CI<>?H$*5@;4E&A2)0N-<>*EELFW2B:\P#&FUW5[;:QI:;#/&;7B[48,R
M07.RU$:B-0HJG??$49V)ME'S$%G6H4V1RI.A#LN'JD:9MBJK6/(W[]O<GB_+
M\Y&21MBR).>2JBE+ ]$@< @R5]:'&)44;9(B;R.I(=F'7)I.]#U:H?LRCC#_
M-)ND$: !DU >PK@$(K55Q(MBY#B*4J<HE&J3ZW$_IB&MFSMQXFXE5Q4U5"RE
MF -^3<E7?@-?8#+K&Q-=.L/)QU1.47CB. >C%R59GQ,.T<EB!DG19@=]$-:0
M+,VJY*BGC'K%K-"ORG^'*9JM$P3V,IV,I^/YHABQ7R[-UY2S$ZED<JC^[-Y1
MXJPJG1Z"!&6IDJQ-2'HS?$,*/55E3 /UU"VZ>7=RZL==H?'K8]\=H;B")@,L
MH,/$!8JK>4(K0F3"; Z9!1=SHSY2Z_$,Z;2\*C4J#'_-%H07#D/@CAK@EAC(
MI6#0Y%4Z!YIVVM H@C#[=<J&%5*U7"BAP9,<# Y/-K[TEF*XTG.9=8X1<IM,
MQ+V%5 ]KS&W)Q+O'0,.@0.5C @1ZOO:<Y^>->.!">YJ(YPIW#B8#"=9;@E",
M+O=I6=_&<;X'T*#<XZIDVFWLZV>^77/\2]6O1]<$=R I2S]CBD"*#2%D A<2
M"ZG-_3N/GE]LX_!\@>D2+J;M[18REUTWR_:)_Y5<U5&@($(YJ;,<<!!<0L],
M)DH4Y=3K"";F-KE<6X =TF*[*Y?N^D=M==<NC,2RE*[4A( Q:(5+M,*M $&B
M#4) %FC9M3%Z'PXC'7C]K,V/G8;]D"F -[IL]*M<BTS NT_90T+@(Z)5R@M<
MTZ;DHD7)EA>:!)6\BP1H:;5<B!,84$(5TRF$'%HU.ZXL2-T3PL29YJQTG,[%
M,F6B= 41BA@'T2F>3>1M$HL>."$\=&SX<+Q[\(CE2;JJFYBV9DQ*\8^?E-*?
M_YI-^I[F?CPM,#],KSH@O.S&<WSK#?Z(@P;=>)8NVPQ%(7&U9B6#NU0)^>30
MO,;!H<EXK;/SS#1L3-U HF'%L(=#XD$PJ/E\Z ,'LPZ5.UT51,:SSYV?SM&@
M+8,\3?U/YX1(_UJN4H\O97%*VKX0"F0LB820B67H&.8DF9?6"=6HRUX;>885
MG1_^7-@C>VI>[WO?N(ZBP0U)!D6"S"7WJ?0F9."),9G&'*+2ODWBT0.@&LJ[
M%8]8UI8+BTHS4*Z4<AX]&<6)P3<\C]X+VL;T:FJ0#M9X>Q(GUW1K/9CN#^K%
M^OGQKY/9UT;>Z^6W[\-K72]*K2HV6)0'_-[-OHSQVUZ=_3$O]<^_CJ=^&DO\
M"A?R+ZO:R&"-UK[<K"E+%E2@EEC-+4G*\QREM1&:N5P;8JQP.(A"I/XDY=U\
MOL3OAP_YT[%'\O^!H]WAI$&MX%PJ&3/EY5>^5]U)B?+TNB\W:\TOYU;?U/+#
M:7\,,^+)<>Z#(\R4LIS,&+$JH#/DF&,Z,QX;':@U%6M(RV@C-J]).AT(3>H=
MB_NS?KWY"'V+U,\SW"%*0/MXY>*@C;=>CI&PH&S)B*2]":<X1ZO2.F(L-QS_
M)R)M<R"S+>)!A9WW1=A]:+<V%Q'5ZC3[J.2,X,S $>K.]]?SI@OKQLDZ'E20
MC@C+BW<M(@GH<1/M?,:ATB+8-O'2G6 _T?'\D5BY!SU77R8_Y#<0%A=K?W_8
M@X# HOT;2"PG15*'4*Y/BR0FH)EE?%.W\1T? /7$E+(?B58[ZZAB8O/I)21T
M#0#_>MU!&B]&V:,G5Q)J-"ZG1$:%'$:YRQ7>,H%F)MHVI7/W0GIB8Y8?@C!U
M]%.SI&B=U)<GU->DSIQI%I@D@OI"9P[$<VL)[?-UHE&AT=G@YACK'ONA8:P,
ML$Q !D$D#YY8@Z*SP+D&Z5.V>RB>^@Y<GEW9\O")WE/44+%3WFD'<>S/(\LO
M3TK<ZO]6=JHV"7#+Y\0IAA,UL')3!%-$2F-<*$4KK(UK_0"H(9VK[8DEM52T
M,V=*4*^4.!>A;_=)H=0$X=")T<K*<LMC))[%3+C.GCK&M+B=1WHW1/C ]P_I
M"*FQVFN-<J->B1_+"'_(*'-?@'"=C9>%3$H)$,(3(TL)@C*4..X3H3$J&Y+
M_;U-N]6G(AU2;<B>%I.FRJQ7E;8^<,(,,X%G3C(7I8(R:+0<>2**.1&E!IM\
MFPUI^Z#7OOHM[HD^%133KLDOE-Q0_'OE9\Q'5$:N$^=$00I$VG+:9[4B&6G+
MO<Z@5)NV/(\A&U*#^[T9,1655<>202A=603?P.KO=]/[>EB[1!VN@D# ]%>F
M@<<U,)2$XT@3#:6O5]K(N-GXD9LPQ/P8#&FHB]:EKLYK2,F4*Q'[EH"XXEE
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M89,G@:X4/%D]\^I95[=#CHQB62G+2(HE.FUSZ7J/T]YZ86A0SD"CT_+[,1W
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M'ZDB9=&DQ$#25&<&&-3.9^>+-!PAR=2F=Z2U9$^>K =E^A9=CS>JB:3@VL8
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M6.+UZBB.G@%Z8,$XE8)7$J'39,E#M/VF'1_]FWX3[0[>\6&C\")8P8H0H<X
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MC>8-1BB=#3 ;$Z&Q13$0M,FKX"-8<CAUHU/L=8B>K4O4BPD:%"S>AVNU>79
MUM3C68]M/^Y-/S;L0(P=#-!@DWD H>#22JLR,P2,:6,BBTIJEF2]-<\E;U2;
MTNJAJ?&(7S(T,S;1^P",^.G/3U@/'6IJ:K7C:30E\,*BI#^T(IB^@*4_"NU^
MPG&OVIS$/(YM>">D+TL^0I =S;#6\6A] G/YPTFYS(B]F,UP,15IE0?=;0I6
M+\]M<WZSD_2WCG>*B2D9@]XZK8O%R#TI ;VQ.EL4YA%WN"."GF*6BT>\N/&(
M):S\=OR^EG--R?>B7_AM,IZNOEWTAEZE1RTZ\!(%@Y!#/;3,-1&>F,^"Y"[
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MV607L-].P?NW^TZ'E-L8;>],*T"0<ZHUR-$P3=$1 ^":%9%$YA&C-VT2B ?
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M-KKE83VFY^Y1;J7[EK'I#62K5Z #MH$]RWVWL_5ER4X$V<$,@RT@JSN/M-9
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MO"OP?B$!-<8 I:T!K\:(?_EQ#<_0 SH=]S!-^QTAHSU8&W,%MH?LKAZRE?+
M:'\%6G-?]5^F4^,/Z;_0F0!WVOF<RM6?P7O]EZMVL T*( $M+" ,CH[YG&]9
M6PN8%[MC,^?]CLV:_4H-:STPBI:L1K85K$<I"G^4TZI<?@+-)S (6U?NG_O1
M\,>]5^2Z6&)&"W[F6]5>\2.?:\_VN8);7S"S$A@ W&H^P-O5?'VTN7\!\T+(
M0J^2#D"WQRYWU9S__E4^ZS?L47OG7XKY0T&?KA?5X[PP(K2LQ:P*)X0FB)%,
M0BP%AB@@"C*6ZO50S-,HBK,DB[#+1& I=VP4?_=("PF*E=[@N5%<O_<KU0&M
M=7=C>=MQL./O'M#MF9EKC<%:9?!E">Q::W!]&EAG*G6$R2M)VLH>E/X< =DE
M-M?;W2BK+*K)9_T5NE6_T/^<%^\6935_DL7[^1/-9Q-,"**I]LH1$P%$@BE(
M$QI"%H8!BE22IBRT(:B34L9&1TOMP&^-?O^?'>F<1O(TQ7C#IV="L8?&FC:L
M3#]%$OH!&P2A?]LEA],2!J$"*R.7+[[=Q1T]$S/5_J1I1+LY3\]R5M8;D==%
MH4=9FKW=GU[7EWRAK^:CZS]H(3[\8Z'=\9M9617U'G!Y6SW*XOZ1SFZ?S2/*
MO\E2^_ WLV9'9(*5)%F4"NW0< 61C"-(,DT?8233D).0A!F?;&Y)G)]^!U+=
MZG4[NVOC\ZW[>O=K"5YJ)<%WI;&Q_-[1$1IJV"T]J3$-Y4"NF+$'FKUZLP)>
M&PTVK ;L%6Q>UUH.:M.O0&,\V+ >U.:#2ML/6@"N0 ,!R&>@ <&C9S?PL/EU
M#8=2?EC?<N AV7-.AY;?;=K[)+7\Q_E4W#SIM>5+K5GYBWQBLI@D&0J0( 'D
MG"40$:27XTQB*$)L#B>CA%#NL@@_(6MLGNY*59!OZ.HVM9R"UFXV\ 18SP2^
MQFI33?!;HZ@'1]@!#J_$>$K>H%QF8?@N_=C<THTQ/M*\^!N=+N0O6L2B:)Z\
M^O#?<UGH1SZ^MJL[*10F81I"'&<FDD$OEBF)]3J9,HX4)ZD*A N'.$D?&ZL8
M/4&M*%AI6N_M?[[^F^.:NMMHV-%.;QCW3$27P>M,1YU@\DI0;AH,2EF=P-DE
ML6X/Z49KGV5U,^/S)_EI7I;F_(%%F&0P":, HD03&%-,0I1QH?\;H"##DVIU
M!'_VE=IZNA,M'8DF\/G>:.7 5.L%:%45.5M4YK (5'/PRVN14P%^EC-9Y5RO
MH+0-/X#2;+N:J46ZGBUO8ZQ0&(9,.Y6QB/34@*,84A0J&$1,?XXY#9#387]W
MC >@_C?".)28!Y&(8<B4<>%#!K$)$Y0::1QB$<=I-GF1!9OWCO*FE'YQSFO]
MP'<&;\?MH&WT[*;+SHCT/!T:*&Y:*(QJWX/KG>_>%[W^]'G =1 )KS/>MH1!
M9[2#QNW.6(<OZC8CW3[K^:W*9P^U+__5A O?JE]+>5V6LIHD.)%(9 R2-*)Z
MA@H)I)(2&&.2(A8K&C'JPIXGI8V-35?*@JG1%M2QU'"NX$+_0HW&CJQY&FL[
M'O"&8,^\L :O5O0*?%VBIY4%M;;^*,$*%*\4<5KBH)1A9?PNA=C=U(U2OFB@
M95%(41^=U_N/Y>VB,H'X)K=APH(TI!G75(*I)A691-I=$"E4"/-,H31.4>!"
M*F?DC8U65NHV_A>8KU7M>+QT#G [9O$(8\_<LD:P5O6J.;4IP8:V_KC%$A:O
M[').YJ#\8@G +L/8WM:-8SX\/4_GKU)^E=/Z!#BG+)_6 8;O%H7Q-R=IS' 6
MI@*21(80,9)"0E(%%:<Q"55$5!"YL,Q9B6/CF:7"@&^>=YJ=*J:7@2IW]5[.
M0V[',UZ![)EIEKK"HE$6;&A[!5I]_7&--31>V>:\U$'YQAJ$7<:QO[$;YS1K
MKKM*/]SL$2[3"*^_Y>4$QS3A>K&D,<X"B"(90(Q""7$2QFFL5TF".ODT)V2-
MC6?:U?]*5[!4%OQFU'4\:C@%LAV_>(*N9V;IC)HSJ5C@X95.3LD;E$@L#-^E
M$)M;W -\OYIHC&6X0Q31),@$3!1/(0I""DD0)Y#$G#"I>!R'L6U([\9SQT8*
M!L*\K').IV#C7*5#3.\F>*<)X )(>G[9.Z/A%,9[P/:+ W<WGSE8J.X!0S:#
M<P_]N6.403[+*_DI?S&13GIA\I"S:;,%4EYSOGA:U(Y$FYI4,\%$HE2P*& P
M3#F!*,DX) AE,$EY@$1"$XD2M\!:=R6LOMF#ALAN* HV-74,,W ?#CN7H">(
M!PHXJ)6'M?9@K7ZSAVK2/5VQ=X]!Z R?WT $=S6&C4;H#-->2$+W)[D1X=/K
MPZR)XMJ(&:U];4Y$)(3,8" 1A0A) 3&-(AB0.,!$LE %5B<_1R6,S6.I==P*
M!W=9OAP'\C1#>8&G9P+J"QG1UC-J)]8^$=H2-2!2EW/P6?,;BC67&=Z,@KAE
MS>,W#D**9_5><M[Y"]TH3<A\TB:?OW[XQA_-(TTZUT2P) UC4^5$$0X1C4Q\
MJ! P0[%*PTS@E%M% AT3,#9"6^H(EDH"HZ7=2WL4Q--LY@.:OI=B;JA8OZ?G
M3#_@"962__ P?_E1WUH[0?] YD?8_%B_PT<?.L@K?,ZDY1M\]CKW%_C#K*K3
M4_B\>)X7-6O7FS+O3*YU\?IN+N0$\3A* J8@#T(!41!'D/$@T0LS@1!*5<J"
MQ/9]MI WMM>[41ELZ7S5["=JF$&K.3"JV[_S-KB?IP#/:/9]QN,!2">:<("G
M,VO8R!B,1!P,WN04E]O&EH[]<5XHF5<+_47]NS31-7JY]B(+^B!_U@^O3%FE
M58CY)$QEI@*.882QJ?7 4D@8)C#.TB0-B/9:>.94AV849HV-,.LT;FZ*@4Y-
M(K>83Z>T*,&S+$ ==3.:G&ZG[X[=!M@XE!T1Z0^7#[X!T!580@1:C$ -4EUE
M#:P3B_X,*>-=QOU/DE#N9-I_DW3S+L,Y7#)Z)^T&=@E^H=_RI\73YX4YE[I5
M3<#;%UDLHU(F@@8X2X2$&<OT+)^H&&)!)20899Q&>I;'3DFJO6DZMHF[U1?,
M:H7!7#7S=3-U/].BRGG^;&CTN?ZKDH4)I7T^77UCX,'O>9KV.:3CGWF77XC/
MJR]$&P"L+09+DT<PB=J.RCCFQ;/:_CFF.EO0O<U>U@*[34A?Y8N<+>1'C="[
MN5[W4E[]/:\>EV7)KEE9?S9124IC'"NH*-/3BS#!AV:B(5+%4A(DLL0I M%2
M[M@FBU;MIB'&4O&F4\:Z>MY2><?81-NAL"/['@#NF;H]8>M,P(Y(>:536]F#
MDJ,C(+M4YWI[-^(Z^&@3PW ]6\5FO]Z;+.%[^:WZ2=OW^R3A(F4L2"!!^A\D
MHPC2+,E@@E6:<255A*WV]"_087R$9KX46M'&2]+.SOME]M/R??R)3LVVEF,^
M1Y?QL6.VGE'OF>4.$]O5FO!J4S9^7YET56?7Z &3^4N=_?Y;;20P5H+:3(^D
M> '(7@FRBQZ#DN4%0.T2YR6/ZIA+VSB:'^>%D:W7M?H7_5.9"]F<B*S$?LQG
MF@3T%=>\RE_JM)=)0B1#@8BAD#$U(0\$$A)0DVD;9:D,J2+8+5CU(GW&%[>Z
M7%AJ5N4K>\R/:X- H0GX8=84P:\ Y?]8Y&7N'MQZV4C:$6__HS-0@F\[+*H^
M?UV-RY8IF[2[L@:LS?&8 >P#5;_YP1=I-&SVL _P]G*+O3RT&R-?"U&__73Z
MA>;B9O:./N<5G;Z;/SV9\VGC)<4I5R%-]%*<!:C)$<"!$E RDE(I8Q4F3N>Y
MYT6.S6E=:PR>M<HPGP'>*.W8)^H\V';,Z!?"GNEO SVCK:DEW>IKO$ZC<5/X
MP&/_)6MX_#95.B]VV$Y)UC#LM3^RO[-CG29S)-:D 'S6QK09]TSI-7)HRIW6
ME=<RO6AF. E@F- XC)"(D7(J<G!0RMC(I3EE[U2 Z2"(=@QR,30]DT:#RC(I
M:*VBQRI+IQ#P6UWIH*1AJRJ=,G:OFM+)BSL>1/-'*193V9XHG#J9*(\=3=1+
MT4E(4<@$#F&&&(&(1!AB4QA%13A*!1:24:=--6^:C8U8EH:M3A3/'%.6)\\I
MV]T?QS,&?\-N>>3\%H/9]Q'SL./H?J#L&W._!\C>M!OVP-@WJ'L'Q-X%#!RA
MM'U"O=FPLXZBFG"1I@IG <S2)()(Z2F""A1!C(@(*8TP15:E*?I6='331A-\
M0I=ZUMM6#T;3@:*/S@VLY4PP@N'J>V*X//9H+^;H>FO8?SXY[,.%'EF.R3@B
MC\XI^^<(/+*$W%O<D:V\CJ?WM'PT_S>QN2]T:B:UK[*LBIQ76E/]A^N9V/Y@
MX\JF:=3-C!<FK_>];/ZK?Y\N3.W'99+@5UK)#TI)7DUBQ7%$ PR36'*(.,L@
M)5$,PPRA$"O*$Y&ZM$(85GVG&6F@7@MYJS[X3K0&? _J;=CRL3ZFKG^0:Z,=
M@P>&_7I8QAV,=M#[#EG0IEP!\R_8L.@*K(UM_MB$)VQ_MG5# P*X67UWECA\
M7[>,:*!8ITX;,$"#AL? AC<91;\Q$<.:,&PXQ9L,SUXDQMMHT363_6,^E<U\
M/4&"9"3&$8RY(A!)IB!!.(0BCI,T#'$81HYIZ^N'CVUEU.@'C(*MX^R:BKX!
MW.DYX%(X>F9H!R0ZY)+OFWQAXOC& P?.$M\W93\E_, U%W89W*@5W-9G%+>S
MKZ:FA<DETJYW7OXZF[-2%G5@W\WL>5%M!V:^HU-NRG+I'[_.IU/MA1L??2(B
M+FF6I#"-4_VV9TD(,8DY%)BCF$D5">*T]]Z[QF.CD/WPU];WT+ZL,AFS+W4K
MOA,!7!U;'?;VE;#S94<UT#V3XSKS^6JSP/JR5*H >N!7%H/:Y"NP:32HK0;;
M9AN'>&4X^,V8#EK;^^C/V/<X]=/3L3>MWZ8/9-^#<+1W9.^"NP:K_>>BK.HC
MB?OYD1B5>O^([6Y ?95-G*N\TRKG7#8^\]<F%M9<T)2?,"W HH@SB#.90!0+
M$^I&A:FLEL24$I5DH5NH6[\*CVUZJT.#VIWFYW:G67XS1EE6;1ILI.VFK3&-
M7\^SUO67FW=7AX\*UINW5^N]E":8N6RFJ=8FGQ%\PP#O.?ZO9Z4'CAX<9@CV
M8P\'DNNOE;M)H-F;#\OM"7%[]EQ%=/],\YGI>]ELUY@"R1]H,=.7E1.,".61
MC"%*S"%"B 0D*!0PY*G*L)0X"^@RW>7^LF[PO1A@16[;^3'W \Q1[PXMN#:R
M8O0?JL?-5B9Z,=;V%]3KL,L[S??S97%<AHUB[(=?CFUVJZCS(?>77>7>NFMO
MK;:1JF,06'8*7J)@OD%+''I8F0TU=/VLT'K7_FU6:D,-RM$5VV *#!SEM5\R
MZWHF/GQ[SEL^OIDUL_PDBN($813!, P#B)B2D'+]#Q(XS5"<":*D6W)H[SIW
MF"![GAM;S==U);63+XWBIL1DIV:N_0]\S^%@7@?S3Q,7=JC>8WW>OF&YF>>^
MG"Y+-ER$F.LPC2-4S%KK/T?,F.L@> L><Q;<H:^,V>RX55^T_"?]VBWJ]F=:
MRCM]O?FQ77.6J\9X21:D(H(!57KQ)O3BC1*F])Q$0H88(QFV;SCC)'IL>X+U
M)I%>0SUOJ=\$;;4&@+*UP*$'B]MPG)XD^@6Y[V@I@^^M MN: ZTZ6.H.ELJ#
MWQKU79K=N 'MT 6G-\ ':H_SI<B?:/$*5).4;[[&JST#3FM&,E/D'X\Y?ZRW
M% KY/"],I)JB7*\S*9LOJOH/W.$56>ZG@T?Z(@&3T@AIO/4?//7GZ30P)QOW
MN#UQN(X^G2S=:O73[0G=%E&?9%E*^:F)\BIYD3\WQ2%F\D9_[<H)"V20(*3=
MDTQAB.(00:)8 &42).8/2<R=TJ?/R!O;1-.H>P5JA:_ ALK@-Z,TJ+5V3& \
MA[G=ZL,CDCW/)I>"Z.SQ6T+CU5\_)W-0;]L2@%U?V?:VCOLU"U;*?RST5/;A
M1?]SKY_2-/>=Q#$)4)9&,,N(*<(52X@Y#F"H(D)3&I!8NG7W."9I;/2R5A34
MF@*CJF,'Z//P6NYF^ "M[UV(;GBY;QF<P\+O4O^HM&&7Z.>,WEM:G[VA8R&7
MXH'.VJZMIF;5?)J+9M4^$U_TUVGIAM^JCTLW>76R5JY*#&NP%4E$"%6<IA!Q
MHCT7$4=0XBCC01J%.$-.A5]\:#4V MHTJJ[7N3:K7BIL&F96$RO3UF>99>=B
MT7[&V8[=!A^]GIEPJ(%S+X'C$VB_)7.\:#9LB1V?8.Z5Y/'Z\([1EQL-NF_5
M;B?O"<(JR%3&(*$LA(@D'+)099"@& F<R"R(4Z?8R9/BQD;.F]J:=SA?=[;O
M4MKK#-9V/.H/P9X)<A>\M:IM!3"/@856F/@-"SPM<MB@/BOS]T+R[.[JN-0T
M,<-?Y;/^,CWJQ>R78OY0T*>OTCBGIM+IHGJ<%R8R:WV-UF<QJ\*)5 F.D1(P
MI2;Y4# ",6$2,HR1PISQF#.GM6AG5<9&1_4QF=EP;M4$SXTM5_JSUIK-O]+6
ML@X91A<,G^5:=Y!!Z7LQ;(P :PW!E^5XK P!:TLV+VQL\;A<OAA.O^OI[NH,
MN^"^&+:]%?GE3^QPBMUL&[;QK+.'>O_PNI#T5M4_BCOS!9YPJJ(D40E42'MP
M*"0<XH0%D*$T385>J].46Y]>6XD<&X&NU 73.MU!TRD%WY7_ *JRC(!R@-OB
M=-H[B .=(ZQQ;$\4C-+FN+I1&]1Z>P?4X13:.[ #G3[[ =CM8-@)JY,'PG9/
M&NX@V,FRK0-@MSL[KKQG52[RZ:+*7^2=B=RM,S,_?&N._9O&5T_/B^46P#)F
M]XLL:C^PF38F,H[3(!(1#%D8011K9J<"9Y %L21$("DBIY9Z7K0:&^\;H^#2
M*C!OXV'K2D.FX;ILK6N:QGWX<@?XVD;');Z70;7<"1AZJ/K>,-BP!ZP- A^V
MAF?#)K.KL+2J[JM:VW7EW;OV"K3?70@OF@V[6>$3S+T]#:\/[]H,M93Z)E/=
MZ;U\D=/YLW$</C0!7FU 790$%,4LA4PD&"*2:2\\E*:1(!<D"!),,J<RMA8R
MQ\;)2Y5K&A9KI;NEEMN ;L>JGJ'LF3.W4-S0%[0*GX\-[=#IU!H@SUU.S\L=
MN,.I-1#[W4WM;_42Z[,^K<64*2$# @,12>TPHA 2*B6,4]-V#Z4B%.2"4)_1
M'K3O1JYT/S4_"JWEUJ<'P/K>V.R"U:4Q/OV>/1\5]I81/F=/B,]>W[%C9R%-
MR[-[^DV6$Q;'/%%9!&5"&43FY 5G"$/,4\&8DIG(K+8%#SU\;"30Z@8JHYQC
M;\Q-S.S>]*Y(]/QV+T&X/PF">PO* ];Z[2BY*6#8!I$'3-OK]WCHFH'SJDW]
MV.KU9J9)HMZM+.NF3_>/=-;FTM55UU>)<W^7^<-C)<7UBRSH@ZS_^)Y6<I5_
M/E$4)R'),J@R8I(/8@0QH1%,5!P%J8SU5\TI^6 TEHV-F.I]J+H?ATG*%O/I
ME!8E>)8%J!.TA\K/]OX%LG2)QJ+OB%C:0[YW@P[8@ <T'?@J#= Z&[S!:)WX
M?066.($6J.828* "Z\HK(T@0[VO\QY%([MVZ/T?">5^#ZBTQO3<%N[D+ORQF
M.<^?Z?2G^4PL4W8CHG BA(0A3SA$),P@B[G^248H)@%.%76:N0\)&=LDNM(1
M,*.DVYQY$$6[Z>M2;'J>2=:PU/KUL"5X"@"O5'I0T*"L=LK478(Y>:W;NUX6
MU>0^KTQGOYN9R%]RL:!34Q/JJVSJ\9:/^?/]_$-=>[[-.@LSB63,$4RCE$*4
MX@P2J3@468*H#),T"*T6]AUDCXT9:O6;(.2E 8Y)?ET&X#1[] QKSZ32"5%K
M8KD FU-\HQ^[P37ZMUV>Z2)W$/JY ) E*UWRB OZP1O?JI"/VKW*7TS_FOF3
M_'562#HU49#_/I^:;C;+"G6WL_6A[761E_I/[Q>FH%WC2'V6U:VZI]\F+$BY
M1&$*J10F1#Q+($;Z'X(P10I)*HC3&49?BHZ-!M?V@*FVPO0L6'4$A6I>P)+J
MEUI(5H%R9=\5F,FZD$E%OW5H9=_'^-NY96,8U9Y9^/;=C2GGH,?K;F.\KK?&
M]$Z/J6E%L1KZUNK-,J=7@$E]K03K.LU7@"K]G32[Q!YS$WL>$K_IBGTI.VP&
M8\^0[R4U]BVOVUS4**&?TX;@5Z^?]7MU_2TO)X@':4HE@3A.)$2A$I#$401%
M'/$@BV.)J%,(Y7%18YL/&DW-*PY6NEX!HRWXS>CK>#!^ F,[QO:#7,^<VQTT
M9[H\CX=7PCLA;E#*.F_V+NE8W-'Q*(X_2K%H?6:I\EE>R4^:T\1NON2]F6_O
MY;?J)VW)[Y,HBR*%$8>AJ0^)9"(@RW@$4Q$QC)*0T=@MB;&;'F,CG*49QIW\
M/)]!VN:@-H7:;?.#O8Z4Y0E5__CW?9ZT ?W:!E@;L8\]^*TV!!A+0&V*S\"?
MR\#T>SC349=ACU(N VSOX./"Q_44U5 >.V^I_S'%C4Q=#/VE-MS>;K%1@@.F
MA"DOQ!*($A5#9A(;19SA0*:2"^H4O-2'DF,CX5K3BPJ=]3&2GB(%>AZ?GDG:
M96C\G[)?@-VP!^9=%!W7V?<%4#L?8U\BR[V9^"?]/9Q^>9S/ECVQ&4ZRC.CE
M=<9C 1&A#-(TTXR=\#@32"(2"MMFXKL/'QNUUOJ!6D'G9N)[P)UFQ$OAZ)G)
M')!P:B9^S.3.S<3W'CA8,_%CIFPV$S]Z33<?[%TA15Y]I+QN#-3.O$E  DD)
MA8HB#)%^62%)@@1*'@4XRF)&F557@U-"QO:B-CJ"I9(=':&#<-HY,I>"U//K
MZXR/LS=R"@"OWL1!08-Z Z=,W9W-3U[;L=! O99;EV6-DRQ5>BK&E.GYF";Z
M=4]#"54<2,:3D$9*.E4,V'K\V%[TZ[N[#_=WCDG\VX#9O=#=8>A[3=%NZ/20
MP7789K\9[MLBADU5/VC>7L[YX:LNW6]>'>)^G!?F"'=]2+;=]&]G.S/-!"5*
M(9@%9N,YI0)2SBA,$DE(Q(C0OG>WC>=N"HV-#S:W0=>A['7CZ_UC\\TJ%.P5
M_$+_4U_6?O;:+--IW9&'FF *M?I3UYWKCF/NNH7=_T@.N)=]O1_ LC%JVP8-
MM*M]&;X];6]W5.J-]KDO@_#XAO>%SWV;/JD?OLF"YZ51J=T:R"*]9DLQ@BHU
M?5$3$D."&(&,*1IPSFE,W(X7?6LX-MI?]D"5:T4!K8#4[&U:=-61)F_4#'5_
M=#UMA?<Y9GT3O,=FIQMV7GG;BNI]$,:1@794RW'MIG<%V7>KTN.".A1UW:X^
MN.KF_:&L]//S4L]HDYA1S?HTT^--)$28<KVH3Y&>"Y0D,<5$A%8=5BSEC8_4
MM\NY3EN=<Z>>HQ8XGR;D'M#KF5YWRHN"E;I@0U^_$#H4;_4+Y4"56R^#U*UB
MJSU )\NU6CQFN%JM]C9M%6IUN*WCB<E\5N_KF$29=XNRFC_)HM[Q>;=X6IB\
MF1?YCE;\\=?G=>C\_?RK?)&SA7SW:":.FYE6)W^BE5Y_W.NII-2/T]_%+T7.
MY22BB5"QHC#(D/;D<<@ATQ] S!'G21:$/'4*/NY9W[%- :WBIEMN4;]WWPG9
M_/0]$/KS:@YX;51=WT"V=@E0K>T"S\:PU=4M?B:?C:X0<HQ%[/M+8WG$-)ZO
M0M^G5:VEX ]M*EC:>M7$,EZ!M;V@-A@NGC<27<RHMT;K2VNSS7=E:;A9'VZ8
M#FK;/1Z##3-(?D_4>M9YV,.Y809@[YQO(+%=LV5>9,M\]>9VKG(I?GI]MR;'
M7VA5;W6;0A8[V]$XY;&(!(*"AM+T#*.0)%C ))"2A9)D-'(J;GN),F.;KS9W
MKM_1\O&J_K>NU/-"I\;$J_I(H;7(;&'K*W<R_, :!D#+C1WPC_OG%JX9/!>,
MN]VL--1H]CSE;)BQ.1SL%6Q8LAS&UZ9T4I^G#SY@]9Q,=(%" Z<;70[=?D*2
MAV>.NWK@)"$QQE&80A1E%*(PTDL7%#(HTS16 HN $Z>XL:$4']N<L%W[;]@S
M"-<Q[_EHHL>1'/^)1<=R?2,XS.@X;.,XXW!5_L]Q]-%Q2-ZJ1MZENW3:B=[P
MH=OJ;2(,>2+" *:AT!,4TDL22D@ A41Z"9(EDF56F0<GI8QM-JG7$W*MI>/.
MU4$@+?>;+H6G[UVBG956#X7P3D+@=P_FH*1A=TY.&;NWWW'RXFYO_<_SN?@C
MGTZO9WN9J^_SDD_GY:+86)\J' :$9PPF02),YPL,<1QA&%*"2:JRE&"G7%$W
M\6/CB:7V]7;#A;GWC@-A1R?]P=LSSYQ&%JR5![_ULA70#3BO[.2HPJ"TU0V>
M73[K^)3.AY!<FIT#XSE]S<O?M=-D/J /,IS0(#:A'@0RQ8R7(P4D828A1SP4
M*@U$%%@%@=@(&QN);>D*"JTL^.ZY4==Q!7T28NOS-B_ ]7]8MH&9T?,*K#7U
M>K)U%@[?QU+'!0Y]IG36] ,'0N?OZ=KN9\ZE%*7I?WA3E@NJ)=VJ>MU6_CK3
MS[FI1><O)A'\\(K/I(?KQ9KIHYC/'NHNY^TZ;J*(X"S#& :FMSA*$8=$!1'$
M2<9Q&H:2":>,DUZU'1N!+8UM>IOR^=.3?B=+HS#(M>U2@(4QN?FHW3;BF]M+
MS\94UTY&?7X=[+AR-(/<,]DN[;P"2ROK/*':SJO#FX'KO15]T]*\=OMO&<SL
M(Y1LT*'PW BJ3XT'[BPU /C[K:J&$/HVN3*WBZK4[KC1JLVF"&D8,A(%D+$X
MUO.3TLO^,-+N<D8(XEG,L8HG30;(746+JN?#JF-ZNI#6KK9]AK4V>3/SM;JF
M5O!#/C.-D]\H8V9_C#.&@PR1%"91C$P@/($$B1!F29S2*([#.(W:,?XP$W^:
M$5[J.O#XROJ_HQG<GL\<?0S7^ \75\>'MYLC/;9TJ*.#,(ZCPJ-:_CG.!,^!
M[#L=ZKB@;K[!5UG1?";%!UJ8V6?5ZDH&(:>Q@G&$,X@$BR&A>KY/E6(TH7&D
M_^NR #TL9FPKQVO.FTA1_:Z;(IX\K]R(^@B:=FQ[.48]4^920;#4L(?3OM,@
M>*6L(Z(&[G=_RMS]%O<GK^[& "80=AU34%>6CT2F9$ 45$)H]SX)**1!QF$F
M(YK&6<QPY!2%MB]B;&]^'0V\5K%3J?X#0-J]^)?!T_-+[XB,\PM_W'BO+_L!
M,8.^Z,?-W'W)3US9L5;9T?H<JW)<J="K>1P0*&.<0)0QO;*/: +3$%-&PP0A
MM_2"\R+'1@#[)6_^ZEC@[#S*=FS@%[LAV.%XGZ2Z=% O5=*L0?);.>V\V&&K
MJ5G#L%=AS?[."QK5?5I7#UB?X*_>APQC'L9Q"AEF(40**TACJ1<9+$Y1$FD'
M1#KEZ9X7.3;6:6*1-U3>BF0Y_]YT1=Z.B?SBV3,370IEM[YK5NCX[Z!V6NSP
MO="L8#C8U<SNS@ZE7C[)LI1RNY;!AV_/DNO%_<=%I:5\U>Y5N\-2+WDHCS&&
M22@E1!('D*1(HY_0C(1(\%3:EWUQDSTV4KJ?5W0*9*LO4+7"H##._W.KLD,=
M$\=Q.,U,/:/;,T4UBIM]XZVZ)J:<5HMUHSXP^B\WFWO$VJ%^3'^8#U1+QC/V
M;L5ENJ%WLM",XR.'*SK3S=:M C0=']$U#O3I*6^R2J]GPB23:I%RQK<FI'6<
M=4Q1&L9AJE?*-(,HC$UE,(IAEHA48,$8BA*WR% 7\6.;*C:T;ZKV;NKO&BSJ
M- YV'FQ_Z/8\59P$MO]P]VZX>8X\=5)AX%C4+O#L1Z=V>DH'7_B++-2\>*IC
MDM@T?ZCGVF6A$[%;YZ0]M&)8X#C,4#- 2(4A) HCR .9*HDR)NWJX7;68&QD
MMV$#F*^,6!7 <O#3.HV'A6?<-\H]D]XFP&O]5U6CQ'[-J/,'D)[ =W"5^QZ$
M@1QF]\'PY"Q?@M])E[G3@X=SG"^Q>\M]ONA!G3O!UP4"W[>% F]FUYS/%WIF
M^RJYS%_,1O,D,L5T!=,32H0E1"A@$&=!"JD*HCA((YYHUWDF'XR6=LZSC5BK
M5XLTK]:F\![W5PHJ)*"MIJ!8J>K<&?X\YG9NLC<<!^L6WQ:F?+\J3)G/P%)G
M\/4\HEW:QEM#Y+N!_'G!0[>2MX;B0%-Y^WN[UJUXSBLZ-1L&,Y&;W0(35+\H
M"BE^6E2?Y]5_R.H+S<6$)]@TYLL@CP(%41;'D&8201:H$(<J19%TREVW%3PZ
MOU8_Z%&/15T6[[F8/\NB>KVJLZ"J>O%I*E\\U\$?^BU;\=8S?74G+>O!L5S?
M]P!YWRO[1F6PJ3-8*@W8H@):;? JS29D[C$ER14JSY4U+(4/7&S##9+]^AN.
M]W<,T<T?'JM;]6O9Y,+?LB8(\&;VX5M3A_GCO#A2LWO""9<1HAG$C"?:Y\()
M9"'/H/:[XC3D88(SMSC>[KJ,C?9V.QT4QC0X5W"A?Z$=*G9<,DYV=#<0^CTS
MX-<ET-J.IH '6%I2%XEN;:G[QQUM > QXOAR4/V&)5^@S["QRY<#MQ?@[.&1
MG?/Y:[_')&%6U[.ZUEKM\WS2"MQ4\JF<J 2%5!(]8)+$$,59"HD(8L@XXXC3
M4!*1.B;EGQ$Y-LK\LG(.OZR<PY76X#>C-Z@5=XQ8L@#?CB#]0MKW=N?E:'9)
M3+<$R'=V^3FQ0Z>(6\)P(,_;]LX+DK79^00QMIL@5O_S-W,:,7NH>;1<5SN9
M1 R30$8$2I8*B+A((=:$!:E@2G.72 *W@B*]:#DVNFO5!'](HVC7*DC]#*@=
M'[[Y,/5,H1Z2>.O_@.50-[;V4[RIU\'PG\SK7=/A$WK[ OM@4F]OPKK-(Z81
M=]V'^Q?M)B^*6@W3&.77V9R5LJAW6F]FSXMJITOO5Y,(4&A]?J)E7J[<ZY^U
M(_YI7K;U28Q+7H?O&GL+^:A-SE_TX_C\24Y(G$5A@ A4(DD@2A(.:4PC&&(9
MDCAB-!!H><YS;S_EO)E!'4Z0[H<(TS4'>=.&[C:Z:IGSI/G#+/^O9C7=A,7S
M3:O 5)OM-H>]W9?);IX;]W=CF+G08 !J$*[ !@Q-_ZY-($"#Q$X?]RNP @/4
M:%RM-UNN@$$$?&<P^1XL45E_O;:  0TR[=7^IL\W'V.O4^S;63/H-/SF@[8[
M5;^]0CV&*:_RNXA D@<!A0%),$0J81#747Q2!@RK(")9Z#U*>:Q)=O:QM!T3
M[MS&QO)DLR_$^S[>] AV/V'+O6;GN6DPOJ#E<SE[W1[2F?)V2?2SK&[5/?VV
MJI+X95[42ZVJ*G*VJ.J>7_//&A#3%&P^U4]_N)EIDM%+K(E*8\IPRF&BT@PB
M:M8E849@FE"4(AD&TL1[F.0W:U+TJ9\3;:ZT[/5-OFC-X'OXK'GSK0:E?V8]
MYF1? 6UCW527?MLL<-L:"C8M-:UYMVT%2V.]$G$?H^";JKWJ.#29]P'P ;KO
M1<P%)27,DTV(C3EQ6:6.[W1-)2$/T\C4KPI"#A'/$,2(!E $<2QQ0+E23B>U
MMH+'YOEN=L9MZR/,9P_P7A9/FY42.I27L!D%.\+N ]N>F;B!<JWS5M6)/AO2
MNF+EO_"$C?#ART\X0'*P"(7+_=VH2Q-FTY3O_?R)YK-)%J<BBE$*(Y&D$"4\
MA9@+ 5-&D<08ZS\2%X;:>?[8B$BKUW;6!+\U&CHNL7?QL^.6"U#IF4)< '&F
MB2-F>V6#71F#OO1'#-Q]MX]=UNT5_O#T/)V_2GDGBY><RR.%?*?U\.B?;M77
MU4%,H\6[>5F5JS"129QF** J@Y1&F@+B,(8XBBB,A<@0I3)+E5/Z@6?]QD8A
MS1'^3_M'_77X=2DO"#_S/;)VY/2&XS5@5,;!%BSMD(EFA[")HC=V78'K)Y-<
MTE/P6T^(>^55WSH.RLL] ;S+ZWV)Z38O_+0H]9/*4@MG^:R6N-H7K?1/92YD
MTX%L=6KTKG$V)Q%/$BG3& :29'J=&F00Q]0$&*,X3802@72*RNNNROC8?EY4
ML#(+5;ZRP/RX-L&-XR\8)3LZ'P;[GIE[:038L.)J?893@2U#MB($6F/\L?7E
M@'HEY@O4&92#+X=MEVX]/+&CQ]V6N=>DO>3XG$\"@1*49!RBS/C-E(>0!%D*
M61RG$8D"%3KZS8>DC(T/:Z7 =_D,B/ET2HL2/)L.AD9?QW#DPZ!:NJR70M4S
M?:WZ4F@%FYC?JSJ6B7OT(4]!X-<3/"AI6'_NE+%[7MG)B[LQP*]W]T4=I_-Z
M/1,_SU]D,3,KB+8H#Y9<42*D*4EE"HI(#DD4*2@HPSAF4::(4]7ZD]+&Q@@?
MI6'=*:#F^/VUZ6SJN)-_&ET[2O"&6<_4\.L=6"I:KSK7JO;0Q,8*%*]D<5KB
MH*1A9?PN>=C=U+7%U8N<+:3IS&G\%A.98B+^WBW*:OXDB_6!59#P4"^\&$0J
MTGP22ZP]"_T3"13") THEDYM;VP%CXU:6KU=6U]9HFS'*WU@US/%M"HW;:>7
M2C?AUTNU>RK7Z0J6YS9:EL(';JSE!LE^JRW'^[MQTR=:R;*ZI]_^0]*BG7@I
M5DE (PI5%)E<31KHM0UAD$=IG"1ABB*,76CH@(RQ,4ZC(JCH-_"JE71CGD,8
MVI',A<CTS"<M*.:HT.C7@Y]RPGZO%'%(SJ!L<,+0W1?_U*4#M]\VN>75Z[H7
M6%D'*]P_TEG;#/3S?/:BE96B[>JK9!H)B@.8F-A_% @%:1)G,!*,)1@'<8#4
M@&VY7?5W>?>&:]?]]>[7L?3J=OY"B""+HRAA,,J"!"*A%,0TS""CC$6(R3#-
M@L%Z>/?_=>B_M_?^E^%M&GL[?Q/L)L11CNV I]4=:P@TUF]TR2S;<,M* [!N
M$[["8$1-PKL.W#B:ASMK_^=H*MYU4+PU&^^LP+"U"LHC69GULR92\A0C&4*4
M"-/2*Z2FOBN%<<(CA=-(A@%S]X9ZT76<GL]/*S^'T:DI)SY,T8#3HXIDP"5)
M0\@3GFD?EQ+(&%<PEDFFW1U!4)2ZNC0C&=/^W9</C;,RHN&T\TO>?(!Z]D%Z
MK-W0//;MRS!8#<4H2BR<UO1/43[!"FQ?I1'LA/GN76XZ3_]"JV738E7)XG8F
M[Q^+^>+A\6/^(LW^37G]9++3_DO6(7^34,_X818R*+#$VBW($"19$,.0)P&*
M6))@'/EI<]Y!N['MR>YW\KX"[Q<24&,,F,]DO56KESBU34"9K%3SB>,AM-\1
MMIM.WFS<>IY&SG1COZO'<*4\,-KK^:8Q]U7_I0F9;>.R[_0+K2><Y9_!>_V7
MJW;TZ_UH#0QHD0$&FB&ZNU\P/@,U@N^BX4AZQE\ KGU[^4N$=)M#WN<E?7@H
MY,,J&KP^VMO)5@V%E$K%##*J8H@B$4%LLG.4"F.611F/4ZL&T$Y2Q\;YFPG#
M31OHY:$V>P7O- $\S-OX&?W[KS_<@1>MU,*XHV5=?^#O\V)ZO&?%!:-CQ^O>
M,>^;K[?T-0 NX>XSB]@)):^L:2=Y4#9T F.7Y=QN'NWIX=?Y=*IYVMPTH5F0
MI2EED&,20L0E@T0E$42*$QS'*$F$4TSEL.J/C4_-<=%RL]^\WLTAT>C.B#:_
M *,Y*.HXK/]]3XO,%ZA^; E^,^" %AV/4\/;#.N?[2QITX3_;@=*!X;G#4Z5
M#FG1H>_UM98BC*3[^;M"BKRZUI.UW(AQ#P,B1*Q22$680I0Q!7'&,21I*DD4
M$,:I59U,*VECFYQJ?34]*<I/MU3J .SI6<0[7#V3_DI5O2@"C;)@I6V7'M1G
M\7/H-^T3QX%Z2Z_QK$[@^8.GAM*V )UL'GWV(<,UBK:U9ZLIM/5- Z]2&M?F
M5C6.S?6B>IP79M]G@I5*I$H%C.( 0U,4"5*>9OH?F8A(DI02IQINWC4<&YWO
MKC( 7:DZT(+CZ%CVO*;P,4+C7S;L+0*NSX_O< N <V,P#A__J)9_#C?^',C>
M//6S@CHXXS>U;U_[_:9T-"T?K[GV-A93<^+T<S$ORU]GA6P* 9FJMC])-2_D
M/?TV80QG1+ ,,J9,$]LTA#2*]1=#BC (:<I,7IY]0YG+M+$BE3?H!F-VZZ]
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M?\SE2[-G.C7ANR5H*A'-9^##ESM0F4G'-5O%92SL"*TGA'MFM(.5G=:5>*Y
MJWO=5L%_)'L'T(8HV710_AB*,9T"QK+,TLE'=".V0ZW(5_UVEOL921 B%6<1
MQ"&2$(51!$G$$L@4"E2<<$F)DZ]F(W1L5/9>*JD5$Z!H2K([DI85SAQ%"$NB
M8$RB&**4*LBB#,,P4#11>F&=,>S>7] WVL.U"]S%',"-3LF=6LY9#4,0*CUK
M\QB*,,@@(C&%%$<8,H)4RB0A62!<&P+V,PC]]_<[, 3R@I9_5OC;3=J^$>W]
MQ+Y1M^G MU1XHZU>#YNI+A!YG9NM! \Z*;M L3L;.]WK-@V7136Y6X85W'$Y
MH_JUKHN=! 2C+%$I3%,3(!P*!"FB&&8XS0C2:PRE ILY]ZB$L4VP2]V<ZL0<
MQ^\TB7A!I6__WA(0:UHX:_0I#M W;[S_^K?==__XTP=YT<\:MWRKSU_84\'J
M\EAMU+97P8=OLN!Y*<N;V9=Z=E^F#UTWV4/+OW\I<BXG<1B1@)  JD2F$ D4
M:5^142C3B 9Q3)EV8;Q6L_:J_MC(I[4!R%9) ;X3\^F4%B70GE:3M_6]YZ+7
M?K\/%^UTC&"4!]PL.58NNSQ3+WO52&<%@@D ;&"X JMDOQ:)U56@QF+ BMJ]
MC.&PY;;]FC"&[9^>A\>Y4'<_6G2;.G^]^WFNGSJK=7B0,]YV]5QOX[?;N5E
MPCAA$0QY1"&BH:G@'2*H6,95F+ P4TX;4;:"QS9=_7H''E:*@W*EK=L,90V[
MW=S2!Y@]SPH:Q[7.8*DTV.EZW,/FN2M67MG76OB@O.D*R2[C.=_?,9);EJ64
MGZ2FS?>RY$5>TV7=H'/"$2("JP F46B"N'D 248Y#)DBDD0\XXE;R<CCLL;&
M2(VJIG*25M8<L*_4;3O/.@8MG(+9CHX\@=<S UV FWO,]GE$_(9KGY W;*3V
M></W@K0M;NFX3[!X?I[6+AB=FNHN'Z?S/SXT'ZP#<=),TI@E!,:$,.WH! 12
MCC#D(M3\@B+M_RBGU;V%T+%1RJ;.3?TCHS58JMTY'LIJ "R7TYYA[7L1?#FB
M[JM5!XC\KC%M! ^[,G2 8F\]YW)OYU  +LU)AV&ZKWGY^Z=\)F\J^51. DHB
M0F*A84X)1$@IB--,P#A)-%,%8191)SHZ+FIL)-0V8*^#!;>T!D9M\)M1'-2:
M.[+0";2MSS\]8-C_J6<GR+H<=9Y!P_<!YS%Q0Q]KGC'[P&'FN3OZ27%=1WY'
ME& 999 0$TV4$ PI8ID)EU0I"5.1Q4YD8BMX;-3RZ>;ZIYM/=9E,</WY/;B[
MOWWW__[[[:?W'[[>_=_@P__^]>;^/_RFN3IZ-WT V_=RZF#::R^.C2LZ@V;"
MOHV#XPJ):V:LOPIM1;.P:_Y[,[OF?+[0GM07^EKO,! 5,4PS@WQ&S>&JT&25
MI5#35!9PHA1B3K7"STH<&S<MU0//C7[.U=G. &Q'0%YAZYEYEKJ"[Y;:?F].
M!U= ?CD#9)>";7;@^"[;=D;JT,7;[$ X4,+-\L8+JT":X+%\9O:C7YO=2XKC
M@&4IAXQSS2V2(XC-@HJS& 6!""E3KMQR6-+8.&6CEN&&JMVVAX_#:\TLEX/6
M/Z-TP:M[Y<=C6/13]W%/VMM4?3QF]-&:CT=OZ)A>_RS-6FSV4.\UKQ-R39_1
M"<TBGLA80APK#A%F*60A36!&PSC"42P$MBK_:"-L;'1A= )B(4$U!Y1I9W[>
MG-+.E2FP5<?>.J;<GT+:CC9\X=<S<ZS47!XK;63>&U4]IMU; .(W[_Z4P&$3
M[RU,W\N\M[FG:^78FYE^+:EI"2#?TXHNLRG2F..(X@SRE&@.B40*<2(EC&(>
M8\2CB'+J5D+VL*"Q\4>C*]A0%AAMSV99N*%[FC=\8M8S9W2%JT/%V=-87%AZ
M]LC#!ZY!>]K$_6*T9Z[OYEI\E655Y+R234OSIK.YV4EYH5-S;G3XTV6[M#"*
MDR@-()5U T49:B>$1C",)18:>$(Y=G$]+E%F;-12'YW6)T+FAPUUP6_OYT\T
MGSFN9BX:*#O/92CX^SY/ZHZ\LV_C S*OOL]%"@WJ&_F ;M=W\O),]^R\7_)9
M_K1X:E^V(!4H3@(!)3(%SY(@AA2)""K%8ZDPD1&V8L6])X^-XEKE[+/PMG$Z
M34H76=\SP[1Z>8SY/6KMQ>EVVT\=+,WNH#&;Z76'+^BX/U(\T%G^7_5Q];OY
MK)Q/<]'D,LS$%SWPLBT$?JM6/9!7V7WENC_'O?Q6_:0-^'V"XTCR0$C(XD0U
MO<I81C$,LAA1DF41<TN<\ZW@V)C =$TJS:[+IC&..R^^Q]!RM^8-1Z;O'9X-
MTZ[ EG&U>[1IGAF[=7_PM85;'86,D:"VTJ,'U=< ^-U1\JWDL+M0/4&\MW/5
MEYQNL\(OM/A=5F;[?9W>L=R2$9Q+:=I[9YPCB*@F>(HCS?<!5U*E4BGA5)3V
MA*RQ<?5:59"O2N-US@\[!;(= WN"KF^7;XW:6LT>RK%8H.&5V4[)&Y2D+ S?
MY1N;6SKVN%5*\NI6??C&'TTR[%?-4K<SLVS<63KN+3BW/]BX<I))+)#DD68;
MF4#$!(&,IQP2%1 4I(D*&'+J?^M?Q[%156-B?9HW+V3^, .R-184VMK2E(CD
MR]V>^@>Y-L:Q:6X/(V['?V\\CGT?&:R&<&D?, ::D3-*7^UMTEV!M5E@M96W
M^]D'BW%V[\7;WTCX[=/;@Y[#]O#M#^B]_KX]BKHX!OXCS8N_T>E"KIW?28*(
M8$P$D% 35IHE*62I$*;=4T CAG <)Y.9?-!VB/M. ? 'I%H1!FD(8T]V?^2Q
M7I%V[L)R!FT[BO8 WC!LNP;,D.;G^6S=F&ZK)8NQ M1F;"SP>PE[/X%77\'N
MAT2^58C["?-/!+:?NJMC0K&<ZK\^_"QGLJ!3S6[7XBF?Y66=X_,B/S2-!2<X
MU.AB33XBRS3E8*R7Q1%CD+$H1BK &8F=XD[MQ([-[6RUO@(/C=Y7]=M$MU1?
M]F)T3"NV&P8[5O(/;L_LM,*U5;F&=5MI\.$,K.ZYQ4XH^<TNMA,];'ZQ$QQ[
M&<9N=_=4)/%,5:J/\T+)O-*D:3*$M$YYD\AH5R,OQ:'@&9.090F&2!,A)$*O
MU4D0\9@Q4[5%>*V9V*<U8V/690E%;JI"3TV/A\(0:5X,4DRQU^^-)6?_6;X-
M?4\%%J46;2LM;F#2Y'.N41EG[<4AQGC84HR]6C2NRHQ##)YSH<9!E.HVFW\I
MVNX =:INK69YO:@>YT7^7U),DB"BB4PE#/3R J(T32!!3$'!54S23":*$9?I
M]K2XL<V'*VV;+M: KC0%W]538.DX!YY!VVZ2\H=AS[/(&KY:TZMFNBC!6EE_
MK&X'BE?:/2-R4%ZT,W^7N"SOZLHL^;QH^.NKY%-:EKG*>4.-XC\7S<'V1F&V
M21PK&O PA%A% B*2A9 ASJ$("<*4BSB,G []7148&_OL*NVXM>J,ORW[](=J
MSWRTJ^]5[=O2HFT# M;Z@]^^S*<Y?P6]Q%1UA= S>SDJ,3"?=8-HG^$Z/J=C
M%>Q9(?G\86;H\YY^^TG.I,JK<I(P&7"5F/X.IJILA+BF-D5A%!-.LH"S.':B
MMB-RQL9@FVJ"BGX#K%74L<CU$53M",L#5CWSTA9,IE; 3^=@<B]6?1H$O[6I
MC\@:MA3U:8/W*D^?N?S""B*M4U6]-AE.$X+#3$09A9B'""*EJ8"Q,(,\D#R*
M,998Q)T*B.P(&ALA;-3#6&G:,>'N*+9VK. #L9YIH1M8W6N''$&BG](AN\+>
MIG+($9./%@XY=GW7?'_M?S[-9QNKK]M%55:T[LXX"1*<"A8PB%&80"1#[3X(
MA6 4AG$2T(2'+)J\R(+-[?/^3PET^>IOBNTQ.JU):&^4WME$V%#<M0[ 2=1/
MTX=_)'LFD4LA[% ;P :9"RL$G!0Q<)T &W/WJP58W=7-Z[A^H?G4A%U_G!=W
M="JW.VA<<[YX6DQ-C-C/Q;PLC>=#I\;O^5DSVD_2A/)JIINPE+-(12D4IK"K
MJ9H(*=<KF-!4'LD8X31Q<E&\:#4V?V9E%-0*PE*;=05J_<%B90 P]2]-(9\'
M;8GCRL?/4-IY1(,/4,_,M],!Z H<&JP-L]J!6QL&C&57>LUJ;#-NF#^?RRO6
M7ATT/YH-ZLUY!7/7]?/[\&Z$OHHW_"RKZ[*4U:IS\22)2""",(8A(I%F::4@
MX8&""8\2R>((IR8B<%[1J1U+'Q?E1+TK@?V]WO=&AAN;GL#1CB+]H-,S[ZV#
MAZ^ UA/4BH+O5JH>/[)TIK'S>'CEIA/B!B6<\V;OLHC%'5V7D-="Z&]/66?J
MWA9?BOE+KHV81&'&$Z97BR(R;18C[<CAE"K(,8U$P",E4JO>X^<$C<TC:]<[
MK;)73:Z\B6-;*NRZ6#R"K^TR\7+4AED@=@"LP]+P-!H7+@J//'S@Y>!I$_<7
M@F>NOSB)J<VX7?6-D$BDF)$ QM1X#"%+M<= "4P3%F72',$'3NNZXZ+&1@VM
M>IO)2G_MG*VT"ZN= ^$'K)X982L5:0E:S^TWCJ#15P[2KKBWRC\Z8O:)W*-C
M=W3L%]:V(=ML3;9.:BK7U7H"3HA>3$0P2,V!5:)"R%22P4PAED1"A2AUJF)M
M*WAL''*D_=[-3*_TGCJ45;(> #M^Z0/6GMEF!:)V/3;!W5"[I])&KF#Y[3YF
M*WS87F2.D.QU)G.]WXVVGEX?9J;[64U]?\^KQW>+LIH_R6*UG+J9\>G"[+9^
MEG\L+VS[_WU='?!/TC!A2.$(IC3D$#%$(!6<P2#B@4I1Q.)(+I.X3_.9)XVL
MWL?M!.^>B6[9-'$=%F%';+Z&Z#3?#0G[8%T6:QV!L08LS;E:Y86_7H&524#;
M!)8WF((<S5!]?:.A$G.^>%H6#QO3D&TI]F<?.NOIS3/0S:QG'FJFLBB(VXG,
MEYA!YC?/F"RG/=^/[>;$FR.)0Q4V46#:0\019"A)(**,0DJ)@E0C%]"4\R!Q
M"CH](F=L+OJG^>P!WLOB"1B%W=SQ8U#:>=\> !KB3+3WFJ%G</#J1Q^3-:C;
M?,;@72_YW.5ODY??9A6:L\Z3F=1<Q)B8BIP\I *B,$LA#64 24832AE# 7/J
M*C&0WF.CJ66NO5RK#V@%Y$R8:FS/=<K"VR?=VWXI[ ARA$/=,^'Z3*3?L/Y/
ME"[O.&:C2HRWU?U/E0+O.""^D]U=Q7?TB5?3ZZW:U/.KK(-UWLW+JMQ3<V.[
M-94AIT)BF"4B@TB06'O160:#.(U%F@C"$Z>\]POU&=OD5<>MPI_V:,W1V[YP
MD"R]\N&@'W R64T2&_-(3]Z\'_S\>OT7ZC3LZL /@'NK"$^/O3 F\6;VO*C*
M3_)%3N.V<Y 2FB.S-(-*)7J%$'$.:< (1!(3$0=42NE$GB=DC8T8:]U W#$N
M\0"6=ASG":&>^6LS,K%1] JT@'GLU>2 23_1B0?DO4UXXG'#C\8GGKC%/4#Q
M?;O_?J^GJ#)ON.EY7E23A"<X1-JQDB%)(:((:>^*24AD&,I$1EFDK&*03@D9
M&S,L]01K14&CJ7U$XE% 3[.$+YCZWIQT1\@I!/$<!)W##X\^>+#0PW.F;88=
MGKVV8RC1.J&M9I*)5)*$ 8E@PI(8HA0C2!1.8,:3%(M \3!Q:JBQ*V!L+WB;
M8EDV*98X^"$&3_ETNFSGI3\(5A\TQ</ ?)WS9_;^?M&@/_Z/?P[3X'_&X14P
MQVWUK>\EKZD8M)_J?_7=S[+N-3Q]=8PXVATG.P_C$O1[/SK?S&U=^A=EN?!9
M7^R8_7Z#@G:%#!O\<\3$O2"?8]=UWJJA#P^%B6JIFX^UQZ.?\IF\J>13.4EH
M)-,@3F"<)!E$)NR0A%$,:1J&B0@$PM(JE<%6X-B(95M?<SJP#!OXS>@,:J4=
MJV><!=UZ;\4;E'U[%Y>AV&7;Q H:W_LBIX4.O?%A!<&!G0V[^[H1SN?Y;/XL
M38G5V4-3V6-9V#] ,=5^20HI"B*(3%UQBDW=4\8(CE%"*2(NV91')3E1S%#)
ME&!>/6HG(V_*SGS7=E#X_@K,I&,8Q7&$[6C%"VX]\\FFCJ MU?-=JZ;'%,NS
M4'CEC^/2!B6.LT;O,L;Y&SHV&GQZGLY?I;R3Q4O.Y>&S+RW<].F4HC[F*NMW
M:?/O9B?V\[SZ#UFM0[Z:DH0?YT7[D;DNG$28I8@$$M($<8A,:Q>L2  I36B,
MPC0)T]2I!^&@ZH_-;UH>+T+:'I&W015J7BS#FFM7X+M\!EXE+5R+.0_\Y;"C
MSO$.^=L>CEV!E='+P ICI?ZTTH-?;43@7K4M">KOR8:Q'AL9OLD8^>UQ.*P)
MP[8_?)/AV>N,^#9:#!Q[:/HVFBCILBKJ3<GRUOB@]X]TUH:+K"S<"1;Y63^Z
M>D\KN3JZF,0!"7%&0_V=C97VV6,S<3+][<61GE4CPK!DDV8.N*MH4=G-H6,P
MS85F=PWLCW&_WOVZM85I2B4]Y+.9<8C?+G#1YS<*X2QDPM3/2&.]'HR4]L<$
MQI"S$,5QD(21B-MOU(?9F4RQ,1GF_GU:FC?DMTDV&^/_/;Y*=M[;&%0=J4_7
M,7JV 09L( -J:$"EL5G'UJ[@.1!96T,$#$8;C5E'$&#;PYB/(_K6IV%_CM#<
M'H;26]QN'[IU\S*U:GEYJZXYGR]F9JNG:=+1_+M1JR)$D1!1 I6>H_6L+4-(
M!,<PD3R2+$HPQTZ[*'9BQ[;[46MMCCF^Z*<NDV#=)DY+O.VF-O\H]CSYK !<
MJWP%VK8PO;:'<4/**V5;BAZ45-W@V*4]Q[N[Q[[D=2L9T\#/Y/EJ07+&<UE.
M"$N21&493#.3A1N1&&(221BJ+,XPDC3C3J?7)V2-C8(V5*WC6/BFLNY1*\<0
MM@]@\8#; +$LFY"]LX*L4S3+&3"\![8<DS=XC,L9PP^%NYR[I4,9FU^TUGRA
M%[;O<_HPFY=5SK]H_^N)\KE^^OPIYV4; BZ3F 4AP5#(6$*$&8<X2;13$V&J
M:)*&04AM&,1-[-C(9*4X6&L.(-A5WJ'TB?T(G&:8_G#MF6P.0KJK]?G(_$N0
M=:@=TPO" Y6(L4+:4^D79YQ.5GBQ?]IPA5R<+=RJU^)^=\<SD04KY3\6^LOU
MX<6$6YN,UTG$)4*,:1JGB8(HP ED"8T@X9%>F0H2!MRI^NHA(6-C[K6.H%82
M_%:KZ1BQ>!!.RUW5"T'J>Y?3%1_W+<83 /C=\CLD:-@MN!.F[FV)G;JV8^%E
M6992WBYCD3Y)6FZ54<6"Q()+F!',S:F2Z0,J3:A/%*$P10AAI\7@:7%C(X)&
M/<>2RZ<!M2, ?S#U3 6-HJ;FQS*RL-&UI]1N.US\%F$^+7+80LQ6YN\58[:[
MJV/OKG5#F7J;W>S5%_)1SLK\13:1C9_F9?E95K?*M'8*94R$S *82J']B1#'
MVI6( QB+-"8R33$35FO#CO+'QC";[9R::&:^:0"8:MT=.W Y#H@=(?4(<\\,
MM8EP<Y"ZI?LJ$MJH_WW3@&:N/#?/Z@:>WS99CCH,VQ"K&T![K:\Z/J9K)YL/
M3[)XT(SZ<S'_HWHTTNCL=4+#5*8QY9!3IATE&5"S\<5A)#(]-BBA86;%<&?D
MC(W)&E7!4E?0* M:;5V;V!R&]C17>02L9T[JB%6'_C4GD;BP?<WA9P_<O>:D
M@?O-:TY?WF%7_*M4BYDHO]!7LQB[GHFOLI3%BVS;7DP0CGF$] )*A&;_A,D
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M@-'4 (6Y21%#2,$@]K96:6.;]GME$]<#&-AMO*ST#0RRMT+LYP6B =>S0SC
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M2OMR;4KN]]^6B]7*51SQF:LW^LUN+]]JLUBZK><$*RD*2 D@S#" -.: Y;P
M4O 4<81RK;V:7UVGQMC<>\E&=).4*I?U<Y7.B3OV<UN=.ZM\6*EBU_'Q\/F#
MH-[[,G%G0^G_G14WR8$=]5CL+4F<*3>)*(UQ!UR##$=0)>D PS)896E_PQ-:
M:WHEJA=J3[L^?<A:U"L1>%&;>NW3NAT4?-=K^S2M/O"E(QQ:'4A]K\U43M<3
M^^5)C2KK4%,#$&(NZQ=QD.,,$L5ID5,><D1Y6>38/D.'$TQ5*H:=)GB@['?
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M  I& :)V/4Y3P8 P!)-":(*0]LT(.WKRV)S&3KG$:>>? G8,5[M;N J$OGV
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M71^.(B.X22D"$BH&D%8(4%(4P""I,\-D80SQ]I$!@L?F-3.89LE6Y8".+L&
M>_C.GF#LV9MNM4Y*M8^Q3"K-DTKU+ODG(1 '.-V>H![(#<>$/,Q/=\"MU7.'
M/&\X7][!RB/OWN7^^-THMXW'OKD-\F)^NUXOIV)3-H_XN?C&R_8EJD BTYD"
MB.H<(%*D@ IH0)YEF2'<[G%%$-/HE?J,[>M0I<_)H[:$=0[*FUG5EK"/?I(^
M(^=WO#?@>/3\F?'H$+EO]'B3U$8EAU8YRK_*KF$:008 /%C'1Q^=1M/:,0#
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MK__[J9W^=@1NY_9[/E]M9FL^7[M,O/6SW6O::^VFTQWZU1\6QMT7.<< 9MH
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M#M(BSP!R9(Y"2P&R3&M64*(@AD%\.T>/']LNHHSE=.@I= 8\/R_1'9*>?4(
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M1.'J$X[S$@8[Y;AHY.%)Q^6+.U'?/^G5VCD0]UP7KCOJ@C$QK$B9AA 0#0N
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M ESR B"90H%A1I ).E Z)VAT+F*G9U(J>DU8[QRVGL&Z"(CU[1LZ@14>4;N
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M/#=)K64\;W,!AJA^Y9RL03W(!8-?^HI+EW<\+W?+7!?&L^,S^]^;Y72EIO*
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M@I-B7ZDYP3D83C<K.'NG';G4Z\WB1I5LXNM'LMX\?Y'?D>M?9;T(<01YD82
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M1R]VW%CA&[57\W6]^EDRSMX^_U$KTOE8_>2U<K#:>-22UXN"Y"(C>0)B'!$
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MV3D)Z3 )C 64[]U@%XRLPGC.@> <S'/RP9.%])PSK1_8<_9:NY?]X?E[U2M
MO5^WJ)FFBB(/29BE@.>17/US' ."H,I=BB!"898A9I2[9")L;B__MCK\K3@L
MWV6W&##">I@-QD;0,RM,#1Y;41W8VH0M3 7B"ZD3@+ER =.8:VW0:3A7W:%(
M-0Z3=B5E](Q)Z-7&FHYFK>YQ/>M?EF*UKDKR84TJ^J.L58/GMRNR9NTF04J3
M."I8#G)*).?2#(,"9@7(643C4*1Q(JS.O<Y*G!OQ[A2V/9L_!ZV9US4J8+Y7
M7UM=@ZVR.H9)J^MA6\88G)$/WL])G?C W1"$PX-VTQO':+_9*[8J<H9YRBF@
M*!0 ,B94W?T0B##),A(G41%9!0Z=$C0W+CEH"'E!@=N3X)K1RAB0>6831[0N
M;)?IN0#M26&OV [S?$G9L]>[GE'_Y.M*/5+M&JF0'K5]I'K-KO4B]EM9_]5.
MEB1,2<XS#C CB?3]T@@0%A4 A2SD**&41E9U*\Q%SXU$=IH'M%,]H'W=@[54
MWO;,VG@DS/C%#[Z>&:<'[5;KX(7:@=+;PT+&'JZ13ZR-Q4]\8FT+R^&)M?43
M'-L"=-FHC7=V7;%>9LQG3E1_379;?5/MU-8JJ+%B7U;5NOM1MQ36+MVN*2*$
M.4]B$8.$9S& 49H 3%D!>)C#C,!(Y"2QZAPPNHISX\;^WL0NT5[_5%9RB:LZ
M8%[OPJ\_N09>>QAL,UI]W2'T3+^]$6M-T=%75\'6'#UJ?8.\=KCT!_:X/0W&
M5W/:M@?>8#[HC.!/TH4=+IM]XQRGO%"!F'F1AY+P10:*E$<@S_.4)5R$J+#R
MBU\^?G9DO>W%Z!3+L(>=&7^Z(^+[B,(8#/<^E/Y"%?9$O$ZOR<'0A!-7C58;
M7%4PD5S1YN0W_+(H1!$6NCUMF&-5&!S)!1S, )/?AICC+ ]#[I"1;"C>Z-L]
M?0)R4T*I28*[N!KX4=C-J&!,%%^W#K@&=*=WN\+U6@)\""G?];^/RG[MXM]#
M@!A4_AZ\W8ZDZO5F\4TEA.N6B2E/,BS"$&0H+ #D<0AR+%2V+A:IR,.,F]5[
M??'4.:XDRGI3JI"?GN=@U7;R)6S#%.(,Q@2+" <<C GAJ-U#K[N\H?>JRY_V
M7_.73YSD)3YJ1/>*'O^CX^+^J:CY_SS) 7C_4_[3;I_2D)*8T! @PAF "<D!
MR1E5X8M1+$*8Y=1J(_NHE-F]H%LE _[3.C?T.)"&"_Y+X?']RNZ0T0IZV%L>
MA&!<-^"HI&F]@2%C#YR"P8M';P_[A6\6>4RB,",8H"+,Y"PL_?R"B11@)'A&
M$&:QZ@5M7JQL6)P5#TS3^NPJ(&UE?*GH:#U=%;2&.ZBC >9[-_1,QU:I[22]
M67NH3-6*58F<2^?5GOD6C5;[=UV6O[U(LA32'$6 11D"$#($"BP7# F-1,*3
M$,,L=<G.GML:H=/++=EZD1"<X2+* ,IC#"##&& <Y2"+BY D).8ICA:/NJ"L
M7":O-_[ VA?B#[*W_'M95>H8I"#R#]223[?808QP2HCT"I,D!S D&<@1IR!.
MH@CF*8'R"]AB][XR;.WDCEPGPA]N4L+EH)E--RXP>)Y8SKYHSOGVGF(3VH>_
M2J[\Z;B"O;\[YKF7U6JMBV%+BN7U9I%&*()AB(% @LI7,0D!(4*UZXDY%8RJ
M(R*K#/<] 7-C_2^K"N@PIM5RJ=[)LM73,L-]'T:SE_,2<+QOY:SH7ZK2GQR#
M?^XZ$5QO-NNR>-KH(^_-2N_Y]K#[> X[^[3W$P"-F_"^+V3:5/<3)AXDN9^Z
MSB7130WN1UU?]=V3.EEN"MWK<H[U8<W\77U/U3OLX7&Y>N9</^.K_+K]D)>J
MQF+UHH PRU-1@)2JXZ:(18 (*!U,B'*:"01I9)2KX5''N='/S;&*MX_R-_P7
M7U.5OJ"K.;:=/KJ.T?)WZBNP+JEJ\M'<_"1]@;KI$?C86ERWQ7-Y"T=[9?=G
M73O7)NO,S[=FF"IG\EV8@FV#QL*@,7';S*6QLBN]^_94Z=W@6G6'[$:Z>6!G
MKFX@:7C8Z7.H;?(27WW(ITIG?-6AMTR']#HHPUF4?D1/F'SI%;N7.9M^1=D?
M!]]17A&IPA]5_<AI*4JI6),L1*2?CWDJ !*) % 4.2 H3T',"IB&B5!GQ*;'
MPR>ES&W2[Q2US+P:1O+\B?$H^/B>"(VAL3HT/FOZQ8?(IR5,=JA\ULC^(?/Y
MBQT/G;?YXMT.Q2[$O"ARI@^;$H$+ !&"(,\8!2R&@O&"9"2W:T9Y6M;\7OE=
M8L#-#\6WM0J=NB'K];,N&/ZP>FI*M[MM0P_!;GA0/0Z8WOEAAV.GI]<8? -8
MQCW"'I W[4'V><,/CK,-;G%CE>M=+=S[U3>N3"B7_ O??*SHZH&KNE_W*]N6
MUR04D(N8R+6'.K&)$[GV2'$,>%*0,,(QSB*K]"8?2LZ-QWHVJ@W =6=E4/%-
ML%3U[^1OU6>JVB(\]AMM/W6-MG?-*<C67LL&YUZ^#V8\^=JC[)E@]P9X:Z Z
M[@\:$]MRR>K/<VBG[G- 1J5V+XI..B?XA'I_,O$J:Y2 RGOY%!VL&R'(J( 0
M\%C7A*48Y) 3$&<12>2J%M(07Q!2V<F9VUQP$#JH%+6*>3X'K.'*]7*X?*]:
M79"Z-,YR'P>?D99;6:\9:[EO\)EHRX/+'9>F/TFY5/Z'ZH=&EOQ.96MJUE%%
M2SZ33?N3ZIQ65K<55\4JMXF@"XI3EDJB #!3I8A25=H,LAC$1!#(D:06:A5=
M=9DZ<Z.8K35 K-:@EO9<!>^>N.X:*=WG5<6#9ZF_Y>+QLA$S7"9.-@Z>N4M7
M0=II?Q6\'),[/2:[S'G5)DC;]BRO7&K2D@M"=2IY)Z=DN8[L_JQ+XEXU%7*E
M^2.N!T=!?MR5WV4J3;O&&P6^@]7<.$]UB'7XI#+<>F<<[79YD3.&,R8 +D(*
MH$ 4Y"&. (M1@D+,"@Z-G/\!&7,C4ZWEBW-#N_.'(3@-#O$O!\DST_G$Q^+D
M^W*<)CJY=L#+[KAY&(G!X^(3MTYWW#NL^XOCVC.7NG?1O:Z8^I\*WOLI.5=Z
MTMJK8BB-8UA@("A" !+& $GB&&!>Q%&".<H*JR7G:5%S8T"]7:76(OI#3UDG
MKW4 8K,UXCC >69%9\R<NMD.PS%Z^]H3XB;O5SML]K$&M6?N<"2-_<IT;Y_?
M\HK^4*V_]/<:IUC$!%+ 56T@&*I54XIRD(20L:PH0H[MJ..,P-D1R&$MQJV^
M;AQR#G%#)AD11]]\<@&$]I1BB,NXQ').Z+3T8@C! <F8WG=IG$@3 JWCS6Z?
M-O6&Z.2H;RO=Y?%OLF9[A0H9R3->$ @HXY'TW*A<N9 HD9240Y9CA%(HW*)(
M+#69&SG=/3W(P7G6(29-6'D3\=<%EZI)O&>7:X")[7@9;N)/,0J^M_G[03[M
M".A@W)X=@3(D:"V9*'+%$5%/<2VVVKQ2U(LC:*=C8EP?Z+#G]5E:3)^69/VN
M)-^KE:K(<]^DCK2U2V*1492K[K6)R %DE(,<P0*$"<P83Z(X"XTB\8RDS8TG
MM_H&;*MPL&DTMMCI.0NRP9[8F-!Y)K<=:CM=@U;9\T5C'."SV#(;$\:)-L^&
MOH3_,M+^F2DL@SMI9Q\RW9Z:J3TO=M>,;SK%L_W!^"0__=L_=;^1_Q2DYO_V
M3_\'4$L#!!0    (  2"IE1YMJ1_8GX  $3$!0 5    ;7EG;BTR,#(R,#,S
M,5]P<F4N>&UL[+W9DIPWDBYXWT^AJ7,[7L*^E'7W,2Z26C:4R"&IKG/F)@R+
M(QE=D1'LB$Q*64\_CLA]C^5'_$C-F%51R<QDP)</#G>'P_U?_^<?Q[/OON%R
M-5W,_^TO_*_L+]_A/"WR='[T;W_Y[?./X/[R/__]7_[E7_\/@/_U^N.[[]XN
MTNDQSD^^>[/$<(+YN]^G)U^^^WO&U3^^*\O%\7=_7RS_,?T6 /Y]_8_>++Z>
M+:='7TZ^$TR(NS]=_LTD%600":+1!E0P!J+(''@,/B:!6OOT?Q[]+1G%L^8>
M2JB_QK4%+[F$R)D-&C$PH=<?.IO.__&W^D<,*_R.F)NOUG_]M[]\.3GY^K?O
MO__]]]__^D=<SOZZ6!Y]+QB3WU_^]E\N?OV/>[__NUS_-O?>?[_^Z=6OKJ8/
M_2)]+/_^?_WR[E/Z@L<!IO/529BGNL!J^K?5^IOO%BF<K&7^+%W?/?H;]6]P
M^6M0OP5<@.1__6.5__+O__+==^?B6"YF^!'+=_6_OWW\^=:2QZ2=D/^:%L??
MUQ]__V9!8"!"U__PY.PK_MM?5M/CKS.\_-Z7)99_^\OQV=$<JD:9/%_N?YS_
MP^^O5_VZQ!4!9<WE._K&Q;^OJVQ+ ?YQ@O.,YSQ=?OYLD6[]TJQ*=''U+V<A
MXFS]W4G&Z63]J:_BZF09TLD$/8LY$<RB29K@9"R$'")(](Z^4TKP[C;#E> 5
M4;Q6P K37X\6W[ZG#R9%"/[?JGX)YU^NI7%OR7/)[$;[Y9[[3+\[T=)'FRV'
MD%*@#<-H)SB)I'BOE?"1.:[V)OWFBK<IOZG55\OTW6*9<4F&XW+)L$SW-'P;
MM!>_\?W7L*0/@O1E.LN7_[I:D"%T=K(80'KGJB%R__(=<5UPN<3\[EPSCS*W
MYNR$S"FN?W,(K?_?IV%)GS@[^XA?%\N3B9.::Z(<@LHD!R4<N!P]F*A1&1\D
M&</! '!G\8VP(/K'PCXR[006'W Y7>0?YODM'<,3'WC23&I"LR!<6R8@,DUG
M@A0H;'&F6#$8*&XMO1$D9/^0V%V>G0#B\S+,5],J^ M01V%CR1E!H28>#!(/
MY&5!ED6J8D+ 8(<[*>ZLOA$L5/^PV$NJ(R/CA_G)].3LQ^D,?ST]CKB<\&1B
M9BF#25R!8L6"L]8#+XY'SEW,+NZ-B+NK;H0$W2\2]I)B%PCXB$?3*H3YR:_A
M&"<E:E,8(H10)-DVG\'Y*$ KFSTWJ+C2 Z'@]LH;(<'TCH0]I-D%&MZ0K)9A
M]C,%5'_\7W@VX39@(A<'9#0%E$P>O! 92D81?!$L8AH(#G>6W@@/MG<\["//
MD0'QYG19)?7C=)7"[']C6%ZZ/\D)(Y264#2/%"9QDDU6$43,)B416<;]3<1C
MJV\$"]<O+ :1:B=.Y343/])W5A.'(N48%"1CZ]DG-#@G'0C'4+BB2DPXF$]Y
M9_&-<.'[Q<40,NT*%N<ATSD31BEM')&>M"8FN",F,"+0]ZPFK]@GS@<&QHWE
M-\M1L9>"C5T%.S(Z7A$'><W%+!Q-A$!3L@G B7=07B+$8!,D%[+-0KFLY-Z(
MN+7D9BCH.%6YNP"[\"Q_GJ?%DH+DM<@_D>3QS>*4G*.S-XN,D^R3"%PJ,&34
M0&7/(%HZ_;1*7G%F5 A#^9E/$K(92CI.8@XM["ZP\SG\\7,F\4W+]/QB["+8
MSF3Z7#5_PH6Z"6K"OM[^I5(4F<;"B)V!4/,("9OAI>,,YW "[@(IKW(F':PN
M_O-N.D<^X<E9KZ,!KI@'E9PAT5@+F94LC)0J\C 02AY8?C.$=)SL'$:P/:'C
M#7WY?OEY\?M\(ISC.@>B/M=TG92^5@TP<#HY[8O23NT?LCRR^&;(Z#[YN9]0
M>\+%^J!\O_RP7'R;SA-./(HL9*E\$/4*C0.7Z _DVB'C,3DU5$;\80HV0TCW
M2=$!Q-L33#XL5B=A]O],OZZ=*:V39ED5R*FF>*,6Y$R9&JHSRYRV@;.A?)"'
MUM\,(MWG2?<6[=C)TLK#$L.:;E-X\2DS$!E)%"5P",(;L#H@3\F(<KUG=T^0
MWEAQ,Q#TG!7=57PCJ[T6ZLT^?%G,+Z__HL@R,F[ .4^0K:G<6,L6!6&6Y83"
MI+RWZN^NNIGZ.TY^[B7&D2'P"=/IDN#+1?P\/9GA1!65H_<.DG-(M*L,+A"0
M-6/)J)*,L?N[E'=7W:SVJN,<YUYB'!D"GY>AED1_.CN.B]DDQ222%APX%X*B
MHB@A)LG!9R]S<2$4OG\JZ]:2FRF_X]3F[@+L9//_\$?Z$N9'N+[T=U85ADJ#
M22Z2VU+(>.7"(04=B^/.ZP'*[1Y:>3,<=)R\W%N<780)%U>\YR5A%=:D@]/5
M)$<T+"@&F%DB/D@H45@')J.R)FBMS5"!PL,4; :/[G.5 XBW"YC\/*=/(W%,
MO^';<!(NV)K4,"=;;8"I9$ YP\"SC" B_83YD$W>_V;L*0HV@TGW"<L!Q-L%
M3&IMX?)-.,&CQ?*,SD;/78D!$CI">7$&O.:$<EML<,PZJ<J 19I7"V\&BNYS
ME;L+LPLL?#H.L]GKT]5TCJO5A R:C<5HB-HX4((9",EZR)G9(CWJR(:Z,[VU
M\&98Z#XKN;LPN\#"#\>X/*+C[Z?EXO>3+V\6QU_#_&S"M12J6 (RBGIA%R2$
M8@5PC*4D"IV#\0-AXD$"-L-&]^G(_87;!48^?<'9[))ZEZT1B$0XRX4":JW
M1>%!A1*,,LB4W/]MX/UU-T-$Q[G)/479!1"(\.-:"+)(__CTA>2V>G]Z4I\=
MUZA[$E,0.HD,@1<Z!KE%\"E&2$F5:+DB!WHHC_,I.C8#2L=9S(%%O3-PB)>X
MN 6=?_W^GDS?T3=V?00^SSA?8:8O5HO9-->7_J_#K#YBIUV")ZO;'&SZ0OS9
M3QWD^?AVM._YMOQT!4<A?)VL;SYKZ=[[\N-T3HM-P^S#XOSEV!7L" #6BRC
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M_N0++F_):!(%"E&O2[VF.$.EZ,%IY<!X'J4TD?[;QG?>@+AQ&H@TQ])@^N@
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M_,DX91L%=(">6U%]#<GG:3K#6RQ]7FPM36EHN\HZXEA3K)8$;=A" 1LG:6)
M[:UK4Y79@IN1&](?%LNCPZ&#+?$6:>4T#1<OI%X=5S?YG^>I6Y*K\H;\WI@T
MN<%"DALLB@2K!3%BBC.^C6/S!%'C&MOQ$;-HH[X1D5A#B]J#O8KM[LR(@"F+
M0GY0R$J#4D6!LZY +6VC'WDK-7\N4'GB\\>U=MV :2@-=&#.KD3S#L,*/];>
M)^\+26T]U._F[KB:2H+92:Q7I"G3^8&8P26%D)VPS#%NR,-IDWC<DM)QKU>Z
MP>I!%-T!D!^Y317*(SJC00=%<D.FP?F(X%E&G3&JF!N]=]K]<KO9%4QWH!Q
M:1U [^W%LC<F1=2W\^&/-_3-Z<EJHHUB7D1.@JGOA+UDX*1.P+-@A2,S*-I<
M83]'V;BW,=W!<5!%CGK-N/90B(UE-?9O\?R_/\]K(Y3UO?H_L;)U,7)B-:D=
M&Z+3&D0PLG9RB+37//V5,ZLRL6:%W<AMW'C)<6]1ND%>0SUU8!@?F0R=G!*6
M4V!%?G(!%9B#:*6"5)3-7FL569L.2WO,YFXV,Z0;* ZHM"XJ+.[OJNM1UN?U
M2-<3K%5!+Z0$GVH5*),>HJKU]-$9*]&G(%M-M]R4QG&GCG0'TD;*[<!FWN?L
MPQ)I,UZ-2%\7G4P\HQB,F0#DCB"YR XA6&_JVT5A5;(ZQ#8-9#>C;]RL8RMT
M/ O"O56U[QS7SPUQ^"JEQ2E9 -K_./VV?E82F#?%( ,F1:K/2BA&\]I!*=:F
M8G,QH4W">Q/JQDU6CH;!/=74Q23A^US5P=IS^D=T@$QL((%I@8 8Z.#@/D/P
M29%GPGF)A6M,S<82/D[6N/G&T>"VJV(ZQ=F%!5_'_F2Y"W.( GQV#)1>2TI%
M"(S;HA1SMM$H@:?I&C>)./;ANKUJ.H7:Y7#NM&Z]>;*.NU83SK1>S_MTQF1B
MS-2FFDJ#X5ZA17(F1)O@>$,"QTT9C@:^_97U$ER[#^%L[3#HZ#T6+4"&4..S
M["!([L%8)U4(1?D<#NS779 V;MYP=*=N%P5U&=020\M3HF,:XG2VS@M,O+9*
M!4^;R:$$%5P IZP'D53DG&'QC>K"-J%NW"3AF+C;1TU=0J^.>J^B^OOTY,N;
MT]7)XAB7EPR>38+(J4A1VSY9BM835A\V9W""O(I@LN&-1F]L2>BX"<'1 #F<
M\CK YN;EFQ.3HW$I5">C-LB3U>![<G^#E#X6%QEKU+=U<QK'#8 /7];=0G4=
M= E_A+,:YZ\>$Z2R(EL>0!E3AUU&"U%P"UZ;6*PO.F,Y)#B?H+63[A('>L@R
ME-(ZL)7D^5YV%TC_?3I=(O&:3RM;>!&,%<6#]KD HB&?V-E P9C+0 =,#E88
M%TT;$_DL:5T^>!D,&XN6BNHB=W./I5??PG16 [$?%\M/88;74X3>8CR96)N#
M8TQ#<$+4F:Y8>U4$L"F$R"@VD[%-)+,EH5T^7CD8+@=48A\H72X28E[]2)*N
M_+R:YU_"267I['WY)2S_@>M'W-=L3E(Q$2UM1*&% H6\@$O&@Y1&Y)*-+Z7-
M<\"M2>W2MVR&U*:*[. LWUR>$UN"BNLW.;&VI(S!T5G!'*!#G9A +5*SSCD;
MTCCN=<R!L=E(=?W&/3].YV&>'A9D\,S:5-MHLDS2S.3-..8YZ#JB6FNM6&J3
M)M^>UDZ:C1TH[AE*:1W8RIN'06TD2'SAY=3TW^:DMI_I&_.U=SW/#[^G^# +
M\]557Y=URY?W7^L/5A-75/*H'4A'*%-":' J9Q!<ZBQ#X2RU:6G:E*TNXZW!
M,/F$MS N0'K8+1=._D=<]TK_O/@<_JBIXB_G<U^KI__(DR.6>;96@RG,@@JF
MWFHDA&B*4+P4QE*;M/^N%'<9NS7#^"'4VL\%_06[Q%:][B &:QT^[482]?*B
M$]3%C<<# I]P*Z3WR@&K+;A480:"9B1W*1SWJ02>VY3'[45VEQ%>8SP?0,%]
M9"8NMN_[4C,KEX?4F\7J9#7Q3F&H+SR%5.O)3QZ\XQ3$:D;"+8E8:A/@/4%4
MEQ%=:]NZKW+Z,9\?\>L53^^F<Z3_G#_@G,2D2D*7*-2-M4VLRT#_7$"RK$@7
M+8NFS4.?1TD:MYSNP% ;1C%=F+3-)3?)CF<O2X3B))EK7S)X00QJ'1.)KU8*
MMKD-V)S&<:OJ#HS"1JKK((7U0RF83MZ7'_Y(7P(Y%1\)[N_776KJ_VM_UV]A
M=NY'DQRGB39#_0'%A;>_<>,W:R\&%Q13X'0FPY^YIYW)"@6 0;H<A0R^33UR
M V8Z:8 ^=!)L;+5W$/?OQ>SYQ('[M687^9";8CT7]418168F""C6LCJ,@#QP
MB0FB+5C%I IO\^[ML'QVTJQ]Z/W2,5@Z.$3VLQLY((^E<(BYU*ET04$HD8'/
M6F<1K?6E32E8^X.A?4_WKH"^E2J[F8VU)\N%@EKD&DHL%(;(0 &)U0Z8H9UJ
M&>.Z46?R]NAM]C:A5_1NH<I^1Q*\#JOI:E$^W/BPVT1O-GO@H8\98,C L]0-
M-$W@_?(HS"_:$U[/,SCOX'IS\??E(H@+L^M1!]=E#Z8HJVNW))8(BSXC.$>(
MT%ESC]9+B6WRXH.0OW>CSWV(>#M=I=EB=;K$SZ32U_2Y_YAHS5%;)L"I6CWO
MI(2 0M/Q4)RK(X=Y;)-+&YJ3<6^+#X_M>YU!QT3&8+%C:[/[@<22:JIL&/-[
M]7%MS/##U'9ECDO0W(;B $LNH%!$"#IY2,F45!RBU&U*3[HPQVN=O2\7[WK7
MXY9(8V?G?UYO)50B*V\R>(D4.[* X(4D;UQY&15*F;"-0[H9?7\&T[D-#N^:
MS@9:[""9]H&<VN75&,Y96*VF99K.)7O5".XMKM)R^O6\RB)J*YVQD$5M%:W)
MX7;!(9B8$5$5KE6CES=;4CINT<SX>&VJV3Z/\H_X#>>GN,NQ??E/!SBB'Z1B
MH./XXK-K_=]#KZ.O?42.*EKO :TB7>:D("I6@#/.%)ID7*/7'AL2N/^U_Y/+
M7)OC$FFO<"3.USN(\ V1&P]6&2^R8,[[-CG*32D<]UAM@:?[E0 -=-6U ?I<
MG^SL%#W<_H#AC-%#%!W8),EB"R+WX+ ("EMY ,^5!I0Y)(\Q</>B31)%Q^'H
M:%GK3M;G^DW)7V/<JVQ1:PLQ" 05D3!N5*Z=ECTWG#&M&HT'V(2\EV&,MD'2
MO;;_@VNI R?^06FM9[W,K]KYG-UA4:BB17 ,."91Y[YX"#P9""ESEK44(;>I
M]=B!V'%=^4/ LK4&^SXNZWWVQ=?Q[ U%04>+Y5F8YWCVVZ=O1,#I^C)H4?Z^
M6,[R6SP)T]E>I^M.ZPUX&._/[X'/[LR"+G;=T3JP.@O%$;19 !E,,<H4AB'_
M6<_N261)F9PM6!%#;1WD(4:B-@C.112^^$8UG4]1]3).ZFUPL\U)O95.1CR@
M5\N3R45+E/?+3[C\-DWXZH_I:I*]4,DY!RCJ;&#EL#83#9#06AM*=H)O] 2-
M%KB!)_K;72P]1L&X^!E.MXL!!=T'4.H8J@L.5F\7QV$Z)\]"6$3)(3&*B15#
M!P$=N1?:RN2=%!@V\M6V0<M],L:!S#":O0^3/<4\]DS87^BSTNDL+-].P]%\
ML3J9IL_G71E^P>.(RXF)W'%O.!1.+JF2M7VVS@B^2/(;M&59EN?\I8U6&AT6
M^VIRT4JL'6+D/W#]!B<LR>V<IYI\N\D<"T)*7S0P5EM<UWG(01.;@D)AX;5+
MUH1=,?/DRN-@J('&G\'2<.+O$%N?3X\72]J3A8+5*YZ"4Q2CQ@+H%7F 7":(
M.410N?A" :K,=QL];V&&'EAPG%3!X9&TM[ [!- '$G&@T/BVU'S,C+/:BR)K
MVA5*21)8]""9SCD:D?W=1TF;(^C!%<=YG7YX".TO[AXQ]"4LCT-:'.%\<3Q-
MJTO3FJ,LU3LL0150T2CPBF>P2'&HU<P[ZW<&T8-+CO/^; 04[2_P#F'TZO1D
M,3T^/IWC)3]:&^$R@QR(%54\>911>>"&6S0R<Z=V/L?N+C;.4ZS#0V<O(7<(
MFO7<F-OBXE:)Y"V=R)+7)O5K:UHB<.5CH!#%W:O#V!PV]Y<;YVG3X8&SIZ#'
MALZ%R<138B7,*'I]0[]6O[R,8B]XLD8F9,*"3E90/& M..43A)**""DR9_-&
MX-EPP7%\YT:1? LACYP@O"H0_ D71\OP]<N:LYH+8YDI+,E!P?I\3W,Z;7E4
M$$-!67+T(6Q4Y;11@O!1,L:]IFV24QY&Y&/C!H_NLG"QNSA%AH5G!<G(B]<;
MGB%936,+&F&U51M-%MX,-X^1,5X&<2#U+H:6]8B 65>W+\\FOWV:>*-2CBX"
M65HRC5(A!!TCB22F;(-Q#/43Z%AA^NO1XMOW%Y]X#I"+OZSQL4;&]7HCPF 8
MI2WVDF '=42_+N:_79Z+4LABI:CSE.K$=H,2G"R. CAE1,D&,W]*^7MT,KHF
M8CR'9%A$["O?#J#QR.GZ;CK'G\F$KB92Z91"\F!"K1"N0\ B,Q:,XTGFVK@0
MV_3V>XZR<9M-#NZ5-%%(!P![IJ3DAS\NFJ[4JCCZ7QT-/*&=Z&*H>Z@X74?
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M^0#\%PJH\:1:[)_GW_"\JO 3IM/E]&3'V='/?.( 9>_;T#Q0]?OU0JNW&.M
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MM^- "Y,T#/<[@-'F!=Q3SNL-R%K>+0.I0"%F."\""+\\7F":RT9)CCL-"IX
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MAJ6D-JF67NYS;S7U^.1L^4CZ[$.Y/==X2>GJ.D:TRCOK++GTW +MY9Y<>N[
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M9;G56'T19+2R*! "0P-:>-*YJ)R]?7[Q*(BV?.VX1XA-L=2"\1WL<Y](1$3
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M:\$1N2E)H6M3(GT?-3V<1 Z,H8.9W@%P[C*F-DI?6NR@F"PV6C#5=53D1%+
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M IGO__M__C]02P$"% ,4    "  $@J946AS</0L(  "K*   '@
M    @ $     97AH:6)I=#,Q,2UC97)T:69I8V%T:6]N;V8N:'1M4$L! A0#
M%     @ !(*F5"A3( $)"   NR@  !X              ( !1P@  &5X:&EB
M:70S,3(M8V5R=&EF:6-A=&EO;F]F+FAT;5!+ 0(4 Q0    (  2"IE0*4+Q3
MS@0  +D7   >              "  8P0  !E>&AI8FET,S(Q+6-E<G1I9FEC
M871I;VYP=2YH=&U02P$"% ,4    "  $@J94 NBZ-X:4 0 Q&1( $0
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64$L%!@     )  D ;@(  .]^ P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
